

REC'D 15 OCT 2001

WIPO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference PHM.70569/WO	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/02566	International filing date (day/month/year) 04/07/2000	Priority date (day/month/year) 07/07/1999
International Patent Classification (IPC) or national classification and IPC C07D239/94		
Applicant ASTRAZENECA UK LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 9 sheets, including this cover sheet.
- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 23/01/2001	Date of completion of this report 11.10.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Schmid, J-C Telephone No. +49 89 2399 8347 

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/02566

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-147 as originally filed

**Claims, No.:**

1 (part), 2, 3, 6-14, as originally filed  
15 (part)

1 (part), 4, 5, 15 (part), as received on 13/06/2001 with letter of 07/06/2001  
16

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/02566

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 1(part).

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 1(part).

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims 3-12
	No: Claims 1,2,13-16

Inventive step (IS)	Yes: Claims 6-12
---------------------	------------------

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/02566

	No:	Claims	1-5, 13-16
Industrial applicability (IA)	Yes:	Claims	1-15
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VI. Certain documents cited**

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

### **SECTION III**

Claim 16 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

### **SECTION V**

Reference is made to the following documents:

- D1: WO 98 50047 A (UNIV PENNSYLVANIA ;LIANG BRUCE T (US); JACOBSON KENNETH A (US)) 12 November 1998 (1998-11-12)
- D2: WO 98 50370 A (KUTSCHER BERNHARD ;WEINBERGER HEINZ (DE); SUGEN INC (US); TANG PEN) 12 November 1998 (1998-11-12) cited in the application
- D3: WO 98 38984 A (SUGEN INC ;SHENOY NARMADA (US); WAGNER GREGORY S (US)) 11 September 1998 (1998-09-11)
- D4: WO 99 09024 A (JOHNS AMANDA ;PORTER RODERICK ALAN (GB); SMITHKLINE BEECHAM PLC (G) 25 February 1999 (1999-02-25) cited in the application
- D5: WO 97 03069 A (GLAXO GROUP LTD ;COCKERILL GEORGE STUART (GB); CARTER MALCOLM CLIV) 30 January 1997 (1997-01-30) cited in the application
- D6: MYERS M R ET AL: 'The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56and EGF-R tyrosine kinase activity' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 4, 18 February 1997 (1997-02-18), pages 417-420, XP004136037 ISSN: 0960-894X
- D7: GIBSON K H ET AL: 'Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 21, 4 November 1997 (1997-11-04), pages 2723-2728, XP004136520 ISSN: 0960-894X cited in the application
- D8: HONG C I ET AL: 'SYNTHESIS AND BIOLOGICAL ACTIVITIES OF SOME N4-SUBSTITUTED 4-AMINOPYRAZOLO[3,4d]PYRIMIDINES' JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 19, no. 4, 1976, pages 555-558, XP000916640 ISSN: 0022-2623 cited in the application

D9: VAN MUIJLWIJK-KOEZEN ET AL: 'Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A3 Receptor' JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 5, 1 June 2000 (2000-06-01), pages 2227- 2238, XP002147879 ISSN: 0022-2623

- 1). D2 and D3 disclose three compounds that have been disclaimed in claims 1 to 14. However, the compounds have been disclosed in D2 and D3 for some of the claimed uses (autoimmune disease, psoriasis, arthritis... -see D2, page 33, line 13; D3, page 29, line 9). The fact that these prior art compounds have been disclosed to act against those diseases by another mechanism of action cannot restore novelty.

D2 and D3 are therefore novelty-destroying for claims 15 and 16.

The compounds of present claims 1 and 2 generically overlap with the compounds of formula (I) of D4.

The overlap concerns the compounds of D4 wherein X and Y represent N.

This overlap is considered to be novelty-destroying for present claim 1 since a selection from known subject-matter to be novel must fulfil the requirement that the selection portion is small and that a technical rule of selection has been applied, so that a technical teaching results which is different from that of the state of the art.

In the Examiner's judgment a true selection from a broader technical disclosure to be novel must add a new element to the state of the art. The mere selection of one from three alternatives disclosed in a document belonging to the state of the art is no more than a repetition of what already belongs to the state of the art and cannot, therefore, be novel.

Either the whole overlap has to be removed by the mean of a proviso or the novelty should be restored by the mean of positive features which provide a technical rule of selection.

The subject-matter of claims 6 to 9 is regarded as a novel selection over the overlap with the compounds generically disclosed in D4 on account of the combination of selection of the nucleus (Y = N) with the substitution in specific positions.

Accordingly, the subject-matter of claim 1, 2 and 14 to 16 lacks novelty over D2-D4 (Article 33(2) PCT).

Compound MRS 1364 disclosed on page 28 of D1 has been excluded from the claimed scope by means of disclaimer. The claimed-matter is therefore novel over D1.

D5 and D6 disclose no urea derivatives (see the meaning of Y and X for the compounds disclosed respectively in D5 and D6).

D7 discloses the 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea (compound 18) which is excluded from the scope of product-claims 1 to 14. This compound is inactive as an EGF RTK inhibitor.

D8 disclosed some pyrazolo[3,4-d]pyrimidine derivative which are excluded from the scope of claim 1 to 14 by means of the provisos.

The compounds of D8 are disclosed as inhibitors of L1210 leukemia and human leukemic myeloblasts.

Accordingly, the subject-matter of claims 1 to 16 is novel over D1 and D5-D8 (Article 33(2) PCT).

- 2). The technical problem underlying the application is the provision of compounds which selectively inhibit enzyme p56<sup>lck</sup> tyrosine kinase (see present description on page 3, lines 4-11).

Tyrosine kinase inhibitors have been disclosed in D5. However, these compounds are not selective inhibitors of p56<sup>lck</sup> tyrosine kinase (see table 1 and 2 of D5).

The closest prior art is therefore seen in D6 which discloses a selective p56<sup>lck</sup> tyrosine kinase inhibitor (see compound 10).

It was not obvious in the light of D6, also taken in combination with the teaching of D5, that the replacement of the NH, O or S link of the quinazoline derivatives by an urea or thiourea would result in a selective p56<sup>lck</sup> tyrosine kinase inhibitory activity of the resulting compounds.

An inventive step can therefore be acknowledged for those present compounds which effectively solve the above-mentioned technical problem, i.e. for the present working examples 1-34 and the obvious equivalents thereof which can be represented by those of claims 6 to 12. The Applicant confirmed that about 250 compounds disclosed in examples 1-34 of the application have been found to possess (valuable) p56<sup>lck</sup> tyrosine kinase inhibitory activity (IC<sub>50</sub> comprised within the range of 0.0001-5 µM). However, the selectivity of this inhibitory activity has still not been confirmed.

It must furthermore be noted that the breadth of the claims should be such that it represents a reasonable generalisation over the examples provided, and such that substantially all compounds falling within their scope actually are solutions to the technical problem underlying the invention (Article 33(3) EPC).

In this respect it must be noted that most of the compounds claimed in claims 1 to 5 cannot be regarded as obvious modifications or equivalents of the examples which have been given in the description if the specificity of the technical problem underlying the application is taken into account. Examination of the examples indicates that there are no working examples with compounds of formula V, one working example for those of formula III (example 18). It is pointed out that all the quinazoline and quinoline derivatives derivative of the working example are substituted in positions 6 and/or 7 by an optionally substituted alkoxy group. This very few variations of the substituents R<sup>1</sup> cannot support the broad generalisation made in claims 1 to 5.

Still with respect to the breath of the claims, it must be noted that expressions in the claims, such as "aryl", "heteroaryl", "heterocyclic"..., are non-limitative in scope and therefore cannot be regarded as obvious modifications or equivalents of the examples which have been given in the description. Accordingly, the said expressions should be restricted in this respect to the particular meanings specified in the general part of description which can be regarded as obvious equivalents over the tested compounds.

It must further be noticed that the inventive step has been acknowledged for a structural difference which must be regarded rather as minor, when the generalisation made by the Applicant in the claim is considered.

The examiner is therefore not satisfied that substantially all the compounds of the formula (I) with the substituents as recited claims 1 to 5 are selective p56<sup>lck</sup> tyrosine kinase inhibitors.

Consequently, at the present stage of the examining procedure, for claims 1 to 5, the technical problem underlying the application must be reformulated into the provision of further organic compounds.

As there is no technical prejudice for the preparation of the claimed compounds, no inventive step can be acknowledged for the whole subject-matter of claims 1 to

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB00/02566

5 due to the compounds encompassed by these claims which are likely not selective p56<sup>lck</sup> tyrosine kinase inhibitority  
Accordingly, claims 1 to 5 do not meet the requirement of Article 33(3) PCT.

**SECTION VI**

D9 was published between the priority and filing dates of the present application.  
No check has been made as to whether the priority of the present application has been validly claimed.

- 152 -

halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,

- 5 di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^8$  is a direct bond or is selected from O and N( $R^{16}$ ), wherein  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $R^{15}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

- 15 and wherein any heterocyclyl group within a substituent on  $Q^2$  optionally bears 1 or 2 oxo or thioxo substituents;


or a pharmaceutically-acceptable salt thereof;

provided that the compounds :-

- 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,  
 20 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,  
 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,  
 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.  
 1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 25 1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
 30 1-{8-[3,4-dihydroxy-5(N-ethylcarbamoyl)tetrahydrofuran-2-yl]-7,8-dihydropteridin-4-yl}-3-(4-nitrophenyl)urea are excluded.

- 154 -

## 4. A pyrimidine derivative of the Formula IV



IV

wherein each of  $m$ ,  $R^1$ ,  $Y^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;

## 5 or a pharmaceutically-acceptable salt thereof;

provided that the compounds :-

1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

10 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,


1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and

1-{8-[3,4-dihydroxy-5(*N*-ethylcarbamoyl)tetrahydrofuran-2-yl]-7,8-dihydropteridin-4-yl}-

15 3-(4-nitrophenyl)urea are excluded.

## 5. A quinazoline derivative of the Formula V



V

wherein each of  $m$ ,  $R^1$ ,  $Y^2$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;

20 or a pharmaceutically-acceptable salt thereof.

- 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.  
1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
5 1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
10 1-{8-[3,4-dihydroxy-5(N-ethylcarbamoyl)tetrahydrofuran-2-yl]-7,8-dihydropteridin-4-yl}-  
3-(4-nitrophenyl)urea,  
in the manufacture of a medicament for use in the prevention or treatment of T cell mediated  
diseases or medical conditions in a warm-blooded animal such as man.
- 15 16. A method for the prevention or treatment of T cell mediated diseases or medical  
conditions in a warm-blooded animal in need of such treatment which comprises  
administering to said animal an effective amount of a quinazoline derivative of the Formula I,  
or a pharmaceutically-acceptable salt thereof, according to claim 1 but without the proviso  
that the group of formula Ic so formed is not a purine ring and including the compounds :-  
20 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.  
1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
25 1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
30 1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
1-{8-[3,4-dihydroxy-5(N-ethylcarbamoyl)tetrahydrofuran-2-yl]-7,8-dihydropteridin-4-yl}-  
3-(4-nitrophenyl)urea.

(19) World Intellectual Property Organization  
International Bureau✓ (43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
**WO 02/00644 A1**(51) International Patent Classification<sup>7</sup>: C07D 401/12,  
239/94, 401/14, 405/14, 403/12, 405/12, 409/12, 409/14,  
413/12, A61K 31/505, A61P 37/02(74) Agent: TAIT, Brian; AstraZeneca, Global Intellectual  
Property, P.O. Box 272, Mereside, Alderley Park, Mac-  
clesfield, Cheshire SK10 4GR (GB).

(21) International Application Number: PCT/GB01/02698

(22) International Filing Date: 19 June 2001 (19.06.2001)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:  
0015376.7 24 June 2000 (24.06.2000) GB  
0030989.8 19 December 2000 (19.12.2000) GB(71) Applicant (for all designated States except MG, US): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).(71) Applicant (for MG only): ASTRAZENECA UK LIM-  
ITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN  
(GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): POYSER, Jeffrey,  
Philip [GB/GB]; Alderley Park, Macclesfield, Cheshire  
SK10 4TG (GB).(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.(54) Title: GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AU-  
TOIMMUNE DISEASES

(57) Abstract: The invention concerns quinazoline and quinoline derivatives of Formula (I) wherein Q<sup>1</sup> includes a quinazoline or quinoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q<sup>3</sup> - X<sup>1</sup> - wherein X<sup>1</sup> includes a direct bond and O and Q<sup>3</sup> includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen or (1-6C)alkyl, provides that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond; R<sup>6</sup> is an optionally substituted group selected from (2-6C) alkenyl, (2-6C) alkynyl, (3-7C)cycloalkyl and (3-7C) cycloalkenyl, or R<sup>6</sup> is a substituted (1-6C) alkyl group; and Q<sup>2</sup> includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical

compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

WO 02/00644 A1

## GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES

This invention concerns certain novel quinazoline derivatives which possess pharmacological properties of use in the treatment of autoimmune diseases or medical conditions, for example T cell mediated disease such as transplant rejection or rheumatoid arthritis. The invention also concerns processes for the manufacture of the quinazoline derivatives of the invention, pharmaceutical compositions containing them and their use in therapeutic methods, for example by virtue of inhibition of T cell mediated disease.

A critical requirement of the immune system is the ability to differentiate between "self" and "non-self" (*i.e.* foreign) antigens. This discrimination is required to enable the immune system to mount a response to foreign proteins such as those on the surface of pathogens whilst maintaining tolerance to endogenous proteins and thereby preventing damage to normal tissues. An autoimmune disease results when self-tolerance breaks down and the immune system reacts against tissues such as the joints in rheumatoid arthritis or nerve fibres in multiple sclerosis. Stimulation of the human immune response is dependent on the recognition of protein antigens by T cells. However T cells do not become activated by and respond to antigen alone but are only triggered into action when the antigen is complexed with major histocompatibility complex (MHC) molecules on the surface of an antigen-presenting cell such as a B cell, macrophage or dendritic cell. Thus T cell activation requires the docking into the T cell receptor of the peptide/MHC complex expressed on an antigen-presenting cell. This interaction, which confers the antigen specificity to the T cell response, is essential for full activation of T lymphocytes. Subsequent to this docking, some of the earliest signal transduction events leading to full T cell activation are mediated through the action of multiple tyrosine-specific protein kinases (E. Hsi *et al.*, J. Biol. Chem., 1989, 264, 10836) including p56<sup>lck</sup> and ZAP-70. The tyrosine kinase p56<sup>lck</sup> is a lymphocyte specific member of the src family of non-receptor protein tyrosine kinases (J. D. Marth *et al.*, Cell, 1985, 43, 393). The enzyme is associated with the inner surface of the plasma membrane where it binds to the T cell receptor associated glycoproteins CD4 (in helper T cells) and CD8 (in cytotoxic or killer T cells) (C. E. Rudd *et al.*, Proc. Natl. Acad. Sci. USA, 1988, 85, 5190 and M. A. Campbell *et al.*, EMBO J, 1990, 9, 2125).

It is believed that p56<sup>lck</sup> tyrosine kinase plays an essential role in T cell activation as, for example, the loss of p56<sup>lck</sup> expression in a human Jurkat T cell line prevents the normal T cell response to stimulation of the T cell receptor (D. B. Straus *et al.*, Cell, 1992, 70, 585)

and a deficiency in p56<sup>lck</sup> expression causes severe immune deficiency in humans

(F. D. Goldman *et al.*, *J. Clin. Invest.*, 1998, 102, 421).

Certain autoimmune conditions or diseases such as inflammatory diseases (for example rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis and lung  
5 fibrosis), multiple sclerosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma and insulin-dependent diabetes are believed to be associated with inappropriate T cell activation (see, for example, J. H. Hanke *et al.*, *Inflamm. Res.*, 1995, 44, 357). In addition the acute rejection of transplanted organs can also be interpreted as a consequence of inappropriate T cell activation. Therefore, compounds which modulate T cell  
10 activation by way of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation, for example by way of inhibition of p56<sup>lck</sup> tyrosine kinase, are expected to provide therapeutic agents for such pathological conditions.

Without wishing to imply that the compounds disclosed in the present invention  
15 possess pharmacological activity only by virtue of an effect on a single biological process, it is believed that the compounds modulate T cell activation by way of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation, for example by way of inhibition of p56<sup>lck</sup> tyrosine kinase.

20 In particular, the quinazoline derivatives of the invention are expected to be useful as immunoregulation or immunosuppressive agents for the prevention or treatment of organ rejection following transplant surgery.

Agents of this kind would offer therapy for transplant rejection and autoimmune diseases whilst avoiding toxicities associated with the commonly used, less selective  
25 immunosuppressants. The leading agent for the prevention or treatment of transplant rejection is cyclosporin A which, although effective, is often associated with side-effects such as renal damage and hypertension which results in kidney failure in a substantial number of patients. It is contemporary practice to treat rheumatoid arthritis initially with symptom relief agents such as NSAIDs, which do not have any beneficial effect on disease progression and are often  
30 associated with unwanted side-effects. A rationally based, disease modifying agent, without such deleterious side-effects, would therefore offer significant benefits in the prevention or treatment of transplant rejection or autoimmune conditions such as rheumatoid arthritis.

As stated above, the present invention is based, in particular, on the discovery that the quinazoline derivatives of the invention modulate T cell activation by way of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation. Accordingly compounds of the present invention possess higher inhibitory potency against particular non-receptor tyrosine kinases such as p56<sup>lck</sup> tyrosine kinase than against other non-receptor tyrosine kinases or against receptor tyrosine kinases (RTKs) such as epidermal growth factor (EGF) RTK. In general, the quinazoline derivatives of the invention possess sufficient potency in inhibiting non-receptor tyrosine kinases such as p56<sup>lck</sup> tyrosine kinase that they may be used in an amount sufficient to inhibit, for example, p56<sup>lck</sup> tyrosine kinase whilst demonstrating reduced potency, preferably whilst demonstrating no significant activity, against RTKs such as EGF RTK. Thus the quinazoline derivatives of the invention can be used in the clinical management of those particular diseases which are sensitive to inhibition of such non-receptor tyrosine kinases, for example autoimmune diseases or medical conditions, for example T cell mediated disease such as transplant rejection or rheumatoid arthritis.

It is disclosed by K. H. Gibson *et al.*, Bioorganic & Medicinal Chemistry Letters, 1997, 7, 2723-2728 that certain 4-anilinoquinazoline derivatives possess useful EGF RTK inhibitory properties. It is also disclosed that 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea is inactive as an EGF RTK inhibitor.

It is disclosed in International Patent Application WO 98/50370 that certain 5-substituted quinazoline derivatives may be useful as inhibitors of serine/threonine protein kinases. Whilst most of the examples are 4-amino-5-phenoxyquinazolines, there is the disclosure of three 4-ureido-5-phenoxyquinazolines, namely of :-

- 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,
- 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea and
- 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.

It is disclosed by C. I. Hong *et al.*, J. Med. Chem., 1976, 19, 555-558 that certain 4-aminopyrazolo[3,4-*d*]pyrimidine derivatives possess growth inhibitory activity against cultured L1210 leukaemia cells. The disclosed compounds include:-

- 1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,
- 1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,
- 1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,
- 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and


1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea.

It is disclosed in International Patent Application WO 97/03069 that certain quinoline  
5 and quinazoline derivatives may be useful as protein tyrosine kinase inhibitors. All of the  
disclosed examples are 4-heteroarylaminquinazoline derivatives and none of them are  
1-heteroaryl-3-(quinazolin-4-yl)urea derivatives.

It is disclosed in International Patent Application WO 98/43960 that certain  
3-cyanoquinoline derivatives may be useful as protein tyrosine kinase inhibitors. Almost all  
10 of the 398 disclosed examples were 3-cyano-4-anilinoquinoline or  
3-cyano-4-benzylaminoquinoline derivatives. There is no disclosure of any  
(3-cyanoquinolin-4-yl)urea derivatives.



It is disclosed in International Patent Application WO 99/09024 that certain  
1-phenyl-3-(quinolin-4-yl)urea derivatives may be useful as antagonists of the human  
15 HFGAN72 receptor, a G-protein coupled neuropeptide receptor, and hence may be of  
potential use in the treatment of obesity. There is no disclosure as examples of any 1-phenyl-  
3-(quinazolin-4-yl)urea or 1-phenyl-3-(3-cyanoquinolin-4-yl)urea compounds.



According to one aspect of the invention there is provided a quinazoline derivative of  
the Formula I



20

wherein Q<sup>1</sup> is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id





wherein :

$Y^1$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$Y^2$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$m$  is 0, 1, 2, 3 or 4;


each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :

$Q^3 - X^1 -$

wherein  $X^1$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO, CH(OR<sup>7</sup>), CON(R<sup>7</sup>), N(R<sup>7</sup>)CO, SO<sub>2</sub>N(R<sup>7</sup>), N(R<sup>7</sup>)SO<sub>2</sub>, OC(R<sup>7</sup>)<sub>2</sub>, SC(R<sup>7</sup>)<sub>2</sub> and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, wherein R<sup>7</sup> is hydrogen or (1-6C)alkyl, and Q<sup>3</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R<sup>1</sup>)<sub>m</sub> is (1-3C)alkylenedioxy, and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>,


$N(R^8)$ , CO,  $CH(OR^8)$ ,  $CON(R^8)$ ,  $N(R^8)CO$ ,  $SO_2N(R^8)$ ,  $N(R^8)SO_2$ ,  $CH=CH$  and  $C\equiv C$  wherein  $R^8$  is hydrogen or (1-6C)alkyl,

and wherein any  $CH_2=CH-$  or  $HC\equiv C-$  group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein  $X^2$  is a direct bond or is selected from CO and  $N(R^9)CO$ , wherein  $R^9$  is hydrogen or (1-6C)alkyl, and  $Q^4$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^3$  is a direct bond or is selected from O, S, SO,  $SO_2$ ,  $N(R^{10})$ , CO,  $CH(OR^{10})$ ,  $CON(R^{10})$ ,  $N(R^{10})CO$ ,  $SO_2N(R^{10})$ ,  $N(R^{10})SO_2$ ,  $C(R^{10})_2O$ ,  $C(R^{10})_2S$  and  $N(R^{10})C(R^{10})_2$ , wherein  $R^{10}$  is hydrogen or (1-6C)alkyl, and  $Q^5$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,

N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^4$  is a direct bond or is selected from O and N( $R^{12}$ ), wherein  $R^{12}$  is hydrogen or (1-6C)alkyl, and  $R^{11}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl or

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, or from a group of the formula :



wherein  $X^5$  is a direct bond or is selected from O and N( $R^{13}$ ), wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $Q^6$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any  $Q^6$  group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo or thioxo substituents;

$R^2$  is hydrogen or (1-6C)alkyl and  $R^3$  is hydrogen or (1-6C)alkyl, or  $R^2$  and  $R^3$  together form a  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group,

$R^5$  is hydrogen or (1-6C)alkyl, or  $R^5$  and  $R^6$  together with the N atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from O, N and S,

provided that one of the pairs of groups  $R^2$  and  $R^4$  together,  $R^3$  and  $R^4$  together and  $R^5$  and  $R^4$  together forms a bond;

$Q^2$  is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and

$Q^2$  is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl,

(1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, 5 (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :

10 
$$-X^6-R^{14}$$

wherein  $X^6$  is a direct bond or is selected from O and  $N(R^{15})$ , wherein  $R^{15}$  is hydrogen or (1-6C)alkyl, and  $R^{14}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :

15 
$$-X^7-Q^7$$

wherein  $X^7$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>,  $N(R^{16})$ , CO, CH(OR<sup>16</sup>), CON(R<sup>16</sup>),  $N(R^{16})CO$ , SO<sub>2</sub> $N(R^{16})$ ,  $N(R^{16})SO_2$ ,  $C(R^{16})_2O$ ,  $C(R^{16})_2S$  and  $C(R^{16})_2N(R^{16})$ , wherein each  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $Q^2$  is optionally

20 substituted with a (1-3C)alkylenedioxy group,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, 25 (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl- 30 (1-6C)alkanesulphonylamino, or from a group of the formula :

$$-X^8-R^{17}$$

wherein  $X^8$  is a direct bond or is selected from O and  $N(R^{18})$ , wherein  $R^{18}$  is hydrogen or (1-6C)alkyl, and  $R^{17}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on Q<sup>2</sup> optionally bears 1 or 2 oxo or thioxo substituents; and


- 5 R<sup>6</sup> is an optionally substituted group selected from (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl and (3-7C)cycloalkenyl, or R<sup>6</sup> is a substituted (1-6C)alkyl group,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>6</sup> group are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>, N(R<sup>19</sup>), CO, CH(OR<sup>19</sup>), CON(R<sup>19</sup>), N(R<sup>19</sup>)CO, SO<sub>2</sub>N(R<sup>19</sup>), N(R<sup>19</sup>)SO<sub>2</sub>, CH=CH and C≡C

- 10 wherein R<sup>19</sup> is hydrogen or (1-6C)alkyl,

and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a R<sup>6</sup> group optionally bears at the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or

- 15 from a group of the formula :



wherein X<sup>9</sup> is a direct bond or is selected from CO and N(R<sup>20</sup>)CO, wherein R<sup>20</sup> is hydrogen or (1-6C)alkyl, and Q<sup>8</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


- 20 and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> group optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more of the following substituents, provided that the R<sup>6</sup> group when it is (1-6C)alkyl must bear at least one such substituent,

one or more halogeno substituents or a substituent selected from hydroxy, cyano, amidino, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio,

- 25 (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl- (2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, 30 (1-6C)alkoxycarbonylamino, N-(1-6C)alkyl-(1-6C)alkoxycarbonylamino, N-[hydroxy-(2-6C)alkyl]carbamoyl, N-[(1-6C)alkoxy-(2-6C)alkyl]carbamoyl, N-[amino-(2-6C)alkyl]carbamoyl, N-[(1-6C)alkylamino-(2-6C)alkyl]carbamoyl,

N-{di-[(1-6C)alkyl]amino-(2-6C)alkyl}carbamoyl, N,N-di-[hydroxy-(2-6C)alkyl]carbamoyl, N,N-di-[(1-6C)alkoxy-(2-6C)alkyl]carbamoyl, N,N-di-[amino-(2-6C)alkyl]carbamoyl, N,N-di-[(1-6C)alkylamino-(2-6C)alkyl]carbamoyl and N,N-di-{di-[(1-6C)alkyl]amino-(2-6C)alkyl}carbamoyl,

5 or from a group of the formula :



wherein  $X^{10}$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>21</sup>), CO, CH(OR<sup>21</sup>), CON(R<sup>21</sup>), N(R<sup>21</sup>)CO, SO<sub>2</sub>N(R<sup>21</sup>), N(R<sup>21</sup>)SO<sub>2</sub>, C(R<sup>21</sup>)<sub>2</sub>O, C(R<sup>21</sup>)<sub>2</sub>S and N(R<sup>21</sup>)C(R<sup>21</sup>)<sub>2</sub>, wherein R<sup>21</sup> is hydrogen or (1-6C)alkyl, and Q<sup>9</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,

10 (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl,


heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a R<sup>6</sup> group, or any heterocyclic group formed when R<sup>5</sup> and R<sup>6</sup> together with the N atom to which they are attached form a ring, optionally bears 1, 2 or 3 substituents, which may be the same or

15 different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,

20 N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,

N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^{11}$  is a direct bond or is selected from O and N(R<sup>23</sup>), wherein R<sup>23</sup> is hydrogen or 25 (1-6C)alkyl, and R<sup>22</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl or

N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, or from a group of the formula :

30  $-X^{12}-Q^{10}$

wherein  $X^{12}$  is a direct bond or is selected from O and N(R<sup>24</sup>), wherein R<sup>24</sup> is hydrogen or (1-6C)alkyl, and Q<sup>10</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl

or heterocyclyl-(1-6C)alkyl, and any  $Q^{10}$  group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a  $R^6$  group, or the heterocyclic group formed when  $R^5$  and  $R^6$  together with the N atom to which they are attached form a ring, optionally bears 1 or 2 oxo or thioxo substituents;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.


According to a further aspect of the invention, there is provided a quinazoline derivative of the Formula I as disclosed hereinbefore wherein  $Q^1$  is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id as disclosed hereinbefore wherein :

$Y^1$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$Y^2$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$m$  is 0, 1, 2, 3 or 4;


each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  $N$ -(1-6C)alkylcarbamoyl,  $N,N$ -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  $N$ -(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino,  $N$ -(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,  $N$ -(1-6C)alkyl-(3-6C)alkynoylamino, (1-6C)alkanesulphonylamino and  $N,N$ -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and  $N$ -(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^1$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>,  $N(R^7)$ , CO,  $CH(OR^7)$ ,  $CON(R^7)$ ,  $N(R^7)CO$ ,  $SO_2N(R^7)$ ,  $N(R^7)SO_2$ ,  $OC(R^7)_2$ ,  $SC(R^7)_2$  and  $N(R^7)C(R^7)_2$ , wherein  $R^7$  is hydrogen or (1-6C)alkyl, and  $Q^3$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $(R^1)_m$  is (1-3C)alkylenedioxy,


and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO,  $SO_2$ ,  $N(R^8)$ , CO,  $CH(OR^8)$ ,  $CON(R^8)$ ,  $N(R^8)CO$ ,  $SO_2N(R^8)$ ,  $N(R^8)SO_2$ ,  $CH=CH$  and  $C\equiv C$  wherein  $R^8$  is hydrogen or (1-6C)alkyl,

5 and wherein any  $CH_2=CH-$  or  $HC\equiv C-$  group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl,  $N$ -(1-6C)alkylcarbamoyl,  $N,N$ -di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



10 wherein  $X^2$  is a direct bond or is selected from CO and  $N(R^9)CO$ , wherein  $R^9$  is hydrogen or (1-6C)alkyl, and  $Q^4$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each  
15 said  $CH_2$  or  $CH_3$  group one or more halogeno substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  $N$ -(1-6C)alkylcarbamoyl,  $N,N$ -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  $N$ -(1-6C)alkyl-  
20 (2-6C)alkanoylamino,  $N$ -(1-6C)alkylsulphamoyl,  $N,N$ -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and  $N$ -(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein  $X^3$  is a direct bond or is selected from O, S, SO,  $SO_2$ ,  $N(R^{10})$ , CO,  $CH(OR^{10})$ ,  
25  $CON(R^{10})$ ,  $N(R^{10})CO$ ,  $SO_2N(R^{10})$ ,  $N(R^{10})SO_2$ ,  $C(R^{10})_2O$ ,  $C(R^{10})_2S$  and  $N(R^{10})C(R^{10})_2$ , wherein  $R^{10}$  is hydrogen or (1-6C)alkyl, and  $Q^5$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $R^1$   
30 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,

(1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, 5 N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^4$  is a direct bond or is selected from O and N( $R^{12}$ ), wherein  $R^{12}$  is hydrogen or (1-6C)alkyl, and  $R^{11}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, 10 cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl or N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, or from a group of the formula :



15 wherein  $X^5$  is a direct bond or is selected from O and N( $R^{13}$ ), wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $Q^6$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any  $Q^6$  group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 20 oxo or thioxo substituents;


$R^2$  is hydrogen or (1-6C)alkyl and  $R^3$  is hydrogen or (1-6C)alkyl, or  $R^2$  and  $R^3$  together form a  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group,

$R^5$  is hydrogen or (1-6C)alkyl, or  $R^5$  and  $R^6$  together with the N atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally containing a further heteroatom 25 selected from O, N and S,


provided that one of the pairs of groups  $R^2$  and  $R^4$  together,  $R^3$  and  $R^4$  together and  $R^5$  and  $R^4$  together forms a bond;

$Q^2$  is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each 30 heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and

Q<sup>2</sup> is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, 5 N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, 10 N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein X<sup>6</sup> is a direct bond or is selected from O and N(R<sup>15</sup>), wherein R<sup>15</sup> is hydrogen or (1-6C)alkyl, and R<sup>14</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, 15 cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



wherein X<sup>7</sup> is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>16</sup>), CO, CH(OR<sup>16</sup>), CON(R<sup>16</sup>), N(R<sup>16</sup>)CO, SO<sub>2</sub>N(R<sup>16</sup>), N(R<sup>16</sup>)SO<sub>2</sub>, C(R<sup>16</sup>)<sub>2</sub>O, C(R<sup>16</sup>)<sub>2</sub>S and C(R<sup>16</sup>)<sub>2</sub>N(R<sup>16</sup>), 20 wherein each R<sup>16</sup> is hydrogen or (1-6C)alkyl, and Q<sup>7</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or Q<sup>2</sup> is optionally substituted with a (1-3C)alkylenedioxy group,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on Q<sup>2</sup> optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from 25 halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, 30 N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein  $X^8$  is a direct bond or is selected from O and  $N(R^{18})$ , wherein  $R^{18}$  is hydrogen or (1-6C)alkyl, and  $R^{17}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

- 5 and wherein any heterocyclyl group within a substituent on  $Q^2$  optionally bears 1 or 2 oxo or thioxo substituents; and

$R^6$  is an optionally substituted group selected from (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl and (3-7C)cycloalkenyl, or  $R^6$  is a substituted (1-6C)alkyl group,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^6$  group are  
 10 optionally separated by the insertion into the chain of a group selected from O, S, SO,  $SO_2$ ,  $N(R^{19})$ , CO,  $CH(OR^{19})$ ,  $CON(R^{19})$ ,  $N(R^{19})CO$ ,  $SO_2N(R^{19})$ ,  $N(R^{19})SO_2$ ,  $CH=CH$  and  $C\equiv C$  wherein  $R^{19}$  is hydrogen or (1-6C)alkyl,

- and wherein any  $CH_2=CH-$  or  $HC\equiv C-$  group within a  $R^6$  group optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from halogeno, carboxy, carbamoyl,  
 15 (1-6C)alkoxycarbonyl,  $\underline{N}$ -(1-6C)alkylcarbamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :




- wherein  $X^9$  is a direct bond or is selected from CO and  $N(R^{20})CO$ , wherein  $R^{20}$  is hydrogen or  
 20 (1-6C)alkyl, and  $Q^8$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^6$  group optionally bears on each said  $CH_2$  or  $CH_3$  group one or more of the following substituents, provided that the  $R^6$  group when it is (1-6C)alkyl must bear at least one such substituent,


- 25 one or more halogeno substituents or a substituent selected from hydroxy, cyano, amidino, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  $\underline{N}$ -(1-6C)alkylcarbamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  $\underline{N}$ -(1-6C)alkyl-  
 30 (2-6C)alkanoylamino,  $\underline{N}$ -(1-6C)alkylsulphamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  $\underline{N}$ -(1-6C)alkyl-(1-6C)alkanesulphonylamino,

(1-6C)alkoxycarbonylamino and N-(1-6C)alkyl-(1-6C)alkoxycarbonylamino, or from a group of the formula :




wherein  $X^{10}$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>21</sup>), CO, CH(OR<sup>21</sup>),  
 5 CON(R<sup>21</sup>), N(R<sup>21</sup>)CO, SO<sub>2</sub>N(R<sup>21</sup>), N(R<sup>21</sup>)SO<sub>2</sub>, C(R<sup>21</sup>)<sub>2</sub>O, C(R<sup>21</sup>)<sub>2</sub>S and N(R<sup>21</sup>)C(R<sup>21</sup>)<sub>2</sub>,  
 wherein R<sup>21</sup> is hydrogen or (1-6C)alkyl, and Q<sup>9</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,  
 (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl,  
 heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a R<sup>6</sup> group, or any  
 10 heterocyclic group formed when R<sup>5</sup> and R<sup>6</sup> together with the N atom to which they are  
 attached form a ring, optionally bears 1, 2 or 3 substituents, which may be the same or  
 different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy,  
 carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,  
 (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,  
 15 (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,  
N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  
N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,  
N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-  
 (1-6C)alkanesulphonylamino, or from a group of the formula :



20

wherein  $X^{11}$  is a direct bond or is selected from O and N(R<sup>23</sup>), wherein R<sup>23</sup> is hydrogen or  
 (1-6C)alkyl, and R<sup>22</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,  
 cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-  
 (1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl,  
 25 carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl or  
N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, or from a group of the formula :




wherein  $X^{12}$  is a direct bond or is selected from O and N(R<sup>24</sup>), wherein R<sup>24</sup> is hydrogen or  
 (1-6C)alkyl, and Q<sup>10</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl  
 30 or heterocyclyl-(1-6C)alkyl, and any Q<sup>10</sup> group optionally bears 1 or 2 substituents, which may  
 be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a R<sup>6</sup> group, or the heterocyclic group formed when R<sup>5</sup> and R<sup>6</sup> together with the N atom to which they are attached form a ring, optionally bears 1 or 2 oxo or thioxo substituents;  
or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

5 In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight-chain version only and references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched-chain version only. An analogous convention applies to other generic terms.

10 It is to be understood that the compounds of Formula I defined above may exhibit the phenomenon of tautomerism. In particular, tautomerism may affect the guanidino group formed when one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond. For example, when each of R<sup>2</sup> and R<sup>3</sup> is hydrogen and R<sup>5</sup> and R<sup>4</sup> together form a bond, the generic structure of Formula I becomes the first of the three  
15 structures shown below and tautomeric equilibrium may give rise to the other two structures.



It is to be understood that the present invention includes in its definition any such tautomeric form, or a mixture thereof, which possesses the above-mentioned activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings or named in  
20 the Examples.

It is to be understood that, insofar as certain of the compounds of Formula I defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the above-mentioned activity. The synthesis of optically active forms may be  
25 carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

It is to be understood that the hydrogen atom which is shown at the 2-position in each of the part structures of the formulae Ia, Ib, Ic and Id indicates that that position remains unsubstituted by any R<sup>1</sup> group.

Suitable values for the generic radicals referred to above include those set out below.

- 5 A suitable value for any one of the 'Q' groups (Q<sup>2</sup> to Q<sup>10</sup>) when it is aryl or for the aryl group within a 'Q' group is, for example, phenyl or naphthyl, preferably phenyl.

- A suitable value for a (3-7C)cycloalkyl group within Q<sup>2</sup> or for Q<sup>3</sup>, Q<sup>5</sup>, Q<sup>9</sup> or R<sup>6</sup> when it is (3-7C)cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl and a suitable value for Q<sup>3</sup>, Q<sup>5</sup>, Q<sup>9</sup> or R<sup>6</sup> when it is  
10 (3-7C)cycloalkenyl is, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.

- A suitable value for Q<sup>2</sup> when it is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur is, for example,  
15 pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, indolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl, preferably isoxazolyl, 1,2,3-triazolyl, pyridyl, benzothiazolyl, quinolyl or quinazolinyl.

- 20 A suitable value for any one of the 'Q' groups, Q<sup>3</sup> to Q<sup>10</sup>, when it is heteroaryl or for the heteroaryl group within a 'Q' group is, for example, an aromatic 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring with up to five ring heteroatoms selected from oxygen, nitrogen and sulphur, for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl,  
25 tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl, preferably thienyl, 1,2,3-triazolyl, pyridyl, quinolyl, quinazolinyl or quinoxalinyl.

- A suitable value for any one of the 'Q' groups, Q<sup>3</sup> to Q<sup>10</sup>, when it is heterocyclyl or for  
30 the heterocyclyl group within a 'Q' group is, for example, a non-aromatic saturated or partially saturated 3 to 10 membered monocyclic or bicyclic ring with up to five heteroatoms selected from oxygen, nitrogen and sulphur, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolinyl, pyrrolidinyl, 1,4-dioxanyl, morpholinyl,

tetrahydro-1,4-thiazinyl, 1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl, or a benzo derivative thereof such as 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indolinyl, chromanyl, 1,4-benzodioxanyl and

5 1,2,3,4-tetrahydroquinolinyl. Preferably any one of the 'Q' groups, Q<sup>3</sup> to Q<sup>10</sup>, when it is heterocyclyl or for the heterocyclyl group within a 'Q' group is, for example, pyrrolidin-1-yl, pyrrolidin-2-yl, 1,4-dioxan-2-yl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperazin-1-yl or homopiperazin-1-yl. A suitable value for such a group which bears 1 or 2 oxo or thioxo

10 substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.

A suitable value for the heterocyclyl ring formed when R<sup>5</sup> and R<sup>6</sup> together with the N atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally

15 containing a further heteroatom selected from O, N and S is, for example, pyrrolin-1-yl, pyrrolidin-1-yl, morpholino, tetrahydro-4H-1,4-thiazin-4-yl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, homopiperidin-1-yl, piperazin-1-yl or homopiperazin-1-yl.

A suitable value for a 'Q' group when it is heteroaryl-(1-6C)alkyl is, for example, heteroarylmethyl, 2-heteroarylethyl and 3-heteroarylpropyl. The invention comprises

20 corresponding suitable values for 'Q' groups when, for example, rather than a heteroaryl-(1-6C)alkyl group, an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group is present.

When, as defined hereinbefore, Y<sup>1</sup> together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3

25 heteroatoms selected from O, N and S, ring Y<sup>1</sup> is suitably unsaturated or partially unsaturated wherein a -CH<sub>2</sub>- group can optionally be replaced by a -CO- group and a ring nitrogen atom may optionally bear a (1-6C)alkyl group. Diradicals of suitable fused Y<sup>1</sup> rings include thiendiyl, furandiyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, 1,2,3-oxadiazole-diyl, 1,2,3-triazole-diyl, pyridinediyl, pyrimidinediyl,

30 pyrazinediyl, pyridazinediyl and 1,3,4-triazinediyl. Examples of suitable bicyclic rings of formula Ic formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring include furopyrimidinyl, thienopyrimidinyl, purinyl, pyrrolopyrimidinyl, pyrrolinopyrimidinyl, oxopyrrolinopyrimidinyl, oxazolopyrimidinyl, oxazolinopyrimidinyl,

oxooxazolinopyrimidinyl, isoxazolopyrimidinyl, thiazolopyrimidinyl, thiazolinopyrimidinyl, oxothiazolinopyrimidinyl, isothiazolopyrimidinyl, oxoimidazolinopyrimidinyl, pyrazolopyrimidinyl, pyrazolinopyrimidinyl, oxopyrazolinopyrimidinyl, pyridopyrimidinyl, pyrimidopyrimidinyl and pteridinyl. Preferably the bicyclic ring of formula Ic is

5 furo[3,2-*d*]pyrimidinyl, furo[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, purinyl, pyrrolo[3,2-*d*]pyrimidinyl, pyrrolo[2,3-*d*]pyrimidinyl, oxazolo[5,4-*d*]pyrimidinyl, oxazolo[4,5-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, thiazolo[4,5-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl, pyrimido[4,5-*d*]pyrimidinyl,

10 pyrimido[5,6-*d*]pyrimidinyl or pteridinyl. More specifically the bicyclic ring of formula Ic is 6-oxopyrrolino[2,3-*d*]pyrimidin-4-yl, 6-oxopyrrolino[3,2-*d*]pyrimidin-4-yl, 2-oxooxazolino[5,4-*d*]pyrimidin-7-yl, 2-oxothiazolino[5,4-*d*]pyrimidin-7-yl, 2-oxooxazolino[4,5-*d*]pyrimidin-7-yl, 2-oxothiazolino[4,5-*d*]pyrimidin-7-yl, 2-oxoimidazolino[4,5-*d*]pyrimidin-7-yl, 3-oxopyrazolino[3,4-*d*]pyrimidin-4-yl or

15 3-oxopyrazolino[4,3-*d*]pyrimidin-7-yl. Further preferred bicyclic rings of formula Ic include thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, 6-purinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl and pteridinyl, more specifically thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, pyrido[2,3-*d*]pyrimidin-4-yl,

20 pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl, pyrido[3,2-*d*]pyrimidin-4-yl and pteridin-4-yl.

When, as defined hereinbefore, Y<sup>2</sup> together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S, ring Y<sup>2</sup> is suitably unsaturated or partially unsaturated

25 wherein a -CH<sub>2</sub>- group can optionally be replaced by a -CO- group and a ring nitrogen atom may optionally bear a (1-6C)alkyl group. Diradicals of suitable fused Y<sup>2</sup> rings include thiendiyl, furandiyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, 1,2,3-oxadiazole-diyl, 1,2,3-triazole-diyl, pyridinediyl, pyrimidinediyl, pyrazinediyl, pyridazinediyl and 1,3,4-triazinediyl. Examples of suitable tricyclic rings of

30 formula Id formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include imidazoquinazolinyl, oxazoloquinazolinyl, thiazoloquinazolinyl, [1,2,3]triazoloquinazolinyl, pyrazoloquinazolinyl, pyrroloquinazolinyl, oxoimidazolinoquinazolinyl, oxooxazolinoquinazolinyl, oxothiazolinoquinazolinyl and oxopyrazolinoquinazolinyl.

- Preferably the tricyclic ring of formula Id is 3H-imidazo[4,5-g]quinazolinyl, oxazolo[4,5-g]quinazolinyl, thiazolo[4,5-g]quinazolinyl, 3H-[1,2,3]triazolo[4,5-g]quinazolinyl, 1H-pyrazolo[3,4-g]quinazolinyl, 6H-pyrrolo[2,3-g]quinazolinyl, 2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolinyl, 2-oxo-1,2-dihydrooxazolo[4,5-g]quinazolinyl, 2-oxo-1,2-dihydrothiazolo[4,5-g]quinazolinyl, 3-oxo-2,3-dihydro-1H-pyrazolo[3,4-g]quinazolinyl, pyrido[2,3-g]quinazolinyl, pyrimidino[4,5-g]cinnolinyl, pyrimidino[4,5-g]quinazolinyl, pyrazino[2,3-g]quinazolinyl, 7-oxo-6,7-dihydropyrido[2,3-g]quinazolinyl, pyrazino[2,3-g]quinazolinyl and 8-oxo-8,9-dihydropyrazino[2,3-g]quinazolinyl. More specifically the tricyclic ring of formula Id is 3H-imidazo[4,5-g]quinazolin-8-yl, oxazolo[4,5-g]quinazolin-8-yl, thiazolo[4,5-g]quinazolin-8-yl, 3H-[1,2,3]triazolo[4,5-g]quinazolin-8-yl, 1H-pyrazolo[3,4-g]quinazolin-8-yl, 6H-pyrrolo[2,3-g]quinazolin-4-yl, 2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolin-8-yl, 2-oxo-1,2-dihydrooxazolo[4,5-g]quinazolin-8-yl, 2-oxo-1,2-dihydrothiazolo[4,5-g]quinazolin-8-yl, 3-oxo-2,3-dihydro-1H-pyrazolo[3,4-g]quinazolin-8-yl, pyrido[2,3-g]quinazolin-4-yl, pyrimidino[4,5-g]cinnolin-9-yl, pyrimidino[4,5-g]quinazolin-4-yl, pyrazino[2,3-g]quinazolin-4-yl, 7-oxo-6,7-dihydropyrido[2,3-g]quinazolin-4-yl, pyrazino[2,3-g]quinazolin-4-yl or 8-oxo-8,9-dihydropyrazino[2,3-g]quinazolin-4-yl. Further preferred tricyclic rings of formula Id include 3-methyl-3H-imidazo[4,5-g]quinazolin-8-yl, 3-methyl-3H-[1,2,3]triazolo[4,5-g]quinazolin-8-yl, 3-methyl-2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolin-8-yl, pyrazino[2,3-g]quinazolin-4-yl and 9-methyl-8-oxo-8,9-dihydropyrazino[2,3-g]quinazolin-4-yl.

Suitable values for any of the 'R' groups ( $R^1$  to  $R^{24}$ ), or for various groups within an  $R^1$  substituent, or within a substituent on  $R^6$  or  $Q^2$  include:-

- |                           |  |
|---------------------------|--|
| 25 for halogeno           | fluoro, chloro, bromo and iodo;                          |
| for (1-6C)alkyl:          | methyl, ethyl, propyl, isopropyl and <u>tert</u> -butyl; |
| for (2-8C)alkenyl:        | vinyl, allyl and but-2-enyl;                             |
| for (2-8C)alkynyl:        | ethynyl, 2-propynyl and but-2-ynyl;                      |
| for (1-6C)alkoxy:         | methoxy, ethoxy, propoxy, isopropoxy and butoxy;         |
| 30 for (2-6C)alkenyloxy:  | vinylloxy and allyloxy;                                  |
| for (2-6C)alkynyloxy:     | ethynyloxy and 2-propynyloxy;                            |
| for (1-6C)alkylthio:      | methylthio, ethylthio and propylthio;                    |
| for (1-6C)alkylsulphinyl: | methylsulphinyl and ethylsulphinyl;                      |

- for (1-6C)alkylsulphonyl: methylsulphonyl and ethylsulphonyl;  
 for (1-6C)alkylamino: methylamino, ethylamino, propylamino,  
 isopropylamino and butylamino;  
 for di-[(1-6C)alkyl]amino: dimethylamino, diethylamino, N-ethyl-  
 5 N-methylamino and diisopropylamino;  
 for (1-6C)alkoxycarbonyl: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl  
 and tert-butoxycarbonyl;  
 for N-(1-6C)alkylcarbamoyl: N-methylcarbamoyl, N-ethylcarbamoyl and  
N-propylcarbamoyl;  
 10 for N,N-di-[(1-6C)alkyl]carbamoyl: N,N-dimethylcarbamoyl, N-ethyl-  
N-methylcarbamoyl and N,N-diethylcarbamoyl;  
 for (2-6C)alkanoyl: acetyl and propionyl;  
 for (2-6C)alkanoyloxy: acetoxy and propionyloxy;  
 for (2-6C)alkanoylamino: acetamido and propionamido;  
 15 for N-(1-6C)alkyl-(2-6C)alkanoylamino: N-methylacetamido and N-methylpropionamido;  
 for N-(1-6C)alkylsulphamoyl: N-methylsulphamoyl and N-ethylsulphamoyl;  
 for N,N-di-[(1-6C)alkyl]sulphamoyl: N,N-dimethylsulphamoyl;  
 for (1-6C)alkanesulphonylamino: methanesulphonylamino and ethanesulphonylamino;  
 for N-(1-6C)alkyl-(1-6C)alkanesulphonylamino: N-methylmethanesulphonylamino and  
 20 N-methylethanesulphonylamino;  
 for (3-6C)alkenoylamino: acrylamido, methacrylamido and crotonamido;  
 for N-(1-6C)alkyl-(3-6C)alkenoylamino: N-methylacrylamido and N-methylcrotonamido;  
 for (3-6C)alkynoylamino: propiolamido;  
 for N-(1-6C)alkyl-(3-6C)alkynoylamino: N-methylpropiolamido;  
 25 for (1-6C)alkoxycarbonylamino: methoxycarbonylamino, ethoxycarbonylamino and  
tert-butoxycarbonylamino;  
 for N-(1-6C)alkyl-(1-6C)alkoxycarbonylamino: N-methylmethoxycarbonylamino,  
N-methylethoxycarbonylamino and N-methyl-  
tert-butoxycarbonylamino;  
 30 for N-[hydroxy-(2-6C)alkyl]carbamoyl: N-(2-hydroxyethyl)carbamoyl and  
N-(3-hydroxypropyl)carbamoyl;  
 for N-[(1-6C)alkoxy-(2-6C)alkyl]carbamoyl: N-(2-methoxyethyl)carbamoyl and  
N-(3-methoxypropyl)carbamoyl;

- for N-[amino-(2-6C)alkyl]carbamoyl: N-(2-aminoethyl)carbamoyl and  
N-(3-aminopropyl)carbamoyl;
- for N-[(1-6C)alkylamino-(2-6C)alkyl]carbamoyl: N-(2-methylaminoethyl)carbamoyl and  
N-(3-methylaminopropyl)carbamoyl;
- 5 for N-{di-[(1-6C)alkyl]amino-(2-6C)alkyl}carbamoyl:  
N-(2-dimethylaminoethyl)carbamoyl and  
N-(3-dimethylaminopropyl)carbamoyl;
- for N,N-di-[hydroxy-(2-6C)alkyl]carbamoyl: N,N-di-(2-hydroxyethyl)carbamoyl and  
N,N-di-(3-hydroxypropyl)carbamoyl;
- 10 for N,N-di-[(1-6C)alkoxy-(2-6C)alkyl]carbamoyl: N,N-di-(2-methoxyethyl)carbamoyl and  
N,N-di-(3-methoxypropyl)carbamoyl;
- for N,N-di-[amino-(2-6C)alkyl]carbamoyl: N,N-di-(2-aminoethyl)carbamoyl and  
N,N-di-(3-aminopropyl)carbamoyl;
- for N,N-di-[(1-6C)alkylamino-(2-6C)alkyl]carbamoyl:  
15 N,N-di-(2-methylaminoethyl)carbamoyl and  
N,N-di-(3-methylaminopropyl)carbamoyl;
- for N,N-di-{di-[(1-6C)alkyl]amino-(2-6C)alkyl}carbamoyl:  
N,N-di-(2-dimethylaminoethyl)carbamoyl and  
N,N-di-(3-dimethylaminopropyl)carbamoyl;
- 20 for amino-(1-6C)alkyl: aminomethyl, 2-aminoethyl, 1-aminoethyl and  
3-aminopropyl;
- for (1-6C)alkylamino-(1-6C)alkyl: methylaminomethyl, ethylaminomethyl,  
1-methylaminoethyl, 2-methylaminoethyl,  
2-ethylaminoethyl and 3-methylaminopropyl;
- 25 for di-[(1-6C)alkyl]amino-(1-6C)alkyl: dimethylaminomethyl, diethylaminomethyl,  
1-dimethylaminoethyl, 2-dimethylaminoethyl and  
3-dimethylaminopropyl;
- for halogeno-(1-6C)alkyl: chloromethyl, 2-chloroethyl, 1-chloroethyl and  
3-chloropropyl;
- 30 for hydroxy-(1-6C)alkyl: hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl and  
3-hydroxypropyl;
- for (1-6C)alkoxy-(1-6C)alkyl: methoxymethyl, ethoxymethyl, 1-methoxyethyl,  
2-methoxyethyl, 2-ethoxyethyl and

- 24 -

- 3-methoxypropyl;  
 for cyano-(1-6C)alkyl: cyanomethyl, 2-cyanoethyl, 1-cyanoethyl and  
 3-cyanopropyl;  
 for (2-6C)alkanoylamino-(1-6C)alkyl: acetamidomethyl, propionamidomethyl and  
 5 2-acetamidoethyl;  
 for (1-6C)alkoxycarbonylamino-(1-6C)alkyl: methoxycarbonylaminomethyl,  
 ethoxycarbonylaminomethyl,  
tert-butoxycarbonylaminomethyl and  
 2-methoxycarbonylaminoethyl;  
 10 for carbamoyl-(1-6C)alkyl: carbamoylmethyl and 2-carbamoylethyl;  
 for N-(1-6C)alkylcarbamoyl-(1-6C)alkyl: N-methylcarbamoylmethyl,  
N-ethylcarbamoylmethyl and  
 2-(N-methylcarbamoyl)ethyl;  
 for N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl: N,N-dimethylcarbamoylmethyl,  
 15 N-ethyl-N-methylcarbamoylmethyl,  
N,N-diethylcarbamoylmethyl and  
 2-(N,N-dimethylcarbamoyl)ethyl.

A suitable value for  $(R^1)_m$  or for a substituent on  $Q^2$  when it is (1-3C)alkylenedioxy is,  
 for example, methylenedioxy or ethylenedioxy and the oxygen atoms thereof occupy adjacent  
 20 ring positions.

When, as defined hereinbefore, an  $R^1$  group forms a group of the formula  $Q^3-X^1$ - and,  
 for example,  $X^1$  is a  $OC(R^7)_2$  linking group, it is the carbon atom, not the oxygen atom, of the  
 $OC(R^7)_2$  linking group which is attached to the quinazoline-like ring such as the ring of  
 formula Ia and the oxygen atom is attached to the  $Q^3$  group. Similarly, when, for example a  
 25  $CH_3$  group within a  $R^1$  substituent bears a group of the formula  $-X^3-Q^5$  and, for example,  $X^3$  is  
 a  $C(R^{10})_2O$  linking group, it is the carbon atom, not the oxygen atom, of the  $C(R^{10})_2O$  linking  
 group which is attached to the  $CH_3$  group and the oxygen atom is linked to the  $Q^5$  group. A  
 similar convention applies to the attachment of the groups of the formulae  $Q^4-X^2$ -,  $-X^7-Q^7$  and  
 $-X^{10}-Q^9$ .

30 As defined hereinbefore, adjacent carbon atoms in any (2-6C)alkylene chain within a  
 $R^1$  substituent or a  $R^6$  group may be optionally separated by the insertion into the chain of a  
 group such as O,  $CON(R^5)$  or  $C\equiv C$ . For example, insertion of a  $C\equiv C$  group into the ethylene

chain within a 2-morpholinoethoxy group gives rise to a 4-morpholinobut-2-ynyloxy group and, for example, insertion of a CONH group into the ethylene chain within a 3-methoxypropoxy group gives rise to, for example, a 2-(2-methoxyacetamido)ethoxy group.

When, as defined hereinbefore, any  $\text{CH}_2=\text{CH}-$  or  $\text{HC}\equiv\text{C}-$  group within a  $\text{R}^1$  substituent optionally bears at the terminal  $\text{CH}_2=$  or  $\text{HC}\equiv$  position a substituent such as a group of the formula  $\text{Q}^4-\text{X}^2$  - wherein  $\text{X}^2$  is, for example, NHCO and  $\text{Q}^4$  is a heterocyclyl-(1-6C)alkyl group, suitable  $\text{R}^1$  substituents so formed include, for example, N-(heterocyclyl-(1-6C)alkyl)carbamoylvinyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylvinyl or N-(heterocyclyl-(1-6C)alkyl)carbamoylethynyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylethynyl. Similar suitable values are applicable to any such substituted  $\text{CH}_2=\text{CH}-$  or  $\text{HC}\equiv\text{C}-$  group within a  $\text{R}^6$  group.

When, as defined hereinbefore, any  $\text{CH}_2$  or  $\text{CH}_3$  group within a  $\text{R}^1$  substituent or a  $\text{R}^6$  group bears on each said  $\text{CH}_2$  or  $\text{CH}_3$  group one or more halogeno substituents, there are suitably 1 or 2 halogeno substituents present on each said  $\text{CH}_2$  group and there are suitably 1, 2 or 3 halogeno substituents present on each said  $\text{CH}_3$  group.


When, as defined hereinbefore, any  $\text{CH}_2$  or  $\text{CH}_3$  group within a  $\text{R}^1$  substituent or a  $\text{R}^6$  group bears on each said  $\text{CH}_2$  or  $\text{CH}_3$  group a substituent as defined hereinbefore, suitable  $\text{R}^1$  substituents or  $\text{R}^6$  groups so formed include, for example, hydroxy-substituted heterocyclyl-(1-6C)alkoxy groups such as 2-hydroxy-3-piperidinopropoxy and 2-hydroxy-3-morpholinopropoxy, hydroxy-substituted amino-(2-6C)alkoxy groups such as 3-amino-2-hydroxypropoxy, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkoxy groups such as 2-hydroxy-3-methylaminopropoxy, hydroxy-substituted di-[(1-6C)alkyl]amino-(2-6C)alkoxy groups such as 3-dimethylamino-2-hydroxypropoxy, hydroxy-substituted heterocyclyl-(1-6C)alkylamino groups such as 2-hydroxy-3-piperidinopropylamino and 2-hydroxy-3-morpholinopropylamino, hydroxy-substituted amino-(2-6C)alkylamino groups such as 3-amino-2-hydroxypropylamino, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkylamino groups such as 2-hydroxy-3-methylaminopropylamino, hydroxy-substituted di-[(1-6C)alkyl]amino-(2-6C)alkylamino groups such as 3-dimethylamino-2-hydroxypropylamino, hydroxy-substituted (1-6C)alkyl groups such as 2-hydroxyethyl and 2,3-dihydroxypropyl, hydroxy-substituted (1-6C)alkoxy groups such as 2-hydroxyethoxy and 2,3-dihydroxypropoxy, (1-6C)alkoxy-substituted (1-6C)alkyl groups such as 2-methoxyethyl and 3-ethoxypropyl, (1-6C)alkoxy-substituted (1-6C)alkoxy groups such as 2-methoxyethoxy.

and 3-ethoxypropoxy, di-[(1-6C)alkyl]amino-(2-6C)alkyl groups such as  
 2-dimethylaminoethyl and 3-dimethylaminopropyl, (1-6C)alkylsulphonyl-substituted  
 (1-6C)alkyl groups such as 2-methylsulphonylethyl, (1-6C)alkylsulphonyl-substituted  
 (1-6C)alkoxy groups such as 2-methylsulphonylethoxy, hydroxy-substituted (3-7C)cycloalkyl  
 5 groups such as 4-hydroxycyclohexyl and heterocyclyl-substituted (1-6C)alkylamino-  
 (1-6C)alkyl groups such as 2-morpholinoethylaminomethyl,  
 2-piperazin-1-ylethylaminomethyl and 3-morpholinopropylaminomethyl.

A suitable pharmaceutically-acceptable salt of a compound of the Formula I is, for  
 example, an acid-addition salt of a compound of the Formula I, for example an acid-addition  
 10 salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric,  
 trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the Formula I  
 which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a  
 calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as  
 methylamine, dimethylamine, trimethylamine, piperidine, morpholine or  
 15 tris-(2-hydroxyethyl)amine.

Particular novel compounds of the invention include, for example,


(i) quinazoline derivatives of the Formula II



II

wherein each of m, R¹, R², R³, R⁴, R⁵, R⁶ and Q² has any of the meanings defined  
 20 hereinbefore;


(ii) quinoline derivatives of the Formula III



III

wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $Q^2$  has any of the meanings defined hereinbefore;

(iii) pyrimidine derivatives of the Formula IV




IV

5

wherein each of  $m$ ,  $R^1$ ,  $Y^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $Q^2$  has any of the meanings defined hereinbefore; and

(iv) quinazoline derivatives of the Formula V



V

wherein each of  $m$ ,  $R^1$ ,  $Y^2$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $Q^2$  has any of the meanings defined hereinbefore.

Subject to the provisos described hereinbefore, further particular novel compounds of the invention include, for example, quinazoline derivatives of the Formula II, or  
 5 pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $Q^2$  has any of the meanings defined hereinbefore or in paragraphs (a) to (j) hereinafter :-

- (a)  $m$  is 1, 2 or 3, and each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl,  
 10 (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino and N-(1-6C)alkyl-(3-6C)alkynoylamino, or from a group of the formula :




wherein  $X^1$  is a direct bond or is selected from O,  $N(R^7)$ ,  $CON(R^7)$ ,  $N(R^7)CO$  and  $OC(R^7)_2$  wherein  $R^7$  is hydrogen or (1-6C)alkyl, and  $Q^3$  is aryl, aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent  
 20 are optionally separated by the insertion into the chain of a group selected from O,  $N(R^8)$ ,  $CON(R^8)$ ,  $N(R^8)CO$ ,  $CH=CH$  and  $C\equiv C$  wherein  $R^8$  is hydrogen or (1-6C)alkyl,

and wherein any  $CH_2=CH-$  or  $HC\equiv C-$  group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from carbamoyl,


- N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,  
 25 (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein  $X^2$  is a direct bond or is CO or  $N(R^9)CO$ , wherein  $R^9$  is hydrogen or (1-6C)alkyl, and  $Q^4$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- 30 and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group a substituent selected from hydroxy, amino, (1-6C)alkoxy,

(1-6C)alkylsulphonyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino, or from a group of the formula :



wherein  $X^3$  is a direct bond or is selected from O,  $N(R^{10})$ ,  $CON(R^{10})$ ,  $N(R^{10})CO$  and  $C(R^{10})_2O$ , wherein  $R^{10}$  is hydrogen or (1-6C)alkyl, and  $Q^5$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy,

15  $N$ -(1-6C)alkylcarbamoyl,  $N,N$ -di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl and (1-6C)alkoxycarbonylamino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo substituents;

15 (b)  $m$  is 1, 2 or 3, and each  $R^1$  group, which may be the same or different, is selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, dipropylamino,  $N$ -methylcarbamoyl,  $N,N$ -dimethylcarbamoyl, acetamido, propionamido, acrylamido and propiolamido, or from a group of the formula :




wherein  $X^1$  is a direct bond or is selected from O, NH, CONH, NHCO and  $OCH_2$  and  $Q^3$  is phenyl, benzyl, cyclopropylmethyl, thienyl, 1-imidazolyl, 1,2,3-triazolyl, pyridyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino,

25 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperazin-1-yl, homopiperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 30 piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent are optionally separated by the insertion into the chain of a group selected from O, NH, CONH, NHCO, CH=CH and C≡C,

and wherein any  $CH_2=CH-$  or  $HC≡C-$  group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC≡$  position a substituent selected from carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl or 4-dimethylaminobutyl, or from a group of the formula :



wherein  $X^2$  is a direct bond or is CO, NHCO or N(Me)CO and  $Q^4$  is pyridyl, pyridylmethyl, 2-pyridylethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino and dimethylamino, or from a group of the formula :



wherein  $X^3$  is a direct bond or is selected from O, NH, CONH, NHCO and  $CH_2O$  and  $Q^5$  is pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl and tert-butoxycarbonylaminomethyl,

and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo substituents;


- (c) m is 1 or 2 and the R<sup>1</sup> groups, which may be the same or different, are located at the 6- and/or 7-positions and are selected from hydroxy, amino, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, benzyloxy, cyclopropylmethoxy, 2-imidazol-1-ylethoxy, 3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, pyrrolidin-1-yl, morpholino, piperidino, piperazin-1-yl, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino, pyrrolidin-3-ylamino, pyrrolidin-2-ylmethylamino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino, 2-morpholinoethylamino, 3-morpholinopropylamino, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino, 2-piperidinoethylamino, 3-piperidinopropylamino, piperidin-3-ylamino, piperidin-4-ylamino, piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino, piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino, 2-homopiperidin-1-ylethylamino, 3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino, 2-homopiperazin-1-ylethylamino or 3-homopiperazin-1-ylpropylamino,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH and C≡C,

and when R<sup>1</sup> is a vinyl or ethynyl group, the R<sup>1</sup> substituent optionally bears at the  
5 terminal CH<sub>2</sub>= or HC≡ position a substituent selected from

N-(2-dimethylaminoethyl)carbamoyl, N-(3-dimethylaminopropyl)carbamoyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl and 4-dimethylaminobutyl, or from a group of the formula :

10



wherein X<sup>2</sup> is a direct bond or is NHCO or N(Me)CO and Q<sup>4</sup> is imidazolylmethyl, 2-imidazolylethyl, 3-imidazolylpropyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, morpholinomethyl,  
15 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each  
20 said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino and dimethylamino,


and wherein any phenyl, pyridyl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, aminomethyl,  
25 acetamidomethyl and tert-butoxycarbonylaminomethyl,

and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo substituents;

- (d) each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen or methyl except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;
- 30 (e) each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;


(f) each of  $R^2$  and  $R^3$  is hydrogen and  $R^5$  and  $R^6$  together with the N atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from O, N and S, provided that one of the pairs of groups  $R^2$  and  $R^4$  together and  $R^3$  and  $R^4$  together forms a bond;

- 5 (g)  $Q^2$  is phenyl, benzyl,  $\alpha$ -methylbenzyl, phenethyl, naphthyl, 1-(1-naphthyl)ethyl or 2-phenylcyclopropyl which is optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, 10 (2-6C)alkanoylamino, or from a group of the formula :



wherein  $X^6$  is a direct bond or is selected from O and N( $R^{15}$ ), wherein  $R^{15}$  is hydrogen or (1-6C)alkyl, and  $R^{14}$  is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the


15 formula :



wherein  $X^7$  is a direct bond or is selected from O, N( $R^{16}$ ), CO, CON( $R^{16}$ ), N( $R^{16}$ )CO and C( $R^{16}$ )<sub>2</sub>O, wherein each  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is phenyl, benzyl, heteroaryl or heteroaryl-(1-6C)alkyl,

- 20 and wherein any phenyl or heteroaryl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, (1-6C)alkyl and (1-6C)alkoxy;


- (h)  $Q^2$  is phenyl, benzyl,  $\alpha$ -methylbenzyl or phenethyl which is optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, 25 bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, tert-butyl, vinyl, ethynyl and methoxy, or from a group of the formula :



- wherein  $X^7$  is a direct bond or is selected from O and CO, and  $Q^7$  is phenyl, benzyl, pyridyl or pyridylmethyl, and wherein any phenyl or pyridyl group within a substituent on  $Q^2$  optionally 30 bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, methyl and methoxy;

- (i)  $Q^2$  is phenyl, benzyl or phenethyl which is substituted with 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, tert-butyl, vinyl, ethynyl and methoxy provided that at least one substituent is located at an ortho position (for example the 2-position on a phenyl group);
- (j)  $Q^2$  is phenyl, benzyl or phenethyl which is substituted with 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, tert-butyl, vinyl, ethynyl and methoxy provided that two substituents are located at ortho positions (for example the 2- and 6-positions on a phenyl group);
- (k)  $R^6$  is an optionally substituted group selected from (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl and (3-7C)cycloalkenyl, or  $R^6$  is a substituted (1-6C)alkyl group, and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^6$  group are optionally separated by the insertion into the chain of a group selected from O, N( $R^{19}$ ), CON( $R^{19}$ ), N( $R^{19}$ )CO, CH=CH and C≡C wherein  $R^{19}$  is hydrogen or (1-6C)alkyl, and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a  $R^6$  group optionally bears at the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :
- $$Q^8 - X^9 -$$
- wherein  $X^9$  is a direct bond or is CO or N( $R^{20}$ )CO, wherein  $R^{20}$  is hydrogen or (1-6C)alkyl, and  $Q^8$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a  $R^6$  group optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more of the following substituents, provided that the  $R^6$  group when it is (1-6C)alkyl must bear at least one such substituent,
- one or more halogeno substituents or a substituent selected from hydroxy, cyano, amidino, amino, carboxy, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, (1-6C)alkoxycarbonylamino and N-(1-6C)alkyl-(1-6C)alkoxycarbonylamino, or from a group of the formula :

- 35 -



wherein  $X^{10}$  is a direct bond or is selected from O,  $N(R^{21})$ ,  $CON(R^{21})$ ,  $N(R^{21})CO$  and  $C(R^{21})_2O$ , wherein  $R^{21}$  is hydrogen or (1-6C)alkyl, and  $Q^9$  is phenyl, phenyl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl,

5 heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a  $R^6$  group optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy,

N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,

10 (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl and (1-6C)alkoxycarbonylamino-(1-6C)alkyl,

and wherein any heterocyclyl group within a  $R^6$  group optionally bears 1 or 2 oxo substituents;

(I)  $R^6$  is an optionally substituted group selected from allyl, 2-propynyl, cyclopropyl,

15 cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, or  $R^6$  is a substituted methyl, ethyl, propyl or butyl group,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^6$  group are optionally separated by the insertion into the chain of a group selected from O, NH, CONH, NHCO, CH=CH and C≡C,


20 and wherein any  $CH_2=CH-$  or  $HC\equiv C-$  group within a  $R^6$  group optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from carbamoyl,

N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl,

aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methylaminomethyl,

2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl,

25 2-dimethylaminoethyl, 3-dimethylaminopropyl or 4-dimethylaminobutyl, or from a group of the formula :



wherein  $X^9$  is a direct bond or is CO, NHCO or  $N(Me)CO$  and  $Q^8$  is pyridyl, pyridylmethyl, 2-pyridylethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,

30 piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl,


3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl,

3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl,

4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl,  
 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl,  
 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or  
 4-piperazin-1-ylbutyl,

5 and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> group optionally bears on each said  
 CH<sub>2</sub> or CH<sub>3</sub> group one or more of the following substituents, provided that the R<sup>6</sup> group when  
 it is a methyl, ethyl, propyl or butyl group must bear at least one such substituent,

one or more substituents selected from fluoro, chloro and bromo or a substituent  
 selected from hydroxy, cyano, amidino, amino, carboxy, methoxy, ethoxy, methylthio,  
 10 methylsulphinyl, methylsulphonyl, methylamino, dimethylamino, methoxycarbonyl,  
 ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, acetamido, propionamido,  
N-methylacetamido, N-methylpropionamido, methoxycarbonylamino, ethoxycarbonylamino  
 and tert-butoxycarbonylamino, or from a group of the formula :



15 wherein X<sup>10</sup> is a direct bond or is selected from O, NH, CONH, NHCO and CH<sub>2</sub>O and Q<sup>9</sup> is  
 phenyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,  
 cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl,  
 imidazolyl, imidazolylmethyl, 1,2,3-triazolyl, 1,2,3-triazolylmethyl, pyridyl, pyridylmethyl,  
 tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, 1,4-dioxan-2-yl,  
 20 morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl,  
 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,  
 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl,  
 piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl,  
 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

25 and wherein any aryl, heteroaryl or heterocyclyl group within a R<sup>6</sup> group optionally  
 bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro,  
 trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, aminomethyl,  
 methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminoethyl,  
 ethoxycarbonylaminoethyl and tert-butoxycarbonylaminoethyl,

30 and wherein any heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 oxo  
 substituents; and

(m)  $R^6$  is an optionally substituted group selected from allyl, 2-propynyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or  $R^6$  is a substituted methyl, ethyl, propyl or butyl group,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^6$  group are optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH and C≡C,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a  $R^6$  group optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more of the following substituents, provided that the  $R^6$  group when it is a methyl, ethyl, propyl or butyl group must bear at least one such substituent,

one, two or three fluoro substituents or a substituent selected from hydroxy, cyano, amidino, amino, carboxy, methoxy, methylthio, methylsulphinyl, methylsulphonyl, methylamino, dimethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, acetamido, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, tetrahydrofuran-2-yl, pyrrolidin-1-yl, 1,4-dioxan-2-yl, morpholino, piperidino, piperazin-1-yl, homopiperidin-1-yl and homopiperazin-1-yl,

and wherein any phenyl, imidazolyl, pyridyl or heterocyclyl group within a  $R^6$  group optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and methoxy,

and wherein any heterocyclyl group within a  $R^6$  group optionally bears 1 or 2 oxo substituents.

Further particular novel compounds of the invention include, for example, quinoline derivatives of the Formula III, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of m,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $Q^2$  has any of the meanings defined hereinbefore or in any of the paragraphs (a) to (m) immediately hereinbefore.

Further particular novel compounds of the invention include, for example, pyrimidine derivatives of the Formula IV, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of m,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $Q^2$  has any of the meanings defined hereinbefore or in any of the paragraphs (a) to (m) immediately hereinbefore and  $Y^1$  has any of the meanings defined hereinbefore or in paragraphs (a) to (c) hereinafter :-

(a) bicyclic rings formed by the fusion of ring  $Y^1$  to the adjacent pyrimidine ring include thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl,

pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl and pyrido[3,2-*d*]pyrimidin-4-yl;

(b) bicyclic rings formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring include thieno[3,2-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl and  
5 pyrido[3,2-*d*]pyrimidin-4-yl; and

(c) the bicyclic ring formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring is thieno[3,2-*d*]pyrimidin-4-yl.

Further particular novel compounds of the invention include, for example, quinazoline derivatives of the Formula V, or pharmaceutically-acceptable salts thereof, wherein, unless  
10 otherwise stated, each of m, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and Q<sup>2</sup> has any of the meanings defined hereinbefore or in any of the paragraphs (a) to (m) immediately hereinbefore and Y<sup>2</sup> has any of the meanings defined hereinbefore or in paragraphs (a) and (b) hereinafter :-

(a) tricyclic rings formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include 3H-imidazo[4,5-*g*]quinazolin-8-yl and 2-oxo-1,2-dihydro-3H-imidazo[4,5-*g*]quinazolin-8-yl;  
15 and

(b) tricyclic rings formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include 3-methyl-3H-imidazo[4,5-*g*]quinazolin-8-yl and 3-methyl-2-oxo-1,2-dihydro-3H-imidazo[4,5-*g*]quinazolin-8-yl.

A preferred compound of the invention is a quinazoline derivative of the Formula II  
20 wherein :

m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from methoxy, benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy,  
25 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinoethoxy,  
30 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy,

- 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-1-yl)propoxy, 3-(4-tert-butoxycarbonylamino piperidin-1-yl)propoxy, 3-(4-carbamoylpiperidin-1-yl)propoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 5 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy, 3-[N-(2-methoxyethyl)-N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-methylamino-1-propynyl, 10 3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl, 6-methylamino-1-hexynyl, 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl, 3-(piperidino)-1-propynyl, 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-1-propynyl, 6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-1-hexynyl, 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl, 15 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino, 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,

or m is 2 and the R<sup>1</sup> groups are located at the 6- and 7-positions, one R<sup>1</sup> group is located at the 6- or 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a methoxy group;

- 20 each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho

- 25 position; and

R<sup>6</sup> is an optionally substituted group selected from allyl, 2-propynyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or R<sup>6</sup> is a substituted methyl, ethyl, propyl or butyl group,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>6</sup> group are 30 optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH and C≡C,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> group optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more of the following substituents, provided that the R<sup>6</sup> group when it is a methyl, ethyl, propyl or butyl group must bear at least one such substituent,

one, two or three fluoro substituents or a substituent selected from hydroxy, cyano,  
 5 amidino, amino, carboxy, methoxy, methylthio, methylsulphinyl, methylsulphonyl,  
 methylamino, dimethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,  
tert-butoxycarbonyl, acetamido, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,  
 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, tetrahydrofuran-2-yl,  
 pyrrolidin-1-yl, 1,4-dioxan-2-yl, morpholino, piperidino, piperazin-1-yl, homopiperidin-1-yl  
 10 and homopiperazin-1-yl,

and wherein any phenyl, imidazolyl, pyridyl or heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and methoxy,

and wherein any heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 oxo  
 15 substituents;  
 or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

m is 1 and the R<sup>1</sup> group is located at the 7-position and is selected from  
 20 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy,  
 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,  
 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,  
 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy,  
 piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy,  
 25 3-(4-methylpiperazin-1-yl)propoxy, cyclopropylmethoxy, 3-methylsulphonylpropoxy and  
 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;

or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup>  
 30 together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position; and

$R^6$  is allyl, 2-propynyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or 4-hydroxycyclohexyl, or  $R^6$  is a substituted methyl, ethyl, propyl or butyl group,

and wherein adjacent carbon atoms in any propyl or butyl group are optionally separated by the insertion into the chain of an O group,

- 5 and wherein any  $CH_2$  or  $CH_3$  group within a  $R^6$  group when it is a methyl, ethyl, propyl or butyl group bears one, two or three fluoro substituents or a substituent selected from hydroxy, cyano, amidino, amino, carboxy, methoxy, methylthio, methylsulphinyl, methylsulphonyl, methylamino, dimethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, acetamido, phenyl, cyclopropyl, 4-imidazolyl, 10 2-pyridyl, tetrahydrofuran-2-yl, pyrrolidin-1-yl, 2-oxopyrrolidin-1-yl, 1,4-dioxan-2-yl, morpholino, piperidino and piperazin-1-yl,

and wherein any phenyl, imidazolyl, pyridyl or heterocyclyl group within a  $R^6$  group optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, methyl, ethyl and methoxy;

- 15 or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

- m is 2 and one  $R^1$  group is a 6-methoxy group and the other  $R^1$  group is located at the 7-position and is selected from 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 20 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy and 3-(4-methylpiperazin-1-yl)propoxy;

each of  $R^2$ ,  $R^3$  and  $R^5$  is hydrogen except that one of the pairs of groups  $R^2$  and  $R^4$  together,  $R^3$  and  $R^4$  together and  $R^5$  and  $R^4$  together forms a bond;

- 25  $Q^2$  is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent is located at an ortho position; and

- $R^6$  is allyl, 2-propynyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, 4-hydroxycyclohexyl, 2,2,2-trifluoroethyl, 2,3-dihydroxypropyl, 2-aminoethyl, 30 3-aminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-methylthioethyl, 3-methylthiopropyl, 2-methylsulphonyl, 3-methylsulphonylpropyl, 2-(2-hydroxyethoxy)ethyl, 2-cyanoethyl, 2-amidinoethyl, carboxymethyl, 2-carboxyethyl, methoxycarbonylmethyl,

2-methoxycarbonylethyl, tert-butoxycarbonylmethyl, 2-(tert-butoxycarbonyl)ethyl, benzyl, 2,6-difluorobenzyl, phenethyl, 2-imidazol-4-ylethyl, 2-pyrid-2-ylethyl, tetrahydrofuran-2-ylmethyl, 1,4-dioxan-2-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-(2-oxopyrrolidin-1-yl)ethyl, 3-pyrrolidin-1-ylpropyl, 3-(2-oxopyrrolidin-1-yl)propyl, 5 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl, N-methylpiperidin-3-ylmethyl or N-methylpiperidin-4-ylmethyl; or a pharmaceutically-acceptable acid-addition salt thereof.

A preferred compound of the invention is a quinazoline derivative of the Formula II  
10 wherein :

m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from hydroxy, methoxy, benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(2-methoxyethoxy)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuran-2-ylmethoxy, 15 tetrahydrofuran-3-ylmethoxy, tetrahydropyran-2-ylmethoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy, 20 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinylmethoxy, 3-morpholinylmethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, 25 N-methylpiperidin-4-yloxy, N-(2-methoxyethyl)piperidin-4-yloxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-1-yl)propoxy, 3-(4-tert-butoxycarbonylamino)piperidin-1-yl)propoxy, 3-(4-carbamoylpiperidin-1-yl)propoxy, 30 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-en-1-yloxy, 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy,

3-[N-(2-methoxyethyl)-N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy,  
 3-methylamino-1-propynyl, 3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl,  
 6-methylamino-1-hexynyl, 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl,  
 3-(piperidino)-1-propynyl, 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-  
 5 1-propynyl, 6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-  
 1-hexynyl, 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl,  
 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino,  
 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,

or m is 2 and the R<sup>1</sup> groups are located at the 6- and 7-positions, one R<sup>1</sup> group is  
 10 located at the 6- or 7-position and is selected from the groups defined immediately  
 hereinbefore and the other R<sup>1</sup> group is a methoxy group;

each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup>  
 together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which  
 15 may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro,  
 methyl, ethyl and methoxy provided that at least one substituent is located at an ortho  
 position; and

R<sup>6</sup> is an optionally substituted group selected from allyl, 2-propynyl, cyclopropyl,  
 cyclobutyl, cyclopentyl and cyclohexyl, or R<sup>6</sup> is a substituted methyl, ethyl, propyl or butyl  
 20 group,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>6</sup> group are  
 optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH  
 and C≡C,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> group optionally bears on each said  
 25 CH<sub>2</sub> or CH<sub>3</sub> group one or more of the following substituents, provided that the R<sup>6</sup> group when  
 it is a methyl, ethyl, propyl or butyl group must bear at least one such substituent,

one, two or three fluoro substituents or a substituent selected from hydroxy, cyano,  
 amidino, amino, carboxy, methoxy, ethoxy, methylthio, methylsulphinyl, methylsulphonyl,  
 methylamino, ethylamino, isopropylamino, dimethylamino, methoxycarbonyl,  
 30 ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, N-methylcarbamoyl,  
N-ethylcarbamoyl, N-isopropylcarbamoyl, N-tert-butylcarbamoyl, acetamido, phenyl,  
 cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2-furyl, 2-thienyl,

1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, tetrahydrofuran-2-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, 1,4-dioxan-2-yl, morpholino, piperidino, piperidin-2-yl, piperazin-1-yl, homopiperidin-1-yl and homopiperazin-1-yl,

and wherein any phenyl, heteroaryl or heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and methoxy,

and wherein any heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 oxo substituents;

or a pharmaceutically-acceptable acid-addition salt thereof.

10 A further preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from 2-(2-methoxyethoxy)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-2-ylmethoxy, 15 N-methylpyrrolidin-3-yloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 3-morpholinylmethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 20 N-(2-methoxyethyl)piperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, benzyloxy, cyclopropylmethoxy, 3-methylsulphonylpropoxy and 2-[[N-(2-methoxyethyl)-N-methylamino]ethoxy;

or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

25 or m is 2 and one R<sup>1</sup> group is located at the 6-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a 7-methoxy group;

each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, 30 selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position; and

R<sup>6</sup> is allyl, 2-propynyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or 4-hydroxycyclohexyl, or R<sup>6</sup> is a substituted methyl, ethyl, propyl or butyl group,

and wherein adjacent carbon atoms in any propyl or butyl group are optionally separated by the insertion into the chain of an O group,

- and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> group when it is a methyl, ethyl, propyl or butyl group bears one, two or three fluoro substituents or a substituent selected from
- 5 hydroxy, cyano, amidino, amino, carboxy, methoxy, ethoxy, methylthio, methylsulphinyl, methylsulphonyl, methylamino, ethylamino, isopropylamino, dimethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-tert-butylcarbamoyl, acetamido, phenyl, cyclopropyl, 2-furyl, 2-thienyl, 4-imidazolyl, 2-pyridyl, 3-pyridyl,
- 10 4-pyridyl, tetrahydrofuran-2-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, 2-oxopyrrolidin-1-yl, 1,4-dioxan-2-yl, morpholino, piperidino, piperidin-2-yl and piperazin-1-yl,
- and wherein any phenyl, heteroaryl or heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, methyl, ethyl and methoxy;
- 15 or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

- m is 2 and one R<sup>1</sup> group is a 6-methoxy group and the other R<sup>1</sup> group is located at the 7-position and is selected from 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy,
- 20 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy, N-(2-methoxyethyl)piperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy and 3-(4-methylpiperazin-1-yl)propoxy;

each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;

- 25 Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and methyl provided that at least one substituent is located at an ortho position; and

- R<sup>6</sup> is allyl, 2-propynyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, 4-hydroxycyclohexyl, 2,2,2-trifluoroethyl, 2,3-dihydroxypropyl, 2-aminoethyl,
- 30 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-methylthioethyl, 3-methylthiopropyl, 2-methylsulphonylethyl, 3-methylsulphonylpropyl, 2-(2-hydroxyethoxy)ethyl, 2-cyanoethyl, 5-cyanopentyl, 2-amidinoethyl, carboxymethyl,

- 2-carboxyethyl, methoxycarbonylmethyl, 2-methoxycarbonylethyl, tert-butoxycarbonylmethyl, 2-(tert-butoxycarbonyl)ethyl, N-methylcarbamoylethyl, N-isopropylcarbamoylethyl, N-tert-butylcarbamoylethyl, benzyl, 2-fluorobenzyl, 3-fluorobenzyl, 2,6-difluorobenzyl, phenethyl, 2-furylmethyl, 2-thienylmethyl, 2-imidazol-4-ylethyl, 2-pyridylmethyl, 5 3-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, tetrahydrofuran-2-ylmethyl, 1,4-dioxan-2-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-(2-oxopyrrolidin-1-yl)ethyl, 2-(N-methylpyrrolidin-2-yl)ethyl, 3-pyrrolidin-1-ylpropyl, 3-(2-oxopyrrolidin-1-yl)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl, 10 N-methylpiperidin-3-ylmethyl or N-methylpiperidin-4-ylmethyl; or a pharmaceutically-acceptable acid-addition salt thereof.


A particular preferred compound of the invention is, for example, a quinazoline derivative of the Formula II selected from :-

- N-(2-chloro-6-methylphenyl)-N'-(2-hydroxyethyl)-N''-[6-methoxy-7-(N-methylpiperidin- 15 4-ylmethoxy)quinazolin-4-yl]guanidine, N-allyl-N'-(2-chloro-6-methylphenyl)-N''-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]guanidine, N-allyl-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine, and 20 N-(2-chloro-6-methylphenyl)-N'-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-N''-(2-propynyl)guanidine; or a pharmaceutically-acceptable acid-addition salt thereof.

- A quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, may be prepared by any process known to be applicable to the preparation of 25 chemically-related compounds. Such processes, when used to prepare a quinazoline derivative of the Formula I are provided as a further feature of the invention and are illustrated by the following representative process variants in which, unless otherwise stated, Q<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and Q<sup>2</sup> have any of the meanings defined hereinbefore. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of 30 such starting materials is described in conjunction with the following representative process variants and within the accompanying Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

A quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, may be prepared by :-


- (a) the reaction, conveniently in the presence of a suitable metallic salt catalyst, of a thiourea of the Formula VI



VI

5

wherein  $Q^1$ ,  $R^2$ ,  $Q^2$  and  $R^3$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the Formula VII




VII

wherein  $R^5$  and  $R^6$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable metallic salt catalyst is, for example, a mercuric salt such as mercuric(II) oxide and the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, or a dipolar aprotic solvent such as acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently carried out at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

As stated hereinbefore, the compounds of Formula I defined above may exhibit the phenomenon of tautomerism. In particular, tautomerism may affect the guanidino group formed when one of the pairs of groups  $R^2$  and  $R^4$  together,  $R^3$  and  $R^4$  together and  $R^5$  and  $R^4$  together forms a bond. The generic structure of Formula I produced by process variant (a) may therefore give rise to the three structures.

20



Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question and may be introduced by conventional methods. Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower", as in, for example, lower alkyl, signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned are, of course, within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or arylaliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms). Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (for example isopropyl, and tert-butyl); lower alkoxy-lower alkyl groups (for example methoxymethyl, ethoxymethyl and isobutoxymethyl); lower acyloxy-lower alkyl groups, (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl); lower alkoxycarbonyloxy-lower alkyl groups (for example 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl); aryl-lower alkyl groups (for example benzyl, 4-methoxybenzyl, 2-nitrobenzyl, 4-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (for example trimethylsilyl and tert-butyldimethylsilyl); tri(lower alkyl)silyl-lower alkyl groups (for example trimethylsilylethyl); and (2-6C)alkenyl groups (for example allyl). Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed cleavage.

Examples of hydroxy protecting groups include lower alkyl groups

(for example tert-butyl), lower alkenyl groups (for example allyl); lower alkanoyl groups (for example acetyl); lower alkoxy carbonyl groups (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); aryl-lower alkoxy carbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (for example trimethylsilyl and tert-butyldimethylsilyl) and aryl-lower alkyl (for example benzyl) groups.


Examples of amino protecting groups include formyl, aryl-lower alkyl groups (for example benzyl and substituted benzyl, 4-methoxybenzyl, 2-nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-4-anisylmethyl and furylmethyl groups; lower alkoxy carbonyl (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); aryl-lower alkoxy carbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); trialkylsilyl (for example trimethylsilyl and tert-butyldimethylsilyl); alkylidene (for example methylenediphenyl and substituted benzyldiene groups).

Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis for groups such as 2-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for groups such as 2-nitrobenzyloxycarbonyl.

The reader is referred to Advanced Organic Chemistry, 4th Edition, by J. March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents and to Protective Groups in Organic Synthesis, 2<sup>nd</sup> Edition, by T. Green *et al.*, also published by John Wiley & Son, for general guidance on protecting groups.

A thiourea of the Formula VI, wherein R<sup>3</sup> is hydrogen, may be prepared by the reaction, conveniently in the presence of a suitable base, of an amine of the Formula VIII

wherein Q<sup>1</sup> and R<sup>2</sup> have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isothiocyanate of the Formula IX, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



IX

wherein Q<sup>2</sup> has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate, alkoxide or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium ethoxide, potassium tert-butoxide, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal hydride, for example sodium hydride or potassium hydride, or an organometallic base such as an alkyl-lithium, for example n-butyl-lithium or a dialkylamino-lithium, for example lithium di-isopropylamide.

A suitable conventional chemical equivalent of an isothiocyanate of the Formula IX is, for example, a compound of the Formula X



wherein  $\text{Q}^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group. On treatment with a suitable base as defined hereinbefore, the compound of the Formula X reacts to form the desired isothiocyanate of the Formula IX.

A suitable displaceable or leaving group L is, for example, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.

A suitable conventional chemical precursor of an isothiocyanate of the Formula IX is, for example, an acyl azide of the Formula XI




wherein  $\text{Q}^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary. On thermal or photolytic treatment the thioacyl azide of the Formula XI decomposes and rearranges to form the desired isothiocyanate of the Formula IX.

When L is, for example, a chloro group, the compound of the Formula X may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of thiophosgene with an amine of the Formula XII.



The compound of the Formula XI may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XIII.



A thiourea of the Formula VI, wherein  $R^2$  is hydrogen, may be prepared by the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of an amine of the Formula XIV



5 wherein  $Q^2$  and  $R^3$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isothiocyanate of the Formula XV, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is  
10 protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable conventional chemical equivalent of an isothiocyanate of the Formula XV is, for example, a compound of the Formula XVI




15 wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group as defined hereinbefore. On treatment with a suitable base as defined hereinbefore, the compound of the Formula XVI reacts to form the desired isothiocyanate of the Formula XV.

A suitable conventional chemical precursor of an isothiocyanate of the Formula XV is,  
20 for example, an acyl azide of the Formula XVII



wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary. On thermal or photolytic treatment the thioacyl azide of the Formula XVII decomposes and rearranges to form the desired isothiocyanate of the  
25 Formula XV.

When L is, for example, a chloro group, the compound of the Formula XVII may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of thiophosgene with an amine of the Formula XVIII



30 The compound of the Formula XVII may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XIX.



(b) For the production of those compounds of the Formula I wherein  $Q^1$ ,  $R^6$  or  $Q^2$  contains a carboxy group, the cleavage of the corresponding compound of Formula I wherein  $Q^1$ ,  $R^6$  or  $Q^2$  contains a protected carboxy group.

Suitable protecting groups for a carboxy are, for example, any such protecting group disclosed hereinbefore. Suitable methods for the cleavage of such carboxy protecting groups are also disclosed hereinbefore. In particular, a suitable protecting group is a lower alkoxy ester such as a *tert*-butoxy ester which may be cleaved under conventional reaction conditions such as under acid-catalysed hydrolysis, for example in the presence of trifluoroacetic acid.

(c) For those compounds of the Formula I wherein  $R^6$  or a substituent on  $Q^1$  or  $Q^2$  contains an alkylcarbonyl group or a substituted alkylcarbonyl group, the reaction of the corresponding compound of Formula I wherein  $R^6$  or a substituent on  $Q^1$  or  $Q^2$  is a carboxy group, or a reactive derivative thereof, with an amine or substituted amine as appropriate.

A suitable reactive derivative of a compound of Formula I wherein  $R^6$  or a substituent on  $Q^1$  or  $Q^2$  contains a carboxy group is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid and a phenol such as pentafluorophenol, an ester formed by the reaction of the acid and an ester such as pentafluorophenyl trifluoroacetate or an ester formed by the reaction of the acid and an alcohol such as *N*-hydroxybenzotriazole; an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cyanide; or the product of the reaction of the acid and a carbodiimide such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

The reaction is conveniently carried out in the presence of a suitable base as defined hereinbefore and in the presence of a suitable inert solvent or diluent as defined hereinbefore.

Typically a carbodiimide coupling reagent is used in the presence of an organic solvent (preferably an anhydrous polar aprotic organic solvent) at a non-extreme temperature, for example in the region -10 to 40°C, typically at ambient temperature of about 20°C.

A compound of Formula I wherein R<sup>6</sup> or a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains a carboxy group may conveniently be prepared by the cleavage of the corresponding ester such as a (1-12C)alkyl ester, for example by acid-, base- metal- or enzymatically-catalysed cleavage.

(d) For those compounds of the Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains an amino-(1-6C)alkyl group or R<sup>6</sup> is an amino-(1-6C)alkyl group, the cleavage of the corresponding compound of Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> is a protected amino-(1-6C)alkyl group or R<sup>6</sup> is a protected amino-(1-6C)alkyl group as appropriate.

Suitable protecting groups for an amino-(1-6C)alkyl group are, for example, any of the protecting groups disclosed hereinbefore for an amino group. Suitable methods for the cleavage of such amino protecting groups are also disclosed hereinbefore. In particular, a suitable protecting group is a lower alkoxycarbonyl group such as a *tert*-butoxycarbonyl group which may be cleaved under conventional reaction conditions such as under acid-catalysed hydrolysis.

(e) For those compounds of the Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains an amino group, the reduction of a corresponding compound of Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains a nitro group.

Typical reaction conditions include the use of ammonium formate or hydrogen gas in the presence of a catalyst, for example a metallic catalyst such as palladium-on-carbon.

Alternatively a dissolving metal reduction may be carried out, for example using iron in the presence of an acid, for example an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric or acetic acid. The reaction is conveniently carried out in the presence of an organic solvent (preferably a polar protic solvent) and preferably with heating, for example to about 60°C. Any functional groups are protected and deprotected as necessary.

(f) For the production of those compounds of the Formula I wherein Q<sup>1</sup> contains a R<sup>1</sup> group in a quinazoline-like ring of the formula Ia, Ib, Ic or Id that is linked via an oxygen atom, the alkylation of the corresponding compound of Formula I wherein the R<sup>1</sup> group in Q<sup>1</sup> is a hydroxy group.

The alkylation reaction may, for example, comprise the coupling of a hydroxy-substituted quinazoline-like ring of the formula Ia, Ib, Ic or Id with an alcohol. The reaction may conveniently be carried out in the presence of a suitable dehydrating agent.

A suitable dehydrating agent is, for example, a carbodiimide reagent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or a mixture of

an azo compound such as diethyl or di-tert-butyl azodicarboxylate or or 1,1'-(azodicarbonyl)dipiperidine and a phosphine such as triphenylphosphine or tributylphosphine. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example tetrahydrofuran or a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride and at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

Alternatively, the alkylation reaction may comprise the reaction of a hydroxy-substituted quinazoline-like ring of the formula Ia, Ib, Ic or Id with a suitable alkylating agent. The reaction may conveniently be carried out in the presence of a suitable base as defined hereinbefore.

A suitable alkylating agent is, for example, a compound which contains a suitable displaceable group, for example, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, pentafluorophenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently carried out at a temperature in the range, for example, 10 to 250°C, preferably in the range 40 to 80°C.

When a pharmaceutically-acceptable salt of a quinazoline derivative of the Formula I is required, for example an acid-addition salt, it may be obtained by, for example, reaction of said quinazoline derivative with a suitable acid using a conventional procedure.

## 25 Biological Assays

The following assays can be used to measure the effects of the compounds of the present invention as p56<sup>lck</sup> inhibitors, as inhibitors of T cell activation, as inhibitors of cytokine production in mice and as inhibitors of transplant rejection.

### (a) In vitro Enzyme Assay

30 The ability of test compounds to inhibit phosphorylation by the enzyme p56<sup>lck</sup> of a tyrosine-containing polypeptide substrate was assessed using a conventional Elisa assay.

The following conventional procedure was used to obtain p56<sup>lck</sup> enzyme. An EcoR1/Not1 fragment containing the entire coding sequence of p56<sup>lck</sup> was generated by the

technique of polymerase chain reaction (PCR) from Incyte clone No. 2829606. A 6-His tag was added to the sequence at the N-terminus during the PCR stage. Conventional sequence analysis identified a number of changes compared to the published sequence and these were found also to have been present in the original Incyte template. To achieve expression of the enzyme, the PCR fragment was inserted downstream of the polyhedrin promoter of pFASTBAC1 (Life Technologies Limited, Paisley, UK, Catalogue No. 10360-014). A recombinant Baculovirus was constructed using the Bac-to-Bac system (Life Technologies Limited). High Five insect cells (Invitrogen BV, PO Box 2312, 9704 CH Groningen, The Netherlands, Catalogue No. B855-02) were infected with the recombinant Baculovirus at a multiplicity of infection of 1 and incubated for 48 hours. The cells were harvested. Groups of  $1.6 \times 10^9$  cells were lysed by incubation in 20 mM Hepes pH7.5 buffer containing 10% glycerol, 1% Triton-X-100, magnesium chloride (1.5mM), ethylene glycol bis(2-aminoethyl ether N,N,N',N'-tetraacetic acid) (EGTA, 1mM), sodium vanadate (1mM), sodium fluoride (10mM), imidazole (5mM), sodium chloride (150mM), phenylmethanesulphonyl fluoride (0.1mM), pepstatin (1 mg/ml) and leupeptin (1 mg/ml). A soluble fraction was obtained by centrifugation and 6-His-p56<sup>lck</sup> was purified by column chromatography on a 1 ml Ni-NTA agarose column (Qiagen Limited, Crawley, West Sussex, UK). The protein was eluted using the above-mentioned buffer except that imidazole (100mM) was also present. The p56<sup>lck</sup> enzyme so obtained was stored at -80°C.

Substrate solution [100µl of a 2µg/ml solution of the polyamino acid Poly(Glu, Ala, Tyr) 6:3:1 (Sigma Catalogue No. P3899) in phosphate buffered saline (PBS)] was added to each well of a Nunc 96-well immunoplate (Catalogue No. 439454) and the plate was sealed and stored at 4°C for 16 hours. The excess of substrate solution was discarded, the substrate-coated wells were washed with Hepes pH7.4 buffer (50mM, 300µl) and blotted dry.

Each test compound was dissolved in DMSO and diluted to give a series of dilutions (from 100µM to 0.001µM) of the compound in a 10:1 mixture of water and DMSO. Portions (25µl) of each dilution of test compound were transferred to the 96-well assay plate. Aliquots (25µl) of a 10:1 mixture of water and DMSO were added followed by aliquots (25µl) of a mixture of adenosine triphosphate (ATP; 24µl of a 1mM aqueous solution) and manganese chloride (3ml of a 40mM aqueous solution).

p56<sup>lck</sup> enzyme (0.3µl of a 0.5mg/ml stock solution) was diluted in a mixture of Hepes pH 7.4 buffer (200mM, 3ml), sodium orthovanadate (2mM, 0.6ml), 1% Triton X-100

(0.6ml), dithiothreitol (25mM, 48µl) and distilled water (1.8ml). Aliquots (50µl) of the resultant solution were transferred to each well in the assay plate and the plate was incubated at ambient temperature for 8 minutes. The wells were washed sequentially with two aliquots (300µl) of phosphate-buffered saline (PBS) containing 0.1% Tween 20 (hereinafter PBS/T).

- 5 Aliquots (100µl) were added to each well of a mixture of antiphosphotyrosine-4G10 monoclonal IgG2bk antibody (UBI Catalogue No. 05-321; 30µl of a 50µg/ml solution of the antibody in PBS/T), PBS/T (11ml) and bovine serum albumin (BSA; Sigma Catalogue No. A6793; 55mg) and the plate was incubated at ambient temperature for 1 hour. The wells were washed sequentially with two aliquots (300µl) of PBS/T and blotted dry. Aliquots (100µl)
- 10 were added to each well of a mixture of sheep anti-mouse IgG-peroxidase antibody (Amersham Catalogue No. NXA931; 20µl), PBS/T (11ml) and BSA (55mg) and the plate was incubated at ambient temperature for 1 hour. The wells were washed sequentially with two aliquots (300µl) of PBS/T and blotted dry.

- Aliquots (100µl) were added to each well of an ABTS solution [prepared by adding an
- 15 2,2'-azinobis(3-ethylbenzothiazolinesulphonic acid) (ABTS) tablet (50mg; Boehringer Catalogue No. 1204521) to a mixture (50mM) of phosphate-citrate pH5.0 buffer and 0.03% sodium perborate (obtained by adding a PCSB capsule (Sigma Catalogue No. P-4922) to distilled water (100ml))]. The plate was incubated at ambient temperature for 1.5 hours and the absorbance at 405nm was determined.

- 20 The extent of inhibition of the phosphorylation reaction at a range of concentrations of each test compound was determined and an IC<sub>50</sub> value was calculated.

(b) In vitro T cell proliferation assays

- The ability of test compounds to inhibit T cell proliferation was assessed by using human peripheral blood mononuclear cells and stimulation of the T cells by way of the T cell
- 25 receptor or other than by way of the T cell receptor.

- Peripheral blood mononuclear cells (PBMC) were isolated from heparinised (10units/ml heparin) human blood by density centrifugation (Lymphoprep<sup>TM</sup>; Nycomed) spinning initially at 2000rpm at ambient temperature for 20 minutes. Cells at the interphase were transferred to clean tubes, diluted 1:1 with RPMI 1640 medium (Gibco) and spun at
- 30 2000rpm at ambient temperature for 10 minutes. The cell pellet was resuspended in RPMI 1640 medium and spun at 1400rpm at ambient temperature for 10 minutes. The cell pellet was resuspended in RPMI 1640 medium and spun at 900rpm at ambient temperature for

10 minutes to remove platelets. The prepared mononuclear cells were resuspended in an assay medium comprising RPMI 1640 culture medium supplemented with 50 units/ml penicillin, 50µg/ml streptomycin, 1mM glutamine and 10% heat-inactivated human AB serum.

Test compounds were solubilised in DMSO at a concentration of 10mM and diluted 5 1:83.3 in assay medium. Aliquots (75µl) were added to each well of a 96 well flat-bottomed tissue culture plate and subsequently serial 1 to 3 dilutions were made into assay medium giving final test concentrations in the range 0.1 to 30µM. Control wells contained assay medium (50µl) containing 1.2% DMSO. PBMCs (100µl of a suspension of  $2 \times 10^6$  cells/ml in assay medium) were added to each well and incubated for 1 hour at 37°C in a humidified 10 (5%CO<sub>2</sub>/95% air) incubator.

The extent of inhibition of T cell proliferation at a range of concentrations of each test compound was determined and an IC<sub>50</sub> value was calculated.

(b)(i) T cell receptor stimulation

Aliquots (50µl) of the T cell receptor stimulatory anti-CD3 antibody (Pharmingen 15 Catalogue No. 30100D; 40ng/ml in assay medium) were added to each well and the cells were incubated for 24 hours at 37°C in a humidified (5%CO<sub>2</sub>/95% air) incubator. Tritiated thymidine (1µCi per well) was added and the cells were incubated for up to a further 24 hours at 37°C. The cells were harvested onto a filter mat and radioactivity was counted using a Wallac 1450 Microbeta Plus liquid scintillation counter.

20 (b)(ii) Non T cell receptor stimulation

Aliquots (50µl) of a mixture of the cell stimulants PMA (phorbol-12-myristate-13-acetate, Sigma Catalogue No. P8139; 40ng/ml) and Ionomycin (Sigma Catalogue No. I0684; 1.2µM) were added to each well and the cells were incubated and analysed as described in paragraph (b)(i).

25 (c) In vivo skin graft rejection test

The ability of test compounds to inhibit rodent skin allograft rejection was assessed using analogous procedures to those disclosed by J. Magae *et al.*, Cellular Immunology, 1996, 173, 276-281 and R. Tsuji *et al.*, J. Antibiot., 1992, 45, 1295 to assess the effect of cyclosporin A on T cell properties *in vivo*.

30 (d) Test as anti-arthritis agent

Activity of a test compound as an anti-arthritis agent was assessed as follows. Acid soluble native type II collagen has been shown to be arthritogenic in rats causing polyarthritis

when administered in Freund's incomplete adjuvant by (D. E. Trentham *et al.* J. Exp. Med., 1977, 146, 857). This is now known as collagen-induced arthritis (CIA) and similar conditions can be induced in mice and primates. CIA in DBA/1 mice as described by R.O. Williams *et al.*, Proc Natl. Acad. Sci., 1992, 89, 9784 and Immunology, 1995, 84, 433 is a tertiary model which can be used to demonstrate the anti-arthritis activity of a test compound.

Although the pharmacological properties of the compounds of the Formula I vary with structural change as expected, in general activity possessed by compounds of the Formula I, including those compounds excluded by way of one of the provisos in the definition hereinbefore, may be demonstrated at the following concentrations or doses in one or more of the above tests (a), (b), (c) and (d):-

- Test (a):-  $IC_{50}$  in the range, for example, 0.0001 - 5  $\mu M$ ;
- Test (b)(i):-  $IC_{50}$  in the range, for example, 0.001 - 10  $\mu M$ ;
- Test (b)(ii):-  $IC_{50}$  in the range, for example, 0.5 - >30  $\mu M$ ;
- 15 Test (c):- activity in the range, for example, 0.1-100 mg/kg;
- Test (d):- activity in the range, for example, 1-100 mg/kg.

No physiologically-unacceptable toxicity was observed at the effective dose for compounds tested of the present invention. Accordingly no untoward toxicological effects are expected when a compound of Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore is administered at the dosage ranges defined hereinafter.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

25 The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using

conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.

According to a further aspect of the invention there is provided a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that the compounds of the present invention are of use in the prevention or treatment of autoimmune diseases or medical conditions, for example T cell mediated disease such as transplant rejection, rheumatoid arthritis or multiple sclerosis. We have further found that these effects are believed to arise by virtue of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation, for example by way of inhibition of the enzyme p56<sup>lck</sup>. Accordingly the compounds of the present invention are expected to be useful

in the prevention or treatment of T cell mediated diseases or medical conditions. In particular the compounds of the present invention are expected to be useful in the prevention or treatment of those pathological conditions which are sensitive to inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to T cell activation, for example by way of inhibition of p56<sup>lck</sup> tyrosine kinase. Further, the compounds of the present invention are expected to be useful in the prevention or treatment of those diseases or medical conditions which are mediated alone or in part by inhibition of the enzyme p56<sup>lck</sup>, i.e. the compounds may be used to produce a p56<sup>lck</sup> enzyme inhibitory effect in a warm-blooded animal in need of such treatment.

10 Specifically, the compounds of the present invention are expected to be useful in the prevention or treatment of autoimmune conditions or diseases such as inflammatory diseases (for example rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis and lung fibrosis), multiple sclerosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma and insulin-dependent diabetes. In particular the compounds of the

15 present invention are expected to be useful in the prevention or treatment of the acute rejection of transplanted tissue or organs.

Thus according to this aspect of the invention there is provided the use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the prevention or

20 treatment of T cell mediated diseases or medical conditions in a warm-blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering

25 to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further feature of the invention there is provided the use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined immediately hereinbefore in the manufacture of a medicament for use in the

30 prevention or treatment of those pathological conditions which are sensitive to inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to T cell activation.

According to a further feature of the invention there is provided a method for the prevention or treatment of those pathological conditions which are sensitive to inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to T cell activation which comprises administering to said  
5 animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined immediately hereinbefore.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of T cell mediated disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the  
10 range, for example, 0.1 mg/kg to 75 mg/kg body weight, conveniently 0.1 mg/kg to 30 mg/kg body weight, is envisaged, given if required in divided doses.

The compounds of this invention may be used in combination with other drugs and therapies used in the treatment of T cell mediated disease. For example, the compounds of the Formula I could be used in combination with drugs and therapies used in the treatment of  
15 autoimmune conditions or diseases such as inflammatory diseases (for example rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis and lung fibrosis), multiple sclerosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma and insulin-dependent diabetes. In particular the compounds of the Formula I could be used in combination with drugs and therapies such as cyclosporin A used in the prevention or  
20 treatment of the acute rejection of transplanted organs,

For example, the compounds of the Formula I are of value in the treatment of certain inflammatory and non-inflammatory diseases which are currently treated with a cyclooxygenase-inhibitory non-steroidal anti-inflammatory drug (NSAID) such as indomethacin, ketorolac, acetylsalicylic acid, ibuprofen, sulindac, tolmetin and piroxicam.  
25 Co-administration of a compound of the Formula I with a NSAID can result in a reduction of the quantity of the latter agent needed to produce a therapeutic effect. Thereby the likelihood of adverse side-effects from the NSAID such as gastrointestinal effects are reduced. Thus according to a further feature of the invention there is provided a pharmaceutical composition which comprises a compound of the Formula I, or a pharmaceutically-acceptable salt thereof,  
30 in conjunction or admixture with a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent, and a pharmaceutically-acceptable diluent or carrier.

The compounds of the invention may also be used with anti-inflammatory agents such as an inhibitor of the enzyme 5-lipoxygenase. The compounds of the invention may also be

used with anti-inflammatory agents such as an inhibitor of the enzyme COX-2 such as celecoxib or rofecoxib.

The compounds of the Formula I may also be used in the treatment of conditions such as rheumatoid arthritis in combination with antiarthritic agents such as gold, methotrexate, 5 steroids and penicillinamine, and in conditions such as osteoarthritis in combination with steroids.

The compounds of the present invention may also be administered in degradative diseases, for example osteoarthritis, with chondroprotective, anti-degradative and/or reparative agents such as Diacerhein, hyaluronic acid formulations such as Hyalan, Rumalon, 10 Arteparon and glucosamine salts such as Anril.

The compounds of the Formula I may be used in the treatment of asthma in combination with antiasthmatic agents such as bronchodilators and leukotriene antagonists.

If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically-active 15 agent within its approved dosage range. Sequential use is contemplated when a combination formulation is inappropriate.

Although the compounds of the Formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of T cell activation. Thus, they are useful as pharmacological standards 20 for use in the development of new biological tests and in the search for new pharmacological agents.

The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated :-

(i) operations were carried out at ambient temperature, *i.e.* in the range 17 to 25°C 25 and under an atmosphere of an inert gas such as argon unless otherwise stated;

(ii) evaporations were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids by filtration;

(iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck 30 Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) was performed on C18 reverse phase silica, for example on a Dynamax C-18 60Å preparative reversed-phase column;

(iv) yields, where present, are given for illustration only and are not necessarily the maximum attainable;

(v) in general, the end-products of the Formula I have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer and, where appropriate, either positive ion data or negative ion data were collected; NMR chemical shift values were measured on the delta scale [proton magnetic resonance spectra were determined using a Jeol JNM EX 400 spectrometer operating at a field strength of 400MHz, a Varian Gemini 2000 spectrometer operating at a field strength of 300MHz or a Bruker AM300 spectrometer operating at a field strength of 300MHz]; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad;

(vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) and/or NMR analysis;

(vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the Formula I were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture; and

(viii) the following abbreviations have been used:-

DMF	<u>N,N</u> -dimethylformamide
DMSO	dimethylsulphoxide
THF	tetrahydrofuran
NMP	<u>N</u> -methylpyrrolidin-2-one

**Example 1** N-(2-chloro-6-methylphenyl)-N'-(2-hydroxyethyl)-N''-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine

Mercuric(II) oxide (0.107 g) was added to a mixture of 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea (0.118 g), 2-aminoethanol (0.03 ml), chloroform (5 ml) and methanol (5 ml) and the resultant mixture was stirred at ambient temperature for 2 hours. The reaction mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia gas in methanol as eluent. There was thus obtained the title compound (0.128 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> + CD<sub>3</sub>CO<sub>2</sub>D) 1.47–1.62 (m, 2H), 1.85–2.11 (m, 5H), 2.29 (s, 3H), 2.67 (s, 3H), 2.87 (t, 2H), 3.33 (d, 2H), 3.59 (t, 4H), 3.79 (s, 3H), 4.0 (d, 2H), 7.08 (s, 1H), 7.19–7.32 (m, 3H), 7.4 (d, 1H), 8.43 (s, 1H), 10.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 513 and 515.

The 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

A solution of di-tert-butyl dicarbonate (41.7 g) in ethyl acetate (75 ml) was added dropwise to a stirred solution of ethyl piperidine-4-carboxylate (30 g) in ethyl acetate (150 ml) which had been cooled to 0 to 5°C in an ice-bath. The resultant mixture was stirred at ambient temperature for 48 hours. The mixture was poured into water (300 ml). The organic layer was separated, washed in turn with water (200 ml), 0.1N aqueous hydrochloric acid solution (200 ml), a saturated aqueous sodium bicarbonate solution (200 ml) and brine (200 ml), dried over magnesium sulphate and evaporated. There was thus obtained ethyl N-tert-butoxycarbonylpiperidine-4-carboxylate (48 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.25 (t, 3H), 1.45 (s, 9H), 1.55–1.7 (m, 2H), 1.8–2.0 (d, 2H), 2.35–2.5 (m, 1H), 2.7–2.95 (t, 2H), 3.9–4.1 (br s, 2H), 4.15 (q, 2H).

A solution of the material so obtained in THF (180 ml) was cooled at 0°C and lithium aluminium hydride (1M solution in THF; 133 ml) was added dropwise. The mixture was stirred at 0°C for 2 hours. Water (30 ml) and 2N aqueous sodium hydroxide solution (10 ml) were added in turn and the mixture was stirred for 15 minutes. The resultant mixture was filtered through diatomaceous earth and the solids were washed with ethyl acetate. The filtrate was washed in turn with water and with brine, dried over magnesium sulphate and evaporated. There was thus obtained N-tert-butoxycarbonyl-4-hydroxymethylpiperidine (36.3 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.05–1.2 (m, 2H), 1.35–1.55 (m, 10H), 1.6–1.8 (m, 2H), 2.6–2.8 (t, 2H), 3.4–3.6 (t, 2H), 4.0–4.2 (br s, 2H).

1,4-Diazabicyclo[2.2.2]octane (42.4 g) was added to a solution of N-tert-butoxycarbonyl-4-hydroxymethylpiperidine (52.5 g) in tert-butyl methyl ether (525 ml) and the mixture was stirred at ambient temperature for 15 minutes. The mixture was then cooled in an ice-bath to 5°C and a solution of 4-toluenesulphonyl chloride (62.8 g) in tert-butyl methyl ether (525 ml) was added dropwise over 2 hours while maintaining the reaction temperature at approximately 0°C. The resultant mixture was allowed to warm to ambient temperature and was stirred for 1 hour. Petroleum ether (b.p. 60-80°C, 1L) was added and the precipitate was removed by filtration. The filtrate was evaporated to give a solid residue which was dissolved in diethyl ether. The organic solution was washed in turn with 0.5N aqueous hydrochloric acid solution, water, a saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulphate and evaporated. There was thus obtained N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine (76.7 g), NMR Spectrum: (CDCl<sub>3</sub>) 1.0-1.2 (m, 2H), 1.45 (s, 9H), 1.65 (d, 2H), 1.75-1.9 (m, 2H), 2.45 (s, 3H), 2.55-2.75 (m, 2H), 3.85 (d, 1H), 4.0-4.2 (br s, 2H), 7.35 (d, 2H), 7.8 (d, 2H).

A portion (40 g) of the material so obtained was added to a suspension of ethyl 4-hydroxy-3-methoxybenzoate (19.6 g) and potassium carbonate (28 g) in DMF (200 ml) and the resultant mixture was stirred and heated to 95°C for 2.5 hours. The mixture was cooled to ambient temperature and partitioned between water and a mixture of ethyl acetate and diethyl ether. The organic layer was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The resulting oil was crystallised from petroleum ether (b.p. 60-80°C) and the suspension was stored overnight at 5°C. The resultant solid was collected by filtration, washed with petroleum ether and dried under vacuum. There was thus obtained ethyl 4-(N-tert-butoxycarbonylpiperidin-4-ylmethoxy)-3-methoxybenzoate (35 g), m.p. 81-83°C; NMR Spectrum: (CDCl<sub>3</sub>) 1.2-1.35 (m, 2H), 1.4 (t, 3H), 1.48 (s, 9H), 1.8-1.9 (d, 2H), 2.0-2.15 (m, 2H), 2.75 (t, 2H), 3.9 (d, 2H), 3.95 (s, 3H), 4.05-4.25 (br s, 2H), 4.35 (q, 2H), 6.85 (d, 1H), 7.55 (s, 1H), 7.65 (d, 1H).

The material so obtained was dissolved in formic acid (35 ml), formaldehyde (12M, 37% in water, 35 ml) was added and the mixture was stirred and heated to 95°C for 3 hours. The resultant mixture was evaporated. The residue was dissolved in methylene chloride and hydrogen chloride (3M solution in diethyl ether; 40 ml) was added. The mixture was diluted with diethyl ether and the mixture was triturated until a solid was formed. The solid was collected, washed with diethyl ether and dried under vacuum overnight at 50°C. There was thus obtained ethyl 3-methoxy-4-(N-methylpiperidin-4-ylmethoxy)benzoate (30.6 g),

NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.29 (t, 3H), 1.5-1.7 (m, 2H), 1.95 (d, 2H), 2.0-2.15 (br s, 1H), 2.72 (s, 3H), 2.9-3.1 (m, 2H), 3.35-3.5 (br s, 2H), 3.85 (s, 3H), 3.9-4.05 (br s, 2H), 4.3 (q, 2H), 7.1 (d, 1H), 7.48 (s, 1H), 7.6 (d, 1H).

The material so obtained was dissolved in methylene chloride (75 ml) and the solution  
5 was cooled in an ice-bath to 0-5°C. Trifluoroacetic acid (37.5 ml) was added followed by the  
dropwise addition over 15 minutes of a solution of fuming nitric acid (24M; 7.42 ml) in  
methylene chloride (15 ml). The resultant solution was allowed to warm to ambient  
temperature and was stirred for 2 hours. Volatile materials were evaporated. The residue was  
dissolved in methylene chloride (50 ml) and the solution was cooled in an ice-bath to 0-5°C.  
10 Diethyl ether was added and the resultant precipitate was collected and dried under vacuum at  
50°C. The solid was dissolved in methylene chloride (500 ml) and hydrogen chloride (3M  
solution in diethyl ether; 30 ml) was added followed by diethyl ether (500 ml). The resultant  
solid was collected and dried under vacuum at 50°C. There was thus obtained ethyl  
5-methoxy-4-(N-methylpiperidin-4-ylmethoxy)-2-nitrobenzoate (28.4 g), NMR Spectrum:  
15 (DMSO<sub>d</sub><sub>6</sub>) 1.3 (t, 3H), 1.45-1.65 (m, 2H), 1.75-2.1 (m, 3H), 2.75 (s, 3H), 2.9-3.05 (m, 2H),  
3.4-3.5 (d, 2H), 3.95 (s, 3H), 4.05 (d, 2H), 4.3 (q, 2H), 7.32 (s, 1H), 7.66 (s, 1H).

A mixture of a portion (3.89 g) of the material so obtained, 10% platinum-on-activated  
carbon (50% wet, 0.389 g) and methanol (80 ml) was stirred under 1.8 atmospheres pressure  
of hydrogen until uptake of hydrogen ceased. The mixture was filtered and the filtrate was  
20 evaporated. The residue was dissolved in water (30 ml) and basified to pH10 by the addition  
of a saturated aqueous sodium bicarbonate solution. The mixture was diluted with a 1:1  
mixture of ethyl acetate and diethyl ether and the organic layer was separated. The aqueous  
layer was further extracted with a 1:1 mixture of ethyl acetate and diethyl ether and the  
organic extracts were combined, washed in turn with water and brine, dried over magnesium  
25 sulphate and evaporated. The residue was triturated under a mixture of petroleum ether  
(b.p. 60-80°C) and diethyl ether. The solid so obtained was isolated, washed with petroleum  
ether and dried under vacuum at 60°C. There was thus obtained ethyl 2-amino-5-methoxy-  
4-(N-methylpiperidin-4-ylmethoxy)benzoate (2.58 g), m.p. 111-112°C; NMR Spectrum:  
(CDCl<sub>3</sub>) 1.35 (t, 3H), 1.4-1.5 (m, 2H), 1.85 (m, 3H), 1.95 (t, 2H), 2.29 (s, 3H), 2.9 (d, 2H), 3.8  
30 (s, 3H), 3.85 (d, 2H), 4.3 (q, 2H), 5.55 (br s, 2H), 6.13 (s, 1H), 7.33 (s, 1H).

A mixture of ethyl 2-amino-5-methoxy-4-(N-methylpiperidin-4-ylmethoxy)benzoate  
(16.1 g), formamidine acetic acid salt (5.2 g) and 2-methoxyethanol (160 ml) was stirred and  
heated at 115°C for 2 hours. Further formamidine acetic acid salt (10.4 g) was added in

portions every 30 minutes during 4 hours and heating was continued for 30 minutes after the last addition. The resultant mixture was evaporated. The solid residue was stirred under a mixture of methylene chloride (50ml) and ethanol (100ml). The precipitate was removed by filtration and the filtrate was concentrated to a final volume of 100ml. The resultant

5 suspension was cooled to 5°C. The solid so obtained was collected, washed with cold ethanol and with diethyl ether and dried under vacuum at 60°C. There was thus obtained 6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)-3,4-dihydroquinazolin-4-one (12.7 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.25-1.4 (m, 2H), 1.75 (d, 2H), 1.9 (t, 1H), 1.9 (s, 3H), 2.16 (s, 2H), 2.8 (d, 2H), 3.9 (s, 3H), 4.0 (d, 2H), 7.11 (s, 1H), 7.44 (s, 1H), 7.97 (s, 1H).

10 A mixture of a portion (2.8 g) of the material so obtained, thionyl chloride (28 ml) and DMF (0.28 ml) was heated to reflux for 1 hour. The mixture was evaporated and the precipitate was triturated under diethyl ether. The resultant solid was isolated and washed with diethyl ether. The solid was then dissolved in methylene chloride and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic layer was washed  
15 in turn with water and brine, dried over magnesium sulphate and evaporated. There was thus obtained 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (2.9 g), NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.5 (m, 2H), 1.75-1.9 (m, 4H), 2.0 (t, 1H), 2.25 (s, 3H), 2.85 (d, 2H), 4.02 (s, 3H), 4.12 (d, 2H), 7.41 (s, 1H), 7.46 (s, 1H), 8.9 (s, 1H).

A mixture of 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline  
20 (11.17 g), 4-bromo-2-fluorophenol (4.57 ml), potassium carbonate (7.19 g) and DMF (110 ml) was stirred and heated at 100°C for 2.5 hours. The mixture was allowed to cool to ambient temperature and was poured into a mixture (1L) of ice and water. The precipitate was collected, washed with water and dried. The solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a  
25 1% aqueous ammonium hydroxide solution (20:1:0 to 10:1:0 to 10:1:1) as eluent. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (13.1 g), NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.9 (t, 1H), 2.15 (s, 3H), 2.5 (br s, 2H), 4.0 (s, 3H), 4.1 (d, 2H), 7.4 (s, 1H), 7.45-7.6 (m, 3H), 7.8 (d, 1H), 8.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 and 478.

30 A portion (9.4 g) of the material so obtained was dissolved in a 2M solution of ammonia in isopropanol (150 ml). Liquid ammonia (10 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 130°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue


was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl *tert*-butyl ether. There was thus obtained 4-amino-6-methoxy-7-(*N*-methylpiperidin-4-ylmethoxy)quinazoline (5.55 g); NMR Spectrum: (DMSO- $d_6$ ) 1.2-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.8 (d, 2H), 3.8 (s, 3H), 3.9 (d, 2H), 7.0 (s, 1H), 7.3 (br s, 2H), 7.5 (s, 1H), 8.2 (s, 1H); Mass Spectrum:  $M+H^+$  303.

- A solution of 4-amino-6-methoxy-7-(*N*-methylpiperidin-4-ylmethoxy)quinazoline (0.15 g) in DMF (4.5 ml) was added to sodium hydride (60% dispersion in mineral oil, 0.03 g) and the reaction mixture was stirred at ambient temperature for 20 minutes.
- 10 2-Chloro-6-methylphenyl isothiocyanate (0.2 g) was added and the mixture was stirred at ambient temperature for 20 hours. The reaction mixture was evaporated and the residual solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia in methanol as eluent. There was thus obtained 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(*N*-methylpiperidin-
- 15 4-ylmethoxy)quinazolin-4-yl]thiourea (0.12 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.45-1.61 (m, 2H), 1.87-2.11 (m, 5H), 2.31 (s, 3H), 2.42 (s, 2H), 3.97 (d, 2H), 4.02 (m, 5H), 7.07 (s, 1H), 7.2-7.3 (m, 3H), 7.38 (t, 1H), 8.7 (s, 1H), 8.9 (s, 1H) 13.51 (s, 1H); Mass Spectrum:  $M+H^+$  486 and 488.

## 20 Example 2

Using an analogous procedure to that described in Example 1, the appropriate 1-aryl-3-quinazolin-4-ylthiourea was reacted with the appropriate amine to give the compounds described in Table I.

Table I



No. & Note	R <sup>6</sup>	R <sup>1</sup>	(R <sup>2</sup> ) <sub>n</sub>
[1]	allyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[2]	2-propynyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[3]	cyclopropyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[4]	cyclopropylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[5]	2-methoxyethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[6]	2-dimethylaminoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[7]	3-dimethylaminopropyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[8]	2-methylthioethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[9]	3-methylthiopropyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[10]	2-(2-hydroxyethoxy)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[11]	allyl	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl
[12]	2,2,2-trifluoroethyl	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl
[13]	2,3-dihydroxypropyl	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl
[14]	2-dimethylaminoethyl	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl
[15]	cyclobutyl	2-morpholinoethoxy	2-chloro-6-methyl
[16]	2-hydroxyethyl	2-morpholinoethoxy	2-chloro-6-methyl
[17]	2,3-dihydroxypropyl	2-morpholinoethoxy	2-chloro-6-methyl
[18]	2-methoxyethyl	2-morpholinoethoxy	2-chloro-6-methyl
[19]	2-dimethylaminoethyl	2-morpholinoethoxy	2-chloro-6-methyl
[20]	2,2,2-trifluoroethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro
[21]	2-methoxyethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro
[22]	2-dimethylaminoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro

[23]	2-acetamidoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro
[24]	2,2,2-trifluoroethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[25]	2-methoxyethyl	3-pyrrolidin-1-ylpropoxy	2,6-difluoro
[26]	2-dimethylaminoethyl	3-pyrrolidin-1-ylpropoxy	2,6-difluoro
[27]	2-dimethylaminoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dichloro
[28]	allyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[29]	2-methylthioethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[30]	2-methoxyethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[31]	2-dimethylaminoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[32]	3-dimethylaminopropyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[33]	4-hydroxycyclohexyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[34]	allyl	2-morpholinoethoxy	2,6-dimethyl
[35]	2-methoxyethyl	2-morpholinoethoxy	2,6-dimethyl
[36]	2-dimethylaminoethyl	2-morpholinoethoxy	2,6-dimethyl
[37]	2-(2-hydroxyethoxy)ethyl	2-morpholinoethoxy	2,6-dimethyl
[38]	2-ethoxyethyl	3-morpholinopropoxy	2,6-dimethyl
[39]	2-dimethylaminoethyl	3-morpholinopropoxy	2,6-dimethyl
[40]	2-cyanoethyl	3-morpholinopropoxy	2,6-dimethyl
[41]	allyl	cyclopropylmethoxy	2,6-dimethyl
[42]	2-methoxyethyl	cyclopropylmethoxy	2,6-dimethyl
[43]	2-dimethylaminoethyl	cyclopropylmethoxy	2,6-dimethyl
[44]	2-ethoxyethyl	2-pyrrolidin-1-ylethoxy	2,6-dimethyl
[45]	allyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl
[46]	2-methylsulphonylethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[47]	<i>t</i> -butoxycarbonylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[48]	2,3-dihydroxypropyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[49]	2-methoxycarbonylethyl	3-morpholinopropoxy	2,6-dimethyl
[50]	<i>t</i> -butoxycarbonylmethyl	2-pyrrolidin-1-ylethoxy	2,6-dimethyl
[51]	2-imidazol-4-ylethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[52]	2-(2-pyridyl)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[53]	2-phenethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl

[54]	2,6-difluorobenzyl	3-morpholinopropoxy	2,6-dimethyl
[55]	tetrahydrofuran-2-ylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[56]	tetrahydrofuran-2-ylmethyl	2-pyrrolidin-1-ylethoxy	2,6-dimethyl
[57]	1,4-dioxan-2-ylmethyl	3-pyrrolidin-1-ylpropoxy	2,6-difluoro
[58]	2-piperidinoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[59]	3-morpholinopropyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[60]	2-piperidinoethyl	cyclopropylmethoxy	2,6-dimethyl
[61]	2-morpholinoethyl	cyclopropylmethoxy	2,6-dimethyl
[62]	3-morpholinopropyl	cyclopropylmethoxy	2,6-dimethyl
[63]	3-(2-oxopyrrolidin-1-yl)propyl	2-morpholinoethoxy	2,6-dimethyl
[64]	1,4-dioxan-2-ylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[65]	2-methylsulphonyl-ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[66]	(2R)-tetrahydrofuran-2-ylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[67]	(2S)-tetrahydrofuran-2-ylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[68]	2-( <u>tert</u> -butoxycarbonyl-amino)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[69]	5-cyanopentyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[70]	2,2-dimethyl-3-hydroxypropyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[71]	2-cyclohexen-1-ylethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[72]	3-( <u>N</u> - <u>t</u> -butoxycarbonyl- <u>N</u> -methylamino)propyl	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl
[73]	3-( <u>N</u> - <u>t</u> -butoxycarbonyl- <u>N</u> -methylamino)propyl	2-morpholinoethoxy	2-methyl
[74]	3-dimethylaminopropyl	2-morpholinoethoxy	2-methyl
[75]	3-dimethylaminopropyl	2-morpholinoethoxy	2-chloro-6-methyl

[76]	3-( <u>N</u> - <u>t</u> -butoxycarbonyl- <u>N</u> -methylamino)propyl	2-morpholinoethoxy	2-chloro-6-methyl
[77]	3-dimethylaminopropyl	2-morpholinoethoxy	2-chloro
[78]	2-dimethylaminoethyl	2-morpholinoethoxy	2,6-dichloro
[79]	3-dimethylaminopropyl	2-morpholinoethoxy	2,6-dichloro
[80]	3-( <u>N</u> - <u>t</u> -butoxycarbonyl- <u>N</u> -methylamino)propyl	2-morpholinoethoxy	2,6-dichloro
[81]	2-dimethylaminopropyl	2-morpholinoethoxy	2,6-dimethyl
[82]	3-dimethylaminopropyl	benzyloxy	2,6-dimethyl
[83]	2-dimethylaminoethyl	benzyloxy	2,6-dimethyl
[84]	3-isopropylaminopropyl	3-morpholinopropoxy	2,6-dimethyl
[85]	5-cyanopentyl	2-morpholinoethoxy	2,6-dimethyl
[86]	3-hydroxy- 2,2-dimethylpropyl	2-morpholinoethoxy	2,6-dimethyl
[87]	2-dimethylaminoethyl	2-morpholinoethoxy	2-methyl
[88]	2-cyclohexen-1-ylethyl	2-morpholinoethoxy	2,6-dimethyl
[89]	3-dimethylaminopropyl	2-pyridylmethoxy	2,6-dimethyl
[90]	2-dimethylaminoethyl	2-pyridylmethoxy	2,6-dimethyl
[91]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	2-pyridylmethoxy	2,6-dimethyl
[92]	( <i>S</i> )-tetrahydrofuran-2-ylmethyl	2-pyridylmethoxy	2,6-dimethyl
[93]	( <i>R</i> )-tetrahydrofuran-2-ylmethyl	2-pyridylmethoxy	2,6-dimethyl
[94]	2-pyridylmethyl	2-pyridylmethoxy	2,6-dimethyl
[95]	2-methoxyethyl	2-pyridylmethoxy	2,6-dimethyl
[96]	5-cyanopentyl	2-pyridylmethoxy	2,6-dimethyl
[97]	<u>N</u> -( <u>tert</u> -butyl)carbamoyl-methyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[98]	<u>N</u> -isopropylcarbamoyl-methyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl

[99]	<u>N</u> -(2-dimethylamino-ethyl)carbamoylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[100]	( <i>S</i> )-1- <u>t</u> -butoxycarbonyl-ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[101]	( <i>R</i> )-1- <u>t</u> -butoxycarbonyl-ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[102]	( <i>S</i> )-1- <u>t</u> -butoxycarbonyl-ethyl	2-pyrrolidin-1-ylethoxy	2,6-dimethyl
[103]	( <i>R</i> )-1- <u>t</u> -butoxycarbonyl-ethyl	2-pyrrolidin-1-ylethoxy	2,6-dimethyl
[104]	<u>t</u> -butoxycarbonylmethyl	2-morpholinoethoxy	2,6-dimethyl
[105]	<u>N</u> -isopropylcarbamoylmethyl	2-morpholinoethoxy	2,6-dimethyl
[106]	<u>t</u> -butoxycarbonylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[107]	<u>N</u> -methylcarbamoylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[108]	<u>N</u> -isopropylcarbamoylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[109]	( <i>S</i> )-1- <u>t</u> -butoxycarbonyl-ethyl	2-pyridylmethoxy	2,6-dimethyl
[110]	2-(2-pyridyl)ethyl	3-morpholinopropoxy	2,6-dimethyl
[111]	2-pyridylmethyl	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl
[112]	3-pyridylmethyl	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl
[113]	4-pyridylmethyl	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl
[114]	2-(2-pyridyl)ethyl	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl
[115]	3-fluorobenzyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[116]	2-(2-pyridyl)ethyl	2-morpholinoethoxy	2,6-dimethyl
[117]	2-pyridylmethyl	2-morpholinoethoxy	2,6-dimethyl
[118]	(5-methyl-2-furyl)methyl	2-morpholinoethoxy	2,6-dimethyl
[119]	2-(2-thienyl)ethyl	2-morpholinoethoxy	2,6-dimethyl
[120]	2-thienylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl

[121]	2-(2-thienyl)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[122]	( <i>S</i> )-tetrahydrofuran-2-ylmethyl	2-morpholinoethoxy	2,6-dimethyl
[123]	( <i>R</i> )-tetrahydrofuran-2-ylmethyl	2-morpholinoethoxy	2,6-dimethyl
[124]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	2-morpholinoethoxy	2-chloro-6-methyl
[125]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	2-morpholinoethoxy	2-chloro
[126]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	2-morpholinoethoxy	2-methyl
[127]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	2-morpholinoethoxy	2,6-dichloro
[128]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	2-morpholinoethoxy	2,6-dimethyl
[129]	2-thienylmethyl	2-morpholinoethoxy	2,6-dimethyl
[130]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl
[131]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl
[132]	2-( <u>N</u> - <i>t</i> -butoxycarbonylpiperidin-2-yl)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[133]	2-pyrrolidin-1-ylethyl	3-morpholinopropoxy	2,6-dimethyl
[134]	3-pyrrolidin-1-ylpropyl	3-morpholinopropoxy	2,6-dimethyl
[135]	2-piperazin-1-ylethyl	3-morpholinopropoxy	2,6-dimethyl
[136]	3-(4-methylpiperazin-1-yl)propyl	3-morpholinopropoxy	2,6-dimethyl
[137]	2-dimethylaminoethyl	<u>N</u> -(2-methoxyethyl)piperidin-4-ylmethoxy	2,6-dimethyl
[138]	<i>t</i> -butoxycarbonylmethyl	<u>N</u> -(2-methoxyethyl)piperidin-4-ylmethoxy	2,6-dimethyl

[139]	(S)-tetrahydrofuran-2-ylmethyl	<u>N</u> -(2-methoxyethyl)piperidin-4-ylmethoxy	2,6-dimethyl
[140]	2-dimethylaminoethyl	<u>N</u> -benzylmorpholin-3-ylmethoxy	2,6-dimethyl
[141]	2-dimethylaminoethyl	<u>N</u> -benzylmorpholin-2-ylmethoxy	2,6-dimethyl
[142]	<u>N</u> -(2-hydroxyethyl)-carbamoylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl
[143]	<u>N</u> -(2-hydroxyethyl)-carbamoylmethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[144]	allyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methoxy
[145]	2-cyanoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methoxy
[146]	2-cyanoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[147]	2-fluorobenzyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[148]	4-dimethylaminobutyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[149]	cyclohexylmethyl	2-morpholinoethoxy	2,6-dimethyl
[150]	4-dimethylaminobutyl	2-morpholinoethoxy	2,6-dimethyl
[151]	2,3-dihydroxypropyl	2-morpholinoethoxy	2-methyl
[152]	4-dimethylaminobutyl	2-morpholinoethoxy	2-chloro-6-methyl
[153]	4-dimethylaminobutyl	2-pyridylmethoxy	2,6-dimethyl
[154]	4-dimethylaminobutyl	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl
[155]	2-dimethylaminoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl
[156]	2-dimethylaminoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-ethyl
[157]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl
[158]	2-dimethylaminoethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl
[159]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl
[160]	2-( <u>N</u> -methylpyrrolidin-2-yl)ethyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dichloro
[161]	4-dimethylaminobutyl	<u>N</u> -methylpiperidin-4-ylmethoxy	2-bromo
[162]	3-dimethylaminopropyl	<u>N</u> -methylpiperidin-3-ylmethoxy	2,6-dimethyl
[163]	2-cyanoethyl	3-dipropylamino-1-propynyl	2,6-dimethyl

Notes

- [1] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (q, 2H), 1.8 (d, 3H), 1.98 (t, 2H), 2.2 (s, 3H), 2.31 (s, 3H), 2.8 (d, 2H), 3.72 (s, 3H), 4.0 (m, 2H), 4.18 (t, 2H), 5.2 (d, 1H), 5.36 (d, 1H), 6.06 (m, 1H), 7.1 (s, 1H), 7.3 (m, 2H), 7.46 (m, 2H), 8.4 (br s, 1H), 8.48 (s, 1H), 10.31 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 509 and 511.
- [2] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.44 (m, 2H), 1.79 (d, 3H), 1.96 (t, 2H), 2.2 (s, 3H), 2.34 (s, 3H), 2.81 (d, 2H), 3.32 (s, 3H), 4.03 (m, 3H), 4.3 (d, 2H), 7.11 (s, 1H), 7.3 (m, 2H), 7.41 (s, 1H), 7.7 (s, 1H), 7.85 (br s, 1H), 8.5 (s, 1H), 10.93 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 507 and 509.
- [3] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.78 (m, 2H), 0.96 (m, 2H), 1.4 (m, 2H), 1.76 (d, 3H), 1.97 (t, 2H), 2.22 (s, 3H), 2.34 (s, 3H), 2.8 (m, 3H), 3.63 (s, 3H), 3.97 (d, 2H), 7.04 (s, 1H), 7.2–7.35 (m, 3H), 7.4 (d, 1H), 8.42 (s, 1H), 8.93 (s, 1H), 9.8 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 509 and 511.
- [4] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.34 (m, 2H), 0.51 (m, 2H), 1.23 (m, 1H), 1.4 (m, 2H), 1.76 (d, 3H), 1.93 (t, 2H), 2.19 (s, 3H), 2.32 (s, 3H), 2.79 (d, 2H), 3.42 (t, 2H), 3.7 (s, 3H), 3.97 (d, 2H), 7.07 (s, 1H), 7.28 (m, 2H), 7.41 (m, 2H), 8.42 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 523 and 525.
- [5] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.32 (m, 2H), 1.72 (d, 5H), 1.86 (t, 2H), 2.14 (s, 3H), 2.28 (s, 3H), 2.77 (m, 2H), 3.31 (m, 8H), 3.94 (d, 2H), 7.01 (s, 1H), 7.28 (m, 3H), 7.41 (d, 1H), 8.42 (s, 1H), 8.5 (br s, 1H), 10.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 527 and 529.
- [6] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.39 (m, 2H), 1.77 (m, 3H), 1.95 (t, 2H), 2.19 (s, 3H), 2.28 (s, 6H), 2.3 (s, 3H), 2.78 (m, 2H), 3.58 (t, 2H), 3.58 (t, 2H), 3.7 (s, 3H), 3.98 (d, 2H), 7.06 (s, 1H), 7.23 (t, 1H), 7.3 (d, 1H), 7.4 (m, 2H), 8.39 (br s, 1H), 8.41 (s, 1H), 10.52 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 540 and 542.
- [7] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.75 (m, 5H), 1.93 (t, 2H), 2.09 (s, 6H), 2.19 (s, 3H), 2.31 (s, 3H), 2.37 (q, 2H), 2.79 (m, 2H), 3.57 (t, 2H), 3.74 (s, 3H), 3.99 (d, 2H), 7.07 (s, 1H), 7.26 (t, 1H), 7.31 (d, 1H), 7.41 (d, 1H), 7.53 (s, 1H), 8.3 (br s, 1H), 8.42 (s, 1H), 10.6 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 554 and 556.
- [8] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.78 (m, 3H), 1.95 (t, 2H), 2.14 (s, 3H), 2.19 (s, 3H), 2.31 (s, 3H), 2.72–2.84 (m, 4H), 3.7 (q, 2H), 3.77 (s, 3H), 3.99 (d, 2H), 7.09 (s, 1H), 7.21–7.32 (m, 2H), 7.4 (d, 2H), 7.44 (s, 1H), 7.9 (br s, 1H), 8.43 (s, 3H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 543 and 545.

[9] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.76 (m, 3H), 1.9–2.0 (m, 3H), 2.08 (s, 3H), 2.19 (s, 3H), 2.31 (s, 3H), 2.6 (t, 2H), 2.78 (d, 2H), 3.59 (q, 2H), 3.75 (s, 3H), 3.98 (d, 2H), 7.08 (s, 1H), 7.21–7.32 (m, 2H), 7.4 (d, 1H), 7.52 (s, 1H), 8.10 (br s, 1H), 8.43 (s, 1H), 10.55 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 557 and 559.

[10] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.39 (m, 2H), 1.76 (m, 3H), 1.92 (t, 2H), 2.08 (s, 3H), 2.31 (s, 3H), 2.69 (t, 2H), 2.77 (m, 2H), 3.33 (t, 2H), 3.36 (m, 2H), 3.7 (m, 5H), 3.98 (d, 2H), 4.14 (s, 1H), 7.06 (s, 1H), 7.23 (t, 1H), 7.3 (d, 1H), 7.4 (d, 2H), 8.42 (s, 1H), 8.48 (br s, 1H), 10.01 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 557 and 559.

[11] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.7 (m, 4H), 1.94 (m, 2H), 2.31 (s, 3H), 2.55 (m, 4H), 2.6 (t, 2H), 3.71 (s, 3H), 4.23 (m, 4H), 5.17 (d, 1H), 5.32 (d, 1H), 6.01 (m, 1H), 7.07 (s, 1H), 7.2–7.3 (m, 2H), 7.39 (d, 1H), 7.44 (s, 1H), 8.32 (br s, 1H), 8.43 (s, 1H), 10.29 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 509 and 511.

15 The 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one ((International Patent Application WO 97/22596, Example 1 thereof; 25.1 g), thionyl chloride (450 ml) and DMF (1 ml) was stirred and heated to reflux for 2 hours. The mixture was evaporated and the residue was dissolved in toluene and the solution was evaporated. The resultant solid was suspended in methylene chloride (500 ml), solid potassium carbonate (39 g) was added and the mixture was stirred for 10 minutes. Water (500 ml) was added and the mixture stirred for another 10 minutes. The methylene chloride layer was separated, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. There was thus obtained 7-benzyloxy-4-chloro-6-methoxyquinazoline (21.54 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 4.0 (s, 3H), 5.36 (s, 2H), 7.31–7.46 (m, 4H), 7.51 (d, 2H), 7.58 (s, 1H), 8.88 (s, 1H).

A portion (3 g) of the material so obtained was dissolved in a 1M solution of ammonia in isopropanol (50 ml). Liquid ammonia (5 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl tert-butyl ether. There was thus obtained 4-amino-

7-benzyloxy-6-methoxyquinazoline (2.65 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.88 (s, 3H), 3.9 (s, 3H), 7.2 (s, 1H), 7.63 (s, 2H), 7.69 (s, 1H), 8.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 230.

A mixture of 4-amino-7-benzyloxy-6-methoxyquinazoline (4.15 g) and trifluoroacetic acid (35 ml) was stirred and heated to reflux for 1 hour. The solvent was evaporated, the residue was redissolved in a mixture of methylene chloride and toluene and the solvent was evaporated. The solid so obtained was suspended in water and basified to pH 11 by the addition of 2N aqueous sodium hydroxide solution. The mixture was then neutralised to pH 7 by the addition of 1N aqueous hydrochloric acid solution. The resultant solid was collected, washed in turn with water and acetonitrile and dried under vacuum over phosphorus pentoxide. There was thus obtained 4-amino-7-hydroxy-6-methoxyquinazoline (2.55 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.9 (s, 3H), 7.05 (s, 1H), 7.65 (s, 1H), 8.0 (br s, 2H), 8.35 (s, 1H), 10.0-11.0 (br s, 1H).

A portion (0.15 g) of the material so obtained and triphenylphosphine (0.31 g) were dissolved in DMF (3 ml). THF (3 ml) was added causing partial precipitation of the starting material. A solution of N-(3-hydroxypropyl)pyrrolidine (0.11 g) in THF (1 ml) was added followed by diethyl azodicarboxylate (0.186 ml) and the reaction mixture was stirred at ambient temperature for 30 minutes. Further portions of triphenylphosphine (0.105 g), N-(3-hydroxypropyl)pyrrolidine (0.02 g) and diethyl azodicarboxylate (0.062 ml) were added and reaction mixture was stirred at ambient temperature for a further 30 minutes. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-amino-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (0.16 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.9 (m, 2H), 2.05 (m, 2H), 2.25 (m, 2H), 3.05 (m, 2H), 3.35 (m, 2H), 3.65 (m, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 303.

The material so obtained was reacted with 2-chloro-6-methylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]thiourea; NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.18 (m, 2H), 2.4 (s, 3H), 2.55 (m, 4H), 2.68 (t, 2H), 4.02 (s, 3H), 4.3 (t, 2H), 7.07 (s, 1H), 7.26 (m, 2H), 7.31 (s, 1H), 7.37 (m, 1H), 8.7 (s, 1H), 8.94 (br s, 1H), 13.51 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 486 and 488.

The N-(3-hydroxypropyl)pyrrolidine used as a starting material was prepared as follows :-

A mixture of 3-chloropropanol (66 g), pyrrolidine (50 g), potassium carbonate (145 g) and acetonitrile (1 L) was stirred and heated to reflux for 20 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by distillation to give the required starting material as an oil (62 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.6-1.8 (m, 6H), 2.55 (br s, 4H), 2.75 (t, 2H), 3.85 (t, 2H), 5.5 (br s, 1H).

[12] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.73 (m, 4H), 1.95 (m, 2H), 2.3 (s, 3H), 2.67 (m, 2H), 3.8 (s, 3H), 3.88-3.97 (d, 1H), 4.1-4.25 (m, 3H), 4.35 (m, 2H), 7.1 (s, 1H), 7.2-7.3 (m, 2H), 7.4 (d, 1H), 7.64 (br s, 2H), 8.5 (s, 1H), 11.43 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 551 and 553.

[13] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.7 (m, 4H), 1.95 (m, 2H), 2.32 (s, 3H), 2.63 (m, 2H), 3.53 (m, 4H), 3.73 (m, 5H), 3.8 (br s, 1H), 4.18 (t, 2H), 4.33 (m, 1H), 4.75 (br s, 1H), 7.07 (s, 1H), 7.2-7.3 (m, 2H), 7.42 (m, 1H), 8.47 (br s, 2H), 10.15 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 543 and 545.

[14] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.71 (m, 4H), 1.95 (m, 2H), 2.26 (s, 6H), 2.31 (s, 3H), 2.55 (m, 4H), 2.6 (t, 4H), 3.58 (q, 2H), 3.7 (s, 3H), 4.16 (t, 2H), 7.06 (s, 1H), 7.2-7.3 (m, 2H), 7.39 (d, 1H), 8.4 (br s, 1H), 8.41 (s, 1H), 10.56 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 540 and 542.

[15] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.71-1.9 (m, 2H), 2.1 (m, 2H), 2.3 (s, 3H), 2.5 (m, 6H), 2.78 (t, 2H), 3.59 (t, 4H), 3.68 (s, 3H), 4.21 (t, 2H), 4.48 (q, 1H), 7.08 (s, 1H), 7.2-7.4 (m, 4H), 8.43 (s, 1H), 8.98 (br s, 1H), 9.53 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 525 and 527.

The 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

A mixture of 7-acetoxy-6-methoxyquinazolin-4-one (International Patent Application WO 96/15118, Example 17 thereof; 15 g), thionyl chloride (225 ml) and DMF (5 ml) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and the thionyl chloride was evaporated. The material so obtained was dissolved in toluene and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. There was thus obtained 7-acetoxy-4-chloro-6-methoxyquinazoline (13.2 g) which was used without further purification.

A mixture of the material so obtained was reacted with 2-bromo-4-fluorophenol using an analogous procedure to that described in the third last paragraph of the portion of Example 1 above which is concerned with the preparation of starting materials. There was thus obtained 7-acetoxy-4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazoline (14.7 g).

5 A mixture of a portion (3 g) of the material so obtained, concentrated ammonium hydroxide solution (0.88 g/ml, approximately 14M; 60 ml) and methanol (120 ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was triturated under diethyl ether. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (2.2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.99 (s, 3H), 7.25 (s, 1H), 7.39 (m, 1H), 7.54 (m, 2H), 7.78 (m, 1H), 8.47 (s, 1H), 10.82 (s, 1H); Mass Spectrum: M-H<sup>+</sup> 363 & 365.

A mixture of 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (0.94 g), 2-morpholinoethyl chloride (0.4 g), potassium carbonate (1.42 g) and DMF (20 ml) was stirred and heated to 65°C for 16 hours. The mixture was filtered and evaporated. The  
15 resulting oil was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M methanolic ammonia solution as eluent. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline (0.72 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.63 (t, 4H), 2.98 (t, 2H), 3.76 (t, 4H), 4.06 (s, 3H), 4.34 (t, 2H), 7.22 (t, 1H), 7.32 (s, 1H), 7.41 (t, 2H), 7.52 (s, 1H), 8.6 (s, 1H); Mass Spectrum:  
20 M+H<sup>+</sup> 478 and 480.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the second last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained 4-amino-6-methoxy-7-(2-morpholinoethoxy)quinazoline; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.5 (m, 4H), 2.75 (t, 2H),  
25 3.58 (t, 4H), 3.87 (s, 3H), 4.2 (t, 2H), 7.09 (s, 1H), 7.39 (s, 2H), 7.58 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 305.

The material so obtained was reacted with 2-chloro-6-methylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of  
Example 1 which is concerned with the preparation of starting materials. There was thus  
30 obtained the required starting material 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea; NMR Spectrum: (CDCl<sub>3</sub>) 2.43 (s, 3H), 2.66 (t, 4H), 2.97 (t, 2H), 3.78 (t, 4H), 4.07 (s, 3H), 4.36 (t, 2H), 7.11 (s, 1H), 7.26 (s, 1H), 7.32 (s,

1H), 7.39 (m, 1H), 8.73 (s, 1H), 8.94 (s, 1H), 13.55 (s, 1H); Mass Spectrum:  $M+H^+$  488 and 490.

[16] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 2.3 (s, 3H), 2.5 (m, 4H), 2.78 (t, 2H), 3.6 (m, 6H), 3.7 (m, 5H), 4.22 (t, 2H), 4.64 (s, 1H), 7.1 (s, 1H), 7.22 (t, 1H), 7.3 (d, 1H), 7.4 (d, 1H), 8.42 (s, 1H), 8.5 (br s, 1H), 10.02 (br s, 1H); Mass Spectrum:  $M+H^+$  515 and 517.

[17] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 2.3 (s, 3H), 2.5 (m, 4H), 2.78 (t, 2H), 3.49 (m, 3H), 3.59 (t, 4H), 3.69 (m, 4H), 3.8 (s, 1H), 4.22 (t, 2H), 4.29 (s, 1H), 4.74 (s, 1H), 7.1 (s, 1H), 7.28 (m, 2H), 7.4 (m, 2H), 8.4 (br s, 1H), 8.45 (s, 1H), 10.2 (br s, 1H); Mass Spectrum:  $M+H^+$  545 and 547.

[18] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 2.3 (s, 3H), 2.52 (m, 4H), 2.79 (t, 2H), 3.35 (s, 3H), 3.57 (t, 4H), 3.64 (m, 4H), 3.7 (s, 3H), 4.21 (t, 2H), 7.1 (s, 1H), 7.26 (m, 2H), 7.4 (t, 2H), 8.33 (br s, 1H), 8.44 (s, 1H), 10.25 (br s, 1H); Mass Spectrum:  $M+H^+$  529 and 531.

[19] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 2.25 (s, 6H), 2.3 (s, 3H), 2.5 (m, 4H), 2.59 (t, 2H), 2.76 (t, 2H), 3.59 (t, 6H), 3.7 (s, 3H), 4.22 (t, 2H), 7.1 (s, 1H), 7.21 (t, 1H), 7.29 (d, 1H), 7.41, (t, 2H), 8.35 (br s, 1H), 8.43 (s, 1H), 10.55 (br s, 1H); Mass Spectrum:  $M+H^+$  542 and 544.

[20] The product gave the following data: Mass Spectrum:  $M+H^+$  539.

The 1-(2,6-difluorophenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline was reacted with 2,6-difluorophenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material : NMR Spectrum: (CDCl<sub>3</sub>) 1.43–1.6 (m, 2H), 1.83–2.09 (m, 5H), 2.33 (s, 3H), 2.94 (d, 2H), 4.04 (m, 5H), 7.0–7.14 (m, 4H), 7.27 (m, 1H), 7.35 (m, 1H), 8.7 (s, 1H), 13.49 (s, 1H); Mass Spectrum:  $M+H^+$  474.

[21] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.41 (m, 2H), 1.77 (m, 3H), 1.94 (t, 2H), 2.2 (s, 3H), 2.8 (d, 2H), 3.39 (s, 3H), 3.68 (m, 4H), 3.71 (s, 3H), 3.99 (d, 2H), 7.09 (s, 1H), 7.2 (t, 2H), 7.39 (s, 2H), 8.46 (s, 1H), 9.34 (br s, 1H), 9.69 (br s, 1H); Mass Spectrum:  $M+H^+$  515.

[22] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.41 (m, 2H), 1.78 (m, 3H), 1.97 (t, 2H), 2.2 (s, 3H), 2.31 (s, 6H), 2.63 (t, 2H), 2.8 (d, 2H), 3.6 (t, 2H),

3.71 (s, 3H), 3.99 (d, 2H), 7.09 (s, 1H), 7.19 (t, 2H), 7.39 (m, 2H), 8.47 (s, 1H), 9.4 (br s, 1H), 10.2 (br s, 1H); Mass Spectrum:  $M+H^+$  528.

[23] The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.67 (m, 2H), 1.98–2.10 (m, 6H), 2.19 (t, 2H), 2.44 (s, 3H), 3.04 (m, 2H), 3.63 (q, 2H), 3.87 (q, 2H), 4.01 (s, 3H), 4.24 (d, 2H), 7.32 (s, 1H), 7.42 (t, 2H), 7.61 (m, 1H), 7.7 (s, 1H), 7.94 (s, 1H), 8.7 (s, 1H), 9.11 (br s, 1H), 10.26 (br s, 1H); Mass Spectrum:  $M+H^+$  542.

[24] The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.52 (m, 2H), 1.9 (m, 3H), 2.3 (s, 3H), 2.4 (m, 5H), 3.0 (d, 2H), 3.8 (s, 3H), 4.05 (d, 2H), 4.31 (m, 2H), 7.17 (s, 1H), 7.3 (m, 2H), 7.41 (d, 1H), 7.63 (s, 1H), 7.72 (br s, 1H), 8.5 (s, 1H), 10.41 (br s, 1H); Mass Spectrum:  $M+H^+$  551 and 553.

[25] The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.71 (m, 4H), 1.97 (m, 2H), 2.54 (m, 4H), 2.64 (t, 2H), 3.4 (s, 3H), 3.69 (m, 7H), 4.19 (t, 2H), 7.11 (s, 1H), 7.18 (m, 2H), 7.39 (s, 2H), 8.48 (s, 1H), 9.32 (br s, 1H), 9.6 (br s, 1H); Mass Spectrum:  $M+H^+$  515.

15 The 1-(2,6-difluorophenyl)-3-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]thiourea used as a starting material was prepared by the reaction of 4-amino-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline with 2,6-difluorophenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. The required starting material gave the  
20 following data : NMR Spectrum: (CDCl $_3$ ) 1.83 (s, 4H), 2.2 (m, 2H), 2.61 (s, 4H), 2.74 (t, 2H), 4.04 (s, 3H), 4.48 (t, 2H), 6.98–7.11 (m, 3H), 7.27–7.41 (m, 3H), 8.71 (s, 1H), 13.48 (s, 1H); Mass Spectrum:  $M+H^+$  474.

[26] The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.87 (m, 4H), 2.0 (m, 2H), 2.32 (s, 6H), 2.53–2.7 (m, 8H), 3.6 (t, 2H), 3.7 (s, 3H), 4.2 (t, 2H), 7.09 (s, 1H), 7.18 (m, 2H), 7.31 (m, 2H), 8.48 (s, 1H), 9.43 (br s, 1H); Mass Spectrum:  $M+H^+$  528.

[27] The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.41 (m, 2H), 1.88 (m, 3H), 2.0 (t, 2H), 2.21 (s, 3H), 2.29 (s, 6H), 2.62 (t, 2H), 2.8 (d, 2H), 3.58 (t, 2H), 3.68 (s, 3H), 3.96 (d, 2H), 7.07 (s, 1H), 7.3 (m, 2H), 7.53 (d, 2H), 8.43 (s, 1H), 9.1 (br s, 1H); Mass Spectrum:  $M+H^+$  560, 562 and 564.

30 The 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline was reacted with 2,6-dichlorophenyl isothiocyanate using an analogous procedure to that described in the last

paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material : Mass Spectrum:  $M+H^+$  506 and 508.

[28] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H),  
5 1.76 (m, 3H), 1.96 (m, 2H), 2.2 (s, 3H), 2.24 (s, 6H), 2.8 (m, 2H), 3.77 (s, 3H), 3.99 (m, 2H),  
4.12 (t, 2H), 5.14 (d, 1H), 5.29 (d, 1H), 6.01 (m, 1H), 7.06 (s, 1H), 7.17 (s, 3H), 7.54 (s, 1H),  
8.41 (s, 1H), 8.6 (br s, 1H), 10.5 (br s, 1H); Mass Spectrum:  $M+H^+$  489.

The 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

10 4-Amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline was reacted with  
2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last  
paragraph of the portion of Example 1 which is concerned with the preparation of starting  
materials. There was thus obtained the required starting material : NMR Spectrum: (CDCl<sub>3</sub>)  
1.44–1.61 (m, 2H), 1.87–2.08 (m, 5H), 2.32 (s, 3H), 2.36 (s, 6H), 2.94 (d, 2H), 4.04 (m, 5H),  
15 7.1 (s, 1H), 7.19 (m, 3H), 7.29 (s, 1H), 8.69 (s, 1H), 8.9 (s, 1H), 13.37 (s, 1H); Mass  
Spectrum:  $M+H^+$  466.

[29] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H),  
1.77 (m, 3H), 1.93 (t, 2H), 2.1 (s, 3H), 2.09 (s, 3H), 2.27 (s, 6H), 2.78 (m, 4H), 3.68 (q, 2H),  
3.81 (s, 3H), 4.0 (d, 2H), 7.09 (s, 1H), 7.18 (s, 3H), 7.69 (s, 1H), 8.44 (s, 1H), 11.1 (s, 1H);  
20 Mass Spectrum:  $M+H^+$  523.

[30] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H),  
1.78 (d, 3H), 1.97 (t, 2H), 2.2 (s, 3H), 2.27 (s, 6H), 2.79 (d, 2H), 3.32 (s, 3H), 3.6 (m, 2H),  
3.66 (m, 2H), 3.76 (s, 3H), 3.99 (d, 2H), 7.08 (s, 1H), 7.18 (s, 3H), 7.58 (s, 1H), 8.43 (s, 1H),  
10.54 (br s, 1H); Mass Spectrum:  $M+H^+$  507.

25 [31] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.39 (m,  
2H), 1.75 (m, 3H), 1.92 (t, 2H), 2.19 (s, 3H), 2.22 (s, 6H), 2.25 (s, 6H), 2.54 (t, 2H), 2.77 (m,  
2H), 3.58 (q, 2H), 3.76 (s, 3H), 3.98 (d, 2H), 7.05 (s, 1H), 7.16 (s, 3H), 7.59 (s, 1H), 8.41 (s,  
1H), 10.80 (br s, 1H); Mass Spectrum:  $M+H^+$  520.

[32] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H),  
30 1.75 (m, 5H), 1.94 (t, 2H), 2.02 (s, 6H), 2.19 (s, 3H), 2.24 (s, 6H), 2.33 (t, 2H), 2.8 (d, 2H),  
3.57 (t, 2H), 3.8 (s, 3H), 4.0 (d, 2H), 7.06 (s, 1H), 7.18 (s, 3H), 7.63 (s, 1H), 8.42 (s, 1H), 10.9  
(br s, 1H); Mass Spectrum:  $M+H^+$  534.

[33] trans-4-Hydroxycyclohexylamine was used as the appropriate amine and the reaction mixture also contained diisopropylethylamine (1 equivalent). The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.5 (m, 6H), 1.7-2.1 (m, 9H), 2.18 (s, 3H), 2.25 (s, 6H), 2.77 (d, 2H), 2.97 (br s, 2H), 3.5 (s, 3H), 3.9-4.0 (m, 3H), 4.1 (d, 1H), 7.01 (s, 1H),  
5 7.13 (s, 1H), 7.41 (br s, 1H), 8.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 547.

[34] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.29 (s, 6H), 2.55 (m, 4H), 2.8 (t, 2H), 3.61 (t, 4H), 3.87 (s, 3H), 4.2 (t, 2H), 4.37 (t, 2H), 5.18 (d, 1H), 5.3 (d, 1H), 6.03 (m, 1H), 7.11 (s, 1H), 7.2 (s, 3H), 7.59 (s, 1H), 7.6 (br s, 1H), 8.45 (s, 1H), 10.52 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 491.

10 The 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-6-methoxy-7-(2-morpholinoethoxy)quinazoline was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting  
15 materials. There was thus obtained the required starting material : NMR Spectrum: (CDCl<sub>3</sub>) 2.36 (s, 6H), 2.61 (t, 4H), 2.95 (t, 2H), 3.77 (t, 4H), 4.04 (s, 3H), 4.34 (t, 2H), 7.11 (s, 1H), 7.2 (m, 3H), 7.31 (s, 1H), 8.69 (s, 1H), 8.9 (s, 1H), 13.36 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 468.

[35] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.28 (s, 6H), 2.52 (m, 4H), 2.8 (t, 2H), 3.33 (s, 3H), 3.6 (m, 6H), 3.68 (t, 2H), 3.78 (s, 3H), 4.26 (t, 2H),  
20 7.11 (s, 1H), 7.2 (s, 3H), 7.6 (s, 1H), 8.44 (s, 1H), 10.55 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 509.

[36] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.24 (s, 6H), 2.28 (s, 6H), 2.57 (m, 6H), 2.8 (t, 2H), 3.59 (m, 6H), 3.77 (s, 3H), 4.26 (t, 2H), 7.11 (s, 1H), 7.19 (s, 3H), 7.6 (s, 1H), 8.42 (s, 1H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 522.

25 [37] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.29 (s, 6H), 2.54 (m, 4H), 2.8 (t, 2H), 3.54 (m, 4H), 3.61 (t, 4H), 3.69 (m, 4H), 3.78 (s, 3H), 4.12 (s, 1H), 4.25 (t, 2H), 7.11 (s, 1H), 7.18 (s, 3H), 7.5 (br s, 1H), 7.59 (s, 1H), 8.45 (s, 1H), 10.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 539.

[38] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.12 (t, 3H), 2.13 (m, 2H), 2.33 (s, 6H), 2.5 (m, 4H), 2.58 (t, 2H), 3.45 (d, 2H), 3.61 (d, 2H), 3.73 (m, 6H), 3.98 (s, 3H), 4.26 (t, 2H), 4.7 (s, 1H), 7.18 (s, 4H), 7.86 (s, 1H), 8.56 (s, 1H), 12.53 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 537.

The 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-7-hydroxy-6-methoxyquinazoline was reacted with N-(3-hydroxypropyl)morpholine (Bull. Soc. Chim. Fr. 1962, 1117) using an analogous procedure to that described in the second last paragraph of the portion of Note [11] hereinbefore that is concerned with the preparation of starting materials. There was thus obtained 4-amino-6-methoxy-7-(3-morpholinopropoxy)quinazoline; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.25 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (m, 2H), 3.7 (t, 2H), 3.95 (s, 3H), 4.05 (m, 2H), 4.3 (t, 2H), 7.35 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 319.

4-Amino-6-methoxy-7-(3-morpholinopropoxy)quinazoline was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material : NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.0 (m, 2H), 2.4 (s, 4H), 2.45 (t, 2H), 3.58 (t, 4H), 4.03 (s, 3H), 4.21 (t, 2H), 7.18 (m, 3H), 7.33 (s, 1H), 8.19 (s, 1H), 8.71 (s, 1H), 11.09 (s, 1H), 13.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 482.

[39] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.2-2.31 (m, 8H), 2.33 (s, 6H), 2.5 (s, 6H), 2.59 (t, 2H), 3.65 (d, 2H), 3.73 (t, 4H), 4.02 (s, 3H), 4.26 (t, 2H), 4.85 (s, 1H), 7.17 (m, 4H), 7.9 (s, 1H), 8.55 (s, 1H), 12.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 536.

[40] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.13 (m, 2H), 2.36 (s, 6H), 2.49 (m, 4H), 2.6 (t, 2H), 2.97 (t, 2H), 3.73 (t, 4H), 3.8 (q, 2H), 4.02 (s, 3H), 4.27 (t, 2H), 4.65 (t, 1H), 7.21 (d, 4H), 7.8 (s, 1H), 8.6 (s, 1H), 12.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 518.

[41] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 0.42 (m, 2H), 0.71 (m, 2H), 1.28 (m, 1H), 2.35 (s, 6H), 3.98 (m, 5H), 4.21 (m, 2H), 4.35 (br s, 1H), 5.1-5.25 (m, 2H), 5.97 (m, 1H), 7.15 (s, 1H), 7.18 (s, 3H), 7.91 (br s, 1H), 8.55 (s, 1H), 12.58 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 432.

The 1-(2,6-dimethylphenyl)-3-(7-cyclopropylmethoxy-6-methoxyquinazolin-4-yl)thiourea used as a starting material was prepared as follows :-

A mixture of 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (6.99 g), cyclopropylmethyl chloride (2.16 g), potassium iodide (0.043 g), potassium carbonate (12 g) and DMF (200 ml) was stirred and heated to 45°C for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by

column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-

7-cyclopropylmethoxy-6-methoxyquinazoline (7.6 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.43 (m, 2H), 0.68 (m, 2H), 1.37 (m, 1H), 4.0 (s, 3H), 4.1 (d, 2H), 7.4 (s, 1H), 7.45 (m, 1H), 7.57 (m, 2H), 7.82 (m, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 421 and 423.

Using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials, 4-(4-bromo-2-fluorophenoxy)-7-cyclopropylmethoxy-6-methoxyquinazoline (1.75 g) was reacted with ammonia in isopropanol. There was thus obtained 4-amino-7-cyclopropylmethoxy-6-methoxyquinazoline (1.75 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.36 (m, 2H), 0.58 (m, 2H), 1.3 (m, 1H), 3.88 (s, 3H), 3.94 (d, 2H), 6.97 (s, 1H), 7.39 (br s, 2H), 7.55 (s, 1H), 8.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 246.

4-Amino-7-cyclopropylmethoxy-6-methoxyquinazoline was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material : NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.39 (m, 2H), 0.61 (m, 2H), 1.32 (m, 1H), 2.25 (s, 6H), 4.0 (m, 5H), 7.17 (s, 3H), 7.25 (s, 1H), 8.17 (s, 1H), 8.72 (s, 1H), 11.08 (br s, 1H), 13.67 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 409.

[42] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 0.42 (m, 2H), 0.69 (m, 2H), 1.44 (m, 1H), 2.3 (s, 6H), 3.32 (s, 3H), 3.62 (br s, 2H), 3.77 (m, 2H), 4.02 (d, 5H), 4.65 (br, 1H), 7.15 (s, 1H), 7.17 (s, 3H), 7.88 (br s, 1H), 8.57 (s, 1H), 12.52 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

[43] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.36 (m, 2H), 0.58 (m, 2H), 1.23-1.31 (m, 1H), 2.22 (s, 6H), 2.24 (s, 6H), 2.32-2.66 (m, 2H), 3.55 (m, 2H), 3.75 (br s, 3H), 3.96 (d, 2H), 7.04 (s, 1H), 7.16 (s, 3H), 7.55 (br s, 1H), 8.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 463.

[44] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.1 (t, 3H), 1.72 (m, 4H), 2.27 (s, 6H), 2.64 (m, 4H), 2.9 (m, 2H), 3.52 (q, 2H), 3.65 (s, 4H), 3.75 (s, 3H), 4.23 (m, 2H), 7.07 (s, 1H), 7.17 (s, 3H), 7.56 (s, 1H), 8.42 (s, 1H), 10.3-10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 507.

The 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-pyrrolidin-1-ylethyl chloride using an analogous procedure to that described in the third last paragraph of Note [15] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.83 (m, 4H), 2.69 (m, 4H), 3.06 (t, 2H), 4.04 (s, 3H), 4.34 (t, 2H), 7.21 (t, 1H), 7.31 (s, 1H), 7.4 (t, 2H), 7.53 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 462 & 464.

Using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials, 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline was reacted with ammonia to give 4-amino-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.7 (s, 4H), 2.5 (m, 4H), 2.83 (t, 2H), 3.87 (s, 3H), 4.19 (t, 2H), 7.07 (s, 1H), 7.39 (s, 2H), 7.56 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 289.

4-Amino-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material : NMR Spectrum: (CDCl<sub>3</sub>) 1.78 (m, 4H), 1.95 (br s, 2H), 2.28 (s, 6H), 2.64 (br t, 4H), 2.99 (t, 2H), 3.98 (s, 3H), 4.27 (t, 2H), 7.05 (s, 1H), 7.08-7.17 (m, 3H), 7.26 (s, 1H), 7.97 (s, 1H), 8.64 (s, 1H), 13.34 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 452.

[45] The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>, 100°C) 1.44 (m, 2H), 1.78 (m, 3H), 1.96 (m, 2H), 2.2 (s, 3H), 2.3 (s, 3H), 2.78 (m, 2H), 3.8 (s, 3H), 4.0 (d, 2H), 4.18 (m, 2H), 5.14 (m, 1H), 5.3 (m, 1H), 6.0-6.1 (m, 1H), 7.12 (s, 1H), 7.2-7.32 (m, 4H), 7.64 (s, 1H), 7.96 (m, 1H), 8.44 (s, 1H), 10.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 475.

The 1-(2-methylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline was reacted with 2-methylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material : Mass Spectrum: M+H<sup>+</sup> 452.

[46] The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>, 100°C) 1.42 (m, 2H), 1.8 (m, 3H), 1.96 (t, 2H), 2.19 (s, 3H), 2.31 (s, 3H), 2.79 (m, 2H), 3.0 (s, 3H), 3.49 (t,

2H), 3.85 (s, 3H), 3.95 (m, 2H), 4.01 (d, 01), 7.11 (s, 1H), 7.2 (br s, 1H), 7.3 (m, 2H), 7.4 (d, 1H), 7.71 (s, 1H), 8.48 (s, 1H), 11.67 (br s, 1H); Mass Spectrum:  $M+H^+$  575 and 577.

[47] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.22-1.43 (m, 11H), 1.67-1.95 (m, 5H), 2.13 (s, 3H), 2.27 (s, 6H), 2.77 (d, 2H), 3.8-4.0 (m, 7H), 6.52 (br s, 1H), 7.04 (s, 1H), 7.18 (s, 3H), 7.8 (s, 1H), 8.42 (s, 1H), 12.26 (s, 1H); Mass Spectrum:  $M+H^+$  563.

[48] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.5 (m, 2H), 1.7-1.82 (m, 3H), 1.82-1.95 (m, 2H), 2.17 (s, 3H), 2.24 (s, 6H), 2.75 (d, 2H), 3.35-3.5 (m, 3H), 3.62-3.8 (m, 5H), 3.95 (m, 2H), 4.35 (br s, 1H), 4.75 (br s, 1H), 7.03 (br s, 1H), 7.14 (br s, 3H), 7.52 (br s, 1H), 8.41 (br s, 1H); Mass Spectrum:  $M+H^+$  523.

[49] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.13 (m, 2H), 2.29 (s, 6H), 2.48 (m, 4H), 2.57 (t, 2H), 3.63 (s, 3H), 3.73 (m, 2H), 4.0 (s, 3H), 4.26 (t, 2H), 4.7 (s, 1H), 7.19 (m, 4H), 7.88 (s, 1H), 8.57 (s, 1H), 12.5 (s, 1H); Mass Spectrum:  $M+H^+$  551.

[50] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (s, 9H), 1.72 (m, 4H), 2.31 (s, 6H), 2.6 (m, 4H), 2.9 (t, 2H), 3.88 (s, 3H), 4.06 (d, 2H), 4.25 (t, 2H), 6.75 (br s, 1H), 7.07 (s, 1H), 7.17 (s, 3H), 7.75 (s, 1H), 8.47 (s, 1H), 11.4-11.8 (br s, 1H); Mass Spectrum:  $M+H^+$  549.

[51] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.79 (m, 3H), 1.93 (t, 2H), 2.21 (s, 3H), 2.3 (s, 3H), 2.77 (m, 4H), 3.71 (s, 3H), 3.78 (q, 2H), 3.99 (d, 2H), 6.73 (s, 1H); 6.84 (s, 1H), 7.08 (s, 1H), 7.22-7.31 (m, 2H), 7.39-7.53 (m, 4H), 8.3 (br s, 1H), 8.41 (s, 1H); Mass Spectrum:  $M+H^+$  563 and 565.

[52] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.79 (m, 3H), 1.98 (t, 2H), 2.2 (s, 3H), 2.3 (s, 3H), 2.79 (d, 2H), 3.2 (t, 2H), 3.75 (s, 3H), 3.91 (q, 2H), 4.0 (d, 2H), 7.1 (s, 1H), 7.15-7.33 (m, 4H), 7.41 (d, 1H), 7.58 (s, 1H), 7.7 (m, 1H), 8.11 (br s, 1H), 8.4 (s, 1H), 8.46 (d, 1H), 10.67 (br s, 1H); Mass Spectrum:  $M+H^+$  574 and 576.

[53] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.77 (d, 3H), 1.94 (t, 2H), 2.2 (s, 3H), 2.3 (s, 3H), 2.78 (d, 2H), 3.01 (m, 2H), 3.7 (s, 3H), 3.78 (q, 2H), 4.0 (d, 2H), 7.08 (s, 1H), 7.18-7.36 (m, 7H), 7.41 (d, 1H), 7.49 (s, 1H), 8.3 (br s, 1H), 8.4 (s, 1H), 10.4 (br s, 1H); Mass Spectrum:  $M+H^+$  573 and 575.

[54] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.14 (m, 2H), 2.25 (s, 6H), 2.49 (m, 4H), 2.58 (t, 2H), 3.73 (t, 4H) 4.1 (s, 3H), 4.27 (t, 2H), 4.82 (d, 1H), 4.9 (d, 2H),

6.87 (t, 3H), 7.06 (s, 1H), 7.18 (m, 3H), 8.1 (s, 1H), 8.55 (s, 1H), 12.71 (s, 1H); Mass Spectrum:  $M+H^+$  591.

[55] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.5 (m, 2H), 1.64-2.04 (m, 10H), 2.15 (s, 3H), 2.25 (s, 6H), 2.74 (d, 2H), 3.5-3.9 (m, 8H), 3.95 (d, 2H), 4.14 (m, 1H), 7.02 (s, 1H), 7.14 (s, 3H), 7.44 (s, 1H), 8.41 (s, 1H); Mass Spectrum:  $M+H^+$  533.

[56] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.5 (m, 1H), 1.67 (m, 4H), 1.83 (m, 4H), 1.96 (m, 1H), 2.26 (s, 6H), 2.6 (m, 4H), 2.9 (t, 2H), 3.5-3.8 (m, 4H), 3.75 (s, 3H), 4.18 (m, 1H), 4.21 (t, 2H), 7.06 (s, 1H), 7.17 (s, 3H), 7.52 (s, 1H), 8.47 (s, 1H), 10.0-10.8 (br s, 1H); Mass Spectrum:  $M+H^+$  519.

[57] The 2-aminomethyl-1,4-dioxane, used as a starting material was obtained using the procedure described in Chemical Abstracts, volume 132, abstract 293722. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.72 (m, 4H), 1.99 (m, 2H), 2.56 (m, 4H), 2.62 (t, 2H), 3.41 (m, 1H), 3.5-3.62 (m, 4H), 3.66-3.78 (m, 4H), 3.83-3.92 (m, 3H), 4.2 (t, 2H), 7.11 (s, 1H), 7.2 (m, 2H), 7.34-7.44 (m, 2H), 8.49 (s, 1H), 9.09 (br s, 1H), 9.83 (br s, 1H); Mass Spectrum:  $M+H^+$  557.

[58] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.34-1.54 (m, 8H), 1.78 (m, 3H), 1.95 (t, 2H), 2.2 (s, 3H), 2.34 (s, 3H), 2.5 (m, 4H), 2.62 (t, 2H), 2.79 (d, 2H), 3.61 (q, 2H), 3.73 (s, 3H), 3.99 (d, 2H), 7.11 (s, 1H), 7.24 (m, 1H), 7.31 (m, 1H), 7.42 (m, 2H), 8.46 (s, 1H), 10.63 (s, 1H); Mass Spectrum:  $M+H^+$  580 and 582.

[59] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.78 (m, 3H), 1.88 (m, 2H), 1.97 (t, 2H), 2.2 (s, 3H), 2.32 (s, 3H), 2.39 (t, 4H), 2.44 (t, 2H), 3.58 (m, 6H), 3.8 (d, 2H), 3.74 (s, 3H), 3.99 (d, 2H), 7.08 (s, 1H), 7.21-7.33 (m, 2H), 7.41 (m, 2H), 8.4 (br s, 1H), 8.42 (s, 1H), 10.28 (br s, 1H); Mass Spectrum:  $M+H^+$  596 and 598.

[60] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 0.41 (m, 2H), 0.62 (m, 2H), 1.3 (m, 1H), 1.33-1.47 (m, 6H), 2.27 (s, 6H), 2.43 (m, 4H), 2.55 (m, 2H), 3.57 (m, 2H), 3.75 (s, 3H), 3.97 (d, 2H), 7.04 (s, 1H), 7.16 (s, 3H), 7.59 (s, 1H), 8.43 (s, 1H); Mass Spectrum:  $M+H^+$  503.

[61] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 0.38 (m, 2H), 0.59 (m, 2H), 1.28 (m, 1H), 2.28 (s, 6H), 2.46 (m, 4H), 2.62 (m, 2H), 3.53 (m, 4H), 3.64 (br m, 2H), 3.79 (s, 3H), 3.98 (d, 2H), 7.05 (s, 1H), 7.17 (s, 3H), 7.6 (s, 1H), 8.42 (s, 1H); Mass Spectrum:  $M+H^+$  505.

[62] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 0.38 (m, 2H), 0.59 (m, 2H), 1.27 (m, 1H), 1.84 (m, 2H), 2.27 (s, 6H), 2.37 (m, 4H), 2.44 (m, 2H), 3.48-3.58 (m, 6H), 3.77 (s, 3H), 3.98 (d, 2H), 7.05 (s, 1H), 7.15 (s, 3H), 7.57 (s, 1H), 8.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 519.

5 [63] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.89 (m, 4H), 2.09 (t, 2H), 2.29 (s, 6H), 2.54 (t, 4H), 2.8 (t, 2H), 3.3 (t, 2H), 3.37 (t, 2H), 3.49 (q, 2H), 3.6 (t, 4H), 3.8 (s, 3H), 4.26 (t, 2H), 7.11 (s, 1H), 7.19 (s, 3H), 7.30 (br s, 1H), 7.61 (s, 1H), 8.43 (s, 1H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 576.

[64] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.39 (m, 2H), 1.77 (m, 3H), 1.93 (t, 2H), 2.17 (s, 3H), 2.31 (s, 3H), 2.57 (m, 2H), 2.77 (m, 2H), 3.22 (m, 1H), 3.36-3.9 (m, 9H), 3.96 (d, 2H), 7.09 (s, 1H), 7.23 (t, 1H), 7.3 (d, 1H), 7.39 (d, 1H), 7.47 (s, 1H), 8.18 (br s, 1H), 8.42 (s, 1H), 10.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 569 and 571.

[65] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.78 (d, 3H), 1.96 (t, 2H), 2.19 (s, 3H), 2.27 (s, 6H), 2.79 (m, 2H), 3.0 (s, 3H), 3.49 (t, 2H), 3.89 (s, 3H), 3.95 (m, 2H), 4.01 (d, 2H), 6.56 (br s, 1H), 7.1 (s, 1H), 7.2 (m, 3H), 7.8 (s, 1H), 8.47 (s, 1H), 11.72 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 555.

[66] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.5 (m, 2H), 1.64-2.04 (m, 10H), 2.15 (s, 3H), 2.25 (s, 6H), 2.74 (d, 2H), 3.5-3.9 (m, 8H), 3.95 (d, 2H), 4.14 (m, 1H), 7.02 (s, 1H), 7.14 (s, 3H), 7.44 (s, 1H), 8.41 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533.

[67] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 533.

[68] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 592.

[69] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.58 (m, 3H), 1.65-1.8 (m, 8H), 1.98 (t, 2H), 2.2 (s, 3H), 2.33 (s, 3H), 2.8 (d, 2H), 3.52 (q, 2H), 3.73 (s, 3H), 4.0 (d, 2H), 7.1 (s, 1H), 7.28 (m, 2H), 7.41 (m, 2H), 8.3 (br s, 1H), 8.45 (s, 1H), 10.25 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 564 and 566.

[70] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.18 (s, 6H), 1.6 (m, 2H), 1.97 (d, 3H), 2.25 (t, 2H), 2.4 (s, 3H), 2.51 (s, 3H), 2.99 (d, 2H), 3.51 (s, 2H), 3.62 (d, 2H), 3.9 (s, 3H), 4.26 (d, 2H), 4.71 (s, 1H), 7.21 (s, 1H), 7.4-7.61 (m, 4H), 8.63 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 555 and 557.

[71] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.52 (m, 2H), 1.6 (m, 2H), 1.79 (d, 3H), 1.92-2.07 (m, 6H), 2.2 (s, 3H), 2.31 (m, 5H),

2.79 (d, 2H), 3.61 (q, 2H), 3.72 (s, 3H), 4.0 (d, 2H), 5.53 (s, 1H), 7.09 (s, 1H), 7.23–7.33 (m, 2H), 7.4 (d, 1H), 7.47 (s, 1H), 8.43 (s, 1H); Mass Spectrum:  $M+H^+$  577 and 579.

[72] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.38 (s, 9H), 1.72 (m, 4H), 1.92 (m, 2H), 1.97 (m, 2H), 2.61 (t, 2H), 2.8 (s, 3H), 2.83 (s, 3H), 3.34 (t, 2H), 3.52 (q, 2H), 3.78 (s, 3H), 4.19 (t, 2H), 7.07 (s, 1H), 7.24–7.34 (m, 2H), 7.42 (m, 1H), 7.49 (br s, 1H), 8.0–8.3 (br s, 1H), 8.44 (s, 1H), 10.3–10.7 (br s, 1H); Mass Spectrum:  $M+H^+$  640 and 642.

[73] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.39 (s, 9H), 1.41 (s, 3H), 1.9 (m, 2H), 2.31 (s, 3H), 2.56 (t, 4H), 2.8 (t, 2H), 3.33 (t, 2H), 3.52 (q, 2H), 3.6 (t, 4H), 3.8 (s, 3H), 4.27 (t, 2H), 7.12 (s, 1H), 7.2 (t, 1H), 7.27 (t, 1H), 7.31 (d, 2H), 7.64 (s, 1H), 8.46 (s, 1H); Mass Spectrum:  $M+H^+$  608.

The 1-(2-methylphenyl)-3-[6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-6-methoxy-7-(2-morpholinoethoxy)quinazoline was reacted with 2-methylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 2.44 (s, 3H), 2.66 (t, 4H), 2.96 (t, 2H), 3.76 (t, 4H), 4.09 (s, 3H), 4.37 (t, 2H), 7.11 (s, 1H), 7.33 (m, 4H), 7.76 (d, 1H), 8.71 (s, 1H), 8.86 (s, 1H), 13.73 (s, 1H); Mass Spectrum:  $M+H^+$  454.

[74] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.8 (m, 2H), 2.1 (s, 6H), 2.34 (s, 3H), 2.39 (t, 2H), 2.57 (t, 4H), 2.82 (t, 2H), 3.61 (m, 6H), 3.82 (s, 3H), 4.29 (t, 2H), 7.15 (s, 1H), 7.23 (t, 1H), 7.3 (t, 1H), 7.36 (d, 2H), 7.69 (s, 1H), 8.47 (s, 1H); Mass Spectrum:  $M+H^+$  522.

[75] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.79 (m, 2H), 2.1 (s, 6H), 2.34 (s, 3H), 2.39 (t, 2H), 2.58 (t, 4H), 2.82 (t, 2H), 3.6 (t, 6H), 3.77 (s, 3H), 4.26 (t, 2H), 7.11 (s, 1H), 7.28 (t, 1H), 7.33 (d, 1H), 7.42 (d, 1H), 7.53 (s, 1H), 8.47 (s, 1H); Mass Spectrum:  $M+H^+$  556 and 558.

[76] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.39 (s, 9H), 1.91 (m, 2H), 2.33 (s, 3H), 2.55 (t, 4H), 2.8 (t, 2H), 2.84 (s, 3H), 3.32 (t, 2H), 3.53 (q, 2H), 3.6 (t, 4H), 3.77 (s, 3H), 4.27 (t, 2H), 7.11 (s, 1H), 7.26 (t, 1H), 7.32 (d, 1H), 7.41 (d, 1H), 7.5 (s, 1H), 8.46 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 642 and 644.

[77] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.81 (m, 2H), 2.14 (s, 6H), 2.4 (t, 2H), 2.56 (t, 4H), 2.81 (t, 2H), 3.6 (m, 6H), 3.81 (s, 3H), 4.29 (t, 2H), 7.14 (s, 1H), 7.29 (t, 1H), 7.41 (t, 1H), 7.57 (d, 1H), 7.61 (d, 2H), 8.49 (s, 1H), 8.6 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 542 and 544.

The 1-(2-chlorophenyl)-3-[6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

15 4-Amino-6-methoxy-7-(2-morpholinoethoxy)quinazoline was reacted with 2-chlorophenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 2.65 (t, 4H), 2.99 (t, 2H), 3.77 (t, 4H), 4.07 (s, 3H), 4.35 (t, 2H), 7.11 (s, 1H), 7.26 (m, 1H), 7.36 (m, 2H), 7.52 (d, 1H), 8.4 (d, 1H), 8.76 (s, 1H), 8.87 (s, 1H), 14.37 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 474 and 476.

[78] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.3 (s, 6H), 2.53 (t, 4H), 2.64 (t, 2H), 2.81 (t, 2H), 3.6 (m, 6H), 3.7 (s, 3H), 4.25 (t, 2H), 7.12 (s, 1H), 7.33 (m, 2H), 7.57 (m, 2H), 8.47 (s, 1H), 9.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 562 and 564.

The 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

30 4-Amino-6-methoxy-7-(2-morpholinoethoxy)quinazoline was reacted with 2,6-dichlorophenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 2.68 (t, 4H), 2.97 (t, 2H), 3.75 (t, 4H), 4.06 (s, 3H), 4.38 (t, 2H), 7.17 (s, 1H), 7.31 (d, 1H),

7.47 (t, 2H), 8.03 (s, 1H), 8.75 (s, 1H), 9.09 (s, 1H), 13.72 (s, 1H); Mass Spectrum:  $M+H^+$  508 and 510.

[79] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.83 (m, 2H), 2.15 (s, 6H), 2.4 (t, 2H), 2.57 (t, 4H), 2.81 (t, 2H), 3.58 (m, 6H), 3.73 (s, 3H), 4.25 (t, 2H), 7.12 (s, 1H), 7.36 (t, 1H), 7.42 (s, 1H), 7.59 (d, 2H), 8.47 (s, 1H), 8.8 (br s, 1H); Mass Spectrum:  $M+H^+$  576 and 578.

[80] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (s, 9H), 1.91 (m, 2H), 2.55 (t, 4H), 2.79 (t, 2H), 2.83 (s, 3H), 3.35 (t, 2H), 3.52 (q, 2H), 3.61 (t, 4H), 3.75 (s, 3H), 4.29 (t, 2H), 7.14 (s, 1H), 7.38 (s, 1H), 7.44 (s, 1H), 7.58 (d, 2H), 8.47 (s, 1H); Mass Spectrum:  $M+H^+$  662 and 664.

[81] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 0.98 (d, 3H), 2.2 (s, 6H), 2.27 (s, 6H), 2.52 (t, 4H), 2.79 (t, 2H), 2.88 (m, 1H), 3.49–3.52 (m, 2H), 3.59 (t, 4H), 3.76 (s, 3H), 4.23 (m, 2H), 7.1 (s, 1H), 7.16 (m, 3H), 7.54 (s, 1H), 8.41 (s, 1H), 10.67 (br s, 1H); Mass Spectrum:  $M+H^+$  536.

[82] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.76 (m, 2H), 2.08 (s, 6H), 2.29 (s, 6H), 2.37 (t, 2H), 3.6 (t, 2H), 3.82 (s, 3H), 5.28 (s, 2H), 7.2 (m, 4H), 7.34 (m, 1H), 7.41 (m, 2H), 7.5 (d, 2H), 7.69 (s, 1H), 8.44 (s, 1H), 10.8 (br s, 1H); Mass Spectrum:  $M+H^+$  513.

The 1-(7-benzyloxy-6-methoxyquinazolin-4-yl)-3-(2,6-dimethylphenyl)thiourea used as a starting material was prepared as follows :-

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (International Patent Application WO 97/22596, Example 1 thereof; 25.1 g), thionyl chloride (450 ml) and DMF (1 ml) was stirred and heated to reflux for 2 hours. The mixture was evaporated and the residue was dissolved in toluene and the solution was evaporated. The resultant solid was suspended in methylene chloride (500 ml), solid potassium carbonate (39 g) was added and the mixture was stirred for 10 minutes. Water (500 ml) was added and the mixture stirred for another 10 minutes. The methylene chloride layer was separated, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. There was thus

obtained 7-benzyloxy-4-chloro-6-methoxyquinazoline (21.54 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 4.0 (s, 3H), 5.36 (s, 2H), 7.31–7.46 (m, 4H), 7.51 (d, 2H), 7.58 (s, 1H), 8.88 (s, 1H).

A portion (3 g) of the material so obtained was dissolved in a 1M solution of ammonia in isopropanol (50 ml). Liquid ammonia (5 ml) was added and the reaction mixture was  
5 sealed in a Carius tube. The reaction mixture was heated to 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl *tert*-butyl ether. There was thus obtained 4-amino-7-benzyloxy-6-methoxyquinazoline (2.65 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.88 (s, 3H), 3.9 (s,  
10 3H), 7.2 (s, 1H), 7.63 (s, 2H), 7.69 (s, 1H), 8.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 230.

4-Amino-7-benzyloxy-6-methoxyquinazoline was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material; NMR Spectrum: (DMSO-d<sub>6</sub>)  
15 2.22 (s, 6H), 4.0 (s, 3H), 5.33 (s, 2H), 7.14 (m, 3H), 7.31–7.54 (m, 6H), 8.2 (s, 1H), 8.7 (s, 1H), 11.12 (s, 1H), 13.69 (s, 1H).

[83] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 2.24 (s, 6H), 2.29 (s, 6H), 2.57 (t, 2H), 3.6 (q, 2H), 3.8 (s, 3H), 5.28 (s, 2H), 7.19 (m, 4H), 7.34 (t, 1H) 7.41 (t, 2H), 7.5 (t, 2H), 7.62 (s, 1H), 8.43 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 499.

20 [84] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 0.87 (d, 6H), 1.85 (m, 2H), 2.12 (m, 2H), 2.31 (s, 6H), 2.5 (t, 4H), 2.58 (t, 2H), 2.75 (m, 3H), 3.72 (m, 6H), 4.03 (s, 3H), 4.25 (t, 2H), 5.17 (m, 1H), 7.15 (s, 3H), 7.18 (s, 1H), 7.86 (s, 1H), 8.57 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 564.

[85] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.54 (m, 2H), 1.64–1.78 (m, 4H), 2.27 (s, 6H), 2.47 (t, 2H), 2.54 (t, 4H), 2.8 (t, 2H), 3.52 (q, 2H), 3.61 (t, 4H), 3.77 (s, 3H), 4.26 (t, 2H), 7.11 (s, 1H), 7.18 (s, 3H), 7.58 (s, 1H), 8.43 (s, 1H), 10.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 546.

[86] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 0.94 (s, 6H), 2.28 (s, 6H), 2.55 (t, 4H), 2.8 (t, 2H), 3.29 (s, 2H), 3.47 (d, 2H), 3.61 (t, 4H), 3.73 (s, 3H),  
30 4.25 (t, 2H), 4.5 (s, 1H), 7.1 (s, 1H), 7.17 (s, 3H), 7.5 (s, 1H), 8.44 (s, 1H), 10.2 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 537.

[87] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the

following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.29 (s, 6H), 2.32 (s, 3H), 2.55 (t, 4H), 2.6 (t, 2H), 2.8 (t, 2H), 3.61 (m, 6H), 3.8 (s, 3H), 4.26 (t, 2H), 7.14 (s, 1H), 7.2 (t, 1H), 7.28 (t, 1H), 7.36 (t, 2H), 7.67 (s, 1H), 7.85 (br s, 1H), 8.48 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 508.

[88] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.53 (m, 4H), 1.99 (d, 4H), 2.27 (m, 10H), 2.57 (t, 4H), 2.8 (t, 2H), 3.58 (t, 4H), 3.79 (s, 3H), 4.25 (t, 2H), 5.46 (s, 1H), 7.11 (s, 1H), 7.19 (s, 3H), 7.6 (s, 1H), 8.42 (s, 1H), 10.7 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 559.

[89] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.78 (m, 2H), 2.06 (s, 6H), 2.28 (s, 6H), 2.35 (t, 2H), 3.6 (t, 2H), 3.83 (s, 3H), 5.31 (s, 2H), 7.2 (s, 4H), 7.32 (t, 2H), 7.55 (d, 1H), 7.68 (s, 1H), 7.8 (t, 1H), 8.41 (s, 1H), 8.59 (d, 1H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 514.

The 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(2-pyridylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

A mixture of 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (9.0 g), 2-pyridylmethyl chloride hydrochloride (4.49 g), anhydrous potassium carbonate (17.2 g) and NMP (100 ml) was stirred and heated to 85°C for 16 hours. About half of the solvent was evaporated and the resulting slurry was poured into water (900 ml). The mixture was stirred for two hours and the resultant precipitate was isolated. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-6-methoxy-7-(2-pyridylmethoxy)quinazoline (9.72 g); NMR Spectrum: (CDCl<sub>3</sub>) 4.11 (s, 3H), 5.47 (s, 2H), 7.27 (m, 2H), 7.42 (m, 3H), 7.6 (d, 2H), 7.76 (m, 1H), 8.6 (s, 1H), 8.66 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 456 and 458.

Using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials, 4-(4-bromo-2-fluorophenoxy)-6-methoxy-7-(2-pyridylmethoxy)quinazoline was reacted with ammonia in isopropanol. There was thus obtained 4-amino-6-methoxy-7-(2-pyridylmethoxy)quinazoline; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.9 (s, 3H), 5.31 (s, 2H), 7.13 (s, 1H), 7.39 (m, 3H), 7.56 (d, 1H), 7.62 (s, 1H), 7.86 (m, 1H), 8.24 (s, 1H), 8.61 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 283.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.23 (s, 6H), 4.04 (s, 3H), 5.4 (s, 2H), 7.14 (s, 3H), 7.39 (m, 2H), 7.59 (d, 1H), 7.88 (m, 1H), 8.21 (s, 1H), 8.61 (d, 1H), 8.69 (d, 1H), 11.14 (s, 1H), 13.67 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 446.

- [90] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.27 (d, 12H), 2.6 (t, 2H), 3.6 (t, 2H), 3.86 (s, 3H), 5.31 (s, 2H), 7.19 (m, 4H), 7.32 (m, 1H), 7.55 (d, 1H), 7.61 (s, 1H), 7.82 (t, 1H), 8.42 (s, 1H), 8.6 (s, 1H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 500.
- 5 [91] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.52–1.7 (m, 4H), 1.8–1.94 (m, 2H), 2.01 (q, 1H), 2.1 (s, 3H), 2.28 (s, 7H), 2.75 (s, 1H), 3.52 (m, 1H), 3.66 (m, 1H), 3.86 (s, 3H), 5.32 (s, 2H), 7.19 (s, 4H), 7.31 (t, 1H), 7.54 (d, 1H), 7.71 (s, 1H), 7.82 (t, 1H), 8.43 (s, 1H), 8.6 (s, 1H), 11.1 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 540.
- [92] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.7 (m, 1H),  
10 1.9 (m, 2H), 1.99 (m, 1H), 2.29 (s, 6H), 3.57 (m, 1H), 3.65 (m, 2H), 3.8 (m, 4H), 4.15 (m, 1H), 5.31 (s, 2H), 7.18 (s, 4H), 7.33 (m, 1H), 7.55 (d, 1H), 7.81 (t, 1H), 8.42 (s, 1H), 8.6 (d, 1H), 10.23 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 513.
- [93] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.69 (m, 1H), 1.88 (m, 2H), 1.99 (m, 1H), 2.29 (s, 6H), 3.52 (m, 1H), 3.65 (m, 2H), 3.79 (m, 3H), 3.84  
15 (m, 1H), 4.15 (m, 1H), 5.31 (s, 2H), 7.19 (s, 4H), 7.33 (t, 1H), 7.54 (d, 2H), 7.81 (t, 1H), 8.43 (s, 1H), 8.6 (d, 1H), 10.25 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 513.
- [94] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.3 (s, 6H), 3.79 (s, 3H), 4.8 (d, 2H), 5.3 (s, 2H), 7.17 (s, 1H), 7.2 (s, 3H), 7.25 (m, 1H), 7.33 (m, 1H), 7.43 (d, 1H), 7.55 (m, 2H), 7.74 (t, 1H), 7.81 (t, 1H), 8.41 (s, 1H), 8.5 (d, 1H), 8.6 (d, 1H),  
20 11.03 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 520.
- [95] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.28 (s, 6H), 3.34 (s, 3H), 3.62 (t, 2H), 3.7 (t, 2H), 3.8 (s, 3H), 5.32 (s, 2H), 7.19 (s, 4H), 7.32 (m, 1H), 7.54 (d, 1H), 7.6 (s, 1H), 7.82 (t, 1H), 8.42 (s, 1H), 8.59 (s, 1H), 10.54 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 487.
- 25 [96] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.52 (m, 2H), 1.68 (m, 4H), 2.27 (s, 6H), 2.48 (m, 2H), 3.51 (q, 2H), 3.8 (s, 3H), 5.31 (s, 2H), 7.18 (s, 4H), 7.32 (t, 1H), 7.55 (d, 1H), 7.61 (s, 1H), 7.82 (t, 1H), 8.41 (s, 1H), 8.6 (d, 1H), 10.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 524.
- [97] Glycine *tert*-butylamide (*J. Med. Chem.*, 1979, 22, 931) was used as the appropriate  
30 amine and 1,2-dimethoxyethane was used as a co-solvent. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.22 (s, 9H), 1.24 (q, 2H), 1.7–2.0 (m, 5H), 2.14 (s, 3H), 2.29 (s, 6H), 2.77 (m, 2H), 3.86 (s, 3H), 3.92 (d, 2H), 3.99 (d, 2H), 7.08–7.13 (m, 2H), 7.19 (s, 3H), 7.33 (br s, 1H), 8.48 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 562.

[98] Glycine isopropylamide (J. Amer. Chem. Soc., 1967, 89, 6096) was used as the appropriate amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.04 (d, 6H), 1.36-1.48 (m, 2H), 1.77 (br d, 3H), 1.96 (br t, 2H), 2.19 (s, 3H), 2.28 (s, 6H), 2.78 (br d, 2H), 3.83 (s, 4H), 4.0 (m, 4H), 7.09 (s, 1H), 7.19 (s, 3H), 7.35 (m, 1H), 7.7 (s, 1H),  
5 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 548.

[99] Glycine N-(2-dimethylaminoethyl)amide (J. Amer. Chem. Soc., 1967, 89, 7123) was used as the appropriate amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.44 (m, 2H), 1.68-1.84 (m, 3H), 1.86-1.95 (m, 2H), 2.02 (s, 6H), 2.15 (s, 3H), 2.2-2.3 (m, 2H), 2.26 (s, 6H), 2.76 (d, 2H), 3.12-3.2 (m, 2H), 3.84 (s, 3H), 3.96-4.02  
10 (m, 4H), 7.06 (s, 1H), 7.16 (s, 3H), 7.4 (s, 1H), 7.7 (s, 1H), 8.46 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 577.

[100] (S)-Alanine tert-butyl ester hydrochloride was treated with triethylamine to give the required amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.46 (m, 14H), 1.72-1.8 (br d, 3H), 1.88-1.96 (m, 2H), 2.17 (s, 3H), 2.28 (s, 6H), 2.72-  
15 2.82 (br d, 2H), 3.88 (s, 3H), 3.98 (d, 2H), 4.38 (m 1H), 7.04 (s, 1H), 7.16 (s, 3H), 7.73 (s, 1H), 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 577.

[101] (R)-Alanine tert-butyl ester hydrochloride was treated with triethylamine to give the required amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.46 (m, 14H), 1.72-1.8 (br d, 3H), 1.88-1.96 (m, 2H), 2.17 (s, 3H), 2.28 (s, 6H), 2.72-  
20 2.82 (br d, 2H), 3.88 (s, 3H), 3.98 (d, 2H), 4.38 (m 1H), 7.04 (s, 1H), 7.16 (s, 3H), 7.73 (s, 1H), 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 577.

[102] (S)-Alanine tert-butyl ester hydrochloride was treated with triethylamine to give the required amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.36 (s, 9H), 1.42 (d, 3H), 1.72 (m, 4H), 2.32 (s, 6H), 2.65 (m, 4H), 2.91 (t, 2H), 3.88 (s, 3H),  
25 4.24 (t, 2H), 4.48 (q, 1H), 7.12 (s, 1H), 7.19 (s, 1H), 7.77 (s, 1H), 8.47 (s, 1H), 11.4-11.75 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 563.

[103] (R)-Alanine tert-butyl ester hydrochloride was treated with triethylamine to give the required amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.35 (s, 9H), 1.46 (d, 3H), 1.7 (m, 4H), 2.28 (s, 6H), 2.63 (m, 4H), 2.91 (t, 2H), 3.88 (s, 3H),  
30 4.27 (t, 2H), 4.46 (quintet, 1H), 7.12 (s, 1H), 7.18 (s, 1H), 7.75 (s, 1H), 8.46 (s, 1H), 11.45-11.65 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 563.

[104] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (s, 9H), 2.3 (s, 6H), 2.54 (t, 4H), 2.8 (t, 2H), 3.6 (t, 4H), 3.89 (s, 3H), 4.02 (d, 2H), 4.28 (t, 2H), 7.11 (s, 1H), 7.19 (s, 3H), 7.78 (s, 1H), 8.48 (s, 1H), 11.6 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 565.

[105] Glycine isopropylamide was used as the appropriate amine. The product gave the  
5 following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.05 (d, 6H), 2.27 (s, 6H), 2.48-2.52 (m, 4H), 2.78 (t, 2H), 3.56-3.62 (m, 4H), 3.82-3.9 (m, 4H), 4.02 (d, 2H), 4.25 (t, 2H), 7.15 (s, 1H), 7.20 (s, 3H), 7.35 (br s, 1H), 7.73 (s, 1H), 8.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 550.

[106] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 11H), 1.79 (d, 3H), 1.95 (t, 2H), 2.2 (s, 3H), 2.37 (s, 3H), 2.8 (m, 2H), 3.89 (s, 3H), 4.01 (d,  
10 2H), 4.07 (d, 2H), 7.11 (s, 1H), 7.31 (m, 2H), 7.44 (d, 1H), 7.7 (s, 1H), 8.49 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 583 and 585.

[107] Glycine methylamide was used as the appropriate amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.42 (m, 2H), 1.79 (d, 2H), 1.96 (t, 2H), 2.2 (s, 3H), 2.37 (s, 3H), 2.7 (d, 3H), 2.8 (d, 2H), 3.81 (s, 3H), 4.0 (d, 2H), 4.05 (d, 2H), 7.1 (s,  
15 1H), 7.3 (m, 2H), 7.52 (s, 1H), 7.61 (s, 1H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 540 and 542.

[108] Glycine isopropylamide was used as the appropriate amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.02-1.10 (m, 6H), 1.32-1.44 (m, 2H), 1.76 (br d, 3H), 1.93 (br t, 2H), 2.19 (s, 3H), 2.34 (s, 3H), 2.78 (d, 2H), 3.79 (s, 3H), 3.82-3.96 (m, 1H), 3.98-4.04 (m, 4H), 7.05 (s, 1H), 7.22-7.34 (m, 3H), 7.41 (d, 1H), 7.6 (s, 1H), 8.45 (s,  
20 1H); Mass Spectrum: M+H<sup>+</sup> 568 and 570.

[109] (*S*)-Alanine *tert*-butyl ester hydrochloride was treated with triethylamine to give the required amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.19 (d, 3H), 1.34 (s, 6H), 1.4 (s, 9H), 3.9 (s, 3H), 4.44 (m, 1H), 5.3 (s, 2H), 6.99 (s, 1H), 7.18 (s, 4H), 7.3 (m, 1H), 7.53 (d, 1H), 7.8 (m, 2H), 8.41 (s, 1H), 8.56 (d, 1H), 11.5 (br s, 1H);  
25 Mass Spectrum: M+H<sup>+</sup> 557.

[110] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.13 (m, 2H), 2.2 (s, 6H), 2.5 (t, 4H) 2.58 (t, 2H), 3.13 (t, 2H), 3.72 (t, 4H), 4.0 (m, 5H), 4.28 (t, 2H), 5.6 (m, 1H), 7.05-7.21 (m, 6H), 7.58 (m, 1H), 7.98 (s, 1H), 8.22 (d, 1H), 8.57 (s, 1H), 12.43 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 570.

[111] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.29 (s, 6H), 3.3 (s, 3H), 3.5 (t, 2H), 3.64 (t, 2H), 3.76 (s, 3H), 3.84 (t, 2H), 4.26 (t, 2H), 4.8 (d, 2H), 7.1 (s, 1H), 7.2 (s, 3H), 7.25 (m, 1H), 7.45 (d, 1H), 7.54 (s, 1H), 7.77 (t, 1H), 8.48 (s, 1H), 8.51 (d, 1H), 11.08 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 531.

The 1-(2,6-dimethylphenyl)-3-{6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazolin-4-yl}thiourea used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-(2-methoxyethoxy)ethyl tosylate (prepared from 2-(2-methoxyethoxy)ethanol and tosyl chloride) using an analogous procedure to that described in the third last paragraph of Note [41] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 3.4 (s, 3H), 3.6 (m, 2H), 3.76 (m, 2H), 4.03 (m, 5H), 4.39 (t, 2H), 7.21 (m, 1H), 7.34 (s, 1H), 7.41 (t, 2H), 7.51 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 467 & 469.

10 The material so obtained was reacted with ammonia using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 4-amino-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline; NMR Spectrum: (DMSO-d<sub>6</sub>) 3.23 (s, 3H), 3.46 (m, 2H), 3.6 (m, 2H), 3.79 (t, 2H), 3.88 (s, 3H), 4.2 (t, 2H), 7.08 (s, 1H), 7.39 (s, 2H), 7.57 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 294.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 2.35 (s, 6H), 3.4 (s, 3H), 3.6 (m, 2H), 3.87 (m, 2H), 4.03 (t, 2H), 4.05 (s, 3H), 4.37 (t, 2H), 7.09 (s, 1H), 7.14-7.21 (m, 3H), 7.33 (s, 1H), 8.68 (s, 1H), 8.84 (s, 1H), 13.32 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 457.

[112] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 2.26 (s, 6H), 3.3 (s, 3H), 3.5 (t, 2H), 3.64 (t, 2H), 3.8 (s, 3H), 3.84 (t, 2H), 4.25 (t, 2H), 4.72 (d, 2H), 7.12 (s, 1H), 7.2 (s, 3H), 7.31 (m, 1H), 7.35 (br s, 1H), 7.6 (s, 1H), 7.8 (m, 1H), 8.44 (m, 2H), 8.68 (s, 1H), 11.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 531.

[113] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 2.3 (s, 6H), 3.31 (s, 3H), 3.51 (t, 2H), 3.65 (t, 2H), 3.74 (s, 3H), 3.85 (t, 2H), 4.29 (t, 2H), 4.71 (d, 2H), 7.12 (s, 1H), 7.21 (s, 3H), 7.39 (d, 2H), 7.5 (s, 1H), 8.48 (s, 1H), 8.51 (d, 2H), 11.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 531.

30 [114] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 2.23 (s, 6H), 3.16 (t, 2H), 3.31 (s, 3H), 3.51 (m, 2H), 3.68 (m, 2H), 3.8 (s, 3H), 3.84 (m, 2H), 3.9 (m, 2H), 4.29 (m, 2H), 7.12 (s, 1H), 7.2 (m, 4H), 7.29 (m, 1H), 7.69 (s, 2H), 8.42 (d, 2H) 11.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 545.

- [115] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.79 (d, 3H), 1.97 (t, 2H), 2.2 (s, 3H), 2.3 (s, 3H), 2.8 (d, 2H), 3.74 (s, 3H), 4.0 (d, 2H), 4.71 (d, 2H), 7.02 (t, 1H), 7.10 (s, 1H), 7.21–7.5 (m, 7H), 8.0 (br s, 1H), 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 577 and 579.
- 5 [116] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.23 (s, 6H), 2.55 (m, 4H), 2.8 (t, 2H), 3.16 (t, 2H), 3.61 (t, 4H), 3.8 (s, 3H), 3.9 (m, 2H), 4.29 (t, 2H), 7.11 (s, 1H), 7.2 (m, 4H), 7.29 (d, 1H), 7.7 (m, 2H), 8.41 (s, 2H), 11.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 556.
- [117] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.3 (s, 6H),  
10 2.51 (t, 4H), 2.79 (t, 2H), 3.6 (t, 4H), 3.73 (s, 3H), 4.22 (t, 2H), 4.79 (d, 2H), 7.11 (s, 1H), 7.2 (s, 3H), 7.24 (m, 1H), 7.45 (d, 1H), 7.54 (s, 1H), 7.77 (t, 1H), 8.46 (s, 1H), 8.5 (d, 1H), 11.1 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 542.
- [118] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.22 (d, 9H),  
15 2.54 (t, 4H), 2.8 (t, 2H), 3.6 (m, 4H), 3.8 (s, 3H), 4.27 (t, 2H), 4.65 (d, 2H), 5.99 (m, 1H), 6.2 (d, 1H), 7.12 (s, 1H), 7.16 (s, 3H), 7.62 (s, 1H), 8.45 (s, 1H), 10.79 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 545.
- [119] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.23 (s, 6H),  
2.53 (t, 4H), 2.81 (t, 2H), 3.23 (t, 2H), 3.61 (t, 4H), 3.77 (m, 5H), 4.28 (t, 2H), 6.95 (m, 2H),  
7.11 (s, 1H), 7.18 (s, 3H), 7.3 (d, 1H), 7.64 (s, 1H), 8.42 (s, 1H), 11.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 561.
- 20 [120] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.78 (m, 3H), 1.99 (t, 2H), 2.2 (s, 3H), 2.27 (s, 3H), 2.8 (d, 2H), 3.78 (s, 3H), 4.0 (d, 2H), 4.86 (d, 2H), 6.94 (t, 1H), 7.08 (m, 2H), 7.25 (m, 3H), 7.39 (d, 1H), 7.63 (s, 1H), 7.8 (br s, 1H), 8.41 (s, 1H), 11.3 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 565 and 567.
- 25 [121] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.8 (d, 3H), 1.97 (t, 2H), 2.2 (s, 3H), 2.3 (s, 3H), 2.79 (d, 2H), 3.26 (t, 2H), 3.73 (s, 3H), 3.8 (q, 2H), 4.0 (d, 2H), 6.97 (d, 2H), 7.09 (s, 1H), 7.3 (s, 3H), 7.42 (d, 1H), 7.54 (s, 1H), 8.42 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 579 and 581.
- [122] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.69 (m,  
30 1H), 1.9 (m, 2H), 2.0 (m, 1H), 2.28 (s, 6H), 2.56 (t, 4H), 2.81 (t, 2H), 3.51–3.85 (m, 11H), 4.17 (m, 1H), 4.28 (t, 2H), 7.11 (s, 1H), 7.19 (s, 3H), 7.51 (s, 1H), 8.45 (s, 1H), 10.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 535.

[123] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.6 (m, 1H), 1.79 (m, 2H), 1.9 (m, 1H), 2.18 (s, 6H), 2.42 (t, 4H), 2.69 (t, 2H), 3.41–3.6 (m, 7H), 3.65 (s, 3H), 3.7 (q, 1H), 4.07 (m, 1H), 4.17 (t, 2H), 7.01 (s, 1H), 7.08 (s, 3H), 7.41 (s, 1H), 8.34 (s, 1H), 10.3 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 535.

5 [124] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.56–1.74 (m, 4H), 1.9 (m, 2H), 2.09 (m, 1H), 2.16 (s, 3H), 2.29 (m, 1H), 2.32 (s, 3H), 2.58 (t, 4H), 2.8 (t, 3H), 3.6 (m, 6H), 3.78 (s, 3H), 4.27 (t, 2H), 7.11 (s, 1H), 7.28 (m, 1H), 7.35 (d, 1H), 7.43 (d, 1H), 7.59 (s, 1H), 8.12 (br  
10 s, 1H), 8.44, (s, 1H); Mass Spectrum: M+H<sup>+</sup> 582 and 584.

[125] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.54–1.75 (m, 4H), 1.91 (m, 2H), 2.1 (q, 1H), 2.2 (s, 3H), 2.3 (m, 1H), 2.58 (t, 4H), 2.81 (t, 2H), 2.86 (m, 1H), 3.61 (m, 6H), 3.84 (s,  
15 3H), 4.28 (t, 2H), 7.14 (s, 1H), 7.29 (t, 1H), 7.41 (t, 1H), 7.59 (d, 2H), 7.67 (s, 1H), 8.34 (br s, 1H), 8.47, (s, 1H); Mass Spectrum: M+H<sup>+</sup> 568 and 570.

[126] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.53–1.73 (m, 4H), 1.83–1.97 (m, 2H),  
20 2.06 (q, 1H), 2.17 (s, 3H), 2.28 (m, 1H), 2.32 (s, 3H), 2.55 (t, 4H), 2.8 (m, 3H), 3.6 (m, 6H), 3.82 (s, 3H), 4.29 (t, 2H), 7.14 (s, 1H), 7.2–7.38 (m, 4H), 7.71 (s, 1H), 7.8 (br s, 1H), 8.56 (s, 1H), 11.16 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 548.

[127] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the  
25 following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.53–1.75 (m, 4H), 1.91 (m, 2H), 2.1 (m, 1H), 2.2 (s, 3H), 2.3 (m, 1H), 2.56 (t, 4H), 2.81 (t, 2H), 2.88 (m, 1H), 3.6 (m, 6H), 3.77 (s, 3H), 4.27 (t, 2H), 7.11 (s, 1H), 7.35 (t, 1H), 7.49 (s, 1H), 7.6 (d, 2H), 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 602 and 604.

[128] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.52–1.71  
30 (m, 4H), 1.8–1.92 (m, 2H), 2.01 (q, 1H), 2.1 (s, 3H), 2.27 (s, 6H), 2.55 (t, 4H), 2.76 (m, 1H), 2.81 (t, 2H), 3.56 (m, 1H), 3.61 (t, 4H), 3.67 (m, 1H), 3.82 (s, 3H), 4.27 (t, 2H), 7.12 (s, 1H), 7.19 (s, 3H), 7.5 (br s, 1H), 7.69 (s, 1H), 8.42 (s, 1H), 11.1 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 562.

[129] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.21 (s, 6H), 2.53 (t, 4H), 2.8 (t, 2H), 3.58 (t, 4H), 3.8 (s, 3H), 4.23 (t, 2H), 4.82 (d, 2H), 6.92 (t, 1H), 7.04 (d, 1H), 7.12 (s, 1H), 7.15 (s, 3H), 7.2 (br s, 1H), 7.3 (m, 1H), 7.78 (s, 1H), 8.42 (s, 1H), 11.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 547.

5 [130] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.61–1.7 (m, 4H), 1.78–1.91 (m, 2H), 2.02 (q, 1H), 2.11 (s, 3H), 2.27 (s, 6H), 2.75 (t, 1H), 3.3 (s, 3H), 3.53 (m, 3H), 3.67 (m, 3H), 3.83 (m, 6H), 4.26 (t, 2H), 7.11 (s, 1H), 7.2 (s, 3H), 7.49 (br s, 1H), 7.72 (s, 1H), 8.44 (s, 1H), 11.1 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 551.

[131] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H),  
10 1.5–1.7 (m, 4H), 1.75–1.95 (m, 7H), 2.15 (s, 3H), 2.2 (s, 3H), 2.3 (s, 3H), 2.35 (s, 3H), 2.8 (t, 2H), 3.2 (t, 2H), 3.55 (m, 1H), 3.65 (m, 2H), 3.8 (s, 3H), 4.0 (d, 2H), 7.05 (d, 1H), 7.1 (m, 2H), 7.25 (d, 1H), 7.5 (s, 1H), 7.7 (s, 1H), 8.45 (s, 1H), 11.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 560.

The 1-(2,5-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-

15 ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline was reacted with 2,5-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material : Mass Spectrum:

20 M+H<sup>+</sup> 466.

[132] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.34 (s, 9H), 1.2–1.45 (m, 3H), 1.48–1.6 (m, 5H), 1.72–2.06 (m, 7H), 2.17 (s, 3H), 2.23 (s, 6H), 2.74–2.8 (m, 3H), 3.38–3.56 (m, 2H), 3.77 (s, 3H), 3.83 (s, 1H), 3.98 (d, 2H), 4.18–4.26 (br s, 1H), 7.05 (s, 1H), 7.16 (s, 3H), 7.6 (s, 1H), 8.41 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 660.

25 [133] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.66 (s, 4H), 2.12 (m, 2H), 2.32 (s, 6H), 2.4–2.6 (m, 10H), 2.7 (s, 2H), 3.68 (q, 2H), 3.74 (t, 4H), 4.0 (s, 3H), 4.25 (t, 2H), 4.97 (m, 1H), 7.18 (s, 4H), 7.9 (s, 1H), 8.57 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 562.

[134] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.66 (s, 4H), 1.8 (t, 2H), 2.12 (m, 2H), 2.32 (s, 10H), 2.45–2.63 (m, 8H), 3.74 (t, 6H), 4.0 (s, 3H), 4.25 (t, 2H),  
30 5.77 (m, 1H), 7.12 (s, 4H), 7.9 (s, 1H), 8.55 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 576.

[135] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.11 (m, 2H), 2.35 (s, 10H), 2.5 (m, 6H), 2.58 (t, 2H), 2.68 (s, 4H), 3.62 (q, 2H), 3.72 (t, 4H), 4.0 (s, 3H), 4.25 (t, 2H), 5.12 (m, 1H), 7.18 (s, 4H), 7.9 (s, 1H), 8.57 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 577.

5 [136] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.82 (m, 2H), 2.12 (m, 4H), 2.15-2.31 (m, 5H), 2.35 (s, 6H), 2.4 (m, 6H), 2.5 (t, 4H), 2.58 (t, 2H), 3.7 (q, 2H), 3.72 (t, 4H), 4.0 (s, 3H), 4.25 (t, 2H), 5.12 (m, 1H), 7.18 (s, 4H), 7.9 (s, 1H), 8.57 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 605.

[137] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.3-1.5 (m, 10 2H), 1.7-1.9 (m, 3H), 1.96-2.1 (t, 2H), 2.21 (s, 6H), 2.25 (s, 6H), 2.45-2.5 (m, 4H), 2.86 (d, 2H), 3.23 (s, 3H), 3.42 (t, 2H), 3.56 (q, 2H), 3.72 (s, 3H), 3.94 (d, 2H), 7.04 (s, 1H), 7.15 (s, 3H), 7.53 (s, 1H), 8.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 564.

The 1-(2,6-dimethylphenyl)-3-{6-methoxy-7-[N-(2-methoxyethyl)piperidin-4-ylmethoxy]quinazolin-4-yl}thiourea used as a starting material was prepared as follows :-  
 15 N-tert-Butoxycarbonyl-4-(4-benzenesulphonyloxymethyl)piperidine was obtained by the reaction of N-tert-butoxycarbonyl-4-hydroxymethylpiperidine with benzenesulphonyl chloride using an analogous procedure to that described in the portion of Example 1 that is concerned with the preparation of starting materials which concerns the corresponding reaction with 4-toluenesulphonyl chloride.

20 A mixture of 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (21.9 g), N-tert-butoxycarbonyl-4-(4-benzenesulphonyloxymethyl)piperidine (31 g), anhydrous potassium carbonate (33.1 g) and NMP (200 ml) was stirred and heated to 82°C for 16 hours. The reaction mixture was allowed to cool to 50°C and poured into water (1.2 L). The precipitate was isolated, washed with water, triturated under diethyl ether and isolated. There  
 25 was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-(N-tert-butoxycarbonylpiperidin-4-ylmethoxy)-6-methoxyquinazoline (32.95 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.23 (m, 2H), 1.42 (s, 9H), 1.77-2.2 (m, 2H), 2.8 (m, 2H), 3.97 (s, 3H), 3.99 (m, 2H), 4.1 (d, 2H), 7.36-7.42 (m, 2H), 7.52-7.56 (m, 1H), 7.58 (s, 1H), 7.87 (m, 1H), 8.56 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 562 and 564.

30 Using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials, 4-(2-bromo-4-fluorophenoxy)-7-(N-tert-butoxycarbonylpiperidin-4-ylmethoxy)-6-methoxyquinazoline was reacted with ammonia to give 4-amino-7-(N-tert-butoxycarbonylpiperidin-4-ylmethoxy)-

6-methoxyquinazoline; NMR Spectrum: (DMSO-d<sub>6</sub>) 1.21 (m, 2H), 1.4 (s, 9H), 1.76 (d, 2H), 2.0 (br s, 1H), 2.77 (t, 2H), 3.88 (s, 3H), 3.97 (d, 2H), 3.99 (br s, 2H), 7.05 (s, 1H), 7.36 (br s, 2H), 7.55 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 389.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained

1-(2,6-dimethylphenyl)-3-{7-[N-tert-butoxycarbonylpiperidin-4-ylmethoxy]-6-methoxyquinazolin-4-yl}thiourea; NMR Spectrum: (CDCl<sub>3</sub>) 1.31 (m, 2H), 1.43 (s, 9H), 1.85 (br d, 2H), 2.09 (br s, 1H), 2.29 (s, 6H), 2.74 (t, 2H), 3.96 (m, 5H), 4.14 (m, 2H), 7.0 (s, 1H), 7.09-7.19 (s, 3H), 7.23 (s, 1H), 8.63 (s, 1H), 8.8 (s, 1H), 13.3 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 552.

A mixture of the thiourea so obtained (1.5 g), trifluoroacetic acid (15 ml) and methylene chloride (15 ml) was stirred at ambient temperature for 1 hour. The mixture was evaporated and the residue was azeotroped with toluene. The residue was stirred with a saturated aqueous sodium bicarbonate solution and the resultant solid was isolated and washed with water. There was thus obtained 1-(2,6-dimethylphenyl)-3-(6-methoxy-7-piperidin-4-ylmethoxyquinazolin-4-yl)thiourea (1.25 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.34-1.48 (m, 2H), 1.87 (d, 2H), 2.2 (s, 6H), 2.81 (t, 2H), 3.21 (d, 3H), 3.99 (s, 3H), 4.06 (d, 2H), 7.14 (s, 3H), 7.33 (s, 1H), 8.14 (s, 1H), 8.65 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 452.

Methoxyacetaldehyde (0.314 g) was added to a stirred mixture of 1-(2,6-dimethylphenyl)-3-(6-methoxy-7-piperidin-4-ylmethoxyquinazolin-4-yl)thiourea (1.47g), 3Å molecular sieves (1.0 g) and methanol (75 ml) and the mixture was stirred at ambient temperature for 30 minutes. Sodium cyanoborohydride (0.205 g) and acetic acid (0.105 g) were added in turn and the mixture was stirred at ambient temperature for 16 hours. The mixture was acidified to pH 2 by the addition of concentrated hydrochloric acid. The mixture was evaporated, the residue was dissolved in water (10 ml) and the solution was basified to pH10 by the addition of 10N aqueous potassium hydroxide solution. The mixture was extracted with a 10:1 mixture of methylene chloride and methanol and the combined organic extracts were evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia gas in methanol as eluent. There was thus obtained 1-(2,6-dimethylphenyl)-3-{6-methoxy-7-[N-(2-methoxyethyl)piperidin-4-ylmethoxy]quinazolin-4-yl}thiourea (0.493 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.45-2.1 (m, 7H), 2.35 (s, 6H), 2.59 (t, 2H), 3.01 (d, 2H), 3.37 (s, 3H),

3.54 (m, 2H), 4.02 (s, 5H), 7.06 (s, 1H), 7.12-7.2 (m, 3H), 7.31 (s, 1H), 8.65 (s, 1H), 8.83 (s, 1H), 13.34 (s, 1H); Mass Spectrum:  $M+H^+$  510.

[138] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.5 (m, 2H), 1.7-1.9 (m, 3H), 2.03 (t, 2H), 2.28 (s, 6H), 2.45-2.53 (m, 2H), 2.85-2.91 (m, 2H), 3.14 (s, 3H), 3.43 (t, 2H), 3.87 (s, 3H), 3.95-4.03 (m, 4H), 7.08 (s, 1H), 7.16 (s, 3H), 7.73 (s, 1H), 8.45 (s, 1H); Mass Spectrum:  $M+H^+$  607.

[139] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.3-1.5 (m, 2H), 1.6-2.1 (m, 11H), 2.24 (s, 6H), 2.85 (d, 2H), 3.22 (s, 3H), 3.42 (t, 2H), 3.45-3.86 (m, 7H), 3.95 (d, 2H), 4.14 (m, 1H), 7.03 (s, 1H), 7.14 (s, 3H), 7.48 (s, 1H), 8.41 (s, 1H); Mass Spectrum:  $M+H^+$  577.

[140] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.13 (s, 6H), 2.26 (s, 6H), 2.42 (m, 2H), 2.69 (m, 1H), 3.06 (m, 1H), 3.45-3.7 (m, 8H), 3.83-4.02 (m, 4H), 4.15 (m, 1H), 4.4 (m, 1H), 4.79 (m, 1H), 7.1 (s, 4H), 7.15-7.34 (m, 5H), 7.83 (s, 1H), 8.5 (s, 1H), 12.5 (s, 1H); Mass Spectrum:  $M+H^+$  598.

15 The 1-[7-(N-benzylmorpholin-3-ylmethoxy)-6-methoxyquinazolin-4-yl]-3-(2,6-dimethylphenyl)thiourea used as a starting material was prepared as follows :-

Mesyl chloride (1.87 ml) was added to a mixture of N-benzylmorpholin-3-ylmethanol (J. Chem. Soc. Perkin I, 1985, 2577-2580; 5 g), triethylamine (3.3 ml) and THF (20 ml) which had been cooled in an ice/water bath. The mixture was stirred for 2 hours whilst being allowed to warm to ambient temperature. The mixture was filtered and the filtrate was evaporated. The residual oil was dissolved in DMF (100 ml) and 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (4.56 g) and anhydrous potassium carbonate (5.18 g) were added. The resultant mixture was heated to 70°C for 16 hours. The mixture was evaporated and the residual oil was triturated under diethyl ether. There was thus obtained

25 7-(N-benzylmorpholin-3-ylmethoxy)-4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazoline as a solid (4.11 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.7 (m, 2H), 2.97 (m, 1H), 3.5-3.7 (m, 4H), 3.89 (m, 1H), 4.0 (s, 3H), 4.09 (d, 1H), 4.31 (m, 1H), 4.52 (m, 1H), 7.18-7.45 (m, 6H), 7.5-7.65 (m, 3H), 7.78 (m, 1H), 8.56 (s, 1H); Mass Spectrum:  $M+H^+$  554 and 556.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 4-amino-7-(N-benzylmorpholin-3-ylmethoxy)-6-methoxyquinazoline.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained 1-[7-(N-benzylmorpholin-3-ylmethoxy)-6-methoxyquinazolin-4-yl]-

3-(2,6-dimethylphenyl)thiourea; Mass Spectrum:  $M+H^+$  544.  
 [141] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.02-2.23 (m, 8H), 2.26 (s, 6H), 2.42 (m, 2H), 2.62 (d, 1H), 2.9 (d, 1H), 3.4-3.62 (m, 4H), 3.68 (t, 1H), 3.89 (d, 3H), 4.04 (d, 2H), 4.17 (m, 1H), 4.79 (m, 1H), 7.08 (s, 3H), 7.15 (s, 1H), 7.2-7.33 (m, 5H), 7.83 (s, 1H), 8.5 (s, 1H), 12.42 (s, 1H); Mass Spectrum:  $M+H^+$  598.

The 1-[7-(N-benzylmorpholin-2-ylmethoxy)-6-methoxyquinazolin-4-yl]-3-(2,6-dimethylphenyl)thiourea used as a starting material was prepared as follows :-

Using an analogous procedure to that described in the first paragraph of the portion of Note [140] immediately above which is concerned with the preparation of starting materials, the mesylate of N-benzylmorpholin-2-ylmethanol (Synth. Commun., 1980, 10, 59-73) was reacted with 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (4.56 g) to give 7-(N-benzylmorpholin-2-ylmethoxy)-4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazoline; Mass Spectrum:  $M+H^+$  554 and 556.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 4-amino-7-(N-benzylmorpholin-2-ylmethoxy)-6-methoxyquinazoline.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained 1-[7-(N-benzylmorpholin-2-ylmethoxy)-6-methoxyquinazolin-4-yl]-

3-(2,6-dimethylphenyl)thiourea; Mass Spectrum:  $M+H^+$  544.

[142] Glycine 2-hydroxyethylamide (Helv. Chim. Acta, 1955, 38, 1345) was used as the appropriate amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (q, 2H), 1.79 (d, 3H), 2.02 (t, 2H), 2.2 (s, 3H), 2.27 (s, 6H), 2.82 (d, 2H), 3.14-3.22 (m, 2H), 3.4 (s, 2H), 3.84 (s, 3H), 3.97 (d, 2H), 4.09 (s, 2H), 4.33 (br s, 1H), 7.1 (s, 1H), 7.18 (s, 3H), 7.58 (s, 1H), 7.68 (s, 1H), 8.46 (s, 1H); Mass Spectrum:  $M+H^+$  550.

[143] Glycine 2-hydroxyethylamide was used as the appropriate amine. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.32-1.46 (m, 2H), 1.77 (d, 3H), 2.02

(t, 2H), 2.22 (s, 3H), 2.34 (s, 3H), 2.83 (d, 2H), 3.16-3.24 (m, 2H), 3.42 (s, 2H), 3.78 (s, 3H), 3.97 (d, 2H), 4.06 (s, 2H), 4.33 (s, 1H), 7.04 (s, 1H), 7.22-7.42 (m, 3H), 7.55 (s, 2H), 8.45 (s, 1H); Mass Spectrum:  $M+H^+$  570 and 572.

[144] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.42 (m, 2H), 1.82 (m, 3H), 1.93 (m, 2H), 2.18 (s, 3H), 2.79 (m, 2H), 3.83 (s, 3H), 3.86 (s, 3H), 4.01 (d, 2H), 4.13 (m, 2H), 5.18 (m, 1H), 5.31 (m, 1H), 6.06 (m, 1H), 6.98 (m, 1H), 7.09 (s, 1H), 7.12 (m, 1H), 7.19 (m, 1H), 7.59 (m, 1H), 7.74 (s, 1H), 8.0 (br s, 1H), 8.47 (s, 1H); Mass Spectrum:  $M+H^+$  491.

The 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-(2-methoxyphenyl)thiourea used as a starting material was prepared by the reaction of 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline with 2-methoxyphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-

15 3-(2-methoxyphenyl)thiourea; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.38 (m, 2H), 1.81 (m, 3H), 1.86 (m, 2H), 2.2 (s, 3H), 2.79 (m, 2H), 3.96 (s, 3H), 3.99 (s, 3H), 4.09 (d, 2H), 6.95 (m, 1H), 7.18 (m, 1H), 7.19 (s, 1H), 7.23 (m, 1H), 7.32 (s, 1H), 8.13 (br s, 1H), 8.69 (br s, 1H), 8.78 (s, 1H), 10.96 (br s, 1H), 14.73 (br s, 1H); Mass Spectrum:  $M+H^+$  468.

[145] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.44 (m, 2H), 1.83 (m, 2H), 1.85 (m, 1H), 1.98 (m, 2H), 2.21 (s, 3H), 2.82 (m, 2H), 2.97 (m, 2H), 3.80 (t, 2H), 3.89 (s, 3H), 3.93 (s, 3H), 4.04 (d, 2H), 7.04 (m, 1H), 7.14 (s, 1H), 7.17 (m, 1H), 7.25 (br, 0.5H), 7.27 (m, 1H), 7.44 (m, 1H), 7.80 (s, 1H), 8.51 (s, 1H), 11.75 (br s, 1H); Mass Spectrum:  $M+H^+$  504.

[146] The product gave the following data: Mass Spectrum: :  $M+H^+$  522 and 524.

25 [147] The product gave the following data NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.79 (m, 3H), 1.95 (t, 2H), 2.18 (s, 3H), 2.35 (s, 3H), 2.8 (m, 2H), 3.76 (s, 3H), 4.0 (d, 2H), 4.76 (d, 2H), 6.99 (br s, 1H), 7.11 (s, 1H), 7.15-7.58 (m, 6H), 8.05 (br s, 1H), 8.46 (s, 1H), 11.20 (br s, 1H); Mass Spectrum:  $M+H^+$  577.

[148] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and 30 methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.42 (m, 4H), 1.56 (m, 1H), 1.77 (m, 5H), 1.95 (t, 2H), 2.16 (s, 6H), 2.2 (s, 4H), 2.38 (s, 3H), 2.75 (d, 2H), 3.12 (m, 1H), 3.52 (m, 1H),

3.74 (s, 3H), 3.94 (d, 2H), 6.97 (br s, 1H), 7.07 (m, 1H), 7.27 (t, 1H), 7.29 (d, 1H), 7.38 (d, 1H), 7.46 (br s, 1H), 8.44 (s, 1H), 10.1 (br s, 1H); Mass Spectrum:  $M+H^+$  568 and 570.

[149] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.17 (m, 7H), 2.45 (s, 6H), 2.73 (m, 2H), 3.54 (m, 6H), 3.96 (s, 3H), 4.25 (m, 2H), 7.03 (m, 3H), 7.25  
5 (s, 1H), 8.00 (s, 1H), 8.6 (s, 1H), 10.55 (s, 1H), 13.33 (s, 1H); Mass Spectrum:  $M+H^+$  547.

[150] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.5 (m, 2H), 1.71 (m, 2H), 2.12 (s, 6H), 2.3 (m, 8H), 2.55 (m, 4H), 2.78 (m, 2H), 3.55 (br s, 2H), 3.62 (m, 4H), 3.75 (s, 3H), 4.27 (m,  
10 2H), 7.09 (s, 1H), 7.16 (s, 3H), 7.59 (s, 1H), 8.45 (s, 1H), 10.2-10.7 (br s, 1H); Mass Spectrum:  $M+H^+$  550.

[151] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.34 (s, 3H), 2.86 (m, 4H), 3.51 (m, 2H),  
15 3.65 (m, 6H), 3.81 (s, 3H), 4.00 (s, 1H), 4.28 (m, 2H), 4.37 (m, 2H), 4.81 (s, 1H), 7.11 (s, 1H), 7.15-7.45 (m, 4H), 7.65 (d, 1H), 8.48 (s, 1H), 8.82 (s, 1H), 10.7 (br s, 1H), 13.33 (s, 1H); Mass Spectrum:  $M+H^+$  511.

[152] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the  
20 following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.04 (t, 3H), 1.74 (m, 2H), 1.85 (q, 1H), 1.89 (m, 1H), 2.04 (s, 6H), 2.25 (s, 6H), 2.32 (q, 2H), 2.64 (m, 1H), 2.74 (m, 2H), 3.22 (t, 2H), 3.32 (t, 2H), 3.55 (q, 2H), 3.78 (s, 3H), 4.99 (m, 1H), 6.99 (s, 1H), 7.17 (s, 3H), 7.63 (br s, 1H), 8.42 (s, 1H), 10.5-11.1 (br s, 1H); Mass Spectrum:  $M+H^+$  570 and 572.

[153] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and  
25 methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.52 (m, 2H), 1.72 (m, 2H), 2.15 (s, 6H), 2.3 (m, 8H), 3.53 (t, 2H), 3.81 (s, 3H), 5.34 (s, 2H), 7.17 (s, 3H), 7.19 (s, 1H), 7.36 (m, 1H), 7.58 (d, 1H), 7.6 (s, 1H), 7.83 (t, 1H), 8.42 (s, 1H), 8.61 (d, 1H), 10.2-10.7 (br s, 1H); Mass Spectrum:  $M+H^+$  528.

[154] THF was used as the reaction solvent in place of a 1:1 mixture of chloroform and  
30 methanol and the reaction mixture was heated to reflux for 2 hours. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.55 (m, 2H), 1.72 (m, 6H), 1.94 (m, 2H), 2.17 (s, 6H), 2.32 (m, 5H), 2.5 (m, 4H), 2.63 (t, 2H), 3.53 (t, 2H), 3.72 (s, 3H), 4.19 (m, 2H),

7.07 (s, 1H), 7.24 (t, 1H), 7.28 (d, 1H), 7.41 (d, 1H), 7.43 (s, 1H), 8.42 (m, 2H), 9.9-10.4 (br s, 1H); Mass Spectrum:  $M+H^+$  568 and 570.

[155] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.78 (m, 3H), 1.95 (m, 2H), 2.2 (s, 3H), 2.28 (s, 6H), 2.35 (s, 3H), 2.6 (m, 2H), 2.78 (m, 2H),  
5 3.6 (m, 2H), 3.8 (s, 3H), 3.98 (d, 2H), 7.06 (s, 1H), 7.2 (m, 1H), 7.28 (m, 1H), 7.35 (m, 2H), 7.6 (s, 1H), 8.45 (s, 1H), 10.85 (s, 1H); Mass Spectrum:  $M+H^+$  506.

[156] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.2 (t, 3H), 1.4 (m, 2H), 1.8 (m, 3H), 1.95 (m, 2H), 2.2 (s, 3H), 2.26 (s, 6H), 2.6 (m, 2H), 2.7 (q, 2H), 2.84 (m, 2H), 3.6 (m, 2H), 3.8 (s, 3H), 4.0 (d, 2H), 7.1 (s, 1H), 7.26 (m, 2H), 7.36 (m, 2H),  
10 7.7 (s, 1H), 8.55 (s, 1H), 11.2 (s, 1H); Mass Spectrum  $M+H^+$  520.

The 1-(2-ethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline was reacted with 2-ethylphenyl isothiocyanate using an analogous procedure to that described in the last  
15 paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material: Mass Spectrum:  $M+H^+$  466.

[157] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.43 (m, 2H), 1.5-1.65 (m, 4H), 1.72-2.0 (m, 7H), 2.15 (s, 3H), 2.2 (s, 3H), 2.28 (s, 3H), 2.36 (s, 3H), 2.8 (m, 2H), 3.2 (m, 2H), 3.5 (m, 1H), 3.65 (m, 2H), 3.85 (s, 3H), 4.0 (d, 2H), 7.05 (d, 1H),  
20 7.1 (m, 2H), 7.25 (d, 1H), 7.4-7.68 (s, 1H), 7.7 (s, 1H), 8.4 (s, 1H), 11.2 (s, 1H); Mass Spectrum  $M+H^+$  560.

[158] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.42 (m, 2H), 1.8 (m, 3H), 1.95 (m, 2H), 2.2 (s, 3H), 2.25 (m, 9H), 2.3 (s, 3H), 2.55 (m, 2H), 2.8 (m, 2H), 3.6 (m, 2H), 3.8 (s, 3H), 4.0 (d, 2H), 7.0 (d, 1H), 7.06 (s, 1H), 7.15 (s, 1H), 7.2 (d, 1H),  
25 7.3-7.6 (s, 1H), 7.7 (s, 1H), 8.4 (s, 1H), 11.1 (s, 1H); Mass Spectrum  $M+H^+$  520.

[159] The product gave the following data: Mass Spectrum  $M+H^+$  580.

[160] The product gave the following data: Mass Spectrum  $M+H^+$  600.

[161] The product gave the following data: Mass Spectrum  $M+H^+$  584.

The 1-(2-bromophenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-  
30

4-Amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline was reacted with 2-bromo isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 which is concerned with the preparation of starting materials.

There was thus obtained the required starting material, which was used without further purification.

[162] The product gave the following data: NMR Spectrum (DMSO-d<sub>6</sub>, 100°C) 1.2 (m, 1H), 1.55 (m, 1H), 1.7-1.85 (m, 4H), 1.9-2.15 (m, 9H), 2.2 (s, 3H), 2.25 (s, 6H), 2.35 (t, 2H), 2.6 (m, 1H), 2.8 (d, 1H), 3.6 (t, 2H), 3.8 (s, 3H), 4.05 (d, 2H), 7.05 (s, 1H), 7.2 (m, 3H), 7.7 (s, 1H), 8.4 (s, 1H), 10.8 (s, 1H); Mass Spectrum M+H<sup>+</sup> 534.

The 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-3-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-  
4-Amino-6-methoxy-7-(N-methylpiperidin-3-ylmethoxy)quinazoline was prepared by  
10 reaction of 4-amino-6-methoxy-7-hydroxyquinazoline with 1-methyl-3-piperidinemethanol under analogous conditions to those described Example 2, Note[11] :- Mass Spectrum: M+H<sup>+</sup> 303.

4-Amino-6-methoxy-7-(N-methylpiperidin-3-ylmethoxy)quinazoline was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last  
15 paragraph of the portion of Example 1 which is concerned with the preparation of starting materials. There was thus obtained the required starting material.

[163] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 0.86 (t, 6H), 1.46 (m, 4H), 2.25 (s, 6H), 2.5 (m, 6H), 2.91 (t, 2H), 3.64-4.0 (m, 7H), 6.7 (br s, 1H), 7.2 (s, 3H), 7.66 (s, 1H), 7.85 (s, 1H), 8.48 (s, 1H), 12.2 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 512.

20 The 4-amino-7-(3-dipropylamino-1-propynyl)-6-methoxyquinazoline used as a starting material was prepared as follows :-

4-(2-Bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline was reacted with 3-dipropylamino-1-propyne to give 4-(2-bromo-4-fluorophenoxy)-7-(3-dipropylamino-1-propynyl)-6-methoxyquinazoline. The material so obtained was reacted  
25 with ammonia using an analogous procedure to that disclosed in International Patent Application WO 01/04102 (Example 2, third paragraph of the portion of Note [115] that is concerned with the preparation of starting materials) to give the required starting material.

**Example 3** N-(2-chloro-6-methylphenyl)-N'-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-N''-(1,4-tetramethylene)guanidine  
30

Using an analogous procedure to that described in Example 1, 3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea was reacted with pyrrolidine to

give the title compound in 37% yield; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.41 (m, 2H), 1.76–1.9 (m, 10H), 1.99 (t, 2H), 2.2 (s, 3H), 2.3 (s, 3H), 2.8 (d, 2H), 3.35 (t, 4H), 3.9 (s, 3H), 4.01 (t, 2H), 7.1 (s, 1H), 7.14 (s, 1H), 7.21 (d, 1H), 7.32 (d, 1H), 7.69 (s, 1H), 8.4 (s, 1H), 11.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 523 and 525.

5

**Example 4** N-carboxymethyl-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine

A mixture of N-(tert-butoxycarbonylmethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine (0.09 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) was stirred at ambient temperature for 3 hours. The reaction mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia gas in methanol as eluent. There was thus obtained the title compound in 67% yield; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.2–1.5 (m, 3H), 1.7–1.9 (m, 2H), 2.0–2.1 (m, 2H), 2.14 (s, 3H), 2.19 (s, 6H), 2.84 (d, 2H), 3.82 (s, 3H), 3.95–4.05 (m, 4H), 7.08 (s, 1H), 7.17 (s, 3H), 7.71 (s, 1H), 8.43 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 507.

**Example 5** N-carboxymethyl-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]guanidine

Using an analogous procedure to that described in Example 4, N-(tert-butoxycarbonylmethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]guanidine was reacted with trifluoroacetic acid to give the title compound in 65% yield; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.78 (m, 4H), 2.32 (s, 6H), 2.67 (m, 4H), 2.94 (t, 2H), 3.85 (s, 3H), 4.09 (s, 2H), 4.28 (t, 2H), 7.1 (s, 1H), 7.19 (s, 3H), 7.74 (s, 1H), 8.48 (s, 1H), 10.8–11.7 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 493.

**Example 6** N-(2-aminoethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine

A mixture of N-(2-tert-butoxycarbonylaminoethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine (0.31 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) was stirred at ambient temperature for 20 minutes. The reaction mixture was evaporated and the residue was dissolved in water

(4 ml) and the solution was basified to pH10 by the addition of 10N aqueous potassium hydroxide solution. The mixture was extracted with a 19:1 mixture of methylene chloride and methanol. The organic extract was dried over magnesium sulphate and evaporated. There was thus obtained the title compound (0.16 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.2-1.4 (m, 2H),  
5 1.65-1.94 (m, 5H), 2.12 (s, 3H), 2.21 (s, 6H), 2.7-2.9 (m, 4H), 3.22 (br s, 3H), 3.4-3.8 (m, 4H), 3.91 (d, 2H), 7.0 (s, 1H), 7.13 (s, 3H), 8.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 492.


**Example 7** N-(2-chloro-6-methylphenyl)-N'-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]-N''-(3-methylaminopropyl)guanidine

10 A mixture of N-[3-(N-tert-butoxycarbonyl)-N-methylaminopropyl]-N'-(2-chloro-6-methylphenyl)-N''-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]guanidine (0.42 g), trifluoroacetic acid (1.35 ml) and methylene chloride (15 ml) was stirred at ambient temperature for 3 hours. The reaction mixture was evaporated and the residue was dissolved in water (6 ml) and the solution was basified by the addition of a saturated aqueous sodium  
15 bicarbonate solution. The mixture was extracted with a 19:1 mixture of methylene chloride and methanol. The organic extract was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia gas in methanol as eluent. There was thus obtained the title compound (0.12 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.72 (m, 4H), 1.82  
20 (m, 2H), 1.96 (m, 2H), 2.29 (s, 3H), 2.32 (s, 3H), 2.63 (t, 2H), 2.45-2.55 (m, 4H), 2.69 (t, 2H), 3.61 (t, 2H), 3.73 (s, 3H), 4.19 (t, 2H), 7.09 (s, 1H), 7.27 (t, 1H), 7.34 (d, 1H), 7.41 (d, 1H), 7.48 (s, 1H), 8.46 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 540 and 542.

**Example 8**

25 Using an analogous procedure to that described in Example 7, the appropriate N-tert-butoxycarbonyl protected guanidine derivative was reacted with trifluoroacetic acid to give the compounds described in Table II.

Table II



No. & Note	R <sup>6</sup>	R <sup>1</sup>	(R <sup>2</sup> ) <sub>n</sub>
[1]	3-methylaminopropyl	2-morpholinoethoxy	2-methyl
[2]	3-methylaminopropyl	2-morpholinoethoxy	2-chloro-6-methyl
[3]	3-methylaminopropyl	2-morpholinoethoxy	2,6-dichloro
[4]	2-piperidin-2-ylethyl	N-methylpiperidin-4-ylmethoxy	2,6-dimethyl

## 5 Notes

- [1] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.01 (m, 2H), 2.45 (s, 3H), 2.5 (s, 3H), 2.68 (t, 4H), 2.92 (m, 4H), 3.73 (m, 6H), 3.95 (s, 3H), 4.4 (t, 2H), 7.27 (s, 1H), 7.33 (t, 1H), 7.41 (t, 1H), 7.48 (d, 2H), 7.69 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 508.
- 10 [2] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.69 (m, 2H), 2.16 (d, 6H), 2.39 (t, 4H), 2.6 (t, 2H), 2.65 (t, 2H), 3.42 (m, 6H), 3.59 (s, 3H), 4.1 (t, 2H), 6.95 (s, 1H), 7.09 (t, 1H), 7.16 (d, 1H), 7.25 (d, 1H), 7.31, (s, 1H), 8.29 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 542 and 544.
- 15 [3] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.89 (m, 2H), 2.4 (s, 3H), 2.51 (t, 4H), 2.79 (m, 4H), 3.58 (m, 6H), 3.73 (s, 3H), 4.26 (t, 2H), 7.11 (s, 1H), 7.34 (t, 1H), 7.4 (s, 1H), 7.58 (d, 2H), 8.47 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 562 and 564.
- [4] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CD<sub>3</sub>CO<sub>2</sub>D, 100°C) 1.34-1.48 (m, 2H), 1.52-1.76 (m, 5H), 1.8-2.11 (m, 6H), 2.21 (s, 6H), 2.26 (s, 1H), 2.64 (s, 3H), 2.75-2.86 (m, 3H), 3.0-3.06 (m, 1H), 3.2 (d, 2H), 3.31 (d, 2H), 3.53-3.67 (m, 20 2H), 3.8 (s, 3H), 4.04 (s, 2H), 7.08-7.22 (m, 3H), 7.62 (s, 1H), 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 560.

**Example 9** N-(2-amidinoethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholin propoxy)quinazolin-4-yl]guanidine

A 4M solution of hydrogen chloride in dioxane (0.75 ml) was added to a mixture of N-(2-cyanoethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]guanidine (0.025 g), methanol (0.002 ml), dioxane (0.5 ml) and methylene chloride (0.25 ml). The resultant suspension was stirred at ambient temperature for 16 hours. A further aliquot of methanol (0.002 ml) was added and the mixture was stirred at ambient temperature for a further 16 hours. The mixture was evaporated and the residue was dissolved in a 2M solution of ammonia in ethanol. The resultant solution was allowed to stand for 2 days. The mixture was evaporated. There was thus obtained the title compound (0.022 g); Mass Spectrum:  $M+H^+$  535.

**Example 10** N-(3-dimethylaminopropyl)-N'-(2,6-dimethylphenyl)-N''-(7-hydroxy-6-methoxyquinazolin-4-yl)guanidine

A mixture of N-(7-benzyloxy-6-methoxyquinazolin-4-yl)-N'-(3-dimethylaminopropyl)-N''-(2,6-dimethylphenyl)guanidine (2.21 g) and trifluoroacetic acid (40 ml) was stirred and heated to 70°C for 16 hours. The reaction mixture was evaporated and the residue was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was dried over magnesium sulphate, filtered and evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia gas in methanol as eluent. There was thus obtained the title compound (1.66 g); NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.77 (m, 2H), 2.07 (s, 6H), 2.29 (s, 6H), 2.36 (t, 2H), 3.59 (t, 2H), 3.81 (s, 3H), 7.0 (s, 1H), 7.19 (m, 3H), 7.67 (s, 1H) 8.4 (s, 1H), 9.4 (br s, 1H), 10.8 (br s, 1H); Mass Spectrum:  $M+H^+$  423.

**Example 11** N-(6,7-dimethoxyquinazolin-4-yl)-N'-(3-dimethylaminopropyl)-N''-(2,6-dimethylphenyl)guanidine

An aliquot (0.15 ml) of a 2M solution of trimethylsilyldiazomethane in hexane was added to a mixture of N-(3-dimethylaminopropyl)-N'-(2,6-dimethylphenyl)-N''-(7-hydroxy-6-methoxyquinazolin-4-yl)guanidine (0.1 g), N,N-diisopropylethylamine (0.06 ml), acetonitrile (1.8 ml) and methanol (0.2 ml). The resultant reaction mixture was stirred at

ambient temperature for 16 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia gas in methanol as eluent. There was thus obtained the title compound (0.059 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.78 (m, 2H), 2.06 (s, 6H), 2.3 (s, 6H), 2.38 (t, 2H), 3.6 (q, 2H), 3.81 (s, 3H), 3.93 (s, 3H), 7.11 (s, 1H), 7.2 (s, 3H), 7.66 (s, 1H), 8.47 (s, 1H), 10.9 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 437.

**Example 12** N-(2-dimethylaminoethyl)-N'-(2,6-dimethylphenyl)-N''-(7-hydroxy-6-methoxyquinazolin-4-yl)guanidine

10 Using an analogous procedure to that described in Example 10, N-(7-benzyloxy-6-methoxyquinazolin-4-yl)-N'-(2-dimethylaminoethyl)-N''-(2,6-dimethylphenyl)guanidine was reacted with trifluoroacetic acid to give the title compound in 68% yield; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.22 (s, 6H), 2.26 (s, 6H), 2.55 (t, 2H), 3.6 (t, 2H), 3.79 (s, 3H), 6.99 (s, 1H), 7.17 (s, 3H), 7.6 (s, 1H) 8.39 (s, 1H), 9.4 (br s, 1H), 10.8 (br s, 1H); Mass Spectrum:  
15 M+H<sup>+</sup> 409.

**Example 13** N-(6,7-dimethoxyquinazolin-4-yl)-N'-(2-dimethylaminoethyl)-N''-(2,6-dimethylphenyl)guanidine

Using an analogous procedure to that described in Example 11,  
20 N-(2-dimethylaminoethyl)-N'-(2,6-dimethylphenyl)-N''-(7-hydroxy-6-methoxyquinazolin-4-yl)guanidine was reacted with trimethylsilyldiazomethane to give the title compound in 63% yield; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.21 (s, 6H), 2.24 (s, 6H), 2.54 (t, 2H), 3.57 (q, 2H), 3.75 (s, 3H), 3.9 (s, 3H), 7.08 (s, 1H), 7.17 (s, 3H), 7.58 (s, 1H), 8.43 (s, 1H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 423.

25

**Example 14** N-(3-dimethylaminopropyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(N-methylpyrrolidin-3-yloxy)quinazolin-4-yl]guanidine


1,1'-(Azodicarbonyl)dipiperidine (0.36 g) was added to a mixture of  
N-(3-dimethylaminopropyl)-N'-(2,6-dimethylphenyl)-N''-(7-hydroxy-6-methoxyquinazolin-  
30 4-yl)guanidine (0.1 g), 3-hydroxy-N-methylpyrrolidine (0.143 g), tributylphosphine (0.35 ml) and THF (15 ml). The resultant mixture was stirred at ambient temperature for 2 days. The mixture was filtered and the filtrate was evaporated. The residue so obtained was purified by

column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia gas in methanol as eluent. There was thus obtained the title compound (0.052 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 0.89 (t, 2H), 1.75 (m, 2H), 2.1 (s, 6H), 2.37 (s, 6H), 2.32 (s, 3H), 2.72 (m, 2H), 3.21 (t, 2H), 3.31 (t, 2H), 3.55 (t, 2H), 3.77 (s, 3H), 5.0 (t, 1H), 6.98 (s, 1H), 7.17 (s, 3H), 7.61 (s, 1H), 8.4 (s, 1H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 506.

### Example 15

Using an analogous procedure to that described in Example 14, the appropriate N-(7-hydroxyquinazolin-4-yl)guanidine was reacted with the appropriate alkylating agent to give the compounds described in Table III.

Table III



No. & Note	R <sup>6</sup>	R <sup>1</sup>	(R <sup>2</sup> ) <sub>n</sub>
[1]	3-methylaminopropyl	2-(2-oxopyrrolidin-1-yl)ethoxy	2,6-dimethyl
[2]	3-methylaminopropyl	2-( <u>N</u> -benzyl- <u>N</u> -methylamino)-ethoxy	2,6-dimethyl
[3]	3-methylaminopropyl	1-dimethylaminomethylethoxy	2,6-dimethyl
[4]	3-dimethylaminopropyl	<u>N</u> -ethylpyrrolidin-3-yloxy	2,6-dimethyl
[5]	3-dimethylaminopropyl	<u>N</u> -methylpiperidin-2-ylmethoxy	2,6-dimethyl

15

### Notes


[1] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.75 (m, 2H), 1.94 (m, 2H), 2.02 (s, 6H), 2.2 (t, 2H), 2.24 (s, 6H), 2.33 (t, 2H), 3.56–3.62 (m, 6H), 3.8 (s, 3H), 4.25 (t, 2H), 7.1 (s, 1H), 7.18 (s, 3H), 7.64 (s, 1H), 8.41 (s, 1H), 10.84 (br s, 1H);

20 Mass Spectrum: M+H<sup>+</sup> 534.

- [2] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.7 (m, 2H), 2.01 (s, 6H), 2.24 (s, 6H), 2.28 (s, 3H), 2.32 (m, 2H), 2.86 (t, 2H), 2.52 (m, 2H), 3.62 (s, 2H), 3.88 (s, 3H), 4.22 (t, 2H), 7.08 (s, 1H), 7.15 (m, 3H), 7.3 (m, 5H), 7.62 (s, 1H), 8.41 (s, 1H), 10.85 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 570.
- 5 [3] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.32 (d, 3H), 1.75 (m, 2H), 1.94 (m, 2H), 2.03 (s, 6H), 2.23 (s, 12H), 2.32 (t, 2H), 3.56 (t, 2H), 3.77 (s, 3H), 4.7 (m, 1H), 7.11 (s, 1H), 7.18 (s, 3H), 7.62 (s, 1H), 8.41 (s, 1H), 10.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 508.
- 10 [4] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.04 (t, 3H), 1.74 (m, 2H), 1.85 (q, 1H), 1.89 (m, 1H), 2.04 (s, 6H), 2.25 (s, 6H), 2.32 (q, 2H), 2.64 (m, 1H), 2.74 (m, 2H), 3.22 (t, 2H), 3.32 (t, 2H), 3.55 (q, 2H), 3.78 (s, 3H), 4.99 (m, 1H), 6.99 (s, 1H), 7.17 (s, 3H), 7.63 (br s, 1H), 8.42 (s, 1H), 10.5-11.1 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 520.
- 15 [5] The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.75 (m, 2H), 2.07 (s, 6H), 2.23 (s, 3H), 2.28 (s, 6H), 2.35 (t, 2H), 3.19 (m, 4H), 3.32 (m, 4H), 3.54 (m, 1H), 3.56 (t, 2H), 3.81 (s, 3H), 4.03 (m, 1H), 4.26 (m, 1H), 7.06 (s, 1H), 7.18 (s, 3H), 7.63 (br s, 1H), 8.21 (s, 1H), 8.45 (s, 1H), 10.6-11.1 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 534.

**Example 16**

- 20 Using an analogous procedure to that described in Example 1, the appropriate 1-aryl-3-quinazolin-4-ylthiourea was reacted with the appropriate amine to give the compounds described in Table IV.

**Table IV**

No. & Note	R <sup>6</sup>	R <sup>1</sup>	(R <sup>2</sup> ) <sub>n</sub>
			(R <sup>2</sup> ) <sub>n</sub>
[1]	2-dimethylaminoethyl	1,4-benzodioxan-2-ylmethoxy	2,6-dimethyl

[2]	2-dimethylaminoethyl	cyclohex-1-en-4-ylmethoxy	2,6-dimethyl
[3]	2-dimethylaminoethyl	tetrahydropyran-4-yloxy	2,6-dimethyl
[4]	2-dimethylaminoethyl	tetrahydropyran-2-ylmethoxy	2,6-dimethyl
[5]	2-dimethylaminoethyl	tetrahydrofuran-3-yloxy	2,6-dimethyl
[6]	2-dimethylaminoethyl	tetrahydrofuran-2-ylmethoxy	2,6-dimethyl
[7]	2-dimethylaminoethyl	tetrahydrofuran-3-ylmethoxy	2,6-dimethyl
[8]	2-dimethylaminoethyl	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl
[9]	2-(N-methylpyrrolidin-2-yl)ethyl	tetrahydrofuran-3-ylmethoxy	2,6-dimethyl
[10]	tetrahydrofuran-2-ylmethyl	3-morpholinopropoxy	2,6-dimethyl
[11]	2-cyanoethyl	3-morpholinopropoxy	2,6-dimethyl
[12]	2-dimethylaminoethyl	3-morpholinopropoxy	2,6-dimethyl
[13]	3-hydroxypropyl	3-morpholinopropoxy	2,6-dimethyl
[14]	2,3-dihydroxypropyl	3-morpholinopropoxy	2,6-dimethyl
[15]	2-dimethylaminoethyl	2,2-dimethyl-1,3-dioxolan-4-ylmethoxy	2,6-dimethyl
[16]	2-dimethylaminoethyl	2,3-dihydroxypropoxy	2,6-dimethyl
[17]	2-morpholinoethyl	tetrahydrofuran-3-yloxy	2,6-dimethyl

#### Notes

- [1] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 2.2 (s, 12H), 3.56 (m, 2H), 3.9 (s, 3H), 4.18 (q, 1H), 4.43 (m, 1H), 4.65 (m, 1H), 6.8-7.2 (m, 9H), 8.41 (s, 1H), 12.1-12.4 (br m, 1H); Mass Spectrum: M+H<sup>+</sup> 557.

The 1-[6-(1,4-benzodioxan-2-ylmethoxy)-7-methoxyquinazolin-4-yl]-3-(2,6-dimethylphenyl)thiourea used as a starting material was prepared as follows :-

A mixture of 6-acetoxy-7-methoxyquinazolin-4-one (International Patent Application WO 96/15118, Example 39 thereof; (15 g), thionyl chloride (215 ml) and DMF (4.3 ml) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and the thionyl chloride was evaporated. The material so obtained was dissolved in toluene and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. There was thus obtained

6-acetoxy-4-chloro-7-methoxyquinazoline (14.8 g) which was used without further purification.

Sodium hydride (60% dispersion in mineral oil; 4.8 g) was added portionwise to a stirred solution of 4-chloro-2-fluorophenol (17.5 g) in DMF (100 ml) which had been cooled in an ice bath. The mixture was allowed to warm to ambient temperature and was stirred for 0.5 hours. 6-Acetoxy-4-chloro-7-methoxyquinazoline (10 g) was added and the mixture was stirred and heated to 100°C for 5 hours. The mixture was evaporated under vacuum and the residue was partitioned between ethyl acetate and a dilute aqueous citric acid solution. The resultant solid was isolated and washed in turn with water and diethyl ether. The material so obtained was dried under vacuum at 80°C. There was thus obtained 4-(4-chloro-2-fluorophenoxy)-6-hydroxy-7-methoxyquinazoline (5.3 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.99 (s, 3H), 7.3-7.7 (m, 5H), 8.5 (s, 1H), 10.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 321.

Diisopropyl azodicarboxylate (0.8 ml) was added dropwise during 10 minutes to a stirred mixture of 4-(4-chloro-2-fluorophenoxy)-6-hydroxy-7-methoxyquinazoline (0.4 g), 2-hydroxymethyl-1,4-benzodioxan (0.62 g), triphenylphosphine (0.99 g) and toluene (25 ml) that had been cooled in an ice bath. The temperature was maintained at approximately 10°C during the addition. The reaction mixture was allowed to warm to ambient temperature and was stirred for a further 3 hours. The mixture was partitioned between ethyl acetate and a dilute aqueous potassium carbonate solution. The organic solution was washed with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of isohexane and ethyl acetate as eluent. There was thus obtained 6-(1,4-benzodioxan-2-ylmethoxy)-4-(4-chloro-2-fluorophenoxy)-7-methoxyquinazoline (0.55 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 4.01 (s, 3H), 4.19 (m, 1H), 4.46 (m, 3H), 4.66 (m, 1H), 6.8-6.95 (m, 4H), 7.4-7.75 (m, 5H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 469.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 4-amino-6-(1,4-benzodioxan-2-ylmethoxy)-7-methoxyquinazoline which was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 1-[6-(1,4-benzodioxan-2-ylmethoxy)-7-methoxyquinazolin-4-yl]-3-(2,6-dimethylphenyl)thiourea; Mass Spectrum: M+H<sup>+</sup> 503.

[2] The product gave the following data: NMR Spectrum: ( $\text{CDCl}_3$ ) 1.45 (m, 1H), 1.96 (m, 2H), 2.1-2.38 (br m, 16H), 2.5 (m, 2H), 3.6 (m, 2H), 4.0 (s, 3H), 4.04 (m, 2H), 5.73 (s, 2H), 7.15 (m, 5H), 8.55 (m, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  503.

The 1-(6-cyclohex-1-en-4-ylmethoxy-7-methoxyquinazolin-4-yl)-3-(2,6-dimethylphenyl)thiourea used as a starting material was prepared as follows :-  
 5 4-(4-Chloro-2-fluorophenoxy)-6-hydroxy-7-methoxyquinazoline was reacted with cyclohex-1-en-4-ylmethanol using an analogous procedure to that described in the second last paragraph of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 6-cyclohex-1-en-4-ylmethoxy-4-(4-chloro-2-fluorophenoxy)-7-methoxyquinazoline; NMR Spectrum: ( $\text{CDCl}_3$ ) 1.46 (m, 1H), 1.98 (m, 2H), 2.13 (m, 2H), 2.3 (m, 2H), 4.03 (s, 3H), 4.04 (m, 2H), 5.72 (q, 2H), 7.2-7.35 (m, 4H), 7.51 (s, 1H), 8.6 (s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  415.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 4-amino-6-cyclohex-1-en-4-ylmethoxy-7-methoxyquinazoline which, in turn, was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 1-(6-cyclohex-1-en-4-ylmethoxy-7-methoxyquinazolin-4-yl)-3-(2,6-dimethylphenyl)thiourea; Mass Spectrum:  $\text{M}+\text{H}^+$  503.

[3] The product gave the following data: NMR Spectrum: ( $\text{DMSO-d}_6$ ) 1.6 (br m, 2H), 1.97 (br m, 2H), 2.2 (s, 12H), 3.4-3.6 (m, 4H), 3.85 (m, 2H), 3.9 (s, 3H), 7.1 (s, 1H), 7.17 (s, 3H), 8.43 (s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  493.

The 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydropyran-4-yloxyquinazolin-4-yl)thiourea used as a starting material was prepared as follows :-  
 25 6-Acetoxy-4-chloro-7-methoxyquinazoline (10 g), was added portionwise to a solution of 4-methoxybenzylamine (15.5 ml) in isopropanol (100 ml) and the resultant mixture was stirred and heated to reflux for 4 hours. The mixture was filtered and the filtrate was evaporated. The residue was partitioned between ethyl acetate and brine. The organic solution was evaporated and the crude product was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 6-hydroxy-4-(4-methoxybenzylamino)-7-methoxyquinazoline (8.6 g); NMR

Spectrum: (DMSO-d<sub>6</sub>) 3.7 (s, 3H), 3.91 (s, 3H), 4.63 (d, 2H), 6.82 (d, 2H), 7.08 (s, 1H), 7.25 (d, 2H), 7.49 (s, 1H), 8.18 (t, 1H), 8.25 (s, 1H), 9.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 312.

The material so obtained was reacted with 4-hydroxytetrahydropyran using an analogous procedure to that described in the second last paragraph of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-(4-methoxybenzylamino)-7-methoxy-6-tetrahydropyran-4-yloxyquinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.83 (m, 2H), 2.0 (m, 2H), 3.5 (m, 2H), 3.8 (s, 3H), 3.96 (s, 3H), 4.0 (m, 2H), 4.5 (m, 1H), 4.78 (d, 2H), 5.6 (t, 1H), 6.88 (d, 2H), 7.02 (s, 1H), 7.2 (s, 1H), 7.32 (d, 2H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 396.

A portion (0.54 g) of the material so obtained was dissolved in a solution of trifluoroacetic acid (5 ml) containing anisole (0.2 ml) and concentrated sulphuric acid (3 drops) and the resultant mixture was stirred and heated to 60°C for 16 hours. The mixture was evaporated. The residue was partitioned between diethyl ether and a dilute aqueous potassium carbonate solution. A solid was precipitated which was isolated and washed in turn with water and diethyl ether. The solid was dried under vacuum at 70°C. There was thus obtained 4-amino-7-methoxy-6-tetrahydropyran-4-yloxyquinazoline which was used without further purification.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydropyran-4-yloxyquinazolin-4-yl)thiourea; Mass Spectrum: M+H<sup>+</sup> 439.

[4] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.32 (m, 1H), 1.5 (m, 3H), 1.65 (m, 1H), 1.85 (m, 1H), 2.2 (s, 12H), 3.4 (m, 2H), 3.55 (m, 2H), 3.66 (m, 1H), 3.88 (s, 3H), 3.93 (m, 2H), 5.76 (s, 1H), 7.0-7.2 (m, 4H), 8.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 507.

The 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydropyran-2-ylmethoxyquinazolin-4-yl)thiourea used as a starting material was prepared as follows :-

6-Hydroxy-4-(4-methoxybenzylamino)-7-methoxyquinazoline was reacted with tetrahydropyran-2-ylmethanol using an analogous procedure to that described in the second last paragraph of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-(4-methoxybenzylamino)-7-methoxy-6-tetrahydropyran-2-ylmethoxyquinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.3-2.0 (m, 6H), 3.5 (m, 2H), 3.8 (s, 3H),

3.98 (s, 3H), 4.0-4.15 (m, 3H), 4.76 (d, 2H), 5.62 (t, 1H), 6.9 (d, 2H), 6.95 (s, 1H), 7.19 (s, 1H), 7.32 (d, 2H), 8.59 (s, 1H); Mass Spectrum:  $M+H^+$  410.

The material so obtained was reacted with trifluoroacetic acid and concentrated sulphuric acid using an analogous procedure to that described in the second last paragraph of Note [3] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-amino-7-methoxy-6-tetrahydropyran-2-ylmethoxyquinazoline which was used without further purification.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydropyran-2-ylmethoxyquinazolin-4-yl)thiourea; Mass Spectrum:  $M+H^+$  453.

[5] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.1-2.35 (m, 14H), 2.46 (m, 2H), 3.6 (m, 2H), 3.9-4.2 (br m, 7H), 4.9 (m, 1H), 5.1 (m, 1H), 7.15 (s, 4H), 7.87 (br s, 1H), 8.55 (s, 1H), 12.5 (br s, 1H); Mass Spectrum:  $M+H^+$  479.

The 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydrofuran-3-yloxyquinazolin-4-yl)thiourea used as a starting material was prepared as follows :-

6-Hydroxy-4-(4-methoxybenzylamino)-7-methoxyquinazoline was reacted with 3-hydroxytetrahydrofuran using an analogous procedure to that described in the second last paragraph of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-(4-methoxybenzylamino)-7-methoxy-6-tetrahydrofuran-3-yloxyquinazoline; NMR Spectrum: ( $CDCl_3$ ) 2.2 (m, 2H), 3.81 (s, 3H), 3.85-4.1 (m, 7H), 4.77 (d, 2H), 5.11 (m, 1H), 5.6 (t, 1H), 6.9 (m, 3H), 7.2 (s, 1H), 7.32 (d, 2H), 8.6 (s, 1H); Mass Spectrum:  $M+H^+$  382.

The material so obtained was reacted with trifluoroacetic acid and concentrated sulphuric acid using an analogous procedure to that described in the second last paragraph of Note [3] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-amino-7-methoxy-6-tetrahydrofuran-3-yloxyquinazoline which was used without further purification.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained

1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydrofuran-3-yloxyquinazolin-4-yl)thiourea;

Mass Spectrum:  $M+H^+$  425.

[6] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.6-2.1 (m, 4H), 2.2 (s, 12H), 3.55 (m, 2H), 3.68-3.95 (m, 7H), 4.2 (m, 1H), 7.0-7.2 (m, 5H), 8.4 (s, 1H); Mass

Spectrum:  $M+H^+$  493.

The 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydrofuran-2-ylmethoxyquinazolin-4-yl)thiourea used as a starting material was prepared as follows :-

6-Hydroxy-4-(4-methoxybenzylamino)-7-methoxyquinazoline was reacted with tetrahydrofuran-2-ylmethanol using an analogous procedure to that described in the second last paragraph of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-(4-methoxybenzylamino)-7-methoxy-6-tetrahydrofuran-2-ylmethoxyquinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.7-2.2 (m, 4H), 3.82 (s, 3H), 3.85-3.95 (m, 2H), 3.98 (s, 3H), 4.05 (d, 2H), 4.35 (m, 1H), 4.76 (d, 2H), 5.6 (t, 1H), 6.9 (m, 3H), 7.18 (s, 1H), 7.35 (d, 2H), 8.59 (s, 1H); Mass Spectrum:  $M+H^+$  396.

The material so obtained was reacted with trifluoroacetic acid and concentrated sulphuric acid using an analogous procedure to that described in the second last paragraph of Note [3] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-amino-7-methoxy-6-tetrahydrofuran-2-ylmethoxyquinazoline which was used without further purification.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydrofuran-2-ylmethoxyquinazolin-4-yl)thiourea; Mass Spectrum:  $M+H^+$  439.

[7] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.65 (m, 1H), 2.05 (m, 1H), 2.22 (s, 12H), 2.7 (m, 2H), 3.5-3.95 (m, 11H), 7.0-7.2 (m, 4H), 8.4 (s, 1H); Mass Spectrum:  $M+H^+$  493.

The 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydrofuran-3-ylmethoxyquinazolin-4-yl)thiourea used as a starting material was prepared as follows :-

6-Hydroxy-4-(4-methoxybenzylamino)-7-methoxyquinazoline was reacted with tetrahydrofuran-3-ylmethanol using an analogous procedure to that described in the second last paragraph of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-(4-methoxybenzylamino)-7-methoxy-6-tetrahydrofuran-

3-ylmethoxyquinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.75 (m, 1H), 2.13 (m, 1H), 1.82 (m, 1H), 3.75 (m, 2H), 3.81 (s, 3H), 3.85 (m, 4H), 3.95 (s, 3H), 4.77 (d, 2H), 5.63 (t, 1H), 6.9 (m, 3H), 7.2 (s, 1H), 7.35 (d, 2H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 396.

The material so obtained was reacted with trifluoroacetic acid and concentrated sulphuric acid using an analogous procedure to that described in the second last paragraph of Note [3] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-amino-7-methoxy-6-tetrahydrofuran-3-ylmethoxyquinazoline which was used without further purification.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-tetrahydrofuran-3-ylmethoxyquinazolin-4-yl)thiourea; Mass Spectrum: M+H<sup>+</sup> 439.

[8] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.18 (br s, 6H), 2.29 (s, 6H), 2.5 (m, 2H), 3.4 (s, 3H), 3.6 (m, 4H), 3.75 (m, 2H), 3.96 (m, 5H), 4.32 (m, 2H), 4.9 (br s, 1H), 7.15 (s, 4H), 7.9 (s, 1H), 8.56 (s, 1H), 12.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 511.

The 1-(2,6-dimethylphenyl)-3-{7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]quinazolin-4-yl}thiourea used as a starting material was prepared as follows :-

6-Hydroxy-4-(4-methoxybenzylamino)-7-methoxyquinazoline was reacted with 2-(2-methoxyethoxy)ethanol using an analogous procedure to that described in the second last paragraph of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-(4-methoxybenzylamino)-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 3.51 (m, 2H), 3.68 (m, 2H), 3.82 (s, 3H), 3.88 (m, 2H), 3.96 (s, 3H), 4.26 (m, 2H), 4.76 (d, 2H), 5.87 (t, 1H), 6.89 (d, 2H), 7.13 (s, 1H), 7.19 (s, 1H), 7.34 (d, 2H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 414.

The material so obtained was reacted with trifluoroacetic acid and concentrated sulphuric acid using an analogous procedure to that described in the second last paragraph of Note [3] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-amino-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]quinazoline which was used without further purification.

The material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained

1-(2,6-dimethylphenyl)-3-{7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]quinazolin-4-yl}thiourea; Mass Spectrum:  $M+H^+$  457.

[9] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.5-2.0 (m, 12H), 2.15 (m, 1H), 2.29 (d, 6H), 2.52 (m, 1H), 2.9 (m, 1H), 3.55 (m, 1H), 3.8 (m, 2H), 3.85 (m, 6H), 4.1 (m, 2H), 7.0 (br s, 1H), 7.16 (s, 4H), 7.91 (s, 1H), 8.5 (s, 1H), 12.4 (s, 1H); Mass Spectrum:  $M+H^+$  533.

[10] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.8-2.2 (m, 6H), 2.3 (s, 6H), 2.46 (m, 4H), 2.58 (m, 2H), 3.5-3.9 (m, 8H), 4.0 (s, 3H), 4.1-4.3 (m, 3H), 4.6 (br m, 1H), 7.15 (m, 4H), 7.9 (br m, 1H), 8.55 (s, 1H), 12.55 (br m, 1H); Mass Spectrum:  $M+H^+$  549.

10 The 1-(2,6-dimethylphenyl)-3-(7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)thiourea used as a starting material was obtained by the reaction of 4-amino-7-methoxy-6-(3-morpholinopropoxy)quinazoline (International Patent Appn. WO 01/04102, Example 25 thereof) with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials.

[11] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.13 (m, 2H), 2.3 (s, 6H), 2.4-2.6 (m, 6H), 3.0 (m, 2H), 3.7-3.8 (m, 6H), 4.0 (s, 3H), 4.25 (t, 2H), 4.65 (br m, 1H), 7.19 (m, 4H), 7.82 (s, 1H), 8.6 (s, 1H), 12.55 (s, 1H); Mass Spectrum:  $M+H^+$  518.

[12] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.0-2.25 (m, 8H), 2.3 (s, 6H), 2.45-2.6 (m, 8H), 3.61 (m, 2H), 3.71 (m, 4H), 4.0 (s, 3H), 4.2 (br m, 2H), 4.8 (br m, 1H), 7.15 (m, 4H), 7.9 (br m, 1H), 8.55 (s, 1H), 12.55 (br m, 1H); Mass Spectrum:  $M+H^+$  536.

[13] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78 (t, 2H), 2.14 (t, 2H), 2.34 (s, 6H), 2.5 (m, 4H), 2.6 (m, 2H), 3.65-3.8 (m, 8H), 4.0 (s, 3H), 4.28 (t, 2H), 4.45 (br m, 1H), 7.19 (s, 1H), 7.2 (s, 3H), 7.86 (s, 1H), 8.55 (s, 1H), 12.7 (s, 1H); Mass Spectrum:

25  $M+H^+$  523.

[14] The product was obtained as a dihydrochloride salt by the reaction of N-(2,2-dimethyl-1,3-dioxolan-4-ylmethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]guanidine with a saturated solution of hydrogen chloride in methanol at ambient temperature for 1 hour and gave the following data: Mass

30 Spectrum:  $M+H^+$  539.

The N-(2,2-dimethyl-1,3-dioxolan-4-ylmethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]guanidine used as a starting material was prepared by the reaction of 1-(2,6-dimethylphenyl)-3-[7-methoxy-

6-(3-morpholinopropoxy)quinazolin-4-yl]thiourea with 2,2-dimethyl-1,3-dioxolan-4-ylmethanamine using an analogous procedure to that described in Example 1. The material so obtained gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.17 (s, 3H), 1.3 (s, 3H), 2.11 (m, 2H), 2.32 (m, 6H), 2.5 (m, 4H), 2.58 (m, 2H), 3.7-3.9 (m, 7H), 4.0-4.05 (m, 4H), 4.2 (m, 2H), 4.36 (m, 1H), 4.6 (br m, 1H), 7.19 (m, 4H), 7.85 (m, 1H), 8.58 (s, 1H), 12.55 (br m, 1H); Mass Spectrum: M+H<sup>+</sup> 579.

[15] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4 (s, 3H), 1.5 (s, 3H), 2.2 (s, 6H), 2.3 (s, 6H), 2.49 (br m, 2H), 3.62 (m, 2H), 3.9-4.0 (m, 5H), 4.2 (m, 2H), 4.59 (m, 1H), 4.85 (br m, 1H), 7.1-7.2 (m, 4H), 7.95 (br m, 1H), 8.57 (s, 1H), 12.5 (br m, 1H); Mass Spectrum: M+H<sup>+</sup> 523.

The 1-(2,6-dimethylphenyl)-3-[7-methoxy-6-(2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :- 4-(4-Chloro-2-fluorophenoxy)-6-hydroxy-7-methoxyquinazoline was reacted with 2,2-dimethyl-1,3-dioxolan-4-ylmethanol using analogous conditions to those described in the third paragraph of the portion of Note [1] immediately above that is concerned with the preparation of starting materials. There was thus obtained 4-(4-chloro-2-fluorophenoxy)-6-(2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-7-methoxyquinazoline; NMR Spectrum: 1.4 (s, 3H), 1.5 (s, 3H), 3.95-4.05 (m, 4H), 4.1-4.3 (m, 3H), 4.65 (m, 1H), 7.15-7.3 (m, 4H), 7.6 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 435.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the second last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 4-amino-6-(2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-7-methoxyquinazoline which was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained the required starting material.

[16] The product of Example 16[15] was reacted with sulphuric acid using an analogous procedure to that described in Note [14] immediately above to give the stated product as a dihydrochloride salt which gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 2.3 (s, 6H), 2.85 (s, 6H), 3.35 (m, 2H), 3.56 (m, 2H), 3.85-3.95 (m, 3H), 3.99 (s, 3H), 4.05-4.15 (br m, 1H), 7.1-7.25 (m, 4H), 7.65 (br m, 1H), 8.54 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 483.

[17] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.32 (s, 6H), 2.3-2.4 (m, 6H), 2.54 (br m, 2H), 3.46 (m, 4H), 3.62 (m, 2H), 3.9-4.18 (m, 8H), 5.1 (br m, 2H), 7.18 (m, 4H), 7.86 (br m, 1H), 8.56 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 521.

5 **Example 17** N-(2-carboxyethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]guanidine

A mixture of N-(2-methoxycarbonylethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]guanidine (0.038 g), lithium hydroxide monohydrate (0.0063 g), THF (1 ml), methanol (0.5 ml) and water (0.5 ml) was stirred at ambient  
10 temperature for 16 hours. The mixture was evaporated and the residue was partitioned between water and methylene chloride. The aqueous layer was acidified by the addition of glacial acetic acid and evaporated. The resultant residue was extracted with methylene chloride. The organic extract was filtered and evaporated. There was thus obtained the title compound (0.034 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.15 (m, 2H), 2.28 (s, 6H), 2.58 (s, 3H) 2.6-  
15 2.73 (m, 7H), 3.73 (t, 4H), 3.83 (s, 2H), 4.0 (s, 4H), 4.2 (t, 2H), 7.14 (s, 3H), 7.2 (s, 1H), 7.87 (s, 1H), 8.51 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 538.

**Example 18** N-[(*S*)-1-carboxyethyl]-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]guanidine

20 Using an analogous procedure to that described in Example 4,  
N-[(*S*)-1-tert-butoxycarbonylethyl]-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]guanidine was reacted with trifluoroacetic acid to give the title compound in 68% yield; NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.47 (d, 3H), 1.75 (m, 4H), 2.33 (s, 6H), 2.67 (m, 4H), 2.93 (t, 2H), 3.88 (s, 3H), 4.28 (t, 2H), 4.58 (q, 1H), 7.13 (s, 1H), 7.19  
25 (s, 3H), 7.75 (s, 1H), 8.48 (s, 1H), 11.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 505.

**Example 19** N-[(*R*)-1-carboxyethyl]-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]guanidine

Using an analogous procedure to that described in Example 4,  
30 N-[(*R*)-1-tert-butoxycarbonylethyl]-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]guanidine was reacted with trifluoroacetic acid to give the title compound in 59% yield; NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.48 (d, 3H), 1.76 (m, 4H), 2.32

(s, 6H), 2.69 (m, 4H), 2.98 (t, 2H), 3.88 (s, 3H), 4.27 (t, 2H), 4.59 (q, 1H), 7.15 (s, 1H), 7.18 (s, 3H), 7.76 (s, 1H), 8.49 (s, 1H), 11.45 (br s, 1H); Mass Spectrum:  $M+H^+$  505.

**Example 20** N-carboxymethyl-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-

7-(2-morpholinoethoxy)quinazolin-4-yl]guanidine

Using an analogous procedure to that described in Example 4,

N-(tert-butoxycarbonylmethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-  
7-(2-morpholinoethoxy)quinazolin-4-yl]guanidine was reacted with trifluoroacetic acid to  
 give the title compound in 74% yield; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 2.17 (s, 6H), 3.27  
 (t, 4H), 3.5 (t, 2H), 3.6 (s, 3H), 3.8 (t, 4H), 4.48 (m, 4H), 7.15 (s, 1H), 7.2 (d, 2H), 7.26 (t,  
 2H), 8.7 (s, 1H); Mass Spectrum:  $M+H^+$  509.

**Example 21** N-(2-dimethylaminoethyl)-N'-(2,6-dimethylphenyl)-N''-(6-methoxy-  
7-morpholin-3-ylmethoxyquinazolin-4-yl]guanidine

A mixture of N-(2-dimethylaminoethyl)-N'-(2,6-dimethylphenyl)-N''-[7-(N-  
benzylmorpholin-3-ylmethoxy)-6-methoxyquinazolin-4-yl]guanidine (0.1 g), trifluoroacetic  
 acid (0.091 ml), 10% palladium on carbon catalyst (0.03 g) and ethanol (12 ml) was stirred  
 under an atmosphere pressure of hydrogen for 18 hours. The reaction was filtered and the  
 filtrate was evaporated. The resulting gum was triturated under diethyl ether to give a solid  
 which was dissolved in methylene chloride. The solution was washed with cooled 1N  
 aqueous sodium hydroxide solution and with water. The organic solution was dried over  
 magnesium sulphate and evaporated. There was thus obtained the title compound (0.069 g);  
NMR Spectrum: (CDCl<sub>3</sub>) 2.1 (s, 6H), 2.26 (s, 6H), 2.39 (m, 2H), 2.9 (m, 2H), 3.36 (m, 2H),  
 3.55 (m, 3H), 3.78 (d, 2H) 3.80-4.08 (m, 5H), 4.79 (s, 1H), 7.1 (s, 4H), 7.85 (s, 1H), 8.47 (s,  
 1H), 12.5 (s, 1H); Mass Spectrum:  $M+H^+$  508.

**Example 22** N-(2-dimethylaminoethyl)-N'-(2,6-dimethylphenyl)-N''-(6-methoxy-  
7-morpholin-2-ylmethoxyquinazolin-4-yl]guanidine

Using an analogous procedure to that described in Example 21,

N-(2-dimethylaminoethyl)-N'-(2,6-dimethylphenyl)-N''-[7-(N-benzylmorpholin-  
2-ylmethoxy)-6-methoxyquinazolin-4-yl]guanidine was hydrogenated to give the title  
 compound in 74% yield; NMR Spectrum: (CDCl<sub>3</sub>) 2.19 (s, 6H), 2.31 (s, 6H), 2.5 (m, 2H),

2.76-2.91 (m, 2H), 2.91-3.01 (m, 1H), 3.1 (d, 1H), 3.59-3.76 (m, 4H), 3.88-4.14 (m, 6H), 4.19 (m, 1H), 4.85 (s, 1H), 7.17 (s, 4H), 7.9 (s, 1H), 8.54 (s, 1H), 12.55 (s, 1H); Mass Spectrum:  $M+H^+$  508.

5 **Example 23** N-(6,7-dimethoxyquinazolin-4-yl)-N'-(2,6-dimethylphenyl)-N''-[2-(N-methypyrrolidin-2-yl)ethyl]guanidine

Using an analogous procedure to that described in Example 11,

N-(7-hydroxy-6-methoxyquinazolin-4-yl)-N'-(2,6-dimethylphenyl)-

N''-[2-(N-methypyrrolidin-2-yl)ethyl]guanidine was reacted with trimethylsilyldiazomethane

10 to give the title compound; NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.65 (m, 3H), 1.68 (m, 1H), 1.8-1.96 (m, 2H), 2.07 (q, 1H), 2.15 (s, 3H), 2.32 (s, 6H), 2.79 (br t, 1H), 2.59 (m, 1H), 2.69 (m, 1H), 3.84 (s, 3H), 3.95 (s, 3H), 7.08 (s, 1H), 7.20 (m, 4H), 7.74 (s, 1H), 8.47 (s, 1H), 10.9-11.3 (br s, 1H); Mass Spectrum:  $M+H^+$  463.

The N-(7-hydroxy-6-methoxyquinazolin-4-yl)-N'-(2,6-dimethylphenyl)-

15 N''-[2-(N-methypyrrolidin-2-yl)ethyl]guanidine starting material was prepared as follows :-

Using an analogous procedure to that described in Example 1, the 1-(7-benzyloxy-

6-methoxyquinazolin-4-yl)-3-(2,6-dimethylphenyl)thiourea (0.8 g) was reacted with

2-(N-methylpyrrolidin-2-yl)ethylamine (0.78 ml). There was thus obtained N-(7-benzyloxy-6-methoxyquinazolin-4-yl)-N'-(2,6-dimethylphenyl)-N''-[2-(N-methypyrrolidin-

20 2-yl)ethyl]guanidine (0.6 g); NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.61 (m, 3H), 1.71 (m, 1H), 1.8-1.93 (m, 2H), 2.01 (q, 1H), 2.11 (s, 3H), 2.26 (m, 7H), 2.79 (br t, 1H), 3.54 (m, 1H), 3.65 (m, 1H), 3.84 (s, 3H), 5.30 (s, 2H), 7.20 (s, 4H), 7.35 (m, 1H), 7.41 (t, 2H), 7.51 (d, 2H), 7.7 (s, 1H), 8.42 (s, 1H), 10.8-11.3 (br s, 1H); Mass Spectrum:  $M+H^+$  539.

A portion (0.5 g) of this product was treated with trifluoroacetic acid (50 ml) using an

25 analogous procedure to that described in Example 2 (Note[11]). There was thus was obtained the required starting material; NMR Spectrum: (DMSO<sub>d6</sub>, 100°C) 1.58 (m, 3H), 1.66 (m, 1H), 1.76-1.9 (m, 2H), 2.0 (q, 1H), 2.09 (s, 3H), 2.24 (m, 7H), 2.74 (m, 1H), 3.50 (m, 1H), 3.65 (m, 1H), 3.81 (s, 3H), 6.98 (s, 1H), 7.18 (s, 3H), 7.42 (br s, 1H), 7.67 (s, 1H), 8.38 (s, 1H), 9.5 (br s, 1H), 11.1 (br s, 1H); Mass Spectrum:  $M+H^+$  449.

30

**Example 24** N-(2,5-dimethylphenyl)-N'-(1,5-ethyleneoxyethylene)-N''-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine

Using an analogous procedure to that described in Example 1, 3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea was reacted with morpholine to give the title compound in 94% yield; NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.4 (m, 2H), 1.8 (m, 3H), 1.95 (m, 2H), 2.2 (m, 6H), 2.3 (s, 3H), 2.84 (m, 2H), 3.5 (m, 4H), 3.65 (m, 4H), 3.9 (s, 3H), 4.0 (d, 2H), 6.8 (d, 1H), 6.98 (s, 1H), 7.05 (d, 1H), 7.12 (s, 1H), 7.7 (s, 1H), 8.48 (s, 1H), 11.45 (s, 1H); Mass Spectrum M+H<sup>+</sup> 519.

**Example 25** N-(2-carbamoylethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]guanidine

A mixture of N-(2-cyanoethyl)-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]guanidine (0.05 g) and concentrated sulphuric acid (0.5 ml) was stirred at ambient temperature for 4 hours. The reaction mixture was added dropwise to an ice cold saturated sodium bicarbonate solution and the resulting mixture was extracted with methylene chloride. The organic phase was dried and evaporated. There was thus obtained the title compound (0.025 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.13 (m, 2H), 2.31 (s, 6H), 2.5 (t, 4H), 2.59 (t, 2H), 2.7 (s, 2H), 3.72 (t, 4H), 3.89 (q, 2H), 4.01 (s, 3H), 4.26 (t, 2H), 4.86 (s, 1H), 5.3 (s, 1H), 6.28 (s, 1H), 7.19 (d, 4H), 7.87 (s, 1H), 8.59 (s, 1H), 12.54 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 536.

**Example 26** N-(2-cyanoethyl)-N'-(2,6-dimethylphenyl)-N''-[7-(2-morpholinoethoxy)quinazolin-4-yl]guanidine

Using an analogous procedure to that described in Example 1, 3-[7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea was reacted with 3-aminopropionitrile to give the title compound: NMR Spectrum: (CDCl<sub>3</sub>) 2.27 (s, 6H), 2.55 (t, 4H), 2.86 (q, 4H), 3.69 (m, 6H), 4.21 (t, 2H), 4.63 (t, 1H), 7.08 (m, 1H), 7.16 (m, 4H), 8.3 (d, 1H), 8.59 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 474.

The 3-[7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea used as a starting material was prepared as follows :-

4-Fluoroanthranilic acid (5 g) and formamidine acetate (6.71 g) in 2-methoxyethanol (40 ml) were heated to reflux for 16 hours. The solvent was evaporated and the residue was stirred with 0.02N aqueous ammonium hydroxide solution (100 ml). The resultant solid was filtered off, washed with water and dried. The solid was triturated under diethyl ether. There

was thus obtained 7-fluoro- (4.88 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 7.4 (m, 2H), 8.17 (m, 2H), 12.3 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 165.

A mixture of N-(2-hydroxyethyl)morpholine (2.66 ml), sodium hydride (60% dispersion in mineral oil, 0.88 g) and DMF (25 ml) was warmed to 50°C for 3 minutes. The  
5 resulting solution was allowed to cool for 10 minutes before a solution of 7-fluoro-3,4-dihydroquinazolin-4-one (1.64 g) in DMF (25 ml) was added and the resultant mixture was heated to 125°C for 18 hours. The solvent was evaporated and the residue was partitioned between methylene chloride and 2N hydrochloric acid solution. The organic phase was dried and evaporated to give 7-(2-morpholinoethoxy)-3,4-dihydroquinazolin-4-one  
10 (1.58 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.6 (t, 4H), 2.87 (t, 2H), 3.73 (t, 4H), 4.25 (t, 2H), 7.12 (m, 2H), 8.07 (s, 1H), 8.19 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 276.


The material so obtained was reacted with thionyl chloride using an analogous procedure to that described in Example 1 which is concerned with the preparation of starting materials to give 4-chloro-7-(2-morpholinoethoxy)quinazoline (0.77 g); NMR Spectrum:  
15 (CDCl<sub>3</sub>) 2.6 (t, 4H), 2.9 (t, 2H), 3.74 (t, 4H), 4.28 (t, 2H), 7.35 (m, 2H), 8.17 (d, 1H), 8.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 294.

A portion (0.67 g) of the material so obtained was reacted with ammonia using an analogous procedure to that described in the portion of Example 1 which is concerned with the preparation of starting materials to give 4-amino-7-(2-morpholinoethoxy)quinazoline  
20 (0.67 g); Mass Spectrum: M+H<sup>+</sup> 275.


A portion (0.2 g) of the material so obtained was reacted with 2,6-dimethylphenyl isothiocyanate using an analogous procedure to that described in the portion of Example 1 which is concerned with the preparation of starting materials to give 1-(2,6-dimethylphenyl)-3-[7-(2-morpholinoethoxy)quinazolin-4-yl]thiourea (0.14 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.37  
25 (s, 6H), 2.61 (t, 4H), 2.92 (t, 2H), 3.75 (t, 4H), 4.3 (t, 2H), 7.20 (m, 3H), 7.35 (m, 2H), 7.89 (d, 1H), 8.77 (s, 1H), 8.91(s, 1H), 13.2(s, 1H); Mass Spectrum: M+H<sup>+</sup> 438.

**CLAIMS**


1. A quinazoline derivative of the Formula I




- 5 wherein  $Q^1$  is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id




Ia



Ib



Ic



Id

wherein :


$Y^1$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$Y^2$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

15  $m$  is 0, 1, 2, 3 or 4;

each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,


(2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,  
 (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,  
N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  
N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-  
 5 (3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino,  
N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and  
N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^1$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO, CH(OR<sup>7</sup>),  
 10 CON(R<sup>7</sup>), N(R<sup>7</sup>)CO, SO<sub>2</sub>N(R<sup>7</sup>), N(R<sup>7</sup>)SO<sub>2</sub>, OC(R<sup>7</sup>)<sub>2</sub>, SC(R<sup>7</sup>)<sub>2</sub> and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, wherein R<sup>7</sup> is  
 hydrogen or (1-6C)alkyl, and Q<sup>3</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-  
 (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-  
 (1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R<sup>1</sup>)<sub>m</sub> is (1-3C)alkylenedioxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent  
 15 are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>,  
 N(R<sup>8</sup>), CO, CH(OR<sup>8</sup>), CON(R<sup>8</sup>), N(R<sup>8</sup>)CO, SO<sub>2</sub>N(R<sup>8</sup>), N(R<sup>8</sup>)SO<sub>2</sub>, CH=CH and C=C wherein  
 R<sup>8</sup> is hydrogen or (1-6C)alkyl,


and wherein any CH<sub>2</sub>=CH- or HC=C- group within a R<sup>1</sup> substituent optionally bears at  
 the terminal CH<sub>2</sub>= or HC= position a substituent selected from halogeno, carboxy, carbamoyl,  
 20 (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,  
 amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or  
 from a group of the formula :



wherein  $X^2$  is a direct bond or is selected from CO and N(R<sup>9</sup>)CO, wherein R<sup>9</sup> is hydrogen or  
 25 (1-6C)alkyl, and Q<sup>4</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl  
 or heterocyclyl-(1-6C)alkyl,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each  
 said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno substituents or a substituent selected from  
 hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio,  
 30 (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  
 (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,  
 (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-

(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




- 5 wherein  $X^3$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>10</sup>), CO, CH(OR<sup>10</sup>), CON(R<sup>10</sup>), N(R<sup>10</sup>)CO, SO<sub>2</sub>N(R<sup>10</sup>), N(R<sup>10</sup>)SO<sub>2</sub>, C(R<sup>10</sup>)<sub>2</sub>O, C(R<sup>10</sup>)<sub>2</sub>S and N(R<sup>10</sup>)C(R<sup>10</sup>)<sub>2</sub>, wherein R<sup>10</sup> is hydrogen or (1-6C)alkyl, and Q<sup>5</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,
- 10 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,
- 15 di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :
- 20  $-X^4-R^{11}$
- wherein  $X^4$  is a direct bond or is selected from O and N(R<sup>12</sup>), wherein R<sup>12</sup> is hydrogen or (1-6C)alkyl, and R<sup>11</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl,
- 25 carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl or N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, or from a group of the formula :
- $$-X^5-Q^6$$
- wherein  $X^5$  is a direct bond or is selected from O and N(R<sup>13</sup>), wherein R<sup>13</sup> is hydrogen or (1-6C)alkyl, and Q<sup>6</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl
- 30 or heterocyclyl-(1-6C)alkyl, and any Q<sup>6</sup> group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,
- and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo or thioxo substituents;

$R^2$  is hydrogen or (1-6C)alkyl and  $R^3$  is hydrogen or (1-6C)alkyl, or  $R^2$  and  $R^3$  together form a  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group,


$R^5$  is hydrogen or (1-6C)alkyl, or  $R^5$  and  $R^6$  together with the N atom to which they are attached form a 4- to 7-membered heterocyclic ring optionally containing a further  
5 heteroatom selected from O, N and S,

provided that one of the pairs of groups  $R^2$  and  $R^4$  together,  $R^3$  and  $R^4$  together and  $R^5$  and  $R^4$  together forms a bond;

$Q^2$  is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each  
10 heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and  
 $Q^2$  is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl,  
15 (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,  
20 (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



25 wherein  $X^6$  is a direct bond or is selected from O and N( $R^{15}$ ), wherein  $R^{15}$  is hydrogen or (1-6C)alkyl, and  $R^{14}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :




30 wherein  $X^7$  is a direct bond or is selected from O, S, SO,  $SO_2$ , N( $R^{16}$ ), CO, CH( $OR^{16}$ ), CON( $R^{16}$ ), N( $R^{16}$ )CO,  $SO_2$ N( $R^{16}$ ), N( $R^{16}$ ) $SO_2$ , C( $R^{16}$ ) $_2$ O, C( $R^{16}$ ) $_2$ S and C( $R^{16}$ ) $_2$ N( $R^{16}$ ), wherein each  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is aryl, aryl-(1-6C)alkyl, heteroaryl,

heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $Q^2$  is optionally substituted with a (1-3C)alkylenedioxy group,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from

5 halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,

10 N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^8$  is a direct bond or is selected from O and N( $R^{18}$ ), wherein  $R^{18}$  is hydrogen or

15 (1-6C)alkyl, and  $R^{17}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on  $Q^2$  optionally bears 1 or 2 oxo or thioxo substituents; and


20  $R^6$  is an optionally substituted group selected from (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl and (3-7C)cycloalkenyl, or  $R^6$  is a substituted (1-6C)alkyl group,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^6$  group are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>, N( $R^{19}$ ), CO, CH(OR<sup>19</sup>), CON( $R^{19}$ ), N( $R^{19}$ )CO, SO<sub>2</sub>N( $R^{19}$ ), N( $R^{19}$ )SO<sub>2</sub>, CH=CH and C=C

25 wherein  $R^{19}$  is hydrogen or (1-6C)alkyl,

and wherein any CH<sub>2</sub>=CH- or HC=C- group within a  $R^6$  group optionally bears at the terminal CH<sub>2</sub>= or HC= position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or


30 from a group of the formula :



wherein  $X^9$  is a direct bond or is selected from CO and  $N(R^{20})CO$ , wherein  $R^{20}$  is hydrogen or (1-6C)alkyl, and  $Q^8$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^6$  group optionally bears on each said  
5  $CH_2$  or  $CH_3$  group one or more of the following substituents, provided that the  $R^6$  group when it is (1-6C)alkyl must bear at least one such substituent,

one or more halogeno substituents or a substituent selected from hydroxy, cyano, amidino, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  
10 (1-6C)alkoxycarbonyl,  $N$ -(1-6C)alkylcarbamoyl,  $N,N$ -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  $N$ -(1-6C)alkyl-(2-6C)alkanoylamino,  $N$ -(1-6C)alkylsulphamoyl,  $N,N$ -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino,  $N$ -(1-6C)alkyl-(1-6C)alkanesulphonylamino, (1-6C)alkoxycarbonylamino,  $N$ -(1-6C)alkyl-(1-6C)alkoxycarbonylamino,  
15  $N$ -[hydroxy-(2-6C)alkyl]carbamoyl,  $N$ -[(1-6C)alkoxy-(2-6C)alkyl]carbamoyl,  $N$ -[amino-(2-6C)alkyl]carbamoyl,  $N$ -[(1-6C)alkylamino-(2-6C)alkyl]carbamoyl,  $N$ -{di-[(1-6C)alkyl]amino-(2-6C)alkyl}carbamoyl,  $N,N$ -di-[hydroxy-(2-6C)alkyl]carbamoyl,  $N,N$ -di-[(1-6C)alkoxy-(2-6C)alkyl]carbamoyl,  $N,N$ -di-[amino-(2-6C)alkyl]carbamoyl,  $N,N$ -di-[(1-6C)alkylamino-(2-6C)alkyl]carbamoyl and  $N,N$ -di-{di-[(1-6C)alkyl]amino-  
20 (2-6C)alkyl}carbamoyl,  
or from a group of the formula :




wherein  $X^{10}$  is a direct bond or is selected from O, S, SO,  $SO_2$ ,  $N(R^{21})$ , CO,  $CH(OR^{21})$ ,  $CON(R^{21})$ ,  $N(R^{21})CO$ ,  $SO_2N(R^{21})$ ,  $N(R^{21})SO_2$ ,  $C(R^{21})_2O$ ,  $C(R^{21})_2S$  and  $N(R^{21})C(R^{21})_2$ ,  
25 wherein  $R^{21}$  is hydrogen or (1-6C)alkyl, and  $Q^9$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


and wherein any aryl, heteroaryl or heterocyclyl group within a  $R^6$  group, or any  
30 heterocyclic group formed when  $R^5$  and  $R^6$  together with the N atom to which they are attached form a ring, optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,

(1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-

5 (1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^{11}$  is a direct bond or is selected from O and N( $R^{23}$ ), wherein  $R^{23}$  is hydrogen or (1-6C)alkyl, and  $R^{22}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-  
 10 (1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl or N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, or from a group of the formula :




wherein  $X^{12}$  is a direct bond or is selected from O and N( $R^{24}$ ), wherein  $R^{24}$  is hydrogen or  
 15 (1-6C)alkyl, and  $Q^{10}$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any  $Q^{10}$  group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a  $R^6$  group, or the heterocyclic group formed when  $R^5$  and  $R^6$  together with the N atom to which they are attached form a ring,  
 20 optionally bears 1 or 2 oxo or thioxo substituents;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

2. A quinazoline derivative of the Formula II



II

25 wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $Q^2$  has any of the meanings defined in claim 1.

3. A quinazoline derivative of the Formula II according to claim 2 wherein :-  
 m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from methoxy, benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy,  
 5 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy,  
 10 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy,  
 15 piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-1-yl)propoxy, 3-(4-tert-butoxycarbonylamino) piperidin-1-yl)propoxy, 3-(4-carbamoylpiperidin-1-yl)propoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,  
 20 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy, 3-[N-(2-methoxyethyl)-N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-methylamino-1-propynyl,  
 25 3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl, 6-methylamino-1-hexynyl, 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl, 3-(piperidino)-1-propynyl, 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-1-propynyl, 6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-1-hexynyl, 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl,  
 30 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino, 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,

or m is 2 and the R<sup>1</sup> groups are located at the 6- and 7-positions, one R<sup>1</sup> group is located at the 6- or 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a methoxy group;

each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup> together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position; and

10 R<sup>6</sup> is an optionally substituted group selected from allyl, 2-propynyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, or R<sup>6</sup> is a substituted methyl, ethyl, propyl or butyl group,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>6</sup> group are optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH  
15 and C=C,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> group optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more of the following substituents, provided that the R<sup>6</sup> group when it is a methyl, ethyl, propyl or butyl group must bear at least one such substituent,

one, two or three fluoro substituents or a substituent selected from hydroxy, cyano,  
20 amidino, amino, carboxy, methoxy, methylthio, methylsulphinyl, methylsulphonyl, methylamino, dimethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, acetamido, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, tetrahydrofuran-2-yl, pyrrolidin-1-yl, 1,4-dioxan-2-yl, morpholino, piperidino, piperazin-1-yl, homopiperidin-1-yl  
25 and homopiperazin-1-yl,

and wherein any phenyl, imidazolyl, pyridyl or heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl and methoxy,

and wherein any heterocyclyl group within a R<sup>6</sup> group optionally bears 1 or 2 oxo  
30 substituents;

or a pharmaceutically-acceptable acid-addition salt thereof.

4. A quinazoline derivative of the Formula II according to claim 2 wherein :-  
 m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from  
 2-(2-methoxyethoxy)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy,  
 tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-2-ylmethoxy,  
 5 N-methylpyrrolidin-3-yloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,  
 3-morpholinylmethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-  
 4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,  
 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy,  
N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,  
 10 N-(2-methoxyethyl)piperidin-4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy,  
 3-(4-methylpiperazin-1-yl)propoxy, benzyloxy, cyclopropylmethoxy,  
 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;  
 or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups  
 defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;  
 15 or m is 2 and one R<sup>1</sup> group is located at the 6-position and is selected from the groups  
 defined immediately hereinbefore and the other R<sup>1</sup> group is a 7-methoxy group;  
 each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup>  
 together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;  
 Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different,  
 20 selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy  
 provided that at least one substituent is located at an ortho position; and  
 R<sup>6</sup> is allyl, 2-propynyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl or  
 4-hydroxycyclohexyl, or R<sup>6</sup> is a substituted methyl, ethyl, propyl or butyl group,  
 and wherein adjacent carbon atoms in any propyl or butyl group are optionally  
 25 separated by the insertion into the chain of an O group,  
 and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> group when it is a methyl, ethyl, propyl  
 or butyl group bears one, two or three fluoro substituents or a substituent selected from  
 hydroxy, cyano, amidino, amino, carboxy, methoxy, ethoxy, methylthio, methylsulphanyl,  
 methylsulphonyl, methylamino, ethylamino, isopropylamino, dimethylamino,  
 30 methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl,  
N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-tert-butylcarbamoyl,  
 acetamido, phenyl, cyclopropyl, 2-furyl, 2-thienyl, 4-imidazolyl, 2-pyridyl, 3-pyridyl,

4-pyridyl, tetrahydrofuran-2-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, 2-oxopyrrolidin-1-yl,  
 1,4-dioxan-2-yl, morpholino, piperidino, piperidin-2-yl and piperazin-1-yl,  
 and wherein any phenyl, heteroaryl or heterocyclyl group within a R<sup>6</sup> group optionally  
 bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro,  
 5 trifluoromethyl, hydroxy, methyl, ethyl and methoxy;  
 or a pharmaceutically-acceptable acid-addition salt thereof.


5. A quinazoline derivative of the Formula II according to claim 2 wherein :-  
 m is 2 and one R<sup>1</sup> group is a 6-methoxy group and the other R<sup>1</sup> group is located at the  
 10 7-position and is selected from 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy,  
 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperidinoethoxy,  
 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy, N-(2-methoxyethyl)piperidin-  
 4-ylmethoxy, 2-(4-methylpiperazin-1-yl)ethoxy and 3-(4-methylpiperazin-1-yl)propoxy;  
 each of R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is hydrogen except that one of the pairs of groups R<sup>2</sup> and R<sup>4</sup>  
 15 together, R<sup>3</sup> and R<sup>4</sup> together and R<sup>5</sup> and R<sup>4</sup> together forms a bond;  
 Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different,  
 selected from fluoro, chloro, bromo and methyl provided that at least one substituent is  
 located at an ortho position; and  
 R<sup>6</sup> is allyl, 2-propynyl, cyclopropyl, cyclopropylmethyl, cyclobutyl,  
 20 4-hydroxycyclohexyl, 2,2,2-trifluoroethyl, 2,3-dihydroxypropyl, 2-aminoethyl,  
 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl,  
 3-dimethylaminopropyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl,  
 2-methylthioethyl, 3-methylthiopropyl, 2-methylsulphonyl, 3-methylsulphonylpropyl,  
 2-(2-hydroxyethoxy)ethyl, 2-cyanoethyl, 5-cyanopentyl, 2-amidinoethyl, carboxymethyl,  
 25 2-carboxyethyl, methoxycarbonylmethyl, 2-methoxycarbonyl, tert-butoxycarbonylmethyl,  
 2-(tert-butoxycarbonyl)ethyl, N-methylcarbamoylmethyl, N-isopropylcarbamoylmethyl,  
N-tert-butylcarbamoylmethyl, benzyl, 2-fluorobenzyl, 3-fluorobenzyl, 2,6-difluorobenzyl,  
 phenethyl, 2-furylmethyl, 2-thienylmethyl, 2-imidazol-4-ylethyl, 2-pyridylmethyl,  
 3-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, tetrahydrofuran-2-ylmethyl,  
 30 1,4-dioxan-2-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-(2-oxopyrrolidin-1-yl)ethyl,  
 2-(N-methylpyrrolidin-2-yl)ethyl, 3-pyrrolidin-1-ylpropyl, 3-(2-oxopyrrolidin-1-yl)propyl,  
 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl,

2-(4-methylpiperazin-1-yl)ethyl, 3-(4-methylpiperazin-1-yl)propyl,  
N-methylpiperidin-3-ylmethyl or N-methylpiperidin-4-ylmethyl;  
 or a pharmaceutically-acceptable acid-addition salt thereof.

- 5 6. A quinazoline derivative of the Formula II according to claim 2 selected from :-  
N-(2-chloro-6-methylphenyl)-N'-(2-hydroxyethyl)-N''-[6-methoxy-7-(N-methylpiperidin-  
 4-ylmethoxy)quinazolin-4-yl]guanidine,  
N-allyl-N'-(2-chloro-6-methylphenyl)-N''-[6-methoxy-7-(3-pyrrolidin-  
 1-ylpropoxy)quinazolin-4-yl]guanidine,  
 10 N-allyl-N'-(2,6-dimethylphenyl)-N''-[6-methoxy-7-(N-methylpiperidin-  
 4-ylmethoxy)quinazolin-4-yl]guanidine, and  
N-(2-chloro-6-methylphenyl)-N'-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-  
 4-yl]-N''-(2-propynyl)guanidine;  
 or a pharmaceutically-acceptable acid-addition salt thereof.


15

7. A process for the preparation of a quinazoline derivative of the Formula I, or a  
 pharmaceutically-acceptable salt thereof, according to claim 1 which comprises :-  
 (a) the reaction of a thiourea of the Formula VI



VI

- 20 wherein  $Q^1$ ,  $R^2$ ,  $Q^2$  and  $R^3$  have any of the meanings defined in claim 1 except that any  
 functional group is protected if necessary, with an amine of the Formula VII



VII

- wherein  $R^5$  and  $R^6$  have any of the meanings defined in claim 1 except that any functional  
 group is protected if necessary, whereafter any protecting group that is present is removed by  
 25 conventional means;

- (b) for the production of those compounds of the Formula I wherein  $Q^1$ ,  $R^6$  or  $Q^2$  contains a carboxy group, the cleavage of the corresponding compound of Formula I wherein  $Q^1$ ,  $R^6$  or  $Q^2$  contains a protected carboxy group;
- (c) for those compounds of the Formula I wherein  $R^6$  or a substituent on  $Q^1$  or  $Q^2$  contains  
5 an alkylcarbamoyl group or a substituted alkylcarbamoyl group, the reaction of the corresponding compound of Formula I wherein  $R^6$  or a substituent on  $Q^1$  or  $Q^2$  is a carboxy group, or a reactive derivative thereof, with an amine or substituted amine as appropriate;
- (d) for those compounds of the Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains an amino-(1-6C)alkyl group or  $R^6$  is an amino-(1-6C)alkyl group, the cleavage of the  
10 corresponding compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  is a protected amino-(1-6C)alkyl group or  $R^6$  is a protected amino-(1-6C)alkyl group as appropriate;
- (e) for those compounds of the Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains an amino group, the reduction of a corresponding compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains a nitro group; or
- 15 (f) for the production of those compounds of the Formula I wherein  $Q^1$  contains a  $R^1$  group in a quinazoline-like ring of the formula Ia, Ib, Ic or Id that is linked via an oxygen atom, the alkylation of the corresponding compound of Formula I wherein the  $R^1$  group in  $Q^1$  is a hydroxy group;  
and when a pharmaceutically-acceptable salt of a quinazoline derivative of the  
20 Formula I is required, for example an acid-addition salt, it may be obtained by, for example, reaction of said quinazoline derivative with a suitable acid using a conventional pr  
and when a pharmaceutically-acceptable salt of a quinazoline derivative of the Formula I is required it may be obtained using a conventional procedure.

25 8. A pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

9. A quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt  
30 thereof, according to claim 1 for use in a method of treatment of the human or animal body by therapy.

10. The use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 01/02698

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D401/12 C07D239/94 C07D401/14 C07D405/14 C07D403/12  
C07D405/12 C07D409/12 C07D409/14 C07D413/12 A61K31/505  
A61P37/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

P, X	WO 01 04102 A (PLE PATRICK ;HENNEQUIN LAURENT FRANCOIS AND (FR); LAMBERT CHRISTIN) 18 January 2001 (2001-01-18) claims; tables VIII,,IX	1-10
A	GIBSON K H ET AL: "Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 21, 4 November 1997 (1997-11-04), pages 2723-2728, XP004136520 ISSN: 0960-894X cited in the application the whole document	1-10

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

20 September 2001

Date of mailing of the international search report

02/10/2001

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Johnson, C

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/GB 01/02698

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 15758 A (HSU CHIN YI JENNY ; ZILBERSTEIN ASHER (US); JOHNSON SUSAN E (US); M) 15 June 1995 (1995-06-15) claim 3  —————	1-10

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1 (part)

Present claim 1 relates to an extremely large number of possible compounds. In fact, the claim contains so many options that a lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear, namely for the compound of formula I wherein Q1 is a group of formula Ia, Ib, Ic or Id.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/GB 01/02698

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0104102	A	18-01-2001	AU	6578900 A	30-01-2001
			WO	0104102 A1	18-01-2001
WO 9515758	A	15-06-1995	US	5480883 A	02-01-1996
			US	5710158 A	20-01-1998
			AU	1305095 A	27-06-1995
			EP	0871448 A1	21-10-1998
			SG	54172 A1	16-11-1998
			WO	9515758 A1	15-06-1995
			US	5795889 A	18-08-1998
			US	5646153 A	08-07-1997
			US	5721237 A	24-02-1998
			US	5714493 A	03-02-1998
			US	6057320 A	02-05-2000
			US	RE36256 E	20-07-1999

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



✓ (43) International Publication Date  
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number  
**WO 02/02534 A1**

(51) International Patent Classification<sup>7</sup>: C07D 239/94,  
215/54, 401/12, 495/04, A61K 31/505, 31/4706, A61P  
35/00

(21) International Application Number: PCT/GB01/02874

(22) International Filing Date: 28 June 2001 (28.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
00401897.4 3 July 2000 (03.07.2000) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except MG, US*): ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE).


Published:  
— with international search report

(71) Applicant (*for MG only*): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: TAIT, Brian et al.; AstraZeneca, Global Intellectual Property, Mereside, Alderley Park, P.O. Box 272, Macclesfield, Cheshire SK10 4GR (GB).

(54) Title: QUINAZOLINES WITH THERAPEUTIC USE



(57) Abstract: The invention concerns the use of quinazoline derivatives of Formula (I) wherein Q<sup>1</sup> includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q<sup>3</sup>-X<sup>1</sup>- wherein X<sup>1</sup> includes a direct bond and O and Q<sup>3</sup> includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6)alkyl; each of R<sup>2</sup> and R<sup>3</sup>

is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q<sup>2</sup> includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

WO 02/02534 A1

## QUINAZOLINES WITH THERAPEUTIC USE

The invention concerns a new use of certain novel quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which have been found to possess anti-tumour activity and are accordingly useful in methods of treatment of the human or animal body, for example in the manufacture of medicaments for use in the prevention or treatment of solid tumour disease in a warm-blooded animal such as man.

Many of the current treatment regimes for cell proliferation diseases such as psoriasis and cancer utilise compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on rapidly dividing cells such as tumour cells can be beneficial. Alternative approaches to anti-tumour agents which act by mechanisms other than the inhibition of DNA synthesis have the potential to display enhanced selectivity of action.

In recent years it has been discovered that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene i.e. a gene which, on activation, leads to the formation of malignant tumour cells (Bradshaw, Mutagenesis, 1986, 1, 91).

Several such oncogenes give rise to the production of peptides which are receptors for growth factors. Activation of the growth factor receptor complex subsequently leads to an increase in cell proliferation. It is known, for example, that several oncogenes encode tyrosine kinase enzymes and that certain growth factor receptors are also tyrosine kinase enzymes (Yarden *et al.*, Ann. Rev. Biochem., 1988, 57, 443; Larsen *et al.*, Ann. Reports in Med. Chem., 1989, Chpt. 13). The first group of tyrosine kinases to be identified arose from such viral oncogenes, for example pp60<sup>v-Src</sup> tyrosine kinase (otherwise known as v-Src), and the corresponding tyrosine kinases in normal cells, for example pp60<sup>c-Src</sup> tyrosine kinase (otherwise known as c-Src).

Receptor tyrosine kinases are important in the transmission of biochemical signals which initiate cell replication. They are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor (EGF) and an intracellular portion which functions as a kinase to phosphorylate tyrosine amino acids in proteins and hence to influence cell proliferation. Various classes of receptor tyrosine kinases are known (Wilks, Advances in Cancer Research, 1993, 60, 43-73) based on families of growth factors which bind to different receptor tyrosine kinases. The classification includes Class I receptor tyrosine kinases comprising the EGF family of receptor tyrosine

kinases such as the EGF, TGF $\alpha$ , Neu and erbB receptors, Class II receptor tyrosine kinases comprising the insulin family of receptor tyrosine kinases such as the insulin and IGF1 receptors and insulin-related receptor (IRR) and Class III receptor tyrosine kinases comprising the platelet-derived growth factor (PDGF) family of receptor tyrosine kinases such as the  
5 PDGF $\alpha$ , PDGF $\beta$  and colony-stimulating factor 1 (CSF1) receptors.

It is also known that certain tyrosine kinases belong to the class of non-receptor tyrosine kinases which are located intracellularly and are involved in the transmission of biochemical signals such as those that influence tumour cell motility, dissemination and invasiveness and subsequently metastatic tumour growth (Ullrich *et al.*, Cell, 1990, 61, 203-  
10 212, Bolen *et al.*, FASEB J., 1992, 6, 3403-3409, Brickell *et al.*, Critical Reviews in Oncogenesis, 1992, 3, 401-406, Bohlen *et al.*, Oncogene, 1993, 8, 2025-2031, Courtneidge *et al.*, Semin. Cancer Biol., 1994, 5, 239-246, Lauffenburger *et al.*, Cell, 1996, 84, 359-369, Hanks *et al.*, BioEssays, 1996, 19, 137-145, Parsons *et al.*, Current Opinion in Cell Biology, 1997, 9, 187-192, Brown *et al.*, Biochimica et Biophysica Acta, 1996, 1287, 121-149 and  
15 Schlaepfer *et al.*, Progress in Biophysics and Molecular Biology, 1999, 71, 435-478). Various classes of non-receptor tyrosine kinases are known including the Src family such as the Src, Lyn and Yes tyrosine kinases, the Abl family such as Abl and Arg and the Jak family such as Jak 1 and Tyk 2.

It is known that the Src family of non-receptor tyrosine kinases are highly regulated in  
20 normal cells and in the absence of extracellular stimuli are maintained in an inactive conformation. However, some Src family members, for example c-Src tyrosine kinase, is frequently significantly activated (when compared to normal cell levels) in common human cancers such as gastrointestinal cancer, for example colon, rectal and stomach cancer (Cartwright *et al.*, Proc. Natl. Acad. Sci. USA, 1990, 87, 558-562 and Mao *et al.*, Oncogene,  
25 1997, 15, 3083-3090), and breast cancer (Muthuswamy *et al.*, Oncogene, 1995, 11, 1801-1810). The Src family of non-receptor tyrosine kinases has also been located in other common human cancers such as non-small cell lung cancers (NSCLCs) including adenocarcinomas and squamous cell cancer of the lung (Mazurenko *et al.*, European Journal of Cancer, 1992, 28, 372-7), bladder cancer (Fanning *et al.*, Cancer Research, 1992, 52, 1457-  
30 62), oesophageal cancer (Jankowski *et al.*, Gut, 1992, 33, 1033-8), cancer of the prostate, ovarian cancer (Wiener *et al.*, Clin. Cancer Research, 1999, 5, 2164-70) and pancreatic cancer (Lutz *et al.*, Biochem. and Biophys. Res. Comm., 1998, 243, 503-8). As further human

tumour tissues are tested for the Src family of non-receptor tyrosine kinases it is expected that its widespread prevalence will be established.

It is further known that the predominant role of c-Src non-receptor tyrosine kinase is to regulate the assembly of focal adhesion complexes through interaction with a number of cytoplasmic proteins including, for example, focal adhesion kinase and paxillin. In addition c-Src is coupled to signalling pathways that regulate the actin cytoskeleton which facilitates cell motility. Cellular motility is necessarily required for a localised tumour to progress through the stages of dissemination into the blood stream, invasion of other tissues and initiation of metastatic tumour growth. For example, colon tumour progression from localised to disseminated, invasive metastatic disease has been correlated with c-Src non-receptor tyrosine kinase activity (Brunton *et al.*, Oncogene, 1997, 14, 283-293, Fincham *et al.*, EMBO J., 1998, 17, 81-92 and Verbeek *et al.*, Exp. Cell Research, 1999, 248, 531-537).

Accordingly it has been recognised that an inhibitor of such non-receptor tyrosine kinases should be of value as a selective inhibitor of the motility of tumour cells and as a selective inhibitor of the dissemination and invasiveness of mammalian cancer cells leading to inhibition of metastatic tumour growth. In particular an inhibitor of such non-receptor tyrosine kinases should be of value as an anti-invasive agent for use in the containment and/or treatment of solid tumour disease.

We have now found that surprisingly certain quinazoline derivatives possess potent anti-tumour activity. Without wishing to imply that the compounds disclosed in the present invention possess pharmacological activity only by virtue of an effect on a single biological process, it is believed that the compounds provide an anti-tumour effect by way of inhibition of one or more of the non-receptor tyrosine-specific protein kinases that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells. In particular, it is believed that the compounds of the present invention provide an anti-tumour effect by way of inhibition of the Src family of non-receptor tyrosine kinases.

It is also known that c-Src non-receptor tyrosine kinase enzyme is involved in the control of osteoclast-driven bone resorption (Soriano *et al.*, Cell, 1991, 64, 693-702; Boyce *et al.*, J. Clin. Invest., 1992, 90, 1622-1627; Yoneda *et al.*, J. Clin. Invest., 1993, 91, 2791-2795 and Missbach *et al.*, Bone, 1999, 24, 437-49). An inhibitor of c-Src non-receptor tyrosine kinase is therefore of value in the prevention and treatment of bone diseases such as osteoporosis, Paget's disease, metastatic disease in bone and tumour-induced hypercalcaemia.

It is disclosed by K. H. Gibson *et al.*, Bioorganic & Medicinal Chemistry Letters, 1997, 7, 2723-2728 that certain 4-anilinoquinazoline derivatives possess useful EGF RTK inhibitory properties. It is also disclosed that 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea is inactive as an EGF RTK inhibitor.

5 It is disclosed in International Patent Application WO 98/50370 that certain 5-substituted quinazoline derivatives may be useful as inhibitors of serine/threonine protein kinases. Whilst most of the examples are 4-amino-5-phenoxyquinazolines, there is the disclosure of three 4-ureido-5-phenoxyquinazolines, namely of :-

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,

10 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea and

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.

It is disclosed by C. I. Hong *et al.*, J. Med. Chem., 1976, 19, 555-558 that certain 4-aminopyrazolo[3,4-*d*]pyrimidine derivatives possess growth inhibitory activity against cultured L1210 leukaemia cells. The disclosed compounds include:-

15 1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

20 1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and

1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea.

It is disclosed in International Patent Application WO 97/03069 that certain quinoline and quinazoline derivatives may be useful as protein tyrosine kinase inhibitors. All of the disclosed examples are 4-heteroarylaminquinazoline derivatives and none of them are

25 1-heteroaryl-3-(quinazolin-4-yl)urea derivatives.

It is disclosed in International Patent Application WO 98/43960 that certain 3-cyanoquinoline derivatives may be useful as protein tyrosine kinase inhibitors. Almost all of the 398 disclosed examples were 3-cyano-4-anilinoquinoline or


3-cyano-4-benzylaminoquinoline derivatives. There is no disclosure of any

30 (3-cyanoquinolin-4-yl)urea derivatives.

It is disclosed in International Patent Application WO 99/09024 that certain 1-phenyl-3-(quinolin-4-yl)urea derivatives may be useful as antagonists of the human HFGAN72 receptor, a G-protein coupled neuropeptide receptor, and hence may be of


potential use in the treatment of obesity. There is no disclosure as examples of any 1-phenyl-3-(quinazolin-4-yl)urea or 1-phenyl-3-(3-cyanoquinolin-4-yl)urea compounds.

According to one aspect of the invention there is provided the use of a quinazoline derivative of the Formula I




I


wherein  $Q^1$  is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id




Ia



Ib



Ic



Id

wherein :


$Y^1$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$Y^2$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$m$  is 0, 1, 2, 3 or 4;


each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,

(2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,  
 (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,  
N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  
N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-  
 5 (3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino,  
N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and  
N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^1$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>4</sup>), CO, CH(OR<sup>4</sup>),  
 10 CON(R<sup>4</sup>), N(R<sup>4</sup>)CO, SO<sub>2</sub>N(R<sup>4</sup>), N(R<sup>4</sup>)SO<sub>2</sub>, OC(R<sup>4</sup>)<sub>2</sub>, SC(R<sup>4</sup>)<sub>2</sub> and N(R<sup>4</sup>)C(R<sup>4</sup>)<sub>2</sub>, wherein R<sup>4</sup> is  
 hydrogen or (1-6C)alkyl, and Q<sup>3</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-  
 (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-  
 (1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R<sup>1</sup>)<sub>m</sub> is (1-3C)alkylenedioxy,  
 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent  
 15 are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>,  
 N(R<sup>5</sup>), CO, CH(OR<sup>5</sup>), CON(R<sup>5</sup>), N(R<sup>5</sup>)CO, SO<sub>2</sub>N(R<sup>5</sup>), N(R<sup>5</sup>)SO<sub>2</sub>, CH=CH and C≡C wherein  
 R<sup>5</sup> is hydrogen or (1-6C)alkyl,

and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a R<sup>1</sup> substituent optionally bears at  
 the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl,  
 20 (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,  
 amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or  
 from a group of the formula :



wherein  $X^2$  is a direct bond or is selected from CO and N(R<sup>6</sup>)CO, wherein R<sup>6</sup> is hydrogen or  
 25 (1-6C)alkyl, and Q<sup>4</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl  
 or heterocyclyl-(1-6C)alkyl,


and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each  
 said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno substituents or a substituent selected from  
 hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio,  
 30 (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  
 (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,  
 (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-

(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




5 wherein  $X^3$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO, CH(OR<sup>7</sup>), CON(R<sup>7</sup>), N(R<sup>7</sup>)CO, SO<sub>2</sub>N(R<sup>7</sup>), N(R<sup>7</sup>)SO<sub>2</sub>, C(R<sup>7</sup>)<sub>2</sub>O, C(R<sup>7</sup>)<sub>2</sub>S and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, wherein R<sup>7</sup> is hydrogen or (1-6C)alkyl, and Q<sup>5</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

10 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, 15 di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



20 wherein  $X^4$  is a direct bond or is selected from O and N(R<sup>8</sup>), wherein R<sup>8</sup> is hydrogen or (1-6C)alkyl, and R<sup>8</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or 25 from a group of the formula :




wherein  $X^5$  is a direct bond or is selected from O and N(R<sup>10</sup>), wherein R<sup>10</sup> is hydrogen or (1-6C)alkyl, and Q<sup>6</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any Q<sup>6</sup> group optionally bears 1 or 2 substituents, which may 30 be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy, and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo or thioxo substituents;

$R^2$  is hydrogen or (1-6C)alkyl and  $R^3$  is hydrogen or (1-6C)alkyl, or  $R^2$  and  $R^3$  together form a  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group;


$Z$  is O, S,  $N(C\equiv N)$  or  $N(R^{11})$ , wherein  $R^{11}$  is hydrogen or (1-6C)alkyl; and

$Q^2$  is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl, or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and  $Q^2$  is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



20

wherein  $X^6$  is a direct bond or is selected from O and  $N(R^{13})$ , wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $R^{12}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :




25

wherein  $X^7$  is a direct bond or is selected from O, S, SO,  $SO_2$ ,  $N(R^{14})$ , CO,  $CH(OR^{14})$ ,  $CON(R^{14})$ ,  $N(R^{14})CO$ ,  $SO_2N(R^{14})$ ,  $N(R^{14})SO_2$ ,  $C(R^{14})_2O$ ,  $C(R^{14})_2S$  and  $C(R^{14})_2N(R^{14})$ , wherein each  $R^{14}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $Q^2$  is optionally

substituted with a (1-3C)alkylenedioxy group,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from

halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, 5 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



10 wherein  $X^8$  is a direct bond or is selected from O and N( $R^{16}$ ), wherein  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $R^{15}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on  $Q^2$  optionally bears 1 or 2

15 oxo or thioxo substituents;

or a pharmaceutically-acceptable salt thereof;

in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

According to a further feature of the invention there is provided a method for 20 producing an anti-invasive effect by the containment and/or treatment of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a 25 quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the prevention or treatment of solid tumour disease in a warm-blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a 30 method for the prevention or treatment of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the prevention or treatment of those tumours which are sensitive to inhibition of non-receptor tyrosine kinases such as c-Src kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells.

According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of those tumours which are sensitive to inhibition of non-receptor tyrosine kinases such as c-Src kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in providing a c-Src kinase inhibitory effect.

According to a further feature of this aspect of the invention there is provided a method for providing a c-Src kinase inhibitory effect which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight-chain version only and references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched-chain version only. An analogous convention applies to other generic terms.

It is to be understood that, insofar as certain of the compounds of Formula I defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the above-mentioned activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

It is to be understood that the hydrogen atom which is shown at the 2-position in each of the part structures of the formulae Ia, Ib, Ic and Id indicates that that position remains unsubstituted by any R<sup>1</sup> group.

Suitable values for the generic radicals referred to above include those set out below.

5 A suitable value for any one of the 'Q' groups (Q<sup>2</sup> to Q<sup>7</sup>) when it is aryl or for the aryl group within a 'Q' group is, for example, phenyl or naphthyl, preferably phenyl.

A suitable value for a (3-7C)cycloalkyl group within Q<sup>2</sup> or for Q<sup>3</sup> or Q<sup>4</sup> when it is (3-7C)cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl and a suitable value for Q<sup>3</sup> or Q<sup>4</sup> when it is  
10 (3-7C)cycloalkenyl is, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.

A suitable value for Q<sup>2</sup> when it is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur is, for example,  
15 pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, indolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl, preferably isoxazolyl, 1,2,3-triazolyl, pyridyl, benzothiazolyl, quinolyl or quinazolinyl.

20 A suitable value for any one of the 'Q' groups, Q<sup>3</sup> to Q<sup>7</sup>, when it is heteroaryl or for the heteroaryl group within a 'Q' group is, for example, an aromatic 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring with up to five ring heteroatoms selected from oxygen, nitrogen and sulphur, for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl,  
25 tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl, preferably thienyl, 1,2,3-triazolyl, pyridyl, quinolyl, quinazolinyl or quinoxalinyl.

A suitable value for any one of the 'Q' groups, Q<sup>3</sup> to Q<sup>7</sup>, when it is heterocyclyl or for  
30 the heterocyclyl group within a 'Q' group is, for example, a non-aromatic saturated or partially saturated 3 to 10 membered monocyclic or bicyclic ring with up to five heteroatoms selected from oxygen, nitrogen and sulphur, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl,

1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl, preferably pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperazin-1-yl or  
 5 homopiperazin-1-yl, more preferably piperidin-4-yl. A suitable value for such a group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.

A suitable value for a 'Q' group when it is heteroaryl-(1-6C)alkyl is, for example,  
 10 heteroarylmethyl, 2-heteroarylethyl and 3-heteroarylpropyl. The invention comprises corresponding suitable values for 'Q' groups when, for example, rather than a heteroaryl-(1-6C)alkyl group, an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group is present.

When, as defined hereinbefore, Y<sup>1</sup> together with the carbon atoms to which it is  
 15 attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S, ring Y<sup>1</sup> is suitably unsaturated or partially unsaturated wherein a -CH<sub>2</sub>- group can optionally be replaced by a -CO- group and a ring nitrogen atom may optionally bear a (1-6C)alkyl group. Diradicals of suitable fused Y<sup>1</sup> rings include thiendiyl, furandiyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl,  
 20 isothiazolediyl, 1,2,3-oxadiazole-diyl, 1,2,3-triazole-diyl, pyridinediyl, pyrimidinediyl, pyrazinediyl, pyridazinediyl and 1,3,4-triazinediyl. Examples of suitable bicyclic rings of formula Ic formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring include furopyrimidinyl, thienopyrimidinyl, purinyl, pyrrolopyrimidinyl, pyrrolinopyrimidinyl, oxopyrrolinopyrimidinyl, oxazolopyrimidinyl, oxazolinopyrimidinyl,  
 25 oxooxazolinopyrimidinyl, isoxazolopyrimidinyl, thiazolopyrimidinyl, thiazolinopyrimidinyl, oxothiazolinopyrimidinyl, isothiazolopyrimidinyl, oxoimidazolinopyrimidinyl, pyrazolopyrimidinyl, pyrazolinopyrimidinyl, oxopyrazolinopyrimidinyl, pyridopyrimidinyl, pyrimidopyrimidinyl and pteridinyl. Preferably the bicyclic ring of formula Ic is furo[3,2-*d*]pyrimidinyl, furo[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl,  
 30 thieno[2,3-*d*]pyrimidinyl, 6-purinyl, pyrrolo[3,2-*d*]pyrimidinyl, pyrrolo[2,3-*d*]pyrimidinyl, oxazolo[5,4-*d*]pyrimidinyl, oxazolo[4,5-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, thiazolo[4,5-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl, pyrimido[4,5-*d*]pyrimidinyl,

pyrimido[5,6-*d*]pyrimidinyl or pteridinyl. More specifically the bicyclic ring of formula Ic is 6-oxopyrrolino[2,3-*d*]pyrimidin-4-yl, 6-oxopyrrolino[3,2-*d*]pyrimidin-4-yl, 2-oxooxazolino[5,4-*d*]pyrimidin-7-yl, 2-oxothiazolino[5,4-*d*]pyrimidin-7-yl, 2-oxooxazolino[4,5-*d*]pyrimidin-7-yl, 2-oxothiazolino[4,5-*d*]pyrimidin-7-yl, 5 2-oxoimidazolino[4,5-*d*]pyrimidin-7-yl, 3-oxopyrazolino[3,4-*d*]pyrimidin-4-yl or 3-oxopyrazolino[4,3-*d*]pyrimidin-7-yl. Further preferred bicyclic rings of formula Ic include thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, 6-purinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl and pteridinyl, more specifically thieno[3,2-*d*]pyrimidin-4-yl, 10 thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl, pyrido[3,2-*d*]pyrimidin-4-yl and pteridin-4-yl.

When, as defined hereinbefore, Y<sup>2</sup> together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 15 heteroatoms selected from O, N and S, ring Y<sup>2</sup> is suitably unsaturated or partially unsaturated wherein a -CH<sub>2</sub>- group can optionally be replaced by a -CO- group and a ring nitrogen atom may optionally bear a (1-6C)alkyl group. Diradicals of suitable fused Y<sup>2</sup> rings include thiendiyl, furandiyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, 1,2,3-oxadiazole-diyl, 1,2,3-triazole-diyl, pyridinediyl, pyrimidinediyl, 20 pyrazinediyl, pyridazinediyl and 1,3,4-triazinediyl. Examples of suitable tricyclic rings of formula Id formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include imidazoquinazolinyl, oxazoloquinazolinyl, thiazoloquinazolinyl, [1,2,3]triazoloquinazolinyl, pyrazoloquinazolinyl, pyrroloquinazolinyl, oxoimidazolinoquinazolinyl, oxooxazolinoquinazolinyl, oxothiazolinoquinazolinyl and oxopyrazolinoquinazolinyl. 25 Preferably the tricyclic ring of formula Id is 3H-imidazo[4,5-*g*]quinazolinyl, oxazolo[4,5-*g*]quinazolinyl, thiazolo[4,5-*g*]quinazolinyl, 3H-[1,2,3]triazolo[4,5-*g*]quinazolinyl, 1H-pyrazolo[3,4-*g*]quinazolinyl, 6H-pyrrolo[2,3-*g*]quinazolinyl, 2-oxo-1,2-dihydro-3H-imidazo[4,5-*g*]quinazolinyl, 2-oxo-1,2-dihydrooxazolo[4,5-*g*]quinazolinyl, 2-oxo-1,2-dihydrothiazolo[4,5-*g*]quinazolinyl, 30 3-oxo-2,3-dihydro-1H-pyrazolo[3,4-*g*]quinazolinyl, pyrido[2,3-*g*]quinazolinyl, pyrimidino[4,5-*g*]cinnolinyl, pyrimidino[4,5-*g*]quinazolinyl, pyrazino[2,3-*g*]quinazolinyl, 7-oxo-6,7-dihydropyrido[2,3-*g*]quinazolinyl, pyrazino[2,3-*g*]quinazolinyl and 8-oxo-8,9-dihydropyrazino[2,3-*g*]quinazolinyl. More specifically the tricyclic ring of

formula Id is 3H-imidazo[4,5-g]quinazolin-8-yl, oxazolo[4,5-g]quinazolin-8-yl, thiazolo[4,5-g]quinazolin-8-yl, 3H-[1,2,3]triazolo[4,5-g]quinazolin-8-yl, 1H-pyrazolo[3,4-g]quinazolin-8-yl, 6H-pyrrolo[2,3-g]quinazolin-4-yl, 2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolin-8-yl, 2-oxo-1,2-dihydrooxazolo[4,5-g]quinazolin-8-yl, 2-oxo-1,2-dihydrothiazolo[4,5-g]quinazolin-8-yl, 3-oxo-2,3-dihydro-1H-pyrazolo[3,4-g]quinazolin-8-yl, pyrido[2,3-g]quinazolin-4-yl, pyrimidino[4,5-g]cinnolin-9-yl, pyrimidino[4,5-g]quinazolin-4-yl, pyrazino[2,3-g]quinazolin-4-yl, 7-oxo-6,7-dihydropyrido[2,3-g]quinazolin-4-yl, pyrazino[2,3-g]quinazolin-4-yl or 8-oxo-8,9-dihydropyrazino[2,3-g]quinazolin-4-yl. Further preferred tricyclic rings of formula Id include 3-methyl-3H-imidazo[4,5-g]quinazolin-8-yl, 3-methyl-3H-[1,2,3]triazolo[4,5-g]quinazolin-8-yl, 3-methyl-2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolin-8-yl, pyrazino[2,3-g]quinazolin-4-yl and 9-methyl-8-oxo-8,9-dihydropyrazino[2,3-g]quinazolin-4-yl.

Suitable values for any of the 'R' groups ( $R^1$  to  $R^{16}$ ), or for various groups within an  $R^1$  substituent, or within a substituent on  $Q^2$  include:-

for halogeno

for (1-6C)alkyl:

for (2-8C)alkenyl:

for (2-8C)alkynyl:

20 for (1-6C)alkoxy:

for (2-6C)alkenyloxy:

for (2-6C)alkynyloxy:

for (1-6C)alkylthio:

for (1-6C)alkylsulphinyl:

25 for (1-6C)alkylsulphonyl:

for (1-6C)alkylamino:

for di-[(1-6C)alkyl]amino:

30 for (1-6C)alkoxycarbonyl:

for N-(1-6C)alkylcarbamoyl:

fluoro, chloro, bromo and iodo;

methyl, ethyl, propyl, isopropyl and tert-butyl;

vinyl, allyl and but-2-enyl;

ethynyl, 2-propynyl and but-2-ynyl;

methoxy, ethoxy, propoxy, isopropoxy and butoxy;

vinylloxy and allyloxy;

ethynyloxy and 2-propynyloxy;

methylthio, ethylthio and propylthio;

methylsulphinyl and ethylsulphinyl;

methylsulphonyl and ethylsulphonyl;

methylamino, ethylamino, propylamino,

isopropylamino and butylamino;

dimethylamino, diethylamino, N-ethyl-

N-methylamino and diisopropylamino;

methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl

and tert-butoxycarbonyl;

N-methylcarbamoyl, N-ethylcarbamoyl and

N-propylcarbamoyl;

- for N,N-di-[(1-6C)alkyl]carbamoyl: N,N-dimethylcarbamoyl, N-ethyl-  
N-methylcarbamoyl and N,N-diethylcarbamoyl;
- for (2-6C)alkanoyl: acetyl and propionyl;
- for (2-6C)alkanoyloxy: acetoxy and propionyloxy;
- 5 for (2-6C)alkanoylamino: acetamido and propionamido;
- for N-(1-6C)alkyl-(2-6C)alkanoylamino: N-methylacetamido and N-methylpropionamido;
- for N-(1-6C)alkylsulphamoyl: N-methylsulphamoyl and N-ethylsulphamoyl;
- for N,N-di-[(1-6C)alkyl]sulphamoyl: N,N-dimethylsulphamoyl;
- for (1-6C)alkanesulphonylamino: methanesulphonylamino and ethanesulphonylamino;
- 10 for N-(1-6C)alkyl-(1-6C)alkanesulphonylamino: N-methylmethanesulphonylamino and  
N-methylethanesulphonylamino;
- for (3-6C)alkenoylamino: acrylamido, methacrylamido and crotonamido;
- for N-(1-6C)alkyl-(3-6C)alkenoylamino: N-methylacrylamido and N-methylcrotonamido;
- for (3-6C)alkynoylamino: propiolamido;
- 15 for N-(1-6C)alkyl-(3-6C)alkynoylamino: N-methylpropiolamido;
- for amino-(1-6C)alkyl: aminomethyl, 2-aminoethyl, 1-aminoethyl and  
3-aminopropyl;
- for (1-6C)alkylamino-(1-6C)alkyl: methylaminomethyl, ethylaminomethyl,  
1-methylaminoethyl, 2-methylaminoethyl,  
20 2-ethylaminoethyl and 3-methylaminopropyl;
- for di-[(1-6C)alkyl]amino-(1-6C)alkyl: dimethylaminomethyl, diethylaminomethyl,  
1-dimethylaminoethyl, 2-dimethylaminoethyl and  
3-dimethylaminopropyl;
- for halogeno-(1-6C)alkyl: chloromethyl, 2-chloroethyl, 1-chloroethyl and  
25 3-chloropropyl;
- for hydroxy-(1-6C)alkyl: hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl and  
3-hydroxypropyl;
- for (1-6C)alkoxy-(1-6C)alkyl: methoxymethyl, ethoxymethyl, 1-methoxyethyl,  
2-methoxyethyl, 2-ethoxyethyl and  
30 3-methoxypropyl;
- for cyano-(1-6C)alkyl: cyanomethyl, 2-cyanoethyl, 1-cyanoethyl and  
3-cyanopropyl;

for (2-6C)alkanoylamino-(1-6C)alkyl: acetamidomethyl, propionamidomethyl and 2-acetamidoethyl; and

for (1-6C)alkoxycarbonylamino-(1-6C)alkyl: methoxycarbonylaminoethyl, ethoxycarbonylaminoethyl, tert-butoxycarbonylaminoethyl and 2-methoxycarbonylaminoethyl.

A suitable value for  $(R^1)_m$  or for a substituent on  $Q^2$  when it is (1-3C)alkylenedioxy is, for example, methylenedioxy or ethylenedioxy and the oxygen atoms thereof occupy adjacent ring positions.

When, as defined hereinbefore, an  $R^1$  group forms a group of the formula  $Q^3-X^1$ - and, for example,  $X^1$  is a  $OC(R^4)_2$  linking group, it is the carbon atom, not the oxygen atom, of the  $OC(R^4)_2$  linking group which is attached to the quinazoline-like ring such as the ring of formula Ia and the oxygen atom is attached to the  $Q^3$  group. Similarly, when, for example a  $CH_3$  group within a  $R^1$  substituent bears a group of the formula  $-X^3-Q^5$  and, for example,  $X^3$  is a  $C(R^7)_2O$  linking group, it is the carbon atom, not the oxygen atom, of the  $C(R^7)_2O$  linking group which is attached to the  $CH_3$  group and the oxygen atom is linked to the  $Q^5$  group. A similar convention applies to the attachment of the groups of the formulae  $Q^4-X^2$ - and  $-X^7-Q^7$ .

As defined hereinbefore, adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent may be optionally separated by the insertion into the chain of a group such as O,  $CON(R^5)$  or  $C\equiv C$ . For example, insertion of a  $C\equiv C$  group into the ethylene chain within a 2-morpholinoethoxy group gives rise to a 4-morpholinobut-2-ynyloxy group and, for example, insertion of a CONH group into the ethylene chain within a 3-methoxypropoxy group gives rise to, for example, a 2-(2-methoxyacetamido)ethoxy group.

When, as defined hereinbefore, any  $CH_2=CH$ - or  $HC\equiv C$ - group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent such as a group of the formula  $Q^4-X^2$ - wherein  $X^2$  is, for example,  $NHCO$  and  $Q^4$  is a heterocyclyl-(1-6C)alkyl group, suitable  $R^1$  substituents so formed include, for example, N-[heterocyclyl-(1-6C)alkyl]carbamoylethynyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylethynyl or N-[heterocyclyl-(1-6C)alkyl]carbamoylethynyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylethynyl.

When, as defined hereinbefore, any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno substituents, there are


suitably 1 or 2 halogeno substituents present on each said CH<sub>2</sub> group and there are suitably 1, 2 or 3 halogeno substituents present on each said CH<sub>3</sub> group.

When, as defined hereinbefore, any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent as defined hereinbefore, suitable R<sup>1</sup> substituents so formed include, for example, hydroxy-substituted heterocyclyl- (1-6C)alkoxy groups such as 2-hydroxy-3-piperidinopropoxy and 2-hydroxy-3-morpholinopropoxy, hydroxy-substituted amino-(2-6C)alkoxy groups such as 3-amino-2-hydroxypropoxy, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkoxy groups such as 2-hydroxy-3-methylaminopropoxy, hydroxy-substituted di-[(1-6C)alkyl]amino-(2-6C)alkoxy groups such as 3-dimethylamino-2-hydroxypropoxy, hydroxy-substituted heterocyclyl-(1-6C)alkylamino groups such as 2-hydroxy-3-piperidinopropylamino and 2-hydroxy-3-morpholinopropylamino, hydroxy-substituted amino-(2-6C)alkylamino groups such as 3-amino-2-hydroxypropylamino, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkylamino groups such as 2-hydroxy-3-methylaminopropylamino, hydroxy-substituted di-[(1-6C)alkyl]amino-(2-6C)alkylamino groups such as 3-dimethylamino-2-hydroxypropylamino, hydroxy-substituted (1-6C)alkoxy groups such as 2-hydroxyethoxy, (1-6C)alkoxy-substituted (1-6C)alkoxy groups such as 2-methoxyethoxy and 3-ethoxypropoxy, (1-6C)alkylsulphonyl-substituted (1-6C)alkoxy groups such as 2-methylsulphonylethoxy and heterocyclyl-substituted (1-6C)alkylamino-(1-6C)alkyl groups such as 2-morpholinoethylaminomethyl, 2-piperazin-1-ylethylaminomethyl and 3-morpholinopropylaminomethyl.

A suitable pharmaceutically-acceptable salt of a compound of the Formula I is, for example, an acid-addition salt of a compound of the Formula I, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the Formula I which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

Particular compounds of the Formula I include, for example,


(i) quinazoline derivatives of the Formula II



II

wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore;


(ii) quinoline derivatives of the Formula III



III

5 wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore;

(iii) pyrimidine derivatives of the Formula IV




IV

wherein each of  $m$ ,  $R^1$ ,  $Y^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore;

and


10 (iv) quinazoline derivatives of the Formula V




wherein each of  $m$ ,  $R^1$ ,  $Y^2$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore.

Further particular compounds of the Formula I include, for example, quinazoline derivatives of the Formula II, or pharmaceutically-acceptable salts thereof, wherein, unless  
 5 otherwise stated, each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore or in paragraphs (a) to (l) hereinafter :-

- (a)  $m$  is 1, 2 or 3, and each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  
 10 N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino and N-(1-6C)alkyl-(3-6C)alkynoylamino, or from a group of the formula :




- 15 wherein  $X^1$  is a direct bond or is selected from O,  $N(R^4)$ ,  $CON(R^4)$ ,  $N(R^4)CO$  and  $OC(R^4)_2$  wherein  $R^4$  is hydrogen or (1-6C)alkyl, and  $Q^3$  is aryl, aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent are optionally separated by the insertion into the chain of a group selected from O,  $N(R^5)$ ,  
 20  $CON(R^5)$ ,  $N(R^5)CO$ ,  $CH=CH$  and  $C\equiv C$  wherein  $R^5$  is hydrogen or (1-6C)alkyl, and wherein any  $CH_2=CH$ - or  $HC\equiv C$ - group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the  
 25 formula :



wherein  $X^2$  is a direct bond or is CO or  $N(R^6)CO$ , wherein  $R^6$  is hydrogen or (1-6C)alkyl, and  $Q^4$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each  
 5 said  $CH_2$  or  $CH_3$  group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylsulphonyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino, or from a group of the formula :



wherein  $X^3$  is a direct bond or is selected from O,  $N(R^7)$ ,  $CON(R^7)$ ,  $N(R^7)CO$  and  $C(R^7)_2O$ ,  
 10 wherein  $R^7$  is hydrogen or (1-6C)alkyl, and  $Q^5$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy,  
 15 N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl and (1-6C)alkoxycarbonylamino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo substituents;

20 (b)  $m$  is 1, 2 or 3, and each  $R^1$  group, which may be the same or different, is selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, dipropylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido, propionamido, acrylamido and propiolamido, or from a group of the formula :




wherein  $X^1$  is a direct bond or is selected from O, NH, CONH, NHCO and  $OCH_2$  and  $Q^3$  is phenyl, benzyl, cyclopropylmethyl, thienyl, 1-imidazolyl, 1,2,3-triazolyl, pyridyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino,  
 30 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperazin-1-yl, homopiperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl,

3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,


5 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, NH, CONH, NHCO, CH=CH and C≡C,

and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a R<sup>1</sup> substituent optionally bears at the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from carbamoyl, 10 N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl or 4-dimethylaminobutyl, or from a group of the formula :



15 wherein X<sup>2</sup> is a direct bond or is CO, NHCO or N(Me)CO and Q<sup>4</sup> is pyridyl, pyridylmethyl, 2-pyridylethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 20 3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

25 and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino and dimethylamino, or from a group of the formula :



wherein X<sup>3</sup> is a direct bond or is selected from O, NH, CONH, NHCO and CH<sub>2</sub>O and Q<sup>5</sup> is 30 pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl,

3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,


- and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl and tert-butoxycarbonylaminomethyl,
- 10 and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo substituents;
- (c) m is 1 or 2 and the R<sup>1</sup> groups, which may be the same or different, are located at the 6- and/or 7-positions and are selected from hydroxy, amino, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, benzyloxy, cyclopropylmethoxy, 2-imidazol-1-ylethoxy, 3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, pyrrolidin-1-yl, morpholino, piperidino, piperazin-1-yl, 2-pyrrolidin-1-ylethoxy, 20 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino, pyrrolidin-3-ylamino, pyrrolidin-2-ylmethylamino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino, 2-morpholinoethylamino, 3-morpholinopropylamino, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino, 25 2-piperidinoethylamino, 3-piperidinopropylamino, piperidin-3-ylamino,

piperidin-4-ylamino, piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino, piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino, 2-homopiperidin-1-ylethylamino, 3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino, 2-homopiperazin-1-ylethylamino or 3-homopiperazin-1-ylpropylamino,

- 5 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent are optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH and C≡C,

and when  $R^1$  is a vinyl or ethynyl group, the  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from

- 10 N-(2-dimethylaminoethyl)carbamoyl, N-(3-dimethylaminopropyl)carbamoyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl and 4-dimethylaminobutyl, or from a group of the formula :



- 15 wherein  $X^2$  is a direct bond or is NHCO or N(Me)CO and  $Q^4$  is imidazolylmethyl, 2-imidazolylethyl, 3-imidazolylpropyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group a substituent selected from hydroxy, amino, methoxy,


- 25 methylsulphonyl, methylamino and dimethylamino,

and wherein any phenyl, pyridyl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, aminomethyl, acetamidomethyl and tert-butoxycarbonylaminomethyl,


- 30 and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo substituents;

(d) each of  $R^2$  and  $R^3$  is hydrogen or methyl;


- (e) each of  $R^2$  and  $R^3$  is hydrogen;
- (f) Z is O, S or  $N(R^{11})$ , wherein  $R^{11}$  is hydrogen or (1-6C)alkyl;
- (g) Z is O, S,  $N(R^{11})$ , wherein  $R^{11}$  is hydrogen, methyl, ethyl or propyl;
- (h) Z is O;
- 5 (i)  $Q^2$  is phenyl, benzyl,  $\alpha$ -methylbenzyl, phenethyl, naphthyl, 1-(1-naphthyl)ethyl or 2-phenylcyclopropyl which is optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  $\underline{N}$ -(1-6C)alkylcarbamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl,
- 10 (2-6C)alkanoylamino, or from a group of the formula :



- wherein  $X^6$  is a direct bond or is selected from O and  $N(R^{13})$ , wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $R^{12}$  is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the
- 15 formula :



- wherein  $X^7$  is a direct bond or is selected from O,  $N(R^{14})$ , CO,  $CON(R^{14})$ ,  $N(R^{14})CO$  and  $C(R^{14})_2O$ , wherein each  $R^{14}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is phenyl, benzyl, heteroaryl or heteroaryl-(1-6C)alkyl,
- 20 and wherein any phenyl or heteroaryl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, (1-6C)alkyl and (1-6C)alkoxy;
- (j)  $Q^2$  is phenyl, benzyl,  $\alpha$ -methylbenzyl or phenethyl which is optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro,
- 25 bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, tert-butyl, vinyl, ethynyl and methoxy, or from a group of the formula :



- wherein  $X^7$  is a direct bond or is selected from O and CO, and  $Q^7$  is phenyl, benzyl, pyridyl or pyridylmethyl, and wherein any phenyl or pyridyl group within a substituent on  $Q^2$  optionally
- 30 bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, methyl and methoxy;

- (k)  $Q^2$  is phenyl, benzyl or phenethyl which is substituted with 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, *tert*-butyl, vinyl, ethynyl and methoxy provided that at least one substituent is located at an ortho position (for example the 2-position on a phenyl group); and
- (l)  $Q^2$  is phenyl, benzyl or phenethyl which is substituted with 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, *tert*-butyl, vinyl, ethynyl and methoxy provided that two substituents are located at ortho positions (for example the 2- and 6-positions on a phenyl group).

Further particular compounds of the Formula I include, for example, quinoline derivatives of the Formula III, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore or in any of the paragraphs (a) to (o) immediately hereinbefore.

- 15 Further particular compounds of the Formula I include, for example, pyrimidine derivatives of the Formula IV, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore or in any of the paragraphs (a) to (l) immediately hereinbefore and  $Y^1$  has any of the meanings defined hereinbefore or in paragraphs (a) to (c) hereinafter :-

- 20 (a) bicyclic rings formed by the fusion of ring  $Y^1$  to the adjacent pyrimidine ring include thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl and pyrido[3,2-*d*]pyrimidin-4-yl;
- (b) bicyclic rings formed by the fusion of ring  $Y^1$  to the adjacent pyrimidine ring include
- 25 thieno[3,2-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl and pyrido[3,2-*d*]pyrimidin-4-yl; and
- (c) the bicyclic ring formed by the fusion of ring  $Y^1$  to the adjacent pyrimidine ring is thieno[3,2-*d*]pyrimidin-4-yl.

- Further particular compounds of the Formula I include, for example, quinazoline
- 30 derivatives of the Formula V, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore or in any of the paragraphs (a) to (l) immediately hereinbefore and  $Y^2$  has any of the meanings defined hereinbefore or in paragraphs (a) and (b) hereinafter :-

(a) tricyclic rings formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include 3H-imidazo[4,5-g]quinazolin-8-yl and 2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolin-8-yl; and

(b) tricyclic rings formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include 3-methyl-3H-imidazo[4,5-g]quinazolin-8-yl and 3-methyl-2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolin-8-yl.

A further particular compound of the invention is a quinazoline derivative of the Formula II wherein :

m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from methoxy, benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-ylmethoxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-1-yl)propoxy, 3-(4-tert-butoxycarbonylaminopiperidin-1-yl)propoxy, 3-(4-carbamoylpiperidin-1-yl)propoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy, 3-[N-(2-methoxyethyl)-N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-methylamino-1-propynyl, 3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl, 6-methylamino-1-hexynyl, 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl, 3-(piperidino)-1-propynyl, 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-1-propynyl,

6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-1-hexynyl,  
 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl,  
 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino,  
 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,

- 5 or m is 2 and the R<sup>1</sup> groups are located at the 6- and 7-positions, one R<sup>1</sup> group is located at the 6- or 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a methoxy group;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

- 10 Z is O, S, NH or N(Et); and

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position;

- 15 or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular compound of the invention is a quinazoline derivative of the Formula II wherein :

- m is 1 or 2 and the R<sup>1</sup> groups, which may be the same or different, are located at the  
 20 6- and/or 7-positions and are selected from methoxy, benzyloxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, 1-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 1-methylpyrrolidin-2-ylmethoxy,  
 25 2-pyrrolidin-2-ylethoxy, 2-(1-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(1-methylpyrrolidin-2-yl)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, 1-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, 1-methylpiperidin-3-ylmethoxy,  
 30 2-piperidin-3-ylethoxy, 2-(1-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-

1-yloxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy and 3-[N-(2-methoxyethyl)-N-methylamino]propoxy;

$R^2$  is hydrogen or methyl;

$R^3$  is hydrogen;

5       $Z$  is O; and

$Q^2$  is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl and methyl; or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular compound of the invention is a quinazoline derivative of the

10 Formula II wherein :

$m$  is 1 and the  $R^1$  group is located at the 7-position and is selected from

3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 2-pyrrolidin-1-ylethoxy,

3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,

2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-

15 4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy,

N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,

2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,

4-pyrrolidin-1-ylbut-2-en-1-yloxy, 4-morpholinobut-2-en-1-yloxy,

4-morpholinobut-2-yn-1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-

20 N-methylamino]ethoxy;

or  $m$  is 2 and one  $R^1$  group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other  $R^1$  group is a 6-methoxy group;

$R^2$  is hydrogen or methyl;

$R^3$  is hydrogen;

25       $Z$  is O, S, NH or N(Et); and

$Q^2$  is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position; or a pharmaceutically-acceptable acid-addition salt thereof.

30      A further particular compound of the invention is a quinazoline derivative of the Formula II wherein :

$m$  is 1 and the  $R^1$  group is located at the 7-position and is selected from

3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 3-pyrrolidin-1-ylpropoxy,

3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,  
 2-piperidinoethoxy, 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy,  
 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-  
 1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;

- 5           or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

Z is O; and

- 10           Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent is located at an ortho position;  
 or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular compound of the invention is, for example, a quinazoline

- 15 derivative of the Formula II selected from :-

1-(2,6-dichlorophenyl)-3-[7-(3-morpholinopropoxy)quinazolin-4-yl]urea,

1-(2,6-dichlorophenyl)-3-{7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazolin-4-yl}urea,

1-benzyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

- 20 1-phenethyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-(2,6-difluorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-

- 25 4-yl]urea,

1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-(2,6-difluorophenyl)-3-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]urea,

1-(2,6-difluorophenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-

- 30 4-yl]urea,

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]urea,


1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(3-piperidinopropoxy)quinazolin-4-yl]urea,

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea and  
 1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]guanidine;

5 or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular compound of the invention is a pyrimidine derivative of the Formula IV wherein the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring forms a thieno[3,2-*d*]pyrimidin-4-yl group;

m is 0, or m is 1 and the R<sup>1</sup> group is a methyl, ethyl, vinyl or ethynyl group which is  
 10 located at the 6-position and bears a substituent selected from carboxy, carbamoyl, N-(2-methylaminoethyl)carbamoyl, N-(2-dimethylaminoethyl)carbamoyl, N-(3-methylaminopropyl)carbamoyl or N-(3-dimethylaminopropyl)carbamoyl, or from a group of the formula :



15 wherein X<sup>2</sup> is NHCO or N(Me)CO and Q<sup>4</sup> is 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, 2-pyrrolidin-1-ylethyl, 2-(2-oxopyrrolidin-1-yl)ethyl, 3-pyrrolidin-1-ylpropyl, 3-(2-oxopyrrolidin-1-yl)propyl, pyrrolidin-2-ylmethyl, 1-methylpyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 2-(1-methylpyrrolidin-2-yl)ethyl, 3-pyrrolidin-2-ylpropyl, 3-(1-methylpyrrolidin-2-yl)propyl,  
 20 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 1-methylpiperidin-3-ylmethyl, 2-piperidin-3-ylethyl, 2-(1-methylpiperidin-3-yl)ethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-(1-methylpiperidin-4-yl)ethyl, 2-piperazin-1-ylethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-piperazin-1-ylpropyl or 3-(4-methylpiperazin-1-yl)propyl,

25 R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;


Z is O; and

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl and methyl;

30 or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular compound of the invention is a pyrimidine derivative of the Formula IV wherein the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring forms a thieno[3,2-*d*]pyrimidin-4-yl group;

m is 0, or m is 1 and the R<sup>1</sup> group is a vinyl group located at the 6-position which bears at the terminal CH<sub>2</sub>= position a substituent selected from N-(2-dimethylaminoethyl)carbamoyl or N-(3-dimethylaminopropyl)carbamoyl, or from a group of the formula :



5 wherein X<sup>2</sup> is NHCO or N(Me)CO and Q<sup>4</sup> is 2-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, 2-pyrrolidin-1-ylethyl, 3-(2-oxopyrrolidin-1-yl)propyl, 3-morpholinopropyl, 2-piperidinoethyl or 3-(4-methylpiperazin-1-yl)propyl,

R<sup>2</sup> is hydrogen or methyl;

10 R<sup>3</sup> is hydrogen;

Z is O; and

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent is located at the ortho position;

15 or a pharmaceutically-acceptable acid-addition salt thereof.

A particular compound of this aspect of the invention is, for example, a pyrimidine derivative of the Formula IV selected from:-

1-(2,6-dichlorophenyl)-3-(thieno[3,2-*d*]pyrimidin-4-yl)urea and

(*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}-


20 N-(3-dimethylaminopropyl)acrylamide;

or a pharmaceutically-acceptable acid-addition salt thereof.

A quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a quinazoline derivative of the Formula I are illustrated by the following representative process variants in which, unless otherwise stated, Q<sup>1</sup>, R<sup>2</sup>, Z, R<sup>3</sup> and Q<sup>2</sup> have any of the meanings defined hereinbefore. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the accompanying Examples.


30 Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

(a) For those compounds of the Formula I wherein R<sup>3</sup> is hydrogen and Z is oxygen, the reaction, conveniently in the presence of a suitable base, of an amine of the Formula VI



VI

wherein  $Q^1$  and  $R^2$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isocyanate of the Formula VII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



VII

5 wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable base is, for example, an organic amine base such as, for example, pyridine, 10 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate, alkoxide or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium ethoxide, potassium tert-butoxide, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal hydride, for example sodium hydride or 15 potassium hydride, or an organometallic base such as an alkyl-lithium, for example *n*-butyllithium or a dialkylamino-lithium, for example lithium di-isopropylamide.

The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, or a dipolar aprotic solvent such 20 as acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently carried out at a temperature in the range, for example, 10 to 150°C, preferably in the range 20 to 75°C.

A suitable conventional chemical equivalent of an isocyanate of the Formula VII is, for example, a compound of the Formula VIII




VIII

25

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable or leaving group. On treatment with a suitable base as defined hereinbefore, the compound of the Formula VIII reacts to form the desired isocyanate of the Formula VII.

30 A suitable displaceable or leaving group L is, for example, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.

A suitable conventional chemical precursor of an isocyanate of the Formula VII is, for example, an acyl azide of the Formula IX



IX

wherein  $\text{Q}^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary. On thermal or photolytic treatment the acyl azide of the Formula IX decomposes and rearranges to form the desired isocyanate of the Formula VII.

Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question and may be introduced by conventional methods. Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower", as in, for example, lower alkyl, signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned are, of course, within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or arylaliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms). Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (for example isopropyl, and tert-butyl); lower alkoxy-lower alkyl groups (for example methoxymethyl, ethoxymethyl and isobutoxymethyl); lower acyloxy-lower alkyl groups, (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl); lower alkoxycarbonyloxy-lower alkyl groups (for example 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl); aryl-lower alkyl groups (for example benzyl, 4-methoxybenzyl, 2-nitrobenzyl, 4-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (for example trimethylsilyl and tert-butyldimethylsilyl); tri(lower alkyl)silyl-lower alkyl groups (for example trimethylsilylethyl); and (2-6C)alkenyl groups (for example allyl). Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed cleavage.

Examples of hydroxy protecting groups include lower alkyl groups (for example tert-butyl), lower alkenyl groups (for example allyl); lower alkanoyl groups (for example acetyl); lower alkoxycarbonyl groups (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (for example trimethylsilyl and tert-butyldimethylsilyl) and aryl-lower alkyl (for example benzyl) groups.

Examples of amino protecting groups include formyl, aryl-lower alkyl groups (for example benzyl and substituted benzyl, 4-methoxybenzyl, 2-nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-4-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); trialkylsilyl (for example trimethylsilyl and tert-butyldimethylsilyl); alkylidene (for example methylidene) and benzylidene and substituted benzylidene groups.

Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis for groups such as 2-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for groups such as 2-nitrobenzyloxycarbonyl.

The reader is referred to Advanced Organic Chemistry, 4th Edition, by J. March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents and to Protective Groups in Organic Synthesis, 2<sup>nd</sup> Edition, by T. Green et al., also published by John Wiley & Son, for general guidance on protecting groups.


When L is, for example, a chloro group, the compound of the Formula VIII may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of phosgene with an amine of the Formula X.



The compound of the Formula IX may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XI.




(b) For those compounds of the Formula I wherein R<sup>3</sup> is hydrogen and Z is sulphur, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of an amine of the Formula VI



VI

wherein  $Q^1$  and  $R^2$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isothiocyanate of the Formula XII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



XII

5 wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable conventional chemical equivalent of an isothiocyanate of the Formula XII  
10 is, for example, a compound of the Formula XIII



XIII

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group as defined hereinbefore. On treatment with a suitable base as defined hereinbefore, the compound of the Formula XIII  
15 reacts to form the desired isothiocyanate of the Formula XII.


A suitable conventional chemical precursor of an isothiocyanate of the Formula XII is, for example, an acyl azide of the Formula XIV



XIV

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is  
20 protected if necessary. On thermal or photolytic treatment the thioacyl azide of the Formula XIV decomposes and rearranges to form the desired isothiocyanate of the Formula XII.

When L is, for example, a chloro group, the compound of the Formula XIII may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as  
25 defined hereinbefore, of thiophosgene with an amine of the Formula X.



X

The compound of the Formula XIV may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XV.



XV

30 (c) For those compounds of the Formula I wherein  $R^2$  is hydrogen and Z is oxygen, the reaction, conveniently in the presence of a suitable base, of an amine of the Formula XVI



XVI

wherein  $Q^2$  and  $R^3$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isocyanate of the Formula XVII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



5 wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable conventional chemical equivalent of an isocyanate of the Formula XVII is, for example, a compound of the Formula XVIII



wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group as defined hereinbefore. On treatment with a suitable base as defined hereinbefore, the compound of the Formula XVIII reacts to form the desired isocyanate of the Formula XVII.

15 A suitable conventional chemical precursor of an isocyanate of the Formula XVII is, for example, an acyl azide of the Formula XIX



wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary. On thermal or photolytic treatment the thioacyl azide of the  
20 Formula XIX decomposes and rearranges to form the desired isocyanate of the Formula XVII.

When L is, for example, a chloro group, the compound of the Formula XVIII may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of phosgene with an amine of the Formula XX.




25 The compound of the Formula XIX may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XXI.



(d) For those compounds of the Formula I wherein  $R^2$  is hydrogen and Z is sulphur, the reaction, conveniently in the presence of a suitable base, of an amine of the Formula XVI



wherein  $Q^2$  and  $R^3$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isothiocyanate of the Formula XXII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



XXII

wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

- 5 A suitable conventional chemical equivalent of an isothiocyanate of the Formula XXII is, for example, a compound of the Formula XXIII



XXIII

- wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group as defined hereinbefore. On  
10 treatment with a suitable base as defined hereinbefore, the compound of the Formula XXIII reacts to form the desired isothiocyanate of the Formula XXII.


A suitable conventional chemical precursor of an isothiocyanate of the Formula XXII is, for example, an acyl azide of the Formula XXIV



XXIV

- 15 wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary. On thermal or photolytic treatment the thioacyl azide of the Formula XXIV decomposes and rearranges to form the desired isothiocyanate of the Formula XXII.

- When L is, for example, a chloro group, the compound of the Formula XXIII may be  
20 prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of thiophosgene with an amine of the Formula XX.



XX

The compound of the Formula XXIV may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XXV.

25



XXV

- (e) For those compounds of the Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains an alkylcarbamoyl group or a substituted alkylcarbamoyl group, the reaction of the corresponding compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  is a carboxy group, or a reactive derivative thereof, with an amine or substituted amine as appropriate.

- 30 A suitable reactive derivative of a compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  is a carboxy group is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a

chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid and a phenol such as pentafluorophenol, an ester formed by the reaction of the acid and an ester such as pentafluorophenyl trifluoroacetate or an ester formed by the reaction of the acid and an alcohol such as *N*-hydroxybenzotriazole; an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cyanide; or the product of the reaction of the acid and a carbodiimide such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

10 The reaction is conveniently carried out in the presence of a suitable base as defined hereinbefore and in the presence of a suitable inert solvent or diluent as defined hereinbefore.

Typically a carbodiimide coupling reagent is used in the presence of an organic solvent (preferably an anhydrous polar aprotic organic solvent) at a non-extreme temperature, for example in the region -10 to 40°C, typically at ambient temperature of about 20°C.

15 A compound of Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> is a carboxy group may conveniently be prepared by the cleavage of the corresponding ester such as a (1-12C)alkyl ester, for example by acid-, base- metal- or enzymatically-catalysed cleavage.

(f) For those compounds of the Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains an amino-(1-6C)alkyl group, the cleavage of the corresponding compound of Formula I wherein  
20 a substituent on Q<sup>1</sup> or Q<sup>2</sup> is a protected amino-(1-6C)alkyl group.

Suitable protecting groups for an amino-(1-6C)alkyl group are, for example, any of the protecting groups disclosed hereinbefore for an amino group. Suitable methods for the cleavage of such amino protecting groups are also disclosed hereinbefore. In particular, a suitable protecting group is a lower alkoxycarbonyl group such as a *tert*-butoxycarbonyl group  
25 which may be cleaved under conventional reaction conditions such as under acid-catalysed hydrolysis.

(g) For those compounds of the Formula I wherein Z is a N(R<sup>11</sup>) group wherein R<sup>11</sup> is hydrogen or (1-6C)alkyl, the reaction, conveniently in the presence of a suitable metallic salt catalyst, of a thiourea of the Formula I wherein Q<sup>1</sup>, Q<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup> have any of the meanings  
30 defined hereinbefore except that any functional group is protected if necessary and Z is sulphur, with an amine of formula R<sup>11</sup>NH<sub>2</sub>, whereafter any protecting group that is present is removed by conventional means.

A suitable metallic salt catalyst is, for example, a mercuric salt such as mercuric(II) oxide and the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore.

- (h) For those compounds of the Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains an amino group, the reduction of a corresponding compound of Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains a nitro group.

Typical reaction conditions include the use of ammonium formate or hydrogen gas in the presence of a catalyst, for example a metallic catalyst such as palladium-on-carbon. Alternatively a dissolving metal reduction may be carried out, for example using iron in the presence of an acid, for example an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric or acetic acid. The reaction is conveniently carried out in the presence of an organic solvent (preferably a polar protic solvent) and preferably with heating, for example to about 60°C. Any functional groups are protected and deprotected as necessary.

When a pharmaceutically-acceptable salt of a quinazoline derivative of the Formula I is required, for example an acid-addition salt, it may be obtained by, for example, reaction of said quinazoline derivative with a suitable acid using a conventional procedure.

#### Biological Assays

The following assays can be used to measure the effects of the compounds of the Formula I as c-Src tyrosine kinase inhibitors, as inhibitors in vitro of the proliferation of c-Src transfected fibroblast cells, as inhibitors in vitro of the migration of A549 human lung tumour cells and as inhibitors in vivo of the growth in nude mice of xenografts of A549 tissue.

##### (a) In Vitro Enzyme Assay

The ability of test compounds to inhibit the phosphorylation of a tyrosine containing polypeptide substrate by the enzyme c-Src kinase was assessed using a conventional Elisa assay.

A substrate solution [100µl of a 20µg/ml solution of the polyamino acid Poly(Glu, Tyr) 4:1 (Sigma Catalogue No. P0275) in phosphate buffered saline (PBS) containing 0.2mg/ml of sodium azide] was added to each well of a number of Nunc 96-well immunoplates (Catalogue No. 439454) and the plates were sealed and stored at 4°C for 16 hours. The excess of substrate solution was discarded, and aliquots of Bovine Serum Albumin (BSA; 150µl of a 5% solution in PBS) were transferred into each substrate-coated assay well and incubated for 1 hour at ambient temperature to block non specific binding. The

assay plate wells were washed in turn with PBS containing 0.05% v/v Tween 20 (PBST) and with Hepes pH7.4 buffer (50mM, 300µl/well) before being blotted dry.

Each test compound was dissolved in dimethyl sulphoxide and diluted with distilled water to give a series of dilutions (from 100µM to 0.001µM). Portions (25µl) of each dilution of test compound were transferred to wells in the washed assay plates. "Total" control wells contained diluted DMSO instead of compound. Aliquots (25µl) of an aqueous magnesium chloride solution (80mM) containing adenosine-5'-triphosphate (ATP; 40µM) was added to all test wells except the "blank" control wells which contained magnesium chloride without ATP.

10 Active human c-Src kinase (recombinant enzyme expressed in Sf9 insect cells; obtained from Upstate Biotechnology Inc. product 14-117) was diluted immediately prior to use by a factor of 1:10,000 with an enzyme diluent which comprised 100mM Hepes pH7.4 buffer, 0.2mM sodium orthovanadate, 2mM dithiothreitol and 0.02% BSA. To start the reactions, aliquots (50µl) of freshly diluted enzyme were added to each well and the plates  
15 were incubated at ambient temperature for 20 minutes. The supernatant liquid in each well was discarded and the wells were washed twice with PBST. Mouse IgG anti-phosphotyrosine antibody (Upstate Biotechnology Inc. product 05-321; 100µl) was diluted by a factor of 1:6000 with PBST containing 0.5% w/v BSA and added to each well. The plates were incubated for 1 hour at ambient temperature. The supernatant liquid was discarded and each  
20 well was washed with PBST (x4). Horse radish peroxidase (HRP)-linked sheep anti-mouse Ig antibody (Amersham Catalogue No. NXA 931; 100µl) was diluted by a factor of 1:500 with PBST containing 0.5% w/v BSA and added to each well. The plates were incubated for 1 hour at ambient temperature. The supernatant liquid was discarded and the wells were washed with PBST (x4).

25 A PCSB capsule (Sigma Catalogue No. P4922) was dissolved in distilled water (100ml) to provide phosphate-citrate pH5 buffer (50mM) containing 0.03% sodium perborate. An aliquot (50ml) of this buffer was mixed with a 50mg tablet of 2,2'-azinobis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS; Boehringer Catalogue No. 1204 521). Aliquots (100µl) of the resultant solution were added to each well. The plates  
30 were incubated for 20 to 60 minutes at ambient temperature until the optical density value of the "total" control wells, measured at 405nm using a plate reading spectrophotometer, was

approximately 1.0. "Blank" (no ATP) and "total" (no compound) control values were used to determine the dilution range of test compound which gave 50% inhibition of enzyme activity.

(b) In Vitro c-Src transfected NIH 3T3 (c-src 3T3) Fibroblast Proliferation Assay

This assay determined the ability of a test compound to inhibit the proliferation of  
5 National Institute of Health (NIH) mouse 3T3 fibroblast cells that had been stably-transfected with an activating mutant (Y530F) of human c-Src.

Using a similar procedure to that described by Shalloway *et al.*, Cell, 1987, 49, 65-73, NIH 3T3 cells were transfected with an activating mutant (Y530F) of human c-Src. The resultant c-Src 3T3 cells were typically seeded at  $1.5 \times 10^4$  cells per well into 96-well tissue-  
10 culture-treated clear assay plates (Costar) each containing an assay medium comprising Dulbecco's modified Eagle's medium (DMEM; Sigma) plus 0.5% foetal calf serum (FCS), 2mM glutamine, 100 units/ml penicillin and 0.1mg/ml streptomycin in 0.9% aqueous sodium chloride solution. The plates were incubated overnight at 37°C in a humidified  
(7.5% CO<sub>2</sub> : 95% air) incubator.

15 Test compounds were solubilised in DMSO to form a 10mM stock solution. Aliquots of the stock solution were diluted with the DMEM medium described above and added to appropriate wells. Serial dilutions were made to give a range of test concentrations. Control wells to which test compound was not added were included on each plate. The plates were incubated overnight at 37°C in a humidified (7.5% CO<sub>2</sub> : 95% air) incubator.

20 BrdU labelling reagent (Boehringer Mannheim Catalogue No. 647 229) was diluted by a factor of 1:100 in DMEM medium containing 0.5% FCS and aliquots (20µl) were added to each well to give a final concentration of 10µM. The plates were incubated at 37°C for 2 hours. The medium was decanted. A denaturing solution (FixDenat solution, Boehringer Mannheim Catalogue No. 647 229; 50µl) was added to each well and the plates were placed  
25 on a plate shaker at ambient temperature for 45 minutes. The supernatant was decanted and the wells were washed with PBS (200µl per well). Anti-BrdU-Peroxidase solution (Boehringer Mannheim Catalogue No. 647 229) was diluted by a factor of 1:100 in PBS containing 1% BSA and 0.025% dried skimmed milk (Marvel (registered trade mark), Premier Beverages, Stafford, GB) and an aliquot (100µl) of the resultant solution was added to each  
30 well. The plates were placed on a plate shaker at ambient temperature for 90 minutes. The wells were washed with PBS (x5) to ensure removal of non bound antibody conjugate. The plates were blotted dry and tetramethylbenzidine substrate solution (Boehringer

Mannheim Catalogue No. 647 229; 100µl) was added to each well. The plates were gently agitated on a plate shaker while the colour developed during a 10 to 20 minute period. The absorbance of the wells was measured at 690nm. The extent of inhibition of cellular proliferation at a range of concentrations of each test compound was determined and an anti-proliferative IC<sub>50</sub> value was derived.

(c) In Vitro Microdroplet Migration Assay

This assay determines the ability of a test compound to inhibit the migration of adherent mammalian cell lines, for example the human tumour cell line A549.

RPMI medium(Sigma) containing 10% FCS, 1% L-glutamine and 0.3% agarose (Difco Catalogue No. 0142-01) was warmed to 37°C in a waterbath. A stock 2% aqueous agar solution was autoclaved and stored at 42°C. An aliquot (1.5 ml) of the agar solution was added to RPMI medium (10 ml) immediately prior to its use. A549 cells (Accession No. ATCC CCL185) were suspended at a concentration of  $2 \times 10^7$  cells/ml in the medium and maintained at a temperature of 37°C.

A droplet (2µl) of the cell/agarose mixture was transferred by pipette into the centre of each well of a number of 96-well, flat bottomed non-tissue-culture-treated microtitre plate (Bibby Sterilin Catalogue No. 642000). The plates were placed briefly on ice to speed the gelling of the agarose-containing droplets. Aliquots (90µl) of medium which had been cooled to 4°C were transferred into each well, taking care not to disturb the microdroplets. Test compounds were diluted from a 10mM stock solution in DMSO using RPMI medium as described above. Aliquots (10µl) of the diluted test compounds were transferred to the wells, again taking care not to disturb the microdroplets. The plates were incubated at 37°C in a humidified (7.5% CO<sub>2</sub> : 95% air) incubator for about 48 hours.

Migration was assessed visually and the distance of migration was measured back to the edge of the agar droplet. A migratory inhibitory IC<sub>50</sub> was derived by plotting the mean migration measurement against test compound concentration.

(d) In Vivo A549 Xenograft Growth Assay

This test measures the ability of compounds to inhibit the growth of the A549 human carcinoma grown as a tumour in athymic nude mice (Alderley Park nu/nu strain). A total of about  $5 \times 10^6$  A549 cells in matrigel (Beckton Dickinson Catalogue No. 40234) were injected subcutaneously into the left flank of each test mouse and the resultant tumours were allowed to grow for about 14 days. Tumour size was measured twice weekly using callipers and a

theoretical volume was calculated. Animals were selected to provide control and treatment groups of approximately equal average tumour volume. Test compounds were prepared as a ball-milled suspension in 1% polysorbate vehicle and dosed orally once daily for a period of about 28 days. The effect on tumour growth was assessed.

5        Although the pharmacological properties of the compounds of the Formula I vary with structural change as expected, in general activity possessed by compounds of the Formula I, may be demonstrated at the following concentrations or doses in one or more of the above tests (a), (b), (c) and (d):-

Test (a):-         $IC_{50}$  in the range, for example, 0.001 - 10  $\mu M$ ;

10       Test (b):-         $IC_{50}$  in the range, for example, 0.01 - 20  $\mu M$ ;

Test (c):-        activity in the range, for example, 0.1-25  $\mu M$ ;

Test (d):-        activity in the range, for example, 1-200 mg/kg/day;.

No physiologically-unacceptable toxicity was observed in Test (d) at the effective dose for compounds tested of the present invention. Accordingly no untoward toxicological effects  
15 are expected when a compound of Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore is administered at the dosage ranges defined hereinafter.

A pharmaceutical composition for the compounds of the Formula I comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

20       The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for  
25 example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended  
30 for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the

particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

10 In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will  
15 generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.

As stated above, it is known that the predominant role of c-Src non-receptor tyrosine  
20 kinase is to regulate cell motility which is necessarily required for a localised tumour to progress through the stages of dissemination into the blood stream, invasion of other tissues and initiation of metastatic tumour growth. We have found that the quinazoline derivatives of the Formula I possess potent anti-tumour activity which it is believed is obtained by way of inhibition of one or more of the non-receptor tyrosine-specific protein kinases such as c-Src  
25 kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells.

Accordingly the quinazoline derivatives of the Formula I are of value as anti-tumour agents, in particular as selective inhibitors of the motility, dissemination and invasiveness of mammalian cancer cells leading to inhibition of metastatic tumour growth. Particularly, the  
30 quinazoline derivatives of the Formula I are of value as anti-invasive agents in the containment and/or treatment of solid tumour disease. Particularly, the compounds of the Formula I are expected to be useful in the prevention or treatment of those tumours which are sensitive to inhibition of one or more of the multiple non-receptor tyrosine kinases such as c-

Src kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells. Further, the compounds of the Formula I are expected to be useful in the prevention or treatment of those tumours which are mediated alone or in part by inhibition of the enzyme c-Src, *i.e.* the compounds may be used to produce  
 5 a c-Src enzyme inhibitory effect in a warm-blooded animal in need of such treatment. Specifically, the compounds of the Formula I are expected to be useful in the prevention or treatment of solid tumour disease.

The anti-invasive treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the quinazoline derivative of the invention, conventional surgery  
 10 or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents :-

- (i) other anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (ii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical  
 15 oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European Patent Application No. 562734 such as  
 20 (2S)-2-{ $\alpha$ -fluoro-p-[N-{2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl}-N-(prop-2-ynyl)amino]benzamido}-4-(tetrazol-5-yl)butyric acid); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol  
 25 and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);
- (iii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example  
 30 goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 $\alpha$ -reductase such as finasteride;

- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example the EGFR tyrosine kinase inhibitors N-(3-chloro-4-fluorophenyl)-7-methoxy-  
5 6-(3-morpholinopropoxy)quinazolin-4-amine (ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (CP 358774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family; and
- 10 (v) antiangiogenic agents such as those which inhibit vascular endothelial growth factor such as the compounds disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and those that work by other mechanisms (for example linomide, inhibitors of integrin  $\alpha v \beta 3$  function and angiostatin).

Such conjoint treatment may be achieved by way of the simultaneous, sequential or  
15 separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.

According to this aspect of the invention there is provided a pharmaceutical product comprising a quinazoline derivative of the formula I as defined hereinbefore and an additional  
20 anti-tumour agent as defined hereinbefore for the conjoint treatment of cancer.

Although the compounds of the Formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of c-Src. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.

25 The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated :-

- (i) operations were carried out at ambient temperature, *i.e.* in the range 17 to 25°C and under an atmosphere of an inert gas such as argon unless otherwise stated;
- (ii) evaporations were carried out by rotary evaporation *in vacuo* and work-up  
30 procedures were carried out after removal of residual solids by filtration;
- (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck

Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) was performed on C18 reverse phase silica, for example on a Dynamax C-18 60Å preparative reversed-phase column;

(iv) yields, where present, are given for illustration only and are not necessarily the maximum attainable;

(v) in general, the end-products of the Formula I have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer and, where appropriate, either positive ion data or negative ion data were collected; NMR chemical shift values were measured on the delta scale [proton magnetic resonance spectra were determined using a Jeol JNM EX 400 spectrometer operating at a field strength of 400MHz, a Varian Gemini 2000 spectrometer operating at a field strength of 300MHz or a Bruker AM300 spectrometer operating at a field strength of 300MHz]; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad;

(vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) and/or NMR analysis;

(vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the Formula I were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture; and

(viii) the following abbreviations have been used:-

DMF	<u>N,N</u> -dimethylformamide
DMSO	dimethylsulphoxide
THF	tetrahydrofuran

**Example 1** 1-(2,6-dichlor phenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea

2,6-Dichlorophenyl isocyanate (0.075 g) was added to a solution of 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (0.093 g) in a mixture of methylene chloride (2 ml) and DMF (0.1 ml) and the reaction mixture was stirred at ambient temperature for 16 hours. The resultant solid was isolated, redissolved in a 20:1 mixture of methylene chloride and methanol and purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained the title compound as a white solid (0.029 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.3-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.8 (d, 2H), 3.9 (s, 3H), 4.0 (br d, 2H), 7.3 (br s, 1H), 7.4 (d, 1H), 7.5 (s, 1H), 7.6 (s, 1H), 8.0 (br s, 1H), 8.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490, 492 and 494.

The 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline used as a starting material was prepared as follows :-

A solution of di-tert-butyl dicarbonate (41.7 g) in ethyl acetate (75 ml) was added dropwise to a stirred solution of ethyl piperidine-4-carboxylate (30 g) in ethyl acetate (150 ml) which had been cooled to 0 to 5°C in an ice-bath. The resultant mixture was stirred at ambient temperature for 48 hours. The mixture was poured into water (300 ml). The organic layer was separated, washed in turn with water (200 ml), 0.1N aqueous hydrochloric acid solution (200 ml), a saturated aqueous sodium bicarbonate solution (200 ml) and brine (200 ml), dried over magnesium sulphate and evaporated. There was thus obtained ethyl N-tert-butoxycarbonylpiperidine-4-carboxylate (48 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.25 (t, 3H), 1.45 (s, 9H), 1.55-1.7 (m, 2H), 1.8-2.0 (d, 2H), 2.35-2.5 (m, 1H), 2.7-2.95 (t, 2H), 3.9-4.1 (br s, 2H), 4.15 (q, 2H).

A solution of the material so obtained in THF (180 ml) was cooled at 0°C and lithium aluminium hydride (1M solution in THF; 133 ml) was added dropwise. The mixture was stirred at 0°C for 2 hours. Water (30 ml) and 2N aqueous sodium hydroxide solution (10 ml) were added in turn and the mixture was stirred for 15 minutes. The resultant mixture was filtered through diatomaceous earth and the solids were washed with ethyl acetate. The filtrate was washed in turn with water and with brine, dried over magnesium sulphate and evaporated. There was thus obtained N-tert-butoxycarbonyl-4-hydroxymethylpiperidine (36.3 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.05-1.2 (m, 2H), 1.35-1.55 (m, 10H), 1.6-1.8 (m, 2H), 2.6-2.8 (t, 2H), 3.4-3.6 (t, 2H), 4.0-4.2 (br s, 2H).

1,4-Diazabicyclo[2.2.2]octane (42.4 g) was added to a solution of N-tert-butoxycarbonyl-4-hydroxymethylpiperidine (52.5 g) in tert-butyl methyl ether (525 ml) and the mixture was stirred at ambient temperature for 15 minutes. The mixture was then cooled in an ice-bath to 5°C and a solution of 4-toluenesulphonyl chloride (62.8 g) in tert-butyl methyl ether (525 ml) was added dropwise over 2 hours while maintaining the reaction temperature at approximately 0°C. The resultant mixture was allowed to warm to ambient temperature and was stirred for 1 hour. Petroleum ether (b.p. 60-80°C, 1L) was added and the precipitate was removed by filtration. The filtrate was evaporated to give a solid residue which was dissolved in diethyl ether. The organic solution was washed in turn with 0.5N aqueous hydrochloric acid solution, water, a saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulphate and evaporated. There was thus obtained N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine (76.7 g), NMR Spectrum: (CDCl<sub>3</sub>) 1.0-1.2 (m, 2H), 1.45 (s, 9H), 1.65 (d, 2H), 1.75-1.9 (m, 2H), 2.45 (s, 3H), 2.55-2.75 (m, 2H), 3.85 (d, 1H), 4.0-4.2 (br s, 2H), 7.35 (d, 2H), 7.8 (d, 2H).

A portion (40 g) of the material so obtained was added to a suspension of ethyl 4-hydroxy-3-methoxybenzoate (19.6 g) and potassium carbonate (28 g) in DMF (200 ml) and the resultant mixture was stirred and heated to 95°C for 2.5 hours. The mixture was cooled to ambient temperature and partitioned between water and a mixture of ethyl acetate and diethyl ether. The organic layer was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The resulting oil was crystallised from petroleum ether (b.p. 60-80°C) and the suspension was stored overnight at 5°C. The resultant solid was collected by filtration, washed with petroleum ether and dried under vacuum. There was thus obtained ethyl 4-(N-tert-butoxycarbonylpiperidin-4-ylmethoxy)-3-methoxybenzoate (35 g), m.p. 81-83°C; NMR Spectrum: (CDCl<sub>3</sub>) 1.2-1.35 (m, 2H), 1.4 (t, 3H), 1.48 (s, 9H), 1.8-1.9 (d, 2H), 2.0-2.15 (m, 2H), 2.75 (t, 2H), 3.9 (d, 2H), 3.95 (s, 3H), 4.05-4.25 (br s, 2H), 4.35 (q, 2H), 6.85 (d, 1H), 7.55 (s, 1H), 7.65 (d, 1H).

The material so obtained was dissolved in formic acid (35 ml), formaldehyde (12M, 37% in water, 35 ml) was added and the mixture was stirred and heated to 95°C for 3 hours. The resultant mixture was evaporated. The residue was dissolved in methylene chloride and hydrogen chloride (3M solution in diethyl ether; 40 ml) was added. The mixture was diluted with diethyl ether and the mixture was triturated until a solid was formed. The solid was collected, washed with diethyl ether and dried under vacuum overnight at 50°C. There was thus obtained ethyl 3-methoxy-4-(N-methylpiperidin-4-ylmethoxy)benzoate (30.6 g),

NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.29 (t, 3H), 1.5-1.7 (m, 2H), 1.95 (d, 2H), 2.0-2.15 (br s, 1H), 2.72 (s, 3H), 2.9-3.1 (m, 2H), 3.35-3.5 (br s, 2H), 3.85 (s, 3H), 3.9-4.05 (br s, 2H), 4.3 (q, 2H), 7.1 (d, 1H), 7.48 (s, 1H), 7.6 (d, 1H).

The material so obtained was dissolved in methylene chloride (75 ml) and the solution  
5 was cooled in an ice-bath to 0-5°C. Trifluoroacetic acid (37.5 ml) was added followed by the  
dropwise addition over 15 minutes of a solution of fuming nitric acid (24M; 7.42 ml) in  
methylene chloride (15 ml). The resultant solution was allowed to warm to ambient  
temperature and was stirred for 2 hours. Volatile materials were evaporated. The residue was  
dissolved in methylene chloride (50 ml) and the solution was cooled in an ice-bath to 0-5°C.  
10 Diethyl ether was added and the resultant precipitate was collected and dried under vacuum at  
50°C. The solid was dissolved in methylene chloride (500 ml) and hydrogen chloride (3M  
solution in diethyl ether; 30 ml) was added followed by diethyl ether (500 ml). The resultant  
solid was collected and dried under vacuum at 50°C. There was thus obtained ethyl  
5-methoxy-4-(N-methylpiperidin-4-ylmethoxy)-2-nitrobenzoate (28.4 g), NMR Spectrum:  
15 (DMSO<sub>d</sub><sub>6</sub>) 1.3 (t, 3H), 1.45-1.65 (m, 2H), 1.75-2.1 (m, 3H), 2.75 (s, 3H), 2.9-3.05 (m, 2H),  
3.4-3.5 (d, 2H), 3.95 (s, 3H), 4.05 (d, 2H), 4.3 (q, 2H), 7.32 (s, 1H), 7.66 (s, 1H).

A mixture of a portion (3.89 g) of the material so obtained, 10% platinum-on-activated  
carbon (50% wet, 0.389 g) and methanol (80 ml) was stirred under 1.8 atmospheres pressure  
of hydrogen until uptake of hydrogen ceased. The mixture was filtered and the filtrate was  
20 evaporated. The residue was dissolved in water (30 ml) and basified to pH10 by the addition  
of a saturated aqueous sodium bicarbonate solution. The mixture was diluted with a 1:1  
mixture of ethyl acetate and diethyl ether and the organic layer was separated. The aqueous  
layer was further extracted with a 1:1 mixture of ethyl acetate and diethyl ether and the  
organic extracts were combined, washed in turn with water and brine, dried over magnesium  
sulphate and evaporated. The residue was triturated under a mixture of petroleum ether  
25 (b.p. 60-80°C) and diethyl ether. The solid so obtained was isolated, washed with petroleum  
ether and dried under vacuum at 60°C. There was thus obtained ethyl 2-amino-5-methoxy-  
4-(N-methylpiperidin-4-ylmethoxy)benzoate (2.58 g), m.p. 111-112°C; NMR Spectrum:  
(CDCl<sub>3</sub>) 1.35 (t, 3H), 1.4-1.5 (m, 2H), 1.85 (m, 3H), 1.95 (t, 2H), 2.29 (s, 3H), 2.9 (d, 2H), 3.8  
30 (s, 3H), 3.85 (d, 2H), 4.3 (q, 2H), 5.55 (br s, 2H), 6.13 (s, 1H), 7.33 (s, 1H).

A mixture of ethyl 2-amino-5-methoxy-4-(N-methylpiperidin-4-ylmethoxy)benzoate  
(16.1 g), formamidine acetic acid salt (5.2 g) and 2-methoxyethanol (160 ml) was stirred and  
heated at 115°C for 2 hours. Further formamidine acetic acid salt (10.4 g) was added in

portions every 30 minutes during 4 hours and heating was continued for 30 minutes after the last addition. The resultant mixture was evaporated. The solid residue was stirred under a mixture of methylene chloride (50ml) and ethanol (100ml). The precipitate was removed by filtration and the filtrate was concentrated to a final volume of 100ml. The resultant

5 suspension was cooled to 5°C. The solid so obtained was collected, washed with cold ethanol and with diethyl ether and dried under vacuum at 60°C. There was thus obtained 6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)-3,4-dihydroquinazolin-4-one (12.7 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.25-1.4 (m, 2H), 1.75 (d, 2H), 1.9 (t, 1H), 1.9 (s, 3H), 2.16 (s, 2H), 2.8 (d, 2H), 3.9 (s, 3H), 4.0 (d, 2H), 7.11 (s, 1H), 7.44 (s, 1H), 7.97 (s, 1H).

10 A mixture of a portion (2.8 g) of the material so obtained, thionyl chloride (28 ml) and DMF (0.28 ml) was heated to reflux for 1 hour. The mixture was evaporated and the precipitate was triturated under diethyl ether. The resultant solid was isolated and washed with diethyl ether. The solid was then dissolved in methylene chloride and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic layer was washed  
15 in turn with water and brine, dried over magnesium sulphate and evaporated. There was thus obtained 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (2.9 g), NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.5 (m, 2H), 1.75-1.9 (m, 4H), 2.0 (t, 1H), 2.25 (s, 3H), 2.85 (d, 2H), 4.02 (s, 3H), 4.12 (d, 2H), 7.41 (s, 1H), 7.46 (s, 1H), 8.9 (s, 1H).

A mixture of 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline  
20 (11.17 g), 4-bromo-2-fluorophenol (4.57 ml), potassium carbonate (7.19 g) and DMF (110 ml) was stirred and heated at 100°C for 2.5 hours. The mixture was allowed to cool to ambient temperature and was poured into a mixture (1L) of ice and water. The precipitate was collected, washed with water and dried. The solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a  
25 1% aqueous ammonium hydroxide solution (20:1:0 to 10:1:0 to 10:1:1) as eluent. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (13.1 g), NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.9 (t, 1H), 2.15 (s, 3H), 2.5 (br s, 2H), 4.0 (s, 3H), 4.1 (d, 2H), 7.4 (s, 1H), 7.45-7.6 (m, 3H), 7.8 (d, 1H), 8.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 and 478.


30 A portion (9.4 g) of the material so obtained was dissolved in a 2M solution of ammonia in isopropanol (150 ml). Liquid ammonia (10 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 130°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue

was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl *tert*-butyl ether. There was thus obtained 4-amino-6-methoxy-7-(*N*-methylpiperidin-4-ylmethoxy)quinazoline (5.55 g); NMR Spectrum: (DMSO- $d_6$ ) 1.2-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.8 (d, 2H), 3.8 (s, 3H), 3.9 (d, 2H), 7.0 (s, 1H), 7.3 (br s, 2H), 7.5 (s, 1H), 8.2 (s, 1H); Mass Spectrum:  $M+H^+$  303.

### Example 2

Using an analogous procedure to that described in Example 1, except that, unless otherwise stated, chloroform was used in place of methylene chloride as the reaction solvent, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the compounds described in Table I. In general, unless otherwise stated, the appropriate isocyanates were commercially available. Alternatively appropriate isocyanates could be prepared by the reaction of the appropriate aniline with di-*tert*-butyl dicarbonate in the presence of 4-dimethylaminopyridine and a solvent such as methylene chloride.

Table I



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2-chloro	[1]
2	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2,3-dichloro	[2]
3	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2,4-dichloro	[3]
4	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2-fluoro	[4]
5	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2,6-difluoro	[5]
6	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2-bromo	[6]
7	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2-trifluoromethyl	[7]
8	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2-methyl	[8]
9	methoxy	<i>N</i> -methylpiperidin-4-ylmethoxy	2,6-dimethyl	[9]

10	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2- <u>tert</u> -butyl	[10]
11	methoxy	3-piperidinopropoxy	2,6-dimethyl	[11]
12	hydrogen	3-morpholinopropoxy	2,6-dichloro	[12]
13	hydrogen	3-(1,1-dioxotetrahydro-4 <u>H</u> -1,4-thiazin-4-yl)propoxy	2,6-dichloro	[13]
14	hydrogen	4-morpholinobut-2-ynyloxy	2,6-dichloro	[14]
15	hydrogen	( <i>E</i> )-4-morpholinobut-2-enyloxy	2,6-dichloro	[15]
16	methoxy	2-piperidinoethoxy	2,6-dichloro	[16]
17	methoxy	3-morpholinopropoxy	2,6-dichloro	[17]
18	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,6-dichloro	[18]
19	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	[19]
20	methoxy	3-(1,1-dioxotetrahydro-4 <u>H</u> -1,4-thiazin-4-yl)propoxy	2,6-dichloro	[20]
21	methoxy	2-[ <u>N</u> -(2-methoxyethyl)- <u>N</u> -methylamino]ethoxy	2,6-dichloro	[21]
22	methoxy	3-mesyloxypropoxy	2,6-dichloro	[22]
23	methoxy	3-(1,2,3-triazol-1-yl)propoxy	2,6-dichloro	[23]
24	methoxy	2-(4-pyridyl)ethoxy	2,6-dichloro	[24]
25	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4,6-trichloro	[25]
26	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dichloro	[26]
27	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4-difluoro	[27]
28	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethoxy	[28]
29	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4-dimethoxy	[29]
30	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-diisopropyl	[30]
31	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4,6-trimethyl	[31]
32	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl	[32]
33	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-diethyl	[33]
34	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-ethyl-6-methyl	[34]
35	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-bromo-2,6-dimethyl	[35]
36	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	[36]
37	methoxy	3-pyrrolidin-1-ylpropoxy	2,4,6-trichloro	[37]

38	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,4,6-trichloro	[38]
39	methoxy	3-piperidinopropoxy	2,6-dichloro	[39]
40	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	[40]
41	methoxy	3-piperidinopropoxy	2,6-difluoro	[41]
42	methoxy	3-morpholinopropoxy	2,6-difluoro	[42]
43	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,6-difluoro	[43]
44	methoxy	2-piperidinoethoxy	2,6-difluoro	[44]
45	methoxy	2-piperidinoethoxy	2,4,6-trichloro	[45]
46	methoxy	3-pyrrolidin-1-ylpropoxy	2-fluoro- 6-trifluoromethyl	[46]
47	methoxy	2-dimethylaminoethoxy	2,6-difluoro	[47]
48	methoxy	2-dimethylaminoethoxy	2,6-dichloro	[48]
49	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	2,6-difluoro	[49]
50	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	2,6-dichloro	[50]
51	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dichloro	[51]
52	methoxy	2-pyrrolidin-1-ylethoxy	2,6-difluoro	[52]
53	methoxy	2-morpholinoethoxy	2,6-dichloro	[53]
54	methoxy	2-morpholinoethoxy	2,6-difluoro	[54]
55	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dimethyl	[55]
56	methoxy	3-morpholinopropoxy	2,6-dimethyl	[56]
57	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,6-dimethyl	[57]
58	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dimethyl	[58]
59	methoxy	2-piperidinoethoxy	2,6-dimethyl	[59]
60	methoxy	2-morpholinoethoxy	2,6-dimethyl	[60]
61	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	2,6-dimethyl	[61]
62	methoxy	2-dimethylaminoethoxy	2,6-dimethyl	[62]
63	methoxy	3-pyrrolidin-1-ylpropoxy	4-bromo-2,6-dimethyl	[63]
64	methoxy	3-piperidinopropoxy	4-bromo-2,6-dimethyl	[64]
65	methoxy	3-morpholinopropoxy	4-bromo-2,6-dimethyl	[65]
66	methoxy	3-(4-methylpiperazin-1-yl)propoxy	4-bromo-2,6-dimethyl	[66]
67	methoxy	2-piperidinoethoxy	4-bromo-2,6-dimethyl	[67]

68	methoxy	2-morpholinoethoxy	4-bromo-2,6-dimethyl	[68]
69	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	4-bromo-2,6-dimethyl	[69]
70	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dichloro	[70]
71	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-difluoro	[71]
72	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl	[72]
73	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-fluoro- 6-trifluoromethyl	[73]
74	hydrogen	2-pyrrolidin-1-ylethoxy	2,6-dichloro	[74]
75	hydrogen	2-pyrrolidin-1-ylethoxy	2-chloro-6-methyl	[75]
76	hydrogen	2-pyrrolidin-1-ylethoxy	2-chloro	[76]
77	hydrogen	2-pyrrolidin-1-ylethoxy	2,4,6-trichloro	[77]
78	hydrogen	2-piperidinoethoxy	2,6-dichloro	[78]
79	hydrogen	2-piperidinoethoxy	2,6-difluoro	[79]
80	hydrogen	2-piperidinoethoxy	2-chloro-6-methyl	[80]
81	hydrogen	2-piperidinoethoxy	2-chloro	[81]
82	hydrogen	2-piperidinoethoxy	2,4,6-trichloro	[82]
83	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2,6-dichloro	[83]
84	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2-chloro-6-methyl	[84]
85	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2-chloro	[85]
86	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2,4,6-trichloro	[86]
87	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2,6-dichloro	[87]
88	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2,6-difluoro	[88]
89	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2-chloro-6-methyl	[89]
90	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2-chloro	[90]
91	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2,4,6-trichloro	[91]
92	hydrogen	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	[92]
93	hydrogen	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	[93]
94	hydrogen	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	[94]
95	hydrogen	3-pyrrolidin-1-ylpropoxy	2-chloro	[95]
96	hydrogen	3-pyrrolidin-1-ylpropoxy	2,4,6-trichloro	[96]
97	hydrogen	3-morpholinopropoxy	2,6-difluoro	[97]

98	hydrogen	3-morpholinopropoxy	2-chloro-6-methyl	[98]
99	hydrogen	3-morpholinopropoxy	2,4,6-trichloro	[99]
100	hydrogen	3-(4-methylpiperazin-1-yl)propoxy	2,6-dichloro	[100]
101	hydrogen	3-(4-methylpiperazin-1-yl)propoxy	2-chloro	[101]
102	hydrogen	3-(4-methylpiperazin-1-yl)propoxy	2,4,6-trichloro	[102]
103	hydrogen	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2,6-difluoro	[103]
104	hydrogen	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2-chloro-6-methyl	[104]
105	hydrogen	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2,4,6-trichloro	[105]
106	hydrogen	3-(1,2,3-triazol-1-yl)propoxy	2,4,6-trichloro	[106]
107	hydrogen	(E)-4-pyrrolidin-1-ylbut-2-enyloxy	2,6-difluoro	[107]
108	hydrogen	(E)-4-pyrrolidin-1-ylbut-2-enyloxy	2-chloro-6-methyl	[108]
109	hydrogen	(E)-4-pyrrolidin-1-ylbut-2-enyloxy	2-chloro	[109]
110	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2,6-dichloro	[110]
111	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2,6-difluoro	[111]
112	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2,6-dimethyl	[112]
113	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2-chloro-6-methyl	[113]
114	hydrogen	3-(pyrrolidin-1-yl)-1-propynyl	2,6-dichloro	[114]
115	methoxy	3-(pyrrolidin-1-yl)-1-propynyl	2,6-dichloro	[115]
116	methoxy	6-morpholino-1-hexynyl	2,6-dichloro	[116]
117	methoxy	6-morpholino-1-hexynyl	2,6-difluoro	[117]
118	methoxy	6-(2-methylimidazol-1-yl)-1-hexynyl	2,6-dichloro	[118]
119	methoxy	6-(2-methylimidazol-1-yl)-1-hexynyl	2,6-difluoro	[119]

120	methoxy	3-dimethylamino-1-propynyl	2,6-difluoro	[120]
121	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-nitro	[121]
122	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl-3-fluoro	[122]
123	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dichloro	[123]
124	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl-5-nitro	[124]
125	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro- 5-trifluoromethyl	[125]
126	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	5-chloro-2-methoxy	[126]
127	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methoxy-5-methyl	[127]
128	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	5-chloro-2-methyl	[128]
129	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl-5-fluoro	[129]
130	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-5-methyl	[130]
131	methoxy	3-pyrrolidin-1-ylpropoxy	2,5-difluoro	[131]
132	methoxy	3-pyrrolidin-1-ylpropoxy	2,5-dichloro	[132]
133	methoxy	3-pyrrolidin-1-ylpropoxy	5-chloro-2-methyl	[133]
134	methoxy	3-pyrrolidin-1-ylpropoxy	5-fluoro-2-methyl	[134]
135	methoxy	3-pyrrolidin-1-ylpropoxy	2-methyl-5-nitro	[135]
136	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-5-methyl	[136]
137	methoxy	6-( <u>N</u> -methylpiperazin-1-yl)- 1-hexynyl	2,6-dichloro	[137]
138	methoxy	benzyloxy	3-dimethylcarbamoyl- 2,6-dimethyl	[138]
139	methoxy	cyclopropylmethoxy	2,6-dimethyl	[139]
140	methoxy	6-( <u>N</u> -methylpiperazin- 1-yl)hexyl	2,6-dichloro	[140]
141	methoxy	3-(pyrrolidin-1-yl)propyl	2,6-dichloro	[141]
142	methoxy	<u>N</u> -[3-( <u>N</u> -methylpiperazin- 1-yl)propyl]carbamoyl	2,6-dichloro	[142]
143	methoxy	<u>N</u> -[3-(imidazol-1- yl)propyl]carbamoyl	2,6-dichloro	[143]
144	methoxy	<u>N</u> -methylpiperazin-1-yl	2,6-dichloro	[144]

145	methoxy	<u>N</u> -( <i>tert</i> -butoxycarbonyl)piperazin-1-yl	2,6-dichloro	[145]
146	methoxy	3-morpholinopropylamino	2,6-dichloro	[146]
147	methoxy	3-imidazol-1-ylpropylamino	2,6-dichloro	[147]
148	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	3-dimethylcarbamoyl- 2,6-dimethyl	[148]
149	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	[149]
150	methoxy	3-methoxypropylamino	2,6-dichloro	[150]
151	methoxy	2-aminoethylamino	2,6-dichloro	[151]
152	methoxy	<u>N</u> -(2-diethylaminoethyl)- <u>N</u> -methylamino	2,6-dichloro	[152]

### Notes

[1] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.36 (m, 2H), 1.74 (d, 3H), 1.86 (t, 2H), 2.14 (s, 3H), 2.87 (d, 2H), 3.96 (s, 3H), 4.03 (d, 2H), 7.11 (t, 1H), 7.29 (s, 3H), 7.38 (t, 1H), 7.56 (d, 1H), 8.08 (s, 1H), 8.41 (d, 1H), 8.73 (s, 1H), 10.59 (s, 1H), 13.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 456 and 458.

[2] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.87 (m, 2H), 2.11 (m, 3H), 2.78 (m, 2H), 2.78 (s, 3H), 3.68 (d, 2H), 4.07 (s, 3H), 4.1 (s, 2H), 7.12 (m, 2H), 7.43 (s, 1H), 7.78 (s, 1H), 8.28 (m, 1H), 8.75 (s, 1H), 13.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

[3] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.83 (m, 2H), 2.1 (m, 3H), 2.63 (m, 2H), 2.7 (s, 3H), 3.6 (d, 2H), 4.08 (s, 3H), 4.1 (d, 2H), 7.23 (m, 1H), 7.33 (s, 1H), 7.46 (s, 1H), 7.72 (s, 1H), 8.31 (d, 1H), 8.74 (s, 1H), 13.3 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

[4] Methylene chloride was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.34 (q, 2H), 1.74 (d, 3H), 1.86 (t, 2H), 2.15 (s, 3H), 2.78 (d, 2H), 3.96 (s, 3H), 4.02 (d, 2H), 7.08–7.16 (m, 1H), 7.19–7.36 (m, 3H), 8.06 (s, 1H), 8.27 (s, 1H), 8.69 (s, 1H), 10.56 (s, 1H), 12.81 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 440.

[5] DMF was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.35 (m, 2H), 1.8 (m, 5H), 2.15 (s, 3H), 2.79 (d, 2H), 2.94 (s, 3H), 4.03 (d, 2H), 7.1–7.35 (m, 5H), 8.03 (s, 1H), 8.66 (s, 1H), 10.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

- [6] DMF was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.3–1.5 (m, 2H), 1.7–1.8 (m, 4H), 1.85 (t, 1H), 2.2 (s, 3H), 2.8 (d, 2H), 3.9 (s, 3H), 4.1 (br d, 2H), 7.0 (t, 1H), 7.3 (br s, 1H), 7.4 (t, 1H), 7.7 (d, 1H), 8.1 (br s, 1H), 8.4 (d, 1H), 8.8 (s, 1H), 10.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 500 and 502.
- 5 [7] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (m, 2H), 1.97 (m, 5H), 2.3 (s, 3H), 2.88 (d, 2H), 3.61 (s, 3H), 4.01 (d, 2H), 7.24 (s, partially obscured by CHCl<sub>3</sub> peak), 7.25 (t, partially obscured by CHCl<sub>3</sub> peak), 7.37 (s, 1H), 7.56 (t, 1H), 7.7 (d, 1H), 8.17 (d, 1H), 8.7 (s, 1H), 9.36 (s, 1H), 13.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490.
- [8] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.38–1.55 (m, 2H),  
 10 1.84–2.04 (m, 5H), 2.3 (s, 3H), 2.47 (s, 3H), 2.91 (d, 2H), 3.66 (s, 3H), 4.01 (d, 2H), 7.05–7.14 (m, 1H), 7.17–7.28 (m, 4H), 7.4 (s, 1H), 7.96 (d, 1H), 8.7 (s, 1H), 9.24 (s, 1H), 12.34 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 436.
- [9] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> and CD<sub>3</sub>COOH) 1.5–1.67 (q, 2H), 1.93–2.17 (m, 3H), 2.24 (s, 6H), 2.71 (s, 3H), 2.93 (t, 2H), 3.37 (d, 2H), 3.95 (s,  
 15 3H), 4.09 (d, 2H), 7.1 (s, 3H), 7.31 (s, 1H), 8.07 (s, 1H), 8.66 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.
- [10] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.43 (m, 2H), 1.5 (s, 9H), 1.82 (m, 5H), 2.28 (s, 3H), 2.89 (d, 2H), 3.32 (s, 3H), 4.0 (d, 2H), 7.2 (m, 3H), 7.5 (m, 2H), 7.57 (s, 1H), 8.62 (s, 1H), 9.9 (s, 1H), 12.35 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 478.
- 20 [11] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.45 (m, 2H), 1.59 (m, 4H), 2.11 (m, 2H), 2.33 (s, 6H), 2.4 (br s, 4H), 2.5 (t, 2H), 3.23 (s, 3H), 4.22 (t, 2H), 7.14 (m, 3H), 7.28 (s, 1H), 7.62 (s, 1H), 8.66 (s, 1H), 10.16 (s, 1H), 12.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 513.

The 4-amino-6-methoxy-7-(3-piperidinopropoxy)quinazoline used as a starting  
 25 material was prepared as follows :-

Sodium hydride (60% suspension in mineral oil, 1.44 g) was added portionwise during  
 20 minutes to a solution of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one  
 (International Patent Application WO 97/22596, Example 1 thereof; 8.46 g) in DMF (70 ml).  
 The mixture was stirred at ambient temperature for 1.5 hours. Chloromethyl pivalate (5.65 g)  
 30 was added dropwise and the mixture was stirred at ambient temperature for 2 hours. The  
 mixture was diluted with ethyl acetate (100 ml) and poured onto a mixture (400 ml) of ice and  
 water containing 2N aqueous hydrochloric acid (4 ml). The organic layer was separated and  
 the aqueous layer was extracted with ethyl acetate. The combined extracts were washed with

brine, dried over magnesium sulphate and evaporated. The residue was triturated under a mixture of diethyl ether and petroleum ether (b.p. 60-80°C) and the resultant solid was collected and dried under vacuum. There was thus obtained 7-benzyloxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (10 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.11 (s, 9H), 3.89 (s, 3H), 5.3 (s, 2H), 5.9 (s, 2H), 7.27 (s, 1H), 7.35 (m, 1H), 7.47 (t, 2H), 7.49 (d, 2H), 7.51 (s, 1H), 8.34 (s, 1H).

A mixture of a portion (7 g) of the material so obtained, 10% palladium-on-charcoal catalyst (0.7 g), DMF (50 ml), methanol (50 ml), acetic acid (0.7 ml) and ethyl acetate (250 ml) was stirred under an atmosphere pressure of hydrogen for 40 minutes. The catalyst was removed by filtration and the solvent was evaporated. The residue was triturated under diethyl ether and the resultant solid was collected and dried under vacuum. There was thus obtained 7-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (4.36 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.1 (s, 9H), 3.89 (s, 3H), 5.89 (s, 2H), 7.0 (s, 1H), 7.48 (s, 1H), 8.5 (s, 1H).

Diethyl azodicarboxylate (3.9 ml) was added dropwise to a stirred mixture of 7-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (5 g), 3-bromopropanol (2.21 ml), triphenylphosphine (6.42 g) and methylene chloride (50 ml) and the mixture was stirred at ambient temperature for 2 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 7-(3-bromopropoxy)-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (6 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.12 (s, 9H), 2.32 (t, 2H), 3.7 (t, 2H), 3.9 (s, 3H), 4.25 (t, 2H), 5.9 (s, 2H), 7.20 (s, 1H), 7.61 (s, 1H), 8.36 (s, 1H).

A mixture of a portion (2.89 g) of the material so obtained and piperidine (10 ml) was stirred and heated to 100°C for 1 hour. The mixture was evaporated and the residue was partitioned between methylene chloride and a saturated aqueous ammonium chloride solution. The organic phase was washed with brine, dried over magnesium sulphate and evaporated. There was thus obtained 6-methoxy-7-(3-piperidinopropoxy)-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (2.4 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.15 (s, 9H), 1.35-1.5 (m, 1H), 1.6-1.8 (m, 3H), 1.8-1.9 (d, 2H), 2.2-2.3 (m, 2H), 2.95 (t, 2H), 3.25 (t, 2H), 3.55 (d, 2H), 3.95 (s, 3H), 4.25 (t, 2H), 5.94 (s, 2H), 7.24 (s, 1H), 7.56 (s, 1H), 8.36 (s, 1H).

A mixture of the material so obtained and a 7N solution of ammonia in methanol (50 ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated and the

residue was triturated under diethyl ether. The resultant solid was isolated, washed in turn with diethyl ether and a 1:1 mixture of diethyl ether and methylene chloride and dried under vacuum. There was thus obtained 6-methoxy-7-(3-piperidinopropoxy)-3,4-dihydroquinazolin-4-one (1.65 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.4 (m, 2H), 1.4-1.55 (m, 4H), 1.85-1.95 (m, 2H), 2.35 (br s, 4H), 2.4 (t, 2H), 3.9 (s, 3H), 4.15 (t, 2H), 7.11 (s, 1H), 7.44 (s, 1H), 7.9 (s, 1H).

A mixture of the material so obtained, thionyl chloride (15 ml) and DMF (1.5 ml) was heated to reflux for 3 hours. The mixture was evaporated. Toluene was added and the mixture was again evaporated. The residue was partitioned between methylene chloride and a saturated aqueous sodium bicarbonate solution (the basicity of which was adjusted to pH10 by adding 6N aqueous sodium hydroxide). The organic layer was separated, washed with brine, dried over magnesium sulphate and evaporated. There was thus obtained 4-chloro-6-methoxy-7-(3-piperidinopropoxy)quinazoline (1.2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.35-1.45 (m, 2H), 1.5-1.6 (m, 4H), 1.9-2.05 (m, 2H), 2.4 (br s, 4H), 2.45 (t, 2H), 4.0 (s, 3H), 4.29 (t, 2H), 7.41 (s, 1H), 7.46 (s, 1H), 8.9 (s, 1H).

A portion (0.5 g) of the material so obtained was dissolved in a 1M solution of ammonia in isopropanol (10 ml). Liquid ammonia (1 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl *tert*-butyl ether. There was thus obtained 4-amino-6-methoxy-7-(3-piperidinopropoxy)quinazoline (0.225 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.37 (d, 2H), 1.49 (t, 4H), 1.91 (m, 2H), 2.3 (s, 4H), 2.37 (t, 2H), 3.86 (s, 3H), 4.1 (t, 2H), 7.04 (s, 1H), 7.38 (s, 2H), 7.54 (s, 1H), 8.22 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 317.

[12] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.1 (m, 2H), 2.5 (br s, 4H), 2.7 (t, 2H), 3.75 (t, 4H), 4.25 (t, 2H), 7.15 (d, 1H), 7.3 (m, 2H), 7.5 (d, 2H), 8.1 (d, 1H), 8.85 (s, 1H), 9.05 (s, 1H), 12.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 and 478.

The 4-amino-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

A solution of 2-amino-4-fluorobenzoic acid (3 g) in formamide (30 ml) was heated to 150°C for 6 hours. The reaction mixture was poured onto a 1:1 mixture of ice and water

(250 ml) and the precipitated solid was collected, washed with water and dried to give 7-fluoro-3,4-dihydroquinazolin-4-one (2.6 g).

Sodium metal (4.4 g) was added to benzyl alcohol (100 ml) and the resultant mixture was stirred at ambient temperature for 30 minutes and then heated to 80°C for 1 hour.

- 5 The mixture was cooled to 40°C and 7-fluoro-3,4-dihydroquinazolin-4-one (7.8 g) was added. The reaction mixture was stirred and heated to 130°C for 4 hours. The mixture was allowed to cool to ambient temperature and was stirred for a further 18 hours. The solution was quenched with water (800 ml) and acidified to pH3 by the addition of concentrated hydrochloric acid. The resultant precipitate was collected, washed in turn with water and
- 10 diethyl ether and dried under vacuum for 4 hours at 60°C. There was thus obtained 7-benzyloxy-3,4-dihydroquinazolin-4-one (7.02 g).

- A mixture of the material so obtained, phosphorus pentasulphide (12.5 g) and pyridine (350 ml) was stirred and heated to reflux for 8 hours. After cooling, the mixture was poured into water (1 L). The precipitate was collected and washed with water. The solid so obtained
- 15 was dissolved in 6N aqueous sodium hydroxide solution and the solution was filtered. The filtrate was acidified to pH2 by the addition of 6N aqueous hydrochloric acid. The resultant precipitate was collected, washed with water and dried under vacuum at 60°C. There was thus obtained 7-benzyloxy-3,4-dihydroquinazolin-4-thione (7.42 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 5.32 (s, 2H), 7.25 (d, 1H), 7.32 (m, 1H), 7.4 (m, 1H), 7.45 (t, 2H), 7.55 (d, 2H),
- 20 8.15 (s, 1H), 8.5 (d, 1H).

- A portion (3.45 g) of the material so obtained was dissolved in THF (13 ml) and 1N aqueous sodium hydroxide solution (25.7 ml) was added. Methyl iodide (0.97 ml) was added dropwise and the mixture was stirred at ambient temperature for 30 minutes. The mixture was neutralised by the addition of 2N aqueous hydrochloric acid and the mixture was
- 25 diluted by the addition of water. The resultant solid was collected, washed with water and dried under vacuum to give 7-benzyloxy-4-methylthioquinazoline (3.3 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 2.67 (s, 3H), 5.32 (s, 2H), 7.3-7.45 (m, 5H), 7.5 (d, 2H), 8.05 (d, 1H), 8.9 (s, 1H).

- A mixture of a portion (3 g) of the material so obtained and trifluoroacetic acid (30 ml) was heated to reflux for 5 hours. The mixture was evaporated. The residue was suspended in
- 30 water and solid sodium bicarbonate was added until complete dissolution. The solution was extracted with diethyl ether. The aqueous layer was acidified to pH2 by the addition of 2N aqueous hydrochloric acid and the resultant precipitate was collected, washed in turn with water and diethyl ether and dried under vacuum. There was thus obtained 7-hydroxy-

4-methylthioquinazoline (2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.7 (s, 3H), 7.15 (d, 1H), 7.25 (m, 1H), 8.0 (d, 1H), 8.9 (s, 1H).

Diethyl azodicarboxylate (2.92 g) was added dropwise to a stirred mixture of 7-hydroxy-4-methylthioquinazoline (2.5 g), 4-(3-hydroxypropyl)morpholine (Bull. Soc. Chim. 5 Fr. 1962, 1117; 2.47 g), triphenylphosphine (4.45 g) and methylene chloride (65 ml). The reaction mixture was stirred at ambient temperature for 1 hour. The mixture was evaporated and the residue was partitioned between a 1:1 mixture of ethyl acetate and diethyl ether and a 1N aqueous hydrochloric acid solution. The aqueous layer was separated, basified to pH9 by the addition of solid sodium bicarbonate and extracted with methylene chloride. The organic 10 layer was separated, washed with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, ethyl acetate and methanol (from 6:3:1 to 5:3:2 to 75:0:25) as eluent. There was thus obtained 4-methylthio-7-(3-morpholinopropoxy)-quinazoline (2.03 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, and CF<sub>3</sub>COOD) 2.2-2.3 (m, 2H), 2.7 (s, 3H), 15 3.05-3.25 (m, 2H), 3.35 (t, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.05 (d, 2H), 4.32 (t, 2H), 7.38 (d, 1H), 7.4 (s, 1H), 8.1 (d, 1H), 9.05 (d, 1H); Mass Spectrum : M+H<sup>+</sup> 320.

A mixture of a portion (0.5 g) of the material so obtained and a solution of ammonia gas in methanol (7M; 50 ml) was sealed in a pressure vessel and heated to 120°C for 16 hours. The mixture was cooled to ambient temperature and evaporated. The residue was purified by 20 column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. The material so obtained was triturated under diethyl ether and the resultant solid was isolated, washed with diethyl ether and dried under vacuum. There was thus obtained 4-amino-7-(3-morpholinopropoxy)quinazoline (0.35 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.0-2.15 (m, 2H), 25 2.5 (br s, 4H), 2.6 (t, 2H), 3.75 (br s, 4H), 4.2 (t, 2H), 5.65 (br s, 2H), 7.1 (d, 1H), 7.2 (s, 1H), 7.65 (d, 1H), 8.55 (s, 1H); Mass Spectrum : M+H<sup>+</sup> 280.

[13] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.05 (m, 2H), 2.75 (t, 2H), 3.0-3.15 (m, 8H), 4.2 (t, 2H), 7.1 (d, 1H), 7.2-7.35 (m, 2H), 7.5 (d, 2H), 8.2 (d, 1H), 8.8 (s, 1H), 9.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 30 524 and 526; Elemental Analysis: Found C, 50.0; H, 4.4; N, 13.3; C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>Cl<sub>2</sub>S requires C, 50.39; H, 4.42; N, 13.35%.

The 4-amino-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazoline used as a starting material was prepared as follows :-

A mixture of 3-aminopropan-1-ol (0.650 ml) and divinyl sulphone (1 g) was heated to 110°C for 45 minutes. The mixture was allowed to cool to ambient temperature and was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propan-1-ol (0.8 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.7-1.8 (m, 2H), 2.73 (t, 2H), 3.06 (br s, 8H), 3.25 (s, 1H), 3.78 (t, 2H); Mass Spectrum: M+H<sup>+</sup> 194.

Diethyl azodicarboxylate (3.3 ml) was added dropwise to a stirred mixture of 7-hydroxy-4-methylthioquinazoline (1.34 g), 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propan-1-ol (2.03 g), triphenylphosphine (5.51 g) and methylene chloride (100 ml). The reaction mixture was stirred at ambient temperature for 4 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using initially ethyl acetate and then a 24:1 mixture of ethyl acetate and ethanol as eluent. There was thus obtained 7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]-4-methylthioquinazoline (1.79 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.05 (m, 2H), 2.7 (s, 3H), 2.73 (t, 2H), 3.05 (m, 8H), 4.2 (t, 2H), 7.15 (m, 1H), 7.2 (d, 1H), 8.0 (d, 1H), 8-9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 368.

Using an analogous procedure to that described in the last paragraph of Note [12] immediately above, a portion (0.5 g) of the material so obtained was reacted with ammonia gas in methanol. The reaction product was purified by column chromatography on silica using increasingly polar mixtures of chloroform and methanol as eluent. There was thus obtained 4-amino-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazoline (0.45 g); NMR Spectrum (CDCl<sub>3</sub>) 2.05 (m, 2H), 2.75 (t, 2H), 3.0-3.1 (m, 8H), 4.2 (t, 2H), 5.5 (br s, 2H), 7.15 (m, 1H), 7.2 (s, 1H), 7.65 (d, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 337.

[14] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 3.0-3.4 (m, 2H), 3.4 (br d, 2H), 3.6-3.7 (m, 2H), 3.95 (br d, 2H), 4.25 (s, 2H), 5.2 (s, 2H), 7.32 (t, 1H), 7.5 (d, 2H), 7.5-7.6 (m, 2H), 8.9 (d, 1H), 9.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 486 and 488; Elemental Analysis: Found C, 55.4; H, 4.3; N, 14.1; C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>Cl<sub>2</sub> 0.6 H<sub>2</sub>O requires C, 55.57; H, 4.50; N, 14.09 %.

The 4-amino-7-(4-morpholinobut-2-yn-1-yloxy)quinazoline used as a starting material was prepared as follows :-

Diethyl azodicarboxylate (2.46 ml) was added dropwise to a stirred mixture of 7-hydroxy-4-methylthioquinazoline (1.2 g), 4-morpholinobut-2-yn-1-ol (*J. Amer. Chem. Soc.*, 1957, 79, 6184; 1.26 g), triphenylphosphine (4.09 g) and methylene chloride (35 ml). The reaction mixture was stirred at ambient temperature for 3 hours. The mixture was evaporated

and the residue was purified by column chromatography on silica using initially methylene chloride and then a 19:1 mixture of methylene chloride and methanol as eluent. The material so obtained was triturated under diethyl ether. The resultant solid was collected and dried under vacuum. There was thus obtained 4-methylthio-7-(4-morpholinobut-2-yn-

5 1-yloxy)quinazoline (1.3 g); NMR Spectrum: ( $\text{CDCl}_3$ ) 2.5 (t, 4H), 2.7 (s, 3H), 3.32 (t, 2H), 3.7 (t, 4H), 4.9 (t, 2H), 7.2 (d, 1H), 7.35 (d, 1H), 8.0 (d, 1H), 8.9 (s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  330.

Using an analogous procedure to that described in the last paragraph of Note [12] above, a portion (0.5 g) of the material so obtained was reacted with a saturated solution of ammonia gas in methanol. The reaction product was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained 4-amino-7-(4-morpholinobut-2-yn-1-yloxy)quinazoline (0.283 g); NMR Spectrum: ( $\text{DMSO-d}_6$ ) 2.4 (m, 4H), 3.3 (t, 2H), 3.5 (m, 4H), 5.0 (s, 2H), 7.15 (m, 1H), 7.18 (d, 1H), 7.6 (br s, 2H), 8.15 (d, 1H), 8.32 (s, 1H); Mass Spectrum:  $\text{M}+\text{Na}^+$  321; Elemental Analysis: Found C, 63.8; H, 6.1; N, 18.7;  $\text{C}_{16}\text{H}_{18}\text{N}_4\text{O}_2 \cdot 0.2 \text{ H}_2\text{O}$  requires C, 63.65; H, 6.14; N, 18.55 %.

[15] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: ( $\text{DMSO-d}_6$  and  $\text{CF}_3\text{COOD}$ ) 3.0-3.1 (m, 2H), 3.4 (d, 2H), 3.65 (t, 2H), 3.85 (d, 2H), 4.0 (d, 2H), 4.95 (br s, 2H), 6.0 (m, 1H), 6.3 (m, 1H), 7.4 (t, 1H), 7.45 (s, 1H), 7.55 (m, 1H), 7.6 (d, 2H), 8.85 (d, 1H), 9.17 (s, 1H); Mass Spectrum:  $\text{M}+\text{Na}^+$  510 and 512; Elemental Analysis: Found C, 56.2; H, 4.7; N, 14.2;  $\text{C}_{23}\text{H}_{23}\text{N}_5\text{O}_3\text{Cl}_2$  requires C, 56.57; H, 4.75; N, 14.34 %.

The 4-amino-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline used as a starting material was prepared as follows :-

25 Using an analogous procedure to that described in the second last paragraph of Note [12] above, (*E*)-4-morpholinobut-2-en-1-ol (*J. Med. Chem.*, 1972, 15, 110-112; 1.27 g), was reacted with 7-hydroxy-4-methylthioquinazoline (1.2 g) to give 4-methylthio-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline (1.15 g); NMR Spectrum: ( $\text{CDCl}_3$ ) 2.45 (br s, 4H), 2.7 (s, 3H), 3.05 (d, 2H), 3.7 (t, 4H), 4.7 (d, 2H), 5.9 (m, 2H), 7.15-7.25 (m, 2H), 7.95 (d, 1H), 8.9 (d, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  332.

30 Using an analogous procedure to that described in the last paragraph of Note [12] above, 4-methylthio-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline (0.5 g) was reacted with a saturated solution of ammonia gas in methanol. The reaction product was purified by

column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained 4-amino-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline (0.372 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.35 (br s, 4H), 3.0 (br s, 2H), 3.56 (t, 4H), 4.7 (br s, 2H), 5.9 (br s, 2H), 7.05 (s, 2H), 7.1 (m, 1H), 7.6 (br s, 2H), 8.12 (d, 1H), 8.3 (s, 1H); Mass Spectrum : M+Na<sup>+</sup> 323; Elemental Analysis: Found C, 63.1; H, 6.7; N, 18.4; C<sub>16</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> 0.2 H<sub>2</sub>O requires C, 63.22; H, 6.76; N, 18.51 %.

[16] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.4 (m, 1H), 1.7 (m, 3H), 1.9 (m, 2H), 3.1 (t, 2H), 3.65 (m, 4H), 4.05 (s, 3H), 4.65 (t, 2H), 7.45 (t, 1H), 7.52 (s, 1H), 7.62 (d, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

The 4-amino-6-methoxy-7-(2-piperidinoethoxy)quinazoline used as a starting material was prepared as follows :-

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (25.1 g), thionyl chloride (450 ml) and DMF (1 ml) was stirred and heated to reflux for 2 hours. The mixture was evaporated and the residue was dissolved in toluene and the solution was evaporated. The resultant solid was suspended in methylene chloride (500 ml), solid potassium carbonate (39 g) was added and the mixture was stirred for 10 minutes. Water (500 ml) was added and the mixture stirred for another 10 minutes. The methylene chloride layer was separated, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. There was thus obtained 7-benzyloxy-4-chloro-6-methoxyquinazoline (21.54 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 4.0 (s, 3H), 5.36 (s, 2H), 7.31-7.46 (m, 4H), 7.51 (d, 2H), 7.58 (s, 1H), 8.88 (s, 1H).

A portion (3 g) of the material so obtained was dissolved in a 1M solution of ammonia in isopropanol (50 ml). Liquid ammonia (5 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl tert-butyl ether. There was thus obtained 4-amino-

7-benzyloxy-6-methoxyquinazoline (2.65 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.88 (s, 3H), 3.9 (s, 3H), 7.2 (s, 1H), 7.63 (s, 2H), 7.69 (s, 1H), 8.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 230.

A mixture of 4-amino-7-benzyloxy-6-methoxyquinazoline (4.15 g) and trifluoroacetic acid (35 ml) was stirred and heated to reflux for 1 hour. The solvent was evaporated, the residue was redissolved in a mixture of methylene chloride and toluene and the solvent was evaporated. The solid so obtained was suspended in water and basified to pH11 by the addition of 2N aqueous sodium hydroxide solution. The mixture was then neutralised to pH7 by the addition of 1N aqueous hydrochloric acid solution. The resultant solid was collected, washed in turn with water and acetonitrile and dried under vacuum over phosphorus pentoxide. There was thus obtained 4-amino-7-hydroxy-6-methoxyquinazoline (2.55 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.9 (s, 3H), 7.05 (s, 1H), 7.65 (s, 1H), 8.0 (br s, 2H), 8.35 (s, 1H), 10.0-11.0 (br s, 1H).

A portion (0.15 g) of the material so obtained and triphenylphosphine (0.31 g) were dissolved in DMF (3 ml). THF (3 ml) was added causing partial precipitation of the starting material. A solution of N-(2-hydroxyethyl)piperidine (0.111 g) in THF (1 ml) was added followed by diethyl azodicarboxylate (0.186 ml) and the reaction mixture was stirred at ambient temperature for 30 minutes. Further portions of triphenylphosphine (0.105 g), N-(2-hydroxyethyl)piperidine (0.02 g) and diethyl azodicarboxylate (0.062 ml) were added and reaction mixture was stirred at ambient temperature for a further 30 minutes. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained the required starting material (0.18 g); NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 1.4 (m, 1H), 1.7 (m, 3H), 1.8 (m, 2H), 3.15 (m, 2H), 3.65 (m, 4H), 3.95 (s, 3H), 4.55 (t, 2H), 7.3 (s, 1H), 7.9 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 303.

[17] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (m, 2H), 3.7 (t, 2H), 4.0 (s, 3H), 4.05 (m, 2H), 4.35 (t, 2H), 7.45 (t, 1H), 7.63 (d, 2H), 8.25 (s, 1H), 8.3 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 506 and 508.

The 4-amino-6-methoxy-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N-(3-hydroxypropyl)morpholine using an analogous procedure to that described in the last

paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.25 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (m, 2H), 3.7 (t, 2H), 3.95 (s, 3H), 4.05 (m, 2H), 4.3 (t, 2H), 7.35 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 319.

- 5 [18] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 2.95 (s, 3H), 3.2-3.8 (br s, 8H), 3.45 (m, 2H), 4.05 (s, 3H), 4.35 (t, 2H), 7.45 (t, 1H), 7.47 (s, 1H), 7.62 (d, 2H), 8.3 (s, 1H),  
10 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 519 and 521.

The 4-amino-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and 1-(3-hydroxypropyl)-4-methylpiperazine using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting  
15 material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 2.95 (s, 3H), 3.2-3.8 (br s, 8H), 3.4 (m, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 332.

- [19] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected,  
20 washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.9 (m, 2H), 2.05 (m, 2H), 2.25 (m, 2H), 3.1 (m, 2H), 3.35 (m, 2H), 3.65 (m, 2H), 4.05 (s, 3H), 4.35 (t, 2H), 7.45 (t, 1H), 7.47 (s, 1H), 7.63 (d, 2H), 8.3 (s, 1H), 9.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

The 4-amino-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline used as a starting  
25 material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N-(3-hydroxypropyl)pyrrolidine using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.9 (m, 2H), 2.05 (m, 2H), 2.25 (m, 2H), 3.05 (m, 2H), 3.35 (m, 2H), 3.65 (m, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H),  
30 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 303.

[20] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following

data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.5 (t, 2H), 3.65 (m, 4H), 3.85 (m, 4H), 4.05 (s, 3H), 4.35 (t, 2H), 7.43 (t, 1H), 7.46 (s, 1H), 7.65 (d, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 554 and 556.

The 4-amino-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]-

- 5 6-methoxyquinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N-(3-hydroxypropyl)-1,1-dioxotetrahydro-4H-1,4-thiazine using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.5 (m, 2H), 3.65 (m, 4H), 3.85 (m, 4H), 3.95 (s, 3H),  
10 4.25 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 367.

- [21] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following  
15 data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.95 (s, 3H), 3.35 (s, 3H), 3.4 (m, 1H), 3.55 (m, 1H), 3.75 (m, 4H), 4.05 (s, 3H), 4.65 (t, 2H), 7.45 (t, 1H), 7.50 (s, 1H), 7.65 (d, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 494 and 496.

- The 4-amino-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]-quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-  
20 6-methoxyquinazoline and 2-[N-(2-methoxyethyl)-N-methylamino]ethanol using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.95 (s, 3H), 3.35 (s, 3H), 3.4 (m, 1H), 3.55 (m, 1H), 3.75 (br m, 4H), 3.95 (s, 3H), 4.55 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 307.

- 25 The 2-[N-(2-methoxyethyl)-N-methylamino]ethanol used as a starting material was prepared as follows :-

- A mixture of 2-methylaminoethanol (5.4 g), 2-bromoethyl methyl ether (10 g), triethylamine (10 ml) and acetonitrile (70 ml) was stirred and heated to reflux for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and  
30 the residue was triturated under diethyl ether. The organic solution was separated and evaporated to give 2-[N-(2-methoxyethyl)-N-methylamino]ethanol (3 g, 31%); NMR Spectrum: (CDCl<sub>3</sub>) 2.35 (s, 3H), 2.6 (t, 2H), 2.65 (t, 2H), 3.35 (s, 3H), 3.5 (t, 2H), 3.6 (t, 2H).

[22] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.05 (s, 3H), 3.35 (t, 2H), 4.05 (s, 3H), 4.4 (t, 2H), 7.45 (m, 2H), 7.65 (d, 2H), 8.29 (s, 1H), 9.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 499 and 501.

The 4-amino-6-methoxy-7-(3-mesyloxy)quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and 3-mesyloxypropanol using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.05 (s, 3H), 3.3 (t, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 7.2 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 312.

The 3-mesyloxypropanol used as a starting material was prepared as follows :-

3-Chloroperoxybenzoic acid (25 g) was added in portions to a solution of 3-methylthiopropyl (5 ml) in methylene chloride (100 ml) while maintaining the reaction temperature at 25°C. The mixture was stirred at ambient temperature for 1 hour. The mixture was filtered and the filtrate was diluted with an aqueous solution of sodium sulphite (6.5 g) in water (200 ml). The organic layer was separated and evaporated. The white residue was triturated under acetone and the resultant solution was evaporated to give a solid which was dissolved in methylene chloride. Aluminum oxide (90Å mesh) was added and the mixture was allowed to stand for 15 minutes. The mixture was filtered and the filtrate was evaporated to give 3-mesyloxypropanol as a colourless oil (4.46 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.9-2.1 (br s, 1H), 2.15 (m, 2H), 2.95 (s, 3H), 3.2 (t, 2H), 3.85 (t, 2H).

[23] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 2.45 (m, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 4.6 (t, 2H), 7.38 (s, 1H), 7.43 (t, 1H), 7.63 (d, 2H), 7.77 (s, 1H), 8.22 (s, 1H), 8.26 (s, 1H), 9.03 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 488 and 490.

The 4-amino-6-methoxy-7-[3-(1,2,3-triazol-1-yl)propoxy]quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N<sup>1</sup>-(3-hydroxypropyl)-1,2,3-triazole (see Note [106] hereinafter) using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained

the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.4 (m, 2H), 3.95 (s, 3H), 4.15 (t, 2H), 4.6 (t, 2H), 7.15 (s, 1H), 7.75 (s, 1H), 7.85 (s, 1H), 8.2 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 301.

[24] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 5 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 3.55 (t, 2H), 4.0 (s, 3H), 4.65 (t, 2H), 7.45 (t, 1H), 7.5 (s, 1H), 7.65 (d, 2H), 8.15 (d, 2H), 8.3 (s, 1H), 8.95 (d, 2H), 9.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 484 and 486.

10 The 4-amino-6-methoxy-7-[2-(4-pyridyl)ethoxy]quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and 4-(2-hydroxyethyl)pyridine (Zhur. Obshchei. Khim., 1958, 28, 103-110) using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 3.5 (t, 2H), 3.9 (s, 15 3H), 4.6 (t, 2H), 7.3 (s, 1H), 7.85 (s, 1H), 8.15 (d, 2H), 8.75 (s, 1H), 8.95 (d, 2H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 297.

[25] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub> + CD<sub>3</sub>CO<sub>2</sub>D) 1.78–1.9 (m, 2H), 2.05–2.3 (m, 3H), 2.64 (t, 2H), 2.7 (s, 3H), 3.59 (d, 2H), 4.04 (s, 3H), 4.1 (d, 2H), 7.25 (s, 1H), 7.44 (s, 2H), 7.74 (s, 1H), 8.2–8.6 (m, partially obscured by CD<sub>3</sub>CO<sub>2</sub>H), 8.71 (s, 20 1H), 12.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 524 and 526.

[26] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.41–1.56 (m, 2H), 1.85–2.05 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.96 (s, 3H), 4.03 (d, 2H), 6.74 (m, 1H), 7.1 (m, 1H), 7.18 (s, 1H), 7.28 (s, 1H), 8.11 (m, 1H), 8.46 (s, 1H), 8.88 (s, 1H), 12.86 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

25 [27] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42–1.58 (m, 2H), 1.87–2.08 (m, 5H), 2.31 (s, 3H), 2.93 (d, 2H), 3.84 (s, 3H), 4.02 (d, 2H), 6.9 (m, 2H), 7.28 (m, 2H), 8.16 (m, 1H), 8.76 (s, 1H), 8.86 (s, 1H), 12.65 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

[28] Methylene chloride was used as the reaction solvent. The product was obtained as a 1:1 adduct with DMF and gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.55 (m, 30 2H), 1.9–2.1 (m, 5H), 2.3 (s, 3H), 2.88 (s, 3H), 2.93 (s, 3H), 2.9 (m, partially obscured by DMF signal), 3.72 (s, 3H), 3.85 (s, 3H), 3.91 (s, 3H), 4.01 (d, 2H), 6.6 (m, 1H) 6.86 (d, 1H), 7.28 (s, 1H), 7.36 (s, 1H), 7.98 (d, 1H), 8.02 (s, 1H), 8.55 (s, 1H), 8.87 (s, 1H), 12.75 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 482 (relating to the parent ion).

- [29] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.55 (m, 2H), 1.85–2.1 (m, 5H), 2.29 (s, 3H), 2.9 (d, 2H), 3.8 (s, 3H), 3.82 (s, 3H), 3.96 (s, 3H), 4.03 (d, 2H), 6.48 (m, 1H), 6.56 (d, 1H), 7.25 (s, 1H), 7.38 (s, 1H), 8.08 (d, 1H), 8.72 (s, 1H), 9.07 (s, 1H), 12.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 482.
- 5 [30] Methylene chloride was used as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.17 (br s, 12H), 1.4–1.6 (m, 2H), 1.7 (br s, 2H), 1.85–2.1 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.3 (s, 3H), 4.01 (d, 2H), 7.2–7.22 (m, 3H) 7.3–7.4 (m, 1H), 7.5 (s, 1H), 8.62 (s, 1H), 9.7 (s, 1H), 11.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 506.
- [31] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.55 (m, 2H),  
10 1.85–2.1 (m, 5H), 2.28 (s, 6H), 2.3 (s, 3H), 2.34 (s, 3H), 2.9 (d, 2H), 3.37 (s, 3H), 4.01 (d, 2H), 6.91 (s, 2H), 7.22 (s, 1H), 7.3 (s, 1H), 8.64 (s, 1H), 8.7 (s, 1H), 11.8 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 464.
- [32] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.44–1.59 (m, 2H), 1.86–2.08 (m, 5H), 2.32 (d, 6H), 2.41 (s, 3H), 2.94 (d, 2H), 3.68 (s, 3H), 4.02 (d, 2H), 6.92 (d,  
15 1H), 7.14 (d, 1H), 7.26 (m, 1H), 7.46 (s, 1H), 7.77 (s, 1H), 8.69 (s, 1H), 9.31 (s, 1H), 12.27 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.
- [33] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.18 (t, 6H), 1.4–1.55 (m, 2H), 1.85–2.06 (m, 5H), 2.3 (s, 3H), 2.69 (q, 4H) 2.9 (d, 2H), 3.3 (s, 3H), 4.03 (d, 2H), 7.1–7.3 (m, 4H), 7.51 (s, 1H), 8.63 (s, 1H), 9.73 (s, 1H), 11.87 (s, 1H); Mass Spectrum: M+H<sup>+</sup>  
20 478.
- [34] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.2 (t, 3H), 1.4–1.6 (m, 2H), 1.85–2.06 (m, 5H), 2.3 (s, 6H), 2.7 (q, 2H), 2.92 (d, 2H), 3.32 (s, 3H), 4.02 (d, 2H), 7.1–7.3 (m, 4H), 7.51 (s, 1H), 8.65 (s, 1H), 9.77 (s, 1H), 11.97 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 464.
- [35] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.51 (m, 2H), 1.9–2.1 (m, 5H), 2.3 (s, 9H), 2.95 (d, 2H), 3.52 (s, 3H), 4.02 (d, 2H), 7.23 (s, 1H), 7.25 (s, 2H), 7.37 (s, 1H), 8.67 (s, 1H), 9.32 (s, 1H), 11.82 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 528 and 530.  
25
- [36] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.56 (m, 2H), 1.84–2.05 (m, 5H), 2.3 (s, 3H), 2.38 (s, 3H), 2.9 (d, 2H), 3.44 (s, 3H), 4.03 (d, 2H), 7.19 (d, 2H), 7.22 (s, 1H), 7.33 (t, 1H), 7.47 (s, 1H), 8.70 (s, 1H), 9.67 (s, 1H), 12.21 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 470.  
30
- [37] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.81 (s, 4H), 2.17 (m, 2H), 2.57 (s, 4H), 2.7 (t, 2H), 3.77 (s, 3H), 4.26 (t, 2H), 7.23–7.45 (m, 2H), 7.38–7.45 (m, 2H), 8.7 (s, 1H), 8.96 (s, 1H), 12.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 524 and 526.

The 4-amino-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 3-pyrrolidin-1-ylpropyl chloride (Chemical Abstracts, volume 128, no. 227441; PCT Patent Application WO 98/13354) using an analogous procedure to that described in the second last paragraph of Note [38] below to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.18 (m, 2H), 2.57 (s, 4H), 2.69 (t, 2H), 4.05 (s, 3H), 4.3 (t, 2H), 7.16 (m, 1H), 7.28–7.36 (m, 2H), 7.44 (m, 1H), 7.57 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 & 478.

10 The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] below to give the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.14 (m, 2H), 2.54 (t, 4H), 2.67 (t, 2H), 3.96 (s, 3H), 4.23 (t, 2H), 5.54 (s, 2H), 6.91 (s, 1H), 7.23 (s, 1H), 8.52 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 303. [38] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.68 (s, 4H), 2.11 (m, 15 2H), 2.3 (s, 3H), 2.4–2.6 (m, 6H), 3.72 (s, 3H), 4.24 (t, 2H), 7.31 (s, 2H), 7.43 (s, 2H), 8.71 (s, 1H), 9.07 (s, 1H), 12.27 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 553, 555 and 557.

The 4-amino-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline used as a starting material was prepared as follows :-

A mixture of 7-acetoxy-6-methoxyquinazolin-4-one (International Patent Application WO 96/15118, Example 17 thereof; 15 g), thionyl chloride (225 ml) and DMF (5 ml) was 20 stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and the thionyl chloride was evaporated. The material so obtained was dissolved in toluene and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. There was thus obtained 25 7-acetoxy-4-chloro-6-methoxyquinazoline (13.2 g) which was used without further purification.

A mixture of the material so obtained was reacted with 2-bromo-4-fluorophenol using an analogous procedure to that described in the second last paragraph of the portion of Example 1 above which is concerned with the preparation of starting materials. There was 30 thus obtained 7-acetoxy-4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazoline (14.7 g).

A mixture of a portion (3 g) of the material so obtained, concentrated ammonium hydroxide solution (0.88 g/ml, approximately 14M; 60 ml) and methanol (120 ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was

trituated under diethyl ether. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (2.2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.99 (s, 3H), 7.25 (s, 1H), 7.39 (m, 1H), 7.54 (m, 2H), 7.78 (m, 1H), 8.47 (s, 1H), 10.82 (s, 1H); Mass Spectrum: M-H 363 & 365.

- 5 A mixture of 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (0.94 g), 3-(4-methylpiperazin-1-yl)propyl chloride (0.5 g), potassium carbonate (1.42 g) and DMF (20 ml) was stirred and heated to 65°C for 16 hours. The mixture was filtered and evaporated. The resulting oil was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M methanolic ammonia solution as eluent. There was
- 10 thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline (0.84 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.72 (s, 4H), 2.13 (m, 2H), 2.31 (s, 3H), 2.4-2.6 (m, 6H), 4.05 (s, 3H), 4.29 (t, 2H), 7.16 (m, 1H), 7.3 (s, 1H), 7.35 (s, 1H), 7.44 (m, 1H), 7.57 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 505 & 507.

- A mixture of the material so obtained, liquid ammonia (1 ml) and a 2M solution of
- 15 ammonia in isopropanol (15 ml) was sealed in a Carius tube and heated to 120°C for 16 hours. The mixture was cooled and evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution (200 ml) for 1 hour. The resultant solid was isolated and washed in turn with water (400 ml) and with methyl *tert*-butyl ether. There was thus obtained the required starting material (0.55 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.81 (s, 4H), 2.1 (m, 2H), 2.29 (s, 3H),
- 20 2.4-2.6 (m, 6H), 3.96 (s, 3H), 4.22 (t, 2H), 5.46 (s, 2H), 6.9 (s, 1H), 7.22 (s, 1H), 8.51 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 332.

- The 3-(4-methylpiperazin-1-yl)propyl chloride used as an intermediate was prepared by the reaction of 1-methylpiperazine with 1-bromo-3-chloropropane using an analogous procedure to that described in Note [42] hereinafter for the preparation of 3-morpholinopropyl
- 25 chloride.

- [39] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42 (q, 2H), 1.58 (m, 4H), 2.09 (m, 2H), 2.38 (s, 4H), 2.49 (t, 2H), 3.63 (s, 3H), 4.23 (t, 2H), 7.18-7.27 (m, 2H), 7.37 (m, 2H), 7.41 (s, 1H), 8.71 (s, 1H), 9.3 (s, 1H), 12.34 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 504 and 506.
- 30 [40] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.84 (m, 4H), 2.17 (m, 2H), 2.56 (s, 4H), 2.68 (t, 2H), 3.69 (s, 3H), 4.28 (t, 2H), 6.99 (t, 2H), 7.2-7.3 (m, 2H), 7.38 (s, 1H), 8.71 (s, 1H), 9.3 (s, 1H), 12.04 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

[41] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.43 (m, 2H), 1.57–1.76 (m, 4H), 2.12 (m, 2H), 2.47 (s, 4H), 2.54 (t, 2H), 3.7 (s, 3H), 4.23 (t, 2H), 6.94–7.03 (m, 2H), 7.2–7.31 (m, 2H), 7.37 (s, 1H), 8.71 (s, 1H), 9.26 (s, 1H), 12.03 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 472.

- 5 [42] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.11 (m, 2H), 2.49 (br s, 4H), 2.57 (t, 2H), 3.73 (m, 7H), 4.26 (t, 2H), 7.0 (t, 2H), 7.27 (m, 1H), 7.3 (s, 1H), 7.38 (s, 1H), 8.73 (s, 1H), 9.24 (s, 1H), 12.04 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 474.

The 4-amino-6-methoxy-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

- 10 4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 3-morpholinopropyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 2.13 (m, 2H), 2.49 (t, 4H), 2.58 (t, 2H), 3.74 (t, 4H), 4.06 (s, 3H), 4.29 (t, 2H), 7.15 (m, 1H), 7.31 (m, 1H), 7.37 (s, 1H),  
15 7.43 (m, 1H), 8.58 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 492 & 494.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 2.09 (m, 2H), 2.48 (t, 4H), 2.55 (t, 2H), 3.61 (t, 4H), 3.96 (s, 3H), 4.24 (t, 2H), 5.44 (s, 2H), 6.9 (s, 1H), 7.24 (s, 1H), 8.52 (s, 1H).

- 20 The 3-morpholinopropyl chloride used as an intermediate was prepared as follows :-  
Morpholine (52.2 ml) and 1-bromo-3-chloropropane (30 ml) were taken up in dry toluene (180 ml) and stirred and heated to 70°C for 3 hours. The resultant precipitate was filtered off and the filtrate was evaporated to give an orange oil which was purified by vacuum distillation collecting fractions at 62°C/5mmHg and 58°C/2mmHg. The required compound  
25 was obtained as an oil (37.9 g); NMR Spectrum: 1.85 (m, 2H), 2.3 (t, 4H), 2.38 (t, 2H), 3.53 (t, 4H), 3.65 (t, 2H); M/s: M+H<sup>+</sup> 164.

[43] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.71 (s, 4H), 2.12 (m, 2H), 2.31 (s, 3H), 2.42–2.62 (m, 6H), 3.7 (s, 3H), 4.27 (t, 2H), 7.0 (m, 2H), 7.21–7.32 (m, 2H), 7.38 (s, 1H), 8.73 (s, 1H), 9.62 (s, 1H), 12.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 487.

- 30 [44] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.46 (m, 2H), 1.64 (m, 4H), 2.55 (t, 4H), 2.9 (t, 2H), 3.68 (s, 3H), 4.3 (t, 2H), 6.95–7.04 (m, 3H), 7.28 (m, 1H), 7.4 (s, 1H), 8.73 (s, 1H), 9.38 (s, 1H), 12.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

[45] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.49 (m, 2H), 1.63 (m, 4H), 2.56 (t, 4H), 2.8 (t, 2H), 3.7 (s, 3H), 4.32 (t, 2H), 7.3 (s, 1H), 7.34 (s, 1H), 7.43 (s, 2H), 8.72 (s, 1H), 9.22 (s, 1H), 12.32 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 524 and 526.

[46] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.15 (m, 2H), 2.53 (s, 4H), 2.66 (t, 2H), 3.58 (s, 3H), 4.25 (t, 2H), 7.29 (s, 1H), 7.32–7.45 (m, 3H), 7.54 (d, 1H), 8.68 (s, 1H), 9.38 (s, 1H), 12.55 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 507.

[47] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.38 (s, 6H), 2.88 (t, 2H), 3.57 (s, 3H), 4.27 (t, 2H), 6.98 (t, 3H), 7.27 (s, 1H), 7.51 (s, 1H), 8.71 (s, 1H), 9.81 (s, 1H), 12.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 418.

10 The 4-amino-6-methoxy-7-(2-dimethylaminoethoxy)quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-dimethylaminoethyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-  
15 7-(2-dimethylaminoethoxy)-6-methoxyquinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 2.39 (s, 6H), 2.9 (t, 2H), 4.04 (s, 3H), 4.31 (t, 2H), 7.22 (t, 1H), 7.32 (s, 1H), 7.41 (m, 2H), 7.52 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 436 & 438.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material;  
20 NMR Spectrum: (DMSO-d<sub>6</sub>) 2.21 (s, 6H), 2.68 (t, 2H), 3.87 (s, 3H), 4.14 (t, 2H), 7.07 (s, 1H), 7.37 (s, 2H), 7.55 (s, 1H), 8.22 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 263.

[48] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.38 (s, 6H), 2.87 (t, 2H), 3.49 (s, 3H), 4.26 (t, 2H), 7.24 (s, 2H), 7.4 (d, 2H), 7.53 (s, 1H), 8.72 (s, 1H), 9.8 (s, 1H), 12.47 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450 and 452.

25 [49] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.47 (t, 2H), 3.74 (m, 4H), 3.89 (s, 3H), 4.33 (t, 2H), 4.42 (s, 1H), 7.01 (t, 3H), 7.28 (m, 2H), 8.0 (s, 1H), 8.73 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 459.

The 4-amino-6-methoxy-7-[2-(2-oxoimidazolidin-1-yl)ethoxy]quinazoline used as a starting material was prepared as follows :-

30 4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-(2-oxoimidazolidin-1-yl)ethyl chloride (*Indian J. Chem. Sect. B*, 1982, 21B, 928-940) using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[2-(2-oxoimidazolidin-

1-yl)ethoxy]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 3.47 (t, 2H), 3.75 (m, 4H), 4.05 (s, 3H), 4.35 (t, 2H), 4.47 (s, 1H), 7.21 (t, 1H), 7.30 (s, 1H), 7.41 (t, 2H), 7.54 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 477 & 479.

The material so obtained was reacted with ammonia using an analogous procedure to  
5 that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (DMSO-d<sub>6</sub>) 3.23 (t, 2H), 3.48 (m, 4H), 3.87 (s, 3H), 4.2 (t, 2H), 6.4 (s, 1H), 7.1 (s, 1H), 7.4 (s, 2H), 7.58 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 304.

[50] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.48 (t, 2H), 3.73 (m, 7H), 4.32 (t, 2H), 4.48 (s, 1H), 7.13 (m, 2H), 7.44 (t, 3H), 8.74 (s, 1H), 9.1 (s, 1H), 12.27 (s,  
10 1H); Mass Spectrum: M+H<sup>+</sup> 491 and 493.

[51] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.87 (m, 4H), 2.71 (s, 4H), 3.06 (t, 2H), 3.58 (s, 3H), 4.33 (t, 2H), 7.1–7.27 (m, 2H), 7.36–7.46 (m, 3H), 8.73 (s, 1H), 9.5 (s, 1H), 12.37 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 and 478.

The 4-amino-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline used as a starting  
15 material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-pyrrolidin-1-ylethyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.83 (m, 4H), 2.69 (m, 4H),  
20 3.06 (t, 2H), 4.04 (s, 3H), 4.34 (t, 2H), 7.21 (t, 1H), 7.31 (s, 1H), 7.4 (t, 2H), 7.53 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 462 & 464.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 1.7 (s, 4H), 2.5 (m, 4H), 2.83 (t, 2H), 3.87 (s, 3H), 4.19 (t, 2H), 7.07  
25 (s, 1H), 7.39 (s, 2H), 7.56 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 289.

[52] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.87 (s, 4H), 2.73 (s, 4H), 3.07 (t, 2H), 3.65 (s, 3H), 4.34 (t, 2H), 6.99 (t, 3H), 7.28 (m, 1H), 7.43 (s, 1H), 8.75 (s, 1H), 9.47 (s, 1H), 12.11 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 444.

[53] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.6 (t, 4H), 2.92 (t, 2H), 3.58 (s, 3H), 3.74 (t, 4H), 4.28 (t, 2H), 7.11–7.27 (m, 2H), 7.37–7.45 (m, 3H), 8.73 (s, 1H), 9.47 (s, 1H), 12.36 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 492 and 494.  
30

The 4-amino-6-methoxy-7-(2-morpholinoethoxy)quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-morpholinoethyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 2.63 (t, 4H), 2.98 (t, 2H), 3.76 (t, 4H), 4.06 (s, 3H), 4.34 (t, 2H), 7.22 (t, 1H), 7.32 (s, 1H), 7.41 (t, 2H), 7.52 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 478 & 480.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (DMSO-d<sub>6</sub>) 2.5 (m, 4H), 2.75 (t, 2H), 3.58 (t, 4H), 3.87 (s, 3H), 4.2 (t, 2H), 7.09 (s, 1H), 7.39 (s, 2H), 7.58 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 305.

[54] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.63 (t, 4H), 3.04 (t, 2H), 3.61 (s, 3H), 3.76 (t, 4H), 4.33 (t, 2H), 6.99 (t, 2H), 7.27 (m, 2H), 7.45 (s, 1H), 8.74 (s, 1H), 9.57 (s, 1H), 12.15 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 460.

[55] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.15 (m, 2H), 2.33 (s, 6H), 2.57 (br s, 4H), 2.69 (t, 2H), 3.41 (s, 3H), 4.26 (t, 2H), 7.14 (m, 3H), 7.28 (s, 1H), 7.5 (s, 1H), 8.66 (s, 1H), 9.66 (s, 1H), 11.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

[56] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.09 (m, 2H), 2.32 (s, 6H), 2.46 (t, 4H), 2.55 (t, 2H), 3.4 (s, 3H), 3.71 (t, 2H), 4.25 (t, 2H), 7.11 (m, 3H), 7.28 (s, 1H), 7.49 (s, 1H), 8.66 (s, 1H), 9.61 (s, 1H), 11.91 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 466.

[57] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.72 (s, 4H), 2.1 (m, 2H), 2.3 (s, 3H), 2.33 (s, 6H), 2.4–2.6 (m, 6H), 3.4 (s, 3H), 4.23 (t, 2H), 7.16 (m, 3H), 7.28 (s, 1H), 7.49 (s, 1H), 8.66 (s, 1H), 9.64 (s, 1H), 11.91 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 479.

[58] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.85 (m, 4H), 2.34 (s, 6H), 2.68 (s, 4H), 3.05 (t, 2H), 3.31 (s, 3H), 4.3 (t, 2H), 7.14 (m, 3H), 7.26 (s, 1H), 7.56 (s, 1H), 8.65 (s, 1H), 9.87 (s, 1H), 11.98 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 436.

[59] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (s, 2H), 1.64 (m, 4H), 2.32 (s, 6H), 2.55 (s, 4H), 2.91 (t, 2H), 3.36 (s, 3H), 4.32 (t, 2H), 7.14 (m, 3H), 7.26 (s, 1H), 7.54 (s, 1H), 8.66 (s, 1H), 9.79 (s, 1H), 11.98 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

[60] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.31 (s, 6H), 2.61 (m, 4H), 2.94 (t, 2H), 3.27 (s, 3H), 3.76 (t, 4H), 4.31 (t, 2H), 7.15 (m, 3H), 7.26 (s, 1H), 7.59 (s, 1H), 8.67 (s, 1H), 9.97 (s, 1H), 12.01 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 452.

- [61] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.33 (s, 6H), 3.35 (s, 3H), 3.46 (t, 2H), 3.72 (m, 4H), 4.28 (t, 2H), 4.67 (s, 1H), 7.14 (m, 3H), 7.25 (s, 1H), 7.61 (s, 1H), 8.67 (s, 1H), 9.91 (s, 1H), 11.98 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 451.
- [62] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.33 (s, 6H), 2.39 (s, 6H), 2.87 (t, 2H), 3.28 (s, 3H), 4.26 (t, 2H), 7.12 (m, 3H), 7.26 (s, 1H), 7.58 (s, 1H), 8.66 (s, 1H), 9.97 (s, 1H), 12.02 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 410.
- [63] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.81 (m, 4H), 2.16 (m, 2H), 2.31 (s, 6H), 2.59 (s, 4H), 2.7 (t, 2H), 3.52 (s, 3H), 4.26 (t, 2H), 7.27 (m, 3H), 7.39 (s, 1H), 8.67 (s, 1H), 9.34 (s, 1H), 11.83 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 528 and 530.
- 10 [64] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.45 (q, 2H), 1.6 (m, 4H), 2.13 (m, 2H), 2.3 (s, 6H), 2.44 (s, 4H), 2.54 (t, 2H), 3.53 (s, 3H), 4.25 (t, 2H), 7.29 (m, 3H), 7.37 (s, 1H), 8.68 (s, 1H), 9.27 (s, 1H), 11.81 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 542 and 544.
- [65] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.12 (m, 2H), 2.3 (s, 6H), 2.5 (t, 4H), 2.58 (t, 2H), 3.5 (s, 3H), 3.5 (t, 4H), 4.27 (t, 2H), 7.22–7.29 (m, 3H), 7.41 (s, 1H), 8.67 (s, 1H), 9.44 (s, 1H), 11.87 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 544 and 546.
- [66] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.66 (s, 10H), 2.11 (m, 2H), 2.3 (s, 3H), 2.4–2.6 (m, 6H), 3.58 (s, 3H), 4.24 (t, 2H), 7.25 (s, 3H), 7.34 (s, 1H), 8.67 (s, 1H), 9.2 (s, 1H), 11.79 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 557 and 559.
- 20 [67] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.49 (m, 2H), 1.66 (m, 4H), 2.31 (s, 6H), 2.54 (t, 4H), 2.9 (t, 2H), 3.5 (s, 3H), 4.32 (t, 2H), 7.28 (m, 3H), 7.41 (s, 1H), 8.69 (s, 1H), 9.44 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 528 and 530.
- [68] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.3 (s, 6H), 2.64 (t, 4H), 2.95 (t, 2H), 3.41 (s, 3H), 3.77 (t, 4H), 4.33 (t, 2H), 7.27 (s, 3H), 7.48 (s, 1H), 8.69 (s, 1H), 9.71 (s, 1H), 11.97 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 530 and 532.
- 25 [69] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.29 (s, 6H), 3.47 (t, 2H), 3.62 (s, 3H), 3.75 (m, 4H), 4.33 (t, 2H), 4.44 (s, 1H), 7.28 (m, 3H), 7.39 (s, 1H), 8.68 (s, 1H), 9.18 (s, 1H), 11.77 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 529 and 531.
- [70] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.39 (s, 3H), 3.54 (s, 3H), 3.6 (m, 2H), 3.75 (m, 2H), 3.98 (t, 2H), 4.33 (t, 2H), 7.24 (m, 2H), 7.41 (m, 2H), 7.48 (s, 1H), 8.73 (s, 1H), 9.68 (s, 1H), 12.46 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 481 and 483.
- 30

The 4-amino-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-(2-methoxyethoxy)ethyl tosylate (prepared from 2-(2-methoxyethoxy)ethanol and tosyl chloride) using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-

- 5 7-[2-(2-methoxyethoxy)ethoxy]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 3.4 (s, 3H), 3.6 (m, 2H), 3.76 (m, 2H), 4.03 (m, 5H), 4.39 (t, 2H), 7.21 (m, 1H), 7.34 (s, 1H), 7.41 (t, 2H), 7.51 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 467 & 469.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material;

- 10 NMR Spectrum: (DMSO-d<sub>6</sub>) 3.23 (s, 3H), 3.46 (m, 2H), 3.6 (m, 2H), 3.79 (t, 2H), 3.88 (s, 3H), 4.2 (t, 2H), 7.08 (s, 1H), 7.39 (s, 2H), 7.57 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 294.

[71] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.39 (s, 3H), 3.6 (m, 5H), 3.77 (m, 2H), 4.01 (t, 2H), 4.36 (s, 1H), 7.01 (t, 3H), 7.26 (m, 2H), 7.46 (s, 1H), 8.72 (s, 1H), 9.58 (s, 1H), 12.16 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 449.

- 15 [72] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.31 (s, 6H), 3.27 (s, 3H), 3.4 (s, 3H), 3.6 (m, 2H), 3.75 (m, 2H), 3.97 (t, 2H), 4.34 (t, 2H), 7.14 (m, 3H), 7.26 (s, 1H), 7.57 (s, 1H), 8.66 (s, 1H), 9.95 (s, 1H), 12.03 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 441.

[73] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.54 (m, 2H), 1.82–2.03 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.53 (s, 3H), 4.02 (d, 2H), 7.26 (m, 1H),

- 20 7.31–7.47 (m, 3H), 7.55 (d, 1H), 8.68 (s, 1H), 9.49 (s, 1H), 12.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 508.

[74] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.82 (m, 4H), 2.66 (m, 4H), 3.0 (t, 2H), 4.27 (t, 2H), 7.2–7.4 (m, 3H), 7.5 (d, 2H), 8.05 (d, 1H), 8.78 (s, 1H), 9.1 (br s, 1H), 12.07 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 446 and 448.

- 25 The 4-amino-7-(2-pyrrolidin-1-ylethoxy)quinazoline used as a starting material was prepared as follows :-

A mixture of 7-hydroxy-4-methylthioquinazoline (6 g) and a saturated solution of ammonia gas in methanol (225 ml) was sealed in a pressure vessel and heated at 120°C for 40 hours. The mixture was cooled to ambient temperature and evaporated. The residue was

- 30 purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-amino-7-hydroxyquinazoline (4.9 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 6.9 (s, 1H), 6.9 (d, 1H), 9.5 (br s, 2H), 8.04 (d, 1H), 8.24 (s, 1H).

Diethyl azodicarboxylate (3.3 ml) was added dropwise to a stirred mixture of 4-amino-7-hydroxyquinazoline (5.16 g), triphenylphosphine (16.8 g) and methylene chloride (260 ml) which had been cooled to 0°C. The mixture was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was purified by column

5 chromatography on silica using a 50:45:5 mixture of methylene chloride, ethyl acetate and methanol as eluent. There was thus obtained triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide (9.7 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 6.85 (s, 1H), 7.05 (m, 1H), 7.5-7.95 (m, 15H), 8.12 (s, 1H), 8.5 (d, 1H), 10.3 (br s, 1H).

3,3-Dimethyl-1,2,5-thiadiazolidine-1,1-dioxide (J. Med. Chem. 1994, 37, 3023;

10 0.39 g) was added portionwise to a stirred mixture of triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide (0.2 g), N-(2-hydroxyethyl)pyrrolidine (0.081 g) and methylene chloride (5 ml) and the mixture was stirred at ambient temperature for 1 hour. Diethyl ether (10 ml) was added and the mixture was filtered through diatomaceous earth. The filtrate was evaporated and the residue was purified by column chromatography on silica  
15 using as eluent a 48:50:2 mixture of methylene chloride, ethyl acetate and a saturated ammonia solution in methanol. There was thus obtained triphenylphosphine N-[7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]imide (0.084 g); NMR Spectrum: (DMSO-d<sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 1.93 (m, 2H), 2.08 (m, 2H), 3.2 (m, 2H), 3.66 (m, 2H), 3.73 (m, 2H), 4.5 (m, 2H), 7.16 (s, 1H), 7.42 (m, 1H), 7.6-8.0 (m, 15H), 8.62 (s, 1H), 8.71 (d, 1H); Mass Spectrum:  
20 M+H<sup>+</sup> 519.

A mixture of a portion (0.42 g) of the material so obtained, a 1N aqueous acetic acid solution (2 ml) and ethanol (2 ml) was stirred and heated to 100°C for 15 hours. The mixture was evaporated and the residue was dried under vacuum. There was thus obtained 4-amino-7-(2-pyrrolidin-1-ylethoxy)quinazoline in quantitative yield and this was used directly without  
25 future purification.

[75] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 426 and 428.

[76] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 412 and 414.

[77] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 480 and 482.

[78] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4-1.7 (m, 6H), 2.55  
30 (br s, 4H), 2.85 (t, 2H), 4.25 (t, 2H), 7.1-7.38 (m, 4H), 7.48 (d, 2H), 8.05 (d, 2H), 8.8 (s, 1H), 9.02 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 460 and 462.

The 4-amino-7-(2-piperidinoethoxy)quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N-(2-hydroxyethyl)piperidine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine

N-[7-(2-piperidinoethoxy)quinazolin-4-yl]imide in 21% yield; Mass Spectrum:  $M+H^+$  533.

- 5 The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  273.

[79] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.45 (br m, 2H), 1.55-1.75 (m, 4H), 2.55 (br s, 4H), 2.85 (t, 2H), 4.28 (t, 2H), 7.05 (m, 2H), 7.12-7.4 (m, 4H),

- 10 8.15 (d, 1H), 8.8 (s, 1H), 9.2 (s, 1H); Mass Spectrum:  $M+H^+$  428.

[80] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.4-1.72 (m, 6H), 2.42 (s, 3H), 2.55 (br s, 4H), 2.85 (t, 2H), 4.3 (t, 2H), 7.12-7.32 (m, 5H), 8.35 (d, 1H), 7.95 (d, 1H), 8.6 (s, 1H), 8.8 (s, 1H); Mass Spectrum:  $M+H^+$  440 and 442.

[81] The product gave the following data: Mass Spectrum:  $M+H^+$  426 and 428.

- 15 [82] The product gave the following data: Mass Spectrum:  $M+H^+$  494 and 496.

[83] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.32 (s, 3H), 2.5 (br s, 4H), 2.7 (br s, 4H), 2.9 (t, 2H), 4.3 (t, 2H), 7.2 (d, 1H), 7.25-7.4 (m, 3H), 7.47 (d, 2H), 8.05 (d, 1H), 8.8 (s, 1H), 9.05 (s, 1H); Mass Spectrum:  $M+H^+$  475 and 477.

- The 4-amino-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline used as a starting  
20 material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with 1-(2-hydroxyethyl)-4-methylpiperazine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine

N-{7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazolin-4-yl}imide in 30% yield; Mass Spectrum:

- 25  $M+H^+$  548. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  288.

The 1-(2-hydroxyethyl)-4-methylpiperazine used as a starting material was prepared as follows :-

- 30 A mixture of 2-bromoethanol (2.36 g), N-methylpiperazine (1.26 g), potassium carbonate (5.0 g) and ethanol (150 ml) was stirred and heated to reflux for 18 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was triturated under a mixture of methylene chloride and acetone. The resultant

mixture was filtered and the filtrate was evaporated to give the required starting material as an oil (0.87 g); NMR Spectrum: ( $\text{CDCl}_3$ ) 2.18 (s, 3H), 2.3-2.7 (br m, 8H), 2.56 (t, 2H), 3.61 (t, 2H).

[84] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  455 and 457.

5 [85] The product gave the following data: NMR Spectrum: ( $\text{CDCl}_3$ ) 2.3 (s, 3H), 2.48 (br s, 4H), 2.65 (br s, 4H), 2.9 (t, 2H), 4.3 (t, 2H), 7.1 (m, 1H), 7.2-7.4 (m, 4H), 7.45 (d, 1H), 7.97 (d, 1H), 8.35 (br s, 1H), 8.45 (d, 1H), 8.85 (s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  441 and 443.

[86] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  509 and 511.

[87] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  460 and 462.

10 The 4-amino-7-(N-methylpiperidin-3-ylmethoxy)quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with 3-hydroxymethyl-N-methylpiperidine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine

15 N-[7-(N-methylpiperidin-3-ylmethoxy)quinazolin-4-yl]imide in 49% yield; Mass Spectrum:  $\text{M}+\text{H}^+$  533. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $\text{M}+\text{H}^+$  273.

[88] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  428.

20 [89] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  440 and 442.

[90] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  426 and 428.

[91] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  494 and 496.

[92] The product gave the following data: NMR Spectrum: ( $\text{CDCl}_3$ ) 1.85 (br s, 4H), 2.1 (m, 2H), 2.6 (br s, 4H), 2.7 (t, 2H), 4.2 (t, 2H), 7.15 (d, 1H), 7.2-7.4 (m, 3H), 7.5 (d, 2H), 8.1 (d, 25 1H), 8.8 (s, 1H), 9.2 (br s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  460 and 462.

The 4-amino-7-(3-pyrrolidin-1-ylpropoxy)quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N-(3-hydroxypropyl)pyrrolidine using an analogous procedure to that described in the second 30 last paragraph of Note [74] above to give triphenylphosphine N-[7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]imide in 42% yield; Mass Spectrum:  $\text{M}+\text{H}^+$  533. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described

in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  273.

The N-(3-hydroxypropyl)pyrrolidine used as a starting material was prepared as follows :-

- 5        A mixture of 3-chloropropanol (66 g), pyrrolidine (50 g), potassium carbonate (145 g) and acetonitrile (1 L) was stirred and heated to reflux for 20 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by distillation to give the required starting material as an oil (62 g); NMR Spectrum: ( $CDCl_3$ ) 1.6-1.8 (m, 6H), 2.55 (br s, 4H), 2.75 (t, 2H), 3.85 (t, 2H), 5.5 (br s, 1H).
- 10 [93]    The product gave the following data: Mass Spectrum:  $M+H^+$  428.
- [94]    The product gave the following data: Mass Spectrum:  $M+H^+$  440 and 442.
- [95]    The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.82 (br s, 4H), 2.1 (m, 2H), 2.55 (br s, 4H), 2.65 (t, 4H), 4.25 (t, 2H), 7.1 (m, 1H), 7.2-7.45 (m, 4H), 7.5 (d, 1H), 7.95 (d, 1H), 8.15 (s, 1H), 8.45 (d, 1H), 8.85 (s, 1H); Mass Spectrum:  $M+H^+$  426 and 428.
- 15 [96]    The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 7.2 (m, 1H), 7.25-7.4 (m, 3H), 7.5 (s, 1H), 8.0 (d, 1H), 8.8 (s, 1H), 8.95 (br s, 1H); Mass Spectrum:  $M+H^+$  494 and 496.
- [97]    The product gave the following data: Mass Spectrum:  $M+H^+$  444.

20        The 4-amino-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

- Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N-(3-hydroxypropyl)morpholine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine N-[7-(3-morpholinopropoxy)quinazolin-4-yl]imide and the material so obtained was reacted
- 25        with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  289.
- [98]    The product gave the following data: Mass Spectrum:  $M+H^+$  456 and 458.
- [99]    The product gave the following data: Mass Spectrum:  $M+H^+$  510 and 512.
- [100]   The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.1 (m, 2H), 2.35 (s, 3H), 2.35-2.75 (m, 8H), 2.6 (t, 2H), 4.22 (t, 2H), 7.12 (m, 1H), 7.2-7.38 (m, 3H), 7.5 (d, 2H), 8.15 (d, 1H), 8.8 (s, 1H), 9.5 (br s, 1H); Mass Spectrum:  $M+H^+$  489 and 491.
- 30

The 4-amino-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with 1-(3-hydroxypropyl)-4-methylpiperazine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine

N-{7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl}imide in 44% yield; Mass

- 5 Spectrum:  $M+H^+$  562. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  302.

The 1-(3-hydroxypropyl)-4-methylpiperazine used as a starting material was prepared as follows :-

- 10 A mixture of 3-bromopropanol (20 ml), N-methylpiperazine (29 ml), potassium carbonate (83 g) and ethanol (200 ml) was stirred and heated to reflux for 20 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was triturated under diethyl ether. The resultant mixture was filtered and the filtrate was evaporated. The residue was purified by distillation to give the required starting material
- 15 as an oil; NMR Spectrum: ( $CDCl_3$ ) 1.72 (m, 2H), 2.3 (s, 3H), 2.2-2.8 (m, 8H), 2.6 (t, 2H), 3.8 (t, 2H), 5.3 (br s, 1H).

[101] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.07 (t, 2H), 2.32 (s, 3H), 2.3-2.75 (m, 8H), 2.6 (t, 2H), 4.22 (t, 2H), 7.1 (m, 1H), 7.2-7.45 (m, 4H), 7.5 (d, 1H), 8.05 (d, 1H), 8.45 (d, 1H), 8.55 (s, 1H), 8.85 (s, 1H); Mass Spectrum:  $M+H^+$  455 and 457.

- 20 [102] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.1 (m, 2H), 2.3 (s, 3H), 2.35-2.7 (m, 8H), 2.6 (t, 2H), 4.2 (t, 2H), 7.15 (m, 1H), 7.2-7.4 (m, 3H), 7.5 (s, 1H), 8.05 (d, 1H), 8.8 (s, 1H), 9.02 (br s, 1H); Mass Spectrum:  $M+H^+$  523 and 525.

[103] The product gave the following data: Mass Spectrum:  $M+H^+$  492.

[104] The product gave the following data: Mass Spectrum:  $M+H^+$  504 and 506.

- 25 [105] The product gave the following data: Mass Spectrum:  $M+H^+$  558 and 560.

[106] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.55 (m, 2H), 4.15 (t, 2H), 4.7 (t, 2H), 7.2-7.4 (m, 4H), 7.5 (s, 1H), 7.58 (s, 1H), 7.65 (s, 1H), 7.95 (d, 1H), 8.55 (d, 1H), 8.8 (s, 1H); Mass Spectrum:  $M+H^+$  492 and 494.

- 30 The 4-amino-7-[3-(1,2,3-triazol-1-yl)propoxy]quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N<sup>1</sup>-(3-hydroxypropyl)-1,2,3-triazole using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine N-{7-[3-(1,2,3-triazol-

1-yl)propoxy]quinazolin-4-yl}imide in 18% yield; Mass Spectrum:  $M+H^+$  531. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  271.

5 The  $N^1$ -(3-hydroxypropyl)-1,2,3-triazole used as a starting material was prepared as follows :-

A mixture of 1,2,3-triazole (5 g), ethyl acrylate (7.8 ml) and pyridine (50 drops) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and evaporated. The residue was purified by column chromatography on silica using increasingly  
10 polar mixtures of methylene chloride and diethyl ether as eluent. There was thus obtained ethyl 1,2,3-triazol-1-ylpropanoate (8.96 g); NMR Spectrum: ( $CDCl_3$ ) 1.25 (t, 3H), 2.95 (t, 2H), 4.15 (q, 2H), 4.7 (t, 2H), 7.65 (s, 1H), 7.7 (s, 1H).

A solution of the material so obtained in THF (50 ml) was added dropwise to a suspension of lithium aluminium hydride (3 g) in THF (250 ml) which had been cooled to  
15 0°C. The mixture was stirred at 5°C for 1 hour and at ambient temperature for a further hour. The mixture was cooled to 0°C and 4N aqueous sodium hydroxide solution (30 ml) was added dropwise. The mixture was filtered and the filtrate was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 47:3 mixture of methylene chloride and methanol as eluent. There was thus obtained  
20  $N^1$ -(3-hydroxypropyl)-1,2,3-triazole (6.2 g); NMR Spectrum: ( $CDCl_3$ ) 2.1-2.2 (m, 3H), 3.65 (m, 2H), 4.6 (t, 2H), 7.6 (s, 1H), 7.72 (s, 1H).

[107] The product gave the following data: Mass Spectrum:  $M+H^+$  440.

The 4-amino-7-[(*E*)-4-pyrrolidin-1-ylbut-2-en-1-yloxy]quinazoline used as a starting material was prepared as follows :-

25 Triphenylphosphine  $N$ -(7-hydroxyquinazolin-4-yl)imide was reacted with (*E*)-4-pyrrolidin-1-ylbut-2-en-1-ol using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine  $N$ -{7-[(*E*)-4-pyrrolidin-1-ylbut-2-en-1-yloxy]quinazolin-4-yl}imide in 38% yield; Mass Spectrum:  $M+H^+$  545. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to  
30 that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  285.

The (*E*)-4-pyrrolidin-1-ylbut-2-en-1-ol used as a starting material was prepared as follows :-

Thionyl chloride (9.3 ml) was added portionwise to a stirred mixture of 2-butyne-1,4-diol (10 g), pyridine (10.3 ml) and toluene (15 ml) which had been cooled to 0°C. The mixture was stirred at ambient temperature for 3.5 hours and then poured onto a mixture of ice and water. The mixture was extracted with diethyl ether. The organic extract  
5 was washed with a saturated aqueous sodium bicarbonate solution and with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 7:3 mixture of petroleum ether (b.p. 40-60°C) and diethyl ether as eluent. There was thus obtained 4-chlorobut-2-yn-1-ol (4.74 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.68 (t, 1H), 4.18 (d, 2H), 4.33 (d, 2H).

10 Pyrrolidine (7.8 ml) was added dropwise to a solution of 4-chlorobut-2-yn-1-ol (4.74 g) in toluene (40 ml) and the resultant mixture was stirred and heated to 60°C for 1 hour. The mixture was evaporated and the residue was purified by column chromatography on silica using a 24:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 4-pyrrolidin-1-ylbut-2-yn-1-ol (4.3 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.82 (t, 4H), 2.63 (t,  
15 4H), 3.44 (t, 2H), 4.29 (t, 2H).

A solution of the material so obtained in THF (20ml) was added dropwise to a suspension of lithium aluminium hydride (2.35 g) in THF (8 ml) and the mixture was stirred and heated to 60°C for 2 hours. The mixture was cooled to 5°C and 2N aqueous sodium hydroxide solution (28 ml) was slowly added. The resulting suspension was filtered and the  
20 filtrate was evaporated. The residue was dissolved in a mixture of methylene chloride and ethyl acetate, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on aluminium oxide using a 97:3 mixture of methylene chloride and methanol as eluent. There was thus obtained (*E*)-4-pyrrolidin-1-ylbut-2-en-1-ol (3.09 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.82 (m, 4H), 2.61 (m, 4H), 3.17 (m, 2H), 4.13 (s, 2H), 5.84 (m,  
25 2H).

[108] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 452 and 454.

[109] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 438 and 440.

[110] DMF was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.5-1.65 (m, 2H), 1.68-1.74 (m, 2H), 1.92 (t, 2H), 1.97 (t, 2H), 2.05 (m,  
30 1H), 2.45 (t, 2H), 2.88 (d, 2H), 3.98 (s, 3H), 4.22 (t, 2H), 6.68 (s, 1H), 7.18 (s, 1H), 7.3 (s, 1H), 7.4 (t, 1H), 7.61 (d, 2H), 8.07 (s, 1H), 8.7 (s, 1H), 10.62 (s, 1H), 12.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 547 and 549.

The 4-amino-7-[3-(4-carbamoylpiperidin-1-yl)propoxy]-6-methoxyquinazoline used as a starting material was prepared as follows :-

A mixture of 2-amino-4-benzyloxy-5-methoxybenzamide (*J. Med. Chem.*, 1977, 20, 146-149; 10 g) and Gold's reagent (7.4 g) in dioxane (100 ml) was stirred and heated at reflux  
5 for 24 hours. Sodium acetate (3.02 g) and acetic acid (1.65 ml) were added to the reaction mixture and it was heated for a further 3 hours. The mixture was evaporated to dryness, water was added to the residue and the solid was filtered off, washed with water and dried. Recrystallisation of the solid from acetic acid gave 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.7 g, 84%).

10 7-Benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (20.3 g) was taken up in thionyl chloride (440 ml) and DMF (1.75ml) and heated to reflux for 4 hours. The thionyl chloride was evaporated under vacuum and the residue was azeotroped with toluene three times. There was thus obtained 7-benzyloxy-4-chloro-6-methoxyquinazoline which was used without further purification; NMR Spectrum: 4.88 (s, 3H), 5.25 (s, 2H), 7.44 (s, 1H), 7.49 (s, 1H),  
15 7.32-7.52 (m, 5H), 8.83 (s, 1H).

A mixture of the crude 7-benzyloxy-4-chloro-6-methoxyquinazoline, potassium carbonate (50 g) and 4-bromo-2-fluorophenol (10 ml) in DMF (500 ml) was stirred and heated to 100°C for 5 hours. The mixture was allowed to cool to ambient temperature and was poured into water (2L). The resultant solid was isolated and washed with water. The solid  
20 was dissolved in methylene chloride and filtered. The filtrate was treated with decolourising charcoal, boiled for a few minutes then filtered. The filtrate was evaporated to give a solid residue which was triturated under diethyl ether. There was thus obtained 7-benzyloxy-4-(4-bromo-2-fluorophenoxy)-6-methoxyquinazoline.

A mixture of the material so obtained and trifluoroacetic acid (15 ml) was stirred and  
25 heated to reflux for 3 hours. The reaction mixture was allowed to cool, toluene was added and the mixture was evaporated. The residue was triturated under diethyl ether. The precipitate was collected by filtration and dried to give 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (20.3 g) which was used without further purification.

A mixture of 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (18.2 g),  
30 1,3-dibromopropane (80 ml), potassium carbonate (42 g) and DMF (1.2 L) was stirred and heated to 45°C for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. The product

so obtained was stirred under diethyl ether (150 ml) and the resultant solid was isolated.

There was thus obtained 4-(4-bromo-2-fluorophenoxy)-7-(3-bromopropoxy)-

6-methoxyquinazoline (14.4 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 2.35 (m, 2H), 3.69 (t, 2H), 3.98 (s, 3H), 4.31 (t, 2H), 7.4-7.6 (m, 4H), 7.78 (d, 1H), 8.78 (s, 1H); Mass Spectrum:

5 M+H<sup>+</sup> 485, 487 and 489.

A mixture of a portion (2.4 g) of the material so obtained, piperidine-4-carboxamide (0.82 g), potassium carbonate (3.46 g) and DMF (40 ml) was stirred and heated to 45°C for 20 hours. The resultant solid was isolated, washed in turn with DMF and with water and dried. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-7-[3-(4-carbamoylpiperidin-

10 1-yl)propoxy]-6-methoxyquinazoline (2.5 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.45-1.7 (m, 4H), 1.82-2.1 (m, 5H), 2.22 (t, 2H), 2.86 (m, 2H), 3.96 (s, 3H), 4.03 (t, 2H), 6.65 (s, 1H), 7.14 (s, 1H), 7.38 (s, 1H), 7.42-7.55 (m, 3H), 7.78 (d, 1H), 8.53 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.

A mixture of the material so obtained and a saturated solution of ammonia in

15 isopropanol (100 ml) was sealed in a Carius tube and heated at 130°C for 20 hours. The mixture was cooled and the solvent was evaporated. The residue was stirred with 2N aqueous sodium hydroxide solution (20 ml) for 1 hour. The solid was isolated and washed in turn with water and with methanol. There was thus obtained 4-amino-7-[3-(4-carbamoylpiperidin-1-yl)propoxy]-6-methoxyquinazoline (0.85 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.4-1.7 (m, 4H), 1.8-2.1 (m, 5H), 2.4 (t, 2H), 2.68 (d, 2H), 3.86 (s, 3H), 4.1 (t, 2H), 6.66 (s, 1H), 7.03 (s, 1H), 7.15 (s, 1H), 7.33 (s, 2H), 7.53 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 360.

[111] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.5-1.7 (m, 4H), 1.8-2.1 (m, 5H), 2.4 (t, 2H), 2.88 (d, 2H), 2.94 (s, 3H), 4.0 (t, 2H), 6.65 (s, 1H), 7.1-7.5 (m, 5H), 8.05 (s, 1H), 8.66 (s, 1H), 10.6 (s, 1H), 11.8 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 515.

25 [112] THF was added as a co-solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.6-2.3 (m, 9H), 2.35 (s, 6H), 2.53 (t, 2H), 2.99 (d, 2H), 3.42 (s, 3H), 4.25 (t, 2H), 5.55 (s, 2H), 7.11 (s, 3H), 7.29 (s, 1H), 7.55 (s, 1H), 8.64 (s, 1H), 9.7 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 507.

[113] DMF was used as the reaction solvent. The product was precipitated from the  
30 reaction mixture as a 1:1 adduct with DMF. This gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.7-2.3 (m, 9H), 2.37 (s, 3H), 2.54 (t, 2H), 2.88 (s, 3H), 2.95 (s, 3H), 3.0 (m, partially obscured by DMF), 3.5 (s, 3H), 4.25 (t, 2H), 5.61 (broad d, 2H), 7.16-7.32 (m, 4H), 7.55 (s, 1H), 8.02 (s, 1H), 8.67 (s, 1H), 9.8 (s, 1H), 12.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 527 and 529.

[114] Acetonitrile plus a few drops of DMF was used as the reaction solvent and the reaction mixture was heated to 45°C for 3 hours. The product which was precipitated from the reaction mixture was isolated, washed with acetonitrile and diethyl ether and dried under vacuum. The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 440 and 442.

5 The 4-amino-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline used as a starting material was prepared as follows :-

Trifluoromethanesulphonic anhydride (0.05 ml) was added dropwise to a stirred mixture of triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide (0.1 g), pyridine (0.5 ml) and methylene chloride (1 ml) which had been cooled to 0°C. The reaction mixture was  
10 stirred at 0°C for 2 hours. A second portion (0.012 ml) of trifluoromethanesulphonic anhydride was added and the mixture was stirred at ambient temperature for 1.5 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic solution was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene  
15 chloride and ethyl acetate as eluent. There was thus obtained triphenylphosphine N-(7-trifluoromethanesulphonyloxyquinazolin-4-yl)imide (0.078 g).

A solution of 3-(pyrrolidin-1-yl)-1-propyne (J. Amer. Chem. Soc., 1958, 80, 4609; 0.08 g) in DMF (0.2 ml) was added to a mixture of triphenylphosphine N-(7-trifluoromethanesulphonyloxyquinazolin-4-yl)imide (0.2 g), cuprous iodide (0.004 g),  
20 tetrakis(triphenylphosphine)palladium(0) (0.02 g), triethylamine (0.201 ml) and DMF (8 ml). The mixture was degassed carefully and placed under an atmosphere of argon. The reaction mixture was stirred and heated to 60°C for 2.5 hours. The mixture was cooled to ambient temperature and evaporated. The residue was partitioned between ethyl acetate and water. The organic phase was dried over magnesium sulphate and evaporated. The residue was  
25 purified by column chromatography on silica using a 9:1 mixture of methylene chloride and methanol as eluent. There was thus obtained triphenylphosphine N-{7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazolin-4-yl}imide (0.18 g).

A mixture of the material so obtained, acetic acid (4 ml) and water (4 ml) was stirred and heated at 100°C for 15 hours. The solvent was evaporated and the residue was partitioned  
30 between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic solution was washed with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using initially a 9:1 mixture of methylene chloride and methanol and then a 19:1 mixture of methylene chloride and a

saturated solution of ammonia in methanol as eluent. There was thus obtained 4-amino-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline (0.038 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.75 (m, 4H), 2.6 (m, 4H), 3.65 (s, 2H), 7.45 (m, 1H), 7.25 (d, 1H), 7.85 (br s, 2H), 8.2 (d, 1H), 8.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 253.

- 5 [115] DMF was used as the reaction solvent and 4-dimethylaminopyridine (0.1 equivalents) was added to catalyse the reaction. The product was precipitated from the reaction mixture by the addition of a mixture of diethyl ether and water. The product was isolated and dried under vacuum and gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.72 (m, 4H), 2.6 (m, 4H), 3.69 (s, 2H), 3.97 (s, 3H), 7.4 (m, 1H), 7.58 (m, 2H), 7.9 (s, 1H),  
10 8.15 (s, 1H), 8.75 (s, 1H), 10.8 (s, 1H), 11.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 470 and 472.

The 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline used as a starting material was prepared as follows :-

- Pyridine (1.13 ml) and a solution of trifluoromethanesulphonic anhydride (2.36 ml) in methylene chloride (10 ml) were added in turn to a stirred mixture of 4-(2-bromo-  
15 4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (2.6 g) and methylene chloride (40 ml) which had been cooled in an ice bath to 0-5°C. The resultant mixture was stirred at ambient temperature for 4 hours. The mixture was washed in turn with dilute aqueous citric acid, water and a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. The residue was triturated under a 1:1 mixture of  
20 isohexane and diethyl ether. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline (2.58 g); NMR Spectrum: (CDCl<sub>3</sub>) 4.13 (s, 3H), 7.14-7.5 (m, 3H), 7.81 (s, 1H), 7.91 (s, 1H), 8.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 497 and 499.

- A mixture of a portion (0.8 g) of the material so obtained, 3-(pyrrolidin-1-yl)-  
25 1-propyne (0.57 g), triethylamine (0.8 ml), triphenylphosphine (0.03 g), bis(triphenylphosphine)palladium(II) chloride (0.06 g), cuprous iodide (0.06 g) and THF (5 ml) was stirred and heated to reflux for 3 hours. Dilute aqueous potassium carbonate solution was added and the mixture was extracted with ethyl acetate. The organic solution was dried over sodium sulphate and evaporated. The residue was purified by column  
30 chromatography on silica using a 10:1 mixture of methylene chloride and ethanol as eluent. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline (0.55 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.75 (m, 4H), 2.64 (m, 4H),

3.71 (s, 2H), 4.01 (s, 3H), 7.38-7.81 (m, 3H), 7.66 (s, 1H), 8.0 (s, 1H), 8.62 (s, 1H); Mass Spectrum:  $M+H^+$  456 & 458.

A mixture of the material so obtained and a 2M solution of ammonia in isopropanol (10 ml) was sealed in a Carius tube and heated to 130°C for 18 hours. The reaction mixture  
5 was evaporated. The residue was partitioned between ethyl acetate and a 1N aqueous potassium carbonate solution. The organic solution was washed with brine, dried over anhydrous sodium sulphate and evaporated. The residue was triturated under a 1:1 mixture of isohexane and diethyl ether. The resultant solid was isolated and dried. There was thus obtained 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline (0.24 g); Mass Spectrum:  $M+H^+$  283.

[116] DMF was used as the reaction solvent and 4-dimethylaminopyridine (0.1 equivalents) was added to catalyse the reaction. The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.6 (m, 4H), 2.35 (m, 6H), 2.55 (m, 2H), 3.6 (m, 4H), 3.97 (s, 3H), 7.3-7.6 (m, 3H), 7.83 (s, 1H), 8.11 (s, 1H), 8.72 (s, 1H), 10.78 (s, 1H), 11.95 (s, 1H); Mass Spectrum:  
15  $M+H^+$  528 and 530.

The 4-amino-6-methoxy-7-(6-morpholino-1-hexynyl)quinazoline used as a starting material was prepared as follows:

Using an analogous procedure to that described in the second last paragraph of Note [115] above, 6-morpholino-1-hexyne was reacted with 4-(2-bromo-4-fluorophenoxy)-  
20 6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(6-morpholino-1-hexynyl)quinazoline; NMR Spectrum: ( $DMSO-d_6$ ) 1.63 (m, 4H), 2.33 (m, 6H), 2.55 (m, 2H), 3.56 (m, 4H), 4.0 (s, 3H), 7.35-7.8 (m, 3H), 7.65 (s, 1H), 7.96 (s, 1H), 8.6 (s, 1H); Mass Spectrum:  $M+H^+$  514 and 516.

The material so obtained was reacted with ammonia using an analogous procedure to  
25 that described in the last paragraph of Note [115] above to give the required starting material.

6-Morpholino-1-hexyne was obtained by the reaction of 6-mesyloxy-1-hexyne with morpholine using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, **31**, 1421.

[117] DMF was used as the reaction solvent and 4-dimethylaminopyridine  
30 (0.1 equivalents) was added to catalyse the reaction. The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.6 (m, 4H), 2.32 (m, 6H), 2.55 (m, 2H), 3.55 (m, 4H), 3.98 (s, 3H), 7.1-7.4 (m, 3H), 7.82 (s, 1H), 8.11 (s, 1H), 8.7 (s, 1H), 10.78 (s, 1H), 11.68 (s, 1H); Mass Spectrum:  $M+H^+$  496.

[118] DMF was used as the reaction solvent and 4-dimethylaminopyridine

(0.1 equivalents) was added to catalyse the reaction. The product gave the following data:

NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.55 (m, 2H), 1.85 (m, 2H), 2.28 (s, 3H), 2.56 (m, 2H), 3.9 (m, 2H), 3.96 (s, 3H), 6.7 (s, 1H), 7.07 (s, 1H), 7.36-7.62 (m, 3H), 7.85 (s, 1H), 8.13 (s, 1H), 10.71 (s, 1H), 10.8 (s, 1H), 11.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 523 and 525.

The 4-amino-6-methoxy-7-[6-(2-methylimidazol-1-yl)-1-hexynyl]quinazoline used as a starting material was prepared as follows:

Using an analogous procedure to that described in the second last paragraph of

Note [115] above, 6-(2-methylimidazol-1-yl)-1-hexyne was reacted with 4-(2-bromo-

4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[6-(2-methylimidazol-1-yl)-1-hexynyl]quinazoline; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.56 (m, 2H), 1.85 (m, 2H), 2.28 (s, 3H), 2.56 (m, 2H), 3.9 (m, 2H), 3.98 (s, 3H), 6.75 (br m, 1H), 7.1 (br m, 1H), 7.36-7.82 (m, 3H), 7.63 (s, 1H), 7.98 (s, 1H), 8.61 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 509 and 511.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

6-(2-Methylimidazol-1-yl)-1-hexyne was obtained by the reaction of 6-mesyloxy-1-hexyne with 2-methylimidazole using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, 31, 1421.

[119] DMF was used as the reaction solvent and 4-dimethylaminopyridine

(0.1 equivalents) was added to catalyse the reaction. The product gave the following data:

NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.58 (m, 2H), 1.82 (m, 2H), 2.28 (s, 3H), 2.55 (m, 2H), 3.95 (m, 5H), 6.7 (s, 1H), 7.05 (s, 1H), 7.1-7.4 (m, 3H), 7.85 (s, 1H), 8.12 (s, 1H), 8.74 (s, 1H), 10.79 (s, 1H), 11.69 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 491.

[120] DMF was used as the reaction solvent and 4-dimethylaminopyridine

(0.1 equivalents) was added to catalyse the reaction. The product gave the following data:

NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.28 (s, 6H), 3.54 (s, 2H), 3.98 (s, 3H), 7.18-7.47 (m, 3H), 7.92 (s, 1H), 8.15 (s, 1H), 8.74 (s, 1H), 10.8 (s, 1H), 11.68 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 412.

The 4-amino-6-methoxy-7-(3-dimethylamino-1-propynyl)quinazoline used as a starting material was prepared as follows:

Using an analogous procedure to that described in the second last paragraph of

Note [115] above, 3-dimethylamino-1-propyne was reacted with 4-(2-bromo-

4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-

4-fluorophenoxy)-6-methoxy-7-(3-dimethylamino-1-propynyl)quinazoline; NMR Spectrum: (DMSO-d<sub>6</sub>) 2.29 (s, 6H), 3.55 (s, 2H), 4.0 (s, 3H), 7.38-7.83 (m, 3H), 7.67 (s, 1H), 8.05 (s, 1H), 8.63 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 430 and 432.

The material so obtained was reacted with ammonia using an analogous procedure to  
5 that described in the last paragraph of Note [115] above to give the required starting material.

[121] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 467.

[122] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 454.

[123] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.84-2.06 (m, 5H), 2.3 (s, 3H), 2.86-2.99 (m, 2H), 3.92 (s, 3H), 4.04 (d, 2H), 7.02 (m, 1H),  
10 7.22 (s, 1H), 7.28 (s, 1H), 7.36 (d, 1H), 8.44 (d, 1H), 8.64 (s, 1H), 8.76 (s, 1H), 13.12 (s, 1H);  
Mass Spectrum: M+H<sup>+</sup> 490 and 492.

[124] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.58 (m, 2H),  
1.84-2.06 (m, 5H), 2.3 (s, 3H), 2.58 (s, 3H), 2.86-2.96 (m, 2H), 3.86 (s, 3H), 4.04 (d, 2H),  
7.22-7.28 (m, 2H), 7.36 (d, 1H), 7.92 (m, 1H), 8.6 (s, 1H), 8.76 (s, 1H), 9.06 (d, 1H), 12.62 (s,  
15 1H); Mass Spectrum: M+H<sup>+</sup> 481.

[125] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.84-2.04 (m, 5H), 2.3 (s, 3H), 2.84-2.94 (m, 2H), 3.94 (s, 3H), 4.06 (d, 2H), 7.1 (s, 1H), 7.76-  
7.36 (m, 2H), 7.56 (d, 1H), 8.22 (s, 1H), 8.78 (m, 2H), 13.16 (s, 1H); Mass Spectrum: M+H<sup>+</sup>  
524 and 526.

20 [126] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.86-2.06 (m, 5H), 2.3 (s, 3H), 2.84-2.96 (m, 2H), 3.94 (s, 3H), 3.98 (s, 3H), 4.04 (d, 2H),  
6.84 (d, 1H), 7.04 (m, 1H), 7.2 (s, 1H), 7.28 (s, 1H), 8.3-8.38 (m, 2H), 8.76 (s, 1H), 12.74 (s,  
1H); Mass Spectrum: M+H<sup>+</sup> 486 and 488.

[127] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.44-1.56 (m, 2H),  
25 1.86-2.06 (m, 5H), 2.3-2.34 (m, 6H), 2.84-2.96 (m, 2H), 3.86 (s, 3H), 3.98 (s, 3H), 4.04 (d,  
2H), 6.82-6.9 (m, 2H), 7.24 (s, 1H), 7.36 (s, 1H), 8.06 (s, 1H), 8.76 (s, 1H), 8.9 (s, 1H), 12.64  
(s, 1H); Mass Spectrum: M+H<sup>+</sup> 466.

[128] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4-1.54 (m, 2H), 1.84-  
2.04 (m, 5H), 2.3 (s, 3H), 2.44 (s, 3H), 2.84-2.96 (m, 2H), 3.8 (s, 3H), 4.04 (d, 2H), 7.04 (m,  
30 1H), 7.16 (d, 1H), 7.26 (s, 1H), 7.38 (s, 1H), 8.1 (s, 1H), 8.7 (s, 1H), 9.08 (s, 1H), 12.46 (s,  
1H); Mass Spectrum: M+H<sup>+</sup> 470 and 472.

[129] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.84-2.04 (m, 5H), 2.3 (s, 3H), 2.44 (s, 3H), 2.86-2.96 (m, 2H), 3.86 (s, 3H), 4.04 (d, 2H), 6.8

(m, 1H), 7.18-7.22 (m, 1H), 7.24 (s, 1H), 7.28 (s, 1H), 7.96 (m, 1H), 8.58 (s, 1H), 8.72 (s, 1H), 12.4 (s, 1H); Mass Spectrum:  $M+H^+$  454.

[130] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.42-1.56 (m, 2H), 1.84-2.04 (m, 5H), 2.28 (s, 3H), 2.34 (s, 3H), 2.86-2.96 (m, 2H), 3.86 (s, 3H), 4.04 (d, 2H),

5 6.88 (m, 1H), 7.22-7.32 (m, 3H), 8.12 (s, 1H), 8.76 (m, 2H), 12.78 (s, 1H); Mass Spectrum:  $M+H^+$  470 and 472.

[131] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.16 (m, 2H), 2.5-2.58 (m, 4H), 2.66 (t, 2H), 3.98 (s, 3H), 4.28 (t, 2H), 6.72-6.8 (m, 1H), 7.16-7.18 (m, 1H), 7.2 (s, 1H), 7.34 (s, 1H), 8.06-8.16 (m, 1H), 8.38 (s, 1H), 8.76 (s, 1H), 12.76 (s,

10 1H); Mass Spectrum:  $M+H^+$  458.

[132] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.16 (m, 2H), 2.48-2.58 (m, 4H), 2.66 (t, 2H), 3.96 (s, 3H), 4.28 (t, 2H), 7.02 (m, 1H), 7.14 (s, 1H), 7.32-7.4 (m, 2H), 8.3 (s, 1H), 8.46 (d, 1H), 8.78 (s, 1H), 13.06 (s, 1H); Mass Spectrum:  $M+H^+$  490 and 492.

15 [133] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.16 (m, 2H), 2.44 (s, 3H), 2.54-2.6 (m, 4H), 2.68 (t, 2H), 3.84 (s, 3H), 4.28 (t, 2H), 7.04 (m, 1H), 7.16 (d, 1H), 7.3 (s, 1H), 7.34 (s, 1H), 8.14 (d, 1H), 8.7 (s, 1H), 8.8 (s, 1H), 12.4 (s, 1H); Mass Spectrum:  $M+H^+$  470 and 472.

[134] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H),  
20 2.16 (m, 2H), 2.44 (s, 3H), 2.5-2.6 (m, 4H), 2.66 (t, 2H), 3.86 (s, 3H), 4.28 (t, 2H), 6.72-6.8 (m, 1H), 7.16-7.2 (m, 2H), 7.34 (s, 1H), 7.96 (m, 1H), 8.46 (s, 1H), 8.72 (s, 1H), 12.4 (s, 1H); Mass Spectrum:  $M+H^+$  454.

[135] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.06-2.22 (m, 2H), 2.46-2.6 (m, 7H), 2.68 (t, 2H), 3.84 (s, 3H), 4.28 (t, 2H), 7.28 (m, 2H),  
25 7.36 (d, 1H), 7.92 (d, 1H), 8.7 (s, 1H), 8.8 (s, 1H), 9.08 (s, 1H), 12.66 (s, 1H); Mass Spectrum:  $M+H^+$  481.

[136] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.14 (m, 2H), 2.3 (s, 3H), 2.5-2.6 (m, 4H), 2.64 (t, 2H), 3.84 (s, 3H), 4.28 (t, 2H), 6.88 (m, 1H), 7.28-7.36 (m, 3H), 8.14 (d, 1H), 8.78 (s, 1H), 8.88 (s, 1H), 12.9 (s, 1H); Mass Spectrum:  
30  $M+H^+$  470 and 472.

[137] DMF was used as the reaction solvent. The product was obtained as a dihydrochloride salt and gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.6-1.7 (m, 2H), 1.82-1.96 (m,

2H), 2.58-2.62 (t, 2H), 2.8 (s, 3H), 3.3-3.9 (m, 10H), 4.02 (s, 3H), 7.4-7.6 (m, 3H), 7.95 (s, 1H), 8.21 (s, 1H), 8.8 (s, 1H), 11.6-12.0 (m, 2H); Mass Spectrum:  $M+H^+$  541 and 543.

The 4-amino-6-methoxy-7-[6-(N-methylpiperazin-1-yl)-1-hexynyl]quinazoline used as a starting material was prepared as follows:

5 Using an analogous procedure to that described in the second last paragraph of Note [115] above, 6-(N-methylpiperazin-1-yl)-1-hexyne was reacted with 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[6-(N-methylpiperazin-1-yl)-1-hexynyl]quinazoline; NMR Spectrum: ( $DMSO-d_6$ ) 1.55-1.65 (m, 4H), 2.16 (s, 3H), 2.3-2.45 (m, 10H), 2.5-2.6 (m, 2H), 4.0  
10 (s, 3H), 7.4-7.8 (m, 3H), 7.65 (s, 1H), 7.98 (s, 1H), 8.6 (s, 1H); Mass Spectrum:  $M+H^+$  527 and 529.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

6-(N-Methylpiperazin-1-yl)-1-hexyne was obtained by the reaction of 6-mesyloxy-  
15 1-hexyne with N-methylpiperazine using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, 31, 1421.

[138] The reactants were heated to 45°C for 20 hours. The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.24 (s, 3H), 2.34 (s, 3H), 2.78 (s, 3H), 3.08 (s, 3H), 3.58 (s, 3H), 5.3 (s, 2H), 7.06 (d, 1H), 7.18 (d, 1H), 7.3-7.52 (m, 7H), 8.64 (s, 1H), 9.4 (s, 1H), 11.87 (s,  
20 1H); Mass Spectrum:  $M+H^+$  500.

The 3-(N,N-dimethylcarbamoyl)-2,6-dimethylphenylisocyanate used as a starting material was prepared as follows:

A solution of di-tert-butyl dicarbonate (0.081 g) in methylene chloride (1.6 ml) and a solution of 3-amino-N,N,2,4-tetramethylbenzamide (J. Chem. Soc., Perkin Trans. I 1973, 1-4;  
25 0.072 g) in methylene chloride (1.0 ml) were added in turn to a solution of 4-dimethylaminopyridine (0.004 g) in methylene chloride (0.4 ml). The resultant mixture was stirred at ambient temperature for 20 minutes. There was thus obtained a solution of 3-(N,N-dimethylcarbamoyl)-2,6-dimethylphenylisocyanate which was used without further purification.

30 [139] The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 0.37 (m, 2H), 0.62 (m, 2H), 1.32 (m, 1H), 2.25 (s, 6H), 3.94 (s, 3H), 4.03 (d, 2H), 7.12 (s, 3H), 7.22 (s, 1H), 8.07 (s, 1H), 8.66 (s, 1H), 10.38 (s, 1H), 11.68 (s, 1H); Mass Spectrum:  $M+H^+$  393.

The 4-amino-7-cyclopropylmethoxy-6-methoxyquinazoline used as a starting material was prepared as follows :-

A mixture of 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (6.99 g), cyclopropylmethyl chloride (2.16 g), potassium iodide (0.043 g), potassium carbonate (12 g) and DMF (200 ml) was stirred and heated to 45°C for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-7-cyclopropylmethoxy-6-methoxyquinazoline (7.6 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.43 (m, 2H), 0.68 (m, 2H), 1.37 (m, 1H), 4.0 (s, 3H), 4.1 (d, 2H), 7.4 (s, 1H), 7.45 (m, 1H), 7.57 (m, 2H), 7.82 (m, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 421 and 423.

Using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with starting materials, 4-(4-bromo-2-fluorophenoxy)-7-cyclopropylmethoxy-6-methoxyquinazoline (1.75 g) was reacted with ammonia in isopropanol. There was thus obtained 4-amino-7-cyclopropylmethoxy-6-methoxyquinazoline (1.75 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 0.36 (m, 2H), 0.58 (m, 2H), 1.3 (m, 1H), 3.88 (s, 3H), 3.94 (d, 2H), 6.97 (s, 1H), 7.39 (br s, 2H), 7.55 (s, 1H), 8.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 246.

[140] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.23-1.46 (m, 6H), 1.55-1.69 (m, 2H), 2.1 (s, 3H), 2.1-2.4 (m, 10H), 2.7-2.8 (m, 2H), 3.97 (s, 3H), 7.3-7.6 (m, 3H), 7.65 (s, 1H), 8.05 (s, 1H), 8.7 (s, 1H), 10.7 (s, 1H), 12.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 545 and 547.

The 4-amino-6-methoxy-7-[6-(N-methylpiperazin-1-yl)hexyl]quinazoline used as a starting material was prepared as follows :-

A mixture of 4-amino-6-methoxy-7-[6-(N-methylpiperazin-1-yl)-1-hexynyl]quinazoline (0.145 g), 10% palladium-on-charcoal catalyst (0.02 g) and ethanol (10 ml) was stirred at ambient temperature under 5 atmospheres pressure of hydrogen until uptake of hydrogen ceased. The reaction mixture was filtered and the filtrate was evaporated. There was thus obtained the title compound as a solid (0.142 g); Mass Spectrum: M+H<sup>+</sup> 358.

[141] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8-2.0 (m, 6H), 2.5-2.7 (m, 6H), 2.79-2.85 (t, 2H), 3.6 (s, 3H), 7.2-7.4 (m, 3H), 7.4 (s, 1H), 7.73 (s, 1H), 8.72 (s, 1H), 9.3-9.45 (s, 1H), 12.3 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 474 and 476.

The 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)propyl]quinazoline used as a starting material was prepared by the hydrogenation of 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline using an analogous procedure to that described in Note [139] above.

[142] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.6-1.75 (m, 2H), 2.1 (s, 3H), 2.2-2.4 (m, 10H), 3.3 (m, 2H), 4.0 (s, 3H), 7.25-7.6 (m, 3H), 7.94 (s, 1H), 8.19 (s, 1H), 8.5 (br t, 1H), 8.77 (s, 1H), 10.87 (s, 1H), 11.96 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 546 and 548.

The 4-amino-6-methoxy-7-[N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl]quinazoline used as a starting material was prepared as follows :-

10 A mixture of 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline (9.7 g), palladium acetate (0.137 g), 1,3-bis(diphenylphosphino)propane (0.402 g), triethylamine (5.5 ml), DMF (60 ml) and methanol (1.2L) was stirred and heated to 70°C under 10 atmospheres pressure of carbon monoxide for 2 hours. The reaction mixture was cooled to ambient temperature and the solid  
15 was isolated, washed with methanol and dried under vacuum. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-methoxycarbonylquinazoline (5.96 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.91 (s, 3H), 4.02 (s, 3H), 7.4-7.8 (m, 3H), 7.8 (s, 1H), 8.2 (s, 1H), 8.69 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 407 & 409.

A mixture of a portion (2 g) of the product so obtained, 2,4,6-trimethoxybenzylamine  
20 hydrochloride (2.34 g), anhydrous potassium carbonate (2.76 g) and DMF (20 ml) was stirred and heated to 70°C for 2 hours. The mixture was cooled to ambient temperature and diluted with water. The resultant solid was isolated, washed in turn with water and diethyl ether and dried under vacuum at 80°C. There was thus obtained 6-methoxy-7-methoxycarbonyl-4-(2,4,6-trimethoxybenzylamino)quinazoline (1.9 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.75-3.85  
25 (m, 15H), 4.55 (d, 2H), 6.3 (s, 2H), 7.8 (m, 2H), 7.9 (m, 1H), 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 414.

A portion (1.8 g) of the material so obtained was suspended in a mixture of THF (27 ml), methanol (14 ml) and water (14 ml) and lithium hydroxide (0.945 g) was added portionwise. The resultant mixture was stirred at ambient temperature for 2 hours. The  
30 mixture was concentrated by evaporation and acidified to pH4 by the addition of 2N aqueous hydrochloride acid. The resultant solid was isolated, washed in turn with water and diethyl ether and dried at 80°C. There was thus obtained 7-carboxy-6-methoxy-4-(2,4,6-trimethoxybenzylamino)quinazoline (1.68 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.7-3.9

(m, 12H), 4.55 (s, 2H), 6.28 (s, 2H), 7.7-7.9 (m, 3H), 8.42 (s, 1H); Mass Spectrum:  $M+H^+$  400.

A mixture of a portion (0.3 g) of the material so obtained, 3-(N-methylpiperazin-1-yl)propylamine (0.33 g), N-hydroxybenzotriazole (0.13 g), 5 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.287 g) and DMF (3 ml) was stirred at ambient temperature for 16 hours. Dilute aqueous potassium carbonate solution was added and the resultant solid was isolated, washed in turn with water and diethyl ether and dried at 60°C under vacuum. There was thus obtained 6-methoxy-7-{N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl}-4-(2,4,6-trimethoxybenzylamino)quinazoline 10 (0.285 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.58-1.7 (m, 2H), 2.11 (s, 3H), 2.2-2.4 (m, 10H), 3.2-3.4 (m, 2H), 3.7-3.92 (m, 12H), 4.51 (m, 2H), 6.3 (s, 2H), 7.7-7.86 (m, 3H), 8.3-8.4 (br t, 1H), 8.42 (s, 1H); Mass Spectrum:  $M+H^+$  539.

A mixture of the material so obtained, trifluoroacetic acid (2 ml), anisole (0.2 ml) and concentrated sulphuric acid (0.2 ml) was stirred at ambient temperature for 2 hours. The 15 mixture was evaporated and the residue was partitioned between diethyl ether and a 2M aqueous potassium carbonate solution. The aqueous solution was evaporated and the residue was extracted with methanol. The methanolic extracts were evaporated and the resultant solid was dried under vacuum. There was thus obtained 4-amino-6-methoxy-7-{N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl}quinazoline (0.086 g), Mass Spectrum: 20  $M+H^+$  359.

[143] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.88-2.02 (m, 2H), 3.18-3.25 (m, 2H), 4.0 (s, 3H), 4.0-4.08 (m, 2H), 6.88 (s, 1H), 7.22 (s, 1H), 7.3-7.6 (m, 4H), 7.98 (s, 1H), 8.22 (s, 1H), 8.55-8.6 (br t, 1H), 8.8 (s, 1H), 10.9 (s, 1H), 11.98 (s, 1H); Mass Spectrum:  $M+H^+$  514 and 516.

25 The 4-amino-6-methoxy-7-{N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl}quinazoline used as a starting material was prepared by the reaction of 7-carboxy-6-methoxy-4-(2,4,6-trimethoxybenzylamino)quinazoline and 3-(1-imidazolyl)propylamine and subsequent cleavage of the 2,4,6-trimethoxybenzyl group using analogous procedures to those described in Note [142] above.

30 [144] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.2 (s, 3H), 3.18-3.24 (m, 4H), 3.3-3.4 (m, 4H), 3.97 (s, 3H), 7.18 (s, 1H), 7.3-7.6 (m, 3H), 7.98 (s, 1H), 8.65 (s, 1H), 10.6 (s, 1H), 12.12 (s, 1H); Mass Spectrum:  $M+H^+$  461 and 463.

The 4-amino-6-methoxy-7-(N-methylpiperazin-1-yl)quinazoline used as a starting material was prepared as follows :-

A mixture of 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline (0.8 g), 1-methylpiperazine (0.35 ml), caesium carbonate (0.78g), 1,1'-bis(diphenylphosphino)ferrocene (0.088 g), bis(dibenzylideneacetone)palladium (0.046 g) and toluene (12 ml) was stirred and heated to 100°C for 6 hours. The mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The organic extract was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(N-methylpiperazin-1-yl)quinazoline (0.26 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.4 (s, 3H), 2.66-2.68 (m, 4H), 3.34-3.38 (m, 4H), 4.05 (s, 3H), 7.1-7.44 (m, 3H), 7.38 (s, 1H), 7.55 (s, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 447 and 449.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material. [145] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.43 (s, 9H), 3.13-3.19 (m, 4H), 3.45-3.55 (m, 4H), 4.0 (s, 3H), 7.2 (s, 1H), 7.35-7.6 (m, 3H), 8.02 (s, 1H), 8.65 (s, 1H), 10.65 (s, 1H), 12.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 547 and 549.

The 4-amino-7-[N-(tert-butoxycarbonyl)piperazin-1-yl]-6-methoxyquinazoline used as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that 1-(tert-butoxycarbonyl)piperazine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[N-(tert-butoxycarbonyl)piperazin-1-yl]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.5 (s, 9H), 3.22 (m, 4H), 3.66 (m, 4H), 4.08 (s, 3H), 7.1-7.46 (m, 3H), 7.35 (s, 1H), 7.57 (s, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material. [146] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.75-1.85 (m, 2H), 2.3-2.45 (m, 6H), 3.25-3.35 (m, 2H), 3.6-3.68 (m, 4H), 4.0 (s, 3H), 6.7 (s, 1H), 6.89 (t, 1H),

7.35-7.6 (m, 3H), 7.88 (s, 1H), 8.51 (s, 1H), 10.3 (s, 1H), 12.25 (s, 1H); Mass Spectrum:  $M+H^+$  505 and 507.

The 4-amino-6-methoxy-7-(3-morpholinopropylamino)quinazoline used as a starting material was prepared from as follows :-

5 The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that 3-morpholinopropylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-morpholinopropylamino)quinazoline; NMR Spectrum: ( $CDCl_3$ ) 1.9-2.0 (m, 2H), 2.48-2.6 (m, 6H), 3.35-3.42 (m, 2H), 3.78-3.82 (m, 4H),  
10 4.07 (s, 3H), 6.4-6.48 (t, 1H), 6.86 (s, 1H), 7.1-7.42 (m, 3H), 7.43 (s, 1H), 8.5 (s, 1H); Mass Spectrum:  $M+H^+$  491 and 493.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material. [147] The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 2.0-2.12 (m, 2H),  
15 3.15-3.25 (m, 2H), 4.0 (s, 3H), 4.05-4.12 (m, 2H), 6.45-6.5 (t, 1H), 6.68 (s, 1H), 6.9 (s, 1H), 7.22 (s, 1H), 7.35-7.6 (m, 3H), 7.65 (s, 1H), 7.88 (s, 1H), 8.55 (s, 1H), 10.35 (s, 1H), 12.22 (s, 1H); Mass Spectrum:  $M+H^+$  486 and 488.

The 4-amino-7-(3-imidazol-1-ylpropylamino)-6-methoxyquinazoline used as a starting material was prepared from as follows :-

20 The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that 3-imidazol-1-ylpropylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-(3-imidazol-1-ylpropylamino)-  
6-methoxyquinazoline; NMR Spectrum: ( $CDCl_3$ ) 2.2-2.3 (m, 2H), 3.3-3.4 (m, 2H), 4.05 (s,  
25 3H), 4.1-4.15 (m, 2H), 5.04-5.13 (br t, 1H), 6.88 (s, 1H), 6.96 (s, 1H), 7.1 (s, 1H), 7.15-7.5 (m, 3H), 7.45 (s, 1H), 7.52 (s, 1H), 8.55 (s, 1H); Mass Spectrum:  $M+H^+$  472 and 474.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material. [148] The reactants were heated to 45°C for 20 hours. The product gave the following data:  
30 NMR Spectrum: ( $CDCl_3$ ) 1.2-1.4 (m, 2H), 1.66-1.94 (m, 5H), 2.14 (s, 3H), 2.16 (s, 3H), 2.26 (s, 3H), 2.7 (m, 2H), 2.78 (s, 3H), 2.98 (s, 3H), 3.94 (s, 3H), 4.04 (d, 2H), 7.0 (d, 1H), 7.18 (d, 1H), 7.24 (s, 1H), 8.02 (s, 1H), 8.64 (s, 1H), 10.36 (s, 1H), 11.72 (s, 1H); Mass Spectrum:  $M+H^+$  521.

[149] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.73 (m, 4H), 2.09 (m, 2H), 2.28 (s, 3H), 2.48 (br m, 4H), 2.57 (t, 2H), 3.35 (s, 3H), 4.18 (t, 2H), 5.24 (s, 1H), 7.08 (d, 2H), 7.19 (s, 1H), 7.27 (t, 1H), 7.42 (s, 1H), 8.61 (s, 1H), 9.72 (s, 1H), 12.19 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 470 and 472.

5 [150] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 450 and 452.

The 4-amino-7-(3-methoxypropylamino)-6-methoxyquinazoline used as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that

10 3-methoxypropylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-(3-methoxypropylamino)-6-methoxyquinazoline.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

[151] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 421 and 423.

15 The 4-amino-7-(2-aminoethylamino)-6-methoxyquinazoline used as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that ethylenediamine was used in place of 1-methylpiperazine. There was thus obtained

20 7-(2-aminoethylamino)-4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazoline.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

[152] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 491 and 493.

25 The 4-amino-7-[N-(2-diethylaminoethyl)-N-methylamino]-6-methoxyquinazoline used as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that N-(2-diethylaminoethyl)-N-methylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-[N-(2-diethylaminoethyl)-N-methylamino]-

30 6-methoxyquinazoline.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

**Example 3** 1-(7-benzyloxy-6-methoxyquinazolin-4-yl)-3-(2,6-dichlorophenyl)urea

2,6-Dichlorophenyl isocyanate (0.745 g) was added to a solution of 4-amino-7-benzyloxy-6-methoxyquinazoline (0.279 g) in chloroform (10 ml) and the reaction mixture was stirred at ambient temperature for 16 hours. The resultant precipitate was isolated by filtration. There was thus obtained the title compound (0.343 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.96 (s, 3H), 5.32 (s, 2H), 7.35–7.60 (m, 10H), 8.1 (s, 1H), 8.69 (s, 1H), 10.65 (s, 1H), 12.09 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 467 & 469.

**Example 4** 1-(2,6-dichlorophenyl)-3-(6,7-dimethoxyquinazolin-4-yl)urea

Using an analogous procedure to that described in Example 3, 2,6-dichlorophenyl isocyanate was reacted with 4-amino-6,7-dimethoxyquinazoline (European Patent Application No. 30156, Chemical Abstract volume 95, abstract 187290) to give the title compound; NMR Spectrum: (DMSO-d<sub>6</sub>) 3.96 (s, 3H), 7.31 (m, 2H), 7.38 (t, 1H), 7.5 (d, 2H), 7.6 (d, 2H), 8.43 (s, 1H), 8.7 (s, 1H), 10.61 (s, 1H), 12.09 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 393 & 395.

**Example 5** 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-methylurea

6-Methoxy-4-methylamino-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (0.195 g) was added to 2,6-dichlorophenyl isocyanate (0.3 g) under argon and the solids were mixed together using a spatula. The mixture was heated to 85°C with gentle mixing for 40 minutes. The mixture was cooled to ambient temperature, dissolved in a mixture of chloroform (15 ml) and methanol (5 ml) and purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained the title compound (0.016 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.5 (m, 2H), 1.98 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.6 (s, 3H), 4.02 (s, 3H), 4.03 (d, 2H), 7.1 (t, 1H), 7.28 (s, 2H), 7.37 (d, 2H), 8.61 (s, 1H), 8.96 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 504.

The 6-methoxy-4-methylamino-7-(N-methylpiperidin-4-ylmethoxy)quinazoline used as a starting material was obtained as follows :-

A mixture of 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (1 g) and methylamine (1M solution in THF; 20 ml) was heated with agitation in a Carius tube at 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was partitioned between chloroform and a 2N aqueous sodium

hydroxide solution. The chloroform solution was dried over magnesium sulphate and evaporated and the resultant solid was washed with methyl *tert*-butyl ether (20 ml). There was thus obtained the required starting material (0.48 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.33 (m, 2H), 1.8 (m, 5H), 2.14 (s, 3H), 2.76 (d, 2H), 2.96 (d, 3H), 3.85 (s, 3H), 3.92 (d, 2H), 7.03 (s, 1H), 7.51 (s, 1H), 7.84 (q, 1H), 8.31 (s, 1H).

**Example 6** 1-[6-methoxy-7-(*N*-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-(2-methylbenzyl)urea

Using an analogous procedure to that described in Example 3, 2-methylbenzyl isocyanate was reacted with 4-amino-6-methoxy-7-(*N*-methylpiperidin-4-ylmethoxy)quinazoline. The resultant solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.39–1.56 (m, 2H), 1.84–2.04 (m, 5H), 2.29 (s, 3H), 2.39 (s, 3H), 2.9 (d, 2H), 3.92 (s, 3H), 4.03 (d, 2H), 4.66 (d, 2H), 7.21 (m, 4H), 7.34 (m, 2H), 8.6 (s, 1H), 8.74 (s, 1H), 10.44 (t, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

**Example 7** 1-(2,6-dichlorophenyl)-3-(thieno[3,2-*d*]pyrimidin-4-yl)urea

2,6-Dichlorophenyl isocyanate (0.075 g) was added to a mixture of 4-aminothieno[3,2-*d*]pyrimidine (Tetrahedron, 1971, 27, 487; 0.201 g) and acetonitrile (16 ml) and the resultant mixture was stirred at ambient temperature for 16 hours. The precipitate was isolated and washed in turn with diethyl ether and methanol. There was thus obtained the title compound (0.31 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 7.25 (t, 1H), 7.45 (d, 1H), 7.55 (d, 1H), 7.95 (d, 1H), 8.4 (s, 1H), 8.8 (s, 1H), 11.7 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 339 and 341; Elemental Analysis: Found C, 45.8; H, 2.4; N, 16.5; C<sub>13</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>4</sub>OS requires C, 46.03; H, 2.38; N, 16.52 %.

**Example 8** (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylic acid

Hydrogen chloride gas was bubbled during 3 hours through a stirred solution of *tert*-butyl (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylate (1.4 g) in methylene chloride (200 ml) which had been cooled in an ice-bath to 0°C. The mixture was evaporated and there was thus obtained the title compound as its hydrochloride salt;

(1.3 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 6.6 (d, 1H, J = 16Hz), 7.4 (t, 1H), 7.65 (d, 2H), 7.95 (d, 1H), 7.96 (s, 1H), 8.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 409, 411 and 413.

The tert-butyl (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylate used as a starting material was obtained as follows :-

- 5        A mixture of methyl 3-aminothiophene-2-carboxylate (94 g), formamidine acetic acid salt (187 g) and 2-hydroxyethyl methyl ether (1 L) was stirred and heated to reflux for 3 hours. The mixture was cooled to ambient temperature and water (400 ml) was added. The resultant solid was isolated, washed thoroughly with water and with diethyl ether and dried under vacuum. There was thus obtained 3,4-dihydrothieno[3,2-*d*]pyrimidin-4-one (65 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 7.4 (d, 1H), 8.15 (s, 1H), 8.18 (d, 2H); Mass Spectrum : M+Na<sup>+</sup> 175.

- 10       A mixture of a portion (20 g) of the material so obtained, thionyl chloride (250 ml) and DMF (1 ml) was heated to reflux for 2 hours. The mixture was evaporated. Toluene was added and the mixture was evaporated. The residual solid was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was washed  
15 in turn with water and brine, dried over magnesium sulphate and evaporated. The solid so obtained was triturated under petroleum ether (b.p. 60-80°C), re-isolated and dried under vacuum. There was thus obtained 4-chlorothieno[3,2-*d*]pyrimidine (18.5 g); NMR Spectrum: (CDCl<sub>3</sub>) 7.65 (d, 1H), 8.1 (d, 1H), 9.0 (s, 1H); Mass Spectrum: M<sup>+</sup> 170 and 172.

- 20       A portion (17 g) of the material so obtained was dissolved in DMF (100 ml). Sodium methylthiolate (9.1 g) was added and the mixture was stirred at ambient temperature for 1.5 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulphate and purified by column chromatography on silica using a 9:1 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 4-methylthiothieno[3,2-*d*]pyrimidine (16.5 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.76 (s, 3H), 7.5 (d, 1H), 7.85 (d, 1H), 8.97 (s, 1H).

- 25       A portion (5.5 g) of the material so obtained was dissolved in THF (20 ml) and cooled to -78°C. A solution of lithium diisopropylamide [prepared using diisopropylamine (10.5 ml) and n-butyllithium (2.5M in THF; 30 ml)] was added and the mixture was stirred at -78°C for 1 hour. DMF (7 ml) was added and the mixture was allowed to warm to ambient temperature  
30 and was stirred for 16 hours. The resultant mixture was partitioned between ethyl acetate and a saturated aqueous ammonium chloride solution. The organic layer was evaporated and the residue was purified by column chromatography on silica using a 9:1 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 6-formyl-

4-methylthiothieno[3,2-*d*]pyrimidine (4.1 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.78 (s, 3H), 8.13 (s, 1H), 9.04 (s, 1H), 10.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 211.

tert-Butoxycarbonylmethylenetriphenylphosphorane (20.6 g) was added portionwise to a solution of 6-formyl-4-methylthiothieno[3,2-*d*]pyrimidine (9.6 g) in methylene chloride  
5 (500 ml) and the mixture was stirred at ambient temperature for 16 hours. The mixture was concentrated to half of its original volume and poured onto a column of silica. The column was eluted initially with methylene chloride followed by a 19:1 mixture of methylene chloride and ethyl acetate. The material so obtained was triturated under petroleum ether (b.p. 60-80°C), re-isolated and dried under vacuum. There was thus obtained tert-butyl  
10 (*E*)-3-(4-methylthiothieno[3,2-*d*]pyrimidin-6-yl)acrylate (12 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.54 (s, 9H), 2.76 (s, 3H), 6.42 (d, 1H, J = 15 Hz), 7.53 (s, 1H), 7.8 (d, 1H), 8.94 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 308.

A portion (2.9 g) of the material so obtained was dissolved in methylene chloride (200 ml) and m-chloroperoxybenzoic acid (70% ; 9.25 g) was added. The resultant mixture  
15 was stirred at ambient temperature for 2 hours. The mixture was washed with an aqueous sodium bisulphite solution. The organic layer was washed with a dilute (5%) aqueous sodium bicarbonate solution and with brine, dried over magnesium sulphate and evaporated. There was thus obtained tert-butyl (*E*)-3-(4-methylsulphonylthieno[3,2-*d*]pyrimidin-6-yl)acrylate (3.1 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.55 (s, 9H), 3.39 (s, 3H), 6.6 (d, 1H, J = 16 Hz), 7.71 (s,  
20 1H), 7.85 (d, 1H), 9.3 (s, 1H).

A solution of the sulphone so obtained (3 g) in THF (100 ml) was cooled at 0°C and gaseous ammonia was bubbled through the solution for 2 hours. The mixture was evaporated and the residue was triturated under diethyl ether. The solid so obtained was purified by column chromatography on silica using a 49:1 mixture of methylene chloride and methanol as  
25 eluent. There was thus obtained tert-butyl (*E*)-3-(4-aminothieno[3,2-*d*]pyrimidin-6-yl)acrylate (1.7 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.55 (s, 9H), 5.25 (br s, 2H), 6.38 (d, 1H, J = 16 Hz), 7.51 (s, 1H), 7.76 (d, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 277.

A mixture of the material so obtained, 2,6-dichlorophenyl isocyanate (1.41 g) and methylene chloride (250 ml) was stirred at ambient temperature for 3 hours. Water was added  
30 and the organic layer was separated, washed with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 49:1 mixture of methylene chloride and methanol as eluent. There was thus obtained tert-butyl (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylate

(1.5 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.57 (s, 9H), 6.29 (d, 1H, J = 16 Hz), 7.3 (t, 1H), 7.53 (d, 2H), 7.55 (s, 1H), 7.74 (d, 1H), 8.8 (s, 1H), 9.95 (br s, 1H), 11.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 465, 467 & 469.


5 **Example 9** (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}-  
N-(2-piperidinoethyl)acrylamide

Diphenylphosphoryl azide (0.085 ml) was added to a mixture of  
(*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl} acrylic acid  
hydrochloride salt (0.11 g), 2-piperidinoethylamine (0.064 g), triethylamine (0.07 ml) and  
10 DMF (1.5 ml). The mixture was stirred at ambient temperature for 16 hours. The mixture  
was evaporated and the residue was purified by column chromatography on silica using  
increasingly polar mixtures of methylene chloride and methanol as eluent. The material so  
obtained was triturated under diethyl ether, isolated, washed with diethyl ether and dried under  
vacuum. There was thus obtained the title compound (0.087 g); NMR Spectrum: (DMSO-d<sub>6</sub>  
15 and CF<sub>3</sub>COOD) 1.3-1.5 (m, 1H), 1.6-1.8 (m, 4H), 1.85 (d, 2H), 2.95 (t, 2H), 3.2 (t, 2H), 3.55  
(d, 2H), 3.6 (t, 2H), 6.82 (d, 1H, J = 16 Hz), 7.4 (t, 1H), 7.6 (d, 1H), 7.86 (s, 1H), 7.86 (d, 1H),  
8.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 519 and 521.

**Example 10**

20 Using an analogous procedure to that described in Example 9, the appropriate  
amine was reacted with (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-  
6-yl} acrylic acid to give the compounds described in Table II.

Table II



25

No.	R <sup>a</sup>	R <sup>b</sup>	Note
1	2-dimethylaminoethyl	hydrogen	(a)

2	3-dimethylaminopropyl	hydrogen	(b)
3	2-pyrrolidin-1-ylethyl	hydrogen	(c)
4	3-(2-oxopyrrolidin-1-yl)propyl	hydrogen	(d)
5	3-morpholinopropyl	hydrogen	(e)
6	3-(4-methylpiperazin-1-yl)propyl	hydrogen	(f)
7	3-imidazol-1-ylpropyl	hydrogen	(g)
8	4-pyridylmethyl	hydrogen	(h)
9	2-(2-pyridyl)ethyl	hydrogen	(i)
10	2-(2-pyridyl)ethyl	methyl	(j)

### Notes

- (a) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.9 (s, 6H), 3.25 (t, 2H), 3.6 (t, 2H), 6.9 (d, 1H, J = 16 Hz), 7.42 (t, 1H), 7.65 (d, 2H), 7.85 (d, 1H), 7.88 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 479 and 481.
- (b) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.8-1.9 (m, 2H), 2.81 (s, 3H), 3.15 (m, 2H), 3.3 (t, 2H), 6.84 (d, 1H, J = 19 Hz), 7.45 (t, 1H), 7.6 (d, 2H), 7.81 (d, 1H), 7.85 (s, 1H), 9.02 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 493 and 495.
- (c) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.8-1.95 (m, 2H), 1.95-2.1 (m, 2H), 3.0-3.15 (m, 2H), 3.3 (t, 2H), 3.55 (t, 2H), 3.55-3.7 (m, 2H), 6.8 (d, 1H), 7.42 (t, 1H), 7.6 (d, 2H), 7.82 (d, 1H), 7.84 (s, 1H), 8.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 505 and 507.
- (d) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.65-1.75 (m, 2H), 1.9-2.0 (m, 2H), 2.3 (t, 2H), 3.25 (t, 2H), 3.3 (t, 2H), 3.4 (t, 2H), 6.25 (d, 1H, J = 16 Hz), 7.42 (t, 1H), 7.62 (d, 2H), 7.81 (d, 1H), 7.85 (s, 1H), 9.12 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.
- (e) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.85-2.0 (m, 2H), 3.0-3.25 (m, 4H), 3.3 (t, 2H), 3.5 (d, 2H), 3.7 (t, 2H), 4.0 (d, 2H), 6.9 (d, 1H, J = 16 Hz), 7.45 (t, 1H), 7.61 (d, 2H), 7.85 (d, 1H), 7.87 (s, 1H), 9.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 535 and 537.
- (f) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.85-2.0 (m, 2H), 2.95 (s, 3H), 3.2-3.4 (m, 6H), 3.4-4.0 (br m, 6H), 6.85 (d, 1H, J = 14 Hz),

7.42 (t, 1H), 7.65 (d, 2H), 7.82 (d, 1H), 7.85 (s, 1H), 9.0 (s, 1H); Mass Spectrum:  $M+H^+$  548 and 550.

(g) The product gave the following data: NMR Spectrum: ( $DMSO-d_6$  and  $CF_3COOD$ ) 2.0-2.1 (m, 2H), 3.25 (t, 2H), 4.25 (t, 2H), 6.75 (d, 1H,  $J = 15$  Hz), 7.2-7.3 (d, 1H), 7.4 (t, 2H), 7.6  
5 (d, 2H), 7.85 (m, 2H), 8.9 (s, 1H), 9.2 (s, 1H); Mass Spectrum:  $M+H^+$  516.

(h) The product gave the following data: NMR Spectrum: ( $DMSO-d_6$  and  $CF_3COOD$ ) 4.75 (br s, 2H), 6.95 (d, 1H,  $J = 15$  Hz), 7.4 (t, 1H), 7.6 (d, 1H), 7.85 (s, 1H), 7.87 (d, 1H), 8.05 (d, 2H), 8.9 (d, 2H), 8.93 (s, 1H); Mass Spectrum:  $M+H^+$  499 and 501.

(i) The product gave the following data: NMR Spectrum: ( $DMSO-d_6$  and  $CF_3COOD$ ) 3.25  
10 (t, 2H), 3.7 (t, 2H), 6.8 (d, 1H,  $J = 15$  Hz), 7.42 (t, 1H), 7.62 (d, 2H), 7.75 (d, 1H), 7.83 (s, 1H), 8.0 (t, 1H), 8.05 (d, 1H), 8.58 (t, 1H), 8.9 (d, 1H), 9.0 (s, 1H); Mass Spectrum:  $M+H^+$  513 and 515.

(j) The product gave the following data: NMR Spectrum: ( $DMSO-d_6$  and  $CF_3COOD$ ) 3.4 (s, 3H), 5.0 (s, 2H), 7.35-7.5 (m, 2H), 7.61 (d, 2H), 7.8 (d, 1H), 7.98 (s, 1H), 7.85-8.1 (m, 2H),  
15 8.6 (t, 1H), 8.9 (d, 1H), 9.0 (s, 1H); Mass Spectrum:  $M+H^+$  513 and 515.

**Example 11** 1-benzyl-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea

Using an analogous procedure to that described in Example 1 except that the reaction  
20 mixture was heated to 35°C for 16 hours, benzyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: ( $DMSO-d_6$ ): 1.3-1.5 (m, 2H), 1.8-1.9 (m, 4H), 1.95 (t, 1H), 2.2 (s, 3H), 2.8 (br d, 2H), 3.9 (br s, 3H), 4.0 (br d, 2H), 4.5 (br d, 2H), 7.2-7.3 (m, 2H), 7.3-7.4 (m, 4H), 8.0 (br s, 1H), 8.55 (br s, 1H), 10.2-10.5 (br s, 1H), 10.4 (t, 1H); Mass Spectrum:  $M+H^+$  436.


25

**Example 12** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-phenethylurea

Using an analogous procedure to that described in Example 3, phenethyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give  
30 the title compound; NMR Spectrum: ( $CDCl_3$ ) 1.48 (m, 2H), 1.98 (m, 5H), 2.29 (s, 3H), 2.91 (m, 4H), 3.7 (q, 2H), 4.02 (d, 5H), 7.28 (m, partially obscured by  $CHCl_3$  peak), 8.47 (s, 1H), 8.65 (s, 1H), 10.1 (s, 1H); Mass Spectrum:  $M+H^+$  450.

**Example 13**

Using an analogous procedure to that described in Example 1 except that, unless otherwise stated, chloroform was used in place of methylene chloride as the reaction solvent, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the 5 compounds described in Table III.

**Table III**

No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-chloro	(a)
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	3,4-dichloro	(b)
3	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	3,5-dichloro	(c)
4	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-bromo	(d)
5	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-nitro	(e)

**10 Notes**

(a) DMF was used in place of methylene chloride as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.48 (m, 2H), 1.97 (m, 5H), 2.29 (s, 3H), 2.91 (m, 2H), 3.81 (s, 3H), 4.04 (d, 2H), 7.25 (s, 2H), 7.3 (d, 2H), 7.57 (d, 2H), 8.73 (s, 1H), 8.91 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 456 and 458.

15 (b) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.51 (m, 2H), 1.92 (m, 5H), 2.3 (s, 3H), 2.92 (d, 2H), 3.9 (s, 3H), 4.03 (d, 2H), 7.2 (s, 1H), 7.24 (s, partially obscured by CHCl<sub>3</sub> peak), 7.41 (m, 2H), 7.82 (s, 1H), 8.55 (s, 1H), 8.74 (s, 1H), 12.55 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

20 (c) DMF was used in place of methylene chloride as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.48 (m, 2H), 1.95 (m, 5H), 2.28 (s, 3H), 2.95 (d, 2H), 3.91 (s, 3H), 4.03 (d, 2H), 7.11 (s, 1H), 7.26 (s, 2H), 7.58 (s, 2H), 8.63 (s, 1H), 8.75 (s, 1H), 12.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

(d) Methylene chloride was used as the reaction solvent and the reaction mixture was heated to 35°C for 16 hours. The product gave the following data: NMR Spectrum:

(DMSO-d<sub>6</sub>) 1.2-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.8 (d, 2H), 3.9 (br s, 3H), 4.0 (br d, 2H), 7.2 (s, 1H), 7.4-7.45 (m, 2H), 7.5-7.55 (m, 2H), 7.6-7.7 (m, 2H), 8.0 (br s, 1H), 8.7 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 500 and 502.

(e) Methylene chloride was used as the reaction solvent and the reaction mixture was heated to 35°C for 16 hours. The product gave the following data: NMR Spectrum:

(DMSO-d<sub>6</sub>) 1.3-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.7 (d, 2H), 3.9 (s, 3H), 4.0 (br d, 2H), 7.2 (s, 1H), 7.8 (d, 2H), 7.9 (s, 1H), 8.1 (d, 2H), 8.6 (br s, 1H), 10.2-10.5 (br s, 1H), 12.3-12.7 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 467.

**Example 14** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-(trans-2-phenylcyclopropyl)urea

trans-2-Phenylcyclopropyl isocyanate (0.2 ml) was added to a stirred mixture of 4-amino-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (0.1 g) and chloroform (3 ml) and the resultant mixture was stirred at ambient temperature for 20 hours. The reaction mixture was diluted with chloroform (3 ml) and tris-(2-aminoethyl)amine polystyrene resin (0.5 g) was added. The mixture was stirred at ambient temperature for 1 hour. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and 2M methanolic ammonia as eluent. There was thus obtained the title compound (0.11 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.24-1.38 (m, 2H), 1.41-1.57 (m, 2H), 1.87-2.05 (m, 5H), 2.21 (m, 1H), 2.3 (s, 3H), 2.91 (d, 2H), 3.05 (m, 1H), 3.97 (s, 3H), 4.04 (d, 2H), 7.1-7.26 (m, 6H partially obscured by CHCl<sub>3</sub> peak), 7.34 (m, 1H), 8.66 (s, 1H), 8.72 (s, 1H), 10.31 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 462.

**Example 15** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-[(S)-(-)-α-methylbenzyl]urea

Using an analogous procedure to that described in Example 14, (S)-(-)-α-methylbenzyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.4-1.56 (m, 2H), 1.61 (d, 3H), 1.84-2.05 (m, 5H), 2.31 (s, 3H), 2.91 (d, 2H), 3.88

(s, 3H), 4.04 (d, 2H), 5.2 (m, 1H), 7.23 (d, 2H), 7.3–7.41 (m, 5H), 8.66 (s, 1H), 8.7 (s, 1H), 10.58 (s, 1H); Mass Spectrum:  $M+H^+$  450.

**Example 16** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-

5 3-[(R)-(+)- $\alpha$ -methylbenzyl]urea

Using an analogous procedure to that described in Example 14,

(R)-(+)- $\alpha$ -methylbenzyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: ( $CDCl_3$ ) 1.39–1.56 (m, 2H), 1.64 (d, 3H), 1.86–2.05 (m, 5H), 2.3 (s, 3H), 2.9 (d, 2H), 3.9 (s, 10 3H), 4.01 (d, 2H), 5.19 (m, 1H), 7.24 (d, 2H), 7.32–7.41 (m, 5H), 8.44 (s, 1H), 8.67 (s, 1H), 10.5 (s, 1H); Mass Spectrum:  $M+H^+$  450.

**Example 17** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-

3-[1-(1-naphthyl)ethyl]urea

15 Using an analogous procedure to that described in Example 14,

1-(1-naphthyl)ethyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: ( $CDCl_3$ ) 1.41–1.57 (m, 2H), 1.76 (m, partially obscured by water peak), 1.86–2.05 (m, 5H), 2.02 (s, 3H), 2.91 (s, 2H), 3.87 (s, 3H), 4.02 (d, 2H), 5.95 (s, 1H), 7.19 (s, 1H), 7.23 (s, 1H), 7.39–7.52 (m, 3H), 7.6 (d, 20 1H), 7.71 (d, 1H), 7.84 (m, 1H), 8.12 (m, 1H), 8.57 (s, 1H), 8.64 (s, 1H), 10.67 (t, 1H); Mass Spectrum:  $M+H^+$  500.

**Example 18** 1-(3-cyano-6,7-dimethoxyquinolin-4-yl)-3-(2,6-dichlorophenyl)urea

A solution of 4-amino-3-cyano-6,7-dimethoxyquinoline (0.115 g) in DMF (2 ml) was  
25 added to a stirred mixture of sodium hydride (50% dispersion in mineral oil; 0.04 g) and DMF (3 ml) and the mixture was stirred at ambient temperature for 20 minutes. 2,6-Dichlorophenyl isocyanate (0.17 g) was added and the mixture was stirred at ambient temperature for 20 hours. A second portion of sodium hydride dispersion (0.08 g) was added followed, after 20 minutes, by more 2,6-dichlorophenyl isocyanate (0.3 g). The reaction mixture was stirred  
30 for a further 2 hours. Methanol (1 ml) was added and the mixture was partitioned between ethyl acetate (50 ml) and water (10 ml). The organic layer was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of ethyl

acetate and methanol as eluent. There was thus obtained the title compound (0.03 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 4.05 (s, 6H), 7.4-7.8 (m, 4H), 8.08 (s, 2H), 9.22 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 417 & 419.


The 4-amino-3-cyano-6,7-dimethoxyquinoline used as a starting material was prepared as follows :-

A mixture of 4-chloro-3-cyano-6,7-dimethoxyquinoline (International Patent Application WO 98/43960; 1.24 g) and a 1M solution of ammonia gas in isopropanol (20 ml) was sealed in a Carius tube and heated to 120°C for 16 hours. The mixture was cooled to ambient temperature. A saturated aqueous sodium bicarbonate solution (50 ml) was added and the mixture was stirred for 15 minutes. The precipitate was isolated, washed with water (50 ml) and dried. There was thus obtained the required starting material (0.93 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.88 (s, 3H), 3.9 (s, 3H), 7.2 (s, 1H), 7.63 (s, 2H), 7.69 (s, 1H), 8.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 230.

#### 15 Example 19

Using an analogous procedure to that described in Example 14, the appropriate 4-aminoquinazoline was, unless otherwise stated, reacted with (R)-(+)- $\alpha$ -methylbenzyl isocyanate to give the compounds described in Table IV.

Table IV



20

No.	R <sup>6</sup>	R <sup>7</sup>	Z	Note
1	methoxy	2-pyrrolidin-1-ylethoxy	O	(a)
2	methoxy	2-piperidinoethoxy	O	(b)
3	methoxy	2-piperidinoethoxy	O	(c)
4	methoxy	2-morpholinoethoxy	O	(d)
5	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	O	(e)
6	methoxy	3-pyrrolidin-1-ylpropoxy	O	(f)

7	methoxy	3-piperidinopropoxy	O	(g)
8	methoxy	3-morpholinopropoxy	O	(h)
9	methoxy	3-(4-methylpiperazin-1-yl)propoxy	O	(i)
10	methoxy	2-(2-methoxyethoxy)ethoxy	O	(j)
11	3-piperidinopropoxy	methoxy	O	(k)
12	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	S	(l)

Notes


- (a) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.63 (d, 3H), 1.87 (s, 4H), 2.74 (s, 4H), 3.07 (t, 2H), 3.98 (s, 3H), 4.34 (t, 2H), 5.18 (m, 1H), 7.19–7.4 (m, 7H), 8.68 (d, 2H), 10.54 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 436.
- 5 (b) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (m, 2H), 1.66 (d, 7H), 2.54 (t, 4H), 2.9 (t, 2H), 3.89 (s, 3H), 4.3 (t, 2H), 5.19 (m, 1H), 7.2–7.4 (m, 7H), 8.68 (s, 1H), 8.8 (s, 1H), 10.55 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.
- (c) (S)-(-)- $\alpha$ -Methylbenzyl isocyanate was used in place of (R)-(+)- $\alpha$ -methylbenzyl isocyanate. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (m, 2H), 1.62  
10 (m, 7H), 2.56 (s, 4H), 2.9 (t, 2H), 3.88 (s, 3H), 4.31 (t, 2H), 5.17 (m, 1H), 7.19–7.41 (m, 7H), 8.68 (s, 1H), 8.8 (s, 1H), 10.55 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.
- (d) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4 (d, 3H), 2.65 (t, 4H), 3.05 (t, 2H), 3.75 (t, 4H), 3.87 (s, 3H), 4.31 (t, 2H), 5.18 (m, 1H), 7.14 (d, 2H), 7.19–7.41 (m, 5H), 8.68 (s, 1H), 8.85 (s, 1H), 10.54 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 452.
- 15 (e) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.63 (d, 3H), 3.46 (t, 2H), 3.75 (m, 4H), 3.93 (s, 3H), 4.29 (t, 2H), 4.61 (s, 1H), 5.17 (m, 1H), 7.2–7.41 (m, 7H), 8.57 (s, 1H), 8.67 (s, 1H), 10.5 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 451.
- (f) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.62 (d, 3H), 1.87 (s, 4H), 2.2 (m, 2H), 2.7 (s, 4H), 2.8 (t, 2H), 3.91 (s, 3H), 4.24 (t, 2H), 5.18 (m, 1H), 7.2–7.27 (m,  
20 2H), 7.29–7.32 (m, 5H), 8.44 (s, 1H), 8.67 (s, 1H), 10.47 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.
- (g) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.39 (m, 2H), 1.62 (d, 3H), 1.9 (s, 4H), 2.39 (t, 2H), 2.8–3.01 (br m, 6H), 3.9 (s, 3H), 4.24 (t, 2H), 5.14 (m, 1H), 7.1–7.44 (m, 7H), 8.45 (s, 1H), 8.65 (s, 1H), 10.45 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 464.
- (h) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.62 (d, 3H), 2.13 (m,  
25 2H), 2.59 (m, 6H), 3.85 (t, 4H), 3.91 (s, 3H), 4.26 (t, 2H), 5.18 (m, 1H), 7.2–7.4 (m, 7H), 8.5 (s, 1H), 8.77 (s, 1H), 10.5 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 466.

- (i) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.62 (d, 3H), 1.76 (s, 4H), 2.1 (m, 2H), 2.31 (s, 3H), 2.4–2.6 (m, 6H), 3.92 (s, 3H), 4.24 (t, 2H), 5.19 (m, 1H), 7.21–7.41 (m, 7H), 8.49 (s, 1H), 8.68 (s, 1H), 10.5 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 479.
- (j) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.59 (d, 3H), 3.39 (s, 3H), 3.6 (m, 2H), 3.76 (m, 2H), 3.87 (s, 3H), 4.0 (t, 2H), 4.36 (t, 2H), 5.21 (m, 1H), 7.19–7.39 (m, 7H), 8.69 (s, 1H), 8.97 (s, 1H), 10.58 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 441.
- (k) The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>) 1.38 (br s, 2H), 1.53 (m, 6H), 2.0 (m, 2H), 3.3–3.53 (br s, 6H), 3.95 (s, 3H), 4.17 (t, 2H), 5.04 (m, 1H), 7.25 (s, 1H), 7.37 (br m, 5H), 8.02 (s, 1H), 8.65 (s, 1H), 10.1 (s, 1H), 10.5 (d, 1H); Mass Spectrum:  
 10 M+H<sup>+</sup> 464.
- (l) The 4-aminoquinazoline was reacted with (R)-(+)- $\alpha$ -methylbenzyl isothiocyanate. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42–1.57 (m, 2H), 1.71 (d, 3H), 1.86–2.06 (m, 5H), 2.31 (s, 3H), 2.92 (d, 2H), 4.02 (m, 5H), 5.69 (m, 1H), 6.98 (s, 1H), 7.24–7.31 (m, 2H), 7.34–7.47 (m, 4H), 8.54 (s, 1H), 8.65 (s, 1H), 12.57 (d, 1H); Mass Spectrum:  
 15 M+H<sup>+</sup> 466.

### Example 20

Using an analogous procedure to that described in Example 5, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the compounds  
 20 described in Table V.

Table V



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	3-(4- <u>tert</u> -butoxycarbonylaminoethyl)piperidin-1-ylpropoxy	2,6-dichloro	(a)
2	methoxy	3-(4- <u>tert</u> -butoxycarbonylaminoethyl)piperidin-1-ylpropoxy	2,6-difluoro	(b)

3	methoxy	3-(4- <u>tert</u> -butoxycarbonylaminomethylpiperidin-1-yl)propoxy	2,6-dimethyl	(c)
4	methoxy	3-(4- <u>tert</u> -butoxycarbonylaminomethylpiperidin-1-yl)propoxy	2-chloro-6-methyl	(d)

Notes

- (a) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.2-1.35 (m, 2H), 1.43 (s, 9H), 1.6-1.72 (m, 3H), 1.94 (t, 2H), 2.0-2.15 (m, 2H), 2.52 (t, 2H), 2.9 (d, 2H), 3.02 (t, 2H), 3.6 (s, 3H), 4.23 (t, 2H), 4.6 (s, 1H), 7.1-7.3 (m, 3H), 7.38-7.43 (m, 2H), 8.7 (s, 1H), 9.38  
5 (s, 1H), 12.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 633 and 635.

The 4-amino-7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazoline used as a starting material was prepared as follows :-

- A mixture of 4-(4-bromo-2-fluorophenoxy)-7-(3-bromopropoxy)-6-methoxyquinazoline (0.486 g), 4-(tert-butoxycarbonylaminomethyl)piperidine (Chemical  
10 Abstracts Registry No. 135632-53-0, for example US Patent No. 5,864,039; 0.252 g), potassium carbonate (0.7 g) and DMF (10 ml) was stirred at 45°C for 20 hours. The solvent was evaporated and the residue was stirred with water (20 ml). The resultant solid was isolated and purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2N solution of ammonia in methanol as eluent. There was thus  
15 obtained 4-(4-bromo-2-fluorophenoxy)-7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazoline as a resinous solid (0.4 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.22-1.4 (m, 2H), 1.44 (s, 9H), 1.69 (m, 3H), 1.98 (t, 2H), 2.12 (m, 2H), 2.56 (t, 2H), 2.9-3.1 (m, 4H), 4.04 (s, 3H), 4.26 (t, 2H), 4.6 (br s, 1H), 7.22 (m, 1H), 7.3-7.45 (m, 3H), 7.51 (s, 1H), 8.67 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 619 and 621.

- 20 A mixture of a portion (0.2 g) of the material so obtained and a saturated solution of ammonia in isopropanol (32 ml) was sealed in a Carius tube and heated at 110°C for 20 hours. The mixture was cooled to ambient temperature and the solvent was evaporated. The residue was stirred with a mixture of a 2N aqueous sodium hydroxide solution (5 ml), methylene chloride (18 ml) and methanol (2 ml) for 1 hour. The solid was isolated and dried. There was  
25 thus obtained the required starting material (0.046 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.0-1.15 (m, 2H), 1.4 (m, 1H), 1.45 (s, 9H), 1.56 (d, 2H), 1.75-1.85 (m, 4H), 2.39 (d, 2H), 2.74-2.9 (m, 4H), 3.85 (s, 3H), 4.09 (t, 2H), 6.75 (br s, 1H), 7.02 (s, 1H), 7.32 (s, 2H), 7.54 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 446.

- (b) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.0-1.2 (m, 2H), 1.25-1.3 (m, 1H), 1.35 (s, 9H), 1.58 (d, 2H), 1.8-2.0 (m, 4H), 2.42 (t, 2H), 2.7-2.9 (m, 4H), 3.95 (s, 3H), 4.21 (t, 2H), 6.76 (t, 1H), 7.1-7.5 (m, 4H), 8.04 (s, 1H), 8.67 (s, 1H), 10.6 (s, 1H), 11.8 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 601.
- 5 (c) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.2-1.4 (m, 3H), 1.43 (s, 9H), 1.9-2.15 (m, 4H), 2.33 (s, 6H), 2.52 (t, 2H), 2.92 (d, 4H), 3.02 (t, 2H), 3.38 (s, 3H), 4.21 (t, 2H), 4.6 (s, 1H), 7.05-7.15 (m, 4H), 7.48 (s, 1H), 8.66 (s, 1H), 9.64 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 593.
- (d) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.22-1.35 (m, 3H),  
10 1.42 (s, 9H), 1.7 (m, 2H), 1.95 (t, 2H), 2.09 (m, 2H), 2.35 (s, 3H), 2.52 (t, 2H), 2.91 (d, 2H), 3.02 (t, 2H), 3.5 (s, 3H), 4.22 (t, 2H), 4.6 (s, 1H), 7.17 (m, 2H), 7.25-7.35 (m, 2H), 7.46 (s, 1H), 8.69 (s, 1H), 9.54 (s, 1H), 12.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 613 and 615.

**Example 21** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-  
15 4-yl}-3-(2,6-dichlorophenyl)urea

A mixture of 1-{7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-dichlorophenyl)urea (0.075 g), trifluoroacetic acid (0.35 ml) and chloroform (1.5 ml) was stirred at ambient temperature for 40 minutes. The mixture was evaporated and the residue was stirred under a 1N aqueous sodium hydroxide  
20 solution (3 ml) for 1 hour. The resultant solid was isolated and dried. There was thus obtained the title compound (0.037 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.12 (m, 3H), 1.62-1.7 (m, 2H), 1.9 (t, 2H), 2.0 (m, 4H), 2.38-2.54 (m, 4H), 2.92 (m, 2H), 3.3 (m, partially obscured by a water signal), 3.95 (s, 3H), 4.26 (t, 2H), 7.28 (s, 1H), 7.41 (t, 1H), 7.62 (d, 2H), 8.06 (s, 1H), 8.66 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.

25

**Example 22** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-  
4-yl}-3-(2,6-difluorophenyl)urea

Using an analogous procedure to that described in Example 21,  
1-{7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-  
30 4-yl}-3-(2,6-difluorophenyl)urea was reacted with trifluoroacetic acid to give the title compound; NMR Spectrum: (DMSO-d<sub>6</sub>) 1.0-1.4 (m, 3H), 1.7 (d, 2H), 1.9-2.1 (m, 6H), 2.4 (m, 2H), 2.9 (d, 2H), 3.3 (s, partially obscured by a water signal), 4.0 (s, 3H), 4.24 (t, 3H), 5.0-7.0

(br m, 1H), 7.2-7.4 (m, 4H), 8.05 (s, 1H), 8.68 (s, 1H), 11.75 (s, 1H); Mass Spectrum:  $M+H^+$  501.

**Example 23** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-dimethylphenyl)urea

Using an analogous procedure to that described in Example 21,

1-{7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-dimethylphenyl)urea was reacted with trifluoroacetic acid to give the title compound; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.0-2.0 (m, 9H), 2.23 (s, 6H), 2.4 (m, 2H), 2.7-2.9 (m, 4H), 3.1-3.5 (partially obscured by a water signal), 3.93 (s, 3H); 4.18 (t, 2H), 6.9-7.15 (m, 4H), 7.23 (s, 1H), 8.03 (s, 1H), 8.62 (s, 1H), 11.7 (s, 1H); Mass Spectrum:  $M+H^+$  493.

**Example 24** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2-chloro-6-methylphenyl)urea


Using an analogous procedure to that described in Example 21,

1-{7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2-chloro-6-methylphenyl)urea was reacted with trifluoroacetic acid to give the title compound; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.0-1.3 (m, 3H), 1.63 (d, 2H), 1.7-2.0 (m, 4H), 2.28 (s, 3H), 2.4 (m, 2H), 2.86 (d, 2H), 3.1-3.5 (partially obscured by a water signal) 3.94 (s, 3H), 4.19 (t, 2H), 7.1-7.4 (m, 4H), 8.06 (s, 1H), 8.66 (s, 1H), 11.85 (s, 1H); Mass Spectrum:  $M+H^+$  513 and 515.

**Example 25**

Using an analogous procedure to that described in Example 1, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the compounds described in Table VI.

Table VI



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	3-morpholinopropoxy	methoxy	2-methyl	(a)
2	3-morpholinopropoxy	methoxy	2,6-dichloro	(b)
3	3-morpholinopropoxy	methoxy	2,6-difluoro	(c)
4	3-morpholinopropoxy	methoxy	2,6-dimethyl	(d)
5	3-piperidinopropoxy	methoxy	2,6-dichloro	(e)
6	3-piperidinopropoxy	methoxy	2,6-difluoro	(f)
7	3-piperidinopropoxy	methoxy	2,6-dimethyl	(g)
8	2-pyrrolidin-1-ylethoxy	methoxy	2,6-dichloro	(h)
9	N-(3-morpholinopropyl)carbamoyl	methoxy	2,6-dimethyl	(i)
10	2-(2-methoxyethoxy)ethoxy	methoxy	2,6-dichloro	(j)
11	2-(2-methoxyethoxy)ethoxy	methoxy	2,6-dimethyl	(k)

Notes

- 5 (a) The reaction product was dissolved in methylene chloride and treated with a saturated solution of hydrogen chloride gas in diethyl ether. The hydrochloride salt so obtained gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 2.35 (m, 2H), 2.45 (s, 3H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.75 (t, 2H), 4.0 (m, 2H), 4.05 (s, 3H), 4.4 (m, 2H), 7.1 (m, 1H), 7.3 (m, 2H), 7.5 (s, 1H), 7.95 (d, 1H), 8.45 (s, 1H), 9.15 (s, 1H); Mass Spectrum:  
10 M+H<sup>+</sup> 452.

The 4-amino-7-methoxy-6-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

A mixture of 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline (International Patent Application WO 96/33980,

- 15 Example 1 therein; 6 g) and 6N aqueous hydrochloric acid solution (120 ml) was stirred and

heated to reflux for 6 hours. The mixture was cooled to 0°C and carefully, with cooling, was neutralised by the addition of concentrated aqueous ammonium hydroxide solution. The resultant precipitate was isolated, washed in turn with a dilute aqueous ammonium hydroxide solution and with water and dried under vacuum. There was thus obtained 7-methoxy-

5 6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (4.2 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 2.4 (m, 6H), 3.59 (t, 4H), 3.75 (t, 2H), 3.9 (s, 3H), 4.12 (t, 2H), 7.12 (s, 1H), 7.43 (s, 1H), 7.98 (s, 1H), 12.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 320.

A mixture of a portion (0.99 g) of the material so obtained, thionyl chloride (10 ml) and DMF (0.1 ml) was stirred and heated to 80°C for 1.5 hours. The mixture was cooled to  
10 ambient temperature, toluene (10 ml) was added and the mixture was evaporated. The residue was partitioned between ethyl acetate and water (the acidity of the aqueous layer being adjusted to pH 7.5 by the addition of 2N aqueous sodium hydroxide solution). The organic layer was washed with brine, dried over magnesium sulphate and evaporated. The residue was  
15 purified by column chromatography on silica using a 9:1 mixture of methylene chloride and methanol as eluent. The solid so obtained was triturated under hexane, re-isolated and washed with diethyl ether. There was thus obtained 4-chloro-7-methoxy-

6-(3-morpholinopropoxy)quinazoline (0.614 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.12 (m, 2H), 2.5 (br s, 4H), 2.59 (t, 2H), 3.73 (t, 4H), 4.05 (s, 3H), 4.27 (t, 2H), 7.33 (s, 1H), 7.4 (s, 1H), 8.86 (s, 1H).

20 A mixture of 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline (1.6 g) and isopropanol (50 ml) was placed in a Carius tube which was cooled to -78°C prior to the addition of liquid ammonia (10 ml). The Carius tube was sealed and heated to 130°C for 20 hours. The Carius tube was cooled to ambient temperature, opened and the mixture was evaporated. The residue was triturated under diethyl ether. There was thus obtained 4-amino-  
25 7-methoxy-6-(3-morpholinopropoxy)quinazoline (containing 2.9 equivalents of ammonium chloride; 1.54 g) which was used without further purification. A portion of the material was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and methanol as eluent. The purified product gave the following data :- NMR Spectrum: (DMSO-d<sub>6</sub>) 1.95 (m, 2H), 2.5 (m, 6H), 3.6 (m, 4H), 3.9 (s, 3H), 4.1 (m, 2H), 7.05 (s, 1H), 7.4  
30 (br s, 2H), 7.6 (s, 1H), 8.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 319.

(b) The product gave the following data: NMR Spectrum: 2.35 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.0 (m, 2H), 4.05 (s, 3H), 4.35 (m, 2H), 7.45 (m, 2H), 7.65 (m, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 506 and 508.

- (c) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 2.3 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.0 (m, 2H), 4.05 (m, 5H), 4.3 (m, 2H), 7.25 (m, 2H), 7.4 (m, 2H), 8.25 (s, 1H), 9.0 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 474.
- (d) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 2.35 (m, 8H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.0 (m, 2H), 4.05 (s, 3H), 4.35 (m, 2H), 7.2 (m, 2H), 7.5 (s, 1H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 466.
- (e) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.4 (br s, 2H), 1.55 (br s, 4H), 2.04 (br s, 2H), 3.26-3.48 (m, 6H), 3.95 (s, 3H), 4.20 (t, 2H), 7.32 (s, 1H), 7.39 (t, 1H), 7.56 (m, 2H), 8.08 (s, 1H), 8.69 (s, 1H), 10.64 (s, 1H), 12.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 504 and 506.

The 4-amino-7-methoxy-6-(3-piperidinopropoxy)quinazoline used as a starting material was prepared as follows :-

A mixture of 6-acetoxy-7-methoxyquinazolin-4-one (International Patent Application WO 96/15118, Example 39 thereof; 15 g), thionyl chloride (215 ml) and DMF (4.3 ml) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and the thionyl chloride was evaporated. The material so obtained was dissolved in toluene and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. There was thus obtained 6-acetoxy-4-chloro-7-methoxyquinazoline (14.8 g) which was used without further purification.

A mixture of a portion (5 g) of the material so obtained, diphenylmethyleamine (3.75 g), caesium carbonate (25.67 g) and xylene (200 ml) was stirred at ambient temperature for 30 minutes. Racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (1.227 g) and palladium diacetate (0.221 g) were added and the mixture was stirred and heated to 135°C for 16 hours. The mixture was cooled to ambient temperature and diethyl ether (600 ml) was added. The mixture was filtered and the filtrate was evaporated. There was thus obtained N-diphenylmethyle-6-acetoxy-7-methoxyquinazolin-4-amine (7.12 g); Mass Spectrum: M+H<sup>+</sup> 398.

A mixture of a portion (3.09 g) of the material so obtained, concentrated ammonium hydroxide solution (0.88 g/ml, approximately 14M; 60 ml) and methanol (120 ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated. Toluene (200 ml) was added and the mixture was evaporated again. The residue was triturated under diethyl ether

(50 ml). There was thus obtained N-diphenylmethylene-6-hydroxy-7-methoxyquinazolin-4-amine (0.938 g); Mass Spectrum:  $M+H^+$  356.

A mixture of the material so obtained, 3-piperidinopropyl chloride (0.55 g), potassium carbonate (1.46 g) and DMF (50 ml) was stirred and heated to 65°C for 16 hours. The  
5 resultant mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic solution was washed with a saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained N-diphenylmethylene-6-(3-piperidinopropoxy)-  
10 7-methoxyquinazolin-4-amine (0.277 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3 (br s, 2H), 1.42 (br s, 4H), 1.88 (t, 2H), 2.28 (br s, 4H), 2.38 (t, 2H), 3.92 (s, 3H), 4.07 (t, 2H), 7.0 (s, 1H), 7.23 (s, 1H), 7.2-7.65 (br m, 10H), 8.62 (s, 1H); Mass Spectrum:  $M+H^+$  481.

A mixture of the material so obtained, 3N aqueous hydrochloric acid solution (2 ml) and THF (14 ml) was stirred at ambient temperature for 3 hours. The mixture was evaporated  
15 and the residue was treated with a 2N aqueous sodium hydroxide solution (10 ml). The resultant precipitate was isolated, washed with water (10 ml) and dried under vacuum. There was thus obtained 4-amino-7-methoxy-6-(3-piperidinopropoxy)quinazoline (0.202 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.36 (br s, 2H), 1.47 (br s, 4H), 1.93 (t, 2H), 2.25-2.43 (br m, 6H), 3.88 (s, 3H), 4.05 (t, 2H), 7.04 (s, 1H), 7.35 (br s, 2H), 7.55 (s, 1H), 8.23 (s, 1H); Mass Spectrum:  
20  $M+H^+$  317.

(f) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.4 (br s, 2H), 1.53 (br s, 4H), 2.02 (br s, 2H), 3.24-3.47 (br s, 6H), 3.97 (s, 3H), 4.23 (t, 2H), 7.22 (m, 2H), 7.31 (s, 1H), 7.4 (m, 1H), 8.05 (s, 1H), 8.69 (s, 1H), 10.67 (s, 1H), 11.82 (s, 1H); Mass Spectrum:  $M+H^+$  472.

25 (g) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.38 (br s, 2H), 1.5 (br s, 4H), 1.96 (m, 2H), 2.25 (s, 6H), 2.3-2.48 (br m, 6H), 3.96 (s, 3H), 4.15 (t, 2H), 7.14 (m, 3H), 7.3 (s, 1H), 8.07 (s, 1H), 8.67 (s, 1H), 10.38 (s, 1H), 11.69 (s, 1H); Mass Spectrum:  $M+H^+$  464.

(h) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.72 (br s, 4H), 2.67  
30 (br s, 4H), 2.97 (br s, 2H), 3.99 (s, 3H), 4.3 (t, 2H), 7.31 (s, 1H), 7.37 (t, 1H), 7.59 (d, 2H), 8.07 (s, 1H), 8.72 (s, 1H), 10.52 (s, 1H), 12.06 (s, 1H); Mass Spectrum:  $M+H^+$  476 and 478.

The 4-amino-7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazoline used as a starting material was prepared from N-diphenylmethylene-6-hydroxy-7-methoxyquinazolin-4-amine

and 2-pyrrolidin-1-ylethyl chloride using analogous procedures to those described in the last two paragraphs of Note (e) above. The material so obtained gave the following data :- NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.68 (m, 4H), 2.58 (m, 6H), 3.86 (s, 3H), 4.15 (t, 2H), 7.05 (s, 1H), 7.33 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 289.

- 5 (i) Chloroform was used as the reaction solvent. Triethylamine (1 equivalent) was also added. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.99 (t, 2H), 2.37 (s, 6H), 2.7 (m, 4H), 3.63 (q, 2H), 3.79 (m, 6H), 4.15 (s, 3H), 7.13 (s, 3H), 7.4 (s, 1H), 8.0 (t, 1H), 8.2 (s, 1H), 8.79 (s, 1H), 8.9 (s, 1H), 11.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 493.

The 4-amino-7-methoxy-6-[N-(3-morpholinopropyl)carbamoyl]quinazoline used as a  
10 starting material was prepared as follows :-

Methyl 4-amino-5-cyano-2-hydroxybenzoate (J. Chem. Soc. Perkin I, 1979, 677; 4 g) was added to stirred concentrated sulphuric acid (6 ml) and the mixture was heated to 80°C for 30 minutes. The mixture was cooled to ambient temperature and poured onto crushed ice. The resultant solid was filtered off, washed well with water and dried to give methyl 4-amino-  
15 5-carbamoyl-2-hydroxybenzoate (2.8 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.83 (s, 3H), 6.1 (s, 1H), 6.75 (br m, 2H), 8.08 (s, 1H).

A mixture of methyl 4-amino-5-carbamoyl-2-hydroxybenzoate (5.4 g) and formic acid (50 ml) was heated to reflux for 1 hour. The mixture was evaporated. Toluene (75ml) was added and the mixture was evaporated. The solid residue was washed with methanol and  
20 diethyl ether and dried to give methyl 7-hydroxy-4-oxo-3,4-dihydroquinazoline-6-carboxylate (5.2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 4.9 (s, 3H), 7.09 (s, 1H), 7.39 (s, 1H), 8.5 (s, 1H).

A mixture of methyl 7-hydroxy-4-oxo-3,4-dihydroquinazoline-6-carboxylate (17.7 g) and acetic anhydride (200 ml) was heated to 120°C for 1.5 hours. The mixture was evaporated. Toluene (75ml) was added and the mixture was re-evaporated. There was thus  
25 obtained methyl 7-acetoxy-4-oxo-3,4-dihydroquinazoline-6-carboxylate (20.7 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.33 (s, 3H), 3.86 (s, 3H), 7.5 (s, 1H), 8.28 (s, 1H), 8.68 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 263.

A mixture of a portion (7.2 g) of the material so obtained and thionyl chloride (75 ml) was heated to reflux for 1 hour. The excess thionyl chloride was evaporated. Toluene (50 ml)  
30 was added and the mixture was re-evaporated. The residue was dissolved in methylene chloride and treated with triethylamine (3.34 g). The mixture was passed through a silica gel column (40 g) using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained methyl 7-acetoxy-4-chloroquinazoline-6-carboxylate

(6.88 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.43 (s, 3H), 4.0 (s, 3H), 7.8 (s, 1H), 8.99 (s, 1H), 9.12 (s, 1H).

A mixture of a portion (2.74 g) of the material so obtained, 2,4,6-trimethoxybenzylamine (3.86 g) and methylene chloride (90 ml) was allowed to stand at ambient temperature for 16 hours. The mixture was filtered and the filtrate was evaporated. The residue was triturated under diethyl ether. The resultant solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained methyl 7-hydroxy-4-(2,4,6-trimethoxybenzylamino)quinazoline-6-carboxylate (3.25 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.85 (s, 9H), 3.98 (s, 3H), 4.82 (d, 2H), 6.2 (s, 1H), 7.25 (s, 1H), 7.27 (s, 1H), 8.27 (s, 1H), 8.67 (s, 1H), 10.73 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 400.

(Trimethylsilyl)diazomethane (2M in hexane, 10 ml) was added to a mixture of the material so obtained, di-isopropylethylamine (1.26 g), methanol (10 ml) and methylene chloride (30 ml) and the resultant mixture was stirred at ambient temperature for 3 hours. The reaction mixture was treated with a second aliquot of (trimethylsilyl)diazomethane solution (10 ml) and stirred for a further 18 hours. Silica gel (2 g) was added cautiously and the mixture was stirred for 5 minutes. The mixture was evaporated and the reaction product (adsorbed onto silica) was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained methyl 7-methoxy-4-(2,4,6-trimethoxybenzylamino)quinazoline-6-carboxylate (1.244 g); Mass Spectrum: M+H<sup>+</sup> 414.

A mixture of a portion (0.295 g) of the material so obtained and N-(3-aminopropyl)morpholine (0.5 ml) was stirred and heated to 150°C for 1 hour. The mixture was partitioned between methylene chloride and water. The organic solution was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(2,4,6-trimethoxybenzylamino)-7-methoxy-6-[N-(3-morpholinopropyl)carbamoyl]quinazoline (0.144 g) Mass Spectrum: M+H<sup>+</sup> 526.

Trifluoroacetic acid (1 ml) was added to a mixture of the material so obtained, triethylsilane (0.093 g) and methylene chloride (0.15 ml) and the reaction mixture was stirred and heated to reflux for 2 minutes. The mixture was evaporated and the residue was partitioned between methylene chloride and water. The organic solution was evaporated to

give 4-amino-7-methoxy-6-[N-(3-morpholinopropyl)carbamoyl]quinazoline (0.129 g); Mass Spectrum:  $M+H^+$  346.

(j) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 3.39 (s, 3H), 3.6 (m, 2H), 3.75 (m, 2H), 3.86 (m, 2H), 4.02 (s, 3H), 4.07 (m, 2H), 7.21 (t, 1H), 7.29 (s, 1H), 7.39 (d, 2H), 7.51 (s, 1H), 8.73 (s, 1H), 9.14 (s, 1H), 12.19 (s, 1H); Mass Spectrum:  $M+H^+$  481 and 483.

The 4-amino-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]quinazoline used as a starting material was prepared from N-diphenylmethylene-6-hydroxy-7-methoxyquinazolin-4-amine and 2-(2-methoxyethoxy)ethyl chloride using analogous procedures to those described in the last two paragraphs of Note (e) above. In a further preparation, 2-(2-methoxyethoxy)ethyl 4-toluenesulphonate was used. The required starting material gave the following data: NMR Spectrum: ( $CDCl_3$ ) 3.4 (s, 3H), 3.61 (m, 2H), 3.72 (m, 2H), 3.93 (m, 2H), 3.99 (s, 3H), 4.34 (m, 2H), 5.67 (br s, 2H), 7.2 (s, 1H), 7.32 (s, 1H), 8.5 (s, 1H); Mass Spectrum:  $M+H^+$  294.

(k) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.31 (s, 6H), 3.38 (s, 3H), 3.6 (m, 2H), 3.69 (m, 4H), 3.85 (m, 2H), 4.14 (s, 3H), 7.12 (m, 4H), 7.58 (s, 1H), 8.68 (s, 1H), 9.44 (s, 1H), 11.77 (s, 1H); Mass Spectrum:  $M+H^+$  441.

**Example 26** 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(6-methylamino-1-hexynyl)quinazolin-4-yl]urea

A mixture of 1-(2,6-dichlorophenyl)-3-{7-[6-(N-tert-butoxycarbonylamino)-N-methylamino]-1-hexynyl]-6-methoxyquinazolin-4-yl}urea (0.1 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) was stirred at ambient temperature for 1.5 hours. The mixture was evaporated and a solution of hydrogen chloride gas in ethyl acetate was added. Toluene was added and the mixture was evaporated. The residue was triturated under diethyl ether and the resultant solid was isolated. There was thus obtained the title compound as the hydrochloride salt (0.095g); NMR Spectrum: ( $DMSO-d_6$ ) 1.65 (m, 2H), 1.78 (m, 2H), 2.55 (m, 5H), 2.95 (m, 2H), 4.0 (s, 3H), 7.38 (t, 1H), 7.6 (d, 2H), 7.89 (s, 1H), 8.16 (s, 1H), 8.7 (m, 3H), 10.9 (br, 1H), 11.8 (s, 1H); Mass Spectrum:  $M+H^+$  472 and 474.

The 1-(2,6-dichlorophenyl)-3-{7-[6-(N-tert-butoxycarbonylamino)-N-methylamino-1-hexynyl]-6-methoxyquinazolin-4-yl}urea used as a starting material was prepared as follows :-

Using an analogous procedure to that described in the second last paragraph of Note [115] in Example 2 above, 6-(N-tert-butoxycarbonylamino)-N-methylamino-1-hexyne

was reacted with 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulfonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[6-(N-tert-butoxycarbonylamino)-N-methylamino-1-hexynyl]quinazoline; NMR Spectrum: (DMSO<sub>d6</sub>) 1.4 (s, 9H), 1.55 (m, 2H), 1.65 (m, 2H), 2.57 (t, 2H), 2.79 (s, 3H), 3.24 (t, 2H), 4.0 (s, 3H), 7.35-7.82 (m, 3H), 7.65 (s, 1H), 7.95 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 558 and 560.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] in Example 2 above, except that the ammonia reaction was carried out at 110°C rather than at 130°C. There was thus obtained  
10 4-amino-6-methoxy-7-[6-(N-tert-butoxycarbonylamino)-N-methylamino-1-hexynyl]quinazoline.

The material so obtained was reacted with 2,6-dichlorophenyl isocyanate using an analogous procedure to that described in Example 1. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d6</sub>) 1.39 (s, 9H), 1.55 (m, 2H), 1.67 (m, 2H), 2.56 (m, 2H), 2.79 (s, 3H), 3.2 (m, 2H), 3.97 (s, 3H), 7.4 (m, 1H), 7.6 (m, 2H), 7.84 (s, 1H), 8.14 (s, 1H), 8.75 (s, 1H), 10.8 (s, 1H), 11.95 (s, 1H).

The 6-(N-tert-butoxycarbonylamino)-N-methylamino)-1-hexyne used as a starting material was prepared as follows :-

6-Mesyloxy-1-hexyne was reacted with methylamine using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, 31, 1421 to give 6-methylamino-1-hexyne which was reacted di-tert-butyl dicarbonate using a conventional procedure.

**Example 27 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea**


A solution of 4-amino-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (150 mg) in DMF (4.5 ml) was added to sodium hydride (60% dispersion in mineral oil, 0.03 g) and the reaction mixture was stirred at ambient temperature for 20 minutes. 2,6-Dimethylphenyl isothiocyanate (0.162 g) was added and the mixture was stirred at ambient temperature for 20 hours. The reaction mixture was evaporated and the residual solid  
30 was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia in methanol as eluent. There was thus obtained the title compound (0.112 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.44-1.61 (m, 2H), 1.87-

2.08 (m, 5H), 2.32 (s, 3H), 2.36 (s, 6H), 2.94 (d, 2H), 4.04 (m, 5H), 7.1 (s, 1H), 7.19 (m, 3H), 7.29 (s, 1H), 8.69 (s, 1H), 8.9 (s, 1H), 13.37 (s, 1H); Mass Spectrum:  $M+H^+$  466.

### Example 28

- 5 Using an analogous procedure to that described in Example 27, the appropriate 4-aminoquinazoline was reacted with the appropriate isothiocyanate to give the compounds described in Table VII.

Table VII



10

No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dichloro	(a)
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro	(b)
3	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	(c)
4	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4,6-trichloro	(d)
5	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl-4-bromo	(e)
6	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl	(f)
7	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	(g)
8	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	(h)
9	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	(i)
10	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl	(j)
11	methoxy	2-morpholinoethoxy	2,6-dimethyl	(k)
12	methoxy	3-morpholinopropoxy	2,6-dimethyl	(l)
13	methoxy	cyclopropylmethoxy	2,6-dimethyl	(m)
14	methoxy	2-morpholinoethoxy	2-chloro-6-methyl	(n)
15	methoxy	3-morpholinopropoxy	2-chloro-6-methyl	(o)
16	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl	(p)

17	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dimethyl	(q)
----	---------	-------------------------	--------------	-----

Notes

- (a) The product gave the following data: Mass Spectrum:  $M+H^+$  506 and 508.
- (b) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.43–1.6 (m, 2H), 1.83–2.09 (m, 5H), 2.33 (s, 3H), 2.94 (d, 2H), 4.04 (m, 5H), 7.0–7.14 (m, 4H), 7.27 (m, 1H), 7.35 (m, 1H), 8.7 (s, 1H), 13.49 (s, 1H); Mass Spectrum:  $M+H^+$  474.
- 5 (c) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.45–1.61 (m, 2H), 1.87–2.11 (m, 5H), 2.31 (s, 3H), 2.42 (s, 2H), 3.97 (d, 2H), 4.02 (m, 5H), 7.07 (s, 1H), 7.2–7.3 (m, 3H), 7.38 (t, 1H), 8.7 (s, 1H), 8.9 (s, 1H) 13.51 (s, 1H); Mass Spectrum:  $M+H^+$  486 and 488.
- 10 (d) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.48–1.61 (m, 2H), 1.88–2.16 (m, 5H), 2.36 (s, 3H), 3.0 (d, 2H), 4.07 (m, 5H), 7.11 (s, 1H), 7.3 (d, 2H), 7.43 (s, 1H), 7.49 (s, 1H), 8.72 (s, 1H) 13.71 (s, 1H); Mass Spectrum:  $M+H^+$  540 and 543.
- (e) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.47–1.61 (m, 2H), 1.87–2.11 (m, 5H), 2.32 (d, 9H), 2.99 (d, 2H), 4.04 (m, 5H), 7.1 (s, 1H), 7.3 (s, 1H), 7.32 (s, 1H), 8.7 (s, 1H), 8.9 (s, 1H), 13.31 (s, 1H); Mass Spectrum:  $M+H^+$  544 and 546.
- 15 (f) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.44–1.59 (m, 2H), 1.88–2.07 (m, 5H), 2.31 (s, 3H), 2.35 (d, 6H), 2.94 (d, 2H), 4.04 (m, 5H), 7.08 (d, 1H), 7.2 (d, 1H), 7.29 (s, 1H), 7.55 (s, 1H), 8.68 (s, 1H), 8.77 (s, 1H), 13.63 (s, 1H); Mass Spectrum:  $M+H^+$  466.
- 20 (g) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.83 (s, 4H), 2.21 (m, 2H), 2.63 (s, 4H), 2.76 (t, 2H), 4.03 (s, 3H), 4.29 (t, 2H), 7.08 (t, 1H), 7.27–7.33 (s, 2H), 7.44 (m, 3H), 8.73 (s, 1H), 13.7 (s, 1H); Mass Spectrum:  $M+H^+$  506 and 508.
- (h) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.83 (s, 4H), 2.2 (m, 2H), 2.61 (s, 4H), 2.74 (t, 2H), 4.04 (s, 3H), 4.48 (t, 2H), 6.98–7.11 (m, 3H), 7.27–7.41 (m, 2H), 8.71 (s, 1H), 13.48 (s, 1H); Mass Spectrum:  $M+H^+$  474.
- 25 (i) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.8 (m, 4H), 2.18 (m, 2H), 2.4 (s, 3H), 2.55 (m, 4H), 2.68 (t, 2H), 4.02 (s, 3H), 4.3 (t, 2H), 7.07 (s, 1H), 7.26 (m, 2H), 7.31 (s, 1H), 7.37 (m, 1H), 8.7 (s, 1H), 8.94 (br s, 1H), 13.51 (s, 1H); Mass Spectrum:  $M+H^+$  486 and 488.

- (j) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.35 (s, 6H), 3.4 (s, 3H), 3.6 (m, 2H), 3.87 (m, 2H), 4.03 (t, 2H), 4.05 (s, 3H), 4.37 (t, 2H), 7.09 (s, 1H), 7.14–7.21 (m, 3H), 7.33 (s, 1H), 8.68 (s, 1H), 8.84 (s, 1H), 13.32 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 457.
- (k) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.36 (s, 6H), 2.61 (t, 4H), 2.95 (t, 2H), 3.77 (t, 4H), 4.04 (s, 3H), 4.34 (t, 2H), 7.11 (s, 1H), 7.2 (m, 3H), 7.31 (s, 1H), 8.69 (s, 1H), 8.9 (s, 1H), 13.36 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 468.
- (l) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 2.0 (m, 2H), 2.4 (s, 4H), 2.45 (t, 2H), 3.58 (t, 4H), 4.03 (s, 3H), 4.21 (t, 2H), 7.18 (m, 3H), 7.33 (s, 1H), 8.19 (s, 1H), 8.71 (s, 1H), 11.09 (s, 1H), 13.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 482.
- 10 (m) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 0.39 (m, 2H), 0.61 (m, 2H), 1.32 (m, 1H), 2.25 (s, 6H), 4.0 (m, 5H), 7.17 (s, 3H), 7.25 (s, 1H), 8.17 (s, 1H), 8.72 (s, 1H), 11.08 (br s, 1H), 13.67 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 409.
- (n) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 488 and 490.
- (o) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 502 and 504.
- 15 (p) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 452.
- (q) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 452.


**Example 29** 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine

- 20 Mercuric(II) oxide (0.059 g) was added to a mixture of 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea (0.105 g), a 2M solution of ammonia in methanol (3 ml) and chloroform (1 ml) and the reaction mixture was stirred at ambient temperature for 2 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of
- 25 methylene chloride and a 2M solution of ammonia in methanol as eluent. There was thus obtained the title compound (0.074 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.39–1.53 (m, 2H), 1.87–2.02 (q, 5H), 2.29 (s, 3H), 2.36 (s, 6H), 2.9 (d, 2H), 4.01 (m, 5H), 5.79 (br s, 1H), 7.16 (s, 1H), 7.19 (m, 3H), 7.87 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 449.

30 **Example 30**

Using an analogous procedure to that described in Example 29, the appropriate quinazoline-4-thiourea was reacted with ammonia to give the guanidines described in Table VIII.

Table VIII



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dichloro	(a)
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro	(b)
3	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	(c)
4	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl-4-bromo	(d)
5	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl	(e)
6	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	(f)
7	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	(g)
8	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	(h)
9	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl	(i)
10	methoxy	2-morpholinoethoxy	2,6-dimethyl	(j)
11	methoxy	cyclopropylmethoxy	2,6-dimethyl	(k)
12	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dimethyl	(l)
13	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl	(m)

Notes

- 5 (a) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>, 100°C) 1.4 (m, 2H), 1.78 (m, 3H), 1.96 (t, 2H), 2.2 (s, 3H), 2.8 (m, 2H), 3.76 (s, 3H), 4.0 (d, 2H), 7.11 (s, 1H), 7.28 (t, 2H), 7.47 (s, 1H), 7.54 (d, 2H), 7.98 (s, 1H), 8.5 (s, 1H), 9.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 489 and 491.
- (b) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.34 (m, 2H), 1.73 (d, 3H), 1.88 (t, 2H), 2.16 (s, 3H), 2.79 (d, 2H), 3.3 (s, 2H), 3.69 (s, 3H), 3.95 (d, 2H), 7.07 (s, 1H), 7.2 (t, 2H), 7.34 (br s, 1H), 8.49 (s, 1H), 8.74 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 457.
- 10 (c) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.56 (m, 2H), 1.87–2.05 (q, 5H), 2.3 (s, 3H), 2.4 (s, 3H), 2.9 (d, 2H), 3.98–4.05 (m, 5H), 7.13–7.27 (m, 3H), 7.38 (m, 1H), 7.81 (s, 1H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 469 and 471.

- (d) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.38–1.54 (m, 2H), 1.82–2.02 (q, 5H), 2.28 (s, 3H), 2.32 (s, 6H), 2.89 (d, 2H), 4.0 (m, 5H), 5.7 (br s, 1H), 7.03–7.27 (m, 3H), 7.32 (s, 2H), 7.81 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 526 and 528.
- (e) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.39–1.44 (m, 2H),  
5 1.87–2.04 (q, 5H), 2.29 (s, 3H), 2.34 (d, 6H), 2.89 (d, 2H), 4.02 (m, 5H), 6.19 (br s, 1H), 7.05 (d, 1H), 7.14 (s, 2H), 7.2 (d, 1H), 7.84 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 449.
- (f) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.17 (m, 2H), 2.53 (s, 4H), 2.67 (t, 2H), 3.99 (s, 3H), 4.25 (t, 2H), 7.1 (t, 1H), 7.2 (s, 1H), 7.41 (d, 1H), 7.51 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 489 and 491.
- 10 (g) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.79 (m, 4H), 2.14 (m, 2H), 2.53 (m, 4H), 2.67 (t, 2H), 3.97 (s, 3H), 4.24 (t, 2H), 7.03 (t, 2H), 7.2 (m, 2H), 7.63 (s, 1H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 457.
- (h) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.79 (m, 4H), 2.15 (m, 2H), 2.4 (s, 3H), 2.56 (s, 4H), 2.68 (t, 2H), 3.98 (s, 3H), 4.26 (t, 2H), 6.13 (br s, 1H), 7.14–  
15 7.26 (m, 3H), 7.37 (m, 1H), 7.82 (s, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 469 and 471.
- (i) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.35 (s, 6H), 3.4 (s, 3H), 3.61 (m, 2H), 3.77 (m, 2H), 3.99 (m, 5H), 4.34 (t, 2H), 5.76 (br s, 1H), 7.17 (m, 4H), 7.87 (s, 1H), 8.56 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 440.
- (j) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 2.29 (s, 6H),  
20 2.53 (m, 4H), 2.79 (t, 2H), 3.6 (t, 4H), 3.74 (s, 3H), 4.22 (t, 2H), 7.09 (s, 1H), 7.16 (s, 3H), 7.51 (s, 1H), 7.7 (s, 2H), 8.45 (s, 1H), 8.88 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 451.
- (k) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 0.34 (m, 2H), 0.63 (m, 2H), 1.37 (m, 1H), 2.28 (s, 6H), 3.93 (d, 2H), 3.97 (s, 3H), 5.9 (br m, 1H), 7.07 (s, 1H), 7.12 (m, 4H), 7.79 (s, 1H), 8.48 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 392.
- 25 (l) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 435.
- (m) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 435.

**Example 31** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-  
3-[(R)-(+)-α-methylbenzyl]guanidine

- 30 Using an analogous procedure to that described in Example 29, 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-[(R)-(+)-α-methylbenzyl]thiourea was reacted with ammonia to give the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.38–1.42 (m,

2H), 1.61 (d, 3H), 1.86–2.01 (q, 5H), 2.29 (s, 3H), 2.89 (d, 2H), 3.95 (m, 3H), 4.0 (d, 2H), 4.7 (q, 1H), 6.5 (br s, 1H), 7.12 (s, 1H), 7.29–7.31 (m, 5H), 7.79 (s, 1H), 8.53 (s, 1H); Mass Spectrum:  $M+H^+$  449.

5 **Example 32** 1-(2-aminophenyl)-3-(6,7-dimethoxyquinazolin-4-yl)urea

A mixture of 1-(6,7-dimethoxyquinazolin-4-yl)-3-(2-nitrophenyl)urea (0.18 g), 10% palladium-on-charcoal catalyst (0.023 g) and DMF (10 ml) was stirred at ambient temperature under an atmosphere of hydrogen for 16 hours. The reaction mixture was filtered and the filtrate was evaporated. The resultant gum was triturated under ethyl acetate and there  
10 was thus obtained the title compound as a solid (0.137 g); NMR Spectrum: ( $DMSO-d_6$ ) 3.85–3.95 (br s, 8H), 6.63 (t, 1H), 6.81 (d, 1H), 6.91 (t, 1H), 7.25 (s, 1H), 7.47 (d, 1H), 8.05 (s, 1H), 8.64 (s, 1H), 10.28 (br s, 1H), 11.74 (br s, 1H); Mass Spectrum:  $M+H^+$  340.

The 1-(6,7-dimethoxyquinazolin-4-yl)-3-(2-nitrophenyl)urea used as a starting material was prepared by the reaction of 2-nitrophenylisocyanate and 4-amino-  
15 6,7-dimethoxyquinazoline using an analogous procedure to that described in Example 1. There was thus obtained the required starting material in 62% yield; NMR Spectrum: ( $DMSO-d_6$ ) 3.95 (s, 6H), 7.3 (s, 1H), 7.28–7.35 (t, 1H), 7.74 (t, 1H), 8.05 (s, 1H), 8.13 (m, 1H), 8.51 (m, 1H), 8.72 (s, 1H), 10.61 (s, 1H), 13.67 (br s, 1H); Mass Spectrum:  $M+H^+$  370.


20 **Example 33** 1-(2,6-dichlorophenyl)-3-(6-methoxy-7-piperazin-1-yl)quinazolin-4-yl)urea

A mixture of 1-(2,6-dichlorophenyl)-3-{6-methoxy-7-[N-(tert-butoxycarbonyl)piperazin-1-yl]quinazolin-4-yl}urea (0.075 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) was stirred at ambient temperature for 1 hour. The resultant mixture was evaporated. A saturated solution of hydrogen chloride gas in ethyl  
25 acetate was added and the mixture was evaporated. The resultant solid was triturated under diethyl ether, isolated and dried. There was thus obtained the title compound, as a dihydrochloride salt, (0.042 g); NMR Spectrum: ( $DMSO-d_6$ ) 3.25–3.3 (m, 4H), 3.45–3.5 (m, 4H), 4.03 (s, 3H), 7.3 (s, 1H), 7.36–7.63 (m, 3H), 8.16 (s, 1H), 8.78 (s, 1H), 9.15–9.27 (br s, 2H), 10.9–11.3 (br s, 1H), 10.8 (s, 1H); Mass Spectrum:  $M+H^+$  447 and 449.

**Example 34**

Using an analogous procedure to that described in Example 29, except that the appropriate quinazoline-4-thiourea was reacted with ethylamine rather than with ammonia, there were obtained the 2-ethylguanidines described in Table IX.

5

**Table IX**

No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	N-methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	(a)
2	methoxy	N-methylpiperidin-4-ylmethoxy	2,6-dimethyl	(b)
3	methoxy	2-morpholinoethoxy	2,6-dimethyl	(c)
4	methoxy	cyclopropylmethoxy	2,6-dimethyl	(d)

**Notes**

- (a) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.31 (t, 3H), 1.36–1.47 (m, 2H), 1.74–1.84 (m, 3H), 1.95 (t, 2H), 2.2 (s, 3H), 2.33 (s, 3H), 2.79 (d, 2H), 3.57 (m, 2H), 3.72 (s, 3H), 3.99 (t, 2H), 7.06 (s, 1H), 7.29 (m, 2H), 7.41 (m, 2H), 8.35 (br s, 1H), 8.45 (s, 1H), 10.11 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 497 and 499.
- (b) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.28 (t, 3H), 1.4 (m, 2H), 1.76 (m, 3H), 1.95 (m, 2H), 2.19 (s, 3H), 2.26 (s, 6H), 2.78 (m, 2H), 3.53 (q, 2H), 3.76 (s, 3H), 3.99 (d, 2H), 7.04 (s, 1H), 7.16 (s, 3H), 7.55 (s, 1H), 8.41 (s, 1H), 10.41 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 477.
- (c) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.27 (t, 3H), 2.27 (s, 6H), 2.54 (m, 4H), 2.8 (t, 2H), 3.54 (m, 2H), 3.61 (t, 4H), 3.78 (s, 3H), 4.26 (t, 2H), 7.11 (s, 1H), 7.19 (s, 3H), 7.59 (s, 1H), 8.42 (s, 1H), 10.42 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 479.
- (d) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 0.38 (m, 2H), 0.6 (m, 2H), 1.27 (m, 4H), 2.25 (s, 6H), 3.21 (m), 3.5 (m, 2H), 3.73 (s, 3H), 3.95 (d, 2H), 6.99 (s, 1H), 7.17 (s, 3H), 7.55 (br s, 1H), 8.42 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 420.

**Example 35****Pharmaceutical compositions**

The following illustrate representative pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"), for therapeutic or

5 prophylactic use in humans:

10	(a)	Tablet I	mg/tablet
		Compound X.....	100
		Lactose Ph.Eur.....	182.75
		Croscarmellose sodium.....	12.0
		Maize starch paste (5% w/v paste).....	2.25
		Magnesium stearate.....	3.0
15	(b)	Tablet II	mg/tablet
		Compound X.....	50
		Lactose Ph.Eur.....	223.75
		Croscarmellose sodium.....	6.0
		Maize starch.....	15.0
		Polyvinylpyrrolidone (5% w/v paste).....	2.25
20		Magnesium stearate.....	3.0
	(c)	Tablet III	mg/tablet
		Compound X.....	1.0
		Lactose Ph.Eur.....	93.25
		Croscarmellose sodium.....	4.0
		Maize starch paste (5% w/v paste).....	0.75
		Magnesium stearate.....	1.0
30	(d)	Capsule	mg/capsule
		Compound X.....	10
		Lactose Ph.Eur.....	488.5
		Magnesium.....	1.5

5	(e)	Injection I	(50 mg/ml)
		Compound X.....	5.0% w/v
		1M Sodium hydroxide solution.....	15.0% v/v
		0.1M Hydrochloric acid (to adjust pH to 7.6)	
		Polyethylene glycol 400.....	4.5% w/v
		Water for injection to 100%	
10	(f)	Injection II	(10 mg/ml)
		Compound X.....	1.0% w/v
		Sodium phosphate BP.....	3.6% w/v
		0.1M Sodium hydroxide solution.....	15.0% v/v
		Water for injection to 100%	
15	(g)	Injection III	(1mg/ml, buffered to pH6)
		Compound X.....	0.1% w/v
		Sodium phosphate BP.....	2.26% w/v
		Citric acid.....	0.38% w/v
		Polyethylene glycol 400.....	3.5% w/v
		Water for injection to 100%	
20	(h)	Aerosol I	mg/ml
		Compound X.....	10.0
		Sorbitan trioleate.....	13.5
		Trichlorofluoromethane.....	910.0
		Dichlorodifluoromethane.....	490.0
25			
	(i)	Aerosol II	mg/ml
		Compound X.....	0.2
		Sorbitan trioleate.....	0.27
		Trichlorofluoromethane.....	70.0
30		Dichlorodifluoromethane.....	280.0
		Dichlorotetrafluoroethane.....	1094.0


5	(j)	Aerosol III	mg/ml
		Compound X.....	2.5
		Sorbitan trioleate.....	3.38
		Trichlorofluoromethane.....	67.5
		Dichlorodifluoromethane.....	1086.0
		Dichlorotetrafluoroethane.....	191.6
10	(k)	Aerosol IV	mg/ml
		Compound X.....	2.5
		Soya lecithin.....	2.7
		Trichlorofluoromethane.....	67.5
		Dichlorodifluoromethane.....	1086.0
		Dichlorotetrafluoroethane.....	191.6
15	(l)	Ointment	ml
		Compound X.....	40 mg
		Ethanol.....	300 µl
		Water.....	300 µl
		1-Dodecylazacycloheptan-2-one.....	50 µl
20		Propylene glycol.....	to 1 ml

Note

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.


**CLAIMS**

1. The use of a quinazoline derivative of the Formula I




I


- 5 wherein  $Q^1$  is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id




Ia



Ib



Ic



Id

wherein :


- $Y^1$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$Y^2$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

- 15  $m$  is 0, 1, 2, 3 or 4;


each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,

(1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino,  
 5 N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^1$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>4</sup>), CO, CH(OR<sup>4</sup>), CON(R<sup>4</sup>), N(R<sup>4</sup>)CO, SO<sub>2</sub>N(R<sup>4</sup>), N(R<sup>4</sup>)SO<sub>2</sub>, OC(R<sup>4</sup>)<sub>2</sub>, SC(R<sup>4</sup>)<sub>2</sub> and N(R<sup>4</sup>)C(R<sup>4</sup>)<sub>2</sub>, wherein R<sup>4</sup> is  
 10 hydrogen or (1-6C)alkyl, and Q<sup>3</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R<sup>1</sup>)<sub>m</sub> is (1-3C)alkylenedioxy,  
 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>,  
 15 N(R<sup>5</sup>), CO, CH(OR<sup>5</sup>), CON(R<sup>5</sup>), N(R<sup>5</sup>)CO, SO<sub>2</sub>N(R<sup>5</sup>), N(R<sup>5</sup>)SO<sub>2</sub>, CH=CH and C≡C wherein R<sup>5</sup> is hydrogen or (1-6C)alkyl,


and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a R<sup>1</sup> substituent optionally bears at the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,  
 20 amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein  $X^2$  is a direct bond or is selected from CO and N(R<sup>6</sup>)CO, wherein R<sup>6</sup> is hydrogen or (1-6C)alkyl, and Q<sup>4</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl  
 25 or heterocyclyl-(1-6C)alkyl,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  
 30 (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,

(1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein  $X^3$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO, CH(OR<sup>7</sup>),

- 5 CON(R<sup>7</sup>), N(R<sup>7</sup>)CO, SO<sub>2</sub>N(R<sup>7</sup>), N(R<sup>7</sup>)SO<sub>2</sub>, C(R<sup>7</sup>)<sub>2</sub>O, C(R<sup>7</sup>)<sub>2</sub>S and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, wherein R<sup>7</sup> is hydrogen or (1-6C)alkyl, and Q<sup>5</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup>

- 10 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,
- 15 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



- 20 wherein  $X^4$  is a direct bond or is selected from O and N(R<sup>9</sup>), wherein R<sup>9</sup> is hydrogen or (1-6C)alkyl, and R<sup>8</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the formula :

- 25  $-X^5-Q^6$

wherein  $X^5$  is a direct bond or is selected from O and N(R<sup>10</sup>), wherein R<sup>10</sup> is hydrogen or

(1-6C)alkyl, and Q<sup>6</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any Q<sup>6</sup> group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

- 30 and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo or thioxo substituents;

R<sup>2</sup> is hydrogen or (1-6C)alkyl and R<sup>3</sup> is hydrogen or (1-6C)alkyl, or R<sup>2</sup> and R<sup>3</sup> together form a CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub> group;

Z is O, S, N(C≡N) or N(R<sup>11</sup>), wherein R<sup>11</sup> is hydrogen or (1-6C)alkyl; and

Q<sup>2</sup> is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic

5 heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and

Q<sup>2</sup> is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,

10 (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,

(1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,

N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,


(2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,

(3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino,

15 N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl,

N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-


(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X<sup>6</sup> is a direct bond or is selected from O and N(R<sup>13</sup>), wherein R<sup>13</sup> is hydrogen or

20 (1-6C)alkyl, and R<sup>12</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or

di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



wherein X<sup>7</sup> is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>14</sup>), CO, CH(OR<sup>14</sup>),

25 CON(R<sup>14</sup>), N(R<sup>14</sup>)CO, SO<sub>2</sub>N(R<sup>14</sup>), N(R<sup>14</sup>)SO<sub>2</sub>, C(R<sup>14</sup>)<sub>2</sub>O, C(R<sup>14</sup>)<sub>2</sub>S and C(R<sup>14</sup>)<sub>2</sub>N(R<sup>14</sup>),

wherein each R<sup>14</sup> is hydrogen or (1-6C)alkyl, and Q<sup>7</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl,

heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or Q<sup>2</sup> is optionally

substituted with a (1-3C)alkylenedioxy group,


and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on Q<sup>2</sup>

30 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from

halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl,


(2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,

- (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, 5 N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



- wherein  $X^8$  is a direct bond or is selected from O and  $N(R^{16})$ , wherein  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $R^{15}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, 10 cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, and wherein any heterocyclyl group within a substituent on  $Q^2$  optionally bears 1 or 2 oxo or thioxo substituents; or a pharmaceutically-acceptable salt thereof; 15 in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.


2. The use of a quinazoline derivative of the Formula II



II

- 20 wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1; or a pharmaceutically-acceptable salt thereof; in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

- 25 3. The use of a quinoline derivative of the Formula III



III


wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;

or a pharmaceutically-acceptable salt thereof;

in the manufacture of a medicament for use as an anti-invasive agent in the containment

5 and/or treatment of solid tumour disease.

4. The use of a pyrimidine derivative of the Formula IV



IV


wherein each of  $m$ ,  $R^1$ ,  $Y^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;

10 or a pharmaceutically-acceptable salt thereof;

in the manufacture of a medicament for use as an anti-invasive agent in the containment

and/or treatment of solid tumour disease.

5. The use of a quinazoline derivative of the Formula V



wherein each of  $m$ ,  $R^1$ ,  $Y^2$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;  
or a pharmaceutically-acceptable salt thereof;

in the manufacture of a medicament for use as an anti-invasive agent in the containment

5 and/or treatment of solid tumour disease.

6. The use as claimed in claim 1 of a quinazoline derivative of the Formula II according to claim 2 wherein :

$m$  is 1 and the  $R^1$  group is located at the 6- or 7-position and is selected from methoxy,

- 10 benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy,
- 15 N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,
- 20 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-1-yl)propoxy, 3-(4-tert-butoxycarbonylaminopiperidin-1-yl)propoxy,
- 25 3-(4-carbamoylpiperidin-1-yl)propoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,

- 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,  
 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy,  
 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy,  
 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy, 3-[N-(2-methoxyethyl)-  
 5 N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-methylamino-1-propynyl,  
 3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl, 6-methylamino-1-hexynyl,  
 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl, 3-(piperidino)-1-propynyl,  
 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-1-propynyl,  
 6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-1-hexynyl,  
 10 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl,  
 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino,  
 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,  
 or m is 2 and the R<sup>1</sup> groups are located at the 6- and 7-positions, one R<sup>1</sup> group is  
 located at the 6- or 7-position and is selected from the groups defined immediately  
 15 hereinbefore and the other R<sup>1</sup> group is a methoxy group;  
 R<sup>2</sup> is hydrogen or methyl;  
 R<sup>3</sup> is hydrogen;  
 Z is O, S, NH or N(Et); and  
 Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which  
 20 may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro,  
 methyl, ethyl and methoxy provided that at least one substituent is located at an ortho  
 position;  
 or a pharmaceutically-acceptable acid-addition salt thereof.
- 25 7. The use as claimed in claim 1 of a quinazoline derivative of the Formula II according  
 to claim 2 wherein :
- m is 1 and the R<sup>1</sup> group is located at the 7-position and is selected from  
 3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 2-pyrrolidin-1-ylethoxy,  
 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,  
 30 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-  
 4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy,  
 N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,  
 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,

4-pyrrolidin-1-ylbut-2-en-1-yloxy, 4-morpholinobut-2-en-1-yloxy,  
4-morpholinobut-2-yn-1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-  
N-methylamino]ethoxy;

or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups  
5 defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

Z is O, S, NH or N(Et); and

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different,  
10 selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy  
provided that at least one substituent is located at an ortho position;  
or a pharmaceutically-acceptable acid-addition salt thereof.

8. The use as claimed in claim 1 of a quinazoline derivative of the Formula II according  
15 to claim 2 wherein :

m is 1 and the R<sup>1</sup> group is located at the 7-position and is selected from  
3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 3-pyrrolidin-1-ylpropoxy,  
3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,  
2-piperidinoethoxy, 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy,  
20 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-  
1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;  
or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups  
defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

R<sup>2</sup> is hydrogen or methyl;

25 R<sup>3</sup> is hydrogen;

Z is O; and

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different,  
selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent  
is located at an ortho position;  
30 or a pharmaceutically-acceptable acid-addition salt thereof.

9. A method for producing an anti-invasive effect by the containment and/or treatment of  
solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which

comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined in claim 1.

## INTERNATIONAL SEARCH REPORT

national Application No

PCT/GB 01/02874

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/94 C07D215/54 C07D401/12 C07D495/04 A61K31/505  
A61K31/4706 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 50370 A (SUGEN) 12 November 1998 (1998-11-12) cited in the application page 69; claims	1,2,6,9
X	WO 98 38984 A (SUGEN) 11 September 1998 (1998-09-11) page 75 -page 76; claims	1,2,6,9
A	WO 98 43960 A (AMERICAN CYANAMID) 8 October 1998 (1998-10-08) cited in the application page 1; claims	1,3,6,9
A	WO 99 09024 A (SMITHKLINE) 25 February 1999 (1999-02-25) cited in the application page 1; claims	1-3

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
 "&" document member of the same patent family

Date of the actual completion of the international search

30 July 2001

Date of mailing of the international search report

09/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Francois, J

# INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

PCT/GB 01/02874

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9850370	A	12-11-1998	AU 7282998 A EP 0981519 A US 6204267 B	27-11-1998 01-03-2000 20-03-2001
WO 9838984	A	11-09-1998	AU 6680698 A EP 1014953 A US 6248771 B	22-09-1998 05-07-2000 19-06-2001
WO 9843960	A	08-10-1998	AU 6877798 A CN 1259125 T EP 0973746 A HU 0002112 A NO 994798 A PL 335999 A SK 135799 A TR 9902946 T	22-10-1998 05-07-2000 26-01-2000 28-09-2000 24-11-1999 05-06-2000 16-05-2000 21-03-2000
WO 9909024	A	25-02-1999	AU 8741198 A EP 1003737 A	08-03-1999 31-05-2000

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number  
**WO 01/04102 A1**(51) International Patent Classification<sup>7</sup>: **C07D 239/94**,  
A61K 31/505, C07D 401/12, 403/12, 495/04, A61P 37/06Patrick [FR/FR]; Z.I. La Pompelle, Boîte postale 1050,  
F-51689 Reims Cedex 2 (FR). LAMBERT, Christine,  
Marie-Paul [BE/FR]; Z.I. La Pompelle, Boîte postale  
1050, F-51689 Reims Cedex 2 (FR).

(21) International Application Number: PCT/GB00/02566

(22) International Filing Date: 4 July 2000 (04.07.2000)

(74) Agent: TAIT, Brian, Steele; AstraZeneca, Global Intel-  
lectual Property, P.O. Box 272, Mereside, Alderley Park,  
Macclesfield, Cheshire SK10 4GR (GB).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
99401692.1 7 July 1999 (07.07.1999) EP  
00401221.7 4 May 2000 (04.05.2000) EP(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(71) Applicants (*for all designated States except US*): AS-  
TRAZENECA UK LIMITED [GB/GB]; 15 Stanhope  
Gate, London W1Y 6LN (GB). ZENECA PHARMA  
S.A. [GB/GB]; Le Galien, 1, rue des Chauffours, Boîte  
postale 127, F-95022 Cergy Cedex (FR).(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CRAWLEY, Gra-  
ham, Charles [GB/GB]; Alderley Park, Macclesfield,  
Cheshire SK10 4TG (GB). MCKERRECHER, Darren  
[GB/GB]; Alderley Park, Macclesfield, Cheshire SK10  
4TG (GB). POYSER, Jeffrey, Philip [GB/GB]; Alderley  
Park, Macclesfield, Cheshire SK10 4TG (GB). HEN-  
NEQUIN, Laurent, François, André [FR/FR]; Z.I. La  
Pompelle, B.P. 1050, F-51689 Reims Cedex 2 (FR). PLE,


Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

10/019,945

(54) Title: QUINAZOLINE DERIVATIVES

(57) Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein Q<sup>1</sup> in-  
cludes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl  
and cyano, or a group of the formula: Q<sup>3</sup>-X<sup>1</sup>- wherein X<sup>1</sup> includes a direct bond and O and Q<sup>3</sup>  
includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R<sup>2</sup> and R<sup>3</sup> is  
hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q<sup>2</sup> includes aryl and aryl-(1-3C)alkyl  
or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical  
compositions containing them and their use in the manufacture of a medicament for use in the  
prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded  
animal.

WO 01/04102 A1

## QUINAZOLINE DERIVATIVES

This invention concerns certain novel quinazoline derivatives which possess pharmacological properties of use in the treatment of autoimmune diseases or medical  
5 conditions, for example T cell mediated disease such as transplant rejection or rheumatoid arthritis. The invention also concerns processes for the manufacture of the quinazoline derivatives of the invention, pharmaceutical compositions containing them and their use in therapeutic methods, for example by virtue of inhibition of T cell mediated disease.

A critical requirement of the immune system is the ability to differentiate between  
10 "self" and "non-self" (*i.e.* foreign) antigens. This discrimination is required to enable the immune system to mount a response to foreign proteins such as those on the surface of pathogens whilst maintaining tolerance to endogenous proteins and thereby preventing damage to normal tissues. An autoimmune disease results when self-tolerance breaks down and the immune system reacts against tissues such as the joints in rheumatoid arthritis or  
15 nerve fibres in multiple sclerosis. Stimulation of the human immune response is dependent on the recognition of protein antigens by T cells. However T cells do not become activated by and respond to antigen alone but are only triggered into action when the antigen is complexed with major histocompatibility complex (MHC) molecules on the surface of an antigen-presenting cell such as a B cell, macrophage or dendritic cell. Thus T cell activation requires  
20 the docking into the T cell receptor of the peptide/MHC complex expressed on an antigen-presenting cell. This interaction, which confers the antigen specificity to the T cell response, is essential for full activation of T lymphocytes. Subsequent to this docking, some of the earliest signal transduction events leading to full T cell activation are mediated through the action of multiple tyrosine-specific protein kinases (E. Hsi *et al.*, J. Biol. Chem., 1989, 264,  
25 10836) including p56<sup>lck</sup> and ZAP-70. The tyrosine kinase p56<sup>lck</sup> is a lymphocyte specific member of the src family of non-receptor protein tyrosine kinases (J. D. Marth *et al.*, Cell, 1985, 43, 393). The enzyme is associated with the inner surface of the plasma membrane where it binds to the T cell receptor associated glycoproteins CD4 (in helper T cells) and CD8 (in cytotoxic or killer T cells) (C. E. Rudd *et al.*, Proc. Natl. Acad. Sci. USA,  
30 1988, 85, 5190 and M. A. Campbell *et al.*, EMBO J. 1990, 9, 2125).

It is believed that p56<sup>lck</sup> tyrosine kinase plays an essential role in T cell activation as, for example, the loss of p56<sup>lck</sup> expression in a human Jurkat T cell line prevents the normal T cell response to stimulation of the T cell receptor (D. B. Straus *et al.*, Cell, 1992, 70, 585)

and a deficiency in p56<sup>lck</sup> expression causes severe immune deficiency in humans (F. D. Goldman *et al.*, *J. Clin. Invest.*, 1998, 102, 421).

Certain autoimmune conditions or diseases such as inflammatory diseases (for example rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis and lung  
5 fibrosis), multiple sclerosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma and insulin-dependent diabetes are believed to be associated with inappropriate T cell activation (see, for example, J. H. Hanke *et al.*, *Inflamm. Res.*, 1995, 44, 357). In addition the acute rejection of transplanted organs can also be interpreted as a consequence of inappropriate T cell activation. Therefore, compounds which modulate T cell  
10 activation by way of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation, for example by way of inhibition of p56<sup>lck</sup> tyrosine kinase, are expected to provide therapeutic agents for such pathological conditions.

Without wishing to imply that the compounds disclosed in the present invention  
15 possess pharmacological activity only by virtue of an effect on a single biological process, it is believed that the compounds modulate T cell activation by way of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation, for example by way of inhibition of p56<sup>lck</sup> tyrosine kinase.

20 In particular, the quinazoline derivatives of the invention are expected to be useful as immunoregulation or immunosuppressive agents for the prevention or treatment of organ rejection following transplant surgery.

Agents of this kind would offer therapy for transplant rejection and autoimmune diseases whilst avoiding toxicities associated with the commonly used, less selective  
25 immunosuppressants. The leading agent for the prevention or treatment of transplant rejection is cyclosporin A which, although effective, is often associated with side-effects such as renal damage and hypertension which results in kidney failure in a substantial number of patients. It is contemporary practice to treat rheumatoid arthritis initially with symptom relief agents such as NSAIDs, which do not have any beneficial effect on disease progression and are often  
30 associated with unwanted side-effects. A rationally based, disease modifying agent, without such deleterious side-effects, would therefore offer significant benefits in the prevention or treatment of transplant rejection or autoimmune conditions such as rheumatoid arthritis.

As stated above, the present invention is based, in particular, on the discovery that the quinazoline derivatives of the invention modulate T cell activation by way of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation. Accordingly compounds of the present invention possess higher inhibitory potency against particular non-receptor tyrosine kinases such as p56<sup>lck</sup> tyrosine kinase than against other non-receptor tyrosine kinases or against receptor tyrosine kinases (RTKs) such as epidermal growth factor (EGF) RTK. In general, the quinazoline derivatives of the invention possess sufficient potency in inhibiting non-receptor tyrosine kinases such as p56<sup>lck</sup> tyrosine kinase that they may be used in an amount sufficient to inhibit, for example, p56<sup>lck</sup> tyrosine kinase whilst demonstrating reduced potency, preferably whilst demonstrating no significant activity, against RTKs such as EGF RTK. Thus the quinazoline derivatives of the invention can be used in the clinical management of those particular diseases which are sensitive to inhibition of such non-receptor tyrosine kinases, for example autoimmune diseases or medical conditions, for example T cell mediated disease such as transplant rejection or rheumatoid arthritis.

It is disclosed by K. H. Gibson *et al.*, Bioorganic & Medicinal Chemistry Letters, 1997, 7, 2723-2728 that certain 4-anilinoquinazoline derivatives possess useful EGF RTK inhibitory properties. It is also disclosed that 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea is inactive as an EGF RTK inhibitor.

It is disclosed in International Patent Application WO 98/50370 that certain 5-substituted quinazoline derivatives may be useful as inhibitors of serine/threonine protein kinases. Whilst most of the examples are 4-amino-5-phenoxyquinazolines, there is the disclosure of three 4-ureido-5-phenoxyquinazolines, namely of :-

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea and  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.

It is disclosed by C. I. Hong *et al.*, J. Med. Chem., 1976, 19, 555-558 that certain 4-aminopyrazolo[3,4-*d*]pyrimidine derivatives possess growth inhibitory activity against cultured L1210 leukaemia cells. The disclosed compounds include:-

1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,


1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
 1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea.

5 It is disclosed in International Patent Application WO 97/03069 that certain quinoline and quinazoline derivatives may be useful as protein tyrosine kinase inhibitors. All of the disclosed examples are 4-heteroarylaminquinazoline derivatives and none of them are 1-heteroaryl-3-(quinazolin-4-yl)urea derivatives.

It is disclosed in International Patent Application WO 98/43960 that certain  
 10 3-cyanoquinoline derivatives may be useful as protein tyrosine kinase inhibitors. Almost all of the 398 disclosed examples were 3-cyano-4-anilinoquinoline or 3-cyano-4-benzylaminoquinoline derivatives. There is no disclosure of any (3-cyanoquinolin-4-yl)urea derivatives.


It is disclosed in International Patent Application WO 99/09024 that certain  
 15 1-phenyl-3-(quinolin-4-yl)urea derivatives may be useful as antagonists of the human HFGAN72 receptor, a G-protein coupled neuropeptide receptor, and hence may be of potential use in the treatment of obesity. There is no disclosure as examples of any 1-phenyl-3-(quinazolin-4-yl)urea or 1-phenyl-3-(3-cyanoquinolin-4-yl)urea compounds.

According to one aspect of the invention there is provided a quinazoline derivative of  
 20 the Formula I




I



wherein **Q<sup>1</sup>** is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id



Ia



Ib



wherein :

**Y<sup>1</sup>** together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S provided that the group of formula Ic so formed is not a purine ring;

**Y<sup>2</sup> together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S:**

**m** is 0, 1, 2, 3 or 4;

10 **each R<sup>1</sup> group**, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, 15 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :

20 O<sup>3</sup>-X<sup>1</sup>-


wherein  $X^1$  is a direct bond or is selected from O, S, SO,  $SO_2$ ,  $N(R^4)$ , CO,  $CH(OR^4)$ ,  $CON(R^4)$ ,  $N(R^4)CO$ ,  $SO_2N(R^4)$ ,  $N(R^4)SO_2$ ,  $OC(R^4)_2$ ,  $SC(R^4)_2$  and  $N(R^4)C(R^4)_2$ , wherein  $R^4$  is hydrogen or (1-6C)alkyl, and  $Q^3$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $(R^1)_m$  is (1-3C)alkylenedioxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>,

$N(R^5)$ , CO,  $CH(OR^5)$ ,  $CON(R^5)$ ,  $N(R^5)CO$ ,  $SO_2N(R^5)$ ,  $N(R^5)SO_2$ ,  $CH=CH$  and  $C\equiv C$  wherein  $R^5$  is hydrogen or (1-6C)alkyl,


and wherein any  $CH_2=CH-$  or  $HC\equiv C-$  group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from halogeno, carboxy, carbamoyl,

5 (1-6C)alkoxycarbonyl,  $\underline{N}$ -(1-6C)alkylcarbamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein  $X^2$  is a direct bond or is selected from CO and  $N(R^6)CO$ , wherein  $R^6$  is hydrogen or  
10 (1-6C)alkyl, and  $Q^4$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio,  
15 (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  $\underline{N}$ -(1-6C)alkylcarbamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  $\underline{N}$ -(1-6C)alkyl- (2-6C)alkanoylamino,  $\underline{N}$ -(1-6C)alkylsulphamoyl,  $\underline{N,N}$ -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and  $\underline{N}$ -(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a  
20 group of the formula :




wherein  $X^3$  is a direct bond or is selected from O, S, SO,  $SO_2$ ,  $N(R^7)$ , CO,  $CH(OR^7)$ ,  $CON(R^7)$ ,  $N(R^7)CO$ ,  $SO_2N(R^7)$ ,  $N(R^7)SO_2$ ,  $C(R^7)_2O$ ,  $C(R^7)_2S$  and  $N(R^7)C(R^7)_2$ , wherein  $R^7$  is hydrogen or (1-6C)alkyl, and  $Q^5$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-  
25 (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl,  
30 (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,  $\underline{N}$ -(1-6C)alkylcarbamoyl,

N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^4$  is a direct bond or is selected from O and N( $R^9$ ), wherein  $R^9$  is hydrogen or (1-6C)alkyl, and  $R^8$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or  
10 from a group of the formula :



wherein  $X^5$  is a direct bond or is selected from O and N( $R^{10}$ ), wherein  $R^{10}$  is hydrogen or (1-6C)alkyl, and  $Q^6$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, and any  $Q^6$  group optionally bears 1 or 2 substituents, which may  
15 be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo or thioxo substituents;

$R^2$  is hydrogen or (1-6C)alkyl and  $R^3$  is hydrogen or (1-6C)alkyl, or  $R^2$  and  $R^3$  together form a  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group;

20  $Z$  is O, S, N( $C\equiv N$ ) or N( $R^{11}$ ), wherein  $R^{11}$  is hydrogen or (1-6C)alkyl; and

$Q^2$  is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further  
25 heteroatom selected from nitrogen, oxygen and sulphur, and

$Q^2$  is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,  
30 (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,

- 8 -

(3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^6$  is a direct bond or is selected from O and  $N(R^{13})$ , wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $R^{12}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



wherein  $X^7$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>,  $N(R^{14})$ , CO, CH(OR<sup>14</sup>), CON(R<sup>14</sup>),  $N(R^{14})CO$ , SO<sub>2</sub>N(R<sup>14</sup>),  $N(R^{14})SO_2$ , C(R<sup>14</sup>)<sub>2</sub>O, C(R<sup>14</sup>)<sub>2</sub>S and C(R<sup>14</sup>)<sub>2</sub>N(R<sup>14</sup>), wherein each  $R^{14}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $Q^2$  is optionally

15 substituted with a (1-3C)alkylenedioxy group,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,

20 (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^8$  is a direct bond or is selected from O and  $N(R^{16})$ , wherein  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $R^{15}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or

30 di-[(1-6C)alkyl]amino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on  $Q^2$  optionally bears 1 or 2 oxo or thioxo substituents;

or a pharmaceutically-acceptable salt thereof;

provided that the compounds :-

- 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,  
5 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.  
1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
10 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea are excluded.

In this specification the generic term "alkyl" includes both straight-chain and  
15 branched-chain alkyl groups. However references to individual alkyl groups such as "propyl"  
are specific for the straight-chain version only and references to individual branched-chain  
alkyl groups such as "isopropyl" are specific for the branched-chain version only. An  
analogous convention applies to other generic terms.

It is to be understood that, insofar as certain of the compounds of Formula I defined  
20 above may exist in optically active or racemic forms by virtue of one or more asymmetric  
carbon atoms, the invention includes in its definition any such optically active or racemic  
form which possesses the above-mentioned activity. The synthesis of optically active forms  
may be carried out by standard techniques of organic chemistry well known in the art, for  
example by synthesis from optically active starting materials or by resolution of a racemic  
25 form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory  
techniques referred to hereinafter.

It is to be understood that the hydrogen atom which is shown at the 2-position in each  
of the part structures of the formulae Ia, Ib, Ic and Id indicates that that position remains  
unsubstituted by any R<sup>1</sup> group.

30 Suitable values for the generic radicals referred to above include those set out below.

A suitable value for any one of the 'Q' groups (Q<sup>2</sup> to Q<sup>7</sup>) when it is aryl or for the aryl  
group within a 'Q' group is, for example, phenyl or naphthyl, preferably phenyl.

A suitable value for a (3-7C)cycloalkyl group within Q<sup>2</sup> or for Q<sup>3</sup> or Q<sup>4</sup> when it is (3-7C)cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl and a suitable value for Q<sup>3</sup> or Q<sup>4</sup> when it is (3-7C)cycloalkenyl is, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or  
5 cycloheptenyl.

A suitable value for Q<sup>2</sup> when it is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur is, for example, pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl,  
10 thiadiazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, indolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl, preferably isoxazolyl, 1,2,3-triazolyl, pyridyl, benzothiazolyl, quinolyl or quinazolinyl.

A suitable value for any one of the 'Q' groups, Q<sup>3</sup> to Q<sup>7</sup>, when it is heteroaryl or for the  
15 heteroaryl group within a 'Q' group is, for example, an aromatic 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring with up to five ring heteroatoms selected from oxygen, nitrogen and sulphur, for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl,  
20 benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl, preferably thienyl, 1,2,3-triazolyl, pyridyl, quinolyl, quinazolinyl or quinoxalinyl.

A suitable value for any one of the 'Q' groups, Q<sup>3</sup> to Q<sup>7</sup>, when it is heterocyclyl or for the heterocyclyl group within a 'Q' group is, for example, a non-aromatic saturated or  
25 partially saturated 3 to 10 membered monocyclic or bicyclic ring with up to five heteroatoms selected from oxygen, nitrogen and sulphur, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl, 1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl, preferably  
30 pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperazin-1-yl or homopiperazin-1-yl, more preferably piperidin-4-yl. A suitable value for such a group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl,

2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.

A suitable value for a 'Q' group when it is heteroaryl-(1-6C)alkyl is, for example, heteroarylmethyl, 2-heteroarylethyl and 3-heteroarylpropyl. The invention comprises  
 5 corresponding suitable values for 'Q' groups when, for example, rather than a heteroaryl-(1-6C)alkyl group, an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group is present.

When, as defined hereinbefore, Y<sup>1</sup> together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3  
 10 heteroatoms selected from O, N and S (provided that the group of formula Ic so formed is not a purine ring), ring Y<sup>1</sup> is suitably unsaturated or partially unsaturated wherein a -CH<sub>2</sub>- group can optionally be replaced by a -CO- group and a ring nitrogen atom may optionally bear a (1-6C)alkyl group. Diradicals of suitable fused Y<sup>1</sup> rings include thiendiyl, furandiyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, 1,2,3-oxadiazolediyl,  
 15 1,2,3-triazolediyl, pyridinediyl, pyrimidinediyl, pyrazinediyl, pyridazinediyl and 1,3,4-triazinediyl. Examples of suitable bicyclic rings of formula Ic formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring include furopyrimidinyl, thienopyrimidinyl, pyrrolopyrimidinyl, pyrrolinopyrimidinyl, oxopyrrolinopyrimidinyl, oxazolopyrimidinyl, oxazolinopyrimidinyl, oxooxazolinopyrimidinyl, isoxazolopyrimidinyl, thiazolopyrimidinyl,  
 20 thiazolinopyrimidinyl, oxothiazolinopyrimidinyl, isothiazolopyrimidinyl, oxoimidazolinopyrimidinyl, pyrazolopyrimidinyl, pyrazolinopyrimidinyl, oxopyrazolinopyrimidinyl, pyridopyrimidinyl, pyrimidopyrimidinyl and pteridinyl. Preferably the bicyclic ring of formula Ic is furo[3,2-*d*]pyrimidinyl, furo[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, pyrrolo[3,2-*d*]pyrimidinyl,  
 25 pyrrolo[2,3-*d*]pyrimidinyl, oxazolo[5,4-*d*]pyrimidinyl, oxazolo[4,5-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, thiazolo[4,5-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl, pyrimido[4,5-*d*]pyrimidinyl, pyrimido[5,6-*d*]pyrimidinyl or pteridinyl. More specifically the bicyclic ring of formula Ic is 6-oxopyrrolino[2,3-*d*]pyrimidin-4-yl,  
 30 6-oxopyrrolino[3,2-*d*]pyrimidin-4-yl, 2-oxooxazolino[5,4-*d*]pyrimidin-7-yl, 2-oxothiazolino[5,4-*d*]pyrimidin-7-yl, 2-oxooxazolino[4,5-*d*]pyrimidin-7-yl, 2-oxothiazolino[4,5-*d*]pyrimidin-7-yl, 2-oxoimidazolino[4,5-*d*]pyrimidin-7-yl, 3-oxopyrazolino[3,4-*d*]pyrimidin-4-yl or 3-oxopyrazolino[4,3-*d*]pyrimidin-7-yl. Further

preferred bicyclic rings of formula Ic include thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl and pteridinyl, more specifically thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, 5 thiazolo[5,4-*d*]pyrimidin-7-yl, pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl, pyrido[3,2-*d*]pyrimidin-4-yl and pteridin-4-yl.

When, as defined hereinbefore, Y<sup>2</sup> together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S, ring Y<sup>2</sup> is suitably unsaturated or partially unsaturated 10 wherein a -CH<sub>2</sub>- group can optionally be replaced by a -CO- group and a ring nitrogen atom may optionally bear a (1-6C)alkyl group. Diradicals of suitable fused Y<sup>2</sup> rings include thiendiyl, furandiyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, 1,2,3-oxadiazole-diyl, 1,2,3-triazole-diyl, pyridinediyl, pyrimidinediyl, pyrazinediyl, pyridazinediyl and 1,3,4-triazinediyl. Examples of suitable tricyclic rings of 15 formula Id formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include imidazoquinazolinyl, oxazoloquinazolinyl, thiazoloquinazolinyl, [1,2,3]triazoloquinazolinyl, pyrazoloquinazolinyl, pyrroloquinazolinyl, oxoimidazolinoquinazolinyl, oxooxazolinoquinazolinyl, oxothiazolinoquinazolinyl and oxopyrazolinoquinazolinyl. Preferably the tricyclic ring of formula Id is 3H-imidazo[4,5-*g*]quinazolinyl, 20 oxazolo[4,5-*g*]quinazolinyl, thiazolo[4,5-*g*]quinazolinyl, 3H-[1,2,3]triazolo[4,5-*g*]quinazolinyl, 1H-pyrazolo[3,4-*g*]quinazolinyl, 6H-pyrrolo[2,3-*g*]quinazolinyl, 2-oxo-1,2-dihydro-3H-imidazo[4,5-*g*]quinazolinyl, 2-oxo-1,2-dihydrooxazolo[4,5-*g*]quinazolinyl, 2-oxo-1,2-dihydrothiazolo[4,5-*g*]quinazolinyl, 3-oxo-2,3-dihydro-1H-pyrazolo[3,4-*g*]quinazolinyl, pyrido[2,3-*g*]quinazolinyl, 25 pyrimidino[4,5-*g*]cinnolinyl, pyrimidino[4,5-*g*]quinazolinyl, pyrazino[2,3-*g*]quinazolinyl, 7-oxo-6,7-dihydropyrido[2,3-*g*]quinazolinyl, pyrazino[2,3-*g*]quinazolinyl and 8-oxo-8,9-dihydropyrazino[2,3-*g*]quinazolinyl. More specifically the tricyclic ring of formula Id is 3H-imidazo[4,5-*g*]quinazolin-8-yl, oxazolo[4,5-*g*]quinazolin-8-yl, thiazolo[4,5-*g*]quinazolin-8-yl, 3H-[1,2,3]triazolo[4,5-*g*]quinazolin-8-yl, 30 1H-pyrazolo[3,4-*g*]quinazolin-8-yl, 6H-pyrrolo[2,3-*g*]quinazolin-4-yl, 2-oxo-1,2-dihydro-3H-imidazo[4,5-*g*]quinazolin-8-yl, 2-oxo-1,2-dihydrooxazolo[4,5-*g*]quinazolin-8-yl, 2-oxo-1,2-dihydrothiazolo[4,5-*g*]quinazolin-8-yl, 3-oxo-2,3-dihydro-1H-pyrazolo[3,4-*g*]quinazolin-8-yl, pyrido[2,3-*g*]quinazolin-4-yl,

pyrimidino[4,5-g]cinnolin-9-yl, pyrimidino[4,5-g]quinazolin-4-yl, pyrazino[2,3-g]quinazolin-4-yl, 7-oxo-6,7-dihydropyrido[2,3-g]quinazolin-4-yl, pyrazino[2,3-g]quinazolin-4-yl or 8-oxo-8,9-dihydropyrazino[2,3-g]quinazolin-4-yl. Further preferred tricyclic rings of formula Id include 3-methyl-3H-imidazo[4,5-g]quinazolin-8-yl, 3-methyl-3H-[1,2,3]triazolo[4,5-g]quinazolin-8-yl, 3-methyl-2-oxo-1,2-dihydro-3H-imidazo[4,5-g]quinazolin-8-yl, pyrazino[2,3-g]quinazolin-4-yl and 9-methyl-8-oxo-8,9-dihydropyrazino[2,3-g]quinazolin-4-yl.

Suitable values for any of the 'R' groups ( $R^1$  to  $R^{16}$ ), or for various groups within an  $R^1$  substituent, or within a substituent on  $Q^2$  include:-

- |    |  |   |
|----|--|---|
| 10 | for halogeno                               | fluoro, chloro, bromo and iodo;   |
|    | for (1-6C)alkyl:                           | methyl, ethyl, propyl, isopropyl and <u>tert</u> -butyl;  |
|    | for (2-8C)alkenyl:                         | vinyl, allyl and but-2-enyl;  |
|    | for (2-8C)alkynyl:                         | ethynyl, 2-propynyl and but-2-ynyl;   |
|    | for (1-6C)alkoxy:                          | methoxy, ethoxy, propoxy, isopropoxy and butoxy;  |
| 15 | for (2-6C)alkenyloxy:                      | vinylloxy and allyloxy;   |
|    | for (2-6C)alkynyloxy:                      | ethynyloxy and 2-propynyloxy;   |
|    | for (1-6C)alkylthio:                       | methylthio, ethylthio and propylthio;   |
|    | for (1-6C)alkylsulphinyl:                  | methylsulphinyl and ethylsulphinyl;   |
|    | for (1-6C)alkylsulphonyl:                  | methylsulphonyl and ethylsulphonyl;   |
| 20 | for (1-6C)alkylamino:                      | methylamino, ethylamino, propylamino, isopropylamino and butylamino;  |
|    | for di-[(1-6C)alkyl]amino:                 | dimethylamino, diethylamino, <u>N</u> -ethyl- <u>N</u> -methylamino and diisopropylamino;                   |
|    | for (1-6C)alkoxycarbonyl:                  | methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and <u>tert</u> -butoxycarbonyl;                           |
| 25 | for <u>N</u> -(1-6C)alkylcarbamoyl:        | <u>N</u> -methylcarbamoyl, <u>N</u> -ethylcarbamoyl and <u>N</u> -propylcarbamoyl;                          |
|    | for <u>N,N</u> -di-[(1-6C)alkyl]carbamoyl: | <u>N,N</u> -dimethylcarbamoyl, <u>N</u> -ethyl- <u>N</u> -methylcarbamoyl and <u>N,N</u> -diethylcarbamoyl; |
| 30 | for (2-6C)alkanoyl:                        | acetyl and propionyl;   |
|    | for (2-6C)alkanoyloxy:                     | acetoxy and propionyloxy;   |
|    | for (2-6C)alkanoylamino:                   | acetamido and propionamido;   |

- for N-(1-6C)alkyl-(2-6C)alkanoylamino: N-methylacetamido and N-methylpropionamido;
- for N-(1-6C)alkylsulphamoyl: N-methylsulphamoyl and N-ethylsulphamoyl;
- for N,N-di-[(1-6C)alkyl]sulphamoyl: N,N-dimethylsulphamoyl;
- for (1-6C)alkanesulphonylamino: methanesulphonylamino and ethanesulphonylamino;
- 5 for N-(1-6C)alkyl-(1-6C)alkanesulphonylamino: N-methylmethanesulphonylamino and  
N-methylethanesulphonylamino;
- for (3-6C)alkenoylamino: acrylamido, methacrylamido and crotonamido;
- for N-(1-6C)alkyl-(3-6C)alkenoylamino: N-methylacrylamido and N-methylcrotonamido;
- for (3-6C)alkynoylamino: propiolamido;
- 10 for N-(1-6C)alkyl-(3-6C)alkynoylamino: N-methylpropiolamido;
- for amino-(1-6C)alkyl: aminomethyl, 2-aminoethyl, 1-aminoethyl and  
3-aminopropyl;
- for (1-6C)alkylamino-(1-6C)alkyl: methylaminomethyl, ethylaminomethyl,  
1-methylaminoethyl, 2-methylaminoethyl,  
15 2-ethylaminoethyl and 3-methylaminopropyl;
- for di-[(1-6C)alkyl]amino-(1-6C)alkyl: dimethylaminomethyl, diethylaminomethyl,  
1-dimethylaminoethyl, 2-dimethylaminoethyl and  
3-dimethylaminopropyl;
- for halogeno-(1-6C)alkyl: chloromethyl, 2-chloroethyl, 1-chloroethyl and  
20 3-chloropropyl;
- for hydroxy-(1-6C)alkyl: hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl and  
3-hydroxypropyl;
- for (1-6C)alkoxy-(1-6C)alkyl: methoxymethyl, ethoxymethyl, 1-methoxyethyl,  
2-methoxyethyl, 2-ethoxyethyl and  
25 3-methoxypropyl;
- for cyano-(1-6C)alkyl: cyanomethyl, 2-cyanoethyl, 1-cyanoethyl and  
3-cyanopropyl;
- for (2-6C)alkanoylamino-(1-6C)alkyl: acetamidomethyl, propionamidomethyl and  
2-acetamidoethyl; and
- 30 for (1-6C)alkoxycarbonylamino-(1-6C)alkyl: methoxycarbonylaminomethyl,  
ethoxycarbonylaminomethyl,  
tert-butoxycarbonylaminomethyl and  
2-methoxycarbonylaminoethyl.

A suitable value for  $(R^1)_m$  or for a substituent on  $Q^2$  when it is (1-3C)alkylenedioxy is, for example, methylenedioxy or ethylenedioxy and the oxygen atoms thereof occupy adjacent ring positions.

When, as defined hereinbefore, an  $R^1$  group forms a group of the formula  $Q^3-X^1$ - and, for example,  $X^1$  is a  $OC(R^4)_2$  linking group, it is the carbon atom, not the oxygen atom, of the  $OC(R^4)_2$  linking group which is attached to the quinazoline-like ring such as the ring of formula Ia and the oxygen atom is attached to the  $Q^3$  group. Similarly, when, for example a  $CH_3$  group within a  $R^1$  substituent bears a group of the formula  $-X^3-Q^5$  and, for example,  $X^3$  is a  $C(R^7)_2O$  linking group, it is the carbon atom, not the oxygen atom, of the  $C(R^7)_2O$  linking group which is attached to the  $CH_3$  group and the oxygen atom is linked to the  $Q^5$  group. A similar convention applies to the attachment of the groups of the formulae  $Q^4-X^2$ - and  $-X^7-Q^7$ .

As defined hereinbefore, adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent may be optionally separated by the insertion into the chain of a group such as O,  $CON(R^5)$  or  $C\equiv C$ . For example, insertion of a  $C\equiv C$  group into the ethylene chain within a 2-morpholinoethoxy group gives rise to a 4-morpholinobut-2-ynyloxy group and, for example, insertion of a CONH group into the ethylene chain within a 3-methoxypropoxy group gives rise to, for example, a 2-(2-methoxyacetamido)ethoxy group.

When, as defined hereinbefore, any  $CH_2=CH$ - or  $HC\equiv C$ - group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent such as a group of the formula  $Q^4-X^2$ - wherein  $X^2$  is, for example,  $NHCO$  and  $Q^4$  is a heterocyclyl-(1-6C)alkyl group, suitable  $R^1$  substituents so formed include, for example, N-[heterocyclyl-(1-6C)alkyl]carbamoylvinyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylvinyl or N-[heterocyclyl-(1-6C)alkyl]carbamoylethynyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylethynyl.


When, as defined hereinbefore, any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group one or more halogeno substituents, there are suitably 1 or 2 halogeno substituents present on each said  $CH_2$  group and there are suitably 1, 2 or 3 halogeno substituents present on each said  $CH_3$  group.

When, as defined hereinbefore, any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group a substituent as defined hereinbefore, suitable  $R^1$  substituents so formed include, for example, hydroxy-substituted heterocyclyl-(1-6C)alkoxy groups such as 2-hydroxy-3-piperidinopropoxy and 2-hydroxy-

3-morpholinopropoxy, hydroxy-substituted amino-(2-6C)alkoxy groups such as 3-amino-  
 2-hydroxypropoxy, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkoxy groups such as  
 2-hydroxy-3-methylaminopropoxy, hydroxy-substituted di-[(1-6C)alkyl]amino-(2-6C)alkoxy  
 groups such as 3-dimethylamino-2-hydroxypropoxy, hydroxy-substituted heterocycl-  
 5 (1-6C)alkylamino groups such as 2-hydroxy-3-piperidinopropylamino and 2-hydroxy-  
 3-morpholinopropylamino, hydroxy-substituted amino-(2-6C)alkylamino groups such as  
 3-amino-2-hydroxypropylamino, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkylamino  
 groups such as 2-hydroxy-3-methylaminopropylamino, hydroxy-substituted  
 di-[(1-6C)alkyl]amino-(2-6C)alkylamino groups such as 3-dimethylamino-  
 10 2-hydroxypropylamino, hydroxy-substituted (1-6C)alkoxy groups such as 2-hydroxyethoxy,  
 (1-6C)alkoxy-substituted (1-6C)alkoxy groups such as 2-methoxyethoxy and  
 3-ethoxypropoxy, (1-6C)alkylsulphonyl-substituted (1-6C)alkoxy groups such as  
 2-methylsulphonylethoxy and heterocycl-yl-substituted (1-6C)alkylamino-(1-6C)alkyl groups  
 such as 2-morpholinoethylaminomethyl, 2-piperazin-1-ylethylaminomethyl and  
 15 3-morpholinopropylaminomethyl.


A suitable pharmaceutically-acceptable salt of a compound of the Formula I is, for  
 example, an acid-addition salt of a compound of the Formula I, for example an acid-addition  
 salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric,  
 trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the Formula I  
 20 which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a  
 calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as  
 methylamine, dimethylamine, trimethylamine, piperidine, morpholine or  
 tris-(2-hydroxyethyl)amine.

According to a further aspect of the invention there is provided a quinazoline  
 25 derivative of the Formula I




I


wherein  $\text{Q}^1$  is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id




Ia



Ib



Ic



Id


wherein :

**Y<sup>1</sup>** together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S provided that the group of formula Ic so formed is not a purine ring;

**Y<sup>2</sup>** together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

**m** is 0, 1, 2, 3 or 4;

each **R<sup>1</sup>** group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein **X<sup>1</sup>** is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>4</sup>), CO, CH(OR<sup>4</sup>), CON(R<sup>4</sup>), N(R<sup>4</sup>)CO, SO<sub>2</sub>N(R<sup>4</sup>), N(R<sup>4</sup>)SO<sub>2</sub>, OC(R<sup>4</sup>)<sub>2</sub>, SC(R<sup>4</sup>)<sub>2</sub> and N(R<sup>4</sup>)C(R<sup>4</sup>)<sub>2</sub>, wherein R<sup>4</sup> is

hydrogen or (1-6C)alkyl, and  $Q^3$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $(R^1)_m$  is (1-3C)alkylenedioxy,


and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent  
5 are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>, N(R<sup>5</sup>), CO, CH(OR<sup>5</sup>), CON(R<sup>5</sup>), N(R<sup>5</sup>)CO, SO<sub>2</sub>N(R<sup>5</sup>), N(R<sup>5</sup>)SO<sub>2</sub>, CH=CH and C≡C wherein R<sup>5</sup> is hydrogen or (1-6C)alkyl,

and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a  $R^1$  substituent optionally bears at  
the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl,  
10 (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,  
amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or  
from a group of the formula :



wherein  $X^2$  is a direct bond or is selected from CO and N(R<sup>6</sup>)CO, wherein R<sup>6</sup> is hydrogen or  
15 (1-6C)alkyl, and  $Q^4$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl  
or heterocyclyl-(1-6C)alkyl,


and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a  $R^1$  substituent optionally bears on each  
said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno substituents or a substituent selected from  
hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio,  
20 (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,  
(1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,  
(2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-  
(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,  
(1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a  
25 group of the formula :



wherein  $X^3$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO, CH(OR<sup>7</sup>),  
CON(R<sup>7</sup>), N(R<sup>7</sup>)CO, SO<sub>2</sub>N(R<sup>7</sup>), N(R<sup>7</sup>)SO<sub>2</sub>, C(R<sup>7</sup>)<sub>2</sub>O, C(R<sup>7</sup>)<sub>2</sub>S and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, wherein R<sup>7</sup> is  
hydrogen or (1-6C)alkyl, and  $Q^5$  is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-  
30 (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-  
(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,

- 5 (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-  
10 (1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X<sup>4</sup> is a direct bond or is selected from O and N(R<sup>9</sup>), wherein R<sup>9</sup> is hydrogen or (1-6C)alkyl, and R<sup>8</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or

- 15 di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



wherein X<sup>5</sup> is a direct bond or is selected from O and N(R<sup>10</sup>), wherein R<sup>10</sup> is hydrogen or (1-6C)alkyl, and Q<sup>6</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- 20 and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo or thioxo substituents;


R<sup>2</sup> is hydrogen or (1-6C)alkyl and R<sup>3</sup> is hydrogen or (1-6C)alkyl, or R<sup>2</sup> and R<sup>3</sup> together form a CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub> group;

Z is O, S, N(C≡N) or N(R<sup>11</sup>), wherein R<sup>11</sup> is hydrogen or (1-6C)alkyl; and


- 25 Q<sup>2</sup> is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and

- 30 Q<sup>2</sup> is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,

(2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbonyl, N,N-di-[(1-6C)alkyl]carbonyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, 5 (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



10 wherein  $X^6$  is a direct bond or is selected from O and N( $R^{13}$ ), wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $R^{12}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



15 wherein  $X^7$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N( $R^{14}$ ), CO, CH(OR<sup>14</sup>), CON( $R^{14}$ ), N( $R^{14}$ )CO, SO<sub>2</sub>N( $R^{14}$ ), N( $R^{14}$ )SO<sub>2</sub>, C( $R^{14}$ )<sub>2</sub>O, C( $R^{14}$ )<sub>2</sub>S and C( $R^{14}$ )<sub>2</sub>N( $R^{14}$ ), wherein each  $R^{14}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $Q^2$  is optionally substituted with a (1-3C)alkylenedioxy group,

20 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbonyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, 25 di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbonyl, N,N-di-[(1-6C)alkyl]carbonyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :

30  $-X^8-R^{15}$

wherein  $X^8$  is a direct bond or is selected from O and N( $R^{16}$ ), wherein  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $R^{15}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on Q<sup>2</sup> optionally bears 1 or 2 oxo or thioxo substituents;

5 or a pharmaceutically-acceptable salt thereof;

provided that the compounds :-

1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,

10 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.

1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,


15 1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and

1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea are excluded.

Particular novel compounds of the invention include, for example,

(i) quinazoline derivatives of the Formula II




II

20

wherein each of *m*, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, Z and Q<sup>2</sup> has any of the meanings defined hereinbefore;

(ii) quinoline derivatives of the Formula III


- 22 -



III

wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore;


(iii) pyrimidine derivatives of the Formula IV



IV

5 wherein each of  $m$ ,  $R^1$ ,  $Y^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore;  
and

(iv) quinazoline derivatives of the Formula V



V

wherein each of  $m$ ,  $R^1$ ,  $Y^2$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined hereinbefore.

10 Subject to the provisos described hereinbefore, further particular novel compounds of the invention include, for example, quinazoline derivatives of the Formula II, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of  $m$ ,  $R^1$ ,  $R^2$ ,

$R^3$ , Z and  $Q^2$  has any of the meanings defined hereinbefore or in paragraphs (a) to (o) hereinafter :-

- (a) m is 1, 2 or 3, and each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino and N-(1-6C)alkyl-(3-6C)alkynoylamino, or from a group of the formula :



wherein  $X^1$  is a direct bond or is selected from O,  $N(R^4)$ ,  $CON(R^4)$ ,  $N(R^4)CO$  and  $OC(R^4)_2$

wherein  $R^4$  is hydrogen or (1-6C)alkyl, and  $Q^3$  is aryl, aryl-(1-6C)alkyl, cycloalkyl-


(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent are optionally separated by the insertion into the chain of a group selected from O,  $N(R^5)$ ,  $CON(R^5)$ ,  $N(R^5)CO$ ,  $CH=CH$  and  $C\equiv C$  wherein  $R^5$  is hydrogen or (1-6C)alkyl,

and wherein any  $CH_2=CH-$  or  $HC\equiv C-$  group within a  $R^1$  substituent optionally bears at the terminal  $CH_2=$  or  $HC\equiv$  position a substituent selected from carbamoyl,

N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,


- (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein  $X^2$  is a direct bond or is CO or  $N(R^6)CO$ , wherein  $R^6$  is hydrogen or (1-6C)alkyl, and

$Q^4$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylsulphonyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino, or from a group of the formula :




- wherein  $X^3$  is a direct bond or is selected from O,  $N(R^7)$ ,  $CON(R^7)$ ,  $N(R^7)CO$  and  $C(R^7)_2O$ , wherein  $R^7$  is hydrogen or (1-6C)alkyl, and  $Q^5$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy,

N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,  
 5 (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl and (1-6C)alkoxycarbonylamino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo substituents;

(b) m is 1, 2 or 3, and each R<sup>1</sup> group, which may be the same or different, is selected from  
 10 halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino and N-(1-6C)alkyl-(3-6C)alkynoylamino,  
 15 or from a group of the formula :




wherein X<sup>1</sup> is a direct bond or is selected from O, N(R<sup>4</sup>), CON(R<sup>4</sup>), N(R<sup>4</sup>)CO and OC(R<sup>4</sup>)<sub>2</sub>

wherein R<sup>4</sup> is hydrogen or (1-6C)alkyl, and Q<sup>3</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

20 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, N(R<sup>5</sup>), CON(R<sup>5</sup>), N(R<sup>5</sup>)CO, CH=CH and C≡C wherein R<sup>5</sup> is hydrogen or (1-6C)alkyl,

and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a R<sup>1</sup> substituent optionally bears at the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from carbamoyl,

25 N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :




wherein X<sup>2</sup> is a direct bond or is CO or N(R<sup>6</sup>)CO, wherein R<sup>6</sup> is hydrogen or (1-6C)alkyl, and

30 Q<sup>4</sup> is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, (1-6C)alkoxy,

(1-6C)alkylsulphonyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino, or from a group of the formula :




wherein  $X^3$  is a direct bond or is selected from O,  $N(R^6)$ ,  $CON(R^7)$ ,  $N(R^7)CO$  and  $C(R^7)_2O$ ,

5 wherein  $R^7$  is hydrogen or (1-6C)alkyl, and  $Q^5$  is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, (1-6C)alkyl and (1-6C)alkoxy,

10 and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo substituents;

(c)  $m$  is 1, 2 or 3, and each  $R^1$  group, which may be the same or different, is selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, dimethylamino, 15 diethylamino, dipropylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido, propionamido, acrylamido and propiolamido, or from a group of the formula :



wherein  $X^1$  is a direct bond or is selected from O, NH, CONH, NHCO and  $OCH_2$  and  $Q^3$  is phenyl, benzyl, cyclopropylmethyl, thienyl, 1-imidazolyl, 1,2,3-triazolyl, pyridyl,


20 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperazin-1-yl, homopiperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 25 2-morpholinoethyl, 3-morpholinopropyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,

30 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a  $R^1$  substituent are optionally separated by the insertion into the chain of a group selected from O, NH, CONH, NHCO,  $CH=CH$  and  $C\equiv C$ ,

and wherein any  $\text{CH}_2=\text{CH}-$  or  $\text{HC}\equiv\text{C}-$  group within a  $\text{R}^1$  substituent optionally bears at the terminal  $\text{CH}_2=$  or  $\text{HC}\equiv$  position a substituent selected from carbamoyl,


N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methylaminomethyl,

- 5 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl or 4-dimethylaminobutyl, or from a group of the formula :



- 10 wherein  $\text{X}^2$  is a direct bond or is CO, NHCO or N(Me)CO and  $\text{Q}^4$  is pyridyl, pyridylmethyl, 2-pyridylethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, 15 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

- and wherein any  $\text{CH}_2$  or  $\text{CH}_3$  group within a  $\text{R}^1$  substituent optionally bears on each  
20 said  $\text{CH}_2$  or  $\text{CH}_3$  group a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino and dimethylamino, or from a group of the formula :




- wherein  $\text{X}^3$  is a direct bond or is selected from O, NH, CONH, NHCO and  $\text{CH}_2\text{O}$  and  $\text{Q}^5$  is pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, 25 piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

- 30 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $\text{R}^1$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy,

aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl and tert-butoxycarbonylaminomethyl,

and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2  
5 oxo substituents;


(d) m is 1, 2 or 3, and each R<sup>1</sup> group, which may be the same or different, is selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, dipropylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido,  
10 propionamido, acrylamido and propiolamido, or from a group of the formula :



wherein X<sup>1</sup> is a direct bond or is selected from O, NH, CONH, NHCO and OCH<sub>2</sub> and Q<sup>3</sup> is phenyl, benzyl, thienyl, 1,2,3-triazolyl, pyridyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, pyrrolidin-1-yl,  
15 pyrrolidin-2-yl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, homopiperidin-1-yl, piperazin-1-yl, homopiperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl,  
20 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,


and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent  
25 are optionally separated by the insertion into the chain of a group selected from O, NH, CONH, NHCO, CH=CH and C≡C,

and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a R<sup>1</sup> substituent optionally bears at the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl,  
30 aminomethyl, 2-aminoethyl, methylaminomethyl, 2-methylaminoethyl, dimethylaminomethyl or 2-dimethylaminoethyl, or from a group of the formula :



wherein  $X^2$  is a direct bond or is CO, NHCO or N(Me)CO and  $Q^4$  is pyridyl, pyridylmethyl, 2-pyridylethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino and dimethylamino, or from a group of the formula :



wherein  $X^3$  is a direct bond or is selected from O, NH, CONH, NHCO and  $CH_2O$  and  $Q^5$  is pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,

and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo substituents;

(e)  $m$  is 1 or 2 and the  $R^1$  groups, which may be the same or different, are located at the 6- and/or 7-positions and are selected from hydroxy, amino, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, benzyloxy, cyclopropylmethoxy, 2-imidazol-1-ylethoxy, 3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, pyrrolidin-1-yl, morpholino, piperidino, piperazin-1-yl, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy,

- 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,  
 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,  
 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy,  
 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy,  
 5 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy,  
 3-piperazin-1-ylpropoxy, 2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy,  
 2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino, pyrrolidin-3-ylamino,  
 pyrrolidin-2-ylmethethylamino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino,  
 2-morpholinoethylamino, 3-morpholinopropylamino, 2-(1,1-dioxotetrahydro-  
 10 4H-1,4-thiazin-4-yl)ethylamino, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino,  
 2-piperidinoethylamino, 3-piperidinopropylamino, piperidin-3-ylamino,  
 piperidin-4-ylamino, piperidin-3-ylmethethylamino, 2-piperidin-3-ylethylamino,  
 piperidin-4-ylmethethylamino, 2-piperidin-4-ylethylamino, 2-homopiperidin-1-ylethylamino,  
 3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino,  
 15 2-homopiperazin-1-ylethylamino or 3-homopiperazin-1-ylpropylamino,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH and C≡C,

and when R<sup>1</sup> is a vinyl or ethynyl group, the R<sup>1</sup> substituent optionally bears at the  
 20 terminal CH<sub>2</sub>= or HC≡ position a substituent selected from

N-(2-dimethylaminoethyl)carbonyl, N-(3-dimethylaminopropyl)carbonyl,  
 methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl,  
 dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl and  
 4-dimethylaminobutyl, or from a group of the formula :

25 
$$Q^4 - X^2 -$$

wherein X<sup>2</sup> is a direct bond or is NHCO or N(Me)CO and Q<sup>4</sup> is imidazolylmethyl,  
 2-imidazolylethyl, 3-imidazolylpropyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl,  
 pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl,  
 pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, morpholinomethyl,  
 30 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl,  
 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl,

2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group a substituent selected from hydroxy, amino, methoxy,

5 methylsulphonyl, methylamino and dimethylamino,

and wherein any phenyl, pyridyl or heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, aminomethyl, acetamidomethyl and tert-butoxycarbonylaminoethyl,


10 and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2 oxo substituents;

(f) m is 1 or 2 and the R<sup>1</sup> groups, which may be the same or different, are located at the 6- and/or 7-positions and are selected from hydroxy, amino, methyl, ethyl, propyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, dimethylamino, diethylamino, 15 acetamido, propionamido, benzyloxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 20 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, piperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 25 2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, NH, CH=CH and C≡C,

and when R<sup>1</sup> is a vinyl or ethynyl group, the R<sup>1</sup> substituent optionally bears at the 30 terminal CH<sub>2</sub>= or HC≡ position a substituent selected from N-(2-dimethylaminoethyl)carbamoyl or N-(3-dimethylaminopropyl)carbamoyl, or from a group of the formula :

- 31 -




wherein  $X^2$  is NHCO or N(Me)CO and  $Q^4$  is imidazolylmethyl, 2-imidazolylethyl, 3-imidazolylpropyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

and wherein any  $CH_2$  or  $CH_3$  group within a  $R^1$  substituent optionally bears on each said  $CH_2$  or  $CH_3$  group a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino and dimethylamino,


and wherein any phenyl, pyridyl or heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,

and wherein any heterocyclyl group within a substituent on  $R^1$  optionally bears 1 or 2 oxo substituents;

- (g) each of  $R^2$  and  $R^3$  is hydrogen or methyl;
- (h) each of  $R^2$  and  $R^3$  is hydrogen;
- (i) Z is O, S or  $N(R^{11})$ , wherein  $R^{11}$  is hydrogen or (1-6C)alkyl;
- (j) Z is O, S,  $N(R^{11})$ , wherein  $R^{11}$  is hydrogen, methyl, ethyl or propyl;
- (k) Z is O;
- (l)  $Q^2$  is phenyl, benzyl,  $\alpha$ -methylbenzyl, phenethyl, naphthyl, 1-(1-naphthyl)ethyl or 2-phenylcyclopropyl which is optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, or from a group of the formula :




wherein  $X^6$  is a direct bond or is selected from O and  $N(R^{13})$ , wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $R^{12}$  is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



wherein  $X^7$  is a direct bond or is selected from O,  $N(R^{14})$ , CO,  $CON(R^{14})$ ,  $N(R^{14})CO$  and  $C(R^{14})_2O$ , wherein each  $R^{14}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is phenyl, benzyl, heteroaryl or heteroaryl-(1-6C)alkyl,

and wherein any phenyl or heteroaryl group within a substituent on  $Q^2$  optionally bears  
5 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, (1-6C)alkyl and (1-6C)alkoxy;

(m)  $Q^2$  is phenyl, benzyl,  $\alpha$ -methylbenzyl or phenethyl which is optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, tert-butyl, vinyl, ethynyl  
10 and methoxy, or from a group of the formula :



wherein  $X^7$  is a direct bond or is selected from O and CO, and  $Q^7$  is phenyl, benzyl, pyridyl or pyridylmethyl, and wherein any phenyl or pyridyl group within a substituent on  $Q^2$  optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro,  
15 trifluoromethyl, hydroxy, amino, methyl and methoxy;

(n)  $Q^2$  is phenyl, benzyl or phenethyl which is substituted with 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, tert-butyl, vinyl, ethynyl and methoxy provided that at least one substituent is located at an ortho position (for example the 2-position on a  
20 phenyl group); and

(o)  $Q^2$  is phenyl, benzyl or phenethyl which is substituted with 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, hydroxy, methyl, ethyl, propyl, tert-butyl, vinyl, ethynyl and methoxy provided that two substituents are located at ortho positions (for example the 2- and 6-positions on a phenyl  
25 group).

Further particular novel compounds of the invention include, for example, quinoline derivatives of the Formula III, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of m,  $R^1$ ,  $R^2$ ,  $R^3$ , Z and  $Q^2$  has any of the meanings defined hereinbefore or in any of the paragraphs (a) to (o) immediately hereinbefore.

30 Further particular novel compounds of the invention include, for example, pyrimidine derivatives of the Formula IV, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of m,  $R^1$ ,  $R^2$ ,  $R^3$ , Z and  $Q^2$  has any of the meanings defined

hereinbefore or in any of the paragraphs (a) to (o) immediately hereinbefore and Y<sup>1</sup> has any of the meanings defined hereinbefore or in paragraphs (a) to (c) hereinafter :-

- (a) bicyclic rings formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring include thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl and pyrido[3,2-*d*]pyrimidin-4-yl;
- (b) bicyclic rings formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring include thieno[3,2-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl and pyrido[3,2-*d*]pyrimidin-4-yl; and
- 10 (c) the bicyclic ring formed by the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring is thieno[3,2-*d*]pyrimidin-4-yl.

Further particular novel compounds of the invention include, for example, quinazoline derivatives of the Formula V, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of m, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, Z and Q<sup>2</sup> has any of the meanings defined

15 hereinbefore or in any of the paragraphs (a) to (o) immediately hereinbefore and Y<sup>2</sup> has any of the meanings defined hereinbefore or in paragraphs (a) and (b) hereinafter :-

- (a) tricyclic rings formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include 3H-imidazo[4,5-*g*]quinazolin-8-yl and 2-oxo-1,2-dihydro-3H-imidazo[4,5-*g*]quinazolin-8-yl; and
- 20 (b) tricyclic rings formed by the fusion of ring Y<sup>2</sup> to the adjacent quinazoline ring include 3-methyl-3H-imidazo[4,5-*g*]quinazolin-8-yl and 3-methyl-2-oxo-1,2-dihydro-3H-imidazo[4,5-*g*]quinazolin-8-yl.

A preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

- 25 m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from methoxy, benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinoethoxy,
- 30

- 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,  
 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,  
 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy,  
 piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy,  
 5 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,  
 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-  
 1-yl)propoxy, 3-(4-tert-butoxycarbonylaminopiperidin-1-yl)propoxy,  
 3-(4-carbamoylpiperidin-1-yl)propoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,  
 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,  
 10 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy,  
 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy,  
 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy, 3-[N-(2-methoxyethyl)-  
N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-methylamino-1-propynyl,  
 3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl, 6-methylamino-1-hexynyl,  
 15 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl, 3-(piperidino)-1-propynyl,  
 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-1-propynyl,  
 6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-1-hexynyl,  
 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl,  
 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino,  
 20 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,

or m is 2 and the R<sup>1</sup> groups are located at the 6- and 7-positions, one R<sup>1</sup> group is located at the 6- or 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a methoxy group;

R<sup>2</sup> is hydrogen or methyl;

25 R<sup>3</sup> is hydrogen;

Z is O, S, NH or N(Et); and

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho  
 30 position;

or a pharmaceutically-acceptable acid-addition salt thereof;

and provided that 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea is excluded.

A further preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

m is 1 or 2 and the R<sup>1</sup> groups, which may be the same or different, are located at the 5 6- and/or 7-positions and are selected from methoxy, benzyloxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, 1-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 1-methylpyrrolidin-2-ylmethoxy, 10 2-pyrrolidin-2-ylethoxy, 2-(1-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(1-methylpyrrolidin-2-yl)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, 1-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, 1-methylpiperidin-3-ylmethoxy, 15 2-piperidin-3-ylethoxy, 2-(1-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)- 20 N-methylamino]ethoxy and 3-[N-(2-methoxyethyl)-N-methylamino]propoxy;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

Z is O; and

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which 25 may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl and methyl; or a pharmaceutically-acceptable acid-addition salt thereof; provided that 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea is excluded.

A further preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

30 m is 1 and the R<sup>1</sup> group is located at the 7-position and is selected from 3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-

4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy,  
N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,  
 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,  
 4-pyrrolidin-1-ylbut-2-en-1-yloxy, 4-morpholinobut-2-en-1-yloxy,  
 5 4-morpholinobut-2-yn-1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-  
N-methylamino]ethoxy;

or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

R<sup>2</sup> is hydrogen or methyl;

10 R<sup>3</sup> is hydrogen;

Z is O, S, NH or N(Et); and

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position;

15 or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound of the invention is a quinazoline derivative of the Formula II wherein :

m is 1 and the R<sup>1</sup> group is located at the 7-position and is selected from  
 3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 3-pyrrolidin-1-ylpropoxy,  
 20 3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,  
 2-piperidinoethoxy, 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy,  
 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-  
 1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;

or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups  
 25 defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

Z is O; and

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different,  
 30 selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent is located at an ortho position;

or a pharmaceutically-acceptable acid-addition salt thereof.

A particular preferred compound of the invention is, for example, a quinazoline derivative of the Formula II selected from:-

1-(2,6-dichlorophenyl)-3-[7-(3-morpholinopropoxy)quinazolin-4-yl]urea and

1-(2,6-dichlorophenyl)-3-{7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazolin-  
5 4-yl}urea;  
or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred compound of the invention is, for example, a quinazoline derivative of the Formula II selected from:-

1-benzyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea and

10 1-phenethyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea;  
or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred compound of the invention is, for example, a quinazoline derivative of the Formula II selected from:-

1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea

15 and 1-(2,6-difluorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-  
4-yl]urea;  
or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular preferred compound of the invention is, for example, a quinazoline derivative of the Formula II selected from:-

20 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-  
4-yl]urea,

1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-  
4-yl]urea;

1-(2,6-difluorophenyl)-3-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]urea;

25 1-(2,6-difluorophenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-  
4-yl]urea;

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-  
4-yl]urea;

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(3-piperidinopropoxy)quinazolin-4-yl]urea;

30 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-  
4-yl]thiourea and


1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-

4-yl]guanidine;

or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound of the invention is a pyrimidine derivative of the Formula IV wherein the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring forms a  
 5 thieno[3,2-*d*]pyrimidin-4-yl group;

m is 0, or m is 1 and the R<sup>1</sup> group is a methyl, ethyl, vinyl or ethynyl group which is located at the 6-position and bears a substituent selected from carboxy, carbamoyl, N-(2-methylaminoethyl)carbamoyl, N-(2-dimethylaminoethyl)carbamoyl, N-(3-methylaminopropyl)carbamoyl or N-(3-dimethylaminopropyl)carbamoyl, or from a  
 10 group of the formula :



wherein X<sup>2</sup> is NHCO or N(Me)CO and Q<sup>4</sup> is 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, 2-pyrrolidin-1-ylethyl, 2-(2-oxopyrrolidin-1-yl)ethyl, 3-pyrrolidin-1-ylpropyl, 3-(2-oxopyrrolidin-1-yl)propyl,  
 15 pyrrolidin-2-ylmethyl, 1-methylpyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 2-(1-methylpyrrolidin-2-yl)ethyl, 3-pyrrolidin-2-ylpropyl, 3-(1-methylpyrrolidin-2-yl)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 1-methylpiperidin-3-ylmethyl, 2-piperidin-3-ylethyl, 2-(1-methylpiperidin-3-yl)ethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-piperidin-4-ylethyl,  
 20 2-(1-methylpiperidin-4-yl)ethyl, 2-piperazin-1-ylethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-piperazin-1-ylpropyl or 3-(4-methylpiperazin-1-yl)propyl,

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;


Z is O; and

25 Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl and methyl; or a pharmaceutically-acceptable acid-addition salt thereof.

A further preferred compound of the invention is a pyrimidine derivative of the Formula IV wherein the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring forms a  
 30 thieno[3,2-*d*]pyrimidin-4-yl group;

m is 0, or m is 1 and the R<sup>1</sup> group is a vinyl group located at the 6-position which bears at the terminal CH<sub>2</sub>= position a substituent selected from

N-(2-dimethylaminoethyl)carbamoyl or N-(3-dimethylaminopropyl)carbamoyl, or from a group of the formula :



wherein  $X^2$  is NHCO or N(Me)CO and  $Q^4$  is 2-pyridylmethyl, 4-pyridylmethyl,

- 5 2-pyrid-2-ylethyl, 2-pyrrolidin-1-ylethyl, 3-(2-oxopyrrolidin-1-yl)propyl, 3-morpholinopropyl, 2-piperidinoethyl or 3-(4-methylpiperazin-1-yl)propyl,

$R^2$  is hydrogen or methyl;

$R^3$  is hydrogen;

Z is O; and

- 10  $Q^2$  is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent is located at the ortho position;

or a pharmaceutically-acceptable acid-addition salt thereof.

- A particular preferred compound of this aspect of the invention is, for example, a  
15 pyrimidine derivative of the Formula IV selected from:-

1-(2,6-dichlorophenyl)-3-(thieno[3,2-*d*]pyrimidin-4-yl)urea and

(*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}-

N-(3-dimethylaminopropyl)acrylamide;

or a pharmaceutically-acceptable acid-addition salt thereof.

- 20 A quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a quinazoline derivative of the Formula I are provided as a further feature of the invention and are illustrated by the following representative process variants in which, unless otherwise stated,  $Q^1$ ,  $R^2$ , Z,  
25  $R^3$  and  $Q^2$  have any of the meanings defined hereinbefore. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the accompanying Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic  
30 chemist.

(a) For those compounds of the Formula I wherein  $R^3$  is hydrogen and Z is oxygen, the reaction, conveniently in the presence of a suitable base, of an amine of the Formula VI



VI

wherein  $Q^1$  and  $R^2$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isocyanate of the Formula VII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



VII

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable base is, for example, an organic amine base such as, for example, pyridine,  
10 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine,  
N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline  
earth metal carbonate, alkoxide or hydroxide, for example sodium carbonate, potassium  
carbonate, calcium carbonate, sodium ethoxide, potassium tert-butoxide, sodium hydroxide or  
potassium hydroxide, or, for example, an alkali metal hydride, for example sodium hydride or  
15 potassium hydride, or an organometallic base such as an alkyl-lithium, for example n-butyl-  
lithium or a dialkylamino-lithium, for example lithium di-isopropylamide.

The reaction is conveniently carried out in the presence of a suitable inert solvent or  
diluent, for example a halogenated solvent such as methylene chloride, chloroform or carbon  
tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, or a dipolar aprotic solvent such  
20 as acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one  
or dimethylsulphoxide. The reaction is conveniently carried out at a temperature in the range,  
for example, 10 to 150°C, preferably in the range 20 to 75°C.

A suitable conventional chemical equivalent of an isocyanate of the Formula VII is, for  
example, a compound of the Formula VIII




VIII

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is  
protected if necessary, and L is a suitable displaceable or leaving group. On treatment with a  
suitable base as defined hereinbefore, the compound of the Formula VIII reacts to form the  
desired isocyanate of the Formula VII.

30 A suitable displaceable or leaving group L is, for example, a halogeno, alkoxy, aryloxy  
or sulphonyloxy group; for example a chloro, bromo, methoxy, phenoxy,  
methanesulphonyloxy or toluene-4-sulphonyloxy group.

A suitable conventional chemical precursor of an isocyanate of the Formula VII is, for example, an acyl azide of the Formula IX



wherein  $\text{Q}^2$  has any of the meanings defined hereinbefore except that any functional group is  
5 protected if necessary. On thermal or photolytic treatment the acyl azide of the Formula IX decomposes and rearranges to form the desired isocyanate of the Formula VII.

Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question and may be introduced by conventional methods. Protecting groups may be removed  
10 by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Specific examples of protecting groups are given below for the sake of convenience, in  
15 which "lower", as in, for example, lower alkyl, signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned are, of course, within the scope of the invention.

20 A carboxy protecting group may be the residue of an ester-forming aliphatic or arylaliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms). Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (for example isopropyl, and tert-butyl); lower alkoxy-lower alkyl groups (for example methoxymethyl, ethoxymethyl and isobutoxymethyl); lower  
25 acyloxy-lower alkyl groups, (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl); lower alkoxycarbonyloxy-lower alkyl groups (for example 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl); aryl-lower alkyl groups (for example benzyl, 4-methoxybenzyl, 2-nitrobenzyl, 4-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (for example trimethylsilyl and  
30 tert-butyldimethylsilyl); tri(lower alkyl)silyl-lower alkyl groups (for example trimethylsilylethyl); and (2-6C)alkenyl groups (for example allyl). Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed cleavage.

Examples of hydroxy protecting groups include lower alkyl groups (for example tert-butyl), lower alkenyl groups (for example allyl); lower alkanoyl groups (for example acetyl); lower alkoxycarbonyl groups (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (for example trimethylsilyl and tert-butyldimethylsilyl) and aryl-lower alkyl (for example benzyl) groups.

Examples of amino protecting groups include formyl, aryl-lower alkyl groups (for example benzyl and substituted benzyl, 4-methoxybenzyl, 2-nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-4-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); trialkylsilyl (for example trimethylsilyl and tert-butyldimethylsilyl); alkylidene (for example methylidene) and benzylidene and substituted benzylidene groups.

Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis for groups such as 2-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for groups such as 2-nitrobenzyloxycarbonyl.

The reader is referred to Advanced Organic Chemistry, 4th Edition, by J. March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents and to Protective Groups in Organic Synthesis, 2<sup>nd</sup> Edition, by T. Green et al., also published by John Wiley & Son, for general guidance on protecting groups.

When L is, for example, a chloro group, the compound of the Formula VIII may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of phosgene with an amine of the Formula X.



The compound of the Formula IX may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XI.



(b) For those compounds of the Formula I wherein R<sup>3</sup> is hydrogen and Z is sulphur, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of an amine of the Formula VI



VI

wherein  $Q^1$  and  $R^2$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isothiocyanate of the Formula XII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,

5



XII

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable conventional chemical equivalent of an isothiocyanate of the Formula XII  
10 is, for example, a compound of the Formula XIII



XIII

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group as defined hereinbefore. On treatment with a suitable base as defined hereinbefore, the compound of the Formula XIII  
15 reacts to form the desired isothiocyanate of the Formula XII.

A suitable conventional chemical precursor of an isothiocyanate of the Formula XII is, for example, an acyl azide of the Formula XIV



XIV

wherein  $Q^2$  has any of the meanings defined hereinbefore except that any functional group is  
20 protected if necessary. On thermal or photolytic treatment the thioacyl azide of the Formula XIV decomposes and rearranges to form the desired isothiocyanate of the Formula XII.

When L is, for example, a chloro group, the compound of the Formula XIII may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as  
25 defined hereinbefore, of thiophosgene with an amine of the Formula X.



X

The compound of the Formula XIV may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XV.



XV

30 (c) For those compounds of the Formula I wherein  $R^2$  is hydrogen and Z is oxygen, the reaction, conveniently in the presence of a suitable base, of an amine of the Formula XVI



XVI

wherein  $Q^2$  and  $R^3$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isocyanate of the Formula XVII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



5 wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable conventional chemical equivalent of an isocyanate of the Formula XVII is, for example, a compound of the Formula XVIII



wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group as defined hereinbefore. On treatment with a suitable base as defined hereinbefore, the compound of the Formula XVIII reacts to form the desired isocyanate of the Formula XVII.

15 A suitable conventional chemical precursor of an isocyanate of the Formula XVII is, for example, an acyl azide of the Formula XIX




wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary. On thermal or photolytic treatment the thioacyl azide of the Formula XIX decomposes and rearranges to form the desired isocyanate of the Formula XVII.


When L is, for example, a chloro group, the compound of the Formula XVIII may be prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of phosgene with an amine of the Formula XX.



25 The compound of the Formula XIX may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XXI.



(d) For those compounds of the Formula I wherein  $R^2$  is hydrogen and Z is sulphur, the reaction, conveniently in the presence of a suitable base, of an amine of the Formula XVI



wherein  $Q^2$  and  $R^3$  have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an isothiocyanate of the Formula XXII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

- 5        A suitable conventional chemical equivalent of an isothiocyanate of the Formula XXII is, for example, a compound of the Formula XXIII



- wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary, and L is a suitable displaceable group as defined hereinbefore. On  
10 treatment with a suitable base as defined hereinbefore, the compound of the Formula XXIII reacts to form the desired isothiocyanate of the Formula XXII.

A suitable conventional chemical precursor of an isothiocyanate of the Formula XXII is, for example, an acyl azide of the Formula XXIV



- 15 wherein  $Q^1$  has any of the meanings defined hereinbefore except that any functional group is protected if necessary. On thermal or photolytic treatment the thioacyl azide of the Formula XXIV decomposes and rearranges to form the desired isothiocyanate of the Formula XXII.

- When L is, for example, a chloro group, the compound of the Formula XXIII may be  
20 prepared by, for example, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of thiophosgene with an amine of the Formula XX.



The compound of the Formula XXIV may be prepared by, for example, the reaction of a metal azide such as sodium azide with a compound of the Formula XXV.

- 25         $Q^1-CS-L \qquad \text{XXV}$

(e) For those compounds of the Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains an alkylcarbamoyl group or a substituted alkylcarbamoyl group, the reaction of the corresponding compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  is a carboxy group, or a reactive derivative thereof, with an amine or substituted amine as appropriate.

- 30        A suitable reactive derivative of a compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  is a carboxy group is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a

chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid and a phenol such as pentafluorophenol, an ester formed by the reaction of the acid and an ester such as pentafluorophenyl trifluoroacetate or an ester formed by the reaction of the acid and an alcohol such as N-hydroxybenzotriazole; an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cyanide; or the product of the reaction of the acid and a carbodiimide such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

10       The reaction is conveniently carried out in the presence of a suitable base as defined hereinbefore and in the presence of a suitable inert solvent or diluent as defined hereinbefore.

Typically a carbodiimide coupling reagent is used in the presence of an organic solvent (preferably an anhydrous polar aprotic organic solvent) at a non-extreme temperature, for example in the region -10 to 40°C, typically at ambient temperature of about 20°C.

15       A compound of Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> is a carboxy group may conveniently be prepared by the cleavage of the corresponding ester such as a (1-12C)alkyl ester, for example by acid-, base- metal- or enzymatically-catalysed cleavage.

(f)     For those compounds of the Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains an amino-(1-6C)alkyl group, the cleavage of the corresponding compound of Formula I wherein  
20 a substituent on Q<sup>1</sup> or Q<sup>2</sup> is a protected amino-(1-6C)alkyl group.

Suitable protecting groups for an amino-(1-6C)alkyl group are, for example, any of the protecting groups disclosed hereinbefore for an amino group. Suitable methods for the cleavage of such amino protecting groups are also disclosed hereinbefore. In particular, a suitable protecting group is a lower alkoxycarbonyl group such as a tert-butoxycarbonyl group  
25 which may be cleaved under conventional reaction conditions such as under acid-catalysed hydrolysis.

(g)     For those compounds of the Formula I wherein Z is a N(R<sup>11</sup>) group wherein R<sup>11</sup> is hydrogen or (1-6C)alkyl, the reaction, conveniently in the presence of a suitable metallic salt catalyst, of a thiourea of the Formula I wherein Q<sup>1</sup>, Q<sup>2</sup>, R<sup>2</sup> and R<sup>3</sup> have any of the meanings  
30 defined hereinbefore except that any functional group is protected if necessary and Z is sulphur, with an amine of formula R<sup>11</sup>NH<sub>2</sub>, whereafter any protecting group that is present is removed by conventional means.

A suitable metallic salt catalyst is, for example, a mercuric salt such as mercuric(II) oxide and the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore.

(h) For those compounds of the Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains an amino group, the reduction of a corresponding compound of Formula I wherein a substituent on Q<sup>1</sup> or Q<sup>2</sup> contains a nitro group.

Typical reaction conditions include the use of ammonium formate or hydrogen gas in the presence of a catalyst, for example a metallic catalyst such as palladium-on-carbon. Alternatively a dissolving metal reduction may be carried out, for example using iron in the presence of an acid, for example an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric or acetic acid. The reaction is conveniently carried out in the presence of an organic solvent (preferably a polar protic solvent) and preferably with heating, for example to about 60°C. Any functional groups are protected and deprotected as necessary.

When a pharmaceutically-acceptable salt of a quinazoline derivative of the Formula I is required, for example an acid-addition salt, it may be obtained by, for example, reaction of said quinazoline derivative with a suitable acid using a conventional procedure.

### Biological Assays

The following assays can be used to measure the effects of the compounds of the present invention as p56<sup>lck</sup> inhibitors, as inhibitors of T cell activation, as inhibitors of cytokine production in mice and as inhibitors of transplant rejection.

#### (a) In vitro Enzyme Assay

The ability of test compounds to inhibit phosphorylation by the enzyme p56<sup>lck</sup> of a tyrosine-containing polypeptide substrate was assessed using a conventional Elisa assay.

The following conventional procedure was used to obtain p56<sup>lck</sup> enzyme. An EcoR1/Not1 fragment containing the entire coding sequence of p56<sup>lck</sup> was generated by the technique of polymerase chain reaction (PCR) from Incyte clone No. 2829606. A 6-His tag was added to the sequence at the N-terminus during the PCR stage. Conventional sequence analysis identified a number of changes compared to the published sequence and these were found also to have been present in the original Incyte template. To achieve expression of the enzyme, the PCR fragment was inserted downstream of the polyhedrin promotor of pFASTBAC1 (Life Technologies Limited, Paisley, UK, Catalogue No. 10360-014). A

recombinant Baculovirus was constructed using the Bac-to-Bac system (Life Technologies Limited). High Five insect cells (Invitrogen BV, PO Box 2312, 9704 CH Groningen, The Netherlands, Catalogue No. B855-02) were infected with the recombinant Baculovirus at a multiplicity of infection of 1 and incubated for 48 hours. The cells were harvested. Groups of 5  $1.6 \times 10^9$  cells were lysed by incubation in 20 mM Hepes pH7.5 buffer containing 10% glycerol, 1% Triton-X-100, magnesium chloride (1.5mM), ethylene glycol bis(b-aminoethyl ether N,N,N',N'-tetraacetic acid) (EGTA, 1mM), sodium vanadate (1mM), sodium fluoride (10mM), imidazole (5mM), sodium chloride (150mM), phenylmethanesulphonyl fluoride (0.1mM), pepstatin (1 mg/ml) and leupeptin (1 mg/ml). A 10 soluble fraction was obtained by centrifugation and 6-His-p56<sup>lck</sup> was purified by column chromatography on a 1 ml Ni-NTA agarose column (Qiagen Limited, Crawley, West Sussex, UK). The protein was eluted using the above-mentioned buffer except that imidazole (100mM) was also present. The p56<sup>lck</sup> enzyme so obtained was stored at -80°C.

Substrate solution [100µl of a 2µg/ml solution of the polyamino acid 15 Poly(Glu, Ala, Tyr) 6:3:1 (Sigma Catalogue No. P3899) in phosphate buffered saline (PBS)] was added to each well of a Nunc 96-well immunoplate (Catalogue No. 439454) and the plate was sealed and stored at 4°C for 16 hours. The excess of substrate solution was discarded, the substrate-coated wells were washed with Hepes pH7.4 buffer (50mM, 300µl) and blotted dry. Each test compound was dissolved in DMSO and diluted to give a series of dilutions (from 20 100µM to 0.001µM) of the compound in a 10:1 mixture of water and DMSO. Portions (25µl) of each dilution of test compound were transferred to the 96-well assay plate. Aliquots (25µl) of a 10:1 mixture of water and DMSO were added followed by aliquots (25µl) of a mixture of adenosine triphosphate (ATP; 24µl of a 1mM aqueous solution) and manganese chloride (3ml of a 40mM aqueous solution).

25 p56<sup>lck</sup> enzyme (0.3µl of a 0.5mg/ml stock solution) was diluted in a mixture of Hepes pH 7.4 buffer (200mM, 3ml), sodium orthovanadate (2mM, 0.6ml), 1% Triton X-100 (0.6ml), dithiothreitol (25mM, 48µl) and distilled water (1.8ml). Aliquots (50µl) of the resultant solution were transferred to each well in the assay plate and the plate was incubated at ambient temperature for 8 minutes. The wells were washed sequentially with two aliquots 30 (300µl) of phosphate-buffered saline (PBS) containing 0.1% Tween 20 (hereinafter PBS/T).

Aliquots (100µl) were added to each well of a mixture of antiphosphotyrosine-4G10 monoclonal IgG2bk antibody (UBI Catalogue No. 05-321; 30µl of a 50µg/ml solution of the

antibody in PBS/T), PBS/T (11ml) and bovine serum albumin (BSA; Sigma Catalogue No. A6793; 55mg) and the plate was incubated at ambient temperature for 1 hour. The wells were washed sequentially with two aliquots (300µl) of PBS/T and blotted dry. Aliquots (100µl) were added to each well of a mixture of sheep anti-mouse IgG-peroxidase antibody  
5 (Amersham Catalogue No. NXA931; 20µl), PBS/T (11ml) and BSA (55mg) and the plate was incubated at ambient temperature for 1 hour. The wells were washed sequentially with two aliquots (300µl) of PBS/T and blotted dry.

Aliquots (100µl) were added to each well of an ABTS solution [prepared by adding an 2,2'-azinobis(3-ethylbenzothiazolinesulphonic acid) (ABTS) tablet (50mg; Boehringer  
10 Catalogue No. 1204521) to a mixture (50mM) of phosphate-citrate pH5.0 buffer and 0.03% sodium perborate (obtained by adding a PCSB capsule (Sigma Catalogue No. P-4922) to distilled water (100ml))]. The plate was incubated at ambient temperature for 1.5 hours and the absorbance at 405nm was determined.

The extent of inhibition of the phosphorylation reaction at a range of concentrations of  
15 each test compound was determined and an IC<sub>50</sub> value was calculated.

(b) In vitro T cell proliferation assays

The ability of test compounds to inhibit T cell proliferation was assessed by using human peripheral blood mononuclear cells and stimulation of the T cells by way of the T cell receptor or other than by way of the T cell receptor.

20 Peripheral blood mononuclear cells (PBMC) were isolated from heparinised (10units/ml heparin) human blood by density centrifugation (Lymphoprep<sup>TM</sup>; Nycomed) spinning initially at 2000rpm at ambient temperature for 20 minutes. Cells at the interphase were transferred to clean tubes, diluted 1:1 with RPMI 1640 medium (Gibco) and spun at 2000rpm at ambient temperature for 10 minutes. The cell pellet was resuspended in  
25 RPMI 1640 medium and spun at 1400rpm at ambient temperature for 10 minutes. The cell pellet was resuspended in RPMI 1640 medium and spun at 900rpm at ambient temperature for 10 minutes to remove platelets. The prepared mononuclear cells were resuspended in an assay medium comprising RPMI 1640 culture medium supplemented with 50 units/ml penicillin, 50µg/ml streptomycin, 1mM glutamine and 10% heat-inactivated human AB serum.

30 Test compounds were solubilised in DMSO at a concentration of 10mM and diluted 1:83.3 in assay medium. Aliquots (75µl) were added to each well of a 96 well flat-bottomed tissue culture plate and subsequently serial 1 to 3 dilutions were made into assay medium

giving final test concentrations in the range 0.1 to 30µM. Control wells contained assay medium (50µl) containing 1.2% DMSO. PBMCs (100µl of a suspension of  $2 \times 10^6$  cells/ml in assay medium) were added to each well and incubated for 1 hour at 37°C in a humidified (5%CO<sub>2</sub>/95% air) incubator.

- 5           The extent of inhibition of T cell proliferation at a range of concentrations of each test compound was determined and an IC<sub>50</sub> value was calculated.

(b)(i) T cell receptor stimulation

Aliquots (50µl) of the T cell receptor stimulatory anti-CD3 antibody (Pharmingen Catalogue No. 30100D; 40ng/ml in assay medium) were added to each well and the cells were  
10 incubated for 24 hours at 37°C in a humidified (5%CO<sub>2</sub>/95% air) incubator. Tritiated thymidine (1µCi per well) was added and the cells were incubated for up to a further 24 hours at 37°C. The cells were harvested onto a filter mat and radioactivity was counted using a Wallac 1450 Microbeta Plus liquid scintillation counter.

(b)(ii) Non T cell receptor stimulation

15           Aliquots (50µl) of a mixture of the cell stimulants PMA (phorbol-12-myristate-13-acetate, Sigma Catalogue No. P8139; 40ng/ml) and Ionomycin (Sigma Catalogue No. I0684; 1.2µM) were added to each well and the cells were incubated and analysed as described in paragraph (b)(i).

(c) In vivo skin graft rejection test

20           The ability of test compounds to inhibit rodent skin allograft rejection was assessed using analogous procedures to those disclosed by J. Magae *et al.*, Cellular Immunology, 1996, 173, 276-281 and R. Tsuji *et al.*, J. Antibiot., 1992, 45, 1295 to assess the effect of cyclosporin A on T cell properties in vivo.

(d) Test as anti-arthritic agent

25           Activity of a test compound as an anti-arthritic agent was assessed as follows. Acid soluble native type II collagen has been shown to be arthritogenic in rats causing polyarthritis when administered in Freund's incomplete adjuvant by (D. E. Trentham *et al.* J. Exp. Med., 1977, 146, 857). This is now known as collagen-induced arthritis (CIA) and similar conditions can be induced in mice and primates. CIA in DBA/1 mice as described by  
30 R.O. Williams *et al.*, Proc Natl. Acad Sci., 1992, 89, 9784 and Immunology, 1995, 84, 433 is a tertiary model which can be used to demonstrate the anti-arthritic activity of a test compound.

Although the pharmacological properties of the compounds of the Formula I vary with structural change as expected, in general activity possessed by compounds of the Formula I, including those compounds excluded by way of one of the provisos in the definition hereinbefore, may be demonstrated at the following concentrations or doses in one or more of the above tests (a), (b), (c) and (d):-

Test (a):-  $IC_{50}$  in the range, for example, 0.0001 - 5  $\mu$ M;

Test (b)(i):-  $IC_{50}$  in the range, for example, 0.001 - 10  $\mu$ M;

Test (b)(ii):-  $IC_{50}$  in the range, for example, 0.5 - >30  $\mu$ M;

Test (c):- activity in the range, for example, 0.1-100 mg/kg;

Test (d):- activity in the range, for example, 1-100 mg/kg:.

No physiologically-unacceptable toxicity was observed at the effective dose for compounds tested of the present invention. Accordingly no untoward toxicological effects are expected when a compound of Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore but without the proviso that the group of formula Ic so formed is not a purine ring and including the compounds :-

1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.  
1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
is administered at the dosage ranges defined hereinafter.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible

powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile  
5 aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or  
10 preservative agents.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active  
15 agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age  
20 and sex of the animal or patient and the route of administration, according to well known principles of medicine.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses  
25 will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg  
30 to 0.5 g of a compound of this invention.

According to a further aspect of the invention there is provided a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that the compounds of the present invention are of use in the prevention or treatment of autoimmune diseases or medical conditions, for example T cell mediated disease such as transplant rejection, rheumatoid arthritis or multiple sclerosis. We have further found that these effects are believed to arise by virtue of inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to full T cell activation, for example by way of inhibition of the enzyme p56<sup>lck</sup>. Accordingly the compounds of the present invention are expected to be useful in the prevention or treatment of T cell mediated diseases or medical conditions. In particular the compounds of the present invention are expected to be useful in the prevention or treatment of those pathological conditions which are sensitive to inhibition of one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to T cell activation, for example by way of inhibition of p56<sup>lck</sup> tyrosine kinase. Further, the compounds of the present invention are expected to be useful in the prevention or treatment of those diseases or medical conditions which are mediated alone or in part by inhibition of the enzyme p56<sup>lck</sup>, *i.e.* the compounds may be used to produce a p56<sup>lck</sup> enzyme inhibitory effect in a warm-blooded animal in need of such treatment. Specifically, the compounds of the present invention are expected to be useful in the prevention or treatment of autoimmune conditions or diseases such as inflammatory diseases (for example rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis and lung fibrosis), multiple sclerosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma and insulin-dependent diabetes. In particular the compounds of the present invention are expected to be useful in the prevention or treatment of the acute rejection of transplanted tissue or organs.

Thus according to this aspect of the invention there is provided the use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore but without the proviso that the group of formula Ic so formed is not a purine ring and including the compounds :-

- 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,
- 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,
- 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,
- 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.
- 1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 5 1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
 1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 in the manufacture of a medicament for use in the prevention or treatment of T cell mediated  
 diseases or medical conditions in a warm-blooded animal such as man.

According to a further feature of this aspect of the invention there is provided a  
 10 method for the prevention or treatment of T cell mediated diseases or medical conditions in a  
 warm-blooded animal, such as man, in need of such treatment which comprises administering  
 to said animal an effective amount of a quinazoline derivative of the Formula I, or a  
 pharmaceutically-acceptable salt thereof, as defined hereinbefore but without the proviso that  
 the group of formula Ic so formed is not a purine ring and including the compounds :-

15 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,  
 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,  
 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,  
 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.  
 1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 20 1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,  
 1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and  
 25 1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea.

According to a further feature of the invention there is provided the use of a  
 quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as  
 defined immediately hereinbefore in the manufacture of a medicament for use in the  
 prevention or treatment of those pathological conditions which are sensitive to inhibition of  
 30 one or more of the multiple tyrosine-specific protein kinases which are involved in the early  
 signal transduction steps which lead to T cell activation.

According to a further feature of the invention there is provided a method for the  
 prevention or treatment of those pathological conditions which are sensitive to inhibition of

one or more of the multiple tyrosine-specific protein kinases which are involved in the early signal transduction steps which lead to T cell activation which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined immediately hereinbefore.

5       As stated above the size of the dose required for the therapeutic or prophylactic treatment of T cell mediated disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight, preferably 0.1 mg/kg to 30 mg/kg body weight, is envisaged, given if required in divided doses.

10       The compounds of this invention may be used in combination with other drugs and therapies used in the treatment of T cell mediated disease. For example, the compounds of the Formula I could be used in combination with drugs and therapies used in the treatment of autoimmune conditions or diseases such as inflammatory diseases (for example rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis and lung fibrosis), multiple  
15       sclerosis, psoriasis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, allergic asthma and insulin-dependent diabetes. In particular the compounds of the Formula I could be used in combination with drugs and therapies such as cyclosporin A used in the prevention or treatment of the acute rejection of transplanted organs.

For example, the compounds of the Formula I are of value in the treatment of certain  
20       inflammatory and non-inflammatory diseases which are currently treated with a cyclooxygenase-inhibitory non-steroidal anti-inflammatory drug (NSAID) such as indomethacin, ketorolac, acetylsalicylic acid, ibuprofen, sulindac, tolmetin and piroxicam. Co-administration of a compound of the Formula I with a NSAID can result in a reduction of the quantity of the latter agent needed to produce a therapeutic effect. Thereby the likelihood  
25       of adverse side-effects from the NSAID such as gastrointestinal effects are reduced. Thus according to a further feature of the invention there is provided a pharmaceutical composition which comprises a compound of the Formula I, or a pharmaceutically-acceptable salt thereof, in conjunction or admixture with a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent, and a pharmaceutically-acceptable diluent or carrier.

30       The compounds of the invention may also be used with anti-inflammatory agents such as an inhibitor of the enzyme 5-lipoxygenase. The compounds of the invention may also be used with anti-inflammatory agents such as an inhibitor of the enzyme COX-2 such as celecoxib or rofecoxib.

The compounds of the Formula I may also be used in the treatment of conditions such as rheumatoid arthritis in combination with antiarthritic agents such as gold, methotrexate, steroids and penicillinamine, and in conditions such as osteoarthritis in combination with steroids.

5        The compounds of the present invention may also be administered in degradative diseases, for example osteoarthritis, with chondroprotective, anti-degradative and/or reparative agents such as Diacerhein, hyaluronic acid formulations such as Hyalan, Rumalon, Arteparon and glucosamine salts such as Anril.

10        The compounds of the Formula I may be used in the treatment of asthma in combination with antiasthmatic agents such as bronchodilators and leukotriene antagonists.

If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically-active agent within its approved dosage range. Sequential use is contemplated when a combination formulation is inappropriate.

15        Although the compounds of the Formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of T cell activation. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.

20        The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated :-

(i) operations were carried out at ambient temperature, *i.e.* in the range 17 to 25°C and under an atmosphere of an inert gas such as argon unless otherwise stated;

(ii) evaporations were carried out by rotary evaporation *in vacuo* and work-up  
25 procedures were carried out after removal of residual solids by filtration;

(iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) was performed on C18 reverse  
30 phase silica, for example on a Dynamax C-18 60Å preparative reversed-phase column;

(iv) yields, where present, are given for illustration only and are not necessarily the maximum attainable;

(v) in general, the end-products of the Formula I have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer and, where appropriate, either positive ion data or negative ion data were  
5 collected; NMR chemical shift values were measured on the delta scale [proton magnetic resonance spectra were determined using a Jeol JNM EX 400 spectrometer operating at a field strength of 400MHz, a Varian Gemini 2000 spectrometer operating at a field strength of 300MHz or a Bruker AM300 spectrometer operating at a field strength of 300MHz]; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m,  
10 multiplet; br, broad;

(vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) and/or NMR analysis;

(vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the  
15 end-products of the Formula I were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture; and

(viii) the following abbreviations have been used:-

DMF	<u>N,N</u> -dimethylformamide
DMSO	dimethylsulphoxide
THF	tetrahydrofuran

20

**Example 1** 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea

2,6-Dichlorophenyl isocyanate (0.075 g) was added to a solution of 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (0.093 g) in a mixture of methylene chloride (2 ml) and DMF (0.1 ml) and the reaction mixture was stirred at ambient temperature for 16 hours. The resultant solid was isolated, redissolved in a 20:1 mixture of methylene chloride and methanol and purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained the title compound as a white solid (0.029 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.3-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.8 (d, 2H), 3.9 (s, 3H), 4.0 (br d, 2H), 7.3 (br s, 1H), 7.4 (d, 1H), 7.5 (s, 1H), 7.6 (s, 1H), 8.0 (br s, 1H), 8.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490, 492 and 494.

The 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline used as a starting material was prepared as follows :-

A solution of di-tert-butyl dicarbonate (41.7 g) in ethyl acetate (75 ml) was added dropwise to a stirred solution of ethyl piperidine-4-carboxylate (30 g) in ethyl acetate (150 ml) which had been cooled to 0 to 5°C in an ice-bath. The resultant mixture was stirred at ambient temperature for 48 hours. The mixture was poured into water (300 ml). The organic layer was separated, washed in turn with water (200 ml), 0.1N aqueous hydrochloric acid solution (200 ml), a saturated aqueous sodium bicarbonate solution (200 ml) and brine (200 ml), dried over magnesium sulphate and evaporated. There was thus obtained ethyl N-tert-butoxycarbonylpiperidine-4-carboxylate (48 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.25 (t, 3H), 1.45 (s, 9H), 1.55-1.7 (m, 2H), 1.8-2.0 (d, 2H), 2.35-2.5 (m, 1H), 2.7-2.95 (t, 2H), 3.9-4.1 (br s, 2H), 4.15 (q, 2H).

A solution of the material so obtained in THF (180 ml) was cooled at 0°C and lithium aluminium hydride (1M solution in THF; 133 ml) was added dropwise. The mixture was stirred at 0°C for 2 hours. Water (30 ml) and 2N aqueous sodium hydroxide solution (10 ml) were added in turn and the mixture was stirred for 15 minutes. The resultant mixture was filtered through diatomaceous earth and the solids were washed with ethyl acetate. The filtrate was washed in turn with water and with brine, dried over magnesium sulphate and evaporated. There was thus obtained N-tert-butoxycarbonyl-4-hydroxymethylpiperidine (36.3 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.05-1.2 (m, 2H), 1.35-1.55 (m, 10H), 1.6-1.8 (m, 2H), 2.6-2.8 (t, 2H), 3.4-3.6 (t, 2H), 4.0-4.2 (br s, 2H).

1,4-Diazabicyclo[2.2.2]octane (42.4 g) was added to a solution of N-tert-butoxycarbonyl-4-hydroxymethylpiperidine (52.5 g) in tert-butyl methyl ether (525 ml) and the mixture was stirred at ambient temperature for 15 minutes. The mixture was then cooled in an ice-bath to 5°C and a solution of 4-toluenesulphonyl chloride (62.8 g) in tert-butyl methyl ether (525 ml) was added dropwise over 2 hours while maintaining the reaction temperature at approximately 0°C. The resultant mixture was allowed to warm to ambient temperature and was stirred for 1 hour. Petroleum ether (b.p. 60-80°C, 1L) was added and the precipitate was removed by filtration. The filtrate was evaporated to give a solid residue which was dissolved in diethyl ether. The organic solution was washed in turn with 0.5N aqueous hydrochloric acid solution, water, a saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulphate and evaporated. There was thus obtained N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine (76.7 g), NMR Spectrum: (CDCl<sub>3</sub>) 1.0-1.2 (m, 2H), 1.45 (s, 9H), 1.65 (d, 2H), 1.75-1.9 (m, 2H), 2.45 (s, 3H), 2.55-2.75 (m, 2H), 3.85 (d, 1H), 4.0-4.2 (br s, 2H), 7.35 (d, 2H), 7.8 (d, 2H).

A portion (40 g) of the material so obtained was added to a suspension of ethyl 4-hydroxy-3-methoxybenzoate (19.6 g) and potassium carbonate (28 g) in DMF (200 ml) and the resultant mixture was stirred and heated to 95°C for 2.5 hours. The mixture was cooled to ambient temperature and partitioned between water and a mixture of ethyl acetate and diethyl ether. The organic layer was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The resulting oil was crystallised from petroleum ether (b.p. 60-80°C) and the suspension was stored overnight at 5°C. The resultant solid was collected by filtration, washed with petroleum ether and dried under vacuum. There was thus obtained ethyl 4-(N-tert-butoxycarbonylpiperidin-4-ylmethoxy)-3-methoxybenzoate (35 g), m.p. 81-83°C; NMR Spectrum: (CDCl<sub>3</sub>) 1.2-1.35 (m, 2H), 1.4 (t, 3H), 1.48 (s, 9H), 1.8-1.9 (d, 2H), 2.0-2.15 (m, 2H), 2.75 (t, 2H), 3.9 (d, 2H), 3.95 (s, 3H), 4.05-4.25 (br s, 2H), 4.35 (q, 2H), 6.85 (d, 1H), 7.55 (s, 1H), 7.65 (d, 1H).

The material so obtained was dissolved in formic acid (35 ml), formaldehyde (12M, 37% in water, 35 ml) was added and the mixture was stirred and heated to 95°C for 3 hours. The resultant mixture was evaporated. The residue was dissolved in methylene chloride and hydrogen chloride (3M solution in diethyl ether; 40 ml) was added. The mixture was diluted with diethyl ether and the mixture was triturated until a solid was formed. The solid was collected, washed with diethyl ether and dried under vacuum overnight at 50°C. There was thus obtained ethyl 3-methoxy-4-(N-methylpiperidin-4-ylmethoxy)benzoate (30.6 g),

NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.29 (t, 3H), 1.5-1.7 (m, 2H), 1.95 (d, 2H), 2.0-2.15 (br s, 1H), 2.72 (s, 3H), 2.9-3.1 (m, 2H), 3.35-3.5 (br s, 2H), 3.85 (s, 3H), 3.9-4.05 (br s, 2H), 4.3 (q, 2H), 7.1 (d, 1H), 7.48 (s, 1H), 7.6 (d, 1H).

The material so obtained was dissolved in methylene chloride (75 ml) and the solution was cooled in an ice-bath to 0-5°C. Trifluoroacetic acid (37.5 ml) was added followed by the dropwise addition over 15 minutes of a solution of fuming nitric acid (24M; 7.42 ml) in methylene chloride (15 ml). The resultant solution was allowed to warm to ambient temperature and was stirred for 2 hours. Volatile materials were evaporated. The residue was dissolved in methylene chloride (50 ml) and the solution was cooled in an ice-bath to 0-5°C. Diethyl ether was added and the resultant precipitate was collected and dried under vacuum at 50°C. The solid was dissolved in methylene chloride (500 ml) and hydrogen chloride (3M solution in diethyl ether; 30 ml) was added followed by diethyl ether (500 ml). The resultant solid was collected and dried under vacuum at 50°C. There was thus obtained ethyl 5-methoxy-4-(N-methylpiperidin-4-ylmethoxy)-2-nitrobenzoate (28.4 g), NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3 (t, 3H), 1.45-1.65 (m, 2H), 1.75-2.1 (m, 3H), 2.75 (s, 3H), 2.9-3.05 (m, 2H), 3.4-3.5 (d, 2H), 3.95 (s, 3H), 4.05 (d, 2H), 4.3 (q, 2H), 7.32 (s, 1H), 7.66 (s, 1H).

A mixture of a portion (3.89 g) of the material so obtained, 10% platinum-on-activated carbon (50% wet, 0.389 g) and methanol (80 ml) was stirred under 1.8 atmospheres pressure of hydrogen until uptake of hydrogen ceased. The mixture was filtered and the filtrate was evaporated. The residue was dissolved in water (30 ml) and basified to pH10 by the addition of a saturated aqueous sodium bicarbonate solution. The mixture was diluted with a 1:1 mixture of ethyl acetate and diethyl ether and the organic layer was separated. The aqueous layer was further extracted with a 1:1 mixture of ethyl acetate and diethyl ether and the organic extracts were combined, washed in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was triturated under a mixture of petroleum ether (b.p. 60-80°C) and diethyl ether. The solid so obtained was isolated, washed with petroleum ether and dried under vacuum at 60°C. There was thus obtained ethyl 2-amino-5-methoxy-4-(N-methylpiperidin-4-ylmethoxy)benzoate (2.58 g), m.p. 111-112°C; NMR Spectrum: (CDCl<sub>3</sub>) 1.35 (t, 3H), 1.4-1.5 (m, 2H), 1.85 (m, 3H), 1.95 (t, 2H), 2.29 (s, 3H), 2.9 (d, 2H), 3.8 (s, 3H), 3.85 (d, 2H), 4.3 (q, 2H), 5.55 (br s, 2H), 6.13 (s, 1H), 7.33 (s, 1H).

A mixture of ethyl 2-amino-5-methoxy-4-(N-methylpiperidin-4-ylmethoxy)benzoate (16.1 g), formamidine acetic acid salt (5.2 g) and 2-methoxyethanol (160 ml) was stirred and heated at 115°C for 2 hours. Further formamidine acetic acid salt (10.4 g) was added in

portions every 30 minutes during 4 hours and heating was continued for 30 minutes after the last addition. The resultant mixture was evaporated. The solid residue was stirred under a mixture of methylene chloride (50ml) and ethanol (100ml). The precipitate was removed by filtration and the filtrate was concentrated to a final volume of 100ml. The resultant

5 suspension was cooled to 5°C. The solid so obtained was collected, washed with cold ethanol and with diethyl ether and dried under vacuum at 60°C. There was thus obtained 6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)-3,4-dihydroquinazolin-4-one (12.7 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.25-1.4 (m, 2H), 1.75 (d, 2H), 1.9 (t, 1H), 1.9 (s, 3H), 2.16 (s, 2H), 2.8 (d, 2H), 3.9 (s, 3H), 4.0 (d, 2H), 7.11 (s, 1H), 7.44 (s, 1H), 7.97 (s, 1H).

10 A mixture of a portion (2.8 g) of the material so obtained, thionyl chloride (28 ml) and DMF (0.28 ml) was heated to reflux for 1 hour. The mixture was evaporated and the precipitate was triturated under diethyl ether. The resultant solid was isolated and washed with diethyl ether. The solid was then dissolved in methylene chloride and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic layer was washed  
15 in turn with water and brine, dried over magnesium sulphate and evaporated. There was thus obtained 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (2.9 g.), NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.5 (m, 2H), 1.75-1.9 (m, 4H), 2.0 (t, 1H), 2.25 (s, 3H), 2.85 (d, 2H), 4.02 (s, 3H), 4.12 (d, 2H), 7.41 (s, 1H), 7.46 (s, 1H), 8.9 (s, 1H).

A mixture of 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline  
20 (11.17 g), 4-bromo-2-fluorophenol (4.57 ml), potassium carbonate (7.19 g) and DMF (110 ml) was stirred and heated at 100°C for 2.5 hours. The mixture was allowed to cool to ambient temperature and was poured into a mixture (1L) of ice and water. The precipitate was collected, washed with water and dried. The solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a  
25 1% aqueous ammonium hydroxide solution (20:1:0 to 10:1:0 to 10:1:1) as eluent. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (13.1 g), NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.9 (t, 1H), 2.15 (s, 3H), 2.5 (br s, 2H), 4.0 (s, 3H), 4.1 (d, 2H), 7.4 (s, 1H), 7.45-7.6 (m, 3H), 7.8 (d, 1H), 8.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 and 478.


30 A portion (9.4 g) of the material so obtained was dissolved in a 2M solution of ammonia in isopropanol (150 ml). Liquid ammonia (10 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 130°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue

was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl tert-butyl ether. There was thus obtained 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (5.55 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.2-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.8 (d, 2H), 3.8 (s, 3H), 3.9 (d, 2H), 7.0 (s, 1H), 7.3 (br s, 2H), 7.5 (s, 1H), 8.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 303.

### Example 2

Using an analogous procedure to that described in Example 1, except that, unless otherwise stated, chloroform was used in place of methylene chloride as the reaction solvent, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the compounds described in Table I. In general, unless otherwise stated, the appropriate isocyanates were commercially available. Alternatively appropriate isocyanates could be prepared by the reaction of the appropriate aniline with di-tert-butyl dicarbonate in the presence of 4-dimethylaminopyridine and a solvent such as methylene chloride.

Table I



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro	[1]
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,3-dichloro	[2]
3	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4-dichloro	[3]
4	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-fluoro	[4]
5	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro	[5]
6	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-bromo	[6]
7	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-trifluoromethyl	[7]
8	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl	[8]
9	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl	[9]

10	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2- <del>tert</del> -butyl	[10]
11	methoxy	3-piperidinopropoxy	2,6-dimethyl	[11]
12	hydrogen	3-morpholinopropoxy	2,6-dichloro	[12]
13	hydrogen	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2,6-dichloro	[13]
14	hydrogen	4-morpholinobut-2-ynyloxy	2,6-dichloro	[14]
15	hydrogen	( <i>E</i> )-4-morpholinobut-2-enyloxy	2,6-dichloro	[15]
16	methoxy	2-piperidinoethoxy	2,6-dichloro	[16]
17	methoxy	3-morpholinopropoxy	2,6-dichloro	[17]
18	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,6-dichloro	[18]
19	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	[19]
20	methoxy	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2,6-dichloro	[20]
21	methoxy	2-[ <u>N</u> -(2-methoxyethyl)- <u>N</u> -methylamino]ethoxy	2,6-dichloro	[21]
22	methoxy	3-mesylpropoxy	2,6-dichloro	[22]
23	methoxy	3-(1,2,3-triazol-1-yl)propoxy	2,6-dichloro	[23]
24	methoxy	2-(4-pyridyl)ethoxy	2,6-dichloro	[24]
25	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4,6-trichloro	[25]
26	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dichloro	[26]
27	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4-difluoro	[27]
28	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethoxy	[28]
29	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4-dimethoxy	[29]
30	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-diisopropyl	[30]
31	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4,6-trimethyl	[31]
32	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl	[32]
33	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-diethyl	[33]
34	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-ethyl-6-methyl	[34]
35	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-bromo-2,6-dimethyl	[35]
36	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	[36]
37	methoxy	3-pyrrolidin-1-ylpropoxy	2,4,6-trichloro	[37]

38	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,4,6-trichloro	[38]
39	methoxy	3-piperidinopropoxy	2,6-dichloro	[39]
40	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	[40]
41	methoxy	3-piperidinopropoxy	2,6-difluoro	[41]
42	methoxy	3-morpholinopropoxy	2,6-difluoro	[42]
43	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,6-difluoro	[43]
44	methoxy	2-piperidinoethoxy	2,6-difluoro	[44]
45	methoxy	2-piperidinoethoxy	2,4,6-trichloro	[45]
46	methoxy	3-pyrrolidin-1-ylpropoxy	2-fluoro- 6-trifluoromethyl	[46]
47	methoxy	2-dimethylaminoethoxy	2,6-difluoro	[47]
48	methoxy	2-dimethylaminoethoxy	2,6-dichloro	[48]
49	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	2,6-difluoro	[49]
50	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	2,6-dichloro	[50]
51	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dichloro	[51]
52	methoxy	2-pyrrolidin-1-ylethoxy	2,6-difluoro	[52]
53	methoxy	2-morpholinoethoxy	2,6-dichloro	[53]
54	methoxy	2-morpholinoethoxy	2,6-difluoro	[54]
55	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dimethyl	[55]
56	methoxy	3-morpholinopropoxy	2,6-dimethyl	[56]
57	methoxy	3-(4-methylpiperazin-1-yl)propoxy	2,6-dimethyl	[57]
58	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dimethyl	[58]
59	methoxy	2-piperidinoethoxy	2,6-dimethyl	[59]
60	methoxy	2-morpholinoethoxy	2,6-dimethyl	[60]
61	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	2,6-dimethyl	[61]
62	methoxy	2-dimethylaminoethoxy	2,6-dimethyl	[62]
63	methoxy	3-pyrrolidin-1-ylpropoxy	4-bromo-2,6-dimethyl	[63]
64	methoxy	3-piperidinopropoxy	4-bromo-2,6-dimethyl	[64]
65	methoxy	3-morpholinopropoxy	4-bromo-2,6-dimethyl	[65]
66	methoxy	3-(4-methylpiperazin-1-yl)propoxy	4-bromo-2,6-dimethyl	[66]
67	methoxy	2-piperidinoethoxy	4-bromo-2,6-dimethyl	[67]

68	methoxy	2-morpholinoethoxy	4-bromo-2,6-dimethyl	[68]
69	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	4-bromo-2,6-dimethyl	[69]
70	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dichloro	[70]
71	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-difluoro	[71]
72	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl	[72]
73	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-fluoro- 6-trifluoromethyl	[73]
74	hydrogen	2-pyrrolidin-1-ylethoxy	2,6-dichloro	[74]
75	hydrogen	2-pyrrolidin-1-ylethoxy	2-chloro-6-methyl	[75]
76	hydrogen	2-pyrrolidin-1-ylethoxy	2-chloro	[76]
77	hydrogen	2-pyrrolidin-1-ylethoxy	2,4,6-trichloro	[77]
78	hydrogen	2-piperidinoethoxy	2,6-dichloro	[78]
79	hydrogen	2-piperidinoethoxy	2,6-difluoro	[79]
80	hydrogen	2-piperidinoethoxy	2-chloro-6-methyl	[80]
81	hydrogen	2-piperidinoethoxy	2-chloro	[81]
82	hydrogen	2-piperidinoethoxy	2,4,6-trichloro	[82]
83	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2,6-dichloro	[83]
84	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2-chloro-6-methyl	[84]
85	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2-chloro	[85]
86	hydrogen	2-(4-methylpiperazin-1-yl)ethoxy	2,4,6-trichloro	[86]
87	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2,6-dichloro	[87]
88	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2,6-difluoro	[88]
89	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2-chloro-6-methyl	[89]
90	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2-chloro	[90]
91	hydrogen	<u>N</u> -methylpiperidin-3-ylmethoxy	2,4,6-trichloro	[91]
92	hydrogen	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	[92]
93	hydrogen	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	[93]
94	hydrogen	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	[94]
95	hydrogen	3-pyrrolidin-1-ylpropoxy	2-chloro	[95]
96	hydrogen	3-pyrrolidin-1-ylpropoxy	2,4,6-trichloro	[96]
97	hydrogen	3-morpholinopropoxy	2,6-difluoro	[97]

98	hydrogen	3-morpholinopropoxy	2-chloro-6-methyl	[98]
99	hydrogen	3-morpholinopropoxy	2,4,6-trichloro	[99]
100	hydrogen	3-(4-methylpiperazin-1-yl)propoxy	2,6-dichloro	[100]
101	hydrogen	3-(4-methylpiperazin-1-yl)propoxy	2-chloro	[101]
102	hydrogen	3-(4-methylpiperazin-1-yl)propoxy	2,4,6-trichloro	[102]
103	hydrogen	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2,6-difluoro	[103]
104	hydrogen	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2-chloro-6-methyl	[104]
105	hydrogen	3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy	2,4,6-trichloro	[105]
106	hydrogen	3-(1,2,3-triazol-1-yl)propoxy	2,4,6-trichloro	[106]
107	hydrogen	(E)-4-pyrrolidin-1-ylbut-2-enyloxy	2,6-difluoro	[107]
108	hydrogen	(E)-4-pyrrolidin-1-ylbut-2-enyloxy	2-chloro-6-methyl	[108]
109	hydrogen	(E)-4-pyrrolidin-1-ylbut-2-enyloxy	2-chloro	[109]
110	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2,6-dichloro	[110]
111	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2,6-difluoro	[111]
112	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2,6-dimethyl	[112]
113	methoxy	3-(4-carbamoylpiperidin-1-yl)propoxy	2-chloro-6-methyl	[113]
114	hydrogen	3-(pyrrolidin-1-yl)-1-propynyl	2,6-dichloro	[114]
115	methoxy	3-(pyrrolidin-1-yl)-1-propynyl	2,6-dichloro	[115]
116	methoxy	6-morpholino-1-hexynyl	2,6-dichloro	[116]
117	methoxy	6-morpholino-1-hexynyl	2,6-difluoro	[117]
118	methoxy	6-(2-methylimidazol-1-yl)-1-hexynyl	2,6-dichloro	[118]
119	methoxy	6-(2-methylimidazol-1-yl)-1-hexynyl	2,6-difluoro	[119]

120	methoxy	3-dimethylamino-1-propynyl	2,6-difluoro	[120]
121	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-nitro	[121]
122	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl-3-fluoro	[122]
123	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dichloro	[123]
124	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl-5-nitro	[124]
125	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro- 5-trifluoromethyl	[125]
126	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	5-chloro-2-methoxy	[126]
127	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methoxy-5-methyl	[127]
128	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	5-chloro-2-methyl	[128]
129	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl-5-fluoro	[129]
130	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-5-methyl	[130]
131	methoxy	3-pyrrolidin-1-ylpropoxy	2,5-difluoro	[131]
132	methoxy	3-pyrrolidin-1-ylpropoxy	2,5-dichloro	[132]
133	methoxy	3-pyrrolidin-1-ylpropoxy	5-chloro-2-methyl	[133]
134	methoxy	3-pyrrolidin-1-ylpropoxy	5-fluoro-2-methyl	[134]
135	methoxy	3-pyrrolidin-1-ylpropoxy	2-methyl-5-nitro	[135]
136	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-5-methyl	[136]
137	methoxy	6-( <u>N</u> -methylpiperazin-1-yl)- 1-hexynyl	2,6-dichloro	[137]
138	methoxy	benzyloxy	3-dimethylcarbamoyl- 2,6-dimethyl	[138]
139	methoxy	cyclopropylmethoxy	2,6-dimethyl	[139]
140	methoxy	6-( <u>N</u> -methylpiperazin-1-yl)hexyl	2,6-dichloro	[140]
141	methoxy	3-(pyrrolidin-1-yl)propyl	2,6-dichloro	[141]
142	methoxy	<u>N</u> -[3-( <u>N</u> -methylpiperazin-1-yl)propyl]carbamoyl	2,6-dichloro	[142]
143	methoxy	<u>N</u> -[3-(imidazol-1-yl)propyl]carbamoyl	2,6-dichloro	[143]
144	methoxy	<u>N</u> -methylpiperazin-1-yl	2,6-dichloro	[144]
145	methoxy	<u>N</u> -( <u>tert</u> -butoxycarbonyl)piperazin-	2,6-dichloro	[145]

		1-yl		
146	methoxy	3-morpholinopropylamino	2,6-dichloro	[146]
147	methoxy	3-imidazol-1-ylpropylamino	2,6-dichloro	[147]
148	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	3-dimethylcarbamoyl- 2,6-dimethyl	[148]
149	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	[149]
150	methoxy	3-methoxypropylamino	2,6-dichloro	[150]
151	methoxy	2-aminoethylamino	2,6-dichloro	[151]
152	methoxy	<u>N</u> -(2-diethylaminoethyl)- <u>N</u> -methylamino	2,6-dichloro	[152]

### Notes

- [1] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.36 (m, 2H), 1.74 (d, 3H), 1.86 (t, 2H), 2.14 (s, 3H), 2.87 (d, 2H), 3.96 (s, 3H), 4.03 (d, 2H), 7.11 (t, 1H), 7.29 (s, 3H), 7.38 (t, 1H), 7.56 (d, 1H), 8.08 (s, 1H), 8.41 (d, 1H), 8.73 (s, 1H), 10.59 (s, 1H), 13.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 456 and 458.
- [2] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.87 (m, 2H), 2.11 (m, 3H), 2.78 (m, 2H), 2.78 (s, 3H), 3.68 (d, 2H), 4.07 (s, 3H), 4.1 (s, 2H), 7.12 (m, 2H), 7.43 (s, 1H), 7.78 (s, 1H), 8.28 (m, 1H), 8.75 (s, 1H), 13.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.
- [3] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.83 (m, 2H), 2.1 (m, 3H), 2.63 (m, 2H), 2.7 (s, 3H), 3.6 (d, 2H), 4.08 (s, 3H), 4.1 (d, 2H), 7.23 (m, 1H), 7.33 (s, 1H), 7.46 (s, 1H), 7.72 (s, 1H), 8.31 (d, 1H), 8.74 (s, 1H), 13.3 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.
- [4] Methylene chloride was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.34 (q, 2H), 1.74 (d, 3H), 1.86 (t, 2H), 2.15 (s, 3H), 2.78 (d, 2H), 3.96 (s, 3H), 4.02 (d, 2H), 7.08–7.16 (m, 1H), 7.19–7.36 (m, 3H), 8.06 (s, 1H), 8.27 (s, 1H), 8.69 (s, 1H), 10.56 (s, 1H), 12.81 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 440.
- [5] DMF was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.35 (m, 2H), 1.8 (m, 5H), 2.15 (s, 3H), 2.79 (d, 2H), 2.94 (s, 3H), 4.03 (d, 2H), 7.1–7.35 (m, 5H), 8.03 (s, 1H), 8.66 (s, 1H), 10.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

- [6] DMF was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.5 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.2 (s, 3H), 2.8 (d, 2H), 3.9 (s, 3H), 4.1 (br d, 2H), 7.0 (t, 1H), 7.3 (br s, 1H), 7.4 (t, 1H), 7.7 (d, 1H), 8.1 (br s, 1H), 8.4 (d, 1H), 8.8 (s, 1H), 10.5 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 500 and 502.
- 5 [7] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (m, 2H), 1.97 (m, 5H), 2.3 (s, 3H), 2.88 (d, 2H), 3.61 (s, 3H), 4.01 (d, 2H), 7.24 (s, partially obscured by CHCl<sub>3</sub> peak), 7.25 (t, partially obscured by CHCl<sub>3</sub> peak), 7.37 (s, 1H), 7.56 (t, 1H), 7.7 (d, 1H), 8.17 (d, 1H), 8.7 (s, 1H), 9.36 (s, 1H), 13.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490.
- [8] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.38-1.55 (m, 2H),  
10 1.84-2.04 (m, 5H), 2.3 (s, 3H), 2.47 (s, 3H), 2.91 (d, 2H), 3.66 (s, 3H), 4.01 (d, 2H), 7.05-7.14 (m, 1H), 7.17-7.28 (m, 4H), 7.4 (s, 1H), 7.96 (d, 1H), 8.7 (s, 1H), 9.24 (s, 1H), 12.34 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 436.
- [9] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CD<sub>3</sub>COOH) 1.5-1.67 (q, 2H), 1.93-2.17 (m, 3H), 2.24 (s, 6H), 2.71 (s, 3H), 2.93 (t, 2H), 3.37 (d, 2H), 3.95 (s,  
15 3H), 4.09 (d, 2H), 7.1 (s, 3H), 7.31 (s, 1H), 8.07 (s, 1H), 8.66 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.
- [10] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.43 (m, 2H), 1.5 (s, 9H), 1.82 (m, 5H), 2.28 (s, 3H), 2.89 (d, 2H), 3.32 (s, 3H), 4.0 (d, 2H), 7.2 (m, 3H), 7.5 (m, 2H), 7.57 (s, 1H), 8.62 (s, 1H), 9.9 (s, 1H), 12.35 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 478.
- 20 [11] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.45 (m, 2H), 1.59 (m, 4H), 2.11 (m, 2H), 2.33 (s, 6H), 2.4 (br s, 4H), 2.5 (t, 2H), 3.23 (s, 3H), 4.22 (t, 2H), 7.14 (m, 3H), 7.28 (s, 1H), 7.62 (s, 1H), 8.66 (s, 1H), 10.16 (s, 1H), 12.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 513.

The 4-amino-6-methoxy-7-(3-piperidinopropoxy)quinazoline used as a starting  
25 material was prepared as follows :-

Sodium hydride (60% suspension in mineral oil, 1.44 g) was added portionwise during 20 minutes to a solution of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (International Patent Application WO 97/22596, Example 1 thereof; 8.46 g) in DMF (70 ml). The mixture was stirred at ambient temperature for 1.5 hours. Chloromethyl pivalate (5.65 g)  
30 was added dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with ethyl acetate (100 ml) and poured onto a mixture (400 ml) of ice and water containing 2N aqueous hydrochloric acid (4 ml). The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined extracts were washed with

brine, dried over magnesium sulphate and evaporated. The residue was triturated under a mixture of diethyl ether and petroleum ether (b.p. 60-80°C) and the resultant solid was collected and dried under vacuum. There was thus obtained 7-benzyloxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (10 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.11 (s, 9H), 3.89 (s, 3H), 5.3 (s, 2H), 5.9 (s, 2H), 7.27 (s, 1H), 7.35 (m, 1H), 7.47 (t, 2H), 7.49 (d, 2H), 7.51 (s, 1H), 8.34 (s, 1H).

A mixture of a portion (7 g) of the material so obtained, 10% palladium-on-charcoal catalyst (0.7 g), DMF (50 ml), methanol (50 ml), acetic acid (0.7 ml) and ethyl acetate (250 ml) was stirred under an atmosphere pressure of hydrogen for 40 minutes. The catalyst was removed by filtration and the solvent was evaporated. The residue was triturated under diethyl ether and the resultant solid was collected and dried under vacuum. There was thus obtained 7-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (4.36 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.1 (s, 9H), 3.89 (s, 3H), 5.89 (s, 2H), 7.0 (s, 1H), 7.48 (s, 1H), 8.5 (s, 1H).

Diethyl azodicarboxylate (3.9 ml) was added dropwise to a stirred mixture of 7-hydroxy-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (5 g), 3-bromopropanol (2.21 ml), triphenylphosphine (6.42 g) and methylene chloride (50 ml) and the mixture was stirred at ambient temperature for 2 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 7-(3-bromopropoxy)-6-methoxy-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (6 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.12 (s, 9H), 2.32 (t, 2H), 3.7 (t, 2H), 3.9 (s, 3H), 4.25 (t, 2H), 5.9 (s, 2H), 7.20 (s, 1H), 7.61 (s, 1H), 8.36 (s, 1H).

A mixture of a portion (2.89 g) of the material so obtained and piperidine (10 ml) was stirred and heated to 100°C for 1 hour. The mixture was evaporated and the residue was partitioned between methylene chloride and a saturated aqueous ammonium chloride solution. The organic phase was washed with brine, dried over magnesium sulphate and evaporated. There was thus obtained 6-methoxy-7-(3-piperidinopropoxy)-3-pivaloyloxymethyl-3,4-dihydroquinazolin-4-one (2.4 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.15 (s, 9H), 1.35-1.5 (m, 1H), 1.6-1.8 (m, 3H), 1.8-1.9 (d, 2H), 2.2-2.3 (m, 2H), 2.95 (t, 2H), 3.25 (t, 2H), 3.55 (d, 2H), 3.95 (s, 3H), 4.25 (t, 2H), 5.94 (s, 2H), 7.24 (s, 1H), 7.56 (s, 1H), 8.36 (s, 1H).

A mixture of the material so obtained and a 7N solution of ammonia in methanol (50 ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated and the

residue was triturated under diethyl ether. The resultant solid was isolated, washed in turn with diethyl ether and a 1:1 mixture of diethyl ether and methylene chloride and dried under vacuum. There was thus obtained 6-methoxy-7-(3-piperidinopropoxy)-3,4-dihydroquinazolin-4-one (1.65 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.4 (m, 2H), 1.4-1.55 (m, 4H), 1.85-1.95 (m, 2H), 2.35 (br s, 4H), 2.4 (t, 2H), 3.9 (s, 3H), 4.15 (t, 2H), 7.11 (s, 1H), 7.44 (s, 1H), 7.9 (s, 1H).

A mixture of the material so obtained, thionyl chloride (15 ml) and DMF (1.5 ml) was heated to reflux for 3 hours. The mixture was evaporated. Toluene was added and the mixture was again evaporated. The residue was partitioned between methylene chloride and a saturated aqueous sodium bicarbonate solution (the basicity of which was adjusted to pH10 by adding 6N aqueous sodium hydroxide). The organic layer was separated, washed with brine, dried over magnesium sulphate and evaporated. There was thus obtained 4-chloro-6-methoxy-7-(3-piperidinopropoxy)quinazoline (1.2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.35-1.45 (m, 2H), 1.5-1.6 (m, 4H), 1.9-2.05 (m, 2H), 2.4 (br s, 4H), 2.45 (t, 2H), 4.0 (s, 3H), 4.29 (t, 2H), 7.41 (s, 1H), 7.46 (s, 1H), 8.9 (s, 1H).

A portion (0.5 g) of the material so obtained was dissolved in a 1M solution of ammonia in isopropanol (10 ml). Liquid ammonia (1 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl tert-butyl ether. There was thus obtained 4-amino-6-methoxy-7-(3-piperidinopropoxy)quinazoline (0.225 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.37 (d, 2H), 1.49 (t, 4H), 1.91 (m, 2H), 2.3 (s, 4H), 2.37 (t, 2H), 3.86 (s, 3H), 4.1 (t, 2H), 7.04 (s, 1H), 7.38 (s, 2H), 7.54 (s, 1H), 8.22 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 317.

[12] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.1 (m, 2H), 2.5 (br s, 4H), 2.7 (t, 2H), 3.75 (t, 4H), 4.25 (t, 2H), 7.15 (d, 1H), 7.3 (m, 2H), 7.5 (d, 2H), 8.1 (d, 1H), 8.85 (s, 1H), 9.05 (s, 1H), 12.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 and 478.

The 4-amino-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

A solution of 2-amino-4-fluorobenzoic acid (3 g) in formamide (30 ml) was heated to 150°C for 6 hours. The reaction mixture was poured onto a 1:1 mixture of ice and water

(250 ml) and the precipitated solid was collected, washed with water and dried to give 7-fluoro-3,4-dihydroquinazolin-4-one (2.6 g).

Sodium metal (4.4 g) was added to benzyl alcohol (100 ml) and the resultant mixture was stirred at ambient temperature for 30 minutes and then heated to 80°C for 1 hour.

5 The mixture was cooled to 40°C and 7-fluoro-3,4-dihydroquinazolin-4-one (7.8 g) was added. The reaction mixture was stirred and heated to 130°C for 4 hours. The mixture was allowed to cool to ambient temperature and was stirred for a further 18 hours. The solution was quenched with water (800 ml) and acidified to pH3 by the addition of concentrated hydrochloric acid. The resultant precipitate was collected, washed in turn with water and  
10 diethyl ether and dried under vacuum for 4 hours at 60°C. There was thus obtained 7-benzyloxy-3,4-dihydroquinazolin-4-one (7.02 g).

A mixture of the material so obtained, phosphorus pentasulphide (12.5 g) and pyridine (350 ml) was stirred and heated to reflux for 8 hours. After cooling, the mixture was poured into water (1 L). The precipitate was collected and washed with water. The solid so obtained  
15 was dissolved in 6N aqueous sodium hydroxide solution and the solution was filtered. The filtrate was acidified to pH2 by the addition of 6N aqueous hydrochloric acid. The resultant precipitate was collected, washed with water and dried under vacuum at 60°C. There was thus obtained 7-benzyloxy-3,4-dihydroquinazolin-4-thione (7.42 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 5.32 (s, 2H), 7.25 (d, 1H), 7.32 (m, 1H), 7.4 (m, 1H), 7.45 (t, 2H), 7.55 (d, 2H),  
20 8.15 (s, 1H), 8.5 (d, 1H).

A portion (3.45 g) of the material so obtained was dissolved in THF (13 ml) and 1N aqueous sodium hydroxide solution (25.7 ml) was added. Methyl iodide (0.97 ml) was added dropwise and the mixture was stirred at ambient temperature for 30 minutes. The mixture was neutralised by the addition of 2N aqueous hydrochloric acid and the mixture was  
25 diluted by the addition of water. The resultant solid was collected, washed with water and dried under vacuum to give 7-benzyloxy-4-methylthioquinazoline (3.3 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.67 (s, 3H), 5.32 (s, 2H), 7.3-7.45 (m, 5H), 7.5 (d, 2H), 8.05 (d, 1H), 8.9 (s, 1H).

A mixture of a portion (3 g) of the material so obtained and trifluoroacetic acid (30 ml) was heated to reflux for 5 hours. The mixture was evaporated. The residue was suspended in  
30 water and solid sodium bicarbonate was added until complete dissolution. The solution was extracted with diethyl ether. The aqueous layer was acidified to pH2 by the addition of 2N aqueous hydrochloric acid and the resultant precipitate was collected, washed in turn with water and diethyl ether and dried under vacuum. There was thus obtained 7-hydroxy-

4-methylthioquinazoline (2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.7 (s, 3H), 7.15 (d, 1H), 7.25 (m, 1H), 8.0 (d, 1H), 8.9 (s, 1H).

Diethyl azodicarboxylate (2.92 g) was added dropwise to a stirred mixture of 7-hydroxy-4-methylthioquinazoline (2.5 g), 4-(3-hydroxypropyl)morpholine (Bull. Soc. Chim. Fr. 1962, 1117; 2.47 g), triphenylphosphine (4.45 g) and methylene chloride (65 ml). The reaction mixture was stirred at ambient temperature for 1 hour. The mixture was evaporated and the residue was partitioned between a 1:1 mixture of ethyl acetate and diethyl ether and a 1N aqueous hydrochloric acid solution. The aqueous layer was separated, basified to pH9 by the addition of solid sodium bicarbonate and extracted with methylene chloride. The organic layer was separated, washed with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, ethyl acetate and methanol (from 6:3:1 to 5:3:2 to 75:0:25) as eluent. There was thus obtained 4-methylthio-7-(3-morpholinopropoxy)-quinazoline (2.03 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.2-2.3 (m, 2H), 2.7 (s, 3H), 3.05-3.25 (m, 2H), 3.35 (t, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.05 (d, 2H), 4.32 (t, 2H), 7.38 (d, 1H), 7.4 (s, 1H), 8.1 (d, 1H), 9.05 (d, 1H); Mass Spectrum : M+H<sup>+</sup> 320.

A mixture of a portion (0.5 g) of the material so obtained and a solution of ammonia gas in methanol (7M; 50 ml) was sealed in a pressure vessel and heated to 120°C for 16 hours. The mixture was cooled to ambient temperature and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. The material so obtained was triturated under diethyl ether and the resultant solid was isolated, washed with diethyl ether and dried under vacuum. There was thus obtained 4-amino-7-(3-morpholinopropoxy)quinazoline (0.35 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.0-2.15 (m, 2H), 2.5 (br s, 4H), 2.6 (t, 2H), 3.75 (br s, 4H), 4.2 (t, 2H), 5.65 (br s, 2H), 7.1 (d, 1H), 7.2 (s, 1H), 7.65 (d, 1H), 8.55 (s, 1H); Mass Spectrum : M+H<sup>+</sup> 280.

[13] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.05 (m, 2H), 2.75 (t, 2H), 3.0-3.15 (m, 8H), 4.2 (t, 2H), 7.1 (d, 1H), 7.2-7.35 (m, 2H), 7.5 (d, 2H), 8.2 (d, 1H), 8.8 (s, 1H), 9.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 524 and 526; Elemental Analysis: Found C, 50.0; H, 4.4; N, 13.3; C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>Cl<sub>2</sub>S requires C, 50.39; H, 4.42; N, 13.35%.

The 4-amino-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazoline used as a starting material was prepared as follows :-

A mixture of 3-aminopropan-1-ol (0.650 ml) and divinyl sulphone (1 g) was heated to 110°C for 45 minutes. The mixture was allowed to cool to ambient temperature and was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propan-1-ol (0.8 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.7-1.8 (m, 2H), 2.73 (t, 2H), 3.06 (br s, 8H), 3.25 (s, 1H), 3.78 (t, 2H); Mass Spectrum: M+H<sup>+</sup> 194.

Diethyl azodicarboxylate (3.3 ml) was added dropwise to a stirred mixture of 7-hydroxy-4-methylthioquinazoline (1.34 g), 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propan-1-ol (2.03 g), triphenylphosphine (5.51 g) and methylene chloride (100 ml). The reaction mixture was stirred at ambient temperature for 4 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using initially ethyl acetate and then a 24:1 mixture of ethyl acetate and ethanol as eluent. There was thus obtained 7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]-4-methylthioquinazoline (1.79 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.05 (m, 2H), 2.7 (s, 3H), 2.73 (t, 2H), 3.05 (m, 8H), 4.2 (t, 2H), 7.15 (m, 1H), 7.2 (d, 1H), 8.0 (d, 1H), 8-9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 368.

Using an analogous procedure to that described in the last paragraph of Note [12] immediately above, a portion (0.5 g) of the material so obtained was reacted with ammonia gas in methanol. The reaction product was purified by column chromatography on silica using increasingly polar mixtures of chloroform and methanol as eluent. There was thus obtained 4-amino-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazoline (0.45 g); NMR Spectrum (CDCl<sub>3</sub>) 2.05 (m, 2H), 2.75 (t, 2H), 3.0-3.1 (m, 8H), 4.2 (t, 2H), 5.5 (br s, 2H), 7.15 (m, 1H), 7.2 (s, 1H), 7.65 (d, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 337. [14] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 3.0-3.4 (m, 2H), 3.4 (br d, 2H), 3.6-3.7 (m, 2H), 3.95 (br d, 2H), 4.25 (s, 2H), 5.2 (s, 2H), 7.32 (t, 1H), 7.5 (d, 2H), 7.5-7.6 (m, 2H), 8.9 (d, 1H), 9.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 486 and 488; Elemental Analysis: Found C, 55.4; H, 4.3; N, 14.1; C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>Cl<sub>2</sub> 0.6 H<sub>2</sub>O requires C, 55.57; H, 4.50; N, 14.09 %.

The 4-amino-7-(4-morpholinobut-2-yn-1-yloxy)quinazoline used as a starting material was prepared as follows :-

Diethyl azodicarboxylate (2.46 ml) was added dropwise to a stirred mixture of 7-hydroxy-4-methylthioquinazoline (1.2 g), 4-morpholinobut-2-yn-1-ol (*J. Amer. Chem. Soc.*, 1957, **79**, 6184; 1.26 g), triphenylphosphine (4.09 g) and methylene chloride (35 ml). The reaction mixture was stirred at ambient temperature for 3 hours. The mixture was evaporated

and the residue was purified by column chromatography on silica using initially methylene chloride and then a 19:1 mixture of methylene chloride and methanol as eluent. The material so obtained was triturated under diethyl ether. The resultant solid was collected and dried under vacuum. There was thus obtained 4-methylthio-7-(4-morpholinobut-2-yn-

5 1-yloxy)quinazoline (1.3 g); NMR Spectrum: ( $\text{CDCl}_3$ ) 2.5 (t, 4H), 2.7 (s, 3H), 3.32 (t, 2H), 3.7 (t, 4H), 4.9 (t, 2H), 7.2 (d, 1H), 7.35 (d, 1H), 8.0 (d, 1H), 8.9 (s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  330.

Using an analogous procedure to that described in the last paragraph of Note [12] above, a portion (0.5 g) of the material so obtained was reacted with a saturated solution of  
10 ammonia gas in methanol. The reaction product was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained 4-amino-7-(4-morpholinobut-2-yn-1-yloxy)quinazoline (0.283 g); NMR Spectrum: ( $\text{DMSO-d}_6$ ) 2.4 (m, 4H), 3.3 (t, 2H), 3.5 (m, 4H), 5.0 (s, 2H), 7.15 (m, 1H), 7.18 (d, 1H), 7.6 (br s, 2H), 8.15 (d,  
15 1H), 8.32 (s, 1H); Mass Spectrum:  $\text{M}+\text{Na}^+$  321; Elemental Analysis: Found C, 63.8; H, 6.1; N, 18.7;  $\text{C}_{16}\text{H}_{18}\text{N}_4\text{O}_2 \cdot 0.2 \text{ H}_2\text{O}$  requires C, 63.65; H, 6.14; N, 18.55 %.

[15] Acetonitrile was used as the reaction solvent. The product gave the following data: NMR Spectrum: ( $\text{DMSO-d}_6$  and  $\text{CF}_3\text{COOD}$ ) 3.0-3.1 (m, 2H), 3.4 (d, 2H), 3.65 (t, 2H), 3.85 (d, 2H), 4.0 (d, 2H), 4.95 (br s, 2H), 6.0 (m, 1H), 6.3 (m, 1H), 7.4 (t, 1H), 7.45 (s, 1H), 7.55 (m,  
20 1H), 7.6 (d, 2H), 8.85 (d, 1H), 9.17 (s, 1H); Mass Spectrum:  $\text{M}+\text{Na}^+$  510 and 512; Elemental Analysis: Found C, 56.2; H, 4.7; N, 14.2;  $\text{C}_{23}\text{H}_{23}\text{N}_5\text{O}_3\text{Cl}_2$  requires C, 56.57; H, 4.75; N, 14.34 %.

The 4-amino-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline used as a starting material was prepared as follows :-

25 Using an analogous procedure to that described in the second last paragraph of Note [12] above, (*E*)-4-morpholinobut-2-en-1-ol (J. Med. Chem., 1972, 15, 110-112; 1.27 g), was reacted with 7-hydroxy-4-methylthioquinazoline (1.2 g) to give 4-methylthio-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline (1.15 g); NMR Spectrum: ( $\text{CDCl}_3$ ) 2.45 (br s, 4H), 2.7 (s, 3H), 3.05 (d, 2H), 3.7 (t, 4H), 4.7 (d, 2H), 5.9 (m, 2H), 7.15-7.25 (m, 2H), 7.95  
30 (d, 1H), 8.9 (d, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  332.

Using an analogous procedure to that described in the last paragraph of Note [12] above, 4-methylthio-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline (0.5 g) was reacted with a saturated solution of ammonia gas in methanol. The reaction product was purified by

column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained 4-amino-7-[(*E*)-4-morpholinobut-2-en-1-yloxy]quinazoline (0.372 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.35 (br s, 4H), 3.0 (br s, 2H), 3.56 (t, 4H), 4.7 (br s, 2H), 5.9 (br s, 2H), 7.05 (s, 2H), 7.1 (m, 1H), 7.6 (br s, 2H), 8.12 (d, 1H), 8.3 (s, 1H); Mass Spectrum: M+Na<sup>+</sup> 323; Elemental Analysis: Found C, 63.1; H, 6.7; N, 18.4; C<sub>16</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> 0.2 H<sub>2</sub>O requires C, 63.22; H, 6.76; N, 18.51 %.

[16] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.4 (m, 1H), 1.7 (m, 3H), 1.9 (m, 2H), 3.1 (t, 2H), 3.65 (m, 4H), 4.05 (s, 3H), 4.65 (t, 2H), 7.45 (t, 1H), 7.52 (s, 1H), 7.62 (d, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

The 4-amino-6-methoxy-7-(2-piperidinoethoxy)quinazoline used as a starting material was prepared as follows :-

A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (25.1 g), thionyl chloride (450 ml) and DMF (1 ml) was stirred and heated to reflux for 2 hours. The mixture was evaporated and the residue was dissolved in toluene and the solution was evaporated. The resultant solid was suspended in methylene chloride (500 ml), solid potassium carbonate (39 g) was added and the mixture was stirred for 10 minutes. Water (500 ml) was added and the mixture stirred for another 10 minutes. The methylene chloride layer was separated, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. There was thus obtained 7-benzyl-4-chloro-6-methoxyquinazoline (21.54 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 4.0 (s, 3H), 5.36 (s, 2H), 7.31–7.46 (m, 4H), 7.51 (d, 2H), 7.58 (s, 1H), 8.88 (s, 1H).

A portion (3 g) of the material so obtained was dissolved in a 1M solution of ammonia in isopropanol (50 ml). Liquid ammonia (5 ml) was added and the reaction mixture was sealed in a Carius tube. The reaction mixture was heated to 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution for 1 hour. The resultant solid was isolated and washed in turn with water and methyl *tert*-butyl ether. There was thus obtained 4-amino-

7-benzyloxy-6-methoxyquinazoline (2.65 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.88 (s, 3H), 3.9 (s, 3H), 7.2 (s, 1H), 7.63 (s, 2H), 7.69 (s, 1H), 8.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 230.

A mixture of 4-amino-7-benzyloxy-6-methoxyquinazoline (4.15 g) and trifluoroacetic acid (35 ml) was stirred and heated to reflux for 1 hour. The solvent was evaporated, the  
5 residue was redissolved in a mixture of methylene chloride and toluene and the solvent was evaporated. The solid so obtained was suspended in water and basified to pH11 by the addition of 2N aqueous sodium hydroxide solution. The mixture was then neutralised to pH7 by the addition of 1N aqueous hydrochloric acid solution. The resultant solid was collected, washed in turn with water and acetonitrile and dried under vacuum over phosphorus  
10 pentoxide. There was thus obtained 4-amino-7-hydroxy-6-methoxyquinazoline (2.55 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.9 (s, 3H), 7.05 (s, 1H), 7.65 (s, 1H), 8.0 (br s, 2H), 8.35 (s, 1H), 10.0-11.0 (br s, 1H).

A portion (0.15 g) of the material so obtained and triphenylphosphine (0.31 g) were dissolved in DMF (3 ml). THF (3 ml) was added causing partial precipitation of the starting  
15 material. A solution of N-(2-hydroxyethyl)piperidine (0.111 g) in THF (1 ml) was added followed by diethyl azodicarboxylate (0.186 ml) and the reaction mixture was stirred at ambient temperature for 30 minutes. Further portions of triphenylphosphine (0.105 g), N-(2-hydroxyethyl)piperidine (0.02 g) and diethyl azodicarboxylate (0.062 ml) were added and reaction mixture was stirred at ambient temperature for a further 30 minutes. The mixture  
20 was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained the required starting material (0.18 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.4 (m, 1H), 1.7 (m, 3H), 1.8 (m, 2H), 3.15 (m, 2H), 3.65 (m, 4H), 3.95 (s, 3H), 4.55 (t, 2H), 7.3 (s, 1H), 7.9 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 303.

25 [17] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (m, 2H), 3.7 (t, 2H), 4.0 (s, 3H), 4.05 (m, 2H), 4.35 (t, 2H), 7.45 (t, 1H), 7.63 (d, 2H),  
30 8.25 (s, 1H), 8.3 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 506 and 508.

The 4-amino-6-methoxy-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N-(3-hydroxypropyl)morpholine using an analogous procedure to that described in the last

paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.25 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (m, 2H), 3.7 (t, 2H), 3.95 (s, 3H), 4.05 (m, 2H), 4.3 (t, 2H), 7.35 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 319.

- 5 [18] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 2.95 (s, 3H), 3.2-3.8 (br s, 8H), 3.45 (m, 2H), 4.05 (s, 3H), 4.35 (t, 2H), 7.45 (t, 1H), 7.47 (s, 1H), 7.62 (d, 2H), 8.3 (s, 1H),  
10 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 519 and 521.

The 4-amino-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and 1-(3-hydroxypropyl)-4-methylpiperazine using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting  
15 material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 2.95 (s, 3H), 3.2-3.8 (br s, 8H), 3.4 (m, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 332.

- [19] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected,  
20 washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.9 (m, 2H), 2.05 (m, 2H), 2.25 (m, 2H), 3.1 (m, 2H), 3.35 (m, 2H), 3.65 (m, 2H), 4.05 (s, 3H), 4.35 (t, 2H), 7.45 (t, 1H), 7.47 (s, 1H), 7.63 (d, 2H), 8.3 (s, 1H), 9.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

The 4-amino-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline used as a starting  
25 material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N-(3-hydroxypropyl)pyrrolidine using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.9 (m, 2H), 2.05 (m, 2H), 2.25 (m, 2H), 3.05 (m, 2H), 3.35 (m, 2H), 3.65 (m, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H),  
30 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 303.

[20] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following

data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.5 (t, 2H), 3.65 (m, 4H), 3.85 (m, 4H), 4.05 (s, 3H), 4.35 (t, 2H), 7.43 (t, 1H), 7.46 (s, 1H), 7.65 (d, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 554 and 556.

The 4-amino-7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]-  
5 6-methoxyquinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N-(3-hydroxypropyl)-1,1-dioxotetrahydro-4H-1,4-thiazine using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.5 (m, 2H), 3.65 (m, 4H), 3.85 (m, 4H), 3.95 (s, 3H),  
10 4.25 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 367.

[21] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following  
15 data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.95 (s, 3H), 3.35 (s, 3H), 3.4 (m, 1H), 3.55 (m, 1H), 3.75 (m, 4H), 4.05 (s, 3H), 4.65 (t, 2H), 7.45 (t, 1H), 7.50 (s, 1H), 7.65 (d, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 494 and 496.

The 4-amino-6-methoxy-7-{2-[N-(2-methoxyethyl)-N-methylamino]ethoxy}-quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-  
20 6-methoxyquinazoline and 2-[N-(2-methoxyethyl)-N-methylamino]ethanol using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.95 (s, 3H), 3.35 (s, 3H), 3.4 (m, 1H), 3.55 (m, 1H), 3.75 (br m, 4H), 3.95 (s, 3H), 4.55 (t, 2H), 7.25 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 307.

25 The 2-[N-(2-methoxyethyl)-N-methylamino]ethanol used as a starting material was prepared as follows :-

A mixture of 2-methylaminoethanol (5.4 g), 2-bromoethyl methyl ether (10 g), triethylamine (10 ml) and acetonitrile (70 ml) was stirred and heated to reflux for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and  
30 the residue was triturated under diethyl ether. The organic solution was separated and evaporated to give 2-[N-(2-methoxyethyl)-N-methylamino]ethanol (3 g, 31%); NMR Spectrum: (CDCl<sub>3</sub>) 2.35 (s, 3H), 2.6 (t, 2H), 2.65 (t, 2H), 3.35 (s, 3H), 3.5 (t, 2H), 3.6 (t, 2H).

[22] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.05 (s, 3H), 3.35 (t, 2H), 4.05 (s, 3H), 4.4 (t, 2H), 7.45 (m, 2H), 7.65 (d, 2H), 8.29 (s, 1H), 9.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 499 and 501.

The 4-amino-6-methoxy-7-(3-mesyloxypropoxy)quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and 3-mesyloxypropanol using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d6</sub> and CF<sub>3</sub>COOD) 2.3 (m, 2H), 3.05 (s, 3H), 3.3 (t, 2H), 3.95 (s, 3H), 4.3 (t, 2H), 7.2 (s, 1H), 7.85 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 312.

The 3-mesyloxypropanol used as a starting material was prepared as follows :-

3-Chloroperoxybenzoic acid (25 g) was added in portions to a solution of 3-methylthiopropyl alcohol (5 ml) in methylene chloride (100 ml) while maintaining the reaction temperature at 25°C. The mixture was stirred at ambient temperature for 1 hour. The mixture was filtered and the filtrate was diluted with an aqueous solution of sodium sulphite (6.5 g) in water (200 ml). The organic layer was separated and evaporated. The white residue was triturated under acetone and the resultant solution was evaporated to give a solid which was dissolved in methylene chloride. Aluminum oxide (90Å mesh) was added and the mixture was allowed to stand for 15 minutes. The mixture was filtered and the filtrate was evaporated to give 3-mesyloxypropanol as a colourless oil (4.46 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.9-2.1 (br s, 1H), 2.15 (m, 2H), 2.95 (s, 3H), 3.2 (t, 2H), 3.85 (t, 2H).

[23] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d6</sub> and CF<sub>3</sub>COOD) 2.45 (m, 2H), 4.0 (s, 3H), 4.25 (t, 2H), 4.6 (t, 2H), 7.38 (s, 1H), 7.43 (t, 1H), 7.63 (d, 2H), 7.77 (s, 1H), 8.22 (s, 1H), 8.26 (s, 1H), 9.03 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 488 and 490.

The 4-amino-6-methoxy-7-[3-(1,2,3-triazol-1-yl)propoxy]quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and N<sup>1</sup>-(3-hydroxypropyl)-1,2,3-triazole (see Note [106] hereinafter) using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained

the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.4 (m, 2H), 3.95 (s, 3H), 4.15 (t, 2H), 4.6 (t, 2H), 7.15 (s, 1H), 7.75 (s, 1H), 7.85 (s, 1H), 8.2 (s, 1H), 8.75 (s, 1H), 9.45 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 301.

[24] Acetonitrile was used as the reaction solvent and the reaction mixture was heated to 35°C for 7 hours and then to 50°C for 5 hours. The resultant precipitate was collected, washed in turn with acetonitrile and diethyl ether and dried. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 3.55 (t, 2H), 4.0 (s, 3H), 4.65 (t, 2H), 7.45 (t, 1H), 7.5 (s, 1H), 7.65 (d, 2H), 8.15 (d, 2H), 8.3 (s, 1H), 8.95 (d, 2H), 9.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 484 and 486.

10 The 4-amino-6-methoxy-7-[2-(4-pyridyl)ethoxy]quinazoline used as a starting material was prepared by the reaction of 4-amino-7-hydroxy-6-methoxyquinazoline and 4-(2-hydroxyethyl)pyridine (*Zhur. Obshchei. Khim.*, 1958, 28, 103-110) using an analogous procedure to that described in the last paragraph of Note [16] above. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 3.5 (t, 2H), 3.9 (s, 3H), 4.6 (t, 2H), 7.3 (s, 1H), 7.85 (s, 1H), 8.15 (d, 2H), 8.75 (s, 1H), 8.95 (d, 2H), 9.4 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 297.

[25] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub> + CD<sub>3</sub>CO<sub>2</sub>D) 1.78–1.9 (m, 2H), 2.05–2.3 (m, 3H), 2.64 (t, 2H), 2.7 (s, 3H), 3.59 (d, 2H), 4.04 (s, 3H), 4.1 (d, 2H), 7.25 (s, 1H), 7.44 (s, 2H), 7.74 (s, 1H), 8.2–8.6 (m, partially obscured by CD<sub>3</sub>CO<sub>2</sub>H), 8.71 (s, 1H), 12.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 524 and 526.

[26] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.41–1.56 (m, 2H), 1.85–2.05 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.96 (s, 3H), 4.03 (d, 2H), 6.74 (m, 1H), 7.1 (m, 1H), 7.18 (s, 1H), 7.28 (s, 1H), 8.11 (m, 1H), 8.46 (s, 1H), 8.88 (s, 1H), 12.86 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

25 [27] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42–1.58 (m, 2H), 1.87–2.08 (m, 5H), 2.31 (s, 3H), 2.93 (d, 2H), 3.84 (s, 3H), 4.02 (d, 2H), 6.9 (m, 2H), 7.28 (m, 2H), 8.16 (m, 1H), 8.76 (s, 1H), 8.86 (s, 1H), 12.65 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

[28] Methylene chloride was used as the reaction solvent. The product was obtained as a 1:1 adduct with DMF and gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.55 (m, 2H), 1.9–2.1 (m, 5H), 2.3 (s, 3H), 2.88 (s, 3H), 2.93 (s, 3H), 2.9 (m, partially obscured by DMF signal), 3.72 (s, 3H), 3.85 (s, 3H), 3.91 (s, 3H), 4.01 (d, 2H), 6.6 (m, 1H), 6.86 (d, 1H), 7.28 (s, 1H), 7.36 (s, 1H), 7.98 (d, 1H), 8.02 (s, 1H), 8.55 (s, 1H), 8.87 (s, 1H), 12.75 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 482 (relating to the parent ion).

[29] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.55 (m, 2H), 1.85–2.1 (m, 5H), 2.29 (s, 3H), 2.9 (d, 2H), 3.8 (s, 3H), 3.82 (s, 3H), 3.96 (s, 3H), 4.03 (d, 2H), 6.48 (m, 1H), 6.56 (d, 1H), 7.25 (s, 1H), 7.38 (s, 1H), 8.08 (d, 1H), 8.72 (s, 1H), 9.07 (s, 1H), 12.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 482.

5 [30] Methylene chloride was used as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.17 (br s, 12H), 1.4–1.6 (m, 2H), 1.7 (br s, 2H), 1.85–2.1 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.3 (s, 3H), 4.01 (d, 2H), 7.2–7.22 (m, 3H) 7.3–7.4 (m, 1H), 7.5 (s, 1H), 8.62 (s, 1H), 9.7 (s, 1H), 11.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 506.

[31] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.55 (m, 2H),  
10 1.85–2.1 (m, 5H), 2.28 (s, 6H), 2.3 (s, 3H), 2.34 (s, 3H), 2.9 (d, 2H), 3.37 (s, 3H), 4.01 (d, 2H), 6.91 (s, 2H), 7.22 (s, 1H), 7.3 (s, 1H), 8.64 (s, 1H), 8.7 (s, 1H), 11.8 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 464.

[32] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.44–1.59 (m, 2H), 1.86–2.08 (m, 5H), 2.32 (d, 6H), 2.41 (s, 3H), 2.94 (d, 2H), 3.68 (s, 3H), 4.02 (d, 2H), 6.92 (d,  
15 1H), 7.14 (d, 1H), 7.26 (m, 1H), 7.46 (s, 1H), 7.77 (s, 1H), 8.69 (s, 1H), 9.31 (s, 1H), 12.27 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

[33] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.18 (t, 6H), 1.4–1.55 (m, 2H), 1.85–2.06 (m, 5H), 2.3 (s, 3H), 2.69 (q, 4H) 2.9 (d, 2H), 3.3 (s, 3H), 4.03 (d, 2H), 7.1–7.3 (m, 4H), 7.51 (s, 1H), 8.63 (s, 1H), 9.73 (s, 1H), 11.87 (s, 1H); Mass Spectrum: M+H<sup>+</sup>  
20 478.

[34] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.2 (t, 3H), 1.4–1.6 (m, 2H), 1.85–2.06 (m, 5H), 2.3 (s, 6H), 2.7 (q, 2H), 2.92 (d, 2H), 3.32 (s, 3H), 4.02 (d, 2H), 7.1–7.3 (m, 4H), 7.51 (s, 1H), 8.65 (s, 1H), 9.77 (s, 1H), 11.97 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 464.

[35] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.51 (m, 2H), 1.9–2.1 (m, 5H), 2.3 (s, 9H), 2.95 (d, 2H), 3.52 (s, 3H), 4.02 (d, 2H), 7.23 (s, 1H), 7.25 (s, 2H), 7.37 (s, 1H), 8.67 (s, 1H), 9.32 (s, 1H), 11.82 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 528 and 530.  
25

[36] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.56 (m, 2H), 1.84–2.05 (m, 5H), 2.3 (s, 3H), 2.38 (s, 3H), 2.9 (d, 2H), 3.44 (s, 3H), 4.03 (d, 2H), 7.19 (d, 2H), 7.22 (s, 1H), 7.33 (t, 1H), 7.47 (s, 1H), 8.70 (s, 1H), 9.67 (s, 1H), 12.21 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 470.  
30

[37] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.81 (s, 4H), 2.17 (m, 2H), 2.57 (s, 4H), 2.7 (t, 2H), 3.77 (s, 3H), 4.26 (t, 2H), 7.23–7.45 (m, 2H), 7.38–7.45 (m, 2H), 8.7 (s, 1H), 8.96 (s, 1H), 12.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 524 and 526.

The 4-amino-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 3-pyrrolidin-1-ylpropyl chloride (Chemical Abstracts, volume 128, no. 227441; PCT Patent Application WO 98/13354) using an analogous procedure to that described in the second last paragraph of Note [38] below to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.18 (m, 2H), 2.57 (s, 4H), 2.69 (t, 2H), 4.05 (s, 3H), 4.3 (t, 2H), 7.16 (m, 1H), 7.28–7.36 (m, 2H), 7.44 (m, 1H), 7.57 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 & 478.

10 The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] below to give the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.14 (m, 2H), 2.54 (t, 4H), 2.67 (t, 2H), 3.96 (s, 3H), 4.23 (t, 2H), 5.54 (s, 2H), 6.91 (s, 1H), 7.23 (s, 1H), 8.52 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 303. [38] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.68 (s, 4H), 2.11 (m, 15 2H), 2.3 (s, 3H), 2.4–2.6 (m, 6H), 3.72 (s, 3H), 4.24 (t, 2H), 7.31 (s, 2H), 7.43 (s, 2H), 8.71 (s, 1H), 9.07 (s, 1H), 12.27 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 553, 555 and 557.

The 4-amino-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline used as a starting material was prepared as follows :-

A mixture of 7-acetoxy-6-methoxyquinazolin-4-one (International Patent Application 20 WO 96/15118, Example 17 thereof; 15 g), thionyl chloride (225 ml) and DMF (5 ml) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and the thionyl chloride was evaporated. The material so obtained was dissolved in toluene and the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. There was thus obtained 25 7-acetoxy-4-chloro-6-methoxyquinazoline (13.2 g) which was used without further purification.

A mixture of the material so obtained was reacted with 2-bromo-4-fluorophenol using an analogous procedure to that described in the second last paragraph of the portion of Example 1 above which is concerned with the preparation of starting materials. There was 30 thus obtained 7-acetoxy-4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazoline (14.7 g).

A mixture of a portion (3 g) of the material so obtained, concentrated ammonium hydroxide solution (0.88 g/ml, approximately 14M; 60 ml) and methanol (120 ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was

trituated under diethyl ether. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (2.2 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.99 (s, 3H), 7.25 (s, 1H), 7.39 (m, 1H), 7.54 (m, 2H), 7.78 (m, 1H), 8.47 (s, 1H), 10.82 (s, 1H); Mass Spectrum: M-H<sup>-</sup> 363 & 365.

5 A mixture of 4-(2-bromo-4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (0.94 g), 3-(4-methylpiperazin-1-yl)propyl chloride (0.5 g), potassium carbonate (1.42 g) and DMF (20 ml) was stirred and heated to 65°C for 16 hours. The mixture was filtered and evaporated. The resulting oil was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M methanolic ammonia solution as eluent. There was  
10 thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline (0.84 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.72 (s, 4H), 2.13 (m, 2H), 2.31 (s, 3H), 2.4–2.6 (m, 6H), 4.05 (s, 3H), 4.29 (t, 2H), 7.16 (m, 1H), 7.3 (s, 1H), 7.35 (s, 1H), 7.44 (m, 1H), 7.57 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 505 & 507.

A mixture of the material so obtained, liquid ammonia (1 ml) and a 2M solution of  
15 ammonia in isopropanol (15 ml) was sealed in a Carius tube and heated to 120°C for 16 hours. The mixture was cooled and evaporated. The residue was stirred under a 2N aqueous sodium hydroxide solution (200 ml) for 1 hour. The resultant solid was isolated and washed in turn with water (400 ml) and with methyl *tert*-butyl ether. There was thus obtained the required starting material (0.55 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.81 (s, 4H), 2.1 (m, 2H), 2.29 (s, 3H),  
20 2.4–2.6 (m, 6H), 3.96 (s, 3H), 4.22 (t, 2H), 5.46 (s, 2H), 6.9 (s, 1H), 7.22 (s, 1H), 8.51 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 332.

The 3-(4-methylpiperazin-1-yl)propyl chloride used as an intermediate was prepared by the reaction of 1-methylpiperazine with 1-bromo-3-chloropropane using an analogous procedure to that described in Note [42] hereinafter for the preparation of 3-morpholinopropyl  
25 chloride.

[39] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42 (q, 2H), 1.58 (m, 4H), 2.09 (m, 2H), 2.38 (s, 4H), 2.49 (t, 2H), 3.63 (s, 3H), 4.23 (t, 2H), 7.18–7.27 (m, 2H), 7.37 (m, 2H), 7.41 (s, 1H), 8.71 (s, 1H), 9.3 (s, 1H), 12.34 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 504 and 506.

30 [40] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.84 (m, 4H), 2.17 (m, 2H), 2.56 (s, 4H), 2.68 (t, 2H), 3.69 (s, 3H), 4.28 (t, 2H), 6.99 (t, 2H), 7.2–7.3 (m, 2H), 7.38 (s, 1H), 8.71 (s, 1H), 9.3 (s, 1H), 12.04 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

[41] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.43 (m, 2H), 1.57–1.76 (m, 4H), 2.12 (m, 2H), 2.47 (s, 4H), 2.54 (t, 2H), 3.7 (s, 3H), 4.23 (t, 2H), 6.94–7.03 (m, 2H), 7.2–7.31 (m, 2H), 7.37 (s, 1H), 8.71 (s, 1H), 9.26 (s, 1H), 12.03 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 472.

5 [42] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.11 (m, 2H), 2.49 (br s, 4H), 2.57 (t, 2H), 3.73 (m, 7H), 4.26 (t, 2H), 7.0 (t, 2H), 7.27 (m, 1H), 7.3 (s, 1H), 7.38 (s, 1H), 8.73 (s, 1H), 9.24 (s, 1H), 12.04 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 474.

The 4-amino-6-methoxy-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

10 4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 3-morpholinopropyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 2.13 (m, 2H), 2.49 (t, 4H), 2.58 (t, 2H), 3.74 (t, 4H), 4.06 (s, 3H), 4.29 (t, 2H), 7.15 (m, 1H), 7.31 (m, 1H), 7.37 (s, 1H),  
15 7.43 (m, 1H), 8.58 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 492 & 494.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 2.09 (m, 2H), 2.48 (t, 4H), 2.55 (t, 2H), 3.61 (t, 4H), 3.96 (s, 3H), 4.24 (t, 2H), 5.44 (s, 2H), 6.9 (s, 1H), 7.24 (s, 1H), 8.52 (s, 1H).

20 The 3-morpholinopropyl chloride used as an intermediate was prepared as follows :-  
Morpholine (52.2 ml) and 1-bromo-3-chloropropane (30 ml) were taken up in dry toluene (180 ml) and stirred and heated to 70°C for 3 hours. The resultant precipitate was filtered off and the filtrate was evaporated to give an orange oil which was purified by vacuum distillation collecting fractions at 62°C/5mmHg and 58°C/2mmHg. The required compound  
25 was obtained as an oil (37.9 g); NMR Spectrum: 1.85 (m, 2H), 2.3 (t, 4H), 2.38 (t, 2H), 3.53 (t, 4H), 3.65 (t, 2H); M/s: M+H<sup>+</sup> 164.

[43] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.71 (s, 4H), 2.12 (m, 2H), 2.31 (s, 3H), 2.42–2.62 (m, 6H), 3.7 (s, 3H), 4.27 (t, 2H), 7.0 (m, 2H), 7.21–7.32 (m, 2H), 7.38 (s, 1H), 8.73 (s, 1H), 9.62 (s, 1H), 12.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 487.

30 [44] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.46 (m, 2H), 1.64 (m, 4H), 2.55 (t, 4H), 2.9 (t, 2H), 3.68 (s, 3H), 4.3 (t, 2H), 6.95–7.04 (m, 3H), 7.28 (m, 1H), 7.4 (s, 1H), 8.73 (s, 1H), 9.38 (s, 1H), 12.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 458.

[45] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.49 (m, 2H), 1.63 (m, 4H), 2.56 (t, 4H), 2.8 (t, 2H), 3.7 (s, 3H), 4.32 (t, 2H), 7.3 (s, 1H), 7.34 (s, 1H), 7.43 (s, 2H), 8.72 (s, 1H), 9.22 (s, 1H), 12.32 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 524 and 526.

[46] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.15 (m, 2H), 2.53 (s, 4H), 2.66 (t, 2H), 3.58 (s, 3H), 4.25 (t, 2H), 7.29 (s, 1H), 7.32–7.45 (m, 3H), 7.54 (d, 1H), 8.68 (s, 1H), 9.38 (s, 1H), 12.55 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 507.

[47] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.38 (s, 6H), 2.88 (t, 2H), 3.57 (s, 3H), 4.27 (t, 2H), 6.98 (t, 3H), 7.27 (s, 1H), 7.51 (s, 1H), 8.71 (s, 1H), 9.81 (s, 1H), 12.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 418.

10 The 4-amino-6-methoxy-7-(2-dimethylaminoethoxy)quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-dimethylaminoethyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-

15 7-(2-dimethylaminoethoxy)-6-methoxyquinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 2.39 (s, 6H), 2.9 (t, 2H), 4.04 (s, 3H), 4.31 (t, 2H), 7.22 (t, 1H), 7.32 (s, 1H), 7.41 (m, 2H), 7.52 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 436 & 438.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material;

20 NMR Spectrum: (DMSO-d<sub>6</sub>) 2.21 (s, 6H), 2.68 (t, 2H), 3.87 (s, 3H), 4.14 (t, 2H), 7.07 (s, 1H), 7.37 (s, 2H), 7.55 (s, 1H), 8.22 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 263.

[48] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.38 (s, 6H), 2.87 (t, 2H), 3.49 (s, 3H), 4.26 (t, 2H), 7.24 (s, 2H), 7.4 (d, 2H), 7.53 (s, 1H), 8.72 (s, 1H), 9.8 (s, 1H), 12.47 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450 and 452.

25 [49] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.47 (t, 2H), 3.74 (m, 4H), 3.89 (s, 3H), 4.33 (t, 2H), 4.42 (s, 1H), 7.01 (t, 3H), 7.28 (m, 2H), 8.0 (s, 1H), 8.73 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 459.

The 4-amino-6-methoxy-7-[2-(2-oxoimidazolidin-1-yl)ethoxy]quinazoline used as a starting material was prepared as follows :-

30 4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-(2-oxoimidazolidin-1-yl)ethyl chloride (Indian J. Chem. Sect. B, 1982, 21B, 928-940) using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[2-(2-oxoimidazolidin-

1-yl)ethoxy]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 3.47 (t, 2H), 3.75 (m, 4H), 4.05 (s, 3H), 4.35 (t, 2H), 4.47 (s, 1H), 7.21 (t, 1H), 7.30 (s, 1H), 7.41 (t, 2H), 7.54 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 477 & 479.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (DMSO-d<sub>6</sub>) 3.23 (t, 2H), 3.48 (m, 4H), 3.87 (s, 3H), 4.2 (t, 2H), 6.4 (s, 1H), 7.1 (s, 1H), 7.4 (s, 2H), 7.58 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 304.

[50] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.48 (t, 2H), 3.73 (m, 7H), 4.32 (t, 2H), 4.48 (s, 1H), 7.13 (m, 2H), 7.44 (t, 3H), 8.74 (s, 1H), 9.1 (s, 1H), 12.27 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 491 and 493.

[51] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.87 (m, 4H), 2.71 (s, 4H), 3.06 (t, 2H), 3.58 (s, 3H), 4.33 (t, 2H), 7.1–7.27 (m, 2H), 7.36–7.46 (m, 3H), 8.73 (s, 1H), 9.5 (s, 1H), 12.37 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 476 and 478.

The 4-amino-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-pyrrolidin-1-ylethyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.83 (m, 4H), 2.69 (m, 4H), 3.06 (t, 2H), 4.04 (s, 3H), 4.34 (t, 2H), 7.21 (t, 1H), 7.31 (s, 1H), 7.4 (t, 2H), 7.53 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 462 & 464.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (CDCl<sub>3</sub>) 1.7 (s, 4H), 2.5 (m, 4H), 2.83 (t, 2H), 3.87 (s, 3H), 4.19 (t, 2H), 7.07 (s, 1H), 7.39 (s, 2H), 7.56 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 289.

[52] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.87 (s, 4H), 2.73 (s, 4H), 3.07 (t, 2H), 3.65 (s, 3H), 4.34 (t, 2H), 6.99 (t, 3H), 7.28 (m, 1H), 7.43 (s, 1H), 8.75 (s, 1H), 9.47 (s, 1H), 12.11 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 444.

[53] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.6 (t, 4H), 2.92 (t, 2H), 3.58 (s, 3H), 3.74 (t, 4H), 4.28 (t, 2H), 7.11–7.27 (m, 2H), 7.37–7.45 (m, 3H), 8.73 (s, 1H), 9.47 (s, 1H), 12.36 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 492 and 494.

The 4-amino-6-methoxy-7-(2-morpholinoethoxy)quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-morpholinoethyl chloride using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 2.63 (t, 4H), 2.98 (t, 2H), 3.76 (t, 4H), 4.06 (s, 3H), 4.34 (t, 2H), 7.22 (t, 1H), 7.32 (s, 1H), 7.41 (t, 2H), 7.52 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 478 & 480.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material; NMR Spectrum: (DMSOd<sub>6</sub>) 2.5 (m, 4H), 2.75 (t, 2H), 3.58 (t, 4H), 3.87 (s, 3H), 4.2 (t, 2H), 7.09 (s, 1H), 7.39 (s, 2H), 7.58 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 305.

[54] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.63 (t, 4H), 3.04 (t, 2H), 3.61 (s, 3H), 3.76 (t, 4H), 4.33 (t, 2H), 6.99 (t, 2H), 7.27 (m, 2H), 7.45 (s, 1H), 8.74 (s, 1H), 9.57 (s, 1H), 12.15 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 460.

[55] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.15 (m, 2H), 2.33 (s, 6H), 2.57 (br s, 4H), 2.69 (t, 2H), 3.41 (s, 3H), 4.26 (t, 2H), 7.14 (m, 3H), 7.28 (s, 1H), 7.5 (s, 1H), 8.66 (s, 1H), 9.66 (s, 1H), 11.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

[56] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.09 (m, 2H), 2.32 (s, 6H), 2.46 (t, 4H), 2.55 (t, 2H), 3.4 (s, 3H), 3.71 (t, 2H), 4.25 (t, 2H), 7.11 (m, 3H), 7.28 (s, 1H), 7.49 (s, 1H), 8.66 (s, 1H), 9.61 (s, 1H), 11.91 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 466.

[57] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.72 (s, 4H), 2.1 (m, 2H), 2.3 (s, 3H), 2.33 (s, 6H), 2.4–2.6 (m, 6H), 3.4 (s, 3H), 4.23 (t, 2H), 7.16 (m, 3H), 7.28 (s, 1H), 7.49 (s, 1H), 8.66 (s, 1H), 9.64 (s, 1H), 11.91 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 479.

[58] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.85 (m, 4H), 2.34 (s, 6H), 2.68 (s, 4H), 3.05 (t, 2H), 3.31 (s, 3H), 4.3 (t, 2H), 7.14 (m, 3H), 7.26 (s, 1H), 7.56 (s, 1H), 8.65 (s, 1H), 9.87 (s, 1H), 11.98 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 436.

[59] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (s, 2H), 1.64 (m, 4H), 2.32 (s, 6H), 2.55 (s, 4H), 2.91 (t, 2H), 3.36 (s, 3H), 4.32 (t, 2H), 7.14 (m, 3H), 7.26 (s, 1H), 7.54 (s, 1H), 8.66 (s, 1H), 9.79 (s, 1H), 11.98 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

[60] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.31 (s, 6H), 2.61 (m, 4H), 2.94 (t, 2H), 3.27 (s, 3H), 3.76 (t, 4H), 4.31 (t, 2H), 7.15 (m, 3H), 7.26 (s, 1H), 7.59 (s, 1H), 8.67 (s, 1H), 9.97 (s, 1H), 12.01 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 452.

[61] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.33 (s, 6H), 3.35 (s, 3H), 3.46 (t, 2H), 3.72 (m, 4H), 4.28 (t, 2H), 4.67 (s, 1H), 7.14 (m, 3H), 7.25 (s, 1H), 7.61 (s, 1H), 8.67 (s, 1H), 9.91 (s, 1H), 11.98 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 451.

[62] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.33 (s, 6H), 2.39 (s, 6H), 2.87 (t, 2H), 3.28 (s, 3H), 4.26 (t, 2H), 7.12 (m, 3H), 7.26 (s, 1H), 7.58 (s, 1H), 8.66 (s, 1H), 9.97 (s, 1H), 12.02 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 410.

[63] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.81 (m, 4H), 2.16 (m, 2H), 2.31 (s, 6H), 2.59 (s, 4H), 2.7 (t, 2H), 3.52 (s, 3H), 4.26 (t, 2H), 7.27 (m, 3H), 7.39 (s, 1H), 8.67 (s, 1H), 9.34 (s, 1H), 11.83 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 528 and 530.

10 [64] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.45 (q, 2H), 1.6 (m, 4H), 2.13 (m, 2H), 2.3 (s, 6H), 2.44 (s, 4H), 2.54 (t, 2H), 3.53 (s, 3H), 4.25 (t, 2H), 7.29 (m, 3H), 7.37 (s, 1H), 8.68 (s, 1H), 9.27 (s, 1H), 11.81 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 542 and 544.

[65] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.12 (m, 2H), 2.3 (s, 6H), 2.5 (t, 4H), 2.58 (t, 2H), 3.5 (s, 3H), 3.5 (t, 4H), 4.27 (t, 2H), 7.22–7.29 (m, 3H), 7.41 (s, 1H), 8.67 (s, 1H), 9.44 (s, 1H), 11.87 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 544 and 546.

[66] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.66 (s, 10H), 2.11 (m, 2H), 2.3 (s, 3H), 2.4–2.6 (m, 6H), 3.58 (s, 3H), 4.24 (t, 2H), 7.25 (s, 3H), 7.34 (s, 1H), 8.67 (s, 1H), 9.2 (s, 1H), 11.79 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 557 and 559.

20 [67] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.49 (m, 2H), 1.66 (m, 4H), 2.31 (s, 6H), 2.54 (t, 4H), 2.9 (t, 2H), 3.5 (s, 3H), 4.32 (t, 2H), 7.28 (m, 3H), 7.41 (s, 1H), 8.69 (s, 1H), 9.44 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 528 and 530.

[68] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.3 (s, 6H), 2.64 (t, 4H), 2.95 (t, 2H), 3.41 (s, 3H), 3.77 (t, 4H), 4.33 (t, 2H), 7.27 (s, 3H), 7.48 (s, 1H), 8.69 (s, 1H), 9.71 (s, 1H), 11.97 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 530 and 532.

[69] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.29 (s, 6H), 3.47 (t, 2H), 3.62 (s, 3H), 3.75 (m, 4H), 4.33 (t, 2H), 4.44 (s, 1H), 7.28 (m, 3H), 7.39 (s, 1H), 8.68 (s, 1H), 9.18 (s, 1H), 11.77 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 529 and 531.

30 [70] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.39 (s, 3H), 3.54 (s, 3H), 3.6 (m, 2H), 3.75 (m, 2H), 3.98 (t, 2H), 4.33 (t, 2H), 7.24 (m, 2H), 7.41 (m, 2H), 7.48 (s, 1H), 8.73 (s, 1H), 9.68 (s, 1H), 12.46 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 481 and 483.

The 4-amino-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline used as a starting material was prepared as follows :-

4-(4-Bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline was reacted with 2-(2-methoxyethoxy)ethyl tosylate (prepared from 2-(2-methoxyethoxy)ethanol and tosyl chloride) using an analogous procedure to that described in the second last paragraph of Note [38] above to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-

5 7-[2-(2-methoxyethoxy)ethoxy]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 3.4 (s, 3H), 3.6 (m, 2H), 3.76 (m, 2H), 4.03 (m, 5H), 4.39 (t, 2H), 7.21 (m, 1H), 7.34 (s, 1H), 7.41 (t, 2H), 7.51 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 467 & 469.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [38] above to give the required starting material;  
10 NMR Spectrum: (DMSO-d<sub>6</sub>) 3.23 (s, 3H), 3.46 (m, 2H), 3.6 (m, 2H), 3.79 (t, 2H), 3.88 (s, 3H), 4.2 (t, 2H), 7.08 (s, 1H), 7.39 (s, 2H), 7.57 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 294.

[71] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 3.39 (s, 3H), 3.6 (m, 5H), 3.77 (m, 2H), 4.01 (t, 2H), 4.36 (s, 1H), 7.01 (t, 3H), 7.26 (m, 2H), 7.46 (s, 1H), 8.72 (s, 1H), 9.58 (s, 1H), 12.16 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 449.

15 [72] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.31 (s, 6H), 3.27 (s, 3H), 3.4 (s, 3H), 3.6 (m, 2H), 3.75 (m, 2H), 3.97 (t, 2H), 4.34 (t, 2H), 7.14 (m, 3H), 7.26 (s, 1H), 7.57 (s, 1H), 8.66 (s, 1H), 9.95 (s, 1H), 12.03 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 441.

[73] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.54 (m, 2H), 1.82–2.03 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.53 (s, 3H), 4.02 (d, 2H), 7.26 (m, 1H),  
20 7.31–7.47 (m, 3H), 7.55 (d, 1H), 8.68 (s, 1H), 9.49 (s, 1H), 12.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 508.

[74] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.82 (m, 4H), 2.66 (m, 4H), 3.0 (t, 2H), 4.27 (t, 2H), 7.2–7.4 (m, 3H), 7.5 (d, 2H), 8.05 (d, 1H), 8.78 (s, 1H), 9.1 (br s, 1H), 12.07 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 446 and 448.

25 The 4-amino-7-(2-pyrrolidin-1-ylethoxy)quinazoline used as a starting material was prepared as follows :-

A mixture of 7-hydroxy-4-methylthioquinazoline (6 g) and a saturated solution of ammonia gas in methanol (225 ml) was sealed in a pressure vessel and heated at 120°C for 40 hours. The mixture was cooled to ambient temperature and evaporated. The residue was  
30 purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-amino-7-hydroxyquinazoline (4.9 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 6.9 (s, 1H), 6.9 (d, 1H), 9.5 (br s, 2H), 8.04 (d, 1H), 8.24 (s, 1H).

Diethyl azodicarboxylate (3.3 ml) was added dropwise to a stirred mixture of 4-amino-7-hydroxyquinazoline (5.16 g), triphenylphosphine (16.8 g) and methylene chloride (260 ml) which had been cooled to 0°C. The mixture was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was purified by column

5 chromatography on silica using a 50:45:5 mixture of methylene chloride, ethyl acetate and methanol as eluent. There was thus obtained triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide (9.7 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 6.85 (s, 1H), 7.05 (m, 1H), 7.5-7.95 (m, 15H), 8.12 (s, 1H), 8.5 (d, 1H), 10.3 (br s, 1H).

3,3-Dimethyl-1,2,5-thiadiazolidine-1,1-dioxide (J. Med. Chem. 1994, 37, 3023;  
10 0.39 g) was added portionwise to a stirred mixture of triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide (0.2 g), N-(2-hydroxyethyl)pyrrolidine (0.081 g) and methylene chloride (5 ml) and the mixture was stirred at ambient temperature for 1 hour. Diethyl ether (10 ml) was added and the mixture was filtered through diatomaceous earth. The filtrate was evaporated and the residue was purified by column chromatography on silica  
15 using as eluent a 48:50:2 mixture of methylene chloride, ethyl acetate and a saturated ammonia solution in methanol. There was thus obtained triphenylphosphine N-[7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]imide (0.084 g); NMR Spectrum: (DMSO-d<sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 1.93 (m, 2H), 2.08 (m, 2H), 3.2 (m, 2H), 3.66 (m, 2H), 3.73 (m, 2H), 4.5 (m, 2H), 7.16 (s, 1H), 7.42 (m, 1H), 7.6-8.0 (m, 15H), 8.62 (s, 1H), 8.71 (d, 1H); Mass Spectrum:  
20 M+H<sup>+</sup> 519.

A mixture of a portion (0.42 g) of the material so obtained, a 1N aqueous acetic acid solution (2 ml) and ethanol (2 ml) was stirred and heated to 100°C for 15 hours. The mixture was evaporated and the residue was dried under vacuum. There was thus obtained 4-amino-7-(2-pyrrolidin-1-ylethoxy)quinazoline in quantitative yield and this was used directly without  
25 future purification.

[75] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 426 and 428.

[76] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 412 and 414.

[77] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 480 and 482.

[78] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4-1.7 (m, 6H), 2.55  
30 (br s, 4H), 2.85 (t, 2H), 4.25 (t, 2H), 7.1-7.38 (m, 4H), 7.48 (d, 2H), 8.05 (d, 2H), 8.8 (s, 1H), 9.02 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 460 and 462.

The 4-amino-7-(2-piperidinoethoxy)quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N-(2-hydroxyethyl)piperidine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine N-[7-(2-piperidinoethoxy)quinazolin-4-yl]imide in 21% yield; Mass Spectrum:  $M+H^+$  533.

- 5 The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  273.

[79] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.45 (br m, 2H), 1.55-1.75 (m, 4H), 2.55 (br s, 4H), 2.85 (t, 2H), 4.28 (t, 2H), 7.05 (m, 2H), 7.12-7.4 (m, 4H),  
10 8.15 (d, 1H), 8.8 (s, 1H), 9.2 (s, 1H); Mass Spectrum:  $M+H^+$  428.

[80] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.4-1.72 (m, 6H), 2.42 (s, 3H), 2.55 (br s, 4H), 2.85 (t, 2H), 4.3 (t, 2H), 7.12-7.32 (m, 5H), 8.35 (d, 1H), 7.95 (d, 1H), 8.6 (s, 1H), 8.8 (s, 1H); Mass Spectrum:  $M+H^+$  440 and 442.

[81] The product gave the following data: Mass Spectrum:  $M+H^+$  426 and 428.

- 15 [82] The product gave the following data: Mass Spectrum:  $M+H^+$  494 and 496.

[83] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.32 (s, 3H), 2.5 (br s, 4H), 2.7 (br s, 4H), 2.9 (t, 2H), 4.3 (t, 2H), 7.2 (d, 1H), 7.25-7.4 (m, 3H), 7.47 (d, 2H), 8.05 (d, 1H), 8.8 (s, 1H), 9.05 (s, 1H); Mass Spectrum:  $M+H^+$  475 and 477.

- The 4-amino-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline used as a starting  
20 material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with 1-(2-hydroxyethyl)-4-methylpiperazine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine N-{7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazolin-4-yl}imide in 30% yield; Mass Spectrum:  
25  $M+H^+$  548. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  288.

The 1-(2-hydroxyethyl)-4-methylpiperazine used as a starting material was prepared as follows :-

- 30 A mixture of 2-bromoethanol (2.36 g), N-methylpiperazine (1.26 g), potassium carbonate (5.0 g) and ethanol (150 ml) was stirred and heated to reflux for 18 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was triturated under a mixture of methylene chloride and acetone. The resultant

mixture was filtered and the filtrate was evaporated to give the required starting material as an oil (0.87 g); NMR Spectrum: ( $\text{CDCl}_3$ ) 2.18 (s, 3H), 2.3-2.7 (br m, 8H), 2.56 (t, 2H), 3.61 (t, 2H).

[84] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  455 and 457.

5 [85] The product gave the following data: NMR Spectrum: ( $\text{CDCl}_3$ ) 2.3 (s, 3H), 2.48 (br s, 4H), 2.65 (br s, 4H), 2.9 (t, 2H), 4.3 (t, 2H), 7.1 (m, 1H), 7.2-7.4 (m, 4H), 7.45 (d, 1H), 7.97 (d, 1H), 8.35 (br s, 1H), 8.45 (d, 1H), 8.85 (s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  441 and 443.

[86] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  509 and 511.

[87] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  460 and 462.

10 The 4-amino-7-(N-methylpiperidin-3-ylmethoxy)quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with 3-hydroxymethyl-N-methylpiperidine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine

15 N-[7-(N-methylpiperidin-3-ylmethoxy)quinazolin-4-yl]imide in 49% yield; Mass Spectrum:  $\text{M}+\text{H}^+$  533. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $\text{M}+\text{H}^+$  273.

[88] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  428.

20 [89] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  440 and 442.

[90] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  426 and 428.

[91] The product gave the following data: Mass Spectrum:  $\text{M}+\text{H}^+$  494 and 496.

[92] The product gave the following data: NMR Spectrum: ( $\text{CDCl}_3$ ) 1.85 (br s, 4H), 2.1 (m, 2H), 2.6 (br s, 4H), 2.7 (t, 2H), 4.2 (t, 2H), 7.15 (d, 1H), 7.2-7.4 (m, 3H), 7.5 (d, 2H), 8.1 (d, 25 1H), 8.8 (s, 1H), 9.2 (br s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  460 and 462.

The 4-amino-7-(3-pyrrolidin-1-ylpropoxy)quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N-(3-hydroxypropyl)pyrrolidine using an analogous procedure to that described in the second 30 last paragraph of Note [74] above to give triphenylphosphine N-[7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]imide in 42% yield; Mass Spectrum:  $\text{M}+\text{H}^+$  533. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described

in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  273.

The N-(3-hydroxypropyl)pyrrolidine used as a starting material was prepared as follows :-

- 5        A mixture of 3-chloropropanol (66 g), pyrrolidine (50 g), potassium carbonate (145 g) and acetonitrile (1 L) was stirred and heated to reflux for 20 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by distillation to give the required starting material as an oil (62 g); NMR Spectrum: ( $CDCl_3$ ) 1.6-1.8 (m, 6H), 2.55 (br s, 4H), 2.75 (t, 2H), 3.85 (t, 2H), 5.5 (br s, 1H).
- 10 [93]    The product gave the following data: Mass Spectrum:  $M+H^+$  428.
- [94]    The product gave the following data: Mass Spectrum:  $M+H^+$  440 and 442.
- [95]    The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.82 (br s, 4H), 2.1 (m, 2H), 2.55 (br s, 4H), 2.65 (t, 4H), 4.25 (t, 2H), 7.1 (m, 1H), 7.2-7.45 (m, 4H), 7.5 (d, 1H), 7.95 (d, 1H), 8.15 (s, 1H), 8.45 (d, 1H), 8.85 (s, 1H); Mass Spectrum:  $M+H^+$  426 and 428.
- 15 [96]    The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 7.2 (m, 1H), 7.25-7.4 (m, 3H), 7.5 (s, 1H), 8.0 (d, 1H), 8.8 (s, 1H), 8.95 (br s, 1H); Mass Spectrum:  $M+H^+$  494 and 496.
- [97]    The product gave the following data: Mass Spectrum:  $M+H^+$  444.

20        The 4-amino-7-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

- Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N-(3-hydroxypropyl)morpholine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine N-[7-(3-morpholinopropoxy)quinazolin-4-yl]imide and the material so obtained was reacted
- 25 with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  289.
- [98]    The product gave the following data: Mass Spectrum:  $M+H^+$  456 and 458.
- [99]    The product gave the following data: Mass Spectrum:  $M+H^+$  510 and 512.
- [100]   The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.1 (m, 2H), 2.35 (s, 3H), 2.35-2.75 (m, 8H), 2.6 (t, 2H), 4.22 (t, 2H), 7.12 (m, 1H), 7.2-7.38 (m, 3H), 7.5 (d, 2H), 8.15 (d, 1H), 8.8 (s, 1H), 9.5 (br s, 1H); Mass Spectrum:  $M+H^+$  489 and 491.
- 30

      The 4-amino-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline used as a starting material was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with 1-(3-hydroxypropyl)-4-methylpiperazine using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine

N-{7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl}imide in 44% yield; Mass

- 5 Spectrum:  $M+H^+$  562. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  302.

The 1-(3-hydroxypropyl)-4-methylpiperazine used as a starting material was prepared as follows :-

- 10 A mixture of 3-bromopropanol (20 ml), N-methylpiperazine (29 ml), potassium carbonate (83 g) and ethanol (200 ml) was stirred and heated to reflux for 20 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was triturated under diethyl ether. The resultant mixture was filtered and the filtrate was evaporated. The residue was purified by distillation to give the required starting material
- 15 as an oil; NMR Spectrum: ( $CDCl_3$ ) 1.72 (m, 2H), 2.3 (s, 3H), 2.2-2.8 (m, 8H), 2.6 (t, 2H), 3.8 (t, 2H), 5.3 (br s, 1H).

[101] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.07 (t, 2H), 2.32 (s, 3H), 2.3-2.75 (m, 8H), 2.6 (t, 2H), 4.22 (t, 2H), 7.1 (m, 1H), 7.2-7.45 (m, 4H), 7.5 (d, 1H), 8.05 (d, 1H), 8.45 (d, 1H), 8.55 (s, 1H), 8.85 (s, 1H); Mass Spectrum:  $M+H^+$  455 and 457.

- 20 [102] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.1 (m, 2H), 2.3 (s, 3H), 2.35-2.7 (m, 8H), 2.6 (t, 2H), 4.2 (t, 2H), 7.15 (m, 1H), 7.2-7.4 (m, 3H), 7.5 (s, 1H), 8.05 (d, 1H), 8.8 (s, 1H), 9.02 (br s, 1H); Mass Spectrum:  $M+H^+$  523 and 525.

[103] The product gave the following data: Mass Spectrum:  $M+H^+$  492.

[104] The product gave the following data: Mass Spectrum:  $M+H^+$  504 and 506.

- 25 [105] The product gave the following data: Mass Spectrum:  $M+H^+$  558 and 560.

[106] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.55 (m, 2H), 4.15 (t, 2H), 4.7 (t, 2H), 7.2-7.4 (m, 4H), 7.5 (s, 1H), 7.58 (s, 1H), 7.65 (s, 1H), 7.95 (d, 1H), 8.55 (d, 1H), 8.8 (s, 1H); Mass Spectrum:  $M+H^+$  492 and 494.

- The 4-amino-7-[3-(1,2,3-triazol-1-yl)propoxy]quinazoline used as a starting material
- 30 was prepared as follows :-

Triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide was reacted with N<sup>1</sup>-(3-hydroxypropyl)-1,2,3-triazole using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine N-{7-[3-(1,2,3-triazol-

1-yl)propoxy]quinazolin-4-yl}imide in 18% yield; Mass Spectrum:  $M+H^+$  531. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  271.

5 The  $N^1$ -(3-hydroxypropyl)-1,2,3-triazole used as a starting material was prepared as follows :-

A mixture of 1,2,3-triazole (5 g), ethyl acrylate (7.8 ml) and pyridine (50 drops) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and evaporated. The residue was purified by column chromatography on silica using increasingly  
10 polar mixtures of methylene chloride and diethyl ether as eluent. There was thus obtained ethyl 1,2,3-triazol-1-ylpropanoate (8.96 g); NMR Spectrum: ( $CDCl_3$ ) 1.25 (t, 3H), 2.95 (t, 2H), 4.15 (q, 2H), 4.7 (t, 2H), 7.65 (s, 1H), 7.7 (s, 1H).

A solution of the material so obtained in THF (50 ml) was added dropwise to a suspension of lithium aluminium hydride (3 g) in THF (250 ml) which had been cooled to  
15 0°C. The mixture was stirred at 5°C for 1 hour and at ambient temperature for a further hour. The mixture was cooled to 0°C and 4N aqueous sodium hydroxide solution (30 ml) was added dropwise. The mixture was filtered and the filtrate was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 47:3 mixture of methylene chloride and methanol as eluent. There was thus obtained  
20  $N^1$ -(3-hydroxypropyl)-1,2,3-triazole (6.2 g); NMR Spectrum: ( $CDCl_3$ ) 2.1-2.2 (m, 3H), 3.65 (m, 2H), 4.6 (t, 2H), 7.6 (s, 1H), 7.72 (s, 1H).

[107] The product gave the following data: Mass Spectrum:  $M+H^+$  440.

The 4-amino-7-[(*E*)-4-pyrrolidin-1-ylbut-2-en-1-yloxy]quinazoline used as a starting material was prepared as follows :-

25 Triphenylphosphine  $N$ -(7-hydroxyquinazolin-4-yl)imide was reacted with (*E*)-4-pyrrolidin-1-ylbut-2-en-1-ol using an analogous procedure to that described in the second last paragraph of Note [74] above to give triphenylphosphine  $N$ -(7-[(*E*)-4-pyrrolidin-1-ylbut-2-en-1-yloxy]quinazolin-4-yl)imide in 38% yield; Mass Spectrum:  $M+H^+$  545. The material so obtained was reacted with aqueous acetic acid using an analogous procedure to  
30 that described in the last paragraph of Note [74] above to give the required starting material; Mass Spectrum:  $M+H^+$  285.

The (*E*)-4-pyrrolidin-1-ylbut-2-en-1-ol used as a starting material was prepared as follows :-

Thionyl chloride (9.3 ml) was added portionwise to a stirred mixture of 2-butyne-1,4-diol (10 g), pyridine (10.3 ml) and toluene (15 ml) which had been cooled to 0°C. The mixture was stirred at ambient temperature for 3.5 hours and then poured onto a mixture of ice and water. The mixture was extracted with diethyl ether. The organic extract  
5 was washed with a saturated aqueous sodium bicarbonate solution and with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 7:3 mixture of petroleum ether (b.p. 40-60°C) and diethyl ether as eluent. There was thus obtained 4-chlorobut-2-yn-1-ol (4.74 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.68 (t, 1H), 4.18 (d, 2H), 4.33 (d, 2H).

10 Pyrrolidine (7.8 ml) was added dropwise to a solution of 4-chlorobut-2-yn-1-ol (4.74 g) in toluene (40 ml) and the resultant mixture was stirred and heated to 60°C for 1 hour. The mixture was evaporated and the residue was purified by column chromatography on silica using a 24:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 4-pyrrolidin-1-ylbut-2-yn-1-ol (4.3 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.82 (t, 4H), 2.63 (t,  
15 4H), 3.44 (t, 2H), 4.29 (t, 2H).

A solution of the material so obtained in THF (20ml) was added dropwise to a suspension of lithium aluminium hydride (2.35 g) in THF (8 ml) and the mixture was stirred and heated to 60°C for 2 hours. The mixture was cooled to 5°C and 2N aqueous sodium hydroxide solution (28 ml) was slowly added. The resulting suspension was filtered and the  
20 filtrate was evaporated. The residue was dissolved in a mixture of methylene chloride and ethyl acetate, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on aluminium oxide using a 97:3 mixture of methylene chloride and methanol as eluent. There was thus obtained (*E*)-4-pyrrolidin-1-ylbut-2-en-1-ol (3.09 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.82 (m, 4H), 2.61 (m, 4H), 3.17 (m, 2H), 4.13 (s, 2H), 5.84 (m,  
25 2H).

[108] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 452 and 454.

[109] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 438 and 440.

[110] DMF was used as the reaction solvent. The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.5-1.65 (m, 2H), 1.68-1.74 (m, 2H), 1.92 (t, 2H), 1.97 (t, 2H), 2.05 (m,  
30 1H), 2.45 (t, 2H), 2.88 (d, 2H), 3.98 (s, 3H), 4.22 (t, 2H), 6.68 (s, 1H), 7.18 (s, 1H), 7.3 (s, 1H), 7.4 (t, 1H), 7.61 (d, 2H), 8.07 (s, 1H), 8.7 (s, 1H), 10.62 (s, 1H), 12.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 547 and 549.

The 4-amino-7-[3-(4-carbamoylpiperidin-1-yl)propoxy]-6-methoxyquinazoline used as a starting material was prepared as follows :-

A mixture of 2-amino-4-benzyloxy-5-methoxybenzamide (*J. Med. Chem.*, 1977, 20, 146-149; 10 g) and Gold's reagent (7.4 g) in dioxane (100 ml) was stirred and heated at reflux  
5 for 24 hours. Sodium acetate (3.02 g) and acetic acid (1.65 ml) were added to the reaction mixture and it was heated for a further 3 hours. The mixture was evaporated to dryness, water was added to the residue and the solid was filtered off, washed with water and dried. Recrystallisation of the solid from acetic acid gave 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.7 g, 84%).

10 7-Benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (20.3 g) was taken up in thionyl chloride (440 ml) and DMF (1.75ml) and heated to reflux for 4 hours. The thionyl chloride was evaporated under vacuum and the residue was azeotroped with toluene three times. There was thus obtained 7-benzyloxy-4-chloro-6-methoxyquinazoline which was used without further purification; NMR Spectrum: 4.88 (s, 3H), 5.25 (s, 2H), 7.44 (s, 1H), 7.49 (s, 1H),  
15 7.32-7.52 (m, 5H), 8.83 (s, 1H).

A mixture of the crude 7-benzyloxy-4-chloro-6-methoxyquinazoline, potassium carbonate (50 g) and 4-bromo-2-fluorophenol (10 ml) in DMF (500 ml) was stirred and heated to 100°C for 5 hours. The mixture was allowed to cool to ambient temperature and was poured into water (2L). The resultant solid was isolated and washed with water. The solid  
20 was dissolved in methylene chloride and filtered. The filtrate was treated with decolourising charcoal, boiled for a few minutes then filtered. The filtrate was evaporated to give a solid residue which was triturated under diethyl ether. There was thus obtained 7-benzyloxy-4-(4-bromo-2-fluorophenoxy)-6-methoxyquinazoline.

A mixture of the material so obtained and trifluoroacetic acid (15 ml) was stirred and  
25 heated to reflux for 3 hours. The reaction mixture was allowed to cool, toluene was added and the mixture was evaporated. The residue was triturated under diethyl ether. The precipitate was collected by filtration and dried to give 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (20.3 g) which was used without further purification.

A mixture of 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (18.2 g),  
30 1,3-dibromopropane (80 ml), potassium carbonate (42 g) and DMF (1.2 L) was stirred and heated to 45°C for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. The product

so obtained was stirred under diethyl ether (150 ml) and the resultant solid was isolated.

There was thus obtained 4-(4-bromo-2-fluorophenoxy)-7-(3-bromopropoxy)-

6-methoxyquinazoline (14.4 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.35 (m, 2H), 3.69 (t, 2H), 3.98 (s, 3H), 4.31 (t, 2H), 7.4-7.6 (m, 4H), 7.78 (d, 1H), 8.78 (s, 1H); Mass Spectrum:

5 M+H<sup>+</sup> 485, 487 and 489.

A mixture of a portion (2.4 g) of the material so obtained, piperidine-4-carboxamide (0.82 g), potassium carbonate (3.46 g) and DMF (40 ml) was stirred and heated to 45°C for 20 hours. The resultant solid was isolated, washed in turn with DMF and with water and dried. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-7-[3-(4-carbamoylpiperidin-

10 1-yl)propoxy]-6-methoxyquinazoline (2.5 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.45-1.7 (m, 4H), 1.82-2.1 (m, 5H), 2.22 (t, 2H), 2.86 (m, 2H), 3.96 (s, 3H), 4.03 (t, 2H), 6.65 (s, 1H), 7.14 (s, 1H), 7.38 (s, 1H), 7.42-7.55 (m, 3H), 7.78 (d, 1H), 8.53 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.

A mixture of the material so obtained and a saturated solution of ammonia in  
15 isopropanol (100 ml) was sealed in a Carius tube and heated at 130°C for 20 hours. The mixture was cooled and the solvent was evaporated. The residue was stirred with 2N aqueous sodium hydroxide solution (20 ml) for 1 hour. The solid was isolated and washed in turn with water and with methanol. There was thus obtained 4-amino-7-[3-(4-carbamoylpiperidin-  
1-yl)propoxy]-6-methoxyquinazoline (0.85 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.4-1.7 (m, 4H),  
20 1.8-2.1 (m, 5H), 2.4 (t, 2H), 2.68 (d, 2H), 3.86 (s, 3H), 4.1 (t, 2H), 6.66 (s, 1H), 7.03 (s, 1H), 7.15 (s, 1H), 7.33 (s, 2H), 7.53 (s, 1H), 8.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 360.

[111] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.5-1.7 (m, 4H), 1.8-2.1 (m, 5H), 2.4 (t, 2H), 2.88 (d, 2H), 2.94 (s, 3H), 4.0 (t, 2H), 6.65 (s, 1H), 7.1-7.5 (m, 5H), 8.05 (s, 1H), 8.66 (s, 1H), 10.6 (s, 1H), 11.8 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 515.

25 [112] THF was added as a co-solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.6-2.3 (m, 9H), 2.35 (s, 6H), 2.53 (t, 2H), 2.99 (d, 2H), 3.42 (s, 3H), 4.25 (t, 2H), 5.55 (s, 2H), 7.11 (s, 3H), 7.29 (s, 1H), 7.55 (s, 1H), 8.64 (s, 1H), 9.7 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 507.

[113] DMF was used as the reaction solvent. The product was precipitated from the  
30 reaction mixture as a 1:1 adduct with DMF. This gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.7-2.3 (m, 9H), 2.37 (s, 3H), 2.54 (t, 2H), 2.88 (s, 3H), 2.95 (s, 3H), 3.0 (m, partially obscured by DMF), 3.5 (s, 3H), 4.25 (t, 2H), 5.61 (broad d, 2H), 7.16-7.32 (m, 4H), 7.55 (s, 1H), 8.02 (s, 1H), 8.67 (s, 1H), 9.8 (s, 1H), 12.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 527 and 529.

[114] Acetonitrile plus a few drops of DMF was used as the reaction solvent and the reaction mixture was heated to 45°C for 3 hours. The product which was precipitated from the reaction mixture was isolated, washed with acetonitrile and diethyl ether and dried under vacuum. The product gave the following data: Mass Spectrum:  $M+H^+$  440 and 442.

5 The 4-amino-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline used as a starting material was prepared as follows :-

Trifluoromethanesulphonic anhydride (0.05 ml) was added dropwise to a stirred mixture of triphenylphosphine N-(7-hydroxyquinazolin-4-yl)imide (0.1 g), pyridine (0.5 ml) and methylene chloride (1 ml) which had been cooled to 0°C. The reaction mixture was  
10 stirred at 0°C for 2 hours. A second portion (0.012 ml) of trifluoromethanesulphonic anhydride was added and the mixture was stirred at ambient temperature for 1.5 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic solution was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene  
15 chloride and ethyl acetate as eluent. There was thus obtained triphenylphosphine N-(7-trifluoromethanesulphonyloxyquinazolin-4-yl)imide (0.078 g).

A solution of 3-(pyrrolidin-1-yl)-1-propyne (J. Amer. Chem. Soc., 1958, 80, 4609; 0.08 g) in DMF (0.2 ml) was added to a mixture of triphenylphosphine N-(7-trifluoromethanesulphonyloxyquinazolin-4-yl)imide (0.2 g), cuprous iodide (0.004 g),  
20 tetrakis(triphenylphosphine)palladium(0) (0.02 g), triethylamine (0.201 ml) and DMF (8 ml). The mixture was degassed carefully and placed under an atmosphere of argon. The reaction mixture was stirred and heated to 60°C for 2.5 hours. The mixture was cooled to ambient temperature and evaporated. The residue was partitioned between ethyl acetate and water. The organic phase was dried over magnesium sulphate and evaporated. The residue was  
25 purified by column chromatography on silica using a 9:1 mixture of methylene chloride and methanol as eluent. There was thus obtained triphenylphosphine N-{7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazolin-4-yl}imide (0.18 g).

A mixture of the material so obtained, acetic acid (4 ml) and water (4 ml) was stirred and heated at 100°C for 15 hours. The solvent was evaporated and the residue was partitioned  
30 between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic solution was washed with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using initially a 9:1 mixture of methylene chloride and methanol and then a 19:1 mixture of methylene chloride and a

saturated solution of ammonia in methanol as eluent. There was thus obtained 4-amino-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline (0.038 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.75 (m, 4H), 2.6 (m, 4H), 3.65 (s, 2H), 7.45 (m, 1H), 7.25 (d, 1H), 7.85 (br s, 2H), 8.2 (d, 1H), 8.4 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 253.

- 5 [115] DMF was used as the reaction solvent and 4-dimethylaminopyridine (0.1 equivalents) was added to catalyse the reaction. The product was precipitated from the reaction mixture by the addition of a mixture of diethyl ether and water. The product was isolated and dried under vacuum and gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.72 (m, 4H), 2.6 (m, 4H), 3.69 (s, 2H), 3.97 (s, 3H), 7.4 (m, 1H), 7.58 (m, 2H), 7.9 (s, 1H),  
10 8.15 (s, 1H), 8.75 (s, 1H), 10.8 (s, 1H), 11.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 470 and 472.

The 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline used as a starting material was prepared as follows :-

- Pyridine (1.13 ml) and a solution of trifluoromethanesulphonic anhydride (2.36 ml) in methylene chloride (10 ml) were added in turn to a stirred mixture of 4-(2-bromo-  
15 4-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (2.6 g) and methylene chloride (40 ml) which had been cooled in an ice bath to 0-5°C. The resultant mixture was stirred at ambient temperature for 4 hours. The mixture was washed in turn with dilute aqueous citric acid, water and a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. The residue was triturated under a 1:1 mixture of  
20 isohexane and diethyl ether. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline (2.58 g); NMR Spectrum: (CDCl<sub>3</sub>) 4.13 (s, 3H), 7.14-7.5 (m, 3H), 7.81 (s, 1H), 7.91 (s, 1H), 8.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 497 and 499.

- A mixture of a portion (0.8 g) of the material so obtained, 3-(pyrrolidin-1-yl)-  
25 1-propyne (0.57 g), triethylamine (0.8 ml), triphenylphosphine (0.03 g), bis(triphenylphosphine)palladium(II) chloride (0.06 g), cuprous iodide (0.06 g) and THF (5 ml) was stirred and heated to reflux for 3 hours. Dilute aqueous potassium carbonate solution was added and the mixture was extracted with ethyl acetate. The organic solution was dried over sodium sulphate and evaporated. The residue was purified by column  
30 chromatography on silica using a 10:1 mixture of methylene chloride and ethanol as eluent. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline (0.55 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 1.75 (m, 4H), 2.64 (m, 4H),

3.71 (s, 2H), 4.01 (s, 3H), 7.38-7.81 (m, 3H), 7.66 (s, 1H), 8.0 (s, 1H), 8.62 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 456 & 458.

A mixture of the material so obtained and a 2M solution of ammonia in isopropanol (10 ml) was sealed in a Carius tube and heated to 130°C for 18 hours. The reaction mixture  
5 was evaporated. The residue was partitioned between ethyl acetate and a 1N aqueous potassium carbonate solution. The organic solution was washed with brine, dried over anhydrous sodium sulphate and evaporated. The residue was triturated under a 1:1 mixture of isohexane and diethyl ether. The resultant solid was isolated and dried. There was thus obtained 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline (0.24 g); Mass  
10 Spectrum: M+H<sup>+</sup> 283.

[116] DMF was used as the reaction solvent and 4-dimethylaminopyridine (0.1 equivalents) was added to catalyse the reaction. The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>) 1.6 (m, 4H), 2.35 (m, 6H), 2.55 (m, 2H), 3.6 (m, 4H), 3.97 (s, 3H), 7.3-7.6 (m, 3H), 7.83 (s, 1H), 8.11 (s, 1H), 8.72 (s, 1H), 10.78 (s, 1H), 11.95 (s, 1H); Mass Spectrum:  
15 M+H<sup>+</sup> 528 and 530.

The 4-amino-6-methoxy-7-(6-morpholino-1-hexynyl)quinazoline used as a starting material was prepared as follows:

Using an analogous procedure to that described in the second last paragraph of Note [115] above, 6-morpholino-1-hexyne was reacted with 4-(2-bromo-4-fluorophenoxy)-  
20 6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(6-morpholino-1-hexynyl)quinazoline; NMR Spectrum: (DMSOd<sub>6</sub>) 1.63 (m, 4H), 2.33 (m, 6H), 2.55 (m, 2H), 3.56 (m, 4H), 4.0 (s, 3H), 7.35-7.8 (m, 3H), 7.65 (s, 1H), 7.96 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 514 and 516.

The material so obtained was reacted with ammonia using an analogous procedure to  
25 that described in the last paragraph of Note [115] above to give the required starting material.

6-Morpholino-1-hexyne was obtained by the reaction of 6-mesyloxy-1-hexyne with morpholine using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, 31, 1421.

[117] DMF was used as the reaction solvent and 4-dimethylaminopyridine  
30 (0.1 equivalents) was added to catalyse the reaction. The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>) 1.6 (m, 4H), 2.32 (m, 6H), 2.55 (m, 2H), 3.55 (m, 4H), 3.98 (s, 3H), 7.1-7.4 (m, 3H), 7.82 (s, 1H), 8.11 (s, 1H), 8.7 (s, 1H), 10.78 (s, 1H), 11.68 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 496.

[118] DMF was used as the reaction solvent and 4-dimethylaminopyridine (0.1 equivalents) was added to catalyse the reaction. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.55 (m, 2H), 1.85 (m, 2H), 2.28 (s, 3H), 2.56 (m, 2H), 3.9 (m, 2H), 3.96 (s, 3H), 6.7 (s, 1H), 7.07 (s, 1H), 7.36-7.62 (m, 3H), 7.85 (s, 1H), 8.13 (s, 1H), 8.71 (s, 1H) 10.8 (s, 1H), 11.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 523 and 525.

The 4-amino-6-methoxy-7-[6-(2-methylimidazol-1-yl)-1-hexynyl]quinazoline used as a starting material was prepared as follows:

Using an analogous procedure to that described in the second last paragraph of Note [115] above, 6-(2-methylimidazol-1-yl)-1-hexyne was reacted with 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[6-(2-methylimidazol-1-yl)-1-hexynyl]quinazoline; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.56 (m, 2H), 1.85 (m, 2H), 2.28 (s, 3H), 2.56 (m, 2H), 3.9 (m, 2H), 3.98 (s, 3H), 6.75 (br m, 1H), 7.1 (br m, 1H), 7.36-7.82 (m, 3H), 7.63 (s, 1H), 7.98 (s, 1H), 8.61 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 509 and 511.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

6-(2-Methylimidazol-1-yl)-1-hexyne was obtained by the reaction of 6-mesyloxy-1-hexyne with 2-methylimidazole using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, 31, 1421.

[119] DMF was used as the reaction solvent and 4-dimethylaminopyridine (0.1 equivalents) was added to catalyse the reaction. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.58 (m, 2H), 1.82 (m, 2H), 2.28 (s, 3H), 2.55 (m, 2H), 3.95 (m, 5H), 6.7 (s, 1H), 7.05 (s, 1H), 7.1-7.4 (m, 3H), 7.85 (s, 1H), 8.12 (s, 1H), 8.74 (s, 1H), 10.79 (s, 1H), 11.69 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 491.

[120] DMF was used as the reaction solvent and 4-dimethylaminopyridine (0.1 equivalents) was added to catalyse the reaction. The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.28 (s, 6H), 3.54 (s, 2H), 3.98 (s, 3H), 7.18-7.47 (m, 3H), 7.92 (s, 1H), 8.15 (s, 1H), 8.74 (s, 1H), 10.8 (s, 1H), 11.68 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 412.

The 4-amino-6-methoxy-7-(3-dimethylamino-1-propynyl)quinazoline used as a starting material was prepared as follows:

Using an analogous procedure to that described in the second last paragraph of Note [115] above, 3-dimethylamino-1-propyne was reacted with 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-

4-fluorophenoxy)-6-methoxy-7-(3-dimethylamino-1-propynyl)quinazoline; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.29 (s, 6H), 3.55 (s, 2H), 4.0 (s, 3H), 7.38-7.83 (m, 3H), 7.67 (s, 1H), 8.05 (s, 1H), 8.63 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 430 and 432.

The material so obtained was reacted with ammonia using an analogous procedure to  
5 that described in the last paragraph of Note [115] above to give the required starting material.

[121] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 467.

[122] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 454.

[123] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.84-2.06 (m, 5H), 2.3 (s, 3H), 2.86-2.99 (m, 2H), 3.92 (s, 3H), 4.04 (d, 2H), 7.02 (m, 1H),  
10 7.22 (s, 1H), 7.28 (s, 1H), 7.36 (d, 1H), 8.44 (d, 1H), 8.64 (s, 1H), 8.76 (s, 1H), 13.12 (s, 1H);  
Mass Spectrum: M+H<sup>+</sup> 490 and 492.

[124] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.58 (m, 2H),  
1.84-2.06 (m, 5H), 2.3 (s, 3H), 2.58 (s, 3H), 2.86-2.96 (m, 2H), 3.86 (s, 3H), 4.04 (d, 2H),  
7.22-7.28 (m, 2H), 7.36 (d, 1H), 7.92 (m, 1H), 8.6 (s, 1H), 8.76 (s, 1H), 9.06 (d, 1H), 12.62 (s,  
15 1H); Mass Spectrum: M+H<sup>+</sup> 481.

[125] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.84-2.04 (m, 5H), 2.3 (s, 3H), 2.84-2.94 (m, 2H), 3.94 (s, 3H), 4.06 (d, 2H), 7.1 (s, 1H), 7.76-  
7.36 (m, 2H), 7.56 (d, 1H), 8.22 (s, 1H), 8.78 (m, 2H), 13.16 (s, 1H); Mass Spectrum: M+H<sup>+</sup>  
524 and 526.

20 [126] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.86-2.06 (m, 5H), 2.3 (s, 3H), 2.84-2.96 (m, 2H), 3.94 (s, 3H), 3.98 (s, 3H), 4.04 (d, 2H),  
6.84 (d, 1H), 7.04 (m, 1H), 7.2 (s, 1H), 7.28 (s, 1H), 8.3-8.38 (m, 2H), 8.76 (s, 1H), 12.74 (s,  
1H); Mass Spectrum: M+H<sup>+</sup> 486 and 488.

[127] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.44-1.56 (m, 2H),  
25 1.86-2.06 (m, 5H), 2.3-2.34 (m, 6H), 2.84-2.96 (m, 2H), 3.86 (s, 3H), 3.98 (s, 3H), 4.04 (d,  
2H), 6.82-6.9 (m, 2H), 7.24 (s, 1H), 7.36 (s, 1H), 8.06 (s, 1H), 8.76 (s, 1H), 8.9 (s, 1H), 12.64  
(s, 1H); Mass Spectrum: M+H<sup>+</sup> 466.

[128] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4-1.54 (m, 2H), 1.84-  
2.04 (m, 5H), 2.3 (s, 3H), 2.44 (s, 3H), 2.84-2.96 (m, 2H), 3.8 (s, 3H), 4.04 (d, 2H), 7.04 (m,  
30 1H), 7.16 (d, 1H), 7.26 (s, 1H), 7.38 (s, 1H), 8.1 (s, 1H), 8.7 (s, 1H), 9.08 (s, 1H), 12.46 (s,  
1H); Mass Spectrum: M+H<sup>+</sup> 470 and 472.

[129] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42-1.56 (m, 2H),  
1.84-2.04 (m, 5H), 2.3 (s, 3H), 2.44 (s, 3H), 2.86-2.96 (m, 2H), 3.86 (s, 3H), 4.04 (d, 2H), 6.8

(m, 1H), 7.18-7.22 (m, 1H), 7.24 (s, 1H), 7.28 (s, 1H), 7.96 (m, 1H), 8.58 (s, 1H), 8.72 (s, 1H), 12.4 (s, 1H); Mass Spectrum:  $M+H^+$  454.

[130] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.42-1.56 (m, 2H), 1.84-2.04 (m, 5H), 2.28 (s, 3H), 2.34 (s, 3H), 2.86-2.96 (m, 2H), 3.86 (s, 3H), 4.04 (d, 2H),  
5 6.88 (m, 1H), 7.22-7.32 (m, 3H), 8.12 (s, 1H), 8.76 (m, 2H), 12.78 (s, 1H); Mass Spectrum:  $M+H^+$  470 and 472.

[131] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.16 (m, 2H), 2.5-2.58 (m, 4H), 2.66 (t, 2H), 3.98 (s, 3H), 4.28 (t, 2H), 6.72-6.8 (m, 1H), 7.16-7.18 (m, 1H), 7.2 (s, 1H), 7.34 (s, 1H), 8.06-8.16 (m, 1H), 8.38 (s, 1H), 8.76 (s, 1H), 12.76 (s,  
10 1H); Mass Spectrum:  $M+H^+$  458.

[132] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.16 (m, 2H), 2.48-2.58 (m, 4H), 2.66 (t, 2H), 3.96 (s, 3H), 4.28 (t, 2H), 7.02 (m, 1H), 7.14 (s, 1H), 7.32-7.4 (m, 2H), 8.3 (s, 1H), 8.46 (d, 1H), 8.78 (s, 1H), 13.06 (s, 1H); Mass Spectrum:  $M+H^+$  490 and 492.

15 [133] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.16 (m, 2H), 2.44 (s, 3H), 2.54-2.6 (m, 4H), 2.68 (t, 2H), 3.84 (s, 3H), 4.28 (t, 2H), 7.04 (m, 1H), 7.16 (d, 1H), 7.3 (s, 1H), 7.34 (s, 1H), 8.14 (d, 1H), 8.7 (s, 1H), 8.8 (s, 1H), 12.4 (s, 1H); Mass Spectrum:  $M+H^+$  470 and 472.

[134] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H),  
20 2.16 (m, 2H), 2.44 (s, 3H), 2.5-2.6 (m, 4H), 2.66 (t, 2H), 3.86 (s, 3H), 4.28 (t, 2H), 6.72-6.8 (m, 1H), 7.16-7.2 (m, 2H), 7.34 (s, 1H), 7.96 (m, 1H), 8.46 (s, 1H), 8.72 (s, 1H), 12.4 (s, 1H); Mass Spectrum:  $M+H^+$  454.

[135] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.06-2.22 (m, 2H), 2.46-2.6 (m, 7H), 2.68 (t, 2H), 3.84 (s, 3H), 4.28 (t, 2H), 7.28 (m, 2H),  
25 7.36 (d, 1H), 7.92 (d, 1H), 8.7 (s, 1H), 8.8 (s, 1H), 9.08 (s, 1H), 12.66 (s, 1H); Mass Spectrum:  $M+H^+$  481.

[136] The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.78-1.84 (m, 4H), 2.14 (m, 2H), 2.3 (s, 3H), 2.5-2.6 (m, 4H), 2.64 (t, 2H), 3.84 (s, 3H), 4.28 (t, 2H), 6.88 (m, 1H), 7.28-7.36 (m, 3H), 8.14 (d, 1H), 8.78 (s, 1H), 8.88 (s, 1H), 12.9 (s, 1H); Mass Spectrum:  
30  $M+H^+$  470 and 472.

[137] DMF was used as the reaction solvent. The product was obtained as a dihydrochloride salt and gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.6-1.7 (m, 2H), 1.82-1.96 (m,

2H), 2.58-2.62 (t, 2H), 2.8 (s, 3H), 3.3-3.9 (m, 10H), 4.02 (s, 3H), 7.4-7.6 (m, 3H), 7.95 (s, 1H), 8.21 (s, 1H), 8.8 (s, 1H), 11.6-12.0 (m, 2H); Mass Spectrum:  $M+H^+$  541 and 543.

The 4-amino-6-methoxy-7-[6-(N-methylpiperazin-1-yl)-1-hexynyl]quinazoline used as a starting material was prepared as follows:

5 Using an analogous procedure to that described in the second last paragraph of Note [115] above, 6-(N-methylpiperazin-1-yl)-1-hexyne was reacted with 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[6-(N-methylpiperazin-1-yl)-1-hexynyl]quinazoline; NMR Spectrum: ( $DMSO_d_6$ ) 1.55-1.65 (m, 4H), 2.16 (s, 3H), 2.3-2.45 (m, 10H), 2.5-2.6 (m, 2H), 4.0  
10 (s, 3H), 7.4-7.8 (m, 3H), 7.65 (s, 1H), 7.98 (s, 1H), 8.6 (s, 1H); Mass Spectrum:  $M+H^+$  527 and 529.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

6-(N-Methylpiperazin-1-yl)-1-hexyne was obtained by the reaction of 6-mesyloxy-  
15 1-hexyne with N-methylpiperazine using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, 31, 1421.

[138] The reactants were heated to 45°C for 20 hours. The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.24 (s, 3H), 2.34 (s, 3H), 2.78 (s, 3H), 3.08 (s, 3H), 3.58 (s, 3H), 5.3 (s, 2H), 7.06 (d, 1H), 7.18 (d, 1H), 7.3-7.52 (m, 7H), 8.64 (s, 1H), 9.4 (s, 1H), 11.87 (s,  
20 1H); Mass Spectrum:  $M+H^+$  500.

The 3-(N,N-dimethylcarbamoyl)-2,6-dimethylphenylisocyanate used as a starting material was prepared as follows:

A solution of di-tert-butyl dicarbonate (0.081 g) in methylene chloride (1.6 ml) and a solution of 3-amino-N,N,2,4-tetramethylbenzamide (J. Chem. Soc., Perkin Trans. I, 1973, 1-4;  
25 0.072 g) in methylene chloride (1.0 ml) were added in turn to a solution of 4-dimethylaminopyridine (0.004 g) in methylene chloride (0.4 ml). The resultant mixture was stirred at ambient temperature for 20 minutes. There was thus obtained a solution of 3-(N,N-dimethylcarbamoyl)-2,6-dimethylphenylisocyanate which was used without further purification.

30 [139] The product gave the following data: NMR Spectrum: ( $DMSO_d_6$ ) 0.37 (m, 2H), 0.62 (m, 2H), 1.32 (m, 1H), 2.25 (s, 6H), 3.94 (s, 3H), 4.03 (d, 2H), 7.12 (s, 3H), 7.22 (s, 1H), 8.07 (s, 1H), 8.66 (s, 1H), 10.38 (s, 1H), 11.68 (s, 1H); Mass Spectrum:  $M+H^+$  393.

The 4-amino-7-cyclopropylmethoxy-6-methoxyquinazoline used as a starting material was prepared as follows :-

A mixture of 4-(4-bromo-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (6.99 g), cyclopropylmethyl chloride (2.16 g), potassium iodide (0.043 g), potassium carbonate (12 g) and DMF (200 ml) was stirred and heated to 45°C for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-7-cyclopropylmethoxy-6-methoxyquinazoline (7.6 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 0.43 (m, 2H), 0.68 (m, 2H), 1.37 (m, 1H), 4.0 (s, 3H), 4.1 (d, 2H), 7.4 (s, 1H), 7.45 (m, 1H), 7.57 (m, 2H), 7.82 (m, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 421 and 423.

Using an analogous procedure to that described in the last paragraph of the portion of Example 1 that is concerned with starting materials, 4-(4-bromo-2-fluorophenoxy)-7-cyclopropylmethoxy-6-methoxyquinazoline (1.75 g) was reacted with ammonia in isopropanol. There was thus obtained 4-amino-7-cyclopropylmethoxy-6-methoxyquinazoline (1.75 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 0.36 (m, 2H), 0.58 (m, 2H), 1.3 (m, 1H), 3.88 (s, 3H), 3.94 (d, 2H), 6.97 (s, 1H), 7.39 (br s, 2H), 7.55 (s, 1H), 8.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 246.

[140] The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.23-1.46 (m, 6H), 1.55-1.69 (m, 2H), 2.1 (s, 3H), 2.1-2.4 (m, 10H), 2.7-2.8 (m, 2H), 3.97 (s, 3H), 7.3-7.6 (m, 3H), 7.65 (s, 1H), 8.05 (s, 1H), 8.7 (s, 1H), 10.7 (s, 1H), 12.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 545 and 547.

The 4-amino-6-methoxy-7-[6-(N-methylpiperazin-1-yl)hexyl]quinazoline used as a starting material was prepared as follows :-

A mixture of 4-amino-6-methoxy-7-[6-(N-methylpiperazin-1-yl)-1-hexynyl]quinazoline (0.145 g), 10% palladium-on-charcoal catalyst (0.02 g) and ethanol (10 ml) was stirred at ambient temperature under 5 atmospheres pressure of hydrogen until uptake of hydrogen ceased. The reaction mixture was filtered and the filtrate was evaporated. There was thus obtained the title compound as a solid (0.142 g); Mass Spectrum: M+H<sup>+</sup> 358.

[141] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8-2.0 (m, 6H), 2.5-2.7 (m, 6H), 2.79-2.85 (t, 2H), 3.6 (s, 3H), 7.2-7.4 (m, 3H), 7.4 (s, 1H), 7.73 (s, 1H), 8.72 (s, 1H), 9.3-9.45 (s, 1H), 12.3 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 474 and 476.

The 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)propyl]quinazoline used as a starting material was prepared by the hydrogenation of 4-amino-6-methoxy-7-[3-(pyrrolidin-1-yl)-1-propynyl]quinazoline using an analogous procedure to that described in Note [139] above.

[142] The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.6-1.75 (m, 2H), 2.1 (s, 3H), 2.2-2.4 (m, 10H), 3.3 (m, 2H), 4.0 (s, 3H), 7.25-7.6 (m, 3H), 7.94 (s, 1H), 8.19 (s, 1H), 8.5 (br t, 1H), 8.77 (s, 1H), 10.87 (s, 1H), 11.96 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 546 and 548.

The 4-amino-6-methoxy-7-{N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl}quinazoline used as a starting material was prepared as follows :-

10 A mixture of 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline (9.7 g), palladium acetate (0.137 g), 1,3-bis(diphenylphosphino)propane (0.402 g), triethylamine (5.5 ml), DMF (60 ml) and methanol (1.2L) was stirred and heated to 70°C under 10 atmospheres pressure of carbon monoxide for 2 hours. The reaction mixture was cooled to ambient temperature and the solid  
15 was isolated, washed with methanol and dried under vacuum. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-methoxycarbonylquinazoline (5.96 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.91 (s, 3H), 4.02 (s, 3H), 7.4-7.8 (m, 3H), 7.8 (s, 1H), 8.2 (s, 1H), 8.69 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 407 & 409.

A mixture of a portion (2 g) of the product so obtained, 2,4,6-trimethoxybenzylamine  
20 hydrochloride (2.34 g), anhydrous potassium carbonate (2.76 g) and DMF (20 ml) was stirred and heated to 70°C for 2 hours. The mixture was cooled to ambient temperature and diluted with water. The resultant solid was isolated, washed in turn with water and diethyl ether and dried under vacuum at 80°C. There was thus obtained 6-methoxy-7-methoxycarbonyl-4-(2,4,6-trimethoxybenzylamino)quinazoline (1.9 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.75-3.85  
25 (m, 15H), 4.55 (d, 2H), 6.3 (s, 2H), 7.8 (m, 2H), 7.9 (m, 1H), 8.45 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 414.

A portion (1.8 g) of the material so obtained was suspended in a mixture of THF (27 ml), methanol (14 ml) and water (14 ml) and lithium hydroxide (0.945 g) was added portionwise. The resultant mixture was stirred at ambient temperature for 2 hours. The  
30 mixture was concentrated by evaporation and acidified to pH4 by the addition of 2N aqueous hydrochloride acid. The resultant solid was isolated, washed in turn with water and diethyl ether and dried at 80°C. There was thus obtained 7-carboxy-6-methoxy-4-(2,4,6-trimethoxybenzylamino)quinazoline (1.68 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.7-3.9

(m, 12H), 4.55 (s, 2H), 6.28 (s, 2H), 7.7-7.9 (m, 3H), 8.42 (s, 1H); Mass Spectrum:  $M+H^+$  400.

A mixture of a portion (0.3 g) of the material so obtained, 3-(N-methylpiperazin-1-yl)propylamine (0.33 g), N-hydroxybenzotriazole (0.13 g),  
5 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.287 g) and DMF (3 ml) was stirred at ambient temperature for 16 hours. Dilute aqueous potassium carbonate solution was added and the resultant solid was isolated, washed in turn with water and diethyl ether and dried at 60°C under vacuum. There was thus obtained 6-methoxy-7-{N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl}-4-(2,4,6-trimethoxybenzylamino)quinazoline  
10 (0.285 g); NMR Spectrum: ( $DMSO-d_6$ ) 1.58-1.7 (m, 2H), 2.11 (s, 3H), 2.2-2.4 (m, 10H), 3.2-3.4 (m, 2H), 3.7-3.92 (m, 12H), 4.51 (m, 2H), 6.3 (s, 2H), 7.7-7.86 (m, 3H), 8.3-8.4 (br t, 1H), 8.42 (s, 1H); Mass Spectrum:  $M+H^+$  539.

A mixture of the material so obtained, trifluoroacetic acid (2 ml), anisole (0.2 ml) and concentrated sulphuric acid (0.2 ml) was stirred at ambient temperature for 2 hours. The  
15 mixture was evaporated and the residue was partitioned between diethyl ether and a 2M aqueous potassium carbonate solution. The aqueous solution was evaporated and the residue was extracted with methanol. The methanolic extracts were evaporated and the resultant solid was dried under vacuum. There was thus obtained 4-amino-6-methoxy-7-{N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl}quinazoline (0.086 g), Mass Spectrum:  
20  $M+H^+$  359.

[143] The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.88-2.02 (m, 2H), 3.18-3.25 (m, 2H), 4.0 (s, 3H), 4.0-4.08 (m, 2H), 6.88 (s, 1H), 7.22 (s, 1H), 7.3-7.6 (m, 4H), 7.98 (s, 1H), 8.22 (s, 1H), 8.55-8.6 (br t, 1H), 8.8 (s, 1H), 10.9 (s, 1H), 11.98 (s, 1H); Mass Spectrum:  $M+H^+$  514 and 516.

25 The 4-amino-6-methoxy-7-{N-[3-(N-methylpiperazin-1-yl)propyl]carbamoyl}quinazoline used as a starting material was prepared by the reaction of 7-carboxy-6-methoxy-4-(2,4,6-trimethoxybenzylamino)quinazoline and 3-(1-imidazolyl)propylamine and subsequent cleavage of the 2,4,6-trimethoxybenzyl group using analogous procedures to those described in Note [142] above.

30 [144] The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 2.2 (s, 3H), 3.18-3.24 (m, 4H), 3.3-3.4 (m, 4H), 3.97 (s, 3H), 7.18 (s, 1H), 7.3-7.6 (m, 3H), 7.98 (s, 1H), 8.65 (s, 1H), 10.6 (s, 1H), 12.12 (s, 1H); Mass Spectrum:  $M+H^+$  461 and 463.

The 4-amino-6-methoxy-7-(N-methylpiperazin-1-yl)quinazoline used as a starting material was prepared as follows :-

A mixture of 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline (0.8 g), 1-methylpiperazine (0.35 ml), caesium carbonate (0.78g), 1,1'-bis(diphenylphosphino)ferrocene (0.088 g), bis(dibenzylideneacetone)palladium (0.046 g) and toluene (12 ml) was stirred and heated to 100°C for 6 hours. The mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The organic extract was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(N-methylpiperazin-1-yl)quinazoline (0.26 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.4 (s, 3H), 2.66-2.68 (m, 4H), 3.34-3.38 (m, 4H), 4.05 (s, 3H), 7.1-7.44 (m, 3H), 7.38 (s, 1H), 7.55 (s, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 447 and 449.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material. [145] The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>) 1.43 (s, 9H), 3.13-3.19 (m, 4H), 3.45-3.55 (m, 4H), 4.0 (s, 3H), 7.2 (s, 1H), 7.35-7.6 (m, 3H), 8.02 (s, 1H), 8.65 (s, 1H), 10.65 (s, 1H), 12.1 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 547 and 549.

The 4-amino-7-[N-(tert-butoxycarbonyl)piperazin-1-yl]-6-methoxyquinazoline used as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that 1-(tert-butoxycarbonyl)piperazine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[N-(tert-butoxycarbonyl)piperazin-1-yl]quinazoline; NMR Spectrum: (CDCl<sub>3</sub>) 1.5 (s, 9H), 3.22 (m, 4H), 3.66 (m, 4H), 4.08 (s, 3H), 7.1-7.46 (m, 3H), 7.35 (s, 1H), 7.57 (s, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material. [146] The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>) 1.75-1.85 (m, 2H), 2.3-2.45 (m, 6H), 3.25-3.35 (m, 2H), 3.6-3.68 (m, 4H), 4.0 (s, 3H), 6.7 (s, 1H), 6.89 (t, 1H),

7.35-7.6 (m, 3H), 7.88 (s, 1H), 8.51 (s, 1H), 10.3 (s, 1H), 12.25 (s, 1H); Mass Spectrum:  $M+H^+$  505 and 507.

The 4-amino-6-methoxy-7-(3-morpholinopropylamino)quinazoline used as a starting material was prepared from as follows :-

5 The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that 3-morpholinopropylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-(3-morpholinopropylamino)quinazoline; NMR Spectrum: ( $CDCl_3$ ) 1.9-2.0 (m, 2H), 2.48-2.6 (m, 6H), 3.35-3.42 (m, 2H), 3.78-3.82 (m, 4H),  
10 4.07 (s, 3H), 6.4-6.48 (t, 1H), 6.86 (s, 1H), 7.1-7.42 (m, 3H), 7.43 (s, 1H), 8.5 (s, 1H); Mass Spectrum:  $M+H^+$  491 and 493.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

[147] The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 2.0-2.12 (m, 2H),  
15 3.15-3.25 (m, 2H), 4.0 (s, 3H), 4.05-4.12 (m, 2H), 6.45-6.5 (t, 1H), 6.68 (s, 1H), 6.9 (s, 1H), 7.22 (s, 1H), 7.35-7.6 (m, 3H), 7.65 (s, 1H), 7.88 (s, 1H), 8.55 (s, 1H), 10.35 (s, 1H), 12.22 (s, 1H); Mass Spectrum:  $M+H^+$  486 and 488.

The 4-amino-7-(3-imidazol-1-ylpropylamino)-6-methoxyquinazoline used as a starting material was prepared from as follows :-

20 The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that 3-imidazol-1-ylpropylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-(3-imidazol-1-ylpropylamino)-  
6-methoxyquinazoline; NMR Spectrum: ( $CDCl_3$ ) 2.2-2.3 (m, 2H), 3.3-3.4 (m, 2H), 4.05 (s,  
25 3H), 4.1-4.15 (m, 2H), 5.04-5.13 (br t, 1H), 6.88 (s, 1H), 6.96 (s, 1H), 7.1 (s, 1H), 7.15-7.5 (m, 3H), 7.45 (s, 1H), 7.52 (s, 1H), 8.55 (s, 1H); Mass Spectrum:  $M+H^+$  472 and 474.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

[148] The reactants were heated to 45°C for 20 hours. The product gave the following data:  
30 NMR Spectrum: ( $CDCl_3$ ) 1.2-1.4 (m, 2H), 1.66-1.94 (m, 5H), 2.14 (s, 3H), 2.16 (s, 3H), 2.26 (s, 3H), 2.7 (m, 2H), 2.78 (s, 3H), 2.98 (s, 3H), 3.94 (s, 3H), 4.04 (d, 2H), 7.0 (d, 1H), 7.18 (d, 1H), 7.24 (s, 1H), 8.02 (s, 1H), 8.64 (s, 1H), 10.36 (s, 1H), 11.72 (s, 1H); Mass Spectrum:  $M+H^+$  521.

[149] The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.73 (m, 4H), 2.09 (m, 2H), 2.28 (s, 3H), 2.48 (br m, 4H), 2.57 (t, 2H), 3.35 (s, 3H), 4.18 (t, 2H), 5.24 (s, 1H), 7.08 (d, 2H), 7.19 (s, 1H), 7.27 (t, 1H), 7.42 (s, 1H), 8.61 (s, 1H), 9.72 (s, 1H), 12.19 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 470 and 472.

5 [150] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 450 and 452.

The 4-amino-7-(3-methoxypropylamino)-6-methoxyquinazoline used as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that  
10 3-methoxypropylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-(3-methoxypropylamino)-6-methoxyquinazoline.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

[151] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 421 and 423.

15 The 4-amino-7-(2-aminoethylamino)-6-methoxyquinazoline used as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that ethylenediamine was used in place of 1-methylpiperazine. There was thus obtained  
20 7-(2-aminoethylamino)-4-(2-bromo-4-fluorophenoxy)-6-methoxyquinazoline.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

[152] The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 491 and 493.

The 4-amino-7-[N-(2-diethylaminoethyl)-N-methylamino]-6-methoxyquinazoline used  
25 as a starting material was prepared from as follows :-

The procedure described in the first paragraph of the portion of Note [144] above which is concerned with the preparation of starting materials was repeated except that N-(2-diethylaminoethyl)-N-methylamine was used in place of 1-methylpiperazine. There was thus obtained 4-(2-bromo-4-fluorophenoxy)-7-[N-(2-diethylaminoethyl)-N-methylamino]-  
30 6-methoxyquinazoline.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] above to give the required starting material.

**Example 3** 1-(7-benzyloxy-6-methoxyquinazolin-4-yl)-3-(2,6-dichlorophenyl)urea

2,6-Dichlorophenyl isocyanate (0.745 g) was added to a solution of 4-amino-7-benzyloxy-6-methoxyquinazoline (0.279 g) in chloroform (10 ml) and the reaction mixture was stirred at ambient temperature for 16 hours. The resultant precipitate was isolated by  
5 filtration. There was thus obtained the title compound (0.343 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.96 (s, 3H), 5.32 (s, 2H), 7.35–7.60 (m, 10H), 8.1 (s, 1H), 8.69 (s, 1H), 10.65 (s, 1H), 12.09 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 467 & 469.

**Example 4** 1-(2,6-dichlorophenyl)-3-(6,7-dimethoxyquinazolin-4-yl)urea

10 Using an analogous procedure to that described in Example 3, 2,6-dichlorophenyl isocyanate was reacted with 4-amino-6,7-dimethoxyquinazoline (European Patent Application No. 30156, Chemical Abstract volume 95, abstract 187290) to give the title compound; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.96 (s, 3H), 7.31 (m, 2H), 7.38 (t, 1H), 7.5 (d, 2H), 7.6 (d, 2H), 8.43 (s, 1H), 8.7 (s, 1H), 10.61 (s, 1H), 12.09 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 393 & 395.

15

**Example 5** 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-methylurea

6-Methoxy-4-methylamino-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (0.195 g) was added to 2,6-dichlorophenyl isocyanate (0.3 g) under argon and the solids were mixed  
20 together using a spatula. The mixture was heated to 85°C with gentle mixing for 40 minutes. The mixture was cooled to ambient temperature, dissolved in a mixture of chloroform (15 ml) and methanol (5 ml) and purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained the title compound (0.016 g); NMR Spectrum:  
25 (CDCl<sub>3</sub>) 1.5 (m, 2H), 1.98 (m, 5H), 2.3 (s, 3H), 2.91 (d, 2H), 3.6 (s, 3H), 4.02 (s, 3H), 4.03 (d, 2H), 7.1 (t, 1H), 7.28 (s, 2H), 7.37 (d, 2H), 8.61 (s, 1H), 8.96 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 504.

The 6-methoxy-4-methylamino-7-(N-methylpiperidin-4-ylmethoxy)quinazoline used as a starting material was obtained as follows :-

30 A mixture of 4-chloro-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline (1 g) and methylamine (1M solution in THF; 20 ml) was heated with agitation in a Carius tube at 120°C for 16 hours. The Carius tube was cooled and opened and the reaction mixture was evaporated. The residue was partitioned between chloroform and a 2N aqueous sodium

hydroxide solution. The chloroform solution was dried over magnesium sulphate and evaporated and the resultant solid was washed with methyl tert-butyl ether (20 ml). There was thus obtained the required starting material (0.48 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.33 (m, 2H), 1.8 (m, 5H), 2.14 (s, 3H), 2.76 (d, 2H), 2.96 (d, 3H), 3.85 (s, 3H), 3.92 (d, 2H), 7.03 (s, 1H), 7.51 (s, 1H), 7.84 (q, 1H), 8.31 (s, 1H).

**Example 6** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-(2-methylbenzyl)urea

Using an analogous procedure to that described in Example 3, 2-methylbenzyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline. The resultant solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, methanol and a 1% aqueous ammonium hydroxide solution as eluent. There was thus obtained the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.39–1.56 (m, 2H), 1.84–2.04 (m, 5H), 2.29 (s, 3H), 2.39 (s, 3H), 2.9 (d, 2H), 3.92 (s, 3H), 4.03 (d, 2H), 4.66 (d, 2H), 7.21 (m, 4H), 7.34 (m, 2H), 8.6 (s, 1H), 8.74 (s, 1H), 10.44 (t, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

**Example 7** 1-(2,6-dichlorophenyl)-3-(thieno[3,2-*d*]pyrimidin-4-yl)urea

2,6-Dichlorophenyl isocyanate (0.075 g) was added to a mixture of 4-aminothieno[3,2-*d*]pyrimidine (Tetrahedron, 1971, 27, 487; 0.201 g) and acetonitrile (16 ml) and the resultant mixture was stirred at ambient temperature for 16 hours. The precipitate was isolated and washed in turn with diethyl ether and methanol. There was thus obtained the title compound (0.31 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 7.25 (t, 1H), 7.45 (d, 1H), 7.55 (d, 1H), 7.95 (d, 1H), 8.4 (s, 1H), 8.8 (s, 1H), 11.7 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 339 and 341; Elemental Analysis: Found C, 45.8; H, 2.4; N, 16.5; C<sub>13</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>4</sub>OS requires C, 46.03; H, 2.38; N, 16.52 %.

**Example 8** (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylic acid

Hydrogen chloride gas was bubbled during 3 hours through a stirred solution of tert-butyl (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylate (1.4 g) in methylene chloride (200 ml) which had been cooled in an ice-bath to 0°C. The mixture was evaporated and there was thus obtained the title compound as its hydrochloride salt;

(1.3 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 6.6 (d, 1H, J = 16Hz), 7.4 (t, 1H), 7.65 (d, 2H), 7.95 (d, 1H), 7.96 (s, 1H), 8.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 409, 411 and 413.

The *tert*-butyl (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylate used as a starting material was obtained as follows :-

5 A mixture of methyl 3-aminothiophene-2-carboxylate (94 g), formamidine acetic acid salt (187 g) and 2-hydroxyethyl methyl ether (1 L) was stirred and heated to reflux for 3 hours. The mixture was cooled to ambient temperature and water (400 ml) was added. The resultant solid was isolated, washed thoroughly with water and with diethyl ether and dried under vacuum. There was thus obtained 3,4-dihydrothieno[3,2-*d*]pyrimidin-4-one (65 g); NMR  
10 Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 7.4 (d, 1H), 8.15 (s, 1H), 8.18 (d, 2H); Mass Spectrum : M+Na<sup>+</sup> 175.

A mixture of a portion (20 g) of the material so obtained, thionyl chloride (250 ml) and DMF (1 ml) was heated to reflux for 2 hours. The mixture was evaporated. Toluene was added and the mixture was evaporated. The residual solid was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was washed  
15 in turn with water and brine, dried over magnesium sulphate and evaporated. The solid so obtained was triturated under petroleum ether (b.p. 60-80°C), re-isolated and dried under vacuum. There was thus obtained 4-chlorothieno[3,2-*d*]pyrimidine (18.5 g); NMR Spectrum: (CDCl<sub>3</sub>) 7.65 (d, 1H), 8.1 (d, 1H), 9.0 (s, 1H); Mass Spectrum: M<sup>+</sup> 170 and 172.

A portion (17 g) of the material so obtained was dissolved in DMF (100 ml). Sodium  
20 methylthiolate (9.1 g) was added and the mixture was stirred at ambient temperature for 1.5 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulphate and purified by column chromatography on silica using a 9:1 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 4-methylthiothieno[3,2-*d*]pyrimidine (16.5 g); NMR  
25 Spectrum: (CDCl<sub>3</sub>) 2.76 (s, 3H), 7.5 (d, 1H), 7.85 (d, 1H), 8.97 (s, 1H).

A portion (5.5 g) of the material so obtained was dissolved in THF (20 ml) and cooled to -78°C. A solution of lithium diisopropylamide [prepared using diisopropylamine (10.5 ml) and n-butyllithium (2.5M in THF; 30 ml)] was added and the mixture was stirred at -78°C for 1 hour. DMF (7 ml) was added and the mixture was allowed to warm to ambient temperature  
30 and was stirred for 16 hours. The resultant mixture was partitioned between ethyl acetate and a saturated aqueous ammonium chloride solution. The organic layer was evaporated and the residue was purified by column chromatography on silica using a 9:1 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 6-formyl-

4-methylthiothieno[3,2-*d*]pyrimidine (4.1 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.78 (s, 3H), 8.13 (s, 1H), 9.04 (s, 1H), 10.23 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 211.

tert-Butoxycarbonylmethylenetriphenylphosphorane (20.6 g) was added portionwise to a solution of 6-formyl-4-methylthiothieno[3,2-*d*]pyrimidine (9.6 g) in methylene chloride (500 ml) and the mixture was stirred at ambient temperature for 16 hours. The mixture was concentrated to half of its original volume and poured onto a column of silica. The column was eluted initially with methylene chloride followed by a 19:1 mixture of methylene chloride and ethyl acetate. The material so obtained was triturated under petroleum ether (b.p. 60-80°C), re-isolated and dried under vacuum. There was thus obtained tert-butyl (*E*)-3-(4-methylthiothieno[3,2-*d*]pyrimidin-6-yl)acrylate (12 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.54 (s, 9H), 2.76 (s, 3H), 6.42 (d, 1H, J = 15 Hz), 7.53 (s, 1H), 7.8 (d, 1H), 8.94 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 308.

A portion (2.9 g) of the material so obtained was dissolved in methylene chloride (200 ml) and m-chloroperoxybenzoic acid (70% ; 9.25 g) was added. The resultant mixture was stirred at ambient temperature for 2 hours. The mixture was washed with an aqueous sodium bisulphite solution. The organic layer was washed with a dilute (5%) aqueous sodium bicarbonate solution and with brine, dried over magnesium sulphate and evaporated. There was thus obtained tert-butyl (*E*)-3-(4-methylsulphonylthieno[3,2-*d*]pyrimidin-6-yl)acrylate (3.1 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.55 (s, 9H), 3.39 (s, 3H), 6.6 (d, 1H, J = 16 Hz), 7.71 (s, 1H), 7.85 (d, 1H), 9.3 (s, 1H).

A solution of the sulphone so obtained (3 g) in THF (100 ml) was cooled at 0°C and gaseous ammonia was bubbled through the solution for 2 hours. The mixture was evaporated and the residue was triturated under diethyl ether. The solid so obtained was purified by column chromatography on silica using a 49:1 mixture of methylene chloride and methanol as eluent. There was thus obtained tert-butyl (*E*)-3-(4-aminothieno[3,2-*d*]pyrimidin-6-yl)acrylate (1.7 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.55 (s, 9H), 5.25 (br s, 2H), 6.38 (d, 1H, J = 16 Hz), 7.51 (s, 1H), 7.76 (d, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 277.

A mixture of the material so obtained, 2,6-dichlorophenyl isocyanate (1.41 g) and methylene chloride (250 ml) was stirred at ambient temperature for 3 hours. Water was added and the organic layer was separated, washed with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 49:1 mixture of methylene chloride and methanol as eluent. There was thus obtained tert-butyl (*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}acrylate

(1.5 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.57 (s, 9H), 6.29 (d, 1H, J = 16 Hz), 7.3 (t, 1H), 7.53 (d, 2H), 7.55 (s, 1H), 7.74 (d, 1H), 8.8 (s, 1H), 9.95 (br s, 1H), 11.8 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 465, 467 & 469.


**5 Example 9** (E)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-d]pyrimidin-6-yl}-N-(2-piperidinoethyl)acrylamide

Diphenylphosphoryl azide (0.085 ml) was added to a mixture of (E)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-d]pyrimidin-6-yl} acrylic acid hydrochloride salt (0.11 g), 2-piperidinoethylamine (0.064 g), triethylamine (0.07 ml) and 10 DMF (1.5 ml). The mixture was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. The material so obtained was triturated under diethyl ether, isolated, washed with diethyl ether and dried under vacuum. There was thus obtained the title compound (0.087 g); NMR Spectrum: (DMSO-d<sub>6</sub> and CF<sub>3</sub>COOD) 1.3-1.5 (m, 1H), 1.6-1.8 (m, 4H), 1.85 (d, 2H), 2.95 (t, 2H), 3.2 (t, 2H), 3.55 (d, 2H), 3.6 (t, 2H), 6.82 (d, 1H, J = 16 Hz), 7.4 (t, 1H), 7.6 (d, 1H), 7.86 (s, 1H), 7.86 (d, 1H), 8.95 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 519 and 521.

**Example 10**

20 Using an analogous procedure to that described in Example 9, the appropriate amine was reacted with (E)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-d]pyrimidin-6-yl} acrylic acid to give the compounds described in Table II.

**Table II**



25

No.	R <sup>a</sup>	R <sup>b</sup>	Note
1	2-dimethylaminoethyl	hydrogen	(a)

2	3-dimethylaminopropyl	hydrogen	(b)
3	2-pyrrolidin-1-ylethyl	hydrogen	(c)
4	3-(2-oxopyrrolidin-1-yl)propyl	hydrogen	(d)
5	3-morpholinopropyl	hydrogen	(e)
6	3-(4-methylpiperazin-1-yl)propyl	hydrogen	(f)
7	3-imidazol-1-ylpropyl	hydrogen	(g)
8	4-pyridylmethyl	hydrogen	(h)
9	2-(2-pyridyl)ethyl	hydrogen	(i)
10	2-(2-pyridyl)ethyl	methyl	(j)

### Notes

- (a) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.9 (s, 6H), 3.25 (t, 2H), 3.6 (t, 2H), 6.9 (d, 1H, J = 16 Hz), 7.42 (t, 1H), 7.65 (d, 2H), 7.85 (d, 1H), 7.88 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 479 and 481.
- (b) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.8-1.9 (m, 2H), 2.81 (s, 3H), 3.15 (m, 2H), 3.3 (t, 2H), 6.84 (d, 1H, J = 19 Hz), 7.45 (t, 1H), 7.6 (d, 2H), 7.81 (d, 1H), 7.85 (s, 1H), 9.02 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 493 and 495.
- (c) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.8-1.95 (m, 2H), 1.95-2.1 (m, 2H), 3.0-3.15 (m, 2H), 3.3 (t, 2H), 3.55 (t, 2H), 3.55-3.7 (m, 2H), 6.8 (d, 1H), 7.42 (t, 1H), 7.6 (d, 2H), 7.82 (d, 1H), 7.84 (s, 1H), 8.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 505 and 507.
- (d) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.65-1.75 (m, 2H), 1.9-2.0 (m, 2H), 2.3 (t, 2H), 3.25 (t, 2H), 3.3 (t, 2H), 3.4 (t, 2H), 6.25 (d, 1H, J = 16 Hz), 7.42 (t, 1H), 7.62 (d, 2H), 7.81 (d, 1H), 7.85 (s, 1H), 9.12 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.
- (e) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.85-2.0 (m, 2H), 3.0-3.25 (m, 4H), 3.3 (t, 2H), 3.5 (d, 2H), 3.7 (t, 2H), 4.0 (d, 2H), 6.9 (d, 1H, J = 16 Hz), 7.45 (t, 1H), 7.61 (d, 2H), 7.85 (d, 1H), 7.87 (s, 1H), 9.08 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 535 and 537.
- (f) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 1.85-2.0 (m, 2H), 2.95 (s, 3H), 3.2-3.4 (m, 6H), 3.4-4.0 (br m, 6H), 6.85 (d, 1H, J = 14 Hz),

7.42 (t, 1H), 7.65 (d, 2H), 7.82 (d, 1H), 7.85 (s, 1H), 9.0 (s, 1H); Mass Spectrum:  $M+H^+$  548 and 550.

(g) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 2.0-2.1 (m, 2H), 3.25 (t, 2H), 4.25 (t, 2H), 6.75 (d, 1H, J = 15 Hz), 7.2-7.3 (d, 1H), 7.4 (t, 2H), 7.6  
5 (d, 2H), 7.85 (m, 2H), 8.9 (s, 1H), 9.2 (s, 1H); Mass Spectrum:  $M+H^+$  516.

(h) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 4.75 (br s, 2H), 6.95 (d, 1H, J = 15 Hz), 7.4 (t, 1H), 7.6 (d, 1H), 7.85 (s, 1H), 7.87 (d, 1H), 8.05 (d, 2H), 8.9 (d, 2H), 8.93 (s, 1H); Mass Spectrum:  $M+H^+$  499 and 501.

(i) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 3.25  
10 (t, 2H), 3.7 (t, 2H), 6.8 (d, 1H, J = 15 Hz), 7.42 (t, 1H), 7.62 (d, 2H), 7.75 (d, 1H), 7.83 (s, 1H), 8.0 (t, 1H), 8.05 (d, 1H), 8.58 (t, 1H), 8.9 (d, 1H), 9.0 (s, 1H); Mass Spectrum:  $M+H^+$  513 and 515.

(j) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> and CF<sub>3</sub>COOD) 3.4 (s, 3H), 5.0 (s, 2H), 7.35-7.5 (m, 2H), 7.61 (d, 2H), 7.8 (d, 1H), 7.98 (s, 1H), 7.85-8.1 (m, 2H),  
15 8.6 (t, 1H), 8.9 (d, 1H), 9.0 (s, 1H); Mass Spectrum:  $M+H^+$  513 and 515.

**Example 11** 1-benzyl-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea

Using an analogous procedure to that described in Example 1 except that the reaction  
20 mixture was heated to 35°C for 16 hours, benzyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>): 1.3-1.5 (m, 2H), 1.8-1.9 (m, 4H), 1.95 (t, 1H), 2.2 (s, 3H), 2.8 (br d, 2H), 3.9 (br s, 3H), 4.0 (br d, 2H), 4.5 (br d, 2H), 7.2-7.3 (m, 2H), 7.3-7.4 (m, 4H), 8.0 (br s, 1H), 8.55 (br s, 1H), 10.2-10.5 (br s, 1H), 10.4 (t, 1H); Mass Spectrum:  $M+H^+$  436.

25


**Example 12** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-phenethylurea

Using an analogous procedure to that described in Example 3, phenethyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give  
30 the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.48 (m, 2H), 1.98 (m, 5H), 2.29 (s, 3H), 2.91 (m, 4H), 3.7 (q, 2H), 4.02 (d, 5H), 7.28 (m, partially obscured by CHCl<sub>3</sub> peak), 8.47 (s, 1H), 8.65 (s, 1H), 10.1 (s, 1H); Mass Spectrum:  $M+H^+$  450.

**Example 13**

Using an analogous procedure to that described in Example 1 except that, unless otherwise stated, chloroform was used in place of methylene chloride as the reaction solvent, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the

5 compounds described in Table III.

**Table III**

No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-chloro	(a)
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	3,4-dichloro	(b)
3	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	3,5-dichloro	(c)
4	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-bromo	(d)
5	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	4-nitro	(e)

10 **Notes**

(a) DMF was used in place of methylene chloride as the reaction solvent. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.48 (m, 2H), 1.97 (m, 5H), 2.29 (s, 3H), 2.91 (m, 2H), 3.81 (s, 3H), 4.04 (d, 2H), 7.25 (s, 2H), 7.3 (d, 2H), 7.57 (d, 2H), 8.73 (s, 1H), 8.91 (s, 1H), 12.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 456 and 458.

15 (b) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.51 (m, 2H), 1.92 (m, 5H), 2.3 (s, 3H), 2.92 (d, 2H), 3.9 (s, 3H), 4.03 (d, 2H), 7.2 (s, 1H), 7.24 (s, partially obscured by CHCl<sub>3</sub> peak), 7.41 (m, 2H), 7.82 (s, 1H), 8.55 (s, 1H), 8.74 (s, 1H), 12.55 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 490 and 492.

(c) DMF was used in place of methylene chloride as the reaction solvent. The product

20 gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.48 (m, 2H), 1.95 (m, 5H), 2.28 (s, 3H),

2.95 (d, 2H), 3.91 (s, 3H), 4.03 (d, 2H), 7.11 (s, 1H), 7.26 (s, 2H), 7.58 (s, 2H), 8.63 (s, 1H), 8.75 (s, 1H), 12.7 (s, 1H); Mass Spectrum:  $M+H^+$  490 and 492.

(d) Methylene chloride was used as the reaction solvent and the reaction mixture was heated to 35°C for 16 hours. The product gave the following data: NMR Spectrum:

5 (DMSO<sub>d</sub><sub>6</sub>) 1.2-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.8 (d, 2H), 3.9 (br s, 3H), 4.0 (br d, 2H), 7.2 (s, 1H), 7.4-7.45 (m, 2H), 7.5-7.55 (m, 2H), 7.6-7.7 (m, 2H), 8.0 (br s, 1H), 8.7 (br s, 1H); Mass Spectrum:  $M+H^+$  500 and 502.

(e) Methylene chloride was used as the reaction solvent and the reaction mixture was heated to 35°C for 16 hours. The product gave the following data: NMR Spectrum:

10 (DMSO<sub>d</sub><sub>6</sub>) 1.3-1.4 (m, 2H), 1.7-1.8 (m, 4H), 1.85 (t, 1H), 2.1 (s, 3H), 2.7 (d, 2H), 3.9 (s, 3H), 4.0 (br d, 2H), 7.2 (s, 1H), 7.8 (d, 2H), 7.9 (s, 1H), 8.1 (d, 2H), 8.6 (br s, 1H), 10.2-10.5 (br s, 1H), 12.3-12.7 (br s, 1H); Mass Spectrum:  $M+H^+$  467.

**Example 14** 1-[6-methoxy-7-(*N*-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-

15 **3-(*trans*-2-phenylcyclopropyl)urea**

*trans*-2-Phenylcyclopropyl isocyanate (0.2 ml) was added to a stirred mixture of 4-amino-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (0.1 g) and chloroform (3 ml) and the resultant mixture was stirred at ambient temperature for 20 hours. The reaction mixture was diluted with chloroform (3 ml) and tris-(2-aminoethyl)amine polystyrene resin  
20 (0.5 g) was added. The mixture was stirred at ambient temperature for 1 hour. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and 2M methanolic ammonia as eluent. There was thus obtained the title compound (0.11 g);  
NMR Spectrum: (CDCl<sub>3</sub>) 1.24-1.38 (m, 2H), 1.41-1.57 (m, 2H), 1.87-2.05 (m, 5H), 2.21 (m,  
25 1H), 2.3 (s, 3H), 2.91 (d, 2H), 3.05 (m, 1H), 3.97 (s, 3H), 4.04 (d, 2H), 7.1-7.26 (m, 6H partially obscured by CHCl<sub>3</sub> peak), 7.34 (m, 1H), 8.66 (s, 1H), 8.72 (s, 1H), 10.31 (s, 1H);  
Mass Spectrum:  $M+H^+$  462.

**Example 15** 1-[6-methoxy-7-(*N*-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-

30 **3-[(*S*)-(-)- $\alpha$ -methylbenzyl]urea**

Using an analogous procedure to that described in Example 14, (*S*)-(-)- $\alpha$ -methylbenzyl isocyanate was reacted with 4-amino-6-methoxy-

7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.56 (m, 2H), 1.61 (d, 3H), 1.84–2.05 (m, 5H), 2.31 (s, 3H), 2.91 (d, 2H), 3.88 (s, 3H), 4.04 (d, 2H), 5.2 (m, 1H), 7.23 (d, 2H), 7.3–7.41 (m, 5H), 8.66 (s, 1H), 8.7 (s, 1H), 10.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

5

**Example 16** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-[(R)-(+)- $\alpha$ -methylbenzyl]urea

Using an analogous procedure to that described in Example 14,

(R)-(+)- $\alpha$ -methylbenzyl isocyanate was reacted with 4-amino-6-methoxy-

10 7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.39–1.56 (m, 2H), 1.64 (d, 3H), 1.86–2.05 (m, 5H), 2.3 (s, 3H), 2.9 (d, 2H), 3.9 (s, 3H), 4.01 (d, 2H), 5.19 (m, 1H), 7.24 (d, 2H), 7.32–7.41 (m, 5H), 8.44 (s, 1H), 8.67 (s, 1H), 10.5 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

15 **Example 17** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-[1-(1-naphthyl)ethyl]urea

Using an analogous procedure to that described in Example 14,

1-(1-naphthyl)ethyl isocyanate was reacted with 4-amino-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline to give the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.41–1.57 (m, 2H), 1.76 (m, partially obscured by water peak), 1.86–2.05 (m, 5H), 2.02 (s, 3H), 2.91 (s, 2H), 3.87 (s, 3H), 4.02 (d, 2H), 5.95 (s, 1H), 7.19 (s, 1H), 7.23 (s, 1H), 7.39–7.52 (m, 3H), 7.6 (d, 1H), 7.71 (d, 1H), 7.84 (m, 1H), 8.12 (m, 1H), 8.57 (s, 1H), 8.64 (s, 1H), 10.67 (t, 1H); Mass Spectrum: M+H<sup>+</sup> 500.

25 **Example 18** 1-(3-cyano-6,7-dimethoxyquinolin-4-yl)-3-(2,6-dichlorophenyl)urea

A solution of 4-amino-3-cyano-6,7-dimethoxyquinoline (0.115 g) in DMF (2 ml) was added to a stirred mixture of sodium hydride (50% dispersion in mineral oil; 0.04 g) and DMF (3 ml) and the mixture was stirred at ambient temperature for 20 minutes. 2,6-Dichlorophenyl isocyanate (0.17 g) was added and the mixture was stirred at ambient temperature for 30 20 hours. A second portion of sodium hydride dispersion (0.08 g) was added followed, after 20 minutes, by more 2,6-dichlorophenyl isocyanate (0.3 g). The reaction mixture was stirred for a further 2 hours. Methanol (1 ml) was added and the mixture was partitioned between

ethyl acetate (50 ml) and water (10 ml). The organic layer was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of ethyl acetate and methanol as eluent. There was thus obtained the title compound (0.03 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 4.05 (s, 6H), 7.4-7.8 (m, 4H), 8.08 (s, 2H), 9.22 (s, 1H); Mass

5 Spectrum: M+H<sup>+</sup> 417 & 419.


The 4-amino-3-cyano-6,7-dimethoxyquinoline used as a starting material was prepared as follows :-

A mixture of 4-chloro-3-cyano-6,7-dimethoxyquinoline (International Patent Application WO 98/43960; 1.24 g) and a 1M solution of ammonia gas in isopropanol (20 ml)  
 10 was sealed in a Carius tube and heated to 120°C for 16 hours. The mixture was cooled to ambient temperature. A saturated aqueous sodium bicarbonate solution (50 ml) was added and the mixture was stirred for 15 minutes. The precipitate was isolated, washed with water (50 ml) and dried. There was thus obtained the required starting material (0.93 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.88 (s, 3H), 3.9 (s, 3H), 7.2 (s, 1H), 7.63 (s, 2H), 7.69 (s, 1H), 8.38 (s,  
 15 1H); Mass Spectrum: M+H<sup>+</sup> 230.

### Example 19

Using an analogous procedure to that described in Example 14, the appropriate 4-aminoquinazoline was, unless otherwise stated, reacted with (R)-(+)-α-methylbenzyl  
 20 isocyanate to give the compounds described in Table IV.

Table IV



No.	R <sup>6</sup>	R <sup>7</sup>	Z	Note
1	methoxy	2-pyrrolidin-1-ylethoxy	O	(a)
2	methoxy	2-piperidinoethoxy	O	(b)
3	methoxy	2-piperidinoethoxy	O	(c)
4	methoxy	2-morpholinoethoxy	O	(d)

5	methoxy	2-(2-oxoimidazolidin-1-yl)ethoxy	O	(e)
6	methoxy	3-pyrrolidin-1-ylpropoxy	O	(f)
7	methoxy	3-piperidinopropoxy	O	(g)
8	methoxy	3-morpholinopropoxy	O	(h)
9	methoxy	3-(4-methylpiperazin-1-yl)propoxy	O	(i)
10	methoxy	2-(2-methoxyethoxy)ethoxy	O	(j)
11	3-piperidinopropoxy	methoxy	O	(k)
12	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	S	(l)

### Notes

(a) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.63 (d, 3H), 1.87 (s, 4H), 2.74 (s, 4H), 3.07 (t, 2H), 3.98 (s, 3H), 4.34 (t, 2H), 5.18 (m, 1H), 7.19–7.4 (m, 7H), 8.68 (d, 2H), 10.54 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 436.

(b) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (m, 2H), 1.66 (d, 7H), 2.54 (t, 4H), 2.9 (t, 2H), 3.89 (s, 3H), 4.3 (t, 2H), 5.19 (m, 1H), 7.2–7.4 (m, 7H), 8.68 (s, 1H), 8.8 (s, 1H), 10.55 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

(c) (S)-(-)- $\alpha$ -Methylbenzyl isocyanate was used in place of (R)-(+)- $\alpha$ -methylbenzyl isocyanate. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.47 (m, 2H), 1.62 (m, 7H), 2.56 (s, 4H), 2.9 (t, 2H), 3.88 (s, 3H), 4.31 (t, 2H), 5.17 (m, 1H), 7.19–7.41 (m, 7H), 8.68 (s, 1H), 8.8 (s, 1H), 10.55 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.

(d) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4 (d, 3H), 2.65 (t, 4H), 3.05 (t, 2H), 3.75 (t, 4H), 3.87 (s, 3H), 4.31 (t, 2H), 5.18 (m, 1H), 7.14 (d, 2H), 7.19–7.41 (m, 5H), 8.68 (s, 1H), 8.85 (s, 1H), 10.54 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 452.

(e) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.63 (d, 3H), 3.46 (t, 2H), 3.75 (m, 4H), 3.93 (s, 3H), 4.29 (t, 2H), 4.61 (s, 1H), 5.17 (m, 1H), 7.2–7.41 (m, 7H), 8.57 (s, 1H), 8.67 (s, 1H), 10.5 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 451.

(f) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.62 (d, 3H), 1.87 (s, 4H), 2.2 (m, 2H), 2.7 (s, 4H), 2.8 (t, 2H), 3.91 (s, 3H), 4.24 (t, 2H), 5.18 (m, 1H), 7.2–7.27 (m, 2H), 7.29–7.32 (m, 5H), 8.44 (s, 1H), 8.67 (s, 1H), 10.47 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 450.


(g) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.39 (m, 2H), 1.62 (d, 3H), 1.9 (s, 4H), 2.39 (t, 2H), 2.8–3.01 (br m, 6H), 3.9 (s, 3H), 4.24 (t, 2H), 5.14 (m, 1H), 7.1–7.44 (m, 7H), 8.45 (s, 1H), 8.65 (s, 1H), 10.45 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 464.

- (h) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.62 (d, 3H), 2.13 (m, 2H), 2.59 (m, 6H), 3.85 (t, 4H), 3.91 (s, 3H), 4.26 (t, 2H), 5.18 (m, 1H), 7.2–7.4 (m, 7H), 8.5 (s, 1H), 8.77 (s, 1H), 10.5 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 466.
- (i) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.62 (d, 3H), 1.76 (s, 4H), 2.1 (m, 2H), 2.31 (s, 3H), 2.4–2.6 (m, 6H), 3.92 (s, 3H), 4.24 (t, 2H), 5.19 (m, 1H), 7.21–7.41 (m, 7H), 8.49 (s, 1H), 8.68 (s, 1H), 10.5 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 479.
- (j) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.59 (d, 3H), 3.39 (s, 3H), 3.6 (m, 2H), 3.76 (m, 2H), 3.87 (s, 3H), 4.0 (t, 2H), 4.36 (t, 2H), 5.21 (m, 1H), 7.19–7.39 (m, 7H), 8.69 (s, 1H), 8.97 (s, 1H), 10.58 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 441.
- (k) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.38 (br s, 2H), 1.53 (m, 6H), 2.0 (m, 2H), 3.3–3.53 (br s, 6H), 3.95 (s, 3H), 4.17 (t, 2H), 5.04 (m, 1H), 7.25 (s, 1H), 7.37 (br m, 5H), 8.02 (s, 1H), 8.65 (s, 1H), 10.1 (s, 1H), 10.5 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 464.
- (l) The 4-aminoquinazoline was reacted with (R)-(+)- $\alpha$ -methylbenzyl isothiocyanate. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.42–1.57 (m, 2H), 1.71 (d, 3H), 1.86–2.06 (m, 5H), 2.31 (s, 3H), 2.92 (d, 2H), 4.02 (m, 5H), 5.69 (m, 1H), 6.98 (s, 1H), 7.24–7.31 (m, 2H), 7.34–7.47 (m, 4H), 8.54 (s, 1H), 8.65 (s, 1H), 12.57 (d, 1H); Mass Spectrum: M+H<sup>+</sup> 466.

## 20 Example 20

Using an analogous procedure to that described in Example 5, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the compounds described in Table V.

**Table V**



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	3-(4- <u>tert</u> -butoxycarbonylamino)methylpiperidin-	2,6-dichloro	(a)

		1-yl)propoxy		
2	methoxy	3-(4- <u>tert</u> -butoxycarbonylaminomethylpiperidin-1-yl)propoxy	2,6-difluoro	(b)
3	methoxy	3-(4- <u>tert</u> -butoxycarbonylaminomethylpiperidin-1-yl)propoxy	2,6-dimethyl	(c)
4	methoxy	3-(4- <u>tert</u> -butoxycarbonylaminomethylpiperidin-1-yl)propoxy	2-chloro-6-methyl	(d)

### Notes

(a) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.2-1.35 (m, 2H), 1.43 (s, 9H), 1.6-1.72 (m, 3H), 1.94 (t, 2H), 2.0-2.15 (m, 2H), 2.52 (t, 2H), 2.9 (d, 2H), 3.02 (t, 2H), 3.6 (s, 3H), 4.23 (t, 2H), 4.6 (s, 1H), 7.1-7.3 (m, 3H), 7.38-7.43 (m, 2H), 8.7 (s, 1H), 9.38 (s, 1H), 12.38 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 633 and 635.

The 4-amino-7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazoline used as a starting material was prepared as follows :-

A mixture of 4-(4-bromo-2-fluorophenoxy)-7-(3-bromopropoxy)-6-methoxyquinazoline (0.486 g), 4-(tert-butoxycarbonylaminomethyl)piperidine (Chemical Abstracts Registry No. 135632-53-0, for example US Patent No. 5,864,039; 0.252 g), potassium carbonate (0.7 g) and DMF (10 ml) was stirred at 45°C for 20 hours. The solvent was evaporated and the residue was stirred with water (20 ml). The resultant solid was isolated and purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2N solution of ammonia in methanol as eluent. There was thus obtained 4-(4-bromo-2-fluorophenoxy)-7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazoline as a resinous solid (0.4 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.22-1.4 (m, 2H), 1.44 (s, 9H), 1.69 (m, 3H), 1.98 (t, 2H), 2.12 (m, 2H), 2.56 (t, 2H), 2.9-3.1 (m, 4H), 4.04 (s, 3H), 4.26 (t, 2H), 4.6 (br s, 1H), 7.22 (m, 1H), 7.3-7.45 (m, 3H), 7.51 (s, 1H), 8.67 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 619 and 621.

A mixture of a portion (0.2 g) of the material so obtained and a saturated solution of ammonia in isopropanol (32 ml) was sealed in a Carius tube and heated at 110°C for 20 hours. The mixture was cooled to ambient temperature and the solvent was evaporated. The residue was stirred with a mixture of a 2N aqueous sodium hydroxide solution (5 ml), methylene chloride (18 ml) and methanol (2 ml) for 1 hour. The solid was isolated and dried. There was

thus obtained the required starting material (0.046 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.0-1.15 (m, 2H), 1.4 (m, 1H), 1.45 (s, 9H), 1.56 (d, 2H), 1.75-1.85 (m, 4H), 2.39 (d, 2H), 2.74-2.9 (m, 4H), 3.85 (s, 3H), 4.09 (t, 2H), 6.75 (br s, 1H), 7.02 (s, 1H), 7.32 (s, 2H), 7.54 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 446.

- 5 (b) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.0-1.2 (m, 2H), 1.25-1.3 (m, 1H), 1.35 (s, 9H), 1.58 (d, 2H), 1.8-2.0 (m, 4H), 2.42 (t, 2H), 2.7-2.9 (m, 4H), 3.95 (s, 3H), 4.21 (t, 2H), 6.76 (t, 1H), 7.1-7.5 (m, 4H), 8.04 (s, 1H), 8.67 (s, 1H), 10.6 (s, 1H), 11.8 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 601.
- (c) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.2-1.4 (m, 3H), 1.43  
10 (s, 9H), 1.9-2.15 (m, 4H), 2.33 (s, 6H), 2.52 (t, 2H), 2.92 (d, 4H), 3.02 (t, 2H), 3.38 (s, 3H), 4.21 (t, 2H), 4.6 (s, 1H), 7.05-7.15 (m, 4H), 7.48 (s, 1H), 8.66 (s, 1H), 9.64 (s, 1H), 11.9 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 593.
- (d) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.22-1.35 (m, 3H), 1.42 (s, 9H), 1.7 (m, 2H), 1.95 (t, 2H), 2.09 (m, 2H), 2.35 (s, 3H), 2.52 (t, 2H), 2.91 (d, 2H),  
15 3.02 (t, 2H), 3.5 (s, 3H), 4.22 (t, 2H), 4.6 (s, 1H), 7.17 (m, 2H), 7.25-7.35 (m, 2H), 7.46 (s, 1H), 8.69 (s, 1H), 9.54 (s, 1H), 12.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 613 and 615.

**Example 21** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-dichlorophenyl)urea

- 20 A mixture of 1-{7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-dichlorophenyl)urea (0.075 g), trifluoroacetic acid (0.35 ml) and chloroform (1.5 ml) was stirred at ambient temperature for 40 minutes. The mixture was evaporated and the residue was stirred under a 1N aqueous sodium hydroxide solution (3 ml) for 1 hour. The resultant solid was isolated and dried. There was thus  
25 obtained the title compound (0.037 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.12 (m, 3H), 1.62-1.7 (m, 2H), 1.9 (t, 2H), 2.0 (m, 4H), 2.38-2.54 (m, 4H), 2.92 (m, 2H), 3.3 (m, partially obscured by a water signal), 3.95 (s, 3H), 4.26 (t, 2H), 7.28 (s, 1H), 7.41 (t, 1H), 7.62 (d, 2H), 8.06 (s, 1H), 8.66 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 533 and 535.

- 30 **Example 22** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-difluorophenyl)urea

Using an analogous procedure to that described in Example 21,  
1-{7-[3-(4-tert-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-

4-yl}-3-(2,6-difluorophenyl)urea was reacted with trifluoroacetic acid to give the title compound; NMR Spectrum: (DMSO-d<sub>6</sub>) 1.0-1.4 (m, 3H), 1.7 (d, 2H), 1.9-2.1 (m, 6H), 2.4 (m, 2H), 2.9 (d, 2H), 3.3 (s, partially obscured by a water signal), 4.0 (s, 3H), 4.24 (t, 3H), 5.0-7.0 (br m, 1H), 7.2-7.4 (m, 4H), 8.05 (s, 1H), 8.68 (s, 1H), 11.75 (s, 1H); Mass Spectrum: M+H<sup>+</sup>

5 501.

**Example 23** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-dimethylphenyl)urea

Using an analogous procedure to that described in Example 21,

10 1-{7-[3-(4-~~tert~~-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2,6-dimethylphenyl)urea was reacted with trifluoroacetic acid to give the title compound; NMR Spectrum: (DMSO-d<sub>6</sub>) 1.0-2.0 (m, 9H), 2.23 (s, 6H), 2.4 (m, 2H), 2.7-2.9 (m, 4H), 3.1-3.5 (partially obscured by a water signal), 3.93 (s, 3H), 4.18 (t, 2H), 6.9-7.15 (m, 4H), 7.23 (s, 1H), 8.03 (s, 1H), 8.62 (s, 1H), 11.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 493.

15

**Example 24** 1-{7-[3-(4-aminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-4-yl}-3-(2-chloro-6-methylphenyl)urea

Using an analogous procedure to that described in Example 21,


1-{7-[3-(4-~~tert~~-butoxycarbonylaminomethylpiperidin-1-yl)propoxy]-6-methoxyquinazolin-20 4-yl}-3-(2-chloro-6-methylphenyl)urea was reacted with trifluoroacetic acid to give the title compound; NMR Spectrum: (DMSO-d<sub>6</sub>) 1.0-1.3 (m, 3H), 1.63 (d, 2H), 1.7-2.0 (m, 4H), 2.28 (s, 3H), 2.4 (m, 2H), 2.86 (d, 2H), 3.1-3.5 (partially obscured by a water signal) 3.94 (s, 3H), 4.19 (t, 2H), 7.1-7.4 (m, 4H), 8.06 (s, 1H), 8.66 (s, 1H), 11.85 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 513 and 515.

25

**Example 25**

Using an analogous procedure to that described in Example 1, the appropriate 4-aminoquinazoline was reacted with the appropriate isocyanate to give the compounds described in Table VI.

Table VI



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	3-morpholinopropoxy	methoxy	2-methyl	(a)
2	3-morpholinopropoxy	methoxy	2,6-dichloro	(b)
3	3-morpholinopropoxy	methoxy	2,6-difluoro	(c)
4	3-morpholinopropoxy	methoxy	2,6-dimethyl	(d)
5	3-piperidinopropoxy	methoxy	2,6-dichloro	(e)
6	3-piperidinopropoxy	methoxy	2,6-difluoro	(f)
7	3-piperidinopropoxy	methoxy	2,6-dimethyl	(g)
8	2-pyrrolidin-1-ylethoxy	methoxy	2,6-dichloro	(h)
9	<u>N</u> -(3-morpholinopropyl)carbamoyl	methoxy	2,6-dimethyl	(i)
10	2-(2-methoxyethoxy)ethoxy	methoxy	2,6-dichloro	(j)
11	2-(2-methoxyethoxy)ethoxy	methoxy	2,6-dimethyl	(k)

## 5 Notes

- (a) The reaction product was dissolved in methylene chloride and treated with a saturated solution of hydrogen chloride gas in diethyl ether. The hydrochloride salt so obtained gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 2.35 (m, 2H), 2.45 (s, 3H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.75 (t, 2H), 4.0 (m, 2H), 4.05 (s, 3H), 4.4 (m, 2H), 7.1 (m, 1H), 7.3 (m, 2H), 7.5 (s, 1H), 7.95 (d, 1H), 8.45 (s, 1H), 9.15 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 452.

The 4-amino-7-methoxy-6-(3-morpholinopropoxy)quinazoline used as a starting material was prepared as follows :-

- A mixture of 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline (International Patent Application WO 96/33980,

Example 1 therein; 6 g) and 6N aqueous hydrochloric acid solution (120 ml) was stirred and heated to reflux for 6 hours. The mixture was cooled to 0°C and carefully, with cooling, was neutralised by the addition of concentrated aqueous ammonium hydroxide solution. The resultant precipitate was isolated, washed in turn with a dilute aqueous ammonium hydroxide solution and with water and dried under vacuum. There was thus obtained 7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one (4.2 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 2.4 (m, 6H), 3.59 (t, 4H), 3.75 (t, 2H), 3.9 (s, 3H), 4.12 (t, 2H), 7.12 (s, 1H), 7.43 (s, 1H), 7.98 (s, 1H), 12.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 320.

A mixture of a portion (0.99 g) of the material so obtained, thionyl chloride (10 ml) and DMF (0.1 ml) was stirred and heated to 80°C for 1.5 hours. The mixture was cooled to ambient temperature, toluene (10 ml) was added and the mixture was evaporated. The residue was partitioned between ethyl acetate and water (the acidity of the aqueous layer being adjusted to pH 7.5 by the addition of 2N aqueous sodium hydroxide solution). The organic layer was washed with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 9:1 mixture of methylene chloride and methanol as eluent. The solid so obtained was triturated under hexane, re-isolated and washed with diethyl ether. There was thus obtained 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline (0.614 g); NMR Spectrum: (CDCl<sub>3</sub>) 2.12 (m, 2H), 2.5 (br s, 4H), 2.59 (t, 2H), 3.73 (t, 4H), 4.05 (s, 3H), 4.27 (t, 2H), 7.33 (s, 1H), 7.4 (s, 1H), 8.86 (s, 1H).

A mixture of 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline (1.6 g) and isopropanol (50 ml) was placed in a Carius tube which was cooled to -78°C prior to the addition of liquid ammonia (10 ml). The Carius tube was sealed and heated to 130°C for 20 hours. The Carius tube was cooled to ambient temperature, opened and the mixture was evaporated. The residue was triturated under diethyl ether. There was thus obtained 4-amino-7-methoxy-6-(3-morpholinopropoxy)quinazoline (containing 2.9 equivalents of ammonium chloride; 1.54 g) which was used without further purification. A portion of the material was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and methanol as eluent. The purified product gave the following data :- NMR Spectrum: (DMSO-d<sub>6</sub>) 1.95 (m, 2H), 2.5 (m, 6H), 3.6 (m, 4H), 3.9 (s, 3H), 4.1 (m, 2H), 7.05 (s, 1H), 7.4 (br s, 2H), 7.6 (s, 1H), 8.25 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 319.

(b) The product gave the following data: NMR Spectrum: 2.35 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.0 (m, 2H), 4.05 (s, 3H), 4.35 (m, 2H), 7.45 (m, 2H), 7.65 (m, 2H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum:  $M+H^+$  506 and 508.

(c) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 2.3 (m, 2H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.0 (m, 2H), 4.05 (m, 5H), 4.3 (m, 2H), 7.25 (m, 2H), 7.4 (m, 2H), 8.25 (s, 1H), 9.0 (s, 1H); Mass Spectrum:  $M+H^+$  474.

(d) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub> + CF<sub>3</sub>CO<sub>2</sub>D) 2.35 (m, 8H), 3.15 (m, 2H), 3.35 (m, 2H), 3.55 (d, 2H), 3.7 (t, 2H), 4.0 (m, 2H), 4.05 (s, 3H), 4.35 (m, 2H), 7.2 (m, 2H), 7.5 (s, 1H), 8.3 (s, 1H), 9.05 (s, 1H); Mass Spectrum:  $M+H^+$  466.

10 (e) The product gave the following data: NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.4 (br s, 2H), 1.55 (br s, 4H), 2.04 (br s, 2H), 3.26-3.48 (m, 6H), 3.95 (s, 3H), 4.20 (t, 2H), 7.32 (s, 1H), 7.39 (t, 1H), 7.56 (m, 2H), 8.08 (s, 1H), 8.69 (s, 1H), 10.64 (s, 1H), 12.08 (s, 1H); Mass Spectrum:  $M+H^+$  504 and 506.

The 4-amino-7-methoxy-6-(3-piperidinopropoxy)quinazoline used as a starting  
15 material was prepared as follows :-

A mixture of 6-acetoxy-7-methoxyquinazolin-4-one (International Patent Application WO 96/15118, Example 39 thereof; 15 g), thionyl chloride (215 ml) and DMF (4.3 ml) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and the thionyl chloride was evaporated. The material so obtained was dissolved in toluene and  
20 the solution was washed with a saturated aqueous sodium bicarbonate solution. The organic solution was dried over magnesium sulphate and evaporated. There was thus obtained 6-acetoxy-4-chloro-7-methoxyquinazoline (14.8 g) which was used without further purification.

A mixture of a portion (5 g) of the material so obtained, diphenylmethyleamine  
25 (3.75 g), caesium carbonate (25.67 g) and xylene (200 ml) was stirred at ambient temperature for 30 minutes. Racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (1.227 g) and palladium diacetate (0.221 g) were added and the mixture was stirred and heated to 135°C for 16 hours. The mixture was cooled to ambient temperature and diethyl ether (600 ml) was added. The mixture was filtered and the filtrate was evaporated. There was thus obtained  
30 N-diphenylmethyle-6-acetoxy-7-methoxyquinazolin-4-amine (7.12 g); Mass Spectrum:  $M+H^+$  398.

A mixture of a portion (3.09 g) of the material so obtained, concentrated ammonium hydroxide solution (0.88 g/ml, approximately 14M; 60 ml) and methanol (120 ml) was stirred

at ambient temperature for 16 hours. The mixture was evaporated. Toluene (200 ml) was added and the mixture was evaporated again. The residue was triturated under diethyl ether (50 ml). There was thus obtained N-diphenylmethylene-6-hydroxy-7-methoxyquinazolin-4-amine (0.938 g); Mass Spectrum:  $M+H^+$  356.

5 A mixture of the material so obtained, 3-piperidinopropyl chloride (0.55 g), potassium carbonate (1.46 g) and DMF (50 ml) was stirred and heated to 65°C for 16 hours. The resultant mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic solution was washed with a saturated aqueous sodium chloride solution, dried over magnesium sulphate and evaporated. The residue was purified by column  
10 chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained N-diphenylmethylene-6-(3-piperidinopropoxy)-7-methoxyquinazolin-4-amine (0.277 g); NMR Spectrum: ( $DMSO-d_6$ ) 1.3 (br s, 2H), 1.42 (br s, 4H), 1.88 (t, 2H), 2.28 (br s, 4H), 2.38 (t, 2H), 3.92 (s, 3H), 4.07 (t, 2H), 7.0 (s, 1H), 7.23 (s, 1H), 7.2-7.65 (br m, 10H), 8.62 (s, 1H); Mass Spectrum:  $M+H^+$  481.

15 A mixture of the material so obtained, 3N aqueous hydrochloric acid solution (2 ml) and THF (14 ml) was stirred at ambient temperature for 3 hours. The mixture was evaporated and the residue was treated with a 2N aqueous sodium hydroxide solution (10 ml). The resultant precipitate was isolated, washed with water (10 ml) and dried under vacuum. There was thus obtained 4-amino-7-methoxy-6-(3-piperidinopropoxy)quinazoline (0.202 g); NMR Spectrum: ( $DMSO-d_6$ ) 1.36 (br s, 2H), 1.47 (br s, 4H), 1.93 (t, 2H), 2.25-2.43 (br m, 6H), 3.88 (s, 3H), 4.05 (t, 2H), 7.04 (s, 1H), 7.35 (br s, 2H), 7.55 (s, 1H), 8.23 (s, 1H); Mass Spectrum:  $M+H^+$  317.

(f) The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.4 (br s, 2H), 1.53 (br s, 4H), 2.02 (br s, 2H), 3.24-3.47 (br s, 6H), 3.97 (s, 3H), 4.23 (t, 2H), 7.22 (m, 2H), 7.31 (s, 1H), 7.4 (m, 1H), 8.05 (s, 1H), 8.69 (s, 1H), 10.67 (s, 1H), 11.82 (s, 1H); Mass Spectrum:  $M+H^+$  472.

(g) The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.38 (br s, 2H), 1.5 (br s, 4H), 1.96 (m, 2H), 2.25 (s, 6H), 2.3-2.48 (br m, 6H), 3.96 (s, 3H), 4.15 (t, 2H), 7.14 (m, 3H), 7.3 (s, 1H), 8.07 (s, 1H), 8.67 (s, 1H), 10.38 (s, 1H), 11.69 (s, 1H); Mass Spectrum:  $M+H^+$  464.

(h) The product gave the following data: NMR Spectrum: ( $DMSO-d_6$ ) 1.72 (br s, 4H), 2.67 (br s, 4H), 2.97 (br s, 2H), 3.99 (s, 3H), 4.3 (t, 2H), 7.31 (s, 1H), 7.37 (t, 1H), 7.59 (d, 2H), 8.07 (s, 1H), 8.72 (s, 1H), 10.52 (s, 1H), 12.06 (s, 1H); Mass Spectrum:  $M+H^+$  476 and 478.

The 4-amino-7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazoline used as a starting material was prepared from N-diphenylmethylene-6-hydroxy-7-methoxyquinazolin-4-amine and 2-pyrrolidin-1-ylethyl chloride using analogous procedures to those described in the last two paragraphs of Note (e) above. The material so obtained gave the following data :- NMR

5 Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.68 (m, 4H), 2.58 (m, 6H), 3.86 (s, 3H), 4.15 (t, 2H), 7.05 (s, 1H), 7.33 (s, 1H), 8.24 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 289.

(i) Chloroform was used as the reaction solvent. Triethylamine (1 equivalent) was also added. The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.99 (t, 2H), 2.37 (s, 6H), 2.7 (m, 4H), 3.63 (q, 2H), 3.79 (m, 6H), 4.15 (s, 3H), 7.13 (s, 3H), 7.4 (s, 1H), 8.0 (t, 10 1H), 8.2 (s, 1H), 8.79 (s, 1H), 8.9 (s, 1H), 11.2 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 493.

The 4-amino-7-methoxy-6-[N-(3-morpholinopropyl)carbamoyl]quinazoline used as a starting material was prepared as follows :-

Methyl 4-amino-5-cyano-2-hydroxybenzoate (J. Chem. Soc. Perkin I, 1979, 677; 4 g) was added to stirred concentrated sulphuric acid (6 ml) and the mixture was heated to 80°C 15 for 30 minutes. The mixture was cooled to ambient temperature and poured onto crushed ice. The resultant solid was filtered off, washed well with water and dried to give methyl 4-amino-5-carbamoyl-2-hydroxybenzoate (2.8 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 3.83 (s, 3H), 6.1 (s, 1H), 6.75 (br m, 2H), 8.08 (s, 1H).

A mixture of methyl 4-amino-5-carbamoyl-2-hydroxybenzoate (5.4 g) and formic acid 20 (50 ml) was heated to reflux for 1 hour. The mixture was evaporated. Toluene (75ml) was added and the mixture was evaporated. The solid residue was washed with methanol and diethyl ether and dried to give methyl 7-hydroxy-4-oxo-3,4-dihydroquinazoline-6-carboxylate (5.2 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 4.9 (s, 3H), 7.09 (s, 1H), 7.39 (s, 1H), 8.5 (s, 1H).

A mixture of methyl 7-hydroxy-4-oxo-3,4-dihydroquinazoline-6-carboxylate (17.7 g) 25 and acetic anhydride (200 ml) was heated to 120°C for 1.5 hours. The mixture was evaporated. Toluene (75ml) was added and the mixture was re-evaporated. There was thus obtained methyl 7-acetoxy-4-oxo-3,4-dihydroquinazoline-6-carboxylate (20.7 g); NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 2.33 (s, 3H), 3.86 (s, 3H), 7.5 (s, 1H), 8.28 (s, 1H), 8.68 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 263.

30 A mixture of a portion (7.2 g) of the material so obtained and thionyl chloride (75 ml) was heated to reflux for 1 hour. The excess thionyl chloride was evaporated. Toluene (50 ml) was added and the mixture was re-evaporated. The residue was dissolved in methylene chloride and treated with triethylamine (3.34 g). The mixture was passed through a silica gel

column (40 g) using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained methyl 7-acetoxy-4-chloroquinazoline-6-carboxylate (6.88 g); NMR Spectrum: ( $\text{CDCl}_3$ ) 2.43 (s, 3H), 4.0 (s, 3H), 7.8 (s, 1H), 8.99 (s, 1H), 9.12 (s, 1H).

5 A mixture of a portion (2.74 g) of the material so obtained, 2,4,6-trimethoxybenzylamine (3.86 g) and methylene chloride (90 ml) was allowed to stand at ambient temperature for 16 hours. The mixture was filtered and the filtrate was evaporated. The residue was triturated under diethyl ether. The resultant solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and  
10 methanol as eluent. There was thus obtained methyl 7-hydroxy-4-(2,4,6-trimethoxybenzylamino)quinazoline-6-carboxylate (3.25 g); NMR Spectrum: ( $\text{DMSO-d}_6$ ) 3.85 (s, 9H), 3.98 (s, 3H), 4.82 (d, 2H), 6.2 (s, 1H), 7.25 (s, 1H), 7.27 (s, 1H), 8.27 (s, 1H), 8.67 (s, 1H), 10.73 (s, 1H); Mass Spectrum:  $\text{M}+\text{H}^+$  400.

(Trimethylsilyl)diazomethane (2M in hexane, 10 ml) was added to a mixture of the  
15 material so obtained, di-isopropylethylamine (1.26 g), methanol (10 ml) and methylene chloride (30 ml) and the resultant mixture was stirred at ambient temperature for 3 hours. The reaction mixture was treated with a second aliquot of (trimethylsilyl)diazomethane solution (10 ml) and stirred for a further 18 hours. Silica gel (2 g) was added cautiously and the mixture was stirred for 5 minutes. The mixture was evaporated and the reaction product  
20 (adsorbed onto silica) was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained methyl 7-methoxy-4-(2,4,6-trimethoxybenzylamino)quinazoline-6-carboxylate (1.244 g); Mass Spectrum:  $\text{M}+\text{H}^+$  414.

A mixture of a portion (0.295 g) of the material so obtained and  
25 N-(3-aminopropyl)morpholine (0.5 ml) was stirred and heated to  $150^\circ\text{C}$  for 1 hour. The mixture was partitioned between methylene chloride and water. The organic solution was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(2,4,6-trimethoxybenzylamino)-7-methoxy-  
30 6-[N-(3-morpholinopropyl)carbamoyl]quinazoline (0.144 g) Mass Spectrum:  $\text{M}+\text{H}^+$  526.

Trifluoroacetic acid (1 ml) was added to a mixture of the material so obtained, triethylsilane (0.093 g) and methylene chloride (0.15 ml) and the reaction mixture was stirred and heated to reflux for 2 minutes. The mixture was evaporated and the residue was

partitioned between methylene chloride and water. The organic solution was evaporated to give 4-amino-7-methoxy-6-[N-(3-morpholinopropyl)carbamoyl]quinazoline (0.129 g); Mass Spectrum:  $M+H^+$  346.

- (j) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 3.39 (s, 3H), 3.6 (m, 2H), 3.75 (m, 2H), 3.86 (m, 2H), 4.02 (s, 3H), 4.07 (m, 2H), 7.21 (t, 1H), 7.29 (s, 1H), 7.39 (d, 2H), 7.51 (s, 1H), 8.73 (s, 1H), 9.14 (s, 1H), 12.19 (s, 1H); Mass Spectrum:  $M+H^+$  481 and 483.

The 4-amino-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]quinazoline used as a starting material was prepared from N-diphenylmethylene-6-hydroxy-7-methoxyquinazolin-4-amine and 2-(2-methoxyethoxy)ethyl chloride using analogous procedures to those described in the last two paragraphs of Note (e) above. In a further preparation, 2-(2-methoxyethoxy)ethyl 4-toluenesulphonate was used. The required starting material gave the following data: NMR Spectrum: ( $CDCl_3$ ) 3.4 (s, 3H), 3.61 (m, 2H), 3.72 (m, 2H), 3.93 (m, 2H), 3.99 (s, 3H), 4.34 (m, 2H), 5.67 (br s, 2H), 7.2 (s, 1H), 7.32 (s, 1H), 8.5 (s, 1H); Mass Spectrum:  $M+H^+$  294.

- (k) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 2.31 (s, 6H), 3.38 (s, 3H), 3.6 (m, 2H), 3.69 (m, 4H), 3.85 (m, 2H), 4.14 (s, 3H), 7.12 (m, 4H), 7.58 (s, 1H), 8.68 (s, 1H), 9.44 (s, 1H), 11.77 (s, 1H); Mass Spectrum:  $M+H^+$  441.

**Example 26** 1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(6-methylamino-1-hexynyl)quinazolin-4-yl]urea

A mixture of 1-(2,6-dichlorophenyl)-3-{7-[6-(N-tert-butoxycarbonylamino)-N-methylamino)-1-hexynyl]-6-methoxyquinazolin-4-yl}urea (0.1 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) was stirred at ambient temperature for 1.5 hours. The mixture was evaporated and a solution of hydrogen chloride gas in ethyl acetate was added. Toluene was added and the mixture was evaporated. The residue was triturated under diethyl ether and the resultant solid was isolated. There was thus obtained the title compound as the hydrochloride salt (0.095g); NMR Spectrum: ( $DMSO-d_6$ ) 1.65 (m, 2H), 1.78 (m, 2H), 2.55 (m, 5H), 2.95 (m, 2H), 4.0 (s, 3H), 7.38 (t, 1H), 7.6 (d, 2H), 7.89 (s, 1H), 8.16 (s, 1H), 8.7 (m, 3H), 10.9 (br, 1H), 11.8 (s, 1H); Mass Spectrum:  $M+H^+$  472 and 474.

- The 1-(2,6-dichlorophenyl)-3-{7-[6-(N-tert-butoxycarbonylamino)-N-methylamino-1-hexynyl]-6-methoxyquinazolin-4-yl}urea used as a starting material was prepared as follows :-

Using an analogous procedure to that described in the second last paragraph of Note [115] in Example 2 above, 6-(N-tert-butoxycarbonylamino-N-methylamino)-1-hexyne was reacted with 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-trifluoromethanesulphonyloxyquinazoline to give 4-(2-bromo-4-fluorophenoxy)-6-methoxy-7-[6-(N-tert-butoxycarbonylamino)-N-methylamino-1-hexynyl]quinazoline; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.4 (s, 9H), 1.55 (m, 2H), 1.65 (m, 2H), 2.57 (t, 2H), 2.79 (s, 3H), 3.24 (t, 2H), 4.0 (s, 3H), 7.35-7.82 (m, 3H), 7.65 (s, 1H), 7.95 (s, 1H), 8.6 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 558 and 560.

The material so obtained was reacted with ammonia using an analogous procedure to that described in the last paragraph of Note [115] in Example 2 above, except that the ammonia reaction was carried out at 110°C rather than at 130°C. There was thus obtained 4-amino-6-methoxy-7-[6-(N-tert-butoxycarbonylamino)-N-methylamino-1-hexynyl]quinazoline.

The material so obtained was reacted with 2,6-dichlorophenyl isocyanate using an analogous procedure to that described in Example 1. There was thus obtained the required starting material; NMR Spectrum: (DMSO<sub>d</sub><sub>6</sub>) 1.39 (s, 9H), 1.55 (m, 2H), 1.67 (m, 2H), 2.56 (m, 2H), 2.79 (s, 3H), 3.2 (m, 2H), 3.97 (s, 3H), 7.4 (m, 1H), 7.6 (m, 2H), 7.84 (s, 1H), 8.14 (s, 1H), 8.75 (s, 1H), 10.8 (s, 1H), 11.95 (s, 1H).

The 6-(N-tert-butoxycarbonylamino-N-methylamino)-1-hexyne used as a starting material was prepared as follows :-

6-Mesyloxy-1-hexyne was reacted with methylamine using an analogous procedure to that described in J. Heterocyclic Chemistry, 1994, **31**, 1421 to give 6-methylamino-1-hexyne which was reacted di-tert-butyl dicarbonate using a conventional procedure.

**Example 27 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea**


A solution of 4-amino-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (150 mg) in DMF (4.5 ml) was added to sodium hydride (60% dispersion in mineral oil, 0.03 g) and the reaction mixture was stirred at ambient temperature for 20 minutes. 2,6-Dimethylphenyl isothiocyanate (0.162 g) was added and the mixture was stirred at ambient temperature for 20 hours. The reaction mixture was evaporated and the residual solid was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a 2M solution of ammonia in methanol as eluent. There was thus

obtained the title compound (0.112 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.44–1.61 (m, 2H), 1.87–2.08 (m, 5H), 2.32 (s, 3H), 2.36 (s, 6H), 2.94 (d, 2H), 4.04 (m, 5H), 7.1 (s, 1H), 7.19 (m, 3H), 7.29 (s, 1H), 8.69 (s, 1H), 8.9 (s, 1H), 13.37 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 466.

### 5 Example 28

Using an analogous procedure to that described in Example 27, the appropriate 4-aminoquinazoline was reacted with the appropriate isothiocyanate to give the compounds described in Table VII.

**Table VII**



10

No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dichloro	(a)
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro	(b)
3	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	(c)
4	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,4,6-trichloro	(d)
5	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl-4-bromo	(e)
6	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl	(f)
7	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	(g)
8	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	(h)
9	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	(i)
10	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl	(j)
11	methoxy	2-morpholinoethoxy	2,6-dimethyl	(k)
12	methoxy	3-morpholinopropoxy	2,6-dimethyl	(l)
13	methoxy	cyclopropylmethoxy	2,6-dimethyl	(m)
14	methoxy	2-morpholinoethoxy	2-chloro-6-dimethyl	(n)
15	methoxy	3-morpholinopropoxy	2-chloro-6-methyl	(o)

16	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl	(p)
17	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dimethyl	(q)

Notes

- (a) The product gave the following data: Mass Spectrum:  $M+H^+$  506 and 508.
- (b) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.43–1.6 (m, 2H),  
 5 1.83–2.09 (m, 5H), 2.33 (s, 3H), 2.94 (d, 2H), 4.04 (m, 5H), 7.0–7.14 (m, 4H), 7.27 (m, 1H),  
 7.35 (m, 1H), 8.7 (s, 1H), 13.49 (s, 1H); Mass Spectrum:  $M+H^+$  474.
- (c) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.45–1.61 (m, 2H),  
 1.87–2.11 (m, 5H), 2.31 (s, 3H), 2.42 (s, 2H), 3.97 (d, 2H), 4.02 (m, 5H), 7.07 (s, 1H), 7.2–7.3  
 (m, 3H), 7.38 (t, 1H), 8.7 (s, 1H), 8.9 (s, 1H) 13.51 (s, 1H); Mass Spectrum:  $M+H^+$  486 and  
 10 488.
- (d) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.48–1.61 (m, 2H),  
 1.88–2.16 (m, 5H), 2.36 (s, 3H), 3.0 (d, 2H), 4.07 (m, 5H), 7.11 (s, 1H), 7.3 (d, 2H), 7.43 (s,  
 1H), 7.49 (s, 1H), 8.72 (s, 1H) 13.71 (s, 1H); Mass Spectrum:  $M+H^+$  540 and 543.
- (e) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.47–1.61 (m, 2H),  
 15 1.87–2.11 (m, 5H), 2.32 (d, 9H), 2.99 (d, 2H), 4.04 (m, 5H), 7.1 (s, 1H), 7.3 (s, 1H), 7.32 (s,  
 1H), 8.7 (s, 1H), 8.9 (s, 1H), 13.31 (s, 1H); Mass Spectrum:  $M+H^+$  544 and 546.
- (f) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.44–1.59 (m, 2H),  
 1.88–2.07 (m, 5H), 2.31 (s, 3H), 2.35 (d, 6H), 2.94 (d, 2H), 4.04 (m, 5H), 7.08 (d, 1H), 7.2 (d,  
 1H), 7.29 (s, 1H), 7.55 (s, 1H), 8.68 (s, 1H), 8.77 (s, 1H), 13.63 (s, 1H); Mass Spectrum:  
 20  $M+H^+$  466.
- (g) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.83 (s, 4H), 2.21 (m,  
 2H), 2.63 (s, 4H), 2.76 (t, 2H), 4.03 (s, 3H), 4.29 (t, 2H), 7.08 (t, 1H), 7.27–7.33 (s, 2H), 7.44  
 (m, 3H), 8.73 (s, 1H), 13.7 (s, 1H); Mass Spectrum:  $M+H^+$  506 and 508.
- (h) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.83 (s, 4H), 2.2 (m,  
 25 2H), 2.61 (s, 4H), 2.74 (t, 2H), 4.04 (s, 3H), 4.48 (t, 2H), 6.98–7.11 (m, 3H), 7.27–7.41 (m,  
 3H), 8.71 (s, 1H), 13.48 (s, 1H); Mass Spectrum:  $M+H^+$  474.
- (i) The product gave the following data: NMR Spectrum: ( $CDCl_3$ ) 1.8 (m, 4H), 2.18 (m,  
 2H), 2.4 (s, 3H), 2.55 (m, 4H), 2.68 (t, 2H), 4.02 (s, 3H), 4.3 (t, 2H), 7.07 (s, 1H), 7.26 (m,  
 2H), 7.31 (s, 1H), 7.37 (m, 1H), 8.7 (s, 1H), 8.94 (br s, 1H), 13.51 (s, 1H); Mass Spectrum:  
 30  $M+H^+$  486 and 488.

- (j) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.35 (s, 6H), 3.4 (s, 3H), 3.6 (m, 2H), 3.87 (m, 2H), 4.03 (t, 2H), 4.05 (s, 3H), 4.37 (t, 2H), 7.09 (s, 1H), 7.14–7.21 (m, 3H), 7.33 (s, 1H), 8.68 (s, 1H), 8.84 (s, 1H), 13.32 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 457.
- (k) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.36 (s, 6H), 2.61 (t, 4H), 2.95 (t, 2H), 3.77 (t, 4H), 4.04 (s, 3H), 4.34 (t, 2H), 7.11 (s, 1H), 7.2 (m, 3H), 7.31 (s, 1H), 8.69 (s, 1H), 8.9 (s, 1H), 13.36 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 468.
- (l) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 2.0 (m, 2H), 2.4 (s, 4H), 2.45 (t, 2H), 3.58 (t, 4H), 4.03 (s, 3H), 4.21 (t, 2H), 7.18 (m, 3H), 7.33 (s, 1H), 8.19 (s, 1H), 8.71 (s, 1H), 11.09 (s, 1H), 13.7 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 482.
- 10 (m) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 0.39 (m, 2H), 0.61 (m, 2H), 1.32 (m, 1H), 2.25 (s, 6H), 4.0 (m, 5H), 7.17 (s, 3H), 7.25 (s, 1H), 8.17 (s, 1H), 8.72 (s, 1H), 11.08 (br s, 1H), 13.67 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 409.
- (n) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 488 and 490.
- (o) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 502 and 504.
- 15 (p) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 452.
- (q) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 452.


**Example 29** 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]guanidine

- 20 Mercuric(II) oxide (0.059 g) was added to a mixture of 1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]thiourea (0.105 g), a 2M solution of ammonia in methanol (3 ml) and chloroform (1 ml) and the reaction mixture was stirred at ambient temperature for 2 hours. The mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of
- 25 methylene chloride and a 2M solution of ammonia in methanol as eluent. There was thus obtained the title compound (0.074 g); NMR Spectrum: (CDCl<sub>3</sub>) 1.39–1.53 (m, 2H), 1.87–2.02 (q, 5H), 2.29 (s, 3H), 2.36 (s, 6H), 2.9 (d, 2H), 4.01 (m, 5H), 5.79 (br s, 1H), 7.16 (s, 1H), 7.19 (m, 3H), 7.87 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 449.

30 **Example 30**

Using an analogous procedure to that described in Example 29, the appropriate quinazoline-4-thiourea was reacted with ammonia to give the guanidines described in Table VIII.

Table VIII



No.	R <sup>6</sup>	R <sup>7</sup>	(R <sup>2</sup> ) <sub>n</sub>	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dichloro	(a)
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-difluoro	(b)
3	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	(c)
4	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl-4-bromo	(d)
5	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,5-dimethyl	(e)
6	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-dichloro	(f)
7	methoxy	3-pyrrolidin-1-ylpropoxy	2,6-difluoro	(g)
8	methoxy	3-pyrrolidin-1-ylpropoxy	2-chloro-6-methyl	(h)
9	methoxy	2-(2-methoxyethoxy)ethoxy	2,6-dimethyl	(i)
10	methoxy	2-morpholinoethoxy	2,6-dimethyl	(j)
11	methoxy	cyclopropylmethoxy	2,6-dimethyl	(k)
12	methoxy	2-pyrrolidin-1-ylethoxy	2,6-dimethyl	(l)
13	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-methyl	(m)

5 Notes

(a) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>, 100°C) 1.4 (m, 2H), 1.78 (m, 3H), 1.96 (t, 2H), 2.2 (s, 3H), 2.8 (m, 2H), 3.76 (s, 3H), 4.0 (d, 2H), 7.11 (s, 1H), 7.28 (t, 2H), 7.47 (s, 1H), 7.54 (d, 2H), 7.98 (s, 1H), 8.5 (s, 1H), 9.0 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 489 and 491.

- 10 (b) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 1.34 (m, 2H), 1.73 (d, 3H), 1.88 (t, 2H), 2.16 (s, 3H), 2.79 (d, 2H), 3.3 (s, 2H), 3.69 (s, 3H), 3.95 (d, 2H), 7.07 (s, 1H), 7.2 (t, 2H), 7.34 (br s, 1H), 8.49 (s, 1H), 8.74 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 457.

- 141 -

- (c) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.4–1.56 (m, 2H), 1.87–2.05 (q, 5H), 2.3 (s, 3H), 2.4 (s, 3H), 2.9 (d, 2H), 3.98–4.05 (m, 5H), 7.13–7.27 (m, 3H), 7.38 (m, 1H), 7.81 (s, 1H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 469 and 471.
- (d) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.38–1.54 (m, 2H),  
5 1.82–2.02 (q, 5H), 2.28 (s, 3H), 2.32 (s, 6H), 2.89 (d, 2H), 4.0 (m, 5H), 5.7 (br s, 1H), 7.03–7.27 (m, 3H), 7.32 (s, 2H), 7.81 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 526 and 528.
- (e) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.39–1.44 (m, 2H), 1.87–2.04 (q, 5H), 2.29 (s, 3H), 2.34 (d, 6H), 2.89 (d, 2H), 4.02 (m, 5H), 6.19 (br s, 1H), 7.05 (d, 1H), 7.14 (s, 2H), 7.2 (d, 1H), 7.84 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 449.
- 10 (f) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.8 (m, 4H), 2.17 (m, 2H), 2.53 (s, 4H), 2.67 (t, 2H), 3.99 (s, 3H), 4.25 (t, 2H), 7.1 (t, 1H), 7.2 (s, 1H), 7.41 (d, 1H), 7.51 (s, 1H), 8.57 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 489 and 491.
- (g) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.79 (m, 4H), 2.14 (m, 2H), 2.53 (m, 4H), 2.67 (t, 2H), 3.97 (s, 3H), 4.24 (t, 2H), 7.03 (t, 2H), 7.2 (m, 2H), 7.63 (s,  
15 1H), 8.59 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 457.
- (h) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 1.79 (m, 4H), 2.15 (m, 2H), 2.4 (s, 3H), 2.56 (s, 4H), 2.68 (t, 2H), 3.98 (s, 3H), 4.26 (t, 2H), 6.13 (br s, 1H), 7.14–7.26 (m, 3H), 7.37 (m, 1H), 7.82 (s, 1H), 8.58 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 469 and 471.
- (i) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 2.35 (s, 6H), 3.4 (s,  
20 3H), 3.61 (m, 2H), 3.77 (m, 2H), 3.99 (m, 5H), 4.34 (t, 2H), 5.76 (br s, 1H), 7.17 (m, 4H), 7.87 (s, 1H), 8.56 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 440.
- (j) The product gave the following data: NMR Spectrum: (DMSOd<sub>6</sub>, 100°C) 2.29 (s, 6H), 2.53 (m, 4H), 2.79 (t, 2H), 3.6 (t, 4H), 3.74 (s, 3H), 4.22 (t, 2H), 7.09 (s, 1H), 7.16 (s, 3H), 7.51 (s, 1H), 7.7 (s, 2H), 8.45 (s, 1H), 8.88 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 451.
- 25 (k) The product gave the following data: NMR Spectrum: (CDCl<sub>3</sub>) 0.34 (m, 2H), 0.63 (m, 2H), 1.37 (m, 1H), 2.28 (s, 6H), 3.93 (d, 2H), 3.97 (s, 3H), 5.9 (br m, 1H), 7.07 (s, 1H), 7.12 (m, 4H), 7.79 (s, 1H), 8.48 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 392.
- (l) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 435.
- (m) The product gave the following data: Mass Spectrum: M+H<sup>+</sup> 435.

**Example 31** 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-[(R)-(+)- $\alpha$ -methylbenzyl]guanidine

Using an analogous procedure to that described in Example 29, 1-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]-3-[(R)-(+)- $\alpha$ -methylbenzyl]thiourea was  
5 reacted with ammonia to give the title compound; NMR Spectrum: (CDCl<sub>3</sub>) 1.38–1.42 (m, 2H), 1.61 (d, 3H), 1.86–2.01 (q, 5H), 2.29 (s, 3H), 2.89 (d, 2H), 3.95 (m, 3H), 4.0 (d, 2H), 4.7 (q, 1H), 6.5 (br s, 1H), 7.12 (s, 1H), 7.29–7.31 (m, 5H), 7.79 (s, 1H), 8.53 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 449.

10 **Example 32** 1-(2-aminophenyl)-3-(6,7-dimethoxyquinazolin-4-yl)urea

A mixture of 1-(6,7-dimethoxyquinazolin-4-yl)-3-(2-nitrophenyl)urea (0.18 g), 10% palladium-on-charcoal catalyst (0.023 g) and DMF (10 ml) was stirred at ambient temperature under an atmosphere of hydrogen for 16 hours. The reaction mixture was filtered and the filtrate was evaporated. The resultant gum was triturated under ethyl acetate and there  
15 was thus obtained the title compound as a solid (0.137 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.85–3.95 (br s, 8H), 6.63 (t, 1H), 6.81 (d, 1H), 6.91 (t, 1H), 7.25 (s, 1H), 7.47 (d, 1H), 8.05 (s, 1H), 8.64 (s, 1H), 10.28 (br s, 1H), 11.74 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 340.

The 1-(6,7-dimethoxyquinazolin-4-yl)-3-(2-nitrophenyl)urea used as a starting material was prepared by the reaction of 2-nitrophenylisocyanate and 4-amino-  
20 6,7-dimethoxyquinazoline using an analogous procedure to that described in Example 1. There was thus obtained the required starting material in 62% yield; NMR Spectrum: (DMSO-d<sub>6</sub>) 3.95 (s, 6H), 7.3 (s, 1H), 7.28–7.35 (t, 1H), 7.74 (t, 1H), 8.05 (s, 1H), 8.13 (m, 1H), 8.51 (m, 1H), 8.72 (s, 1H), 10.61 (s, 1H), 13.67 (br s, 1H); Mass Spectrum: M+H<sup>+</sup> 370.

25 **Example 33** 1-(2,6-dichlorophenyl)-3-(6-methoxy-7-piperazin-1-ylquinazolin-4-yl)urea


A mixture of 1-(2,6-dichlorophenyl)-3-{6-methoxy-7-[N-(tert-butoxycarbonyl)piperazin-1-yl]quinazolin-4-yl}urea (0.075 g), trifluoroacetic acid (1 ml) and methylene chloride (1 ml) was stirred at ambient temperature for 1 hour. The resultant mixture was evaporated. A saturated solution of hydrogen chloride gas in ethyl  
30 acetate was added and the mixture was evaporated. The resultant solid was triturated under diethyl ether, isolated and dried. There was thus obtained the title compound, as a dihydrochloride salt, (0.042 g); NMR Spectrum: (DMSO-d<sub>6</sub>) 3.25–3.3 (m, 4H), 3.45–3.5 (m,

4H), 4.03 (s, 3H), 7.3 (s, 1H), 7.36-7.63 (m, 3H), 8.16 (s, 1H), 8.78 (s, 1H), 9.15-9.27 (br s, 2H), 10.9-11.3 (br s, 1H), 10.8 (s, 1H); Mass Spectrum:  $M+H^+$  447 and 449.

### Example 34

- 5 Using an analogous procedure to that described in Example 29, except that the appropriate quinazoline-4-thiourea was reacted with ethylamine rather than with ammonia, there were obtained the 2-ethylguanidines described in Table IX.

Table IX



10

No.	$R^6$	$R^7$	$(R^2)_n$	Note
1	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2-chloro-6-methyl	(a)
2	methoxy	<u>N</u> -methylpiperidin-4-ylmethoxy	2,6-dimethyl	(b)
3	methoxy	2-morpholinoethoxy	2,6-dimethyl	(c)
4	methoxy	cyclopropylmethoxy	2,6-dimethyl	(d)

### Notes

- (a) The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.31 (t, 3H), 1.36-1.47 (m, 2H), 1.74-1.84 (m, 3H), 1.95 (t, 2H), 2.2 (s, 3H), 2.33 (s, 3H), 2.79 (d, 2H), 3.57 (m, 2H), 3.72 (s, 3H), 3.99 (t, 2H), 7.06 (s, 1H), 7.29 (m, 2H), 7.41 (m, 2H), 8.35 (br s, 1H), 8.45 (s, 1H), 10.11 (br s, 1H); Mass Spectrum:  $M+H^+$  497 and 499.
- 15 (b) The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.28 (t, 3H), 1.4 (m, 2H), 1.76 (m, 3H), 1.95 (m, 2H), 2.19 (s, 3H), 2.26 (s, 6H), 2.78 (m, 2H), 3.53 (q, 2H), 3.76 (s, 3H), 3.99 (d, 2H), 7.04 (s, 1H), 7.16 (s, 3H), 7.55 (s, 1H), 8.41 (s, 1H), 10.41 (br s, 1H); Mass Spectrum:  $M+H^+$  477.
- 20 (c) The product gave the following data: NMR Spectrum: (DMSO $d_6$ , 100°C) 1.27 (t, 3H), 2.27 (s, 6H), 2.54 (m, 4H), 2.8 (t, 2H), 3.54 (m, 2H), 3.61 (t, 4H), 3.78 (s, 3H), 4.26 (t, 2H),

7.11 (s, 1H), 7.19 (s, 3H), 7.59 (s, 1H), 8.42 (s, 1H), 10.42 (br s, 1H); Mass Spectrum:  
M+H<sup>+</sup> 479.

(d) The product gave the following data: NMR Spectrum: (DMSO-d<sub>6</sub>) 0.38 (m, 2H), 0.6 (m, 2H), 1.27 (m, 4H), 2.25 (s, 6H), 3.21 (m), 3.5 (m, 2H), 3.73 (s, 3H), 3.95 (d, 2H), 6.99 (s, 1H), 7.17 (s, 3H), 7.55 (br s, 1H), 8.42 (s, 1H); Mass Spectrum: M+H<sup>+</sup> 420.

### **Example 35**

#### **Pharmaceutical compositions**

The following illustrate representative pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"), for therapeutic or prophylactic use in humans:

	(a)	Tablet I	mg/tablet
		Compound X.....	100
15		Lactose Ph.Eur.....	182.75
		Croscarmellose sodium.....	12.0
		Maize starch paste (5% w/v paste).....	2.25
		Magnesium stearate.....	3.0
20	(b)	Tablet II	mg/tablet
		Compound X.....	50
		Lactose Ph.Eur.....	223.75
		Croscarmellose sodium.....	6.0
		Maize starch.....	15.0
25		Polyvinylpyrrolidone (5% w/v paste).....	2.25
		Magnesium stearate.....	3.0
	(c)	Tablet III	mg/tablet
		Compound X.....	1.0
30		Lactose Ph.Eur.....	93.25
		Croscarmellose sodium.....	4.0
		Maize starch paste (5% w/v paste).....	0.75

- 145 -

	Magnesium stearate.....	1.0
(d)	Capsule	mg/capsule
	Compound X.....	10
5	Lactose Ph.Eur.....	488.5
	Magnesium.....	1.5
(e)	Injection I	(50 mg/ml)
	Compound X.....	5.0% w/v
10	1M Sodium hydroxide solution.....	15.0% v/v
	0.1M Hydrochloric acid (to adjust pH to 7.6)	
	Polyethylene glycol 400.....	4.5% w/v
	Water for injection to 100%	
15	(f) Injection II	(10 mg/ml)
	Compound X.....	1.0% w/v
	Sodium phosphate BP.....	3.6% w/v
	0.1M Sodium hydroxide solution.....	15.0% v/v
	Water for injection to 100%	
20	(g) Injection III	(1mg/ml, buffered to pH6)
	Compound X.....	0.1% w/v
	Sodium phosphate BP.....	2.26% w/v
	Citric acid.....	0.38% w/v
25	Polyethylene glycol 400.....	3.5% w/v
	Water for injection to 100%	
(h)	Aerosol I	mg/ml
	Compound X.....	10.0
30	Sorbitan trioleate.....	13.5
	Trichlorofluoromethane.....	910.0
	Dichlorodifluoromethane.....	490.0

- 146 -

5	(i)	Aerosol II	mg/ml
		Compound X.....	0.2
		Sorbitan trioleate.....	0.27
		Trichlorofluoromethane.....	70.0
		Dichlorodifluoromethane.....	280.0
		Dichlorotetrafluoroethane.....	1094.0
10	(j)	Aerosol III	mg/ml
		Compound X.....	2.5
		Sorbitan trioleate.....	3.38
		Trichlorofluoromethane.....	67.5
		Dichlorodifluoromethane.....	1086.0
		Dichlorotetrafluoroethane.....	191.6
15	(k)	Aerosol IV	mg/ml
		Compound X.....	2.5
		Soya lecithin.....	2.7
		Trichlorofluoromethane.....	67.5
		Dichlorodifluoromethane.....	1086.0
20		Dichlorotetrafluoroethane.....	191.6
25	(l)	Ointment	ml
		Compound X.....	40 mg
		Ethanol.....	300 µl
		Water.....	300 µl
		1-Dodecylazacycloheptan-2-one.....	50 µl
		Propylene glycol.....	to 1 ml

Note


30 The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k)

- 147 -

may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.


**CLAIMS**

- 5 1. A quinazoline derivative of the Formula I




I


wherein  $Q^1$  is a quinazoline-like ring such as a group of the formula Ia, Ib, Ic or Id




Ia



Ib



Ic



Id

- 10 wherein :


$Y^1$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S provided that the group of formula Ic so formed is not a purine ring;

- $Y^2$  together with the carbon atoms to which it is attached forms a 5- or 6-membered aromatic or partially unsaturated ring comprising 1 to 3 heteroatoms selected from O, N and S;

$m$  is 0, 1, 2, 3 or 4;

each  $R^1$  group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy,

carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




10 wherein  $X^1$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>4</sup>), CO, CH(OR<sup>4</sup>), CON(R<sup>4</sup>), N(R<sup>4</sup>)CO, SO<sub>2</sub>N(R<sup>4</sup>), N(R<sup>4</sup>)SO<sub>2</sub>, OC(R<sup>4</sup>)<sub>2</sub>, SC(R<sup>4</sup>)<sub>2</sub> and N(R<sup>4</sup>)C(R<sup>4</sup>)<sub>2</sub>, wherein R<sup>4</sup> is hydrogen or (1-6C)alkyl, and Q<sup>3</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R<sup>1</sup>)<sub>m</sub> is (1-3C)alkylenedioxy,

15 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R<sup>1</sup> substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO<sub>2</sub>, N(R<sup>5</sup>), CO, CH(OR<sup>5</sup>), CON(R<sup>5</sup>), N(R<sup>5</sup>)CO, SO<sub>2</sub>N(R<sup>5</sup>), N(R<sup>5</sup>)SO<sub>2</sub>, CH=CH and C≡C wherein R<sup>5</sup> is hydrogen or (1-6C)alkyl,

and wherein any CH<sub>2</sub>=CH- or HC≡C- group within a R<sup>1</sup> substituent optionally bears at

20 the terminal CH<sub>2</sub>= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



25 wherein  $X^2$  is a direct bond or is selected from CO and N(R<sup>6</sup>)CO, wherein R<sup>6</sup> is hydrogen or (1-6C)alkyl, and Q<sup>4</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>1</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno substituents or a substituent selected from

30 hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,

- 150 -


(2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-  
 (2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,  
 (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a  
 group of the formula :




wherein  $X^3$  is a direct bond or is selected from O, S, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO, CH(OR<sup>7</sup>),  
 CON(R<sup>7</sup>), N(R<sup>7</sup>)CO, SO<sub>2</sub>N(R<sup>7</sup>), N(R<sup>7</sup>)SO<sub>2</sub>, C(R<sup>7</sup>)<sub>2</sub>O, C(R<sup>7</sup>)<sub>2</sub>S and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, wherein R<sup>7</sup> is  
 hydrogen or (1-6C)alkyl, and Q<sup>5</sup> is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-  
 (1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-  
 10 (1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R<sup>1</sup>  
 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from  
 halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl,  
 (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy,  
 15 (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,  
 di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,  
N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,  
N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,  
N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-

20 (1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^4$  is a direct bond or is selected from O and N(R<sup>9</sup>), wherein R<sup>9</sup> is hydrogen or  
 (1-6C)alkyl, and R<sup>8</sup> is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,  
 cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-  
 25 (1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or  
 from a group of the formula :



wherein  $X^5$  is a direct bond or is selected from O and N(R<sup>10</sup>), wherein R<sup>10</sup> is hydrogen or  
 (1-6C)alkyl, and Q<sup>6</sup> is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl  
 30 or heterocyclyl-(1-6C)alkyl, and any Q<sup>6</sup> group optionally bears 1 or 2 substituents, which may  
 be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R<sup>1</sup> optionally bears 1 or 2  
 oxo or thioxo substituents;

- 151 -

$R^2$  is hydrogen or (1-6C)alkyl and  $R^3$  is hydrogen or (1-6C)alkyl, or  $R^2$  and  $R^3$  together form a  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$  group;

$Z$  is O, S,  $N(C\equiv N)$  or  $N(R^{11})$ , wherein  $R^{11}$  is hydrogen or (1-6C)alkyl; and

$Q^2$  is aryl, aryl-(1-3C)alkyl, aryl-(3-7C)cycloalkyl, heteroaryl, heteroaryl-(1-3C)alkyl  
 5 or heteroaryl-(3-7C)cycloalkyl wherein each aryl group is phenyl or naphthyl and each heteroaryl group is a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl ring containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, and  
 $Q^2$  is optionally substituted with 1, 2, 3 or 4 substituents, which may be the same or different,  
 10 selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,  
 15 (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein  $X^6$  is a direct bond or is selected from O and  $N(R^{13})$ , wherein  $R^{13}$  is hydrogen or (1-6C)alkyl, and  $R^{12}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :




wherein  $X^7$  is a direct bond or is selected from O, S, SO,  $SO_2$ ,  $N(R^{14})$ , CO,  $CH(OR^{14})$ ,  $CON(R^{14})$ ,  $N(R^{14})CO$ ,  $SO_2N(R^{14})$ ,  $N(R^{14})SO_2$ ,  $C(R^{14})_2O$ ,  $C(R^{14})_2S$  and  $C(R^{14})_2N(R^{14})$ , wherein each  $R^{14}$  is hydrogen or (1-6C)alkyl, and  $Q^7$  is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or  $Q^2$  is optionally  
 30 substituted with a (1-3C)alkylenedioxy group,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on  $Q^2$  optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from

- 152 -

halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, 5 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



10 wherein  $X^8$  is a direct bond or is selected from O and N( $R^{16}$ ), wherein  $R^{16}$  is hydrogen or (1-6C)alkyl, and  $R^{15}$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on  $Q^2$  optionally bears 1 or 2

15 oxo or thioxo substituents;

or a pharmaceutically-acceptable salt thereof;

provided that the compounds :-

1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,

20 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.

1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

25 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,


1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and

1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea are excluded.

- 153 -

## 2. A quinazoline derivative of the Formula II



II

wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;  
or a pharmaceutically-acceptable salt thereof;

## 5 provided that the compounds :-

1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,


1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea and

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea are excluded.

10

## 3. A quinoline derivative of the Formula III




III

wherein each of  $m$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;  
or a pharmaceutically-acceptable salt thereof.

- 154 -

## 4. A pyrimidine derivative of the Formula IV




IV

wherein each of  $m$ ,  $R^1$ ,  $Y^1$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;  
or a pharmaceutically-acceptable salt thereof;

## 5 provided that the compounds :-

1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,10 1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea are excluded.

## 5. A quinazoline derivative of the Formula V



V

15

wherein each of  $m$ ,  $R^1$ ,  $Y^2$ ,  $R^2$ ,  $R^3$ ,  $Z$  and  $Q^2$  has any of the meanings defined in claim 1;  
or a pharmaceutically-acceptable salt thereof.

6. A quinazoline derivative of the Formula II according to claim 2 wherein :

- m is 1 and the R<sup>1</sup> group is located at the 6- or 7-position and is selected from methoxy, benzyloxy, cyclopropylmethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 3-dimethylaminopropoxy, 3-diethylaminopropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, N-methylpyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 2-(N-methylpyrrolidin-2-yl)ethoxy, 3-pyrrolidin-2-ylpropoxy, 3-(N-methylpyrrolidin-2-yl)propoxy, 2-(2-oxoimidazolidin-1-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-(4-aminomethylpiperidin-1-yl)propoxy, 3-(4-tert-butoxycarbonylaminopiperidin-1-yl)propoxy, 3-(4-carbamoylpiperidin-1-yl)propoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-1-yloxy, 2-(2-morpholinoethoxy)ethoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy, 3-[N-(2-methoxyethyl)-N-methylamino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-methylamino-1-propynyl, 3-dimethylamino-1-propynyl, 3-diethylamino-1-propynyl, 6-methylamino-1-hexynyl, 6-dimethylamino-1-hexynyl, 3-(pyrrolidin-1-yl)-1-propynyl, 3-(piperidino)-1-propynyl, 3-(morpholino)-1-propynyl, 3-(4-methylpiperazin-1-yl)-1-propynyl, 6-(pyrrolidin-1-yl)-1-hexynyl, 6-(piperidino)-1-hexynyl, 6-(morpholino)-1-hexynyl, 6-(4-methylpiperazin-1-yl)-1-hexynyl, piperazin-1-yl, 4-methylpiperazin-1-yl, 3-imidazol-1-ylpropylamino, 3-pyrrolidin-1-ylpropylamino, 3-morpholinopropylamino, 3-piperidinopropylamino and 3-piperazin-1-ylpropylamino,

or m is 2 and the R<sup>1</sup> groups are located at the 6- and 7-positions, one R<sup>1</sup> group is located at the 6- or 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a methoxy group;

- 156 -

$R^2$  is hydrogen or methyl;

$R^3$  is hydrogen;

Z is O, S, NH or N(Et); and

$Q^2$  is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which

5 may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position;

or a pharmaceutically-acceptable acid-addition salt thereof;

and provided that 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea is excluded.

10

7. A quinazoline derivative of the Formula II according to claim 2 wherein :

m is 1 and the  $R^1$  group is located at the 7-position and is selected from

3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 2-pyrrolidin-1-ylethoxy,

3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,

15 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-

4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy,

N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,

2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,

4-pyrrolidin-1-ylbut-2-en-1-yloxy, 4-morpholinobut-2-en-1-yloxy,

20 4-morpholinobut-2-yn-1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-

N-methylamino]ethoxy;

or m is 2 and one  $R^1$  group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other  $R^1$  group is a 6-methoxy group;

$R^2$  is hydrogen or methyl;

25  $R^3$  is hydrogen;

Z is O, S, NH or N(Et); and

$Q^2$  is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, nitro, methyl, ethyl and methoxy provided that at least one substituent is located at an ortho position;

30 or a pharmaceutically-acceptable acid-addition salt thereof.

8. A quinazoline derivative of the Formula II according to claim 2 wherein :

m is 1 and the R<sup>1</sup> group is located at the 7-position and is selected from

3-(1,2,3-triazol-1-yl)propoxy, 2-pyrid-4-ylethoxy, 3-pyrrolidin-1-ylpropoxy,

3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy,

5 2-piperidinoethoxy, 3-piperidinopropoxy, N-methylpiperidin-4-ylmethoxy,

3-(4-methylpiperazin-1-yl)propoxy, 4-morpholinobut-2-en-1-yloxy, 4-morpholinobut-2-yn-

1-yloxy, 3-methylsulphonylpropoxy and 2-[N-(2-methoxyethyl)-N-methylamino]ethoxy;

or m is 2 and one R<sup>1</sup> group is located at the 7-position and is selected from the groups defined immediately hereinbefore and the other R<sup>1</sup> group is a 6-methoxy group;

10 R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

Z is O; and

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent

15 is located at an ortho position;

or a pharmaceutically-acceptable acid-addition salt thereof.

9. A quinazoline derivative of the Formula II according to claim 2 selected from:-

1-(2,6-dichlorophenyl)-3-[7-(3-morpholinopropoxy)quinazolin-4-yl]urea,

20 1-(2,6-dichlorophenyl)-3-{ 7-[3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy]quinazolin-4-yl} urea,

1-benzyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-phenethyl-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-(2,6-dichlorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

25 1-(2,6-difluorophenyl)-3-[6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-4-yl]urea,

30

1-(2,6-difluorophenyl)-3-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]urea,

1-(2,6-difluorophenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]urea,

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]urea,

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(3-piperidinopropoxy)quinazolin-4-yl]urea,

1-(2,6-dimethylphenyl)-3-[6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazolin-

5 4-yl]thiourea and


1-(2-chloro-6-methylphenyl)-3-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]guanidine;

or a pharmaceutically-acceptable acid-addition salt thereof.

10 10. A pyrimidine derivative of the Formula IV according to claim 4 wherein the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring forms a thieno[3,2-*d*]pyrimidin-4-yl group;

m is 0, or m is 1 and the R<sup>1</sup> group is a methyl, ethyl, vinyl or ethynyl group which is located at the 6-position and bears a substituent selected from carboxy, carbamoyl, N-(2-methylaminoethyl)carbamoyl, N-(2-dimethylaminoethyl)carbamoyl,

15 N-(3-methylaminopropyl)carbamoyl or N-(3-dimethylaminopropyl)carbamoyl, or from a group of the formula :



wherein X<sup>2</sup> is NHCO or N(Me)CO and Q<sup>4</sup> is 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, 2-pyrrolidin-1-ylethyl,

20 2-(2-oxopyrrolidin-1-yl)ethyl, 3-pyrrolidin-1-ylpropyl, 3-(2-oxopyrrolidin-1-yl)propyl, pyrrolidin-2-ylmethyl, 1-methylpyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 2-(1-methylpyrrolidin-2-yl)ethyl, 3-pyrrolidin-2-ylpropyl, 3-(1-methylpyrrolidin-2-yl)propyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 1-methylpiperidin-3-ylmethyl, 2-piperidin-3-ylethyl, 2-(1-methylpiperidin-

25 3-yl)ethyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-(1-methylpiperidin-4-yl)ethyl, 2-piperazin-1-ylethyl, 2-(4-methylpiperazin-1-yl)ethyl, 3-piperazin-1-ylpropyl or 3-(4-methylpiperazin-1-yl)propyl,

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;


30 Z is O; and

Q<sup>2</sup> is phenyl, benzyl or phenethyl which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl and methyl;

or a pharmaceutically-acceptable acid-addition salt thereof.

11. A pyrimidine derivative of the Formula IV according to claim 4 wherein the fusion of ring Y<sup>1</sup> to the adjacent pyrimidine ring forms a thieno[3,2-*d*]pyrimidin-4-yl group;

5 m is 0, or m is 1 and the R<sup>1</sup> group is a vinyl group located at the 6-position which bears at the terminal CH<sub>2</sub>= position a substituent selected from N-(2-dimethylaminoethyl)carbamoyl or N-(3-dimethylaminopropyl)carbamoyl, or from a group of the formula :



10 wherein X<sup>2</sup> is NHCO or N(Me)CO and Q<sup>4</sup> is 2-pyridylmethyl, 4-pyridylmethyl, 2-pyrid-2-ylethyl, 2-pyrrolidin-1-ylethyl, 3-(2-oxopyrrolidin-1-yl)propyl, 3-morpholinopropyl, 2-piperidinoethyl or 3-(4-methylpiperazin-1-yl)propyl,

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

15 Z is O; and

Q<sup>2</sup> is phenyl which bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo and trifluoromethyl provided that at least one substituent is located at the ortho position;

or a pharmaceutically-acceptable acid-addition salt thereof.

20

12. A pyrimidine derivative of the Formula IV according to claim 4 selected from:-

1-(2,6-dichlorophenyl)-3-(thieno[3,2-*d*]pyrimidin-4-yl)urea and

(*E*)-3-{4-[3-(2,6-dichlorophenyl)ureido]thieno[3,2-*d*]pyrimidin-6-yl}-

N-(3-dimethylaminopropyl)acrylamide;

25 or a pharmaceutically-acceptable acid-addition salt thereof.

13. A process for the preparation of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 which comprises :-

(a) for those compounds of the Formula I wherein R<sup>3</sup> is hydrogen and Z is oxygen, the

30 reaction of an amine of the Formula VI



VI

wherein  $Q^1$  and  $R^2$  have any of the meanings defined in claim 1 except that any functional group is protected if necessary, with an isocyanate of the Formula VII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



- 5 wherein  $Q^2$  has any of the meanings defined in claim 1 except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

(b) for those compounds of the Formula I wherein  $R^3$  is hydrogen and Z is sulphur, the reaction of an amine of the Formula VI



wherein  $Q^1$  and  $R^2$  have any of the meanings defined in claim 1 except that any functional group is protected if necessary, with an isothiocyanate of the Formula XII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



- 15 wherein  $Q^2$  has any of the meanings defined in claim 1 except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

(c) for those compounds of the Formula I wherein  $R^2$  is hydrogen and Z is oxygen, the reaction of an amine of the Formula XVI




wherein  $Q^2$  and  $R^3$  have any of the meanings defined in claim 1 except that any functional group is protected if necessary, with an isocyanate of the Formula XVII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



- 25 wherein  $Q^1$  has any of the meanings defined in claim 1 except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

(d) for those compounds of the Formula I wherein  $R^2$  is hydrogen and Z is sulphur, the reaction of an amine of the Formula XVI



wherein  $Q^2$  and  $R^3$  have any of the meanings defined in claim 1 except that any functional group is protected if necessary, with an isothiocyanate of the Formula XXII, or a conventional chemical equivalent thereof or a conventional chemical precursor thereof,



XXII

wherein  $Q^1$  has any of the meanings defined in claim 1 except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means;

- 5 (e) for those compounds of the Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains an alkylcarbamoyl group or a substituted alkylcarbamoyl group, the reaction of the corresponding compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  is a carboxy group, or a reactive derivative thereof, with an amine or substituted amine as appropriate;
- (f) for those compounds of the Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains an  
10 amino-(1-6C)alkyl group, the cleavage of the corresponding compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  is a protected amino-(1-6C)alkyl group;
- (g) for those compounds of the Formula I wherein Z is a  $N(R^{11})$  group wherein  $R^{11}$  is hydrogen or (1-6C)alkyl, the reaction of a thiourea of the Formula I wherein  $Q^1$ ,  $Q^2$ ,  $R^2$  and  $R^3$  have any of the meanings defined in claim 1 except that any functional group is protected if  
15 necessary and Z is sulphur, with an amine of formula  $R^{11}NH_2$ , whereafter any protecting group that is present is removed by conventional means; or
- (h) for those compounds of the Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains an amino group, the reduction of a corresponding compound of Formula I wherein a substituent on  $Q^1$  or  $Q^2$  contains a nitro group;
- 20 and when a pharmaceutically-acceptable salt of a quinazoline derivative of the Formula I is required it may be obtained using a conventional procedure.

14. A pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 in association  
25 with a pharmaceutically-acceptable diluent or carrier.

15. The use of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 but without the proviso that the group of formula Ic so formed is not a purine ring and including the compounds :-

- 30 1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,  
1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.

1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

5 1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and

1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

in the manufacture of a medicament for use in the prevention or treatment of T cell mediated

10 diseases or medical conditions in a warm-blooded animal such as man.

16. A method for the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I,

15 or a pharmaceutically-acceptable salt thereof, according to claim 1 but without the proviso that the group of formula Ic so formed is not a purine ring and including the compounds :-

1-(6,7-dimethoxyquinazolin-4-yl)-3-phenylurea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-phenylurea,

1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea,

20 1-[5-(4-methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea.

1-phenyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(2-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(3-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-(4-chlorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

25 1-(2-fluorophenyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea,

1-benzyl-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea and

1-(3-phenylpropyl)-3-(pyrazolo[3,4-*d*]pyrimidin-4-yl)urea.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02566

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/94 A61K31/505 C07D401/12 C07D403/12 C07D495/04  
A61P37/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 50047 A (UNIV PENNSYLVANIA ;LIANG BRUCE T (US); JACOBSON KENNETH A (US)) 12 November 1998 (1998-11-12) see compound MRS1364 page 28	1,4,13, 14
X	WO 98 50370 A (KUTSCHER BERNHARD ;WEINBERGER HEINZ (DE); SUGEN INC (US); TANG PEN) 12 November 1998 (1998-11-12) cited in the application see compounds A32-A34 page 53, line 5 -page 55, line 9	15,16
X	WO 98 38984 A (SUGEN INC ;SHENOY NARMADA (US); WAGNER GREGORY S (US)) 11 September 1998 (1998-09-11) page 28, line 22 -page 29, line 8 page 76, line 3-24	15,16
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

6 October 2000

Date of mailing of the international search report

26.10.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Schmid, J-C

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02566

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 09024 A (JOHNS AMANDA ;PORTER RODERICK ALAN (GB); SMITHKLINE BEECHAM PLC (G) 25 February 1999 (1999-02-25) cited in the application page 1, line 34 -page 2, line 31 see formula (I) page 3, line 26 -page 4, line 28 ----	1,2, 14-16
A	WO 97 03069 A (GLAXO GROUP LTD ;COCKERILL GEORGE STUART (GB); CARTER MALCOLM CLIV) 30 January 1997 (1997-01-30) cited in the application page 1, line 1 -page 2, line 3 see formula(I) page 7, line 1 -page 9, line 10 ----	1-16
A	MYERS M R ET AL: "The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56and EGF-R tyrosine kinase activity" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 4, 18 February 1997 (1997-02-18), pages 417-420, XP004136037 ISSN: 0960-894X the whole document ----	1-16
A	GIBSON K H ET AL: "Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 21, 4 November 1997 (1997-11-04), pages 2723-2728, XP004136520 ISSN: 0960-894X cited in the application see compound 18 ----	1-16
A	HONG C I ET AL: "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF SOME N4-SUBSTITUTED 4-AMINOPYRAZOLO'3,4d!PYRIMIDINES" JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 19, no. 4, 1976, pages 555-558, XP000916640 ISSN: 0022-2623 cited in the application see compounds 20,22-26 ----- -/--	1-16

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02566

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>VAN MUIJLWIJK-KOEZEN ET AL: "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A3 Receptor"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 5, 1 June 2000 (2000-06-01), pages 2227-2238, XP002147879</p> <p>ISSN: 0022-2623</p> <p>see compound 5a</p> <p>-----</p>	1,2, 14-16

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 00/02566

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 16 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claim 1 relates to an extremely large number of possible compounds. In fact, the claims contain so many options that a lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear, namely for those quinazoline derivatives of claim 1 for which Q1 is a group of formula Ia, Ib, Ic or Id.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02566

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9850047 A	12-11-1998	AU 7367798 A EP 0991414 A	27-11-1998 12-04-2000
WO 9850370 A	12-11-1998	AU 7282998 A EP 0981519 A	27-11-1998 01-03-2000
WO 9838984 A	11-09-1998	AU 6680698 A EP 1014953 A	22-09-1998 05-07-2000
WO 9909024 A	25-02-1999	AU 8741198 A EP 1003737 A	08-03-1999 31-05-2000
WO 9703069 A	30-01-1997	AU 6613996 A EP 0843671 A HR 960316 A JP 11508906 T	10-02-1997 27-05-1998 28-02-1998 03-08-1999